benzonidazole profile

Benzonidazole is a nitroimidazole derivative that has been used for the treatment of Chagas disease, a parasitic infection caused by Trypanosoma cruzi. It is typically administered orally and is effective in reducing the parasite load in patients, particularly in the acute phase of the infection. Benzonidazole is thought to exert its effects by inhibiting the parasite's DNA synthesis and mitochondrial function. Its synthesis involves a multi-step process that includes the nitration of 2-nitroimidazole followed by condensation with benzoyl chloride. The drug has been shown to be safe and effective in clinical trials, although some patients may experience side effects such as nausea, vomiting, and skin rash. Despite its importance in Chagas disease treatment, benzonidazole has several limitations, including its long treatment duration, potential for drug resistance, and limited efficacy in the chronic phase of the infection. Research into benzonidazole focuses on developing more effective and safe treatments for Chagas disease, exploring potential new uses for the drug, and investigating its mechanism of action. The importance of research into benzonidazole stems from the significant burden of Chagas disease, particularly in Latin America, and the need for more effective and accessible treatments. Researchers are also investigating potential new uses for benzonidazole, such as its potential as an anti-cancer drug, and its ability to treat other parasitic infections. Overall, benzonidazole is an important drug for the treatment of Chagas disease, but ongoing research is essential to address its limitations and explore its potential in other medical fields.'

benzonidazole: used in treatment of Chagas' disease [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

benznidazole : A monocarboxylic acid amide obtained by formal condensation of the carboxy group of (2-nitroimidazol-1-yl)acetic acid with the aromatic amino group of benzylamine. Used for treatment of Chagas disease. [Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

ID Source	ID
PubMed CID	31593
CHEMBL ID	110
CHEBI ID	133833
SCHEMBL ID	45081
SCHEMBL ID	22493029
MeSH ID	M0055210

Synonym
radanil
rochagan
ro-7-1051
ragonil
benznidazole [inn]
benzonidazole
ccris 2200
ro 71051
2-nitro-n-(phenylmethyl)-1h-imidazole-1-acetamide
brn 0551486
acetamide, n-benzyl-2-(nitroimidazol-1-yl)-
n-benzyl-2-nitro-1-imidazoleacetamide
benznidazolum [inn-latin]
benznidazol [inn-spanish]
nsc 299972
rochagan (tn)
D02489
benznidazole (tn)
benznidazole (usan/inn)
radanil (tn)
22994-85-0
benznidazole
n-benzyl-2-(2-nitroimidazol-1-yl)acetamide
nsc299972
ro 07-1051
n-benzyl-2-nitroimidazole-1-acetamide
1h-imidazole-1-acetamide, 2-nitro-n-(phenylmethyl)-
imidazole-1-acetamide, n-benzyl-2-nitro-
n-benzyl-2-nitroimidazol-1-yl-acetamide
nsc-299972
MLS001332409
MLS001332410
n-benzyl-2-nitro-1h-imidazole-1-acetamide, 97%
NCGC00166238-01
n-benzyl-2-nitro-1h-imidazole-1-acetamide
smr000857153
MLS001360496
benznidazol
benznidazolum
CHEBI:133833 ,
n-benzyl-2-(2-nitro-1h-imidazol-1-yl)acetamide
n-benzyl-2-(2-nitro-1himidazol-1-yl)acetamide
n-benzyl-2-(2-nitro-imidazol-1-yl)-acetamide
bdbm50089916
n-benzyl-2-(2-nitro-imidazol-1-yl)-acetamide (benznidazole)
n-benzyl-2-(2-nitro-1h-imidazol-5-yl)acetamide
ro-07-1051
benzonidazol
CHEMBL110 ,
FT-0662547
cas-22994-85-0
dtxsid9046570 ,
tox21_112364
dtxcid7026570
AKOS015916722
HMS2233G13
S3741
BRD-K56156805-001-05-4
unii-yc42nrj1zd
benznidazole [usan:inn]
yc42nrj1zd ,
HMS3369C11
benznidazole [mart.]
benznidazole [who-dd]
benznidazole [usan]
benznidazole [mi]
benznidazole [who-ip]
benznidazolum [who-ip latin]
benznidazole [orange book]
SCHEMBL45081
NCGC00166238-02
tox21_112364_1
AKOS024283499
SR-01000841264-3
sr-01000841264
AS-68694
J-014932
mmv688773
DB11989
Q425300
pyridinium,1-dodecyl-2-[(hydroxyimino)methyl]-,iodide(1:1)
Z2044771577
mfcd00243089
2-(2-nitroimidazol-1-yl)-n-(phenylmethyl)acetamide
CS-0013411
HY-B1548
CCG-267054
benznidazol (ro 07-1051; ro 71051)
ro 07-1051;ro 71051
C74184
A912716
SCHEMBL22493029
SR-01000841264-4
1h-imidazole-1-acetamide,2-nitro-n-(phenylmethyl)-
1h-imidazole-1-acetamide, 2-nitro-n-(phenylmethyl)- [
benznidazol (inn-spanish)
benznidazole (mart.)
benznidazolum (inn-latin)
p01ca02
EN300-1716737

Excerpt	Reference	Relevance
"Treatment with benzonidazole was begun leading to suppression of parasitemia."	( [Reactivation of Trypanosoma cruzi infection in patients with acquired immunodeficiency syndrome]. Coelho, JM; dos Santos, RR; Galhardo, MC; Hasslocher-Moreno, A; Junqueira, AC; Martins, IA; Ribeiro, Rdos S; Vasconcelos, AC; Xavier, SS, )	0.47

Excerpt	Reference	Relevance
" Studies on Nfx and Bz biotransformation, activation to reactive metabolites, and potential mechanisms for their toxic effects were analyzed."	( Toxic effects of nifurtimox and benznidazole, two drugs used against American trypanosomiasis (Chagas' disease). Castro, JA; Diaz de Toranzo, EG, 1988)	0.27
" Benznidazole was less toxic (IC(50)=2000 microM) than prodigiosin (IC(50)=1-20 microM) in V79 cells based on the MTT and NAC assays."	( Cytotoxicity of prodigiosin and benznidazole on V79 cells. da Silva Melo, P; Durán, N; Haun, M, 2000)	0.31
" This alkylphospholipid was also extremely toxic against intracellular amastigotes of both strains."	( Proinflammatory and cytotoxic effects of hexadecylphosphocholine (miltefosine) against drug-resistant strains of Trypanosoma cruzi. Bozza, MT; Freire-De-Lima, CG; Gibaldi, D; Heise, N; Mendonça-Previato, L; Previato, JO; Saraiva, VB, 2002)	0.31
" Although toxic effects on growth of colonies were not observed, 75 and 100 microM benznidazole induced an increasing of mitotic recombination events in diploid strain."	( Benznidazole-induced genotoxicity in diploid cells of Aspergillus nidulans. Castro-Prado, MA; Kaneshima, EN, 2005)	0.33
" The most frequent adverse effects observed in the use of Nfx are: anorexia, loss of weight, psychic alterations, excitability, sleepiness, digestive manifestations such as nausea or vomiting, and occasionally intestinal colic and diarrhoea."	( Toxic side effects of drugs used to treat Chagas' disease (American trypanosomiasis). Bartel, LC; Castro, JA; de Mecca, MM, 2006)	0.33
" Essential program components guaranteeing feasibility of implementation were information, education, and communication (IEC) at the community and family level; vector control; health staff training; screening and diagnosis; treatment and compliance, including family-based strategies for early detection of adverse events; and logistics."	( Feasibility, drug safety, and effectiveness of etiological treatment programs for Chagas disease in Honduras, Guatemala, and Bolivia: 10-year experience of Médecins Sans Frontières. Albajar Viñas, P; Castillo, S; Chambi, W; Ellman, T; Flevaud, L; Lima, MA; Palma, PP; Parreño, F; Roddy, P; Yun, O, 2009)	0.35
" Benznidazole-related adverse events were observed in 50."	( Feasibility, drug safety, and effectiveness of etiological treatment programs for Chagas disease in Honduras, Guatemala, and Bolivia: 10-year experience of Médecins Sans Frontières. Albajar Viñas, P; Castillo, S; Chambi, W; Ellman, T; Flevaud, L; Lima, MA; Palma, PP; Parreño, F; Roddy, P; Yun, O, 2009)	0.35
"These results demonstrate the feasibility of implementing Chagas disease diagnosis and treatment programs in resource-limited settings, including remote rural areas, while addressing the limitations associated with drug-related adverse events."	( Feasibility, drug safety, and effectiveness of etiological treatment programs for Chagas disease in Honduras, Guatemala, and Bolivia: 10-year experience of Médecins Sans Frontières. Albajar Viñas, P; Castillo, S; Chambi, W; Ellman, T; Flevaud, L; Lima, MA; Palma, PP; Parreño, F; Roddy, P; Yun, O, 2009)	0.35
" Benznidazole is the most commonly used drug for the etiological treatment of the disease although its effectiveness varies according to the phase of the same and toxic side effects are frequent."	( Side effects of benznidazole treatment in a cohort of patients with Chagas disease in non-endemic country. Carrilero, B; Martínez-Lage, L; Murcia, L; Segovia, M, 2011)	0.37
"The Naranjo algorithm was applied to classify the causality of adverse drug reactions (ADRs)."	( Safety of benznidazole use in the treatment of chronic Chagas' disease. Chambela, MC; de Sousa, AS; do Brasil, PE; Hasslocher-Moreno, AM; Sperandio da Silva, GM; Xavier, SS, 2012)	0.38
"Up to half of patients with Chagas' disease under benznidazole treatment present adverse drug reactions (ADRs) and up to one-third do not complete standard treatment."	( Benznidazole treatment safety: the Médecins Sans Frontières experience in a large cohort of Bolivian patients with Chagas' disease. Brasil, PEAAD; Brum-Soares, LM; Cubides, JC; Fux, CP; Hasslocher-Moreno, AM; Holanda, MT; Mediano, MFF; Mejía, RA; Sangenis, LHC; Saraiva, RM; Silvestre de Sousa, A; Sperandio da Silva, GM, 2017)	0.46
"Benznidazole treatment was safe and a large proportion of patients were able to complete a full course of benznidazole treatment under close treatment surveillance."	( Benznidazole treatment safety: the Médecins Sans Frontières experience in a large cohort of Bolivian patients with Chagas' disease. Brasil, PEAAD; Brum-Soares, LM; Cubides, JC; Fux, CP; Hasslocher-Moreno, AM; Holanda, MT; Mediano, MFF; Mejía, RA; Sangenis, LHC; Saraiva, RM; Silvestre de Sousa, A; Sperandio da Silva, GM, 2017)	0.46
"Etiological treatment of Chagas disease in chronic asymptomatic patients is still in debate and the adverse effects of traditional drugs are one of the main concerns in clinical practice."	( Risk factors for treatment interruption and severe adverse effects to benznidazole in adult patients with Chagas disease. Agreda-Rudenko, D; Cucunubá, ZM; Duque, S; Flórez, C; Herazo, R; Nicholls, RS; Olivera, MJ; Valencia-Hernández, CA, 2017)	0.46
" A multinomial logistic regression model was used to estimate the probability of severe adverse drug reactions (ADRs)."	( Risk factors for treatment interruption and severe adverse effects to benznidazole in adult patients with Chagas disease. Agreda-Rudenko, D; Cucunubá, ZM; Duque, S; Flórez, C; Herazo, R; Nicholls, RS; Olivera, MJ; Valencia-Hernández, CA, 2017)	0.46
"We observed 305 adverse reactions in 85 of 99 participants (85."	( What to expect and when: benznidazole toxicity in chronic Chagas' disease treatment. Aldasoro, E; Calvo-Cano, A; Casellas, A; Gascon, J; Pinazo, MJ; Posada, E; Requena-Méndez, A; Sanz, S; Serret, N; Soy, D, 2018)	0.48
"There is a very high frequency of adverse reactions to benznidazole."	( What to expect and when: benznidazole toxicity in chronic Chagas' disease treatment. Aldasoro, E; Calvo-Cano, A; Casellas, A; Gascon, J; Pinazo, MJ; Posada, E; Requena-Méndez, A; Sanz, S; Serret, N; Soy, D, 2018)	0.48
"The nucleoside antibiotic tubercidin displays strong activity against different target organisms, but it is notoriously toxic to mammalian cells."	( Revisiting tubercidin against kinetoplastid parasites: Aromatic substitutions at position 7 improve activity and reduce toxicity. Caljon, G; Campagnaro, GD; de Koning, HP; Hulpia, F; Maes, L; Scortichini, M; Van Calenbergh, S; Van Hecke, K, 2019)	0.51
" Both drugs present high rates of adverse reactions and treatment discontinuation and there is no consensus regarding the most effective administration schedule for benznidazole or how to prevent and manage treatment toxicity."	( Comparison of the toxicity of two treatment schemes with benznidazole for chronic Chagas disease: a prospective cohort study in two Spanish referral centres. Arsuaga, M; Crespillo-Andújar, C; Díaz-Menéndez, M; López-Vélez, R; Monge-Maillo, B; Norman, F; Pérez-Molina, JA; Trigo, E, 2020)	0.56
" There were also no differences in adverse reactions rate (55."	( Comparison of the toxicity of two treatment schemes with benznidazole for chronic Chagas disease: a prospective cohort study in two Spanish referral centres. Arsuaga, M; Crespillo-Andújar, C; Díaz-Menéndez, M; López-Vélez, R; Monge-Maillo, B; Norman, F; Pérez-Molina, JA; Trigo, E, 2020)	0.56
" The MTT assay showed that no statistically significant toxic effects occurred in the developed system, nor significant effects on cell viability."	( ZIF-8 as a promising drug delivery system for benznidazole: development, characterization, in vitro dialysis release and cytotoxicity. da Silva Nascimento, DDS; de Albuquerque Wanderley Sales, V; de Moura Ferraz, LR; de Souza Pereira, JJ; Ferreira, AS; Júnior, SA; Rolim, LA; Rolim-Neto, PJ; Silva, JYR; Tabosa, AÉGA, 2020)	0.56
" However, adverse drug reactions (ADR) are common and frequently cause patients to discontinue treatment."	( Mitigation of benznidazole toxicity and oxidative stress following ascorbic acid supplementation in an adult traveller with chronic indeterminate Chagas' disease. Breynaert, A; De Bruyne, T; Hermans, N; Huits, R; Truyens, C; Van Den Broucke, S; Van Esbroeck, M; Van Herreweghe, M, 2022)	0.72
" Diagnostic tools, treatment protocols, seroconversion rates and adverse events were investigated."	( Monotherapy and combination chemotherapy for Chagas disease treatment: a systematic review of clinical efficacy and safety based on randomized controlled trials. Cardoso Santos, E; Dias Novaes, R; Lima, GDA; Oliveira Silva, R; Santana Nogueira, S; Vilela Gonçalves, R, 2022)	0.72

Excerpt	Reference	Relevance
" It was found that the effectiveness of these compounds in producing pharmacokinetic effects correlated directly with their lipophilicity, viz."	( Nitroimidazoles as modifiers of nitrosourea pharmacokinetics. Lee, FY; Workman, P, 1984)	0.27
" Pharmacokinetic behaviour was linear except at high doses in mice."	( Preclinical pharmacokinetics of benznidazole. Owen, LN; Twentyman, PR; Walton, MI; White, RA; Workman, P, 1984)	0.27
"Prospective population pharmacokinetic (PK) cohort study in children 2-12 years old with Chagas disease treated with oral benznidazole 5-8 mg/kg/day BID for 60 days."	( Population pharmacokinetic study of benznidazole in pediatric Chagas disease suggests efficacy despite lower plasma concentrations than in adults. Altcheh, J; Ballering, G; Bisio, M; García-Bournissen, F; Giglio, N; Koren, G; Marson, ME; Mastrantonio, G; Moroni, S; Moscatelli, G, 2014)	0.4
" Furthermore, we demonstrated the application of the method in a preclinical pharmacokinetic study after administration of a single oral dose of BNZ in Wistar rats."	( Rapid and sensitive ultra-high-pressure liquid chromatography method for quantification of antichagasic benznidazole in plasma: application in a preclinical pharmacokinetic study. Davanço, MG; de Campos, ML; Peccinini, RG, 2015)	0.42
"The aim of the present study was to build a population pharmacokinetic (popPK) model to characterize benznidazole (BNZ) pharmacokinetics in adults with chronic Chagas disease."	( Population pharmacokinetics of benznidazole in adult patients with Chagas disease. Aldasoro, E; Gascón, J; Guerrero, L; Mejía, T; Posada, E; Serret, N; Soy, D; Urbina, JA, 2015)	0.42
" The pharmacokinetic parameters demonstrated that the extended-release tablets prolonged drug release from the pharmaceutical matrix and provided an increase in the maintenance of the drug concentrationin vivo, which would allow the frequency of administration to be reduced."	( Benznidazole Extended-Release Tablets for Improved Treatment of Chagas Disease: Preclinical Pharmacokinetic Study. Alzate, AH; Campos, ML; Davanço, MG; Padilha, EC; Peccinini, RG; Rolim, LA; Rolim-Neto, PJ; Rosa, TA, 2016)	0.43
" In this study, BNZ tissue biodistribution in a murine model and its pharmacokinetic profile in plasma were monitored."	( Pharmacokinetics and Tissue Distribution of Benznidazole after Oral Administration in Mice. Cardoso, JM; Carneiro, CM; Correa-Oliveira, R; Fonseca, KD; Mathias, FA; Molina, I; Moreira da Silva, R; Perin, L; Reis, LE; Vieira, PM, 2017)	0.46
" The pharmacokinetic analysis of benznidazole was evaluated via non-linear mixed-effects modelling using the NONMEN program."	( Population pharmacokinetics and biodistribution of benznidazole in mice. Balthazar Nardotto, GH; Correa-Oliveira, R; da Silva Fonseca, K; Fernanda Rodrigues Bastos Mendes, T; Martins Carneiro, C; Melo de Abreu Vieira, P; Molina, I; Oliveira Paiva, B; Perin, L; Pinto, L, 2020)	0.56
"Our results demonstrate that mouse weight allometrically influences benznidazole clearance; the AUC curve and the highest plasma concentration are dose proportional; benznidazole does not influence its own metabolism; its tissue distribution is limited; and the standard treatment regimen for Chagas' disease in mice (100 mg/kg/day for 20 days) is inadequate from a pharmacokinetic standpoint, as are the other regimens tested in this study (100 mg/kg/day for 40 days, 200 mg/kg/day for 20 days and 40 mg/kg/day for 20 or 40 days)."	( Population pharmacokinetics and biodistribution of benznidazole in mice. Balthazar Nardotto, GH; Correa-Oliveira, R; da Silva Fonseca, K; Fernanda Rodrigues Bastos Mendes, T; Martins Carneiro, C; Melo de Abreu Vieira, P; Molina, I; Oliveira Paiva, B; Perin, L; Pinto, L, 2020)	0.56
" The population pharmacokinetic model developed here can allow optimization of the dosing regimen of benznidazole to treat experimental Chagas' disease."	( Population pharmacokinetics and biodistribution of benznidazole in mice. Balthazar Nardotto, GH; Correa-Oliveira, R; da Silva Fonseca, K; Fernanda Rodrigues Bastos Mendes, T; Martins Carneiro, C; Melo de Abreu Vieira, P; Molina, I; Oliveira Paiva, B; Perin, L; Pinto, L, 2020)	0.56
"The present study aimed to establish a population pharmacokinetic (PopPK) modeling of benznidazole (BZD) in Brazilian patients with chronic Chagas disease."	( Population pharmacokinetic modeling of benznidazole in Brazilian patients with chronic Chagas disease. Bedor, DCG; Frade, VP; Ghilard, FR; Moreira, CHV; Oliveira, CDL; Sabino, EC; Sanches, C, 2022)	0.72

Excerpt	Reference	Relevance
" In the present study, the effects of benznidazole (BZ) therapy in combination with the iron chelator desferrioxamine (DFO) on the development of infection in mice inoculated with Trypanosoma cruzi Y strain have been investigated."	( Trypanosoma cruzi: effect of benznidazole therapy combined with the iron chelator desferrioxamine in infected mice. Arantes, JM; Bahia, MT; Carneiro, CM; de Abreu Vieira, PM; de Lana, M; Francisco, AF; Martins, HR; Pedrosa, ML; Silva, M; Tafuri, WL; Veloso, VM, 2008)	0.35
"The present work aimed to investigate the curative effect of benznidazole (BZL) in combination with other patented drugs [nifurtimox (NFX), posaconazole (POS) or AmBisome(®) (AMB)] in mice acutely or chronically infected with either a BZL-susceptible (Tulahuen) or a BZL-partially-resistant (Y) strain of Trypanosoma cruzi."	( Evaluation of benznidazole treatment combined with nifurtimox, posaconazole or AmBisome® in mice infected with Trypanosoma cruzi strains. Carlier, Y; Cencig, S; Coltel, N; Truyens, C, 2012)	0.38
" In order to improve the drug armamentarium against Chagas' disease, in the present study we describe the synthesis of the compound 3-chloro-7-methoxy-2-(methylsulfonyl) quinoxaline (quinoxaline 4) and its activity, alone or in combination with benznidazole, against Trypanosoma cruzi in vitro."	( A quinoxaline derivative as a potent chemotherapeutic agent, alone or in combination with benznidazole, against Trypanosoma cruzi. Corrêa, AG; Nakamura, CV; Rodrigues, JH; Sangi, DP; Ueda-Nakamura, T, 2014)	0.4
" Enalapril alone or in combination with benznidazole did not change the number of circulating parasites, but reduced cardiac leukocyte recruitment and total collagen in the cardiac tissue."	( Enalapril in Combination with Benznidazole Reduces Cardiac Inflammation and Creatine Kinases in Mice Chronically Infected with Trypanosoma cruzi. de Paula Costa, G; Horta, AL; Leite, AL; Natali, AJ; Neves, CA; Penitente, AR; Shrestha, D; Talvani, A, 2015)	0.42
" With the aim of finding new therapeutic approaches, in vitro and in vivo anti-Trypanosoma cruzi activity of vitamin C alone and combined with benznidazole were investigated."	( Anti-parasitic effect of vitamin C alone and in combination with benznidazole against Trypanosoma cruzi. Batlle, A; Demaria, A; Frank, FM; Lombardo, ME; Puente, V, 2018)	0.48
" Two mechanisms of action may be postulated for vitamin C: a lethal pro-oxidant effect on the parasite when used alone, and an antioxidant effect, when combined with benznidazole."	( Anti-parasitic effect of vitamin C alone and in combination with benznidazole against Trypanosoma cruzi. Batlle, A; Demaria, A; Frank, FM; Lombardo, ME; Puente, V, 2018)	0.48
"Clove and ginger EOs, administered alone and in combination with BZ, promoted suppression of parasitemia (p < 0."	( Essential oils from Syzygium aromaticum and Zingiber officinale, administered alone or in combination with benznidazole, reduce the parasite load in mice orally inoculated with Trypanosoma cruzi II. de Abreu, AP; de Ornelas Toledo, MJ; de Souza Fernandes, N; Lucas da Silva, HF; Sarto, MPM; Zanusso Junior, G, 2021)	0.62
"Benznidazole induced effective antiparasitic response, regardless of treatment duration, dose, or combination with fosravuconazole, and was well tolerated in adult patients with chronic Chagas disease."	( New regimens of benznidazole monotherapy and in combination with fosravuconazole for treatment of Chagas disease (BENDITA): a phase 2, double-blind, randomised trial. Almeida, IC; Alonso-Vega, C; Barboza, T; Barreira, F; Bilbe, G; Blum, B; Correia, E; Garcia, W; Gascón, J; Ortiz, L; Parrado, R; Ramirez, JC; Ribeiro, I; Sosa-Estani, S; Strub-Wourgaft, N; Torrico, F; Vaillant, M, 2021)	0.62

Excerpt	Reference	Relevance
"Effervescent tablets produced using an inclusion complex of BNZ with CD suggest a possible improvement in the bioavailability of BNZ, and this could represent a relevant advance in Chagas therapy."	( Development of effervescent tablets containing benzonidazole complexed with cyclodextrin. Bahia, MT; Costa, GH; Cunha-Filho, MS; de Sá Barreto, LC; Maximiano, FP, 2011)	0.63
" These promising results, supported by the in silico prediction of high bioavailability and less potential risk than benznidazole, reveal several tetrahydroquinolines as prototypes of potential antichagasic drugs."	( Selective activity of 2,4-diaryl-1,2,3,4-tetrahydroquinolines on Trypanosoma cruzi epimastigotes and amastigotes expressing β-galactosidase. Escario, JA; Fonseca-Berzal, C; Gómez-Barrio, A; Kouznetsov, VV; Merchán Arenas, DR; Romero Bohórquez, AR, 2013)	0.39
" Taken together, the results demonstrated that the studied derivatives had optimal properties for bioavailability and oral absorption."	( Synthesis, physicochemical properties of allopurinol derivatives and their biological activity against Trypanosoma cruzi. Alba-Soto, CD; Briñón, MC; Gualdesi, MS; Novoa, MM; Raviolo, MA; Solana, ME, 2013)	0.39
" Thus, the aim of this study was to evaluate the impact of stoichiometric and non-stoichiometric BZL-cyclodextrins (CDs) complexes on the bioavailability of BZL."	( Effects of benznidazole:cyclodextrin complexes on the drug bioavailability upon oral administration to rats. Bombardiere, ME; Leonardi, D; Salomon, CJ, 2013)	0.39
" These results, supported by the in silico prediction of a good oral bioavailability and a suitable risk profile, propose the 4-amino-7-chloroquinoline scaffold as a potential template for designing trypanocidal prototypes."	( In vitro phenotypic screening of 7-chloro-4-amino(oxy)quinoline derivatives as putative anti-Trypanosoma cruzi agents. Escario, JA; Fonseca-Berzal, C; Gómez-Barrio, A; Kouznetsov, VV; Rojas Ruiz, FA, 2014)	0.4
"This work aims to develop novel benznidazole (BZN) solid dispersions (SD) to improve its solubility and bioavailability properties."	( Development of novel benznidazole formulations: physicochemical characterization and in vivo evaluation on parasitemia reduction in Chagas disease. Arán, VJ; Escario, JA; Fonseca-Berzal, C; Gómez-Barrio, A; Palmeiro-Roldán, R; Torrado-Durán, S; Torrado-Santiago, S, 2014)	0.4
" The bioavailability of BNZ was adequate in the administration of extended-release tablets; however, with the administration of the pediatric tablet, the bioavailability was lower than with other tablets, which showed that the clinical use of this formulation should be monitored."	( Benznidazole Extended-Release Tablets for Improved Treatment of Chagas Disease: Preclinical Pharmacokinetic Study. Alzate, AH; Campos, ML; Davanço, MG; Padilha, EC; Peccinini, RG; Rolim, LA; Rolim-Neto, PJ; Rosa, TA, 2016)	0.43
"Benznidazole (BNZ), the only commercialized antichagasic drug, and the antifungal compound posaconazole (PCZ) have shown synergistic action in the therapy of Chagas disease, however both active pharmaceutical ingredients (APIs) exhibit low aqueous solubility potentially limiting their bioavailability and therapeutic efficacy."	( Enhancement of dissolution rate through eutectic mixture and solid solution of posaconazole and benznidazole. de La Roca Soares, MF; de Medeiros Vieira, ACQ; Figueirêdo, CBM; Lee, PI; Nadvorny, D; Rolim Neto, PJ; Soares Sobrinho, JL, 2017)	0.46
" Thus, the present SD system has the advantage of presenting a fixed-dese combination of two synergistic antichagasic agents PCZ and BNZ together in amorphous form stabilized in the PVPVA matrix with enhanced dissolution, potentially improving their bioavailability and therapeutic activity in treating Chagas disease."	( Enhanced delivery of fixed-dose combination of synergistic antichagasic agents posaconazole-benznidazole based on amorphous solid dispersions. Figueirêdo, CBM; Lee, PI; Nadvorny, D; Rolim Neto, PJ; Schver, GCRM; Soares Sobrinho, JL; Soares, MFR; Vieira, ACQM, 2018)	0.48
" The present work reviews in detail the formulation and in-vitro/in-vivo analysis of different nanoformulations of nifurtimox and benznidazole in order to enhance their solubility, dissolution, bioavailability and trypanocidal activity."	( Nanocarriers for effective delivery of benznidazole and nifurtimox in the treatment of chagas disease: A review. Arrúa, EC; Bedogni, GR; Okulik, NB; Salomon, CJ; Seremeta, KP, 2019)	0.51
"The ATP-binding cassette transporter P-glycoprotein (P-gp) is known to limit both brain penetration and oral bioavailability of many chemotherapy drugs."	( A High-Throughput Screen of a Library of Therapeutics Identifies Cytotoxic Substrates of P-glycoprotein. Ambudkar, SV; Brimacombe, KR; Chen, L; Gottesman, MM; Guha, R; Hall, MD; Klumpp-Thomas, C; Lee, OW; Lee, TD; Lusvarghi, S; Robey, RW; Shen, M; Tebase, BG, 2019)	0.51
" Self-emulsifying drug delivery systems (SEDDS) may improve bioavailability of drugs such as BZ, which have poor water solubility and low permeability."	( Benznidazole self-emulsifying delivery system: A novel alternative dosage form for Chagas disease treatment. Bahia, MT; Gonçalves, KR; Mazzeti, AL; Mosqueira, VCF; Oliveira, LT; Schaun, GC, 2020)	0.56
" Moreover, the relative oral bioavailability of the novel benznidazole microparticles showed that the area under the curve for the microencapsulated drug was 10."	( A Novel Prototype Device for Microencapsulation of Benznidazole: In Vitro/In Vivo Studies. Barrera, MG; Lamas, MC; Leonardi, D; Salomón, CJ; Tejada, G, 2020)	0.56
" The dissolution studies corroborated that a pH sensitive Drug Delivery System capable of vectorizing the release of BNZ was developed, may leading to the improvement in the bioavailability of BNZ."	( ZIF-8 as a promising drug delivery system for benznidazole: development, characterization, in vitro dialysis release and cytotoxicity. da Silva Nascimento, DDS; de Albuquerque Wanderley Sales, V; de Moura Ferraz, LR; de Souza Pereira, JJ; Ferreira, AS; Júnior, SA; Rolim, LA; Rolim-Neto, PJ; Silva, JYR; Tabosa, AÉGA, 2020)	0.56
" However, the Cur therapeutic limitation is its bioavailability and new Cur nanomedicine formulations are developed to overcome this obstacle."	( Dual chemotherapy with benznidazole at suboptimal dose plus curcumin nanoparticles mitigates Trypanosoma cruzi-elicited chronic cardiomyopathy. Corral, RS; Hernández, M; Pérez Caballero, E; Santamaría, MH; Wicz, S, 2021)	0.62
" These systems ensure high patient acceptability and direct access to the systemic circulation, improving drug bioavailability and toxicological profile."	( Development and characterization of thermopressed polyvinyl alcohol films for buccal delivery of benznidazole. Amaral, BR; Argenta, DF; Caon, T; Enumo, A; Kroth, R; Parize, AL; Rauber, GS; Rebelatto, ERL; Saatkamp, RH, 2021)	0.62
" Benznidazole, approved by FDA, is a drug of choice but its poor aqueous solubility may lead to a low bioavailability and efficacy."	( Improving the oral delivery of benznidazole nanoparticles by optimizing the formulation parameters through a design of experiment and optimization strategy. Arrua, EC; Goicoechea, H; Hartwig, O; Lehr, CM; Loretz, B; Murgia, X; Salomon, CJ, 2022)	0.72

Excerpt	Relevance	Reference
" These corresponded to 600 or 900 mg/day of allopurinol for 60 days and benznidazole or nifurtimox at conventional dosage regimens."	( Therapeutic efficacy of allopurinol in patients with chronic Chagas' disease. Gallerano, RH; Marr, JJ; Sosa, RR, 1990)	0.28
" Of 77 patients studied, 27 were treated with nifurtimox and 26 with benznidazole in the dosage of 5 m/kg/day for 30 consecutive days, and 24 received a placebo in tablets similar to benznidazole."	( [Comparative controlled study on the use of benznidazole, nifurtimox and placebo, in the chronic form of Chagas' disease, in a field area with interrupted transmission. I. Preliminary evaluation]. Coura, JR; de Abreu, LL; Petana, W; Willcox, HP, )	0.13
" The in vivo administration of the thiol drugs, at dosage regimes available in literature, was able to markedly prevent the BZ prolongation effect on the sleeping time."	( Prevention of benznidazole-induced prolonging effect on the pentobarbital sleeping time of rats using different thiol-containing compounds. Bernacchi, AS; Castro, JA; Montalto de Mecca, M, )	0.13
" Nevertheless, the cytotoxic effect of miltefosine against intracellular amastigotes was independent of the amount of NO produced by the infected macrophages since the same dose-response curves for miltefosine were observed when the NO production was blocked by the NO synthase inhibitor N(G)-monomethyl-L-arginine monoacetate."	( Proinflammatory and cytotoxic effects of hexadecylphosphocholine (miltefosine) against drug-resistant strains of Trypanosoma cruzi. Bozza, MT; Freire-De-Lima, CG; Gibaldi, D; Heise, N; Mendonça-Previato, L; Previato, JO; Saraiva, VB, 2002)	0.31
"4 mg/ml), which precludes the preparation of liquid dosage forms, in particular, parenteral formulations."	( Development of parenteral formulations and evaluation of the biological activity of the trypanocide drug benznidazole. Bassani, G; Lamas, MC; Leonardi, D; Nocito, I; Pascutti, F; Salomón, CJ; Serra, E; Villaggi, L, 2006)	0.33
" Chronic model of the disease showed that both canthin-6-one (1) and the alkaloidal extract at the above dosage induced 80-100% animal survival compared to untreated controls."	( Effects of canthin-6-one alkaloids from Zanthoxylum chiloperone on Trypanosoma cruzi-infected mice. de Arias, AR; de Bilbao, NV; Ferreira, ME; Fournet, A; Hocquemiller, R; Lagoutte, D; Nakayama, H; Poupon, E; Schinini, A; Serna, E; Soriano-Agatón, F, 2007)	0.34
" The plasma exposure profiles for each compound following a single oral dose in mice and estimated exposure parameters after repeated twice-daily dosing for 20 days are also presented."	( Pharmacological characterization, structural studies, and in vivo activities of anti-Chagas disease lead compounds derived from tipifarnib. Bahia, MT; Buckner, FS; Charman, SA; Chatelain, E; Chennamaneni, NK; Gelb, MH; Hulverson, MA; Laydbak, JU; Lepesheva, GI; Scandale, I; Shackleford, DM; Suryadevara, PK; Verlinde, CL; White, KL, 2012)	0.38
" Despite of the large number of pediatric patients infected, there are no commercial liquid dosage forms available to treat this trypanosomiasis."	( Efficacy of novel benznidazole solutions during the experimental infection with Trypanosoma cruzi. Bottasso, E; Lamas, MC; Manarin, R; Revelli, S; Salomón, CJ; Serra, E, 2013)	0.39
" cruzi infection after once daily oral dosing at 20, 50 and 100 mg/kg for 5 days."	( Design, structure-activity relationship and in vivo efficacy of piperazine analogues of fenarimol as inhibitors of Trypanosoma cruzi. Alexander, PW; Best, WM; Charman, SA; Chatelain, E; Diao, H; Gregg, AD; Keenan, M; Kerfoot, M; Khong, A; Ryan, E; Scandale, I; Shackleford, DM; Thompson, RC; von Geldern, TW; White, KL, 2013)	0.39
" Therefore, the dosage of anti-Tc13Tul antibodies may be useful as a methodology complementary to CS to evaluate chagasic patients undergoing chemotherapy with benznidazole."	( Use of an enzyme-linked immunosorbent assay that utilizes the Tc13Tul antigen of Trypanosoma cruzi to monitor patients after treatment with benznidazole. Bruballa, AC; De Rissio, AM; Garavaglia, PA; García, GA; Irazu, LE; Riarte, A; Rodríguez, MA; Ruiz, AM; Santamaría, AL, 2013)	0.39
" Real samples of human breast milk from patients in treatment with BNZ were dosed to support the validation process of the method."	( A simple and efficient HPLC method for benznidazole dosage in human breast milk. Altcheh, J; García-Bournissen, F; Marson, ME; Mastrantonio, G; Padró, JM; Reta, MR, 2013)	0.39
" Reducing the overall dosage of BZ or NFX by using an intermittent (once every 5 days) schedule or combining 5 daily doses of POS with 7 intermittent doses of BZ also provided approximately 100% cure."	( New, combined, and reduced dosing treatment protocols cure Trypanosoma cruzi infection in mice. Bustamante, JM; Craft, JM; Crowe, BD; Ketchie, SA; Tarleton, RL, 2014)	0.4
"To investigate the direct and indirect photodegradation of BNZ and to evaluate the interference of the excipients used in the forms dosage solid as well as to shed light on the chemical structure of the degradation products obtained."	( A study of photostability and compatibility of the anti-chagas drug Benznidazole with pharmaceutics excipients. Ferraz, LR; Figueirêdo, CB; Lima Leite, AC; Lyra, MA; Neves de Lima, ÁA; Peixoto, MS; Rolim Neto, PJ; Rolim, LA; Santos, FL; Soares-Sobrinho, JL, 2015)	0.42
" The indirect photodegradation of BNZ was carried out using physical mixtures with 13 pharmaceutical excipients commonly used in the preparation of solid dosage forms."	( A study of photostability and compatibility of the anti-chagas drug Benznidazole with pharmaceutics excipients. Ferraz, LR; Figueirêdo, CB; Lima Leite, AC; Lyra, MA; Neves de Lima, ÁA; Peixoto, MS; Rolim Neto, PJ; Rolim, LA; Santos, FL; Soares-Sobrinho, JL, 2015)	0.42
" cruzi infection after once daily oral dosing for 20 days at 20 mg/kg 6 and 10 mg/kg (S)-7."	( Two analogues of fenarimol show curative activity in an experimental model of Chagas disease. Abbott, MJ; Alexander, PW; Best, WM; Botero, A; Campbell, M; Chaplin, JH; Charman, SA; Chatelain, E; Chiu, FC; Cornwall, S; Keenan, M; Khong, A; Koltun, M; Morizzi, J; Perez, C; Ryan, E; Scandale, I; Shackleford, DM; Thompson, RA; von Geldern, TW; White, KL, 2013)	0.39
" cruzi infection, with oral dosing in chow for 28 days at doses from 3 to 50 mg/kg of body weight."	( Reversible cysteine protease inhibitors show promise for a Chagas disease cure. Beaulieu, C; Black, WC; Isabel, E; Massé, F; Mellon, C; Methot, N; Nath-Chowdhury, M; Ndao, M; Nicoll-Griffith, DA; Vasquez-Camargo, F, 2014)	0.4
" Pharmacokinetic data suggested that biological efficacy most likely resides with the sulfone metabolite (or subsequent reactive metabolites formed following reduction of the nitro group) following administration of either the sulfoxide or the sulfone and that prolonged plasma exposure over the 24-h dosing window is required to achieve high cure rates."	( Antitrypanosomal activity of fexinidazole metabolites, potential new drug candidates for Chagas disease. Bahia, MT; Caldas, IS; Charman, SA; Chatelain, E; Diniz, Lde F; Gonçalves, KR; Koltun, M; Marques, LF; Mazzeti, AL; Mota, LW; Nascimento, AF; Saunders, J; Scandale, I; Shackleford, DM; Talvani, A; White, KL, 2014)	0.4
" Later on, simulations were performed to generate BNZ concentration-time course profiles for different dosage regimens."	( Population pharmacokinetics of benznidazole in adult patients with Chagas disease. Aldasoro, E; Gascón, J; Guerrero, L; Mejía, T; Posada, E; Serret, N; Soy, D; Urbina, JA, 2015)	0.42
" The activities of the benznidazole/itraconazole combinations were compared with the results from those receiving the same dosage of each individual drug."	( Benznidazole/Itraconazole Combination Treatment Enhances Anti-Trypanosoma cruzi Activity in Experimental Chagas Disease. Assíria Fontes Martins, T; Bahia, MT; Caldas, IS; Caldas, S; da Silva do Nascimento, ÁF; de Andrade, IM; de Figueiredo Diniz, L; Mazzeti, AL; Ribeiro, I, 2015)	0.42
" In the current study, we sought to identify a dosing regimen of posaconazole that could permanently clear Trypanosoma cruzi from mice with experimental Chagas disease."	( Antitrypanosomal Treatment with Benznidazole Is Superior to Posaconazole Regimens in Mouse Models of Chagas Disease. Glynne, R; Groessl, T; Khare, S; Liu, X; Molteni, V; Rivera, I; Stinson, M; Supek, F; Tuntland, T; Wen, B; Yeh, V, 2015)	0.42
" In short, the quantification of BNZ and ITZ by analysis of mixtures had shown to be efficient and cost-effective alternative for determination of these drugs in a pharmaceutical dosage form."	( Simultaneous determination of benznidazole and itraconazole using spectrophotometry applied to the analysis of mixture: A tool for quality control in the development of formulations. Cunha-Filho, MS; Infante, CM; Pinho, LA; Sá-Barreto, LC, 2016)	0.43
" Since dosage may influence ADE, we aimed to assess Bzl efficacy in terms of parasiticidal and anti-inflammatory activity, using doses lower than those previously reported."	( Low-dose benznidazole treatment results in parasite clearance and attenuates heart inflammatory reaction in an experimental model of infection with a highly virulent Trypanosoma cruzi strain. Cevey, ÁC; Goren, NB; Mirkin, GA; Penas, FN, 2016)	0.43
" We have adapted a continuous enzymatic assay to a medium-throughput format and carried out a primary screening of both collections, followed by construction and analysis of dose-response curves of the most promising hits."	( Novel scaffolds for inhibition of Cruzipain identified from high-throughput screening of anti-kinetoplastid chemical boxes. Agüero, F; Alvarez, VE; Cazzulo, JJ; Karpiak, J; Landaburu, LU; Madauss, KP; Salas-Sarduy, E, 2017)	0.46
" Benznidazole is still the drug of choice in many countries to treat it in spite of its dosage regimen and adverse side effects such as such as allergic dermatitis, peripheral neuropathy and anorexia."	( Elucidating the impact of low doses of nano-formulated benznidazole in acute experimental Chagas disease. Arrúa, EC; Esteva, MI; Fichera, LE; Rial, MS; Salomon, CJ; Scalise, ML, 2017)	0.46
" PCR analysis of blood samples taken after induction of immunosuppression showed that a dosage of 25 mg/kg/day rendered 40% of the mice PCR-negative."	( Elucidating the impact of low doses of nano-formulated benznidazole in acute experimental Chagas disease. Arrúa, EC; Esteva, MI; Fichera, LE; Rial, MS; Salomon, CJ; Scalise, ML, 2017)	0.46
" cruzi acute infections in immunosuppressed and non-immunosuppressed mice and provides further evidence for the optimization of dosage regimens to treat Chagas disease."	( Elucidating the impact of low doses of nano-formulated benznidazole in acute experimental Chagas disease. Arrúa, EC; Esteva, MI; Fichera, LE; Rial, MS; Salomon, CJ; Scalise, ML, 2017)	0.46
" Optimised dosing schedules and/or new drugs are urgently needed."	( Safety Profile of Benznidazole in the Treatment of Chronic Chagas Disease: Experience of a Referral Centre and Systematic Literature Review with Meta-Analysis. Crespillo-Andújar, C; López-Polín, A; López-Vélez, R; Monge-Maillo, B; Norman, F; Pérez-Molina, JA; Venanzi-Rullo, E, 2018)	0.48
"Two hundred mice were divided into five groups according to benznidazole dosing regimens: (1) 100 mg/kg/day for 20 days; (2) 100 mg/kg/day for 40 days; (3) 200 mg/kg/day for 20 days; (4) 40 mg/kg/day for 20 days; or (5) 40 mg/kg/day for 40 days."	( Population pharmacokinetics and biodistribution of benznidazole in mice. Balthazar Nardotto, GH; Correa-Oliveira, R; da Silva Fonseca, K; Fernanda Rodrigues Bastos Mendes, T; Martins Carneiro, C; Melo de Abreu Vieira, P; Molina, I; Oliveira Paiva, B; Perin, L; Pinto, L, 2020)	0.56
" The population pharmacokinetic model developed here can allow optimization of the dosing regimen of benznidazole to treat experimental Chagas' disease."	( Population pharmacokinetics and biodistribution of benznidazole in mice. Balthazar Nardotto, GH; Correa-Oliveira, R; da Silva Fonseca, K; Fernanda Rodrigues Bastos Mendes, T; Martins Carneiro, C; Melo de Abreu Vieira, P; Molina, I; Oliveira Paiva, B; Perin, L; Pinto, L, 2020)	0.56
" Considering our previous data on solubility, together with these on efficacy, this new liquid formulation represents a promising alternative for the treatment of Chagas disease, particularly in cases when dosing poses a challenge, as in infants."	( Benznidazole/Poloxamer 407 Solid Dispersion as a New Strategy to Improve the Treatment of Experimental Trypanosoma cruzi Infection. Bermúdez, JM; Cid, AG; Davies, C; Micheloud, JF; Negrette, OS; Parada, LA; Ragone, PG; Simonazzi, A, 2020)	0.56
" Dose-response curves were calculated for each time point after addition of test compounds, revealing how EC50 values first decreased over the time of drug exposure, and then leveled off."	( Non-invasive monitoring of drug action: A new live in vitro assay design for Chagas' disease drug discovery. Braissant, O; Fesser, AF; Kaiser, M; Kelly, JM; Mäser, P; Olmo, F, 2020)	0.56
" Following initial profiling, a first proof-of-concept in vivo study was undertaken, in which once daily oral dosing of a 7-substituted 2-nitroimidazooxazine analogue suppressed blood parasitemia to low or undetectable levels, although sterile cure was not achieved."	( Re-evaluating pretomanid analogues for Chagas disease: Hit-to-lead studies reveal both in vitro and in vivo trypanocidal efficacy. Avery, VM; Charman, SA; Chatelain, E; Cornwall, S; Denny, WA; Francisco, AF; Keenan, M; Kelly, JM; Marshall, AJ; O'Connor, PD; Perez, CJ; Read, KD; Riley, J; Sykes, ML; Thompson, AM; Thompson, RCA; White, KL; Zulfiqar, B, 2020)	0.56
" To both avoid off-target side effects and reduce the necessary dosage of BNZ, we packaged the drug within poly(ethylene glycol)-block-poly(propylene sulfide) polymersomes (BNZ-PSs)."	( Nanocarrier-enhanced intracellular delivery of benznidazole for treatment of Trypanosoma cruzi infection. Engman, DM; Falk, BA; Li, X; Martinez, SJ; Olson, CL; Romano, PS; Scariot, DB; Scott, EA; Yi, S, 2021)	0.62
" Thus, this work aimed to develop a novel DDS based on BNZ and the ZIF-8 to use it in development of prolonged-release dosage forms to alternative treatment of Chagas disease."	( Benznidazole in vitro dissolution release from a pH-sensitive drug delivery system using Zif-8 as a carrier. da Silva Nascimento, DDS; de Moura Ferraz, LR; Ferreira, AS; Junior, SA; Rolim, LA; Rolim-Neto, PJ; Silva, JYR; Tabosa, AÉGA, 2021)	0.62
" Although these studies suggest that rigorously timed and more potent dosing regimen may be needed to achieve an immediate benefit of prophylaxis, additional studies would be needed to determine if drug prophylaxis reduced disease severity despite this failure to prevent new infections."	( Prophylactic low-dose, bi-weekly benznidazole treatment fails to prevent Trypanosoma cruzi infection in dogs under intense transmission pressure. Auckland, LD; Busselman, RE; Bustamante, JM; Collins, S; Hamer, SA; Malcolm, EL; Padilla, AM; Saunders, AB; Tarleton, RL; White, B; Wilson, BF, 2022)	0.72
"5-fold that of previously used daily dosing protocols, provided the best chance to obtain parasitological cure."	( Frequency Variation and Dose Modification of Benznidazole Administration for the Treatment of Trypanosoma cruzi Infection in Mice, Dogs, and Nonhuman Primates. Auckland, LD; Bustamante, JM; Hamer, SA; Hodo, CL; McCain, S; Saunders, AB; Tarleton, RL; Wang, W; White, BE; Wilkerson, GK, 2023)	0.91

Role	Description
antiprotozoal drug	Any antimicrobial drug which is used to treat or prevent protozoal infections.
[role information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Class	Description
imidazoles	A five-membered organic heterocycle containing two nitrogen atoms at positions 1 and 3, or any of its derivatives; compounds containing an imidazole skeleton.
C-nitro compound	A nitro compound having the nitro group (-NO2) attached to a carbon atom.
monocarboxylic acid amide	A carboxamide derived from a monocarboxylic acid.
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Protein	Taxonomy	Measurement	Average (µ)	Min (ref.)	Avg (ref.)	Max (ref.)	Bioassay(s)
Chain A, Beta-lactamase	Escherichia coli K-12	Potency	5.6234	0.0447	17.8581	100.0000	AID485294
thioredoxin reductase	Rattus norvegicus (Norway rat)	Potency	79.4328	0.1000	20.8793	79.4328	AID588453
cytochrome P450 family 3 subfamily A polypeptide 4	Homo sapiens (human)	Potency	38.9018	0.0123	7.9835	43.2770	AID1645841
geminin	Homo sapiens (human)	Potency	17.7828	0.0046	11.3741	33.4983	AID624297
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Protein	Taxonomy	Measurement	Average	Min (ref.)	Avg (ref.)	Max (ref.)	Bioassay(s)
ATP-binding cassette sub-family C member 3	Homo sapiens (human)	IC50 (µMol)	133.0000	0.6315	4.4531	9.3000	AID1473740
Multidrug resistance-associated protein 4	Homo sapiens (human)	IC50 (µMol)	133.0000	0.2000	5.6774	10.0000	AID1473741
Bile salt export pump	Homo sapiens (human)	IC50 (µMol)	133.0000	0.1100	7.1903	10.0000	AID1473738
Glyceraldehyde-3-phosphate dehydrogenase	Homo sapiens (human)	IC50 (µMol)	50.0000	6.0000	7.3333	8.0000	AID75731
Cytochrome P450 1A2	Homo sapiens (human)	IC50 (µMol)	100.0000	0.0001	1.7740	10.0000	AID1381720
Cytochrome P450 3A4	Homo sapiens (human)	IC50 (µMol)	98.2000	0.0001	1.7536	10.0000	AID1381724
Cytochrome P450 2D6	Homo sapiens (human)	IC50 (µMol)	77.8000	0.0000	2.0151	10.0000	AID1381723
Cytochrome P450 2C9	Homo sapiens (human)	IC50 (µMol)	100.0000	0.0000	2.8005	10.0000	AID1381721
Cytochrome P450 2C19	Homo sapiens (human)	IC50 (µMol)	100.0000	0.0000	2.3983	10.0000	AID1381722
Potassium voltage-gated channel subfamily H member 2	Homo sapiens (human)	IC50 (µMol)	100.0000	0.0009	1.9014	10.0000	AID1381719
Canalicular multispecific organic anion transporter 1	Homo sapiens (human)	IC50 (µMol)	133.0000	2.4100	6.3433	10.0000	AID1473739
Aurora kinase B	Homo sapiens (human)	IC50 (µMol)	100.0000	0.0003	0.9634	9.8000	AID1381725
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Process	via Protein(s)	Taxonomy
xenobiotic metabolic process	ATP-binding cassette sub-family C member 3	Homo sapiens (human)
xenobiotic transmembrane transport	ATP-binding cassette sub-family C member 3	Homo sapiens (human)
bile acid and bile salt transport	ATP-binding cassette sub-family C member 3	Homo sapiens (human)
glucuronoside transport	ATP-binding cassette sub-family C member 3	Homo sapiens (human)
xenobiotic transport	ATP-binding cassette sub-family C member 3	Homo sapiens (human)
transmembrane transport	ATP-binding cassette sub-family C member 3	Homo sapiens (human)
leukotriene transport	ATP-binding cassette sub-family C member 3	Homo sapiens (human)
monoatomic anion transmembrane transport	ATP-binding cassette sub-family C member 3	Homo sapiens (human)
transport across blood-brain barrier	ATP-binding cassette sub-family C member 3	Homo sapiens (human)
prostaglandin secretion	Multidrug resistance-associated protein 4	Homo sapiens (human)
cilium assembly	Multidrug resistance-associated protein 4	Homo sapiens (human)
platelet degranulation	Multidrug resistance-associated protein 4	Homo sapiens (human)
xenobiotic metabolic process	Multidrug resistance-associated protein 4	Homo sapiens (human)
xenobiotic transmembrane transport	Multidrug resistance-associated protein 4	Homo sapiens (human)
bile acid and bile salt transport	Multidrug resistance-associated protein 4	Homo sapiens (human)
prostaglandin transport	Multidrug resistance-associated protein 4	Homo sapiens (human)
urate transport	Multidrug resistance-associated protein 4	Homo sapiens (human)
glutathione transmembrane transport	Multidrug resistance-associated protein 4	Homo sapiens (human)
transmembrane transport	Multidrug resistance-associated protein 4	Homo sapiens (human)
cAMP transport	Multidrug resistance-associated protein 4	Homo sapiens (human)
leukotriene transport	Multidrug resistance-associated protein 4	Homo sapiens (human)
monoatomic anion transmembrane transport	Multidrug resistance-associated protein 4	Homo sapiens (human)
export across plasma membrane	Multidrug resistance-associated protein 4	Homo sapiens (human)
transport across blood-brain barrier	Multidrug resistance-associated protein 4	Homo sapiens (human)
guanine nucleotide transmembrane transport	Multidrug resistance-associated protein 4	Homo sapiens (human)
fatty acid metabolic process	Bile salt export pump	Homo sapiens (human)
bile acid biosynthetic process	Bile salt export pump	Homo sapiens (human)
xenobiotic metabolic process	Bile salt export pump	Homo sapiens (human)
xenobiotic transmembrane transport	Bile salt export pump	Homo sapiens (human)
response to oxidative stress	Bile salt export pump	Homo sapiens (human)
bile acid metabolic process	Bile salt export pump	Homo sapiens (human)
response to organic cyclic compound	Bile salt export pump	Homo sapiens (human)
bile acid and bile salt transport	Bile salt export pump	Homo sapiens (human)
canalicular bile acid transport	Bile salt export pump	Homo sapiens (human)
protein ubiquitination	Bile salt export pump	Homo sapiens (human)
regulation of fatty acid beta-oxidation	Bile salt export pump	Homo sapiens (human)
carbohydrate transmembrane transport	Bile salt export pump	Homo sapiens (human)
bile acid signaling pathway	Bile salt export pump	Homo sapiens (human)
cholesterol homeostasis	Bile salt export pump	Homo sapiens (human)
response to estrogen	Bile salt export pump	Homo sapiens (human)
response to ethanol	Bile salt export pump	Homo sapiens (human)
xenobiotic export from cell	Bile salt export pump	Homo sapiens (human)
lipid homeostasis	Bile salt export pump	Homo sapiens (human)
phospholipid homeostasis	Bile salt export pump	Homo sapiens (human)
positive regulation of bile acid secretion	Bile salt export pump	Homo sapiens (human)
regulation of bile acid metabolic process	Bile salt export pump	Homo sapiens (human)
transmembrane transport	Bile salt export pump	Homo sapiens (human)
microtubule cytoskeleton organization	Glyceraldehyde-3-phosphate dehydrogenase	Homo sapiens (human)
positive regulation of cytokine production	Glyceraldehyde-3-phosphate dehydrogenase	Homo sapiens (human)
glucose metabolic process	Glyceraldehyde-3-phosphate dehydrogenase	Homo sapiens (human)
glycolytic process	Glyceraldehyde-3-phosphate dehydrogenase	Homo sapiens (human)
negative regulation of endopeptidase activity	Glyceraldehyde-3-phosphate dehydrogenase	Homo sapiens (human)
regulation of macroautophagy	Glyceraldehyde-3-phosphate dehydrogenase	Homo sapiens (human)
negative regulation of translation	Glyceraldehyde-3-phosphate dehydrogenase	Homo sapiens (human)
killing of cells of another organism	Glyceraldehyde-3-phosphate dehydrogenase	Homo sapiens (human)
positive regulation of type I interferon production	Glyceraldehyde-3-phosphate dehydrogenase	Homo sapiens (human)
peptidyl-cysteine S-trans-nitrosylation	Glyceraldehyde-3-phosphate dehydrogenase	Homo sapiens (human)
positive regulation of canonical NF-kappaB signal transduction	Glyceraldehyde-3-phosphate dehydrogenase	Homo sapiens (human)
protein stabilization	Glyceraldehyde-3-phosphate dehydrogenase	Homo sapiens (human)
defense response to fungus	Glyceraldehyde-3-phosphate dehydrogenase	Homo sapiens (human)
neuron apoptotic process	Glyceraldehyde-3-phosphate dehydrogenase	Homo sapiens (human)
killing by host of symbiont cells	Glyceraldehyde-3-phosphate dehydrogenase	Homo sapiens (human)
antimicrobial humoral immune response mediated by antimicrobial peptide	Glyceraldehyde-3-phosphate dehydrogenase	Homo sapiens (human)
cellular response to type II interferon	Glyceraldehyde-3-phosphate dehydrogenase	Homo sapiens (human)
steroid catabolic process	Cytochrome P450 1A2	Homo sapiens (human)
porphyrin-containing compound metabolic process	Cytochrome P450 1A2	Homo sapiens (human)
xenobiotic metabolic process	Cytochrome P450 1A2	Homo sapiens (human)
cholesterol metabolic process	Cytochrome P450 1A2	Homo sapiens (human)
estrogen metabolic process	Cytochrome P450 1A2	Homo sapiens (human)
toxin biosynthetic process	Cytochrome P450 1A2	Homo sapiens (human)
post-embryonic development	Cytochrome P450 1A2	Homo sapiens (human)
alkaloid metabolic process	Cytochrome P450 1A2	Homo sapiens (human)
regulation of gene expression	Cytochrome P450 1A2	Homo sapiens (human)
monoterpenoid metabolic process	Cytochrome P450 1A2	Homo sapiens (human)
dibenzo-p-dioxin metabolic process	Cytochrome P450 1A2	Homo sapiens (human)
epoxygenase P450 pathway	Cytochrome P450 1A2	Homo sapiens (human)
lung development	Cytochrome P450 1A2	Homo sapiens (human)
methylation	Cytochrome P450 1A2	Homo sapiens (human)
monocarboxylic acid metabolic process	Cytochrome P450 1A2	Homo sapiens (human)
xenobiotic catabolic process	Cytochrome P450 1A2	Homo sapiens (human)
retinol metabolic process	Cytochrome P450 1A2	Homo sapiens (human)
long-chain fatty acid biosynthetic process	Cytochrome P450 1A2	Homo sapiens (human)
cellular respiration	Cytochrome P450 1A2	Homo sapiens (human)
aflatoxin metabolic process	Cytochrome P450 1A2	Homo sapiens (human)
hydrogen peroxide biosynthetic process	Cytochrome P450 1A2	Homo sapiens (human)
oxidative demethylation	Cytochrome P450 1A2	Homo sapiens (human)
cellular response to cadmium ion	Cytochrome P450 1A2	Homo sapiens (human)
omega-hydroxylase P450 pathway	Cytochrome P450 1A2	Homo sapiens (human)
lipid hydroxylation	Cytochrome P450 3A4	Homo sapiens (human)
lipid metabolic process	Cytochrome P450 3A4	Homo sapiens (human)
steroid catabolic process	Cytochrome P450 3A4	Homo sapiens (human)
xenobiotic metabolic process	Cytochrome P450 3A4	Homo sapiens (human)
steroid metabolic process	Cytochrome P450 3A4	Homo sapiens (human)
cholesterol metabolic process	Cytochrome P450 3A4	Homo sapiens (human)
androgen metabolic process	Cytochrome P450 3A4	Homo sapiens (human)
estrogen metabolic process	Cytochrome P450 3A4	Homo sapiens (human)
alkaloid catabolic process	Cytochrome P450 3A4	Homo sapiens (human)
monoterpenoid metabolic process	Cytochrome P450 3A4	Homo sapiens (human)
calcitriol biosynthetic process from calciol	Cytochrome P450 3A4	Homo sapiens (human)
xenobiotic catabolic process	Cytochrome P450 3A4	Homo sapiens (human)
vitamin D metabolic process	Cytochrome P450 3A4	Homo sapiens (human)
vitamin D catabolic process	Cytochrome P450 3A4	Homo sapiens (human)
retinol metabolic process	Cytochrome P450 3A4	Homo sapiens (human)
retinoic acid metabolic process	Cytochrome P450 3A4	Homo sapiens (human)
long-chain fatty acid biosynthetic process	Cytochrome P450 3A4	Homo sapiens (human)
aflatoxin metabolic process	Cytochrome P450 3A4	Homo sapiens (human)
oxidative demethylation	Cytochrome P450 3A4	Homo sapiens (human)
xenobiotic metabolic process	Cytochrome P450 2D6	Homo sapiens (human)
steroid metabolic process	Cytochrome P450 2D6	Homo sapiens (human)
cholesterol metabolic process	Cytochrome P450 2D6	Homo sapiens (human)
estrogen metabolic process	Cytochrome P450 2D6	Homo sapiens (human)
coumarin metabolic process	Cytochrome P450 2D6	Homo sapiens (human)
alkaloid metabolic process	Cytochrome P450 2D6	Homo sapiens (human)
alkaloid catabolic process	Cytochrome P450 2D6	Homo sapiens (human)
monoterpenoid metabolic process	Cytochrome P450 2D6	Homo sapiens (human)
isoquinoline alkaloid metabolic process	Cytochrome P450 2D6	Homo sapiens (human)
xenobiotic catabolic process	Cytochrome P450 2D6	Homo sapiens (human)
retinol metabolic process	Cytochrome P450 2D6	Homo sapiens (human)
long-chain fatty acid biosynthetic process	Cytochrome P450 2D6	Homo sapiens (human)
negative regulation of binding	Cytochrome P450 2D6	Homo sapiens (human)
oxidative demethylation	Cytochrome P450 2D6	Homo sapiens (human)
negative regulation of cellular organofluorine metabolic process	Cytochrome P450 2D6	Homo sapiens (human)
arachidonic acid metabolic process	Cytochrome P450 2D6	Homo sapiens (human)
xenobiotic metabolic process	Cytochrome P450 2C9	Homo sapiens (human)
steroid metabolic process	Cytochrome P450 2C9	Homo sapiens (human)
cholesterol metabolic process	Cytochrome P450 2C9	Homo sapiens (human)
estrogen metabolic process	Cytochrome P450 2C9	Homo sapiens (human)
monoterpenoid metabolic process	Cytochrome P450 2C9	Homo sapiens (human)
epoxygenase P450 pathway	Cytochrome P450 2C9	Homo sapiens (human)
urea metabolic process	Cytochrome P450 2C9	Homo sapiens (human)
monocarboxylic acid metabolic process	Cytochrome P450 2C9	Homo sapiens (human)
xenobiotic catabolic process	Cytochrome P450 2C9	Homo sapiens (human)
long-chain fatty acid biosynthetic process	Cytochrome P450 2C9	Homo sapiens (human)
amide metabolic process	Cytochrome P450 2C9	Homo sapiens (human)
icosanoid biosynthetic process	Cytochrome P450 2C9	Homo sapiens (human)
oxidative demethylation	Cytochrome P450 2C9	Homo sapiens (human)
omega-hydroxylase P450 pathway	Cytochrome P450 2C9	Homo sapiens (human)
long-chain fatty acid metabolic process	Cytochrome P450 2C19	Homo sapiens (human)
xenobiotic metabolic process	Cytochrome P450 2C19	Homo sapiens (human)
steroid metabolic process	Cytochrome P450 2C19	Homo sapiens (human)
monoterpenoid metabolic process	Cytochrome P450 2C19	Homo sapiens (human)
epoxygenase P450 pathway	Cytochrome P450 2C19	Homo sapiens (human)
xenobiotic catabolic process	Cytochrome P450 2C19	Homo sapiens (human)
omega-hydroxylase P450 pathway	Cytochrome P450 2C19	Homo sapiens (human)
regulation of heart rate by cardiac conduction	Potassium voltage-gated channel subfamily H member 2	Homo sapiens (human)
regulation of heart rate by hormone	Potassium voltage-gated channel subfamily H member 2	Homo sapiens (human)
regulation of membrane potential	Potassium voltage-gated channel subfamily H member 2	Homo sapiens (human)
positive regulation of DNA-templated transcription	Potassium voltage-gated channel subfamily H member 2	Homo sapiens (human)
potassium ion homeostasis	Potassium voltage-gated channel subfamily H member 2	Homo sapiens (human)
cardiac muscle contraction	Potassium voltage-gated channel subfamily H member 2	Homo sapiens (human)
regulation of membrane repolarization	Potassium voltage-gated channel subfamily H member 2	Homo sapiens (human)
regulation of ventricular cardiac muscle cell membrane repolarization	Potassium voltage-gated channel subfamily H member 2	Homo sapiens (human)
cellular response to xenobiotic stimulus	Potassium voltage-gated channel subfamily H member 2	Homo sapiens (human)
potassium ion transmembrane transport	Potassium voltage-gated channel subfamily H member 2	Homo sapiens (human)
ventricular cardiac muscle cell action potential	Potassium voltage-gated channel subfamily H member 2	Homo sapiens (human)
membrane repolarization	Potassium voltage-gated channel subfamily H member 2	Homo sapiens (human)
membrane depolarization during action potential	Potassium voltage-gated channel subfamily H member 2	Homo sapiens (human)
membrane repolarization during action potential	Potassium voltage-gated channel subfamily H member 2	Homo sapiens (human)
membrane repolarization during cardiac muscle cell action potential	Potassium voltage-gated channel subfamily H member 2	Homo sapiens (human)
regulation of heart rate by cardiac conduction	Potassium voltage-gated channel subfamily H member 2	Homo sapiens (human)
potassium ion export across plasma membrane	Potassium voltage-gated channel subfamily H member 2	Homo sapiens (human)
membrane repolarization during ventricular cardiac muscle cell action potential	Potassium voltage-gated channel subfamily H member 2	Homo sapiens (human)
regulation of potassium ion transmembrane transport	Potassium voltage-gated channel subfamily H member 2	Homo sapiens (human)
negative regulation of potassium ion transmembrane transport	Potassium voltage-gated channel subfamily H member 2	Homo sapiens (human)
positive regulation of potassium ion transmembrane transport	Potassium voltage-gated channel subfamily H member 2	Homo sapiens (human)
negative regulation of potassium ion export across plasma membrane	Potassium voltage-gated channel subfamily H member 2	Homo sapiens (human)
potassium ion import across plasma membrane	Potassium voltage-gated channel subfamily H member 2	Homo sapiens (human)
xenobiotic metabolic process	Canalicular multispecific organic anion transporter 1	Homo sapiens (human)
xenobiotic transmembrane transport	Canalicular multispecific organic anion transporter 1	Homo sapiens (human)
negative regulation of gene expression	Canalicular multispecific organic anion transporter 1	Homo sapiens (human)
bile acid and bile salt transport	Canalicular multispecific organic anion transporter 1	Homo sapiens (human)
bilirubin transport	Canalicular multispecific organic anion transporter 1	Homo sapiens (human)
heme catabolic process	Canalicular multispecific organic anion transporter 1	Homo sapiens (human)
xenobiotic export from cell	Canalicular multispecific organic anion transporter 1	Homo sapiens (human)
transmembrane transport	Canalicular multispecific organic anion transporter 1	Homo sapiens (human)
transepithelial transport	Canalicular multispecific organic anion transporter 1	Homo sapiens (human)
leukotriene transport	Canalicular multispecific organic anion transporter 1	Homo sapiens (human)
monoatomic anion transmembrane transport	Canalicular multispecific organic anion transporter 1	Homo sapiens (human)
transport across blood-brain barrier	Canalicular multispecific organic anion transporter 1	Homo sapiens (human)
xenobiotic transport across blood-brain barrier	Canalicular multispecific organic anion transporter 1	Homo sapiens (human)
negative regulation of transcription by RNA polymerase II	Aurora kinase B	Homo sapiens (human)
mitotic cell cycle	Aurora kinase B	Homo sapiens (human)
mitotic cytokinesis	Aurora kinase B	Homo sapiens (human)
negative regulation of B cell apoptotic process	Aurora kinase B	Homo sapiens (human)
protein phosphorylation	Aurora kinase B	Homo sapiens (human)
spindle organization	Aurora kinase B	Homo sapiens (human)
attachment of spindle microtubules to kinetochore	Aurora kinase B	Homo sapiens (human)
abscission	Aurora kinase B	Homo sapiens (human)
negative regulation of protein binding	Aurora kinase B	Homo sapiens (human)
positive regulation of telomere maintenance via telomerase	Aurora kinase B	Homo sapiens (human)
negative regulation of cytokinesis	Aurora kinase B	Homo sapiens (human)
positive regulation of cytokinesis	Aurora kinase B	Homo sapiens (human)
protein localization to kinetochore	Aurora kinase B	Homo sapiens (human)
cellular response to UV	Aurora kinase B	Homo sapiens (human)
cleavage furrow formation	Aurora kinase B	Homo sapiens (human)
post-translational protein modification	Aurora kinase B	Homo sapiens (human)
cell cycle G2/M phase transition	Aurora kinase B	Homo sapiens (human)
mitotic cytokinesis checkpoint signaling	Aurora kinase B	Homo sapiens (human)
negative regulation of innate immune response	Aurora kinase B	Homo sapiens (human)
protein autophosphorylation	Aurora kinase B	Homo sapiens (human)
mitotic spindle midzone assembly	Aurora kinase B	Homo sapiens (human)
positive regulation of telomerase activity	Aurora kinase B	Homo sapiens (human)
regulation of chromosome segregation	Aurora kinase B	Homo sapiens (human)
positive regulation of mitotic sister chromatid segregation	Aurora kinase B	Homo sapiens (human)
positive regulation of mitotic cell cycle spindle assembly checkpoint	Aurora kinase B	Homo sapiens (human)
mitotic spindle assembly	Aurora kinase B	Homo sapiens (human)
negative regulation of cGAS/STING signaling pathway	Aurora kinase B	Homo sapiens (human)
regulation of signal transduction by p53 class mediator	Aurora kinase B	Homo sapiens (human)
positive regulation of mitotic sister chromatid separation	Aurora kinase B	Homo sapiens (human)
positive regulation of attachment of mitotic spindle microtubules to kinetochore	Aurora kinase B	Homo sapiens (human)
positive regulation of mitotic cytokinesis	Aurora kinase B	Homo sapiens (human)
positive regulation of telomere capping	Aurora kinase B	Homo sapiens (human)
positive regulation of lateral attachment of mitotic spindle microtubules to kinetochore	Aurora kinase B	Homo sapiens (human)
mitotic spindle organization	Aurora kinase B	Homo sapiens (human)
regulation of cytokinesis	Aurora kinase B	Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Process	via Protein(s)	Taxonomy
ATP binding	ATP-binding cassette sub-family C member 3	Homo sapiens (human)
ABC-type xenobiotic transporter activity	ATP-binding cassette sub-family C member 3	Homo sapiens (human)
glucuronoside transmembrane transporter activity	ATP-binding cassette sub-family C member 3	Homo sapiens (human)
ABC-type glutathione S-conjugate transporter activity	ATP-binding cassette sub-family C member 3	Homo sapiens (human)
ABC-type bile acid transporter activity	ATP-binding cassette sub-family C member 3	Homo sapiens (human)
ATP hydrolysis activity	ATP-binding cassette sub-family C member 3	Homo sapiens (human)
ATPase-coupled transmembrane transporter activity	ATP-binding cassette sub-family C member 3	Homo sapiens (human)
xenobiotic transmembrane transporter activity	ATP-binding cassette sub-family C member 3	Homo sapiens (human)
ATPase-coupled inorganic anion transmembrane transporter activity	ATP-binding cassette sub-family C member 3	Homo sapiens (human)
icosanoid transmembrane transporter activity	ATP-binding cassette sub-family C member 3	Homo sapiens (human)
ABC-type transporter activity	ATP-binding cassette sub-family C member 3	Homo sapiens (human)
guanine nucleotide transmembrane transporter activity	Multidrug resistance-associated protein 4	Homo sapiens (human)
protein binding	Multidrug resistance-associated protein 4	Homo sapiens (human)
ATP binding	Multidrug resistance-associated protein 4	Homo sapiens (human)
ABC-type xenobiotic transporter activity	Multidrug resistance-associated protein 4	Homo sapiens (human)
prostaglandin transmembrane transporter activity	Multidrug resistance-associated protein 4	Homo sapiens (human)
urate transmembrane transporter activity	Multidrug resistance-associated protein 4	Homo sapiens (human)
purine nucleotide transmembrane transporter activity	Multidrug resistance-associated protein 4	Homo sapiens (human)
ABC-type glutathione S-conjugate transporter activity	Multidrug resistance-associated protein 4	Homo sapiens (human)
ABC-type bile acid transporter activity	Multidrug resistance-associated protein 4	Homo sapiens (human)
efflux transmembrane transporter activity	Multidrug resistance-associated protein 4	Homo sapiens (human)
15-hydroxyprostaglandin dehydrogenase (NAD+) activity	Multidrug resistance-associated protein 4	Homo sapiens (human)
ATP hydrolysis activity	Multidrug resistance-associated protein 4	Homo sapiens (human)
glutathione transmembrane transporter activity	Multidrug resistance-associated protein 4	Homo sapiens (human)
ATPase-coupled transmembrane transporter activity	Multidrug resistance-associated protein 4	Homo sapiens (human)
xenobiotic transmembrane transporter activity	Multidrug resistance-associated protein 4	Homo sapiens (human)
ATPase-coupled inorganic anion transmembrane transporter activity	Multidrug resistance-associated protein 4	Homo sapiens (human)
ABC-type transporter activity	Multidrug resistance-associated protein 4	Homo sapiens (human)
protein binding	Bile salt export pump	Homo sapiens (human)
ATP binding	Bile salt export pump	Homo sapiens (human)
ABC-type xenobiotic transporter activity	Bile salt export pump	Homo sapiens (human)
bile acid transmembrane transporter activity	Bile salt export pump	Homo sapiens (human)
canalicular bile acid transmembrane transporter activity	Bile salt export pump	Homo sapiens (human)
carbohydrate transmembrane transporter activity	Bile salt export pump	Homo sapiens (human)
ABC-type bile acid transporter activity	Bile salt export pump	Homo sapiens (human)
ATP hydrolysis activity	Bile salt export pump	Homo sapiens (human)
glyceraldehyde-3-phosphate dehydrogenase (NAD+) (phosphorylating) activity	Glyceraldehyde-3-phosphate dehydrogenase	Homo sapiens (human)
protein binding	Glyceraldehyde-3-phosphate dehydrogenase	Homo sapiens (human)
microtubule binding	Glyceraldehyde-3-phosphate dehydrogenase	Homo sapiens (human)
aspartic-type endopeptidase inhibitor activity	Glyceraldehyde-3-phosphate dehydrogenase	Homo sapiens (human)
peptidyl-cysteine S-nitrosylase activity	Glyceraldehyde-3-phosphate dehydrogenase	Homo sapiens (human)
identical protein binding	Glyceraldehyde-3-phosphate dehydrogenase	Homo sapiens (human)
NADP binding	Glyceraldehyde-3-phosphate dehydrogenase	Homo sapiens (human)
NAD binding	Glyceraldehyde-3-phosphate dehydrogenase	Homo sapiens (human)
disordered domain specific binding	Glyceraldehyde-3-phosphate dehydrogenase	Homo sapiens (human)
monooxygenase activity	Cytochrome P450 1A2	Homo sapiens (human)
iron ion binding	Cytochrome P450 1A2	Homo sapiens (human)
protein binding	Cytochrome P450 1A2	Homo sapiens (human)
electron transfer activity	Cytochrome P450 1A2	Homo sapiens (human)
oxidoreductase activity	Cytochrome P450 1A2	Homo sapiens (human)
oxidoreductase activity, acting on paired donors, with incorporation or reduction of molecular oxygen, reduced flavin or flavoprotein as one donor, and incorporation of one atom of oxygen	Cytochrome P450 1A2	Homo sapiens (human)
enzyme binding	Cytochrome P450 1A2	Homo sapiens (human)
heme binding	Cytochrome P450 1A2	Homo sapiens (human)
demethylase activity	Cytochrome P450 1A2	Homo sapiens (human)
caffeine oxidase activity	Cytochrome P450 1A2	Homo sapiens (human)
aromatase activity	Cytochrome P450 1A2	Homo sapiens (human)
estrogen 16-alpha-hydroxylase activity	Cytochrome P450 1A2	Homo sapiens (human)
estrogen 2-hydroxylase activity	Cytochrome P450 1A2	Homo sapiens (human)
hydroperoxy icosatetraenoate dehydratase activity	Cytochrome P450 1A2	Homo sapiens (human)
monooxygenase activity	Cytochrome P450 3A4	Homo sapiens (human)
steroid binding	Cytochrome P450 3A4	Homo sapiens (human)
iron ion binding	Cytochrome P450 3A4	Homo sapiens (human)
protein binding	Cytochrome P450 3A4	Homo sapiens (human)
steroid hydroxylase activity	Cytochrome P450 3A4	Homo sapiens (human)
retinoic acid 4-hydroxylase activity	Cytochrome P450 3A4	Homo sapiens (human)
oxidoreductase activity	Cytochrome P450 3A4	Homo sapiens (human)
oxygen binding	Cytochrome P450 3A4	Homo sapiens (human)
enzyme binding	Cytochrome P450 3A4	Homo sapiens (human)
heme binding	Cytochrome P450 3A4	Homo sapiens (human)
vitamin D3 25-hydroxylase activity	Cytochrome P450 3A4	Homo sapiens (human)
caffeine oxidase activity	Cytochrome P450 3A4	Homo sapiens (human)
quinine 3-monooxygenase activity	Cytochrome P450 3A4	Homo sapiens (human)
testosterone 6-beta-hydroxylase activity	Cytochrome P450 3A4	Homo sapiens (human)
1-alpha,25-dihydroxyvitamin D3 23-hydroxylase activity	Cytochrome P450 3A4	Homo sapiens (human)
anandamide 8,9 epoxidase activity	Cytochrome P450 3A4	Homo sapiens (human)
anandamide 11,12 epoxidase activity	Cytochrome P450 3A4	Homo sapiens (human)
anandamide 14,15 epoxidase activity	Cytochrome P450 3A4	Homo sapiens (human)
aromatase activity	Cytochrome P450 3A4	Homo sapiens (human)
vitamin D 24-hydroxylase activity	Cytochrome P450 3A4	Homo sapiens (human)
estrogen 16-alpha-hydroxylase activity	Cytochrome P450 3A4	Homo sapiens (human)
estrogen 2-hydroxylase activity	Cytochrome P450 3A4	Homo sapiens (human)
1,8-cineole 2-exo-monooxygenase activity	Cytochrome P450 3A4	Homo sapiens (human)
monooxygenase activity	Cytochrome P450 2D6	Homo sapiens (human)
iron ion binding	Cytochrome P450 2D6	Homo sapiens (human)
oxidoreductase activity	Cytochrome P450 2D6	Homo sapiens (human)
oxidoreductase activity, acting on paired donors, with incorporation or reduction of molecular oxygen, reduced flavin or flavoprotein as one donor, and incorporation of one atom of oxygen	Cytochrome P450 2D6	Homo sapiens (human)
heme binding	Cytochrome P450 2D6	Homo sapiens (human)
anandamide 8,9 epoxidase activity	Cytochrome P450 2D6	Homo sapiens (human)
anandamide 11,12 epoxidase activity	Cytochrome P450 2D6	Homo sapiens (human)
anandamide 14,15 epoxidase activity	Cytochrome P450 2D6	Homo sapiens (human)
monooxygenase activity	Cytochrome P450 2C9	Homo sapiens (human)
iron ion binding	Cytochrome P450 2C9	Homo sapiens (human)
arachidonic acid epoxygenase activity	Cytochrome P450 2C9	Homo sapiens (human)
steroid hydroxylase activity	Cytochrome P450 2C9	Homo sapiens (human)
arachidonic acid 14,15-epoxygenase activity	Cytochrome P450 2C9	Homo sapiens (human)
arachidonic acid 11,12-epoxygenase activity	Cytochrome P450 2C9	Homo sapiens (human)
oxidoreductase activity	Cytochrome P450 2C9	Homo sapiens (human)
(S)-limonene 6-monooxygenase activity	Cytochrome P450 2C9	Homo sapiens (human)
(S)-limonene 7-monooxygenase activity	Cytochrome P450 2C9	Homo sapiens (human)
caffeine oxidase activity	Cytochrome P450 2C9	Homo sapiens (human)
(R)-limonene 6-monooxygenase activity	Cytochrome P450 2C9	Homo sapiens (human)
aromatase activity	Cytochrome P450 2C9	Homo sapiens (human)
heme binding	Cytochrome P450 2C9	Homo sapiens (human)
oxidoreductase activity, acting on paired donors, with incorporation or reduction of molecular oxygen, reduced flavin or flavoprotein as one donor, and incorporation of one atom of oxygen	Cytochrome P450 2C9	Homo sapiens (human)
monooxygenase activity	Cytochrome P450 2C19	Homo sapiens (human)
iron ion binding	Cytochrome P450 2C19	Homo sapiens (human)
steroid hydroxylase activity	Cytochrome P450 2C19	Homo sapiens (human)
oxidoreductase activity	Cytochrome P450 2C19	Homo sapiens (human)
(S)-limonene 6-monooxygenase activity	Cytochrome P450 2C19	Homo sapiens (human)
(S)-limonene 7-monooxygenase activity	Cytochrome P450 2C19	Homo sapiens (human)
oxygen binding	Cytochrome P450 2C19	Homo sapiens (human)
enzyme binding	Cytochrome P450 2C19	Homo sapiens (human)
heme binding	Cytochrome P450 2C19	Homo sapiens (human)
(R)-limonene 6-monooxygenase activity	Cytochrome P450 2C19	Homo sapiens (human)
aromatase activity	Cytochrome P450 2C19	Homo sapiens (human)
long-chain fatty acid omega-1 hydroxylase activity	Cytochrome P450 2C19	Homo sapiens (human)
arachidonic acid epoxygenase activity	Cytochrome P450 2C19	Homo sapiens (human)
oxidoreductase activity, acting on paired donors, with incorporation or reduction of molecular oxygen, reduced flavin or flavoprotein as one donor, and incorporation of one atom of oxygen	Cytochrome P450 2C19	Homo sapiens (human)
transcription cis-regulatory region binding	Potassium voltage-gated channel subfamily H member 2	Homo sapiens (human)
inward rectifier potassium channel activity	Potassium voltage-gated channel subfamily H member 2	Homo sapiens (human)
voltage-gated potassium channel activity	Potassium voltage-gated channel subfamily H member 2	Homo sapiens (human)
delayed rectifier potassium channel activity	Potassium voltage-gated channel subfamily H member 2	Homo sapiens (human)
protein binding	Potassium voltage-gated channel subfamily H member 2	Homo sapiens (human)
ubiquitin protein ligase binding	Potassium voltage-gated channel subfamily H member 2	Homo sapiens (human)
identical protein binding	Potassium voltage-gated channel subfamily H member 2	Homo sapiens (human)
protein homodimerization activity	Potassium voltage-gated channel subfamily H member 2	Homo sapiens (human)
C3HC4-type RING finger domain binding	Potassium voltage-gated channel subfamily H member 2	Homo sapiens (human)
voltage-gated potassium channel activity involved in cardiac muscle cell action potential repolarization	Potassium voltage-gated channel subfamily H member 2	Homo sapiens (human)
scaffold protein binding	Potassium voltage-gated channel subfamily H member 2	Homo sapiens (human)
voltage-gated potassium channel activity involved in ventricular cardiac muscle cell action potential repolarization	Potassium voltage-gated channel subfamily H member 2	Homo sapiens (human)
protein binding	Canalicular multispecific organic anion transporter 1	Homo sapiens (human)
ATP binding	Canalicular multispecific organic anion transporter 1	Homo sapiens (human)
organic anion transmembrane transporter activity	Canalicular multispecific organic anion transporter 1	Homo sapiens (human)
ABC-type xenobiotic transporter activity	Canalicular multispecific organic anion transporter 1	Homo sapiens (human)
bilirubin transmembrane transporter activity	Canalicular multispecific organic anion transporter 1	Homo sapiens (human)
ABC-type glutathione S-conjugate transporter activity	Canalicular multispecific organic anion transporter 1	Homo sapiens (human)
ATP hydrolysis activity	Canalicular multispecific organic anion transporter 1	Homo sapiens (human)
ATPase-coupled transmembrane transporter activity	Canalicular multispecific organic anion transporter 1	Homo sapiens (human)
xenobiotic transmembrane transporter activity	Canalicular multispecific organic anion transporter 1	Homo sapiens (human)
ATPase-coupled inorganic anion transmembrane transporter activity	Canalicular multispecific organic anion transporter 1	Homo sapiens (human)
ABC-type transporter activity	Canalicular multispecific organic anion transporter 1	Homo sapiens (human)
protein serine/threonine kinase activity	Aurora kinase B	Homo sapiens (human)
protein serine/threonine kinase activity	Aurora kinase B	Homo sapiens (human)
protein serine/threonine/tyrosine kinase activity	Aurora kinase B	Homo sapiens (human)
protein binding	Aurora kinase B	Homo sapiens (human)
ATP binding	Aurora kinase B	Homo sapiens (human)
kinase binding	Aurora kinase B	Homo sapiens (human)
protein serine kinase activity	Aurora kinase B	Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Process	via Protein(s)	Taxonomy
plasma membrane	ATP-binding cassette sub-family C member 3	Homo sapiens (human)
basal plasma membrane	ATP-binding cassette sub-family C member 3	Homo sapiens (human)
basolateral plasma membrane	ATP-binding cassette sub-family C member 3	Homo sapiens (human)
membrane	ATP-binding cassette sub-family C member 3	Homo sapiens (human)
nucleolus	Multidrug resistance-associated protein 4	Homo sapiens (human)
Golgi apparatus	Multidrug resistance-associated protein 4	Homo sapiens (human)
plasma membrane	Multidrug resistance-associated protein 4	Homo sapiens (human)
membrane	Multidrug resistance-associated protein 4	Homo sapiens (human)
basolateral plasma membrane	Multidrug resistance-associated protein 4	Homo sapiens (human)
apical plasma membrane	Multidrug resistance-associated protein 4	Homo sapiens (human)
platelet dense granule membrane	Multidrug resistance-associated protein 4	Homo sapiens (human)
external side of apical plasma membrane	Multidrug resistance-associated protein 4	Homo sapiens (human)
plasma membrane	Multidrug resistance-associated protein 4	Homo sapiens (human)
basolateral plasma membrane	Bile salt export pump	Homo sapiens (human)
Golgi membrane	Bile salt export pump	Homo sapiens (human)
endosome	Bile salt export pump	Homo sapiens (human)
plasma membrane	Bile salt export pump	Homo sapiens (human)
cell surface	Bile salt export pump	Homo sapiens (human)
apical plasma membrane	Bile salt export pump	Homo sapiens (human)
intercellular canaliculus	Bile salt export pump	Homo sapiens (human)
intracellular canaliculus	Bile salt export pump	Homo sapiens (human)
recycling endosome	Bile salt export pump	Homo sapiens (human)
recycling endosome membrane	Bile salt export pump	Homo sapiens (human)
extracellular exosome	Bile salt export pump	Homo sapiens (human)
membrane	Bile salt export pump	Homo sapiens (human)
nucleus	Glyceraldehyde-3-phosphate dehydrogenase	Homo sapiens (human)
cytoplasm	Glyceraldehyde-3-phosphate dehydrogenase	Homo sapiens (human)
lipid droplet	Glyceraldehyde-3-phosphate dehydrogenase	Homo sapiens (human)
cytosol	Glyceraldehyde-3-phosphate dehydrogenase	Homo sapiens (human)
plasma membrane	Glyceraldehyde-3-phosphate dehydrogenase	Homo sapiens (human)
microtubule cytoskeleton	Glyceraldehyde-3-phosphate dehydrogenase	Homo sapiens (human)
membrane	Glyceraldehyde-3-phosphate dehydrogenase	Homo sapiens (human)
nuclear membrane	Glyceraldehyde-3-phosphate dehydrogenase	Homo sapiens (human)
vesicle	Glyceraldehyde-3-phosphate dehydrogenase	Homo sapiens (human)
intracellular membrane-bounded organelle	Glyceraldehyde-3-phosphate dehydrogenase	Homo sapiens (human)
perinuclear region of cytoplasm	Glyceraldehyde-3-phosphate dehydrogenase	Homo sapiens (human)
extracellular exosome	Glyceraldehyde-3-phosphate dehydrogenase	Homo sapiens (human)
GAIT complex	Glyceraldehyde-3-phosphate dehydrogenase	Homo sapiens (human)
ribonucleoprotein complex	Glyceraldehyde-3-phosphate dehydrogenase	Homo sapiens (human)
cytosol	Glyceraldehyde-3-phosphate dehydrogenase	Homo sapiens (human)
endoplasmic reticulum membrane	Cytochrome P450 1A2	Homo sapiens (human)
intracellular membrane-bounded organelle	Cytochrome P450 1A2	Homo sapiens (human)
intracellular membrane-bounded organelle	Cytochrome P450 1A2	Homo sapiens (human)
cytoplasm	Cytochrome P450 3A4	Homo sapiens (human)
endoplasmic reticulum membrane	Cytochrome P450 3A4	Homo sapiens (human)
intracellular membrane-bounded organelle	Cytochrome P450 3A4	Homo sapiens (human)
mitochondrion	Cytochrome P450 2D6	Homo sapiens (human)
endoplasmic reticulum	Cytochrome P450 2D6	Homo sapiens (human)
endoplasmic reticulum membrane	Cytochrome P450 2D6	Homo sapiens (human)
cytoplasm	Cytochrome P450 2D6	Homo sapiens (human)
intracellular membrane-bounded organelle	Cytochrome P450 2D6	Homo sapiens (human)
endoplasmic reticulum membrane	Cytochrome P450 2C9	Homo sapiens (human)
plasma membrane	Cytochrome P450 2C9	Homo sapiens (human)
intracellular membrane-bounded organelle	Cytochrome P450 2C9	Homo sapiens (human)
cytoplasm	Cytochrome P450 2C9	Homo sapiens (human)
intracellular membrane-bounded organelle	Cytochrome P450 2C9	Homo sapiens (human)
endoplasmic reticulum membrane	Cytochrome P450 2C19	Homo sapiens (human)
plasma membrane	Cytochrome P450 2C19	Homo sapiens (human)
intracellular membrane-bounded organelle	Cytochrome P450 2C19	Homo sapiens (human)
intracellular membrane-bounded organelle	Cytochrome P450 2C19	Homo sapiens (human)
cytoplasm	Cytochrome P450 2C19	Homo sapiens (human)
plasma membrane	Potassium voltage-gated channel subfamily H member 2	Homo sapiens (human)
cell surface	Potassium voltage-gated channel subfamily H member 2	Homo sapiens (human)
perinuclear region of cytoplasm	Potassium voltage-gated channel subfamily H member 2	Homo sapiens (human)
voltage-gated potassium channel complex	Potassium voltage-gated channel subfamily H member 2	Homo sapiens (human)
inward rectifier potassium channel complex	Potassium voltage-gated channel subfamily H member 2	Homo sapiens (human)
plasma membrane	Potassium voltage-gated channel subfamily H member 2	Homo sapiens (human)
plasma membrane	Canalicular multispecific organic anion transporter 1	Homo sapiens (human)
cell surface	Canalicular multispecific organic anion transporter 1	Homo sapiens (human)
apical plasma membrane	Canalicular multispecific organic anion transporter 1	Homo sapiens (human)
intercellular canaliculus	Canalicular multispecific organic anion transporter 1	Homo sapiens (human)
apical plasma membrane	Canalicular multispecific organic anion transporter 1	Homo sapiens (human)
kinetochore	Aurora kinase B	Homo sapiens (human)
condensed chromosome, centromeric region	Aurora kinase B	Homo sapiens (human)
nucleus	Aurora kinase B	Homo sapiens (human)
nucleoplasm	Aurora kinase B	Homo sapiens (human)
spindle	Aurora kinase B	Homo sapiens (human)
cytosol	Aurora kinase B	Homo sapiens (human)
chromocenter	Aurora kinase B	Homo sapiens (human)
microtubule cytoskeleton	Aurora kinase B	Homo sapiens (human)
midbody	Aurora kinase B	Homo sapiens (human)
chromosome passenger complex	Aurora kinase B	Homo sapiens (human)
mitotic spindle pole	Aurora kinase B	Homo sapiens (human)
mitotic spindle midzone	Aurora kinase B	Homo sapiens (human)
kinetochore	Aurora kinase B	Homo sapiens (human)
spindle pole centrosome	Aurora kinase B	Homo sapiens (human)
spindle microtubule	Aurora kinase B	Homo sapiens (human)
spindle midzone	Aurora kinase B	Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Bioassays (1875)

Assay ID	Title	Year	Journal	Article
AID588499	High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set	2010	Current protocols in cytometry, Oct, Volume: Chapter 13	Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening.
AID588499	High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set	2006	Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5	Microsphere-based protease assays and screening application for lethal factor and factor Xa.
AID588499	High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set	2010	Assay and drug development technologies, Feb, Volume: 8, Issue:1	High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors.
AID588497	High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set	2010	Current protocols in cytometry, Oct, Volume: Chapter 13	Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening.
AID588497	High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set	2006	Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5	Microsphere-based protease assays and screening application for lethal factor and factor Xa.
AID588497	High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set	2010	Assay and drug development technologies, Feb, Volume: 8, Issue:1	High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors.
AID1745845	Primary qHTS for Inhibitors of ATXN expression
AID588501	High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set	2010	Current protocols in cytometry, Oct, Volume: Chapter 13	Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening.
AID588501	High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set	2006	Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5	Microsphere-based protease assays and screening application for lethal factor and factor Xa.
AID588501	High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set	2010	Assay and drug development technologies, Feb, Volume: 8, Issue:1	High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors.
AID504810	Antagonists of the Thyroid Stimulating Hormone Receptor: HTS campaign	2010	Endocrinology, Jul, Volume: 151, Issue:7	A small molecule inverse agonist for the human thyroid-stimulating hormone receptor.
AID651635	Viability Counterscreen for Primary qHTS for Inhibitors of ATXN expression
AID504812	Inverse Agonists of the Thyroid Stimulating Hormone Receptor: HTS campaign	2010	Endocrinology, Jul, Volume: 151, Issue:7	A small molecule inverse agonist for the human thyroid-stimulating hormone receptor.
AID1296008	Cytotoxic Profiling of Annotated Libraries Using Quantitative High-Throughput Screening	2020	SLAS discovery : advancing life sciences R & D, 01, Volume: 25, Issue:1	Cytotoxic Profiling of Annotated and Diverse Chemical Libraries Using Quantitative High-Throughput Screening.
AID1346987	P-glycoprotein substrates identified in KB-8-5-11 adenocarcinoma cell line, qHTS therapeutic library screen	2019	Molecular pharmacology, 11, Volume: 96, Issue:5	A High-Throughput Screen of a Library of Therapeutics Identifies Cytotoxic Substrates of P-glycoprotein.
AID1346986	P-glycoprotein substrates identified in KB-3-1 adenocarcinoma cell line, qHTS therapeutic library screen	2019	Molecular pharmacology, 11, Volume: 96, Issue:5	A High-Throughput Screen of a Library of Therapeutics Identifies Cytotoxic Substrates of P-glycoprotein.
AID1347113	qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Confirmatory screen for LAN-5 cells	2018	Oncotarget, Jan-12, Volume: 9, Issue:4	Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347124	qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Confirmatory screen for RD cells	2018	Oncotarget, Jan-12, Volume: 9, Issue:4	Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347128	qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Confirmatory screen for OHS-50 cells	2018	Oncotarget, Jan-12, Volume: 9, Issue:4	Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347093	qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for SK-N-MC cells	2018	Oncotarget, Jan-12, Volume: 9, Issue:4	Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347114	qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Confirmatory screen for DAOY cells	2018	Oncotarget, Jan-12, Volume: 9, Issue:4	Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347118	qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Confirmatory screen for TC32 cells	2018	Oncotarget, Jan-12, Volume: 9, Issue:4	Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347098	qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for SK-N-SH cells	2018	Oncotarget, Jan-12, Volume: 9, Issue:4	Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347089	qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for TC32 cells	2018	Oncotarget, Jan-12, Volume: 9, Issue:4	Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347105	qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for MG 63 (6-TG R) cells	2018	Oncotarget, Jan-12, Volume: 9, Issue:4	Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347127	qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Confirmatory screen for Saos-2 cells	2018	Oncotarget, Jan-12, Volume: 9, Issue:4	Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347099	qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for NB1643 cells	2018	Oncotarget, Jan-12, Volume: 9, Issue:4	Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347082	qHTS for Inhibitors of the Functional Ribonucleoprotein Complex (vRNP) of Lassa (LASV) Arenavirus: LASV Primary Screen - GLuc reporter signal	2020	Antiviral research, 01, Volume: 173	A cell-based, infectious-free, platform to identify inhibitors of lassa virus ribonucleoprotein (vRNP) activity.
AID1347083	qHTS for Inhibitors of the Functional Ribonucleoprotein Complex (vRNP) of Lassa (LASV) Arenavirus: Viability assay - alamar blue signal for LASV Primary Screen	2020	Antiviral research, 01, Volume: 173	A cell-based, infectious-free, platform to identify inhibitors of lassa virus ribonucleoprotein (vRNP) activity.
AID1347103	qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for OHS-50 cells	2018	Oncotarget, Jan-12, Volume: 9, Issue:4	Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347108	qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for Rh41 cells	2018	Oncotarget, Jan-12, Volume: 9, Issue:4	Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347129	qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Confirmatory screen for SK-N-SH cells	2018	Oncotarget, Jan-12, Volume: 9, Issue:4	Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347111	qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Confirmatory screen for SK-N-MC cells	2018	Oncotarget, Jan-12, Volume: 9, Issue:4	Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347092	qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for A673 cells	2018	Oncotarget, Jan-12, Volume: 9, Issue:4	Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347110	qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Confirmatory screen for A673 cells)	2018	Oncotarget, Jan-12, Volume: 9, Issue:4	Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347122	qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Confirmatory screen for U-2 OS cells	2018	Oncotarget, Jan-12, Volume: 9, Issue:4	Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347106	qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for control Hh wild type fibroblast cells	2018	Oncotarget, Jan-12, Volume: 9, Issue:4	Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347407	qHTS to identify inhibitors of the type 1 interferon - major histocompatibility complex class I in skeletal muscle: primary screen against the NCATS Pharmaceutical Collection	2020	ACS chemical biology, 07-17, Volume: 15, Issue:7	High-Throughput Screening to Identify Inhibitors of the Type I Interferon-Major Histocompatibility Complex Class I Pathway in Skeletal Muscle.
AID1347125	qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Confirmatory screen for Rh18 cells	2018	Oncotarget, Jan-12, Volume: 9, Issue:4	Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347104	qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for RD cells	2018	Oncotarget, Jan-12, Volume: 9, Issue:4	Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347102	qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for Rh18 cells	2018	Oncotarget, Jan-12, Volume: 9, Issue:4	Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347096	qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for U-2 OS cells	2018	Oncotarget, Jan-12, Volume: 9, Issue:4	Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347109	qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Confirmatory screen for NB1643 cells	2018	Oncotarget, Jan-12, Volume: 9, Issue:4	Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347095	qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for NB-EBc1 cells	2018	Oncotarget, Jan-12, Volume: 9, Issue:4	Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347425	Rhodamine-PBP qHTS Assay for Modulators of WT P53-Induced Phosphatase 1 (WIP1)	2019	The Journal of biological chemistry, 11-15, Volume: 294, Issue:46	Physiologically relevant orthogonal assays for the discovery of small-molecule modulators of WIP1 phosphatase in high-throughput screens.
AID1347121	qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Confirmatory screen for control Hh wild type fibroblast cells	2018	Oncotarget, Jan-12, Volume: 9, Issue:4	Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347115	qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Confirmatory screen for NB-EBc1 cells	2018	Oncotarget, Jan-12, Volume: 9, Issue:4	Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347086	qHTS for Inhibitors of the Functional Ribonucleoprotein Complex (vRNP) of Lymphocytic Choriomeningitis Arenaviruses (LCMV): LCMV Primary Screen - GLuc reporter signal	2020	Antiviral research, 01, Volume: 173	A cell-based, infectious-free, platform to identify inhibitors of lassa virus ribonucleoprotein (vRNP) activity.
AID1347090	qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for DAOY cells	2018	Oncotarget, Jan-12, Volume: 9, Issue:4	Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347126	qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Confirmatory screen for Rh30 cells	2018	Oncotarget, Jan-12, Volume: 9, Issue:4	Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347091	qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for SJ-GBM2 cells	2018	Oncotarget, Jan-12, Volume: 9, Issue:4	Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347094	qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for BT-37 cells	2018	Oncotarget, Jan-12, Volume: 9, Issue:4	Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347117	qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Confirmatory screen for BT-37 cells	2018	Oncotarget, Jan-12, Volume: 9, Issue:4	Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347119	qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Confirmatory screen for MG 63 (6-TG R) cells	2018	Oncotarget, Jan-12, Volume: 9, Issue:4	Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347154	Primary screen GU AMC qHTS for Zika virus inhibitors	2020	Proceedings of the National Academy of Sciences of the United States of America, 12-08, Volume: 117, Issue:49	Therapeutic candidates for the Zika virus identified by a high-throughput screen for Zika protease inhibitors.
AID1347116	qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Confirmatory screen for SJ-GBM2 cells	2018	Oncotarget, Jan-12, Volume: 9, Issue:4	Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1508630	Primary qHTS for small molecule stabilizers of the endoplasmic reticulum resident proteome: Secreted ER Calcium Modulated Protein (SERCaMP) assay	2021	Cell reports, 04-27, Volume: 35, Issue:4	A target-agnostic screen identifies approved drugs to stabilize the endoplasmic reticulum-resident proteome.
AID1347112	qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Confirmatory screen for BT-12 cells	2018	Oncotarget, Jan-12, Volume: 9, Issue:4	Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347097	qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for Saos-2 cells	2018	Oncotarget, Jan-12, Volume: 9, Issue:4	Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347100	qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for LAN-5 cells	2018	Oncotarget, Jan-12, Volume: 9, Issue:4	Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347107	qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for Rh30 cells	2018	Oncotarget, Jan-12, Volume: 9, Issue:4	Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347424	RapidFire Mass Spectrometry qHTS Assay for Modulators of WT P53-Induced Phosphatase 1 (WIP1)	2019	The Journal of biological chemistry, 11-15, Volume: 294, Issue:46	Physiologically relevant orthogonal assays for the discovery of small-molecule modulators of WIP1 phosphatase in high-throughput screens.
AID1347101	qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for BT-12 cells	2018	Oncotarget, Jan-12, Volume: 9, Issue:4	Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347123	qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Confirmatory screen for Rh41 cells	2018	Oncotarget, Jan-12, Volume: 9, Issue:4	Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1687779	Selectivity index, ratio of GI50 for human HepG2 cells assessed as reduction in cell viability measured after 24 hrs by WST1 assay to IC50 for antitrypanosomal activity against bloodstream form of Trypanosoma cruzi Y trypomastigotes infected in African gr	2020	European journal of medicinal chemistry, Jan-15, Volume: 186	Novel nitroimidazole derivatives evaluated for their trypanocidal, cytotoxic, and genotoxic activities.
AID547274	Immunostimulatory activity in mongrel dog infected with Trypanosoma cruzi Berenice-78 assessed as production of antibody IgG2 at 7 mg/kg, po BID for 90 days measured after 6 months by ELISA	2010	Antimicrobial agents and chemotherapy, Jul, Volume: 54, Issue:7	Effects of ravuconazole treatment on parasite load and immune response in dogs experimentally infected with Trypanosoma cruzi.
AID707764	Antitrypanosomal activity against Trypanosoma cruzi IRHOD/VO/2008/SN3 metacyclic forms infected in BALB/c mouse model of acute Chagas disease assessed as reduction parasitemia at 5 mg/kg/day, ip administered for 5 consecutive days starting on day 7 post i	2012	Journal of medicinal chemistry, Nov-26, Volume: 55, Issue:22	Phthalazine derivatives containing imidazole rings behave as Fe-SOD inhibitors and show remarkable anti-T. cruzi activity in immunodeficient-mouse mode of infection.
AID341607	Antimicrobial activity against Babesia divergens 4201	2007	Antimicrobial agents and chemotherapy, Aug, Volume: 51, Issue:8	Peroxide bond-dependent antiplasmodial specificity of artemisinin and OZ277 (RBx11160).
AID496817	Antimicrobial activity against Trypanosoma cruzi	2010	Bioorganic & medicinal chemistry, Mar-15, Volume: 18, Issue:6	Multi-target spectral moment QSAR versus ANN for antiparasitic drugs against different parasite species.
AID1281434	Induction of apoptosis in trypamostigote form of Trypanosoma cruzi Y assessed as late apoptotic cells at 25 uM after 24 hrs by Annexin V-FITC/propidium iodide staining based flow cytometry relative to untreated control	2016	European journal of medicinal chemistry, Mar-23, Volume: 111	Phthalimido-thiazoles as building blocks and their effects on the growth and morphology of Trypanosoma cruzi.
AID426304	Antiparasitic activity against Trichomonas vaginalis GT3 trophozoites after 48 hrs by Hill culture method	2009	European journal of medicinal chemistry, Jul, Volume: 44, Issue:7	Synthesis and in vitro trichomonicidal, giardicidal and amebicidal activity of N-acetamide(sulfonamide)-2-methyl-4-nitro-1H-imidazoles.
AID576949	Antimicrobial activity against Trypanosoma cruzi Tulahuen infected in Swiss mouse assessed as reduction in parasite specific antibodies at 60 mg/kg/day, po for 6 days per week until completion of 60 compound doses administered 5 days post infection measur	2010	Antimicrobial agents and chemotherapy, Sep, Volume: 54, Issue:9	Hydroxymethylnitrofurazone is active in a murine model of Chagas' disease.
AID1518999	Antitrypanosomal activity against Trypanosoma cruzi K98 bloodstream form infected in C3H/HeNk mouse assessed as effect on PR interval at 30 to 75 mg/kg/day, po administered via gavage for 30 consecutive days starting from 90 days post infection and measur	2019	European journal of medicinal chemistry, 12-15, Volume: 184	Combined therapy with Benznidazole and repurposed drugs Clofazimine and Benidipine for chronic Chagas disease.
AID576831	Antitrypanosomal activity against Trypanosoma cruzi infected in african green monkey Vero cells assessed as reduction of parasite infection rate at IC25 after 10 days	2011	Journal of medicinal chemistry, Feb-24, Volume: 54, Issue:4	In vivo trypanosomicidal activity of imidazole- or pyrazole-based benzo[g]phthalazine derivatives against acute and chronic phases of Chagas disease.
AID1854942	Induction of cell death in Trypanosoma cruzi Y epimastigotes assessed as early apoptotic cells at 125 uM incubated for 24 hrs by Annexin V/7-AAD staining based flow cytometric analysis (Rvb = 0.11 %)	2022	European journal of medicinal chemistry, Nov-05, Volume: 241	Rational design of a trypanocidal peptide derived from Dinoponera quadriceps venom.
AID1683675	Toxicity in BALB/c mouse infected with Trypanosomal Trypanosoma cruzi MHOM/Pe/2011/Arequipa(DTU V) assessed as effect on ASG/GOT level at 20 mg/kg, po administered for 5 days starting at 100 days post infection and measured after 2 days post treatment	2020	Journal of natural products, 12-24, Volume: 83, Issue:12	In Vivo Biological Evaluation of a Synthetic Royleanone Derivative as a Promising Fast-Acting Trypanocidal Agent by Inducing Mitochondrial-Dependent Necrosis.
AID1240904	Antitrypanosomal activity against trypomastigote forms of Trypanosoma cruzi Tulahuen C4 expressing LacZ gene infected in rat L6 cells after 96 hrs by inverted microscope analysis	2015	Journal of medicinal chemistry, Aug-27, Volume: 58, Issue:16	2-Phenoxy-1,4-naphthoquinones: From a Multitarget Antitrypanosomal to a Potential Antitumor Profile.
AID1615012	Trypanocidal activity against Trypanosoma cruzi MHOM/Pe/2011/Arequipa DTU 5 epimastigotes after 72 hrs by resazurin dye based assay	2019	Bioorganic & medicinal chemistry, 03-01, Volume: 27, Issue:5	Synthesis and biological evaluation of new long-chain squaramides as anti-chagasic agents in the BALB/c mouse model.
AID776316	Antiparasitic activity against Trypanosoma cruzi amastigotes after 3 days by fluorescence assay	2013	European journal of medicinal chemistry, Nov, Volume: 69	Design, synthesis and biological evaluation of WC-9 analogs as antiparasitic agents.
AID263381	Unspecific cytotoxicity against murine J774 macrophages at 1 ug/ml	2006	Bioorganic & medicinal chemistry letters, Apr-01, Volume: 16, Issue:7	New ligand-based approach for the discovery of antitrypanosomal compounds.
AID1543105	Antitrypanosomal activity against Trypanosoma cruzi Y trypomastigotes infected in LLC-MK2-ATCC CCL7 cells assessed as reduction in parasite growth incubated for 24 hrs by Alamar blue dye based assay	2019	Bioorganic & medicinal chemistry letters, 06-15, Volume: 29, Issue:12	Structure-activity relationship study of antitrypanosomal chalcone derivatives using multivariate analysis.
AID1603753	Antitrypanosomal activity against Trypanosoma cruzi TINF/CH/1956/Tulahuen;DTU 6 epimastigotes measured after 72 hrs by Neubauer hemocytometer	2019	Bioorganic & medicinal chemistry, 09-01, Volume: 27, Issue:17	Rational modification of Mannich base-type derivatives as novel antichagasic compounds: Synthesis, in vitro and in vivo evaluation.
AID576102	Toxicity in human patient infected with Trypanosoma cruzi assessed as occurrence of Vomiting at 5 mg/kg/day for 60 days	2010	Antimicrobial agents and chemotherapy, Nov, Volume: 54, Issue:11	Tolerance of benznidazole in treatment of Chagas' disease in adults.
AID367083	Antitrypanosomal activity against trypomastigotes of Trypanosoma cruzi Tulahuen C2C4 containing lacZ gene in rat L6 cells after 4 days	2009	Bioorganic & medicinal chemistry letters, Feb-01, Volume: 19, Issue:3	Synthesis, in vitro antitrypanosomal and antibacterial activity of phenoxy, phenylthio or benzyloxy substituted quinolones.
AID364956	Antitrypanosomal activity against Trypanosoma cruzi Tulahuen 2 assessed as inhibition of epimastigotes growth after 5 days by MTT assay relative to control	2008	Bioorganic & medicinal chemistry, Sep-01, Volume: 16, Issue:17	Furoxan-, alkylnitrate-derivatives and related compounds as anti-trypanosomatid agents: mechanism of action studies.
AID596493	Antiparasitic activity against Trypanosoma cruzi Tulahuen C4 amastigotes	2011	Journal of natural products, Apr-25, Volume: 74, Issue:4	Marinoquinolines A-F, pyrroloquinolines from Ohtaekwangia kribbensis (Bacteroidetes).
AID1584768	Antiparasitic activity against Trypanosoma cruzi Y strain bloodstream trypomastigotes infected in Swiss Webster mouse assessed as protection against parasite-induced mortality at 100 mg/kg, po sid via gavage administered for 5 consecutive days starting fr	2018	Journal of medicinal chemistry, 10-25, Volume: 61, Issue:20	Discovery of Novel 7-Aryl 7-Deazapurine 3'-Deoxy-ribofuranosyl Nucleosides with Potent Activity against Trypanosoma cruzi.
AID213669	In vitro growth inhibition of epimastigotes of Trypanosoma cruzi	2004	Bioorganic & medicinal chemistry letters, Jul-05, Volume: 14, Issue:13	Toxic effects of natural piperine and its derivatives on epimastigotes and amastigotes of Trypanosoma cruzi.
AID1706434	Cytotoxicity against rat 3T3 cells assessed as reduction in cell viability incubated for 72 hrs by alamar blue assay	2020	European journal of medicinal chemistry, Dec-01, Volume: 207	Re-evaluating pretomanid analogues for Chagas disease: Hit-to-lead studies reveal both in vitro and in vivo trypanocidal efficacy.
AID396021	Antimicrobial activity against Trypanosoma cruzi genotype 20 and genotype 19 dually infected in BALB/c mouse assessed as cure rate	2007	Antimicrobial agents and chemotherapy, Sep, Volume: 51, Issue:9	Impact of dual infections on chemotherapeutic efficacy in BALB/c mice infected with major genotypes of Trypanosoma cruzi.
AID1498335	Hepatotoxicity in Balb/c mouse infected with Trypanosoma cruzi MHOM/Pe/2011/Arequipa DTU 5 trypamastigotes assessed as increase in total bilirubin level at 20 mg/kg, po once daily for 5 consecutive days starting from day 75 post infection measured on day	2018	Journal of medicinal chemistry, 07-12, Volume: 61, Issue:13	Second Generation of Mannich Base-Type Derivatives with in Vivo Activity against Trypanosoma cruzi.
AID1812898	Antitrypanosomal activity against Trypanosoma cruzi infected in mouse C2C12 cells incubated for 2 days by DAPI staining based microscopic analysis	2021	Journal of medicinal chemistry, 08-12, Volume: 64, Issue:15	Self-Masked Aldehyde Inhibitors: A Novel Strategy for Inhibiting Cysteine Proteases.
AID1615030	Selectivity index, ratio of IC50 for African green monkey Vero cells to IC50 for Trypanosoma cruzi TINF/CH/1956/Tulahuen DTU 6 trypomastigotes derived from infected Balb/c mouse	2019	Bioorganic & medicinal chemistry, 03-01, Volume: 27, Issue:5	Synthesis and biological evaluation of new long-chain squaramides as anti-chagasic agents in the BALB/c mouse model.
AID337138	Antitrypanosomal activity against Trypanosoma cruzi 13379 CL5 after 48 hrs
AID1403392	Trypanocidal activity against infected Swiss Webster mouse derived bloodstream form of Trypanosoma cruzi Y after 24 hrs by cell-titer-glo assay	2018	European journal of medicinal chemistry, Jan-20, Volume: 144	Efficacy of 2-hydroxy-3-phenylsulfanylmethyl-[1,4]-naphthoquinone derivatives against different Trypanosoma cruzi discrete type units: Identification of a promising hit compound.
AID1592306	Selectivity index, ratio of CC50 for mouse J774.A1 cells to IC50 for antitrypanosomal activity against Trypanosoma cruzi MHOM/MX/1994/INC5 epimastigotes
AID1361362	Trypanocidal activity against trypomastigote stage of Trypanosoma cruzi NINOA infected in NIH mouse blood assessed as parasite lysis at 10 ug/ml after 24 hrs by optical microscopic method relative to control	2018	European journal of medicinal chemistry, Aug-05, Volume: 156	Synthesis, molecular docking and biological evaluation of novel phthaloyl derivatives of 3-amino-3-aryl propionic acids as inhibitors of Trypanosoma cruzi trans-sialidase.
AID576830	Selectivity index, ratio of IC50 for african green monkey Vero cells to IC50 for epimastigote of Trypanosoma cruzi Maracay	2011	Journal of medicinal chemistry, Feb-24, Volume: 54, Issue:4	In vivo trypanosomicidal activity of imidazole- or pyrazole-based benzo[g]phthalazine derivatives against acute and chronic phases of Chagas disease.
AID1686727	Genotoxicity in Salmonella typhimurium in presence of metabolic activation by SOS/umu test	2016	Journal of medicinal chemistry, 12-22, Volume: 59, Issue:24	In Vitro and in Vivo Anti-Trypanosoma cruzi Activity of New Arylamine Mannich Base-Type Derivatives.
AID1403410	Therapeutic index, ratio of CC50 for Swiss Webster mouse cardiomyocytes to IC50 for Trypanosoma cruzi Y intracellular amastigotes infected in Swiss Webster mouse cardiomyocytes	2018	European journal of medicinal chemistry, Jan-20, Volume: 144	Efficacy of 2-hydroxy-3-phenylsulfanylmethyl-[1,4]-naphthoquinone derivatives against different Trypanosoma cruzi discrete type units: Identification of a promising hit compound.
AID285209	Mortality rate in Trypanosoma cruzi Y infected IL12 knock out C57BL/6 mouse Chagas disease model at 100 mg/kg, po after 20 days	2007	Antimicrobial agents and chemotherapy, Apr, Volume: 51, Issue:4	The Anti-Trypanosoma cruzi activity of posaconazole in a murine model of acute Chagas' disease is less dependent on gamma interferon than that of benznidazole.
AID1498349	Hepatotoxicity in Balb/c mouse infected with Trypanosoma cruzi MHOM/Pe/2011/Arequipa DTU 5 trypamastigotes assessed as increase in alkaline phosphatase level at 20 mg/kg, po once daily for 5 consecutive days starting from day 75 post infection measured on	2018	Journal of medicinal chemistry, 07-12, Volume: 61, Issue:13	Second Generation of Mannich Base-Type Derivatives with in Vivo Activity against Trypanosoma cruzi.
AID1403391	Trypanocidal activity against Trypanosoma cruzi Y trypomastigotes infected in monkey LLC-MK2 cells after 24 hrs by cell-titer-glo assay	2018	European journal of medicinal chemistry, Jan-20, Volume: 144	Efficacy of 2-hydroxy-3-phenylsulfanylmethyl-[1,4]-naphthoquinone derivatives against different Trypanosoma cruzi discrete type units: Identification of a promising hit compound.
AID1498232	Antitrypanosomal activity against Trypanosoma cruzi MHOM/Pe/2011/Arequipa DTU 5 trypamastigotes infected in Balb/c mouse assessed as reduction in parasitaemia reactivation in heart tissue at 20 mg/kg, po pretreated once daily for 5 consecutive days starti	2018	Journal of medicinal chemistry, 07-12, Volume: 61, Issue:13	Second Generation of Mannich Base-Type Derivatives with in Vivo Activity against Trypanosoma cruzi.
AID456260	Antitrypanosomal activity against Trypanosoma cruzi infected in rat L6 cells	2010	Bioorganic & medicinal chemistry, Jan-01, Volume: 18, Issue:1	Synthesis, stereoelectronic characterization and antiparasitic activity of new 1-benzenesulfonyl-2-methyl-1,2,3,4-tetrahydroquinolines.
AID726229	Antitrypanosomal activity against Trypanosoma cruzi Y epimastigotes at 256 uM incubated for 48 hrs by resazurin dye reduction based ELISA method	2013	Journal of medicinal chemistry, Feb-28, Volume: 56, Issue:4	Cloning, characterization, and sulfonamide and thiol inhibition studies of an α-carbonic anhydrase from Trypanosoma cruzi, the causative agent of Chagas disease.
AID576828	Antitrypanosomal activity against epimastigote of Trypanosoma cruzi Maracay after 72 hrs	2011	Journal of medicinal chemistry, Feb-24, Volume: 54, Issue:4	In vivo trypanosomicidal activity of imidazole- or pyrazole-based benzo[g]phthalazine derivatives against acute and chronic phases of Chagas disease.
AID1281412	Cytotoxicity against BALB/c mouse splenocytes assessed as highest non-toxic concentration causing >90 % incorporation of [3H]-thymidine after 24 hrs by beta counting method	2016	European journal of medicinal chemistry, Mar-23, Volume: 111	Phthalimido-thiazoles as building blocks and their effects on the growth and morphology of Trypanosoma cruzi.
AID344432	Antiproliferative activity against Trypanosoma cruzi Y epimastigotes assessed as number of motile forms at 1 mM after 4 hrs by hemocytometer	2008	Journal of medicinal chemistry, Jul-24, Volume: 51, Issue:14	Complexation of the anti-Trypanosoma cruzi drug benznidazole improves solubility and efficacy.
AID1072682	Antitrypanosomal activity against Trypanosoma cruzi Y metacyclic trypomastigotes isolated from infected LLC-MK2 cells assessed as parasite viability after 24 hrs by neubauer chamber analysis	2014	European journal of medicinal chemistry, Mar-21, Volume: 75	Conformational restriction of aryl thiosemicarbazones produces potent and selective anti-Trypanosoma cruzi compounds which induce apoptotic parasite death.
AID1154403	Antitrypanosomal activity against blood stage trypomastigote form of Trypanosoma cruzi Y infected in BALB/c mouse assessed as reduction of blood parasitemia at 100 mg/kg, po qd administered for 5 days relative to control	2014	Journal of natural products, Jun-27, Volume: 77, Issue:6	Dimeric flavonoids from Arrabidaea brachypoda and assessment of their anti-Trypanosoma cruzi activity.
AID1278153	Selectivity index, ratio of CC50 for mouse NCTC-292 cells to IC50 for Trypanosoma cruzi Y amastigotes	2016	Bioorganic & medicinal chemistry letters, Feb-15, Volume: 26, Issue:4	Gibbilimbol analogues as antiparasitic agents--Synthesis and biological activity against Trypanosoma cruzi and Leishmania (L.) infantum.
AID1603771	Selectivity index, ratio of IC50 for African green monkey Vero cells to IC50 for Trypanosoma cruzi TINF/CH/1956/Tulahuen;DTU 6 amastigote forms	2019	Bioorganic & medicinal chemistry, 09-01, Volume: 27, Issue:17	Rational modification of Mannich base-type derivatives as novel antichagasic compounds: Synthesis, in vitro and in vivo evaluation.
AID1432287	Growth inhibition of Trypanosoma cruzi Tulahuen amastigote forms infected in human THP1 cells at 20 uM after 48 hrs relative to control	2017	European journal of medicinal chemistry, Mar-10, Volume: 128	Design and synthesis of a new series of 3,5-disubstituted isoxazoles active against Trypanosoma cruzi and Leishmania amazonensis.
AID1615127	Hepatotoxicity in Balb/c mouse infected with Trypanosoma cruzi MHOM/Pe/2011/Arequipa DTU 5 trypomastigotes assessed as increase in alkaline phosphatase level at 20 mg/kg, po once daily for 5 consecutive days starting from day 75 post infection measured on	2019	Bioorganic & medicinal chemistry, 03-01, Volume: 27, Issue:5	Synthesis and biological evaluation of new long-chain squaramides as anti-chagasic agents in the BALB/c mouse model.
AID364961	Antileishmanial activity against Leishmania pifanoi MHOM/VE/57/LV135 assessed as parasite viability after 5 days by MTT assay	2008	Bioorganic & medicinal chemistry, Sep-01, Volume: 16, Issue:17	Furoxan-, alkylnitrate-derivatives and related compounds as anti-trypanosomatid agents: mechanism of action studies.
AID1613510	Antitrypanosomal activity against Trypanosoma cruzi MHOM/Pe/2011/Arequipa DTU 5 trypomastigotes infected in Balb/c mouse assessed as reduction in splenomegaly at 20 mg/kg, po once daily for 5 consecutive days starting from day 75 post infection measured o	2019	European journal of medicinal chemistry, Feb-15, Volume: 164	New polyamine drugs as more effective antichagas agents than benznidazole in both the acute and chronic phases.
AID1588483	Antiparasitic activity against Trypanosoma cruzi amastigote infected in African green monkey Vero cells decrease in parasite viability measured at day 3 of post infection by red fluorescent protein based fluorescence method	2019	Bioorganic & medicinal chemistry, 08-15, Volume: 27, Issue:16	Synthesis and biological evaluation of 1-alkylaminomethyl-1,1-bisphosphonic acids against Trypanosoma cruzi and Toxoplasma gondii.
AID1879377	Antitrypanosomal activity against intracellular Trypanosoma cruzi Tulahuen amastigotes expressing CL2 beta-galactosidase in human MRC5 cells assessed as parasite growth inhibition using chlorophenol red beta-D-galactopyranoside as substrate treated for 7	2022	European journal of medicinal chemistry, Mar-05, Volume: 231	N
AID1569971	Antitrypanosomal activity against bloodstream form of Trypanosoma cruzi trypomastigotes after 24 hrs by Neubauer chamber method	2019	European journal of medicinal chemistry, Oct-15, Volume: 180	2-(phenylthio)ethylidene derivatives as anti-Trypanosoma cruzi compounds: Structural design, synthesis and antiparasitic activity.
AID1233721	Antiparasite activity against Trypanosoma cruzi Tulahuen expressing beta-galactosidase assessed as growth inhibition incubated for 96 hrs by CPRG dye based assay	2015	Journal of medicinal chemistry, Jul-23, Volume: 58, Issue:14	Protozoan Parasite Growth Inhibitors Discovered by Cross-Screening Yield Potent Scaffolds for Lead Discovery.
AID1070006	Antimicrobial activity against amastigote stage of Trypanosoma cruzi CL Brener infected in mouse NCTC-929 cells assessed as growth inhibition at 2 uM after 7 days by beta-galactosidase reporter gene assay	2014	Bioorganic & medicinal chemistry letters, Feb-15, Volume: 24, Issue:4	In vitro phenotypic screening of 7-chloro-4-amino(oxy)quinoline derivatives as putative anti-Trypanosoma cruzi agents.
AID1238029	Cytotoxicity against BALB/c mouse peritoneal macrophages incubated for 24 hrs by MTT assay	2015	Bioorganic & medicinal chemistry letters, Aug-15, Volume: 25, Issue:16	Synthesis and evaluation of novel prenylated chalcone derivatives as anti-leishmanial and anti-trypanosomal compounds.
AID1074378	Selectivity index, ratio of IC50 for African green monkey Vero cells to IC50 for amastigote stage of Trypanosoma cruzi IRHOD/CO/2008/SN3 infected in African green monkey Vero cells	2014	Journal of medicinal chemistry, Feb-13, Volume: 57, Issue:3	Synthesis and biological evaluation of N,N'-squaramides with high in vivo efficacy and low toxicity: toward a low-cost drug against Chagas disease.
AID774787	Antiprotozoal activity against Trypanosoma cruzi assessed as parasite growth inhibition	2013	Journal of medicinal chemistry, Sep-26, Volume: 56, Issue:18	Natural product derived antiprotozoal agents: synthesis, biological evaluation, and structure-activity relationships of novel chromene and chromane derivatives.
AID1616165	In vivo antitrypanosomal activity against Trypanosoma cruzi Y trypomastigotes infected in Swiss mouse assessed as reduction in parasitemia at 100 mg/kg, po administered once daily via gavage for 5 days starting from 5 days post-infection and measured up t	2019	Journal of medicinal chemistry, 10-10, Volume: 62, Issue:19	Discovery of Pyrrolo[2,3-
AID284137	Trypanocidal activity in Swiss albino mouse inoculated with Trypanosoma cruzi Y blood trypomastigotes assessed as parasitaemia reduction administered after 7th day of inoculation at 250 mg/kg, po after 6 hrs relative to control	2007	Bioorganic & medicinal chemistry, Jan-01, Volume: 15, Issue:1	Synthesis and trypanocidal activity of ent-kaurane glycosides.
AID392009	Antitrypanosomal activity against Trypanosoma cruzi Tulahuen 2 infected Swiss mouse assessed as reduction in circulating trypomastigotes antibody level at 200 mg/kg/day, po after 60 days postinfection	2008	European journal of medicinal chemistry, Oct, Volume: 43, Issue:10	In vivo studies of 5-arylethenylbenzofuroxans in acute murine models of Chagas' disease.
AID1519001	Antitrypanosomal activity against Trypanosoma cruzi K98 bloodstream form infected in C3H/HeNk mouse assessed as effect on heart rate at 30 to 75 mg/kg/day, po administered via gavage for 30 consecutive days starting from 90 days post infection and measure	2019	European journal of medicinal chemistry, 12-15, Volume: 184	Combined therapy with Benznidazole and repurposed drugs Clofazimine and Benidipine for chronic Chagas disease.
AID285215	Antimicrobial activity against Trypanosoma cruzi Y infected IL12 knock out C57BL/6 mouse Chagas disease model assessed as percent of cured mouse at 100 mg/kg, po after 20 days	2007	Antimicrobial agents and chemotherapy, Apr, Volume: 51, Issue:4	The Anti-Trypanosoma cruzi activity of posaconazole in a murine model of acute Chagas' disease is less dependent on gamma interferon than that of benznidazole.
AID1072683	Antitrypanosomal activity against Trypanosoma cruzi Dm28c epimastigotes assessed as inhibition of parasite proliferation after 5 days by hemocytometer analysis	2014	European journal of medicinal chemistry, Mar-21, Volume: 75	Conformational restriction of aryl thiosemicarbazones produces potent and selective anti-Trypanosoma cruzi compounds which induce apoptotic parasite death.
AID1164933	Induction of apoptosis in human monocytes assessed as late apoptotic cells using Annexin V/propidium iodide by flow cytometry (Rvb = 0.27 %)	2014	European journal of medicinal chemistry, Nov-24, Volume: 87	In vitro antiparasitic activity of new thiosemicarbazones in strains of Trypanosoma cruzi.
AID1773691	Selectivity index, ratio of CC50 for cytotoxicity against mouse C2C12 cells to EC50 for trypanocidal activity against Trypanosoma cruzi C-I/72 infected in mouse C2C12 cells	2021	Journal of medicinal chemistry, 09-09, Volume: 64, Issue:17	Structure-Based Optimization of Quinazolines as Cruzain and
AID1300857	Activity at recombinant His-tagged Trypanosoma brucei NTR assessed as oxidation of NADH/min/mg of protein after 5 mins by spectrophotometric analysis	2016	European journal of medicinal chemistry, Jul-19, Volume: 117	Antitrypanosomal activity of 5-nitro-2-aminothiazole-based compounds.
AID1498311	Hepatotoxicity in Balb/c mouse infected with Trypanosoma cruzi MHOM/Pe/2011/Arequipa DTU 5 trypamastigotes assessed as increase in ratio of serum AST to GOT level at 20 mg/kg, po once daily for 5 consecutive days starting from day 75 post infection measur	2018	Journal of medicinal chemistry, 07-12, Volume: 61, Issue:13	Second Generation of Mannich Base-Type Derivatives with in Vivo Activity against Trypanosoma cruzi.
AID1766960	Selectivity index, ratio of CC50 for cytotoxicity against mouse NCTC clone 929 cells to IC50 for trypomastigote forms of Trypanosoma cruzi Y infected in LLC-MK2 cells
AID677564	Antitrypanosomal activity against Trypanosoma cruzi Tulahuen C4 amastigotes	2012	Journal of medicinal chemistry, Jun-14, Volume: 55, Issue:11	Novel 3-nitro-1H-1,2,4-triazole-based amides and sulfonamides as potential antitrypanosomal agents.
AID1615038	Antitrypanosomal activity against Trypanosoma cruzi MHOM/Pe/2011/Arequipa DTU 5 trypomastigotes infected in Balb/c mouse assessed as reduction in parasitaemia reactivation at 20 mg/kg, po pretreated once daily for 5 consecutive days starting from day 75 p	2019	Bioorganic & medicinal chemistry, 03-01, Volume: 27, Issue:5	Synthesis and biological evaluation of new long-chain squaramides as anti-chagasic agents in the BALB/c mouse model.
AID1633358	Antitrypanosomal activity against Trypanosoma cruzi Dm28c trypomastigotes infected in African green monkey Vero cells incubated for 24 hrs by luciferase-luminescence based assay
AID1124783	Cytotoxicity against human HepG2 cells by MTT assay	2014	Bioorganic & medicinal chemistry letters, Apr-01, Volume: 24, Issue:7	Synthesis and tripanocidal activity of ferrocenyl and benzyl diamines against Trypanosoma brucei and Trypanosoma cruzi.
AID1687708	Anti-chagasic activity against Trypanosoma cruzi trypomastigotes infected in C3H mouse assessed as reduction in parasitemia at 50 mg/kg, po treated 10 days post infection for 7 consecutive days by Neubauer chamber counting method relative to control	2020	European journal of medicinal chemistry, Jan-15, Volume: 186	Hit-to-lead optimization of novel 2-alkylaminomethylquinoline derivatives as anti-chagas agents.
AID1707635	Antitrypanosomal activity against Trypanosoma cruzi infected in human MRC-5 SV2 cells	2021	European journal of medicinal chemistry, Feb-15, Volume: 212	Synthesis and evaluation of a collection of purine-like C-nucleosides as antikinetoplastid agents.
AID1196789	Toxicity in Balb/c mouse at 15 mg/kg/day, ip measured after 5 to 10 days	2015	Journal of medicinal chemistry, Feb-12, Volume: 58, Issue:3	Novel 3-nitrotriazole-based amides and carbinols as bifunctional antichagasic agents.
AID753034	Cytotoxicity against human fibroblasts assessed as growth inhibition after 24 hrs by MTT assay	2013	European journal of medicinal chemistry, Jun, Volume: 64	Ligand-based design, synthesis, and experimental evaluation of novel benzofuroxan derivatives as anti-Trypanosoma cruzi agents.
AID1174778	Trypanocidal activity against intracellular amastigote form of Trypanosoma cruzi IRHOD/CO/2008/SN3 in african green monkey Vero cells	2015	European journal of medicinal chemistry, Jan-07, Volume: 89	Prospects of an alternative treatment against Trypanosoma cruzi based on abietic acid derivatives show promising results in Balb/c mouse model.
AID1699437	Selectivity index, ratio of IC50 for cytotoxicity against rat L6 cells to IC50 for growth inhibition of amastigote form of Trypanosoma cruzi Tulahuen C2C4 expressing LacZ infected in rat L6 cells	2020	Journal of natural products, 11-25, Volume: 83, Issue:11	Pyridine-4(1
AID1348368	Antitrypanosomal activity against beta-galactosidase expressing nifurtimox-sensitive Trypanosoma cruzi Tulahuen CL2 infected in human MRC5 SV2 cells assessed as decrease in parasite burden after 168 hrs by spectrophotometric method	2018	European journal of medicinal chemistry, Jan-01, Volume: 143	Novel triazine dimers with potent antitrypanosomal activity.
AID1459244	Trypanocidal activity against Trypanosoma cruzi TCC epimastigotes assessed as parasite duplication time at 1 to 15 uM supplemented with fresh medium containing compound every 9 to 10 days measured on third week	2017	European journal of medicinal chemistry, Jan-05, Volume: 125	Novel 2-arylazoimidazole derivatives as inhibitors of Trypanosoma cruzi proliferation: Synthesis and evaluation of their biological activity.
AID547275	Immunostimulatory activity in mongrel dog infected with Trypanosoma cruzi Y assessed as production of antibody IgG at 7 mg/kg, po BID for 90 days measured after 6 months by ELISA	2010	Antimicrobial agents and chemotherapy, Jul, Volume: 54, Issue:7	Effects of ravuconazole treatment on parasite load and immune response in dogs experimentally infected with Trypanosoma cruzi.
AID1613530	Nephrotoxicity in Balb/c mouse infected with Trypanosoma cruzi MHOM/Pe/2011/Arequipa DTU 5 trypomastigotes assessed as decrease in serum uric acid level at 20 mg/kg, po once daily for 5 consecutive days starting from day 75 post infection measured on day	2019	European journal of medicinal chemistry, Feb-15, Volume: 164	New polyamine drugs as more effective antichagas agents than benznidazole in both the acute and chronic phases.
AID1686726	Genotoxicity in Salmonella typhimurium TA1535/pSK1002 in absence of rat S9 mix incubated for 4 hrs by SOS/umu test	2016	Journal of medicinal chemistry, 12-22, Volume: 59, Issue:24	In Vitro and in Vivo Anti-Trypanosoma cruzi Activity of New Arylamine Mannich Base-Type Derivatives.
AID671575	Antitrypanosomal activity against trypomastigotes of Trypanosoma cruzi Tulahuen infected immunosuppressed Swiss mouse assessed as level of parasite in blood at 20 mg/kg, po administered 8 day after post infection qd for 20 days measured after 3 cycles of	2012	Journal of medicinal chemistry, May-10, Volume: 55, Issue:9	Analogues of fenarimol are potent inhibitors of Trypanosoma cruzi and are efficacious in a murine model of Chagas disease.
AID450067	Antitrypanosomal activity against Trypanosoma cruzi epimastigote Y strain after 24 hrs by trypan blue exclusion assay	2009	Bioorganic & medicinal chemistry, Sep-15, Volume: 17, Issue:18	Design, synthesis and cruzain docking of 3-(4-substituted-aryl)-1,2,4-oxadiazole-N-acylhydrazones as anti-Trypanosoma cruzi agents.
AID634123	Antitrypanosomal activity against Trypanosoma cruzi Tulaheun infected in monkey LLC-MK2 cells after 4 days by beta-galactosidase reporter gene assay	2012	Bioorganic & medicinal chemistry, Jan-01, Volume: 20, Issue:1	Design, synthesis and the effect of 1,2,3-triazole sialylmimetic neoglycoconjugates on Trypanosoma cruzi and its cell surface trans-sialidase.
AID362869	Therapeutic index, ID50 for human THP1 cells to ID50 for Trypanosoma cruzi	2008	European journal of medicinal chemistry, May, Volume: 43, Issue:5	4-nitroacetophenone-derived thiosemicarbazones and their copper(II) complexes with significant in vitro anti-trypanosomal activity.
AID1603868	Toxicity in BALB/c mouse infected with Trypanosoma cruzi MHOM/Pe/2011/Arequipa;DTU 5 bloodstream trypomastigote assessed as increase in serum alanine aminotransferase level in chronic phase at 20 mg/kg/day, po administered for 5 consecutive days starting	2019	Bioorganic & medicinal chemistry, 09-01, Volume: 27, Issue:17	Rational modification of Mannich base-type derivatives as novel antichagasic compounds: Synthesis, in vitro and in vivo evaluation.
AID1603758	Selectivity index, ratio of IC50 for African green monkey Vero cells to IC50 for Trypanosoma cruzi TINF/CH/1956/Tulahuen;DTU 6	2019	Bioorganic & medicinal chemistry, 09-01, Volume: 27, Issue:17	Rational modification of Mannich base-type derivatives as novel antichagasic compounds: Synthesis, in vitro and in vivo evaluation.
AID1854941	Induction of cell death in Trypanosoma cruzi Y epimastigotes assessed as live cells at 125 uM incubated for 24 hrs by Annexin V/7-AAD staining based flow cytometric analysis (Rvb = 98.6 %)	2022	European journal of medicinal chemistry, Nov-05, Volume: 241	Rational design of a trypanocidal peptide derived from Dinoponera quadriceps venom.
AID1399452	Antitrypanosomal activity against Trypanosoma brucei Lister 427 bloodstream forms after 48 hrs by resazurin dye based fluorescence assay	2018	Bioorganic & medicinal chemistry, 08-07, Volume: 26, Issue:14	Quinoxaline derivatives as potential antitrypanosomal and antileishmanial agents.
AID1055185	Cytotoxicity against African green monkey Vero cells after 72 hrs by flow cytometric analysis	2013	European journal of medicinal chemistry, , Volume: 70	Scorpiand-like azamacrocycles prevent the chronic establishment of Trypanosoma cruzi in a murine model.
AID547252	Antimicrobial activity against Trypanosoma cruzi Berenice-78 infected in mongrel dog assessed as suppression of microbial proliferation at 12 mg/kg, po BID started 12 to 22 days postinfection measured after 1 day	2010	Antimicrobial agents and chemotherapy, Jul, Volume: 54, Issue:7	Effects of ravuconazole treatment on parasite load and immune response in dogs experimentally infected with Trypanosoma cruzi.
AID1869516	Antitrypanosomal activity against Trypanosoma cruzi epimastigotes assessed as parasite growth inhibition measured after 24 hrs by CellTiter-glo luminescence assay	2022	Journal of natural products, 07-22, Volume: 85, Issue:7	Phytohabitols A-C, δ-Lactone-Terminated Polyketides from an Actinomycete of the Genus
AID1244474	Selectivity index, ratio of LC50 for human U937 cells to EC50 for intracellular amastigotes of Trypanosoma cruzi Tulahuen	2015	European journal of medicinal chemistry, Aug-28, Volume: 101	Synthesis, leishmanicidal, trypanocidal and cytotoxic activity of quinoline-hydrazone hybrids.
AID1687781	Selectivity index, ratio of GI50 for mouse RAW264.7 cells assessed as reduction in cell viability measured after 24 hrs by WST1 assay to IC50 for antitrypanosomal activity against bloodstream form of Trypanosoma cruzi Y trypomastigotes infected in African	2020	European journal of medicinal chemistry, Jan-15, Volume: 186	Novel nitroimidazole derivatives evaluated for their trypanocidal, cytotoxic, and genotoxic activities.
AID580576	Antitrypanosomal activity against Trypanosoma cruzi Y infected in C57BL/6 mouse assessed as mean survival time at 100 mg/kg/day, po administered once daily for 20 consecutive days measured 60 days post infection	2009	Antimicrobial agents and chemotherapy, Jan, Volume: 53, Issue:1	Absence of CD4+ T lymphocytes, CD8+ T lymphocytes, or B lymphocytes has different effects on the efficacy of posaconazole and benznidazole in treatment of experimental acute Trypanosoma cruzi infection.
AID536025	Antitrypanosomal activity against epimastigotes of Trypanosoma cruzi Y assessed as viability after 11 days by trypan blue exclusion assay	2010	Bioorganic & medicinal chemistry, Nov-15, Volume: 18, Issue:22	Studies toward the structural optimization of novel thiazolylhydrazone-based potent antitrypanosomal agents.
AID1498175	Selectivity index, ratio of IC50 for African green monkey Vero cells to IC50 for Trypanosoma cruzi IRHOD/CO/2008/SN3 DTU 1 epimastigotes	2018	Journal of medicinal chemistry, 07-12, Volume: 61, Issue:13	Second Generation of Mannich Base-Type Derivatives with in Vivo Activity against Trypanosoma cruzi.
AID213672	Inhibitory activity against Trypanosoma cruzi	2003	Bioorganic & medicinal chemistry letters, Jun-16, Volume: 13, Issue:12	The activity of diguanidino and 'reversed' diamidino 2,5-diarylfurans versus Trypanosoma cruzi and Leishmania donovani.
AID1615023	Selectivity index, ratio of IC50 for African green monkey Vero cells to IC50 for Trypanosoma cruzi MHOM/Pe/2011/Arequipa DTU 5 amastigotes infected in African green monkey Vero cells	2019	Bioorganic & medicinal chemistry, 03-01, Volume: 27, Issue:5	Synthesis and biological evaluation of new long-chain squaramides as anti-chagasic agents in the BALB/c mouse model.
AID1683680	Toxicity in BALB/c mouse infected with Trypanosomal Trypanosoma cruzi MHOM/Pe/2011/Arequipa(DTU V) assessed as effect on ALP level at 20 mg/kg, po administered for 5 days starting at 9 days post infection and measured after 2 days post treatment	2020	Journal of natural products, 12-24, Volume: 83, Issue:12	In Vivo Biological Evaluation of a Synthetic Royleanone Derivative as a Promising Fast-Acting Trypanocidal Agent by Inducing Mitochondrial-Dependent Necrosis.
AID1682935	Hepatotoxicity in BALB/c mouse infected with blood trypomastigote form of Trypanosoma cruzi strain Y assessed as ALT level in plasma at 25 mg/kg, po administered via gavage daily for 15 days starting from 2 days post-infection and measured on 16th day pos	2021	Bioorganic & medicinal chemistry, 01-01, Volume: 29	Trypanocidal activity of new 1,6-diphenyl-1H-pyrazolo[3,4-b]pyridine derivatives: Synthesis, in vitro and in vivo studies.
AID1055183	Selectivity index, ratio of IC50 for African green monkey Vero cells to IC50 for intracellular amastigote form of Trypanosoma cruzi IRHOD/CO/2008/SN3	2013	European journal of medicinal chemistry, , Volume: 70	Scorpiand-like azamacrocycles prevent the chronic establishment of Trypanosoma cruzi in a murine model.
AID1613535	Cardiotoxicity in Balb/c mouse infected with Trypanosoma cruzi MHOM/Pe/2011/Arequipa DTU 5 trypomastigotes assessed as decrease in ratio of creatine kinase in muscle to brain at 20 mg/kg, po once daily for 5 consecutive days starting from day 75 post infe	2019	European journal of medicinal chemistry, Feb-15, Volume: 164	New polyamine drugs as more effective antichagas agents than benznidazole in both the acute and chronic phases.
AID1188733	Cytotoxicity against human HepG2 cells after 48 hrs by	2014	European journal of medicinal chemistry, Oct-30, Volume: 86	2-Pyridyl thiazoles as novel anti-Trypanosoma cruzi agents: structural design, synthesis and pharmacological evaluation.
AID1518973	Toxicity in C3H/HeNk mouse infected with Trypanosoma cruzi K98 bloodstream form assessed as decrease in body weight at 30 mg/kg/day, po administered via gavage for 30 consecutive days starting from 90 days post infection measured at 150 days post infectio	2019	European journal of medicinal chemistry, 12-15, Volume: 184	Combined therapy with Benznidazole and repurposed drugs Clofazimine and Benidipine for chronic Chagas disease.
AID1164929	Trypanocidal activity against epimastigote forms of Trypanosoma cruzi Punta Lobos after 24 hrs	2014	European journal of medicinal chemistry, Nov-24, Volume: 87	In vitro antiparasitic activity of new thiosemicarbazones in strains of Trypanosoma cruzi.
AID1687709	Anti-chagasic activity against Trypanosoma cruzi trypomastigotes infected in C3H mouse assessed as increase in body weight at 10 mg/kg, po treated 10 days post infection measured on day 19 (Rvb = -1.8%)	2020	European journal of medicinal chemistry, Jan-15, Volume: 186	Hit-to-lead optimization of novel 2-alkylaminomethylquinoline derivatives as anti-chagas agents.
AID1720858	Cytotoxicity against albino Swiss mouse Peritoneal macrophages in absence of mouse blood incubated for 24 hrs in absence of mouse blood by PrestoBlue dye based fluorescence assay	2020	Bioorganic & medicinal chemistry, 08-01, Volume: 28, Issue:15	Strategies towards potent trypanocidal drugs: Application of Rh-catalyzed [2 + 2 + 2] cycloadditions, sulfonyl phthalide annulation and nitroalkene reactions for the synthesis of substituted quinones and their evaluation against Trypanosoma cruzi.
AID1615107	Hepatotoxicity in Balb/c mouse infected with Trypanosoma cruzi MHOM/Pe/2011/Arequipa DTU 5 trypomastigotes assessed as increase in ratio of serum AST to GOT level at 20 mg/kg, po once daily for 5 consecutive days starting from day 10 post infection measur	2019	Bioorganic & medicinal chemistry, 03-01, Volume: 27, Issue:5	Synthesis and biological evaluation of new long-chain squaramides as anti-chagasic agents in the BALB/c mouse model.
AID1517425	Antitrypanosomal activity against Trypanosoma brucei bloodstream form assessed as parasite growth inhibition incubated for 72 hrs by resazurin dye based assay	2019	European journal of medicinal chemistry, Dec-01, Volume: 183	Discovery of a benzothiophene-flavonol halting miltefosine and antimonial drug resistance in Leishmania parasites through the application of medicinal chemistry, screening and genomics.
AID766417	Antiparasitic activity against amastigotes of Trypanosoma cruzi CL Brener expressing Escherichia coli lacZ gene infected in mouse NCTC-929 cells assessed as parasite growth inhibition after 7 days by colorimetric assay	2013	Bioorganic & medicinal chemistry letters, Sep-01, Volume: 23, Issue:17	Selective activity of 2,4-diaryl-1,2,3,4-tetrahydroquinolines on Trypanosoma cruzi epimastigotes and amastigotes expressing β-galactosidase.
AID1615049	Antitrypanosomal activity against Trypanosoma cruzi MHOM/Pe/2011/Arequipa DTU 5 trypomastigotes infected in Balb/c mouse assessed as parasite-free bone marrow at 20 mg/kg, po pretreated once daily for 5 consecutive days starting from day 75 post infection	2019	Bioorganic & medicinal chemistry, 03-01, Volume: 27, Issue:5	Synthesis and biological evaluation of new long-chain squaramides as anti-chagasic agents in the BALB/c mouse model.
AID1683669	Toxicity in BALB/c mouse infected with Trypanosomal Trypanosoma cruzi MHOM/Pe/2011/Arequipa(DTU V) assessed as reduction in weight at 20 mg/kg, po administered for 5 days starting at 9 days post infection and measured up to 145 days post infection	2020	Journal of natural products, 12-24, Volume: 83, Issue:12	In Vivo Biological Evaluation of a Synthetic Royleanone Derivative as a Promising Fast-Acting Trypanocidal Agent by Inducing Mitochondrial-Dependent Necrosis.
AID396004	Antimicrobial activity against Trypanosoma cruzi infected in BALB/c mouse assessed as parasitemia remaining in hemoculture	2007	Antimicrobial agents and chemotherapy, Sep, Volume: 51, Issue:9	Impact of dual infections on chemotherapeutic efficacy in BALB/c mice infected with major genotypes of Trypanosoma cruzi.
AID693342	Growth inhibition of epimastigote form of Trypanosoma cruzi CL-B5 at 256 uM after 72 hrs by lacZ reporter gene assay	2012	European journal of medicinal chemistry, Dec, Volume: 58	Synthesis, biological evaluation and chemometric analysis of indazole derivatives. 1,2-Disubstituted 5-nitroindazolinones, new prototypes of antichagasic drug.
AID1706435	Antitrypanosomal activity against Trypanosoma cruzi Tulahuen strain C2C4 amastigotes infected in rat 3T3 cells assessed as reduction in parasite growth incubated for 48 hrs by chlorophenol red-fl-D-galactopyranoside based colorimetric analysis relative to	2020	European journal of medicinal chemistry, Dec-01, Volume: 207	Re-evaluating pretomanid analogues for Chagas disease: Hit-to-lead studies reveal both in vitro and in vivo trypanocidal efficacy.
AID1811309	Trypanocidal activity against Trypanosoma cruzi ITRI/MX/2018/TH assessed as inhibition of parasite growth measured after 48 hrs by MTT assay	2021	Bioorganic & medicinal chemistry, 10-15, Volume: 48	In vitro, ex vivo and in vivo short-term screening of DHEA nitrate derivatives activity over Trypanosoma cruzi Ninoa and TH strains from Oaxaca State, México.
AID371470	Antitrypanosomal activity against Trypanosoma cruzi Y trypomastigotes after 1 day	2008	European journal of medicinal chemistry, Aug, Volume: 43, Issue:8	Naphthoquinoidal [1,2,3]-triazole, a new structural moiety active against Trypanosoma cruzi.
AID766420	Antiparasitic activity against epimastigotes of Trypanosoma cruzi CL Brener expressing Escherichia coli lacZ gene infected in mouse NCTC-929 cells assessed as parasite growth inhibition after 72 hrs by colorimetric assay	2013	Bioorganic & medicinal chemistry letters, Sep-01, Volume: 23, Issue:17	Selective activity of 2,4-diaryl-1,2,3,4-tetrahydroquinolines on Trypanosoma cruzi epimastigotes and amastigotes expressing β-galactosidase.
AID1399453	Antitrypanosomal activity against Trypanosoma cruzi Tulahuen trypomastigote forms infected in monkey LLC-MK2 cells after 24 hrs by CellTiter-Glo luminescent cell viability assay	2018	Bioorganic & medicinal chemistry, 08-07, Volume: 26, Issue:14	Quinoxaline derivatives as potential antitrypanosomal and antileishmanial agents.
AID1498253	Antitrypanosomal activity against Trypanosoma cruzi MHOM/Pe/2011/Arequipa DTU 5 trypamastigotes infected in Balb/c mouse assessed as reduction in Ig-G level in serum at 20 mg/kg, po pretreated once daily for 5 consecutive days starting from day 10 post in	2018	Journal of medicinal chemistry, 07-12, Volume: 61, Issue:13	Second Generation of Mannich Base-Type Derivatives with in Vivo Activity against Trypanosoma cruzi.
AID1854943	Induction of cell death in Trypanosoma cruzi Y epimastigotes assessed as late apoptotic cells at 125 uM incubated for 24 hrs by Annexin V/7-AAD staining based flow cytometric analysis (Rvb = 0.12 %)	2022	European journal of medicinal chemistry, Nov-05, Volume: 241	Rational design of a trypanocidal peptide derived from Dinoponera quadriceps venom.
AID1422889	Selectivity index, ratio of IC50 for African green monkey Vero cells to IC50 for Trypanosoma cruzi Dm28c epimastigotes infected in African green monkey Vero cells	2018	ACS medicinal chemistry letters, Oct-11, Volume: 9, Issue:10	Discovery of a Biologically Active Bromodomain Inhibitor by Target-Directed Dynamic Combinatorial Chemistry.
AID1683698	Antitrypanosomal activity against Trypanosoma cruzi MHOM/Pe/2011/Arequipa(DTU V) amastigote form infected in BALB/c mouse assessed as reduction in parasitaemia at 20 mg/kg, po for 5 days and measured after 55 days post infection	2020	Journal of natural products, 12-24, Volume: 83, Issue:12	In Vivo Biological Evaluation of a Synthetic Royleanone Derivative as a Promising Fast-Acting Trypanocidal Agent by Inducing Mitochondrial-Dependent Necrosis.
AID576084	Toxicity in human patient infected with Trypanosoma cruzi assessed as occurrence of Edema at 5 mg/kg/day for 60 days	2010	Antimicrobial agents and chemotherapy, Nov, Volume: 54, Issue:11	Tolerance of benznidazole in treatment of Chagas' disease in adults.
AID1498197	Toxicity in Balb/c mouse assessed as reduction in body mass at 20 mg/kg, po once daily for 5 consecutive days starting from day 10 post infection relative to control	2018	Journal of medicinal chemistry, 07-12, Volume: 61, Issue:13	Second Generation of Mannich Base-Type Derivatives with in Vivo Activity against Trypanosoma cruzi.
AID1603820	Antitrypanosomal activity against Trypanosoma cruzi MHOM/Pe/2011/Arequipa;DTU 5 bloodstream trypomastigote infected in BALB/c mouse assessed as parasite-free brain in acute phase at 20 mg/kg/day, po administered for 5 consecutive days starting from day 8	2019	Bioorganic & medicinal chemistry, 09-01, Volume: 27, Issue:17	Rational modification of Mannich base-type derivatives as novel antichagasic compounds: Synthesis, in vitro and in vivo evaluation.
AID1275382	Selectivity index, ratio of CC50 for African green monkey Vero cells to IC50 for epimastigote stage of Trypanosoma cruzi Dm28c	2016	European journal of medicinal chemistry, Feb-15, Volume: 109	New approach towards the synthesis of selenosemicarbazones, useful compounds for Chagas' disease.
AID1603768	Selectivity index, ratio of IC50 for African green monkey Vero cells to IC50 for Trypanosoma cruzi MHOM/Pe/2011/Arequipa; DTU 5 trypomastigote forms	2019	Bioorganic & medicinal chemistry, 09-01, Volume: 27, Issue:17	Rational modification of Mannich base-type derivatives as novel antichagasic compounds: Synthesis, in vitro and in vivo evaluation.
AID337144	Antitrypanosomal activity against Trypanosoma cruzi M6241CL6 after 48 hrs
AID1351074	Cytotoxicity against human U2OS cells assessed as reduction in cell viability	2018	European journal of medicinal chemistry, Jan-20, Volume: 144	Investigating the structure-activity relationships of N'-[(5-nitrofuran-2-yl) methylene] substituted hydrazides against Trypanosoma cruzi to design novel active compounds.
AID265553	Antitrypanosomatid activity against Trypanosoma cruzi Tulahuen 2 epimastigote form at 25 uM	2006	Journal of medicinal chemistry, Jun-01, Volume: 49, Issue:11	2H-benzimidazole 1,3-dioxide derivatives: a new family of water-soluble anti-trypanosomatid agents.
AID547509	Immunostimulatory activity in mongrel dog infected with Trypanosoma cruzi Berenice-78 assessed as production of antibody IgG2 at 12 mg/kg, po BID for 90 days measured after 6 months by ELISA	2010	Antimicrobial agents and chemotherapy, Jul, Volume: 54, Issue:7	Effects of ravuconazole treatment on parasite load and immune response in dogs experimentally infected with Trypanosoma cruzi.
AID1615097	Cardiotoxicity in Balb/c mouse infected with Trypanosoma cruzi MHOM/Pe/2011/Arequipa DTU 5 trypomastigotes assessed as decrease in ratio of creatine kinase in muscle to brain at 20 mg/kg, po once daily for 5 consecutive days starting from day 75 post infe	2019	Bioorganic & medicinal chemistry, 03-01, Volume: 27, Issue:5	Synthesis and biological evaluation of new long-chain squaramides as anti-chagasic agents in the BALB/c mouse model.
AID577160	Toxicity in Trypanosoma cruzi Tulahuen infected in Swiss mouse assessed as changes in liver SGOT enzyme levels at 60 mg/kg/day, po for 6 days per week until completion of 60 compound doses administered 5 days post infection by hematoxylin-eosin staining	2010	Antimicrobial agents and chemotherapy, Sep, Volume: 54, Issue:9	Hydroxymethylnitrofurazone is active in a murine model of Chagas' disease.
AID1422859	Antitrypanosomal activity against Trypanosoma cruzi Tulahuen intracellular amastigote harboring beta-galactosidase infected in mouse NIH/3T3 cells after 96 hrs by CPRG reagent based assay	2018	ACS medicinal chemistry letters, Oct-11, Volume: 9, Issue:10	Series of Alkynyl-Substituted Thienopyrimidines as Inhibitors of Protozoan Parasite Proliferation.
AID1616173	In vivo antitrypanosomal activity against Trypanosoma cruzi Y trypomastigotes infected in Swiss mouse assessed as reduction in parasitemia at 100 mg/kg, po administered once daily for 5 days with 2 days interval for 3 cycles and measured 9 days post-infec	2019	Journal of medicinal chemistry, 10-10, Volume: 62, Issue:19	Discovery of Pyrrolo[2,3-
AID1498233	Antitrypanosomal activity against Trypanosoma cruzi MHOM/Pe/2011/Arequipa DTU 5 trypamastigotes infected in Balb/c mouse assessed as reduction in parasitaemia reactivation in lung tissue at 20 mg/kg, po pretreated once daily for 5 consecutive days startin	2018	Journal of medicinal chemistry, 07-12, Volume: 61, Issue:13	Second Generation of Mannich Base-Type Derivatives with in Vivo Activity against Trypanosoma cruzi.
AID710879	Antitrypanosomal activity against trypomastigotes of Trypanosoma cruzi Y infected in LLC-MK2 cells assessed as parasite motility after 24 hrs	2012	Journal of medicinal chemistry, Dec-27, Volume: 55, Issue:24	Structural investigation of anti-Trypanosoma cruzi 2-iminothiazolidin-4-ones allows the identification of agents with efficacy in infected mice.
AID285212	Effect on survival in Trypanosoma cruzi Y infected IL12 knock out C57BL/6 mouse Chagas disease model assessed as mean survival time at 100 mg/kg, po after 20 days	2007	Antimicrobial agents and chemotherapy, Apr, Volume: 51, Issue:4	The Anti-Trypanosoma cruzi activity of posaconazole in a murine model of acute Chagas' disease is less dependent on gamma interferon than that of benznidazole.
AID576103	Toxicity in human patient infected with Trypanosoma cruzi assessed as occurrence of Diarrhea at 5 mg/kg/day for 60 days	2010	Antimicrobial agents and chemotherapy, Nov, Volume: 54, Issue:11	Tolerance of benznidazole in treatment of Chagas' disease in adults.
AID779137	Prodrug conversion assessed as Trypanosoma brucei brucei recombinant his-tagged nitroreductase-mediated NADH oxidization by spectrophotometric analysis	2013	Bioorganic & medicinal chemistry, Nov-01, Volume: 21, Issue:21	Novel 3-nitro-1H-1,2,4-triazole-based piperazines and 2-amino-1,3-benzothiazoles as antichagasic agents.
AID1074918	Antitrypanosomal activity against Trypanosoma cruzi (IRHOD/CO/2008/SN3) infected in BALB/c mouse assessed as reduction in parasite specific antibodies level at 1 mg/kg/day, ip treated from day 5 to day 10 post-infection measured from day 30 to day 120 pos	2014	European journal of medicinal chemistry, Mar-03, Volume: 74	New perspectives on the synthesis and antichagasic activity of 3-alkoxy-1-alkyl-5-nitroindazoles.
AID1339473	Antitrypanosomal activity against Trypanosoma cruzi MHOM/BR/OO/Y trypomastigotes infected in CD1 mouse peritoneal macrophages after 3 days	2017	Bioorganic & medicinal chemistry, 02-15, Volume: 25, Issue:4	Antiprotozoal glutathione derivatives with flagellar membrane binding activity against T. brucei rhodesiense.
AID666686	Selectivity index, ratio of IC50 for mouse J774 cells to IC50 for bloodstream form of Trypanosoma cruzi trypomastigote	2012	European journal of medicinal chemistry, Aug, Volume: 54	Design and synthesis of new (E)-cinnamic N-acylhydrazones as potent antitrypanosomal agents.
AID1164930	Trypanocidal activity against epimastigote forms of Trypanosoma cruzi Queretaro after 24 hrs	2014	European journal of medicinal chemistry, Nov-24, Volume: 87	In vitro antiparasitic activity of new thiosemicarbazones in strains of Trypanosoma cruzi.
AID1849826	Cytotoxicity against monkey LLC-MK2 cells assessed as reduction in cell viability incubated for 96 hrs by trypan blue assay	2021	European journal of medicinal chemistry, Jan-15, Volume: 210	A comprehensive review on β-lapachone: Mechanisms, structural modifications, and therapeutic potentials.
AID1381715	Cytotoxicity against human U2OS cells assessed as decrease in viable cells after 72 hrs by MTT assay	2018	European journal of medicinal chemistry, Feb-25, Volume: 146	Aryl thiosemicarbazones for the treatment of trypanosomatidic infections.
AID1379741	Antitrypanosomal activity against Trypanosoma cruzi Y trypomastigotes	2017	European journal of medicinal chemistry, Nov-10, Volume: 140	Synthesis and 2D-QSAR studies of neolignan-based diaryl-tetrahydrofuran and -furan analogues with remarkable activity against Trypanosoma cruzi and assessment of the trypanothione reductase activity.
AID1294227	Selectivity index, ratio of LC50 for mouse L929 cells to IC50 for Trypanosoma cruzi CL-B5 lacZ amastigotes in mouse L929 cells	2016	European journal of medicinal chemistry, Jun-10, Volume: 115	Antichagasic and trichomonacidal activity of 1-substituted 2-benzyl-5-nitroindazolin-3-ones and 3-alkoxy-2-benzyl-5-nitro-2H-indazoles.
AID1639038	Antitrypanosomal activity against tdTomato red expressing Trypanosoma cruzi CL amastigotes infected in gamma-irradiated African green monkey Vero cells after 72 hrs by fluorescence assay	2019	Bioorganic & medicinal chemistry, 04-01, Volume: 27, Issue:7	Further insights of selenium-containing analogues of WC-9 against Trypanosoma cruzi.
AID1065847	Trypanocidal activity against Trypanosoma cruzi Y infected in BALB/c mouse assessed as mouse survival at 100 mg/kg treated from day 2 to day 9 post-infection	2014	Journal of medicinal chemistry, Jan-23, Volume: 57, Issue:2	Design, synthesis, and evaluation of hydroxamic acid derivatives as promising agents for the management of Chagas disease.
AID580593	Antitrypanosomal activity against Trypanosoma cruzi Y infected in B-lymphocyte knockout C57BL/6 mouse assessed as increase in survival of mouse at 100 mg/kg/day, po administered once daily for 20 consecutive days measured 60 days post infection	2009	Antimicrobial agents and chemotherapy, Jan, Volume: 53, Issue:1	Absence of CD4+ T lymphocytes, CD8+ T lymphocytes, or B lymphocytes has different effects on the efficacy of posaconazole and benznidazole in treatment of experimental acute Trypanosoma cruzi infection.
AID337143	Antitrypanosomal activity against Trypanosoma cruzi MIL4CL10 after 48 hrs
AID1683676	Toxicity in BALB/c mouse infected with Trypanosomal Trypanosoma cruzi MHOM/Pe/2011/Arequipa(DTU V) assessed as effect on LDH level at 20 mg/kg, po administered for 5 days starting at 100 days post infection and measured after 2 days post treatment	2020	Journal of natural products, 12-24, Volume: 83, Issue:12	In Vivo Biological Evaluation of a Synthetic Royleanone Derivative as a Promising Fast-Acting Trypanocidal Agent by Inducing Mitochondrial-Dependent Necrosis.
AID396005	Antimicrobial activity against Trypanosoma cruzi genotype 19 and genotype 39 dually infected in BALB/c mouse assessed as cure rate	2007	Antimicrobial agents and chemotherapy, Sep, Volume: 51, Issue:9	Impact of dual infections on chemotherapeutic efficacy in BALB/c mice infected with major genotypes of Trypanosoma cruzi.
AID1064594	Antiparasitic activity against epimastigote form of Trypanosoma cruzi Y after 96 hrs by hemocytometry	2014	Bioorganic & medicinal chemistry, Feb-01, Volume: 22, Issue:3	Unsymmetrical 1,5-diaryl-3-oxo-1,4-pentadienyls and their evaluation as antiparasitic agents.
AID1587055	Cytotoxicity against mouse 3T3 cells infected with Trypanosoma cruzi Tulahuen amastigotes assessed as disruption of cell monolayer at 50 times EC50 supplemented with fresh medium containing compound every 4 days for 16 days followed by compound washout an	2019	ACS medicinal chemistry letters, Jan-10, Volume: 10, Issue:1	Triazolopyrimidines and Imidazopyridines: Structure-Activity Relationships and in Vivo Efficacy for Trypanosomiasis.
AID580665	Antitrypanosomal activity against Trypanosoma cruzi Y infected in B-lymphocyte knockout C57BL/6 mouse assessed as number of mouse with reactivation of infection at 100 mg/kg/day, po administered once daily for 20 consecutive days measured 22 days post inf	2009	Antimicrobial agents and chemotherapy, Jan, Volume: 53, Issue:1	Absence of CD4+ T lymphocytes, CD8+ T lymphocytes, or B lymphocytes has different effects on the efficacy of posaconazole and benznidazole in treatment of experimental acute Trypanosoma cruzi infection.
AID1603765	Trypanocidal activity against Trypanosoma cruzi trypomastigote form infected in African green monkey Vero cells assessed as ratio of infected cells at 50 uM measured after 72 hrs by Giemsa staining based assay relative to control	2019	Bioorganic & medicinal chemistry, 09-01, Volume: 27, Issue:17	Rational modification of Mannich base-type derivatives as novel antichagasic compounds: Synthesis, in vitro and in vivo evaluation.
AID213636	Effective dose required against Trypanosoma cruzi in bloodstream	2001	Bioorganic & medicinal chemistry letters, Jan-22, Volume: 11, Issue:2	A disubstituted NAD+ analogue is a nanomolar inhibitor of trypanosomal glyceraldehyde-3-phosphate dehydrogenase.
AID666683	Antitrypanosomal activity against bloodstream form of Trypanosoma cruzi Y trypomastigotes infected in Swiss mouse	2012	European journal of medicinal chemistry, Aug, Volume: 54	Design and synthesis of new (E)-cinnamic N-acylhydrazones as potent antitrypanosomal agents.
AID1498178	Trypanocidal activity against Trypanosoma cruzi MHOM/Pe/2011/Arequipa DTU 5 trypamastigotes derived from infected Balb/c albino mouse after 24 hrs by resazurin dye based assay	2018	Journal of medicinal chemistry, 07-12, Volume: 61, Issue:13	Second Generation of Mannich Base-Type Derivatives with in Vivo Activity against Trypanosoma cruzi.
AID1615033	Trypanocidal activity against Trypanosoma cruzi MHOM/Pe/2011/Arequipa DTU 5 amastigotes infected in African green monkey Vero cells assessed as reduction in number of amastigotes per infected cells at log -0.41 to 1.7 after 72 hrs by Giemsa-staining based	2019	Bioorganic & medicinal chemistry, 03-01, Volume: 27, Issue:5	Synthesis and biological evaluation of new long-chain squaramides as anti-chagasic agents in the BALB/c mouse model.
AID1584762	Trypanocidal activity against Trypanosoma cruzi Y strain intracellular amastigotes infected in mouse cardiac cells assessed as parasite death after 168 hrs by Giemsa-staining based assay	2018	Journal of medicinal chemistry, 10-25, Volume: 61, Issue:20	Discovery of Novel 7-Aryl 7-Deazapurine 3'-Deoxy-ribofuranosyl Nucleosides with Potent Activity against Trypanosoma cruzi.
AID378743	Antitrypanosomal activity against Trypanosoma cruzi Y trypomastigotes infected in Swiss albino mouse assessed as mortality rate at 100 mg/kg, po daily for 4 days assessed after 6 to 9 days	1999	Journal of natural products, Feb, Volume: 62, Issue:2	Biological activities of 7-epiclusianone.
AID1238020	Selectivity index, ratio of EC50 for BALB/c mouse peritoneal macrophages to EC50 for Leishmania amazonensis MPRO/BR/1972/M1841-LV-79 promastigotes	2015	Bioorganic & medicinal chemistry letters, Aug-15, Volume: 25, Issue:16	Synthesis and evaluation of novel prenylated chalcone derivatives as anti-leishmanial and anti-trypanosomal compounds.
AID1422891	Selectivity index, ratio of IC50 for African green monkey Vero cells to IC50 for Trypanosoma cruzi Dm28c amastigotes infected in African green monkey Vero cells	2018	ACS medicinal chemistry letters, Oct-11, Volume: 9, Issue:10	Discovery of a Biologically Active Bromodomain Inhibitor by Target-Directed Dynamic Combinatorial Chemistry.
AID1519003	Cytotoxicity against African green monkey Vero cells at 0.5 to 20 uM after 72 hrs by propidium iodide staining based flow cytometric analysis	2019	European journal of medicinal chemistry, 12-15, Volume: 184	Combined therapy with Benznidazole and repurposed drugs Clofazimine and Benidipine for chronic Chagas disease.
AID564779	Antitrypanosomal activity against Trypanosoma cruzi Columbian bloodstream forms infected in C3H mouse assessed as survival of mouse at 100 mg/kg/day, ip administered 5 days postinfection for 10 consecutive days measured after 31 days	2010	Antimicrobial agents and chemotherapy, Jul, Volume: 54, Issue:7	Arylimidamide DB766, a potential chemotherapeutic candidate for Chagas' disease treatment.
AID1603878	Toxicity in BALB/c mouse infected with Trypanosoma cruzi MHOM/Pe/2011/Arequipa;DTU 5 bloodstream trypomastigote assessed as decrease in serum lactate dehydrogenase level in chronic phase at 20 mg/kg/day, po administered for 5 consecutive days starting fro	2019	Bioorganic & medicinal chemistry, 09-01, Volume: 27, Issue:17	Rational modification of Mannich base-type derivatives as novel antichagasic compounds: Synthesis, in vitro and in vivo evaluation.
AID1686741	Selectivity index, ratio of IC50 for cytotoxicity in African green monkey Vero cells to IC50 for antitrypanosomal activity against Trypanosoma cruzi Tulahuen epimastigote forms	2016	Journal of medicinal chemistry, 12-22, Volume: 59, Issue:24	In Vitro and in Vivo Anti-Trypanosoma cruzi Activity of New Arylamine Mannich Base-Type Derivatives.
AID315106	Antitrypanosomal activity against Trypanosoma cruzi Tulahuen C4 amastigotes by microplate assay	2008	Bioorganic & medicinal chemistry letters, Apr-01, Volume: 18, Issue:7	Synthesis of a small library of 2-phenoxy-1,4-naphthoquinone and 2-phenoxy-1,4-anthraquinone derivatives bearing anti-trypanosomal and anti-leishmanial activity.
AID1518975	Toxicity in C3H/HeNk mouse infected with Trypanosoma cruzi K98 bloodstream form assessed as decrease in body weight at 15 mg/kg/day, po administered via gavage for 30 consecutive days starting from 90 days post infection measured at 150 days post infectio	2019	European journal of medicinal chemistry, 12-15, Volume: 184	Combined therapy with Benznidazole and repurposed drugs Clofazimine and Benidipine for chronic Chagas disease.
AID576951	Antimicrobial activity against Trypanosoma cruzi Tulahuen infected in Swiss mouse assessed as reduction in parasite specific antibodies at 60 mg/kg/day, po for 6 days per week until completion of 60 compound doses administered 5 days post infection measur	2010	Antimicrobial agents and chemotherapy, Sep, Volume: 54, Issue:9	Hydroxymethylnitrofurazone is active in a murine model of Chagas' disease.
AID1683660	Inhibition of mitochondrial membrane potential in Trypanosoma cruzi MHOM/Pe/2011/Arequipa(DTU V) epimastigote form at IC25 concentration after 72 hrs by Rho (FITC-A) staining based flow cytometric analysis	2020	Journal of natural products, 12-24, Volume: 83, Issue:12	In Vivo Biological Evaluation of a Synthetic Royleanone Derivative as a Promising Fast-Acting Trypanocidal Agent by Inducing Mitochondrial-Dependent Necrosis.
AID1055182	Selectivity index, ratio of IC50 for African green monkey Vero cells to IC50 for extracellular trypomastigote form of Trypanosoma cruzi IRHOD/CO/2008/SN3	2013	European journal of medicinal chemistry, , Volume: 70	Scorpiand-like azamacrocycles prevent the chronic establishment of Trypanosoma cruzi in a murine model.
AID1202577	Selectivity index, ratio of IC50 for human LL24 cells to IC50 for Trypanosoma cruzi Silvio X10 cl1 epimastigote forms	2015	European journal of medicinal chemistry, , Volume: 96	Designing and exploring active N'-[(5-nitrofuran-2-yl) methylene] substituted hydrazides against three Trypanosoma cruzi strains more prevalent in Chagas disease patients.
AID1687712	Toxicity in C3H mouse infected with Trypanosoma cruzi trypomastigotes assessed as mortality at 10 to 50 mg/kg, po treated 10 days post infection for 7 consecutive days	2020	European journal of medicinal chemistry, Jan-15, Volume: 186	Hit-to-lead optimization of novel 2-alkylaminomethylquinoline derivatives as anti-chagas agents.
AID669383	Cytotoxicity against Balb/c mouse peritoneal macrophages after 24 hrs by MTT assay	2012	Journal of natural products, May-25, Volume: 75, Issue:5	Antiprotozoal sesquiterpene pyridine alkaloids from Maytenus ilicifolia.
AID1228672	Antileishmanial activity against promastigote stage of Leishmania infantum MHOM/BR/1972/LD assessed as reduction of cell viability after 48 hrs by MTT assay	2015	Journal of natural products, May-22, Volume: 78, Issue:5	Anti-parasitic Guanidine and Pyrimidine Alkaloids from the Marine Sponge Monanchora arbuscula.
AID1473739	Inhibition of human MRP2 overexpressed in Sf9 cell membrane vesicles assessed as uptake of [3H]-estradiol-17beta-D-glucuronide in presence of ATP and GSH measured after 20 mins by membrane vesicle transport assay	2013	Toxicological sciences : an official journal of the Society of Toxicology, Nov, Volume: 136, Issue:1	A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.
AID1678868	Antitrypanosomal activity against Trypanosoma cruzi Y strain bloodstream trypomastigotes assessed as lysis of parasite in absence of mouse blood incubated for 24 hrs by Neubauer chamber method	2020	RSC medicinal chemistry, Oct-01, Volume: 11, Issue:10	Synthesis of quinone imine and sulphur-containing compounds with antitumor and trypanocidal activities: redox and biological implications.
AID1854932	Selectivity index, ratio of EC50 for Cytotoxicity against monkey LLC-MK2 cells to EC50 for antitrypanosomal activity against Trypanosoma cruzi Y trypomastigotes infected in monkey LLC-MK2 cells	2022	European journal of medicinal chemistry, Nov-05, Volume: 241	Rational design of a trypanocidal peptide derived from Dinoponera quadriceps venom.
AID1079946	Presence of at least one case with successful reintroduction. [column 'REINT' in source]
AID1613485	Trypanocidal activity against Trypanosoma cruzi MHOM/Pe/2011/Arequipa DTU 5 amastigotes infected in African green monkey Vero cells assessed as reduction in infected cells after 72 hrs by Giemsa-staining based assay	2019	European journal of medicinal chemistry, Feb-15, Volume: 164	New polyamine drugs as more effective antichagas agents than benznidazole in both the acute and chronic phases.
AID1613567	Hepatotoxicity in Balb/c mouse infected with Trypanosoma cruzi MHOM/Pe/2011/Arequipa DTU 5 trypomastigotes assessed as increase in alkaline phosphatase level at 20 mg/kg, po once daily for 5 consecutive days starting from day 10 post infection measured on	2019	European journal of medicinal chemistry, Feb-15, Volume: 164	New polyamine drugs as more effective antichagas agents than benznidazole in both the acute and chronic phases.
AID613449	Selectivity index, ratio of CC50 for african green monkey COS7 cells to IC50 for intracellular amastigotes form of Trypanosoma cruzi	2011	European journal of medicinal chemistry, Sep, Volume: 46, Issue:9	Synthesis, trypanocidal activity and molecular modeling studies of 2-alkylaminomethylquinoline derivatives.
AID1164937	Induction of apoptosis in human platelets assessed as late apoptotic cells after 10 mins using Annexin V/propidium iodide by flow cytometry (Rvb = 0.02 %)	2014	European journal of medicinal chemistry, Nov-24, Volume: 87	In vitro antiparasitic activity of new thiosemicarbazones in strains of Trypanosoma cruzi.
AID1422888	Cytotoxicity against African green monkey Vero cells after 72 hrs by MTT assay	2018	ACS medicinal chemistry letters, Oct-11, Volume: 9, Issue:10	Discovery of a Biologically Active Bromodomain Inhibitor by Target-Directed Dynamic Combinatorial Chemistry.
AID1587054	Antitrypanosomal activity against Trypanosoma cruzi Tulahuen amastigotes infected in mouse 3T3 cells assessed as relapse time at 12.5 times EC50 supplemented with fresh medium containing compound every 4 days for 16 days followed by compound washout and m	2019	ACS medicinal chemistry letters, Jan-10, Volume: 10, Issue:1	Triazolopyrimidines and Imidazopyridines: Structure-Activity Relationships and in Vivo Efficacy for Trypanosomiasis.
AID1244577	Cytotoxicity against BALB/c mouse splenocytes assessed as maximum non-toxic concentration by measuring [3H]-thymidine incorporation after 24 hrs by liquid scintillation counting	2015	European journal of medicinal chemistry, Aug-28, Volume: 101	Synthesis and structure-activity relationship study of a new series of antiparasitic aryloxyl thiosemicarbazones inhibiting Trypanosoma cruzi cruzain.
AID1584731	Therapeutic index, ratio EC50 for human MRC5 SV2 cells to EC50 for Trypanosoma cruzi Tulahuen CL2 intracellular amastigotes	2018	Journal of medicinal chemistry, 10-25, Volume: 61, Issue:20	Discovery of Novel 7-Aryl 7-Deazapurine 3'-Deoxy-ribofuranosyl Nucleosides with Potent Activity against Trypanosoma cruzi.
AID1312164	Antitrypanosomal activity against trypomastigote stage of Trypanosoma cruzi Y at 25 uM measured after 24 hrs using propidium iodide by neubauer chamber method relative to control	2016	Bioorganic & medicinal chemistry, 09-15, Volume: 24, Issue:18	Design, synthesis, molecular docking and biological evaluation of thiophen-2-iminothiazolidine derivatives for use against Trypanosoma cruzi.
AID580581	Antitrypanosomal activity against Trypanosoma cruzi Y infected in CD4+ T-lymphocyte knockout C57BL/6 mouse assessed as increase in survival of mouse at 100 mg/kg/day, po administered once daily for 20 consecutive days measured 60 days post infection	2009	Antimicrobial agents and chemotherapy, Jan, Volume: 53, Issue:1	Absence of CD4+ T lymphocytes, CD8+ T lymphocytes, or B lymphocytes has different effects on the efficacy of posaconazole and benznidazole in treatment of experimental acute Trypanosoma cruzi infection.
AID1613476	Selectivity index, ratio of IC50 for African green monkey Vero cells to IC50 for Trypanosoma cruzi MHOM/Pe/2011/Arequipa DTU 5 epimastigotes	2019	European journal of medicinal chemistry, Feb-15, Volume: 164	New polyamine drugs as more effective antichagas agents than benznidazole in both the acute and chronic phases.
AID1615061	Antitrypanosomal activity against Trypanosoma cruzi MHOM/Pe/2011/Arequipa DTU 5 trypomastigotes infected in Balb/c mouse assessed as reduction in Ig-G level in serum at 20 mg/kg, po pretreated once daily for 5 consecutive days starting from day 75 post in	2019	Bioorganic & medicinal chemistry, 03-01, Volume: 27, Issue:5	Synthesis and biological evaluation of new long-chain squaramides as anti-chagasic agents in the BALB/c mouse model.
AID1603748	Antitrypanosomal activity against Trypanosoma cruzi MHOM/Pe/2011/Arequipa;DTU 5 bloodstream trypomastigotes infected in BALB/c mouse assessed as reduction in serum Ig-G level in chronic phase at 20 mg/kg/day, po administered for 5 consecutive days startin	2019	Bioorganic & medicinal chemistry, 09-01, Volume: 27, Issue:17	Rational modification of Mannich base-type derivatives as novel antichagasic compounds: Synthesis, in vitro and in vivo evaluation.
AID1351076	Antitrypanosomal activity against Trypanosoma cruzi Y Tc2 amastigotes infected in human U2OS cells up to 200 uM after 72 hrs by Draq5 staining based HCS analysis relative to control	2018	European journal of medicinal chemistry, Jan-20, Volume: 144	Investigating the structure-activity relationships of N'-[(5-nitrofuran-2-yl) methylene] substituted hydrazides against Trypanosoma cruzi to design novel active compounds.
AID426309	Antiparasitic activity against Giardia intestinalis IMSS:0696 trophozoites after 48 hrs by Hill culture method	2009	European journal of medicinal chemistry, Jul, Volume: 44, Issue:7	Synthesis and in vitro trichomonicidal, giardicidal and amebicidal activity of N-acetamide(sulfonamide)-2-methyl-4-nitro-1H-imidazoles.
AID502042	Antimicrobial activity against epimastigotes form of Trypanosoma cruzi MHOM/MX/1994/Ninoa after 72 hrs	2010	Bioorganic & medicinal chemistry, Sep-01, Volume: 18, Issue:17	Design, synthesis, and in vitro antiprotozoal, antimycobacterial activities of N-{2-[(7-chloroquinolin-4-yl)amino]ethyl}ureas.
AID1603756	Selectivity index, ratio of IC50 for African green monkey Vero cells to IC50 for Trypanosoma cruzi MHOM/Pe/2011/Arequipa;DTU 5	2019	Bioorganic & medicinal chemistry, 09-01, Volume: 27, Issue:17	Rational modification of Mannich base-type derivatives as novel antichagasic compounds: Synthesis, in vitro and in vivo evaluation.
AID1074928	Selectivity index, ratio of IC50 for African green monkey Vero cells to IC50 for Trypanosoma cruzi (IRHOD/CO/2008/SN3) amastigotes	2014	European journal of medicinal chemistry, Mar-03, Volume: 74	New perspectives on the synthesis and antichagasic activity of 3-alkoxy-1-alkyl-5-nitroindazoles.
AID563570	Toxicity in CH3/He(H-2k) mouse assessed as mortality at cumulative dose of 100 mg/kg, po measured after 48 hrs	2010	Antimicrobial agents and chemotherapy, Jul, Volume: 54, Issue:7	Arylimidamide DB766, a potential chemotherapeutic candidate for Chagas' disease treatment.
AID282994	Antiparasitic activity against Trypanosoma brucei rhodesiense STIB900 blood stream form	2005	Journal of medicinal chemistry, Nov-17, Volume: 48, Issue:23	Irreversible inactivation of trypanothione reductase by unsaturated Mannich bases: a divinyl ketone as key intermediate.
AID677310	Trypanosomicidal activity against Trypanosoma cruzi epimastigotes assessed as change in ethanol metabolite excretion after 96 hrs by NMR analysis	2012	Journal of medicinal chemistry, May-10, Volume: 55, Issue:9	In vitro and in vivo trypanosomicidal activity of pyrazole-containing macrocyclic and macrobicyclic polyamines: their action on acute and chronic phases of Chagas disease.
AID1383434	Selectivity index, ratio of LC50 for Swiss Webster mouse cardiac cells by prestoblue assay to EC50 for bloodstream trypomastigote stage of Trypanosoma cruzi Y measured after 24 hrs	2018	European journal of medicinal chemistry, Apr-10, Volume: 149	Identification of Pyrazolo[3,4-e][1,4]thiazepin based CYP51 inhibitors as potential Chagas disease therapeutic alternative: In vitro and in vivo evaluation, binding mode prediction and SAR exploration.
AID1264445	Cytotoxicity against rat L6 cells after 6 days by resazurin staining based fluorescence plate reader assay	2015	European journal of medicinal chemistry, Nov-13, Volume: 105	Multicomponent reaction-based synthesis and biological evaluation of tricyclic heterofused quinolines with multi-trypanosomatid activity.
AID263384	Antitrypanosomal activity against Trypanosoma cruzi amastigotes at 1 ug/ml	2006	Bioorganic & medicinal chemistry letters, Apr-01, Volume: 16, Issue:7	New ligand-based approach for the discovery of antitrypanosomal compounds.
AID1686723	Antitrypanosomal activity against Trypanosoma cruzi infected in African green monkey Vero cells assessed as reduction in number of trypomastigotes measured up to 10 days by Giemsa staining based hemocytometry	2016	Journal of medicinal chemistry, 12-22, Volume: 59, Issue:24	In Vitro and in Vivo Anti-Trypanosoma cruzi Activity of New Arylamine Mannich Base-Type Derivatives.
AID1507437	Selectivity index, ratio of LC50 for cytotoxicity against Swiss albino mouse peritoneal macrophages to IC50 for Antitrypanosomal activity against bloodstream forms of Trypanosoma cruzi Y isolated from parasite infected Albino Swiss mouse	2017	European journal of medicinal chemistry, Aug-18, Volume: 136	Rhodium-catalyzed C-H bond activation for the synthesis of quinonoid compounds: Significant Anti-Trypanosoma cruzi activities and electrochemical studies of functionalized quinones.
AID1398306	Antitrypanosomal activity against Trypanosoma cruzi Tulahuen strain C2C4 amastigote forms harboring LacZ infected in rat L6 cells after 96 hrs by CPRG/Nonidet reagent based photometric method	2018	Bioorganic & medicinal chemistry, 09-01, Volume: 26, Issue:16	Antiprotozoal and cysteine proteases inhibitory activity of dipeptidyl enoates.
AID1381724	Inhibition of human microsomal CYP3A4 expressed in baculovirus infected BTI-TN-5B1-4 cells incubated for 30 mins by luciferase assay	2018	European journal of medicinal chemistry, Feb-25, Volume: 146	Aryl thiosemicarbazones for the treatment of trypanosomatidic infections.
AID453258	Toxicity against rat L6 cells	2009	Bioorganic & medicinal chemistry, Oct-15, Volume: 17, Issue:20	Structure-activity relationship of antiparasitic and cytotoxic indoloquinoline alkaloids, and their tricyclic and bicyclic analogues.
AID1683715	Antitrypanosomal activity against Trypanosoma cruzi IRHOD/CO/2008/SN3 (DTU I) amastigote form infected in Vero cells assessed as parasite growth inhibition incubated for 72 hrs by Giemsa-staining based assay	2020	Journal of natural products, 12-24, Volume: 83, Issue:12	In Vivo Biological Evaluation of a Synthetic Royleanone Derivative as a Promising Fast-Acting Trypanocidal Agent by Inducing Mitochondrial-Dependent Necrosis.
AID396587	Trypanocidal activity against Trypanosoma cruzi CL-B5 clone epimastigotes expressing lacZ gene after 72 hrs at 28 degC	2008	European journal of medicinal chemistry, Sep, Volume: 43, Issue:9	Activity of a hydroxybibenzyl bryophyte constituent against Leishmania spp. and Trypanosoma cruzi: in silico, in vitro and in vivo activity studies.
AID1699436	Cytotoxicity against rat L6 cells assessed as reduction in cell viability after 70 hrs by resazurin dye based inverted microscopic analysis	2020	Journal of natural products, 11-25, Volume: 83, Issue:11	Pyridine-4(1
AID707775	Antitrypanosomal activity against Trypanosoma cruzi IRHOD/VO/2008/SN3 metacyclic forms infected in african green monkey Vero cells assessed as inhibition of infection rate at IC25 level 0.5 to 10 days	2012	Journal of medicinal chemistry, Nov-26, Volume: 55, Issue:22	Phthalazine derivatives containing imidazole rings behave as Fe-SOD inhibitors and show remarkable anti-T. cruzi activity in immunodeficient-mouse mode of infection.
AID1603759	Antitrypanosomal activity against Trypanosoma cruzi MHOM/Pe/2011/Arequipa;DTU 5 amastigote forms measured after 72 hrs by Giemsa staining based assay	2019	Bioorganic & medicinal chemistry, 09-01, Volume: 27, Issue:17	Rational modification of Mannich base-type derivatives as novel antichagasic compounds: Synthesis, in vitro and in vivo evaluation.
AID1686743	Selectivity index, ratio of IC50 for cytotoxicity in African green monkey Vero cells to IC50 for antitrypanosomal activity against Trypanosoma cruzi Tulahuen promastigote forms	2016	Journal of medicinal chemistry, 12-22, Volume: 59, Issue:24	In Vitro and in Vivo Anti-Trypanosoma cruzi Activity of New Arylamine Mannich Base-Type Derivatives.
AID1854957	Induction of mitochondrial membrane potential loss in Trypanosoma cruzi Y epimastigotes at 125 uM incubated for 24 hrs by Rhodamine 123 staining based flow cytometric analysis relative to control	2022	European journal of medicinal chemistry, Nov-05, Volume: 241	Rational design of a trypanocidal peptide derived from Dinoponera quadriceps venom.
AID1079949	Proposed mechanism(s) of liver damage. [column 'MEC' in source]
AID1603862	Toxicity in BALB/c mouse infected with Trypanosoma cruzi MHOM/Pe/2011/Arequipa;DTU 5 bloodstream trypomastigote assessed as decrease in serum uric acid level in chronic phase at 20 mg/kg/day, po administered for 5 consecutive days starting from day 70 pos	2019	Bioorganic & medicinal chemistry, 09-01, Volume: 27, Issue:17	Rational modification of Mannich base-type derivatives as novel antichagasic compounds: Synthesis, in vitro and in vivo evaluation.
AID1348371	Cytotoxicity against human MRC5 SV2 cells assessed as decrease in cell viability after 72 hrs by resazurin dye-based fluorometric method	2018	European journal of medicinal chemistry, Jan-01, Volume: 143	Novel triazine dimers with potent antitrypanosomal activity.
AID1277387	Antiparasitic activity against Trypanosoma cruzi Tulahuen trypomastigotes infected in rat L6 cells using chromogenic substrate beta-D-galactopyranoside after 96 hrs by beta-galactosidase assay	2016	European journal of medicinal chemistry, Feb-15, Volume: 109	Highly improved antiparasitic activity after introduction of an N-benzylimidazole moiety on protein farnesyltransferase inhibitors.
AID1184290	Selectivity index, ratio of IC50 for human U2OS cells to IC50 for intracellular Trypanosoma cruzi	2014	European journal of medicinal chemistry, Sep-12, Volume: 84	Synthesis and biological evaluation of 2,3-dihydroimidazo[1,2-a]benzimidazole derivatives against Leishmania donovani and Trypanosoma cruzi.
AID1603760	Antitrypanosomal activity against bloodstream trypomastigote stage of Trypanosoma cruzi MHOM/Pe/2011/Arequipa; DTU 5 isolated from parasite infected BALB/c Albino mouse cardiac cells after 24 hrs by Neubauer chamber based cell counting method	2019	Bioorganic & medicinal chemistry, 09-01, Volume: 27, Issue:17	Rational modification of Mannich base-type derivatives as novel antichagasic compounds: Synthesis, in vitro and in vivo evaluation.
AID576077	Toxicity in human patient infected with Trypanosoma cruzi assessed as occurrence of agranulocytosis after 2nd week of treatment	2010	Antimicrobial agents and chemotherapy, Nov, Volume: 54, Issue:11	Tolerance of benznidazole in treatment of Chagas' disease in adults.
AID1198733	Cytotoxicity against human U937 cells assessed as cell viability after 72 hrs by MTT assay	2015	European journal of medicinal chemistry, Mar-26, Volume: 93	An efficient synthesis of new caffeine-based chalcones, pyrazolines and pyrazolo[3,4-b][1,4]diazepines as potential antimalarial, antitrypanosomal and antileishmanial agents.
AID1678865	Antitrypanosomal activity against Trypanosoma cruzi Y strain bloodstream trypomastigotes assessed as lysis of parasite in presence of 5 % mouse blood incubated for 24 hrs by Neubauer chamber method	2020	RSC medicinal chemistry, Oct-01, Volume: 11, Issue:10	Synthesis of quinone imine and sulphur-containing compounds with antitumor and trypanocidal activities: redox and biological implications.
AID1498171	Trypanocidal activity against Trypanosoma cruzi IRHOD/CO/2008/SN3 DTU 1 epimastigotes after 48 hrs by resazurin dye based assay	2018	Journal of medicinal chemistry, 07-12, Volume: 61, Issue:13	Second Generation of Mannich Base-Type Derivatives with in Vivo Activity against Trypanosoma cruzi.
AID669300	Cytotoxicity against monkey LLC-MK2 cells after 96 hrs by sulforhodamine B assay	2012	Journal of medicinal chemistry, Apr-12, Volume: 55, Issue:7	Terpenes from Copaifera demonstrated in vitro antiparasitic and synergic activity.
AID576094	Toxicity in human patient infected with Trypanosoma cruzi assessed as occurrence of Arthritis at 5 mg/kg/day for 60 days	2010	Antimicrobial agents and chemotherapy, Nov, Volume: 54, Issue:11	Tolerance of benznidazole in treatment of Chagas' disease in adults.
AID1294224	Cytotoxicity against mouse L929 cells after 48 hrs by resazurin assay	2016	European journal of medicinal chemistry, Jun-10, Volume: 115	Antichagasic and trichomonacidal activity of 1-substituted 2-benzyl-5-nitroindazolin-3-ones and 3-alkoxy-2-benzyl-5-nitro-2H-indazoles.
AID576099	Toxicity in human patient infected with Trypanosoma cruzi assessed as occurrence of Dysphagia at 5 mg/kg/day for 60 days	2010	Antimicrobial agents and chemotherapy, Nov, Volume: 54, Issue:11	Tolerance of benznidazole in treatment of Chagas' disease in adults.
AID341604	Antimicrobial activity against Giardia duodenalis WB	2007	Antimicrobial agents and chemotherapy, Aug, Volume: 51, Issue:8	Peroxide bond-dependent antiplasmodial specificity of artemisinin and OZ277 (RBx11160).
AID1690286	Antitrypanosomal activity against Trypanosoma cruzi CL amastigotes overexpressing tdTomato red fluorescent protein infected in gamma-irradiated African green monkey Vero cells assessed as reduction in parasite growth measured 3 days post-infection by fluo	2020	European journal of medicinal chemistry, Apr-01, Volume: 191	Synthesis and in vitro evaluation of new 5-substituted 6-nitroimidazooxazoles as antikinetoplastid agents.
AID1603841	Toxicity in BALB/c mouse infected with Trypanosoma cruzi MHOM/Pe/2011/Arequipa;DTU 5 bloodstream trypomastigote assessed as change in serum alkaline phosphatase level in acute phase at 20 mg/kg/day, po administered for 5 consecutive days starting from day	2019	Bioorganic & medicinal chemistry, 09-01, Volume: 27, Issue:17	Rational modification of Mannich base-type derivatives as novel antichagasic compounds: Synthesis, in vitro and in vivo evaluation.
AID1498242	Antitrypanosomal activity against Trypanosoma cruzi MHOM/Pe/2011/Arequipa DTU 5 trypamastigotes infected in Balb/c mouse assessed as reduction in parasitaemia reactivation in lung tissue at 20 mg/kg, po pretreated once daily for 5 consecutive days startin	2018	Journal of medicinal chemistry, 07-12, Volume: 61, Issue:13	Second Generation of Mannich Base-Type Derivatives with in Vivo Activity against Trypanosoma cruzi.
AID1519008	Antitrypanosomal activity against Trypanosoma cruzi K98 bloodstream form infected in C3H/HeNk mouse assessed as reduction in skeletal tissue inflammation at 75 mg/kg/day, po administered via gavage for 30 consecutive days starting from 90 days post infect	2019	European journal of medicinal chemistry, 12-15, Volume: 184	Combined therapy with Benznidazole and repurposed drugs Clofazimine and Benidipine for chronic Chagas disease.
AID1483952	Antiprotozoal activity against trypomastigote stage of Trypanosoma cruzi Tulahuen C2C4 infected in rat L6 cells using preincubated for 96 hrs by CPRG/Nonidet-based inverted microscopy	2017	Journal of natural products, 02-24, Volume: 80, Issue:2	Dioncophyllines C
AID1616179	Toxicity in Swiss Webster mouse infected with Trypanosoma cruzi Y trypomastigotes assessed as body weight loss at 100 mg/kg, po administered once daily for 5 days with 2 days interval for 3 cycles	2019	Journal of medicinal chemistry, 10-10, Volume: 62, Issue:19	Discovery of Pyrrolo[2,3-
AID303263	Antiparasitic activity against Trypanosoma cruzi Tulahuen T4 in amastigotes stage	2007	Journal of medicinal chemistry, Nov-15, Volume: 50, Issue:23	Synthesis and evaluation of antiparasitic activities of new 4-[5-(4-phenoxyphenyl)-2H-pyrazol-3-yl]morpholine derivatives.
AID1064591	Cytotoxicity against monkey LLC-MK2 cells after 48 hrs by MTT assay	2014	Bioorganic & medicinal chemistry, Feb-01, Volume: 22, Issue:3	Unsymmetrical 1,5-diaryl-3-oxo-1,4-pentadienyls and their evaluation as antiparasitic agents.
AID1470756	Trypanocidal activity against bloodstream form of Trypanosoma cruzi INC-5 infected in NIH mouse assessed as reduction in parasitemia at 100 mg/kg, po measured up to 6 hrs post dose by microscopic method	2017	European journal of medicinal chemistry, May-26, Volume: 132	An in vitro and in vivo evaluation of new potential trans-sialidase inhibitors of Trypanosoma cruzi predicted by a computational drug repositioning method.
AID1780972	Trypanocidal activity against Trypanosoma cruzi CL-Luc-Neon amastigotes infected in BSR cells assessed as inhibition of parasite growth at 20 times IC50 incubated for 20 days measured after 10 days of compound wash out by epifluorescence microscopy analys	2021	European journal of medicinal chemistry, Nov-05, Volume: 223	Design and synthesis of Mannich base-type derivatives containing imidazole and benzimidazole as lead compounds for drug discovery in Chagas Disease.
AID1608338	Trypanocidal activity against Trypanosoma cruzi Y strain bloodstream trypomastigotes after 24 hrs	2019	European journal of medicinal chemistry, Oct-01, Volume: 179	Synthesis of quinones with highlighted biological applications: A critical update on the strategies towards bioactive compounds with emphasis on lapachones.
AID1238027	Anti-trypanosomal activity against Trypanosoma cruzi Y epimastigotes assessed as parasite growth inhibition incubated for 72 hrs by MTT assay	2015	Bioorganic & medicinal chemistry letters, Aug-15, Volume: 25, Issue:16	Synthesis and evaluation of novel prenylated chalcone derivatives as anti-leishmanial and anti-trypanosomal compounds.
AID1615045	Antitrypanosomal activity against Trypanosoma cruzi MHOM/Pe/2011/Arequipa DTU 5 trypomastigotes infected in Balb/c mouse assessed as parasite-free muscle at 20 mg/kg, po pretreated once daily for 5 consecutive days starting from day 10 post infection foll	2019	Bioorganic & medicinal chemistry, 03-01, Volume: 27, Issue:5	Synthesis and biological evaluation of new long-chain squaramides as anti-chagasic agents in the BALB/c mouse model.
AID580575	Antitrypanosomal activity against Trypanosoma cruzi Y infected in C57BL/6 mouse assessed as increase in survival of mouse at 100 mg/kg/day, po administered once daily for 20 consecutive days measured 60 days post infection	2009	Antimicrobial agents and chemotherapy, Jan, Volume: 53, Issue:1	Absence of CD4+ T lymphocytes, CD8+ T lymphocytes, or B lymphocytes has different effects on the efficacy of posaconazole and benznidazole in treatment of experimental acute Trypanosoma cruzi infection.
AID1584759	Antiparasitic activity against Trypanosoma cruzi Y strain bloodstream trypomastigotes infected in Swiss Webster mouse assessed as protection against parasite-induced mortality at 25 mg/kg, po bid via gavage administered for 5 consecutive days starting fro	2018	Journal of medicinal chemistry, 10-25, Volume: 61, Issue:20	Discovery of Novel 7-Aryl 7-Deazapurine 3'-Deoxy-ribofuranosyl Nucleosides with Potent Activity against Trypanosoma cruzi.
AID1508579	Antitrypanosomal activity against bloodstream trypomastigote stage of Trypanosoma cruzi Y infected in Balb/c mouse assessed as reduction in blood parasitaemia at 100 mg/kg, po qd administered for 5 consecutive days starting from day 5 post infection measu	2017	European journal of medicinal chemistry, Dec-01, Volume: 141	Structural design, synthesis and pharmacological evaluation of thiazoles against Trypanosoma cruzi.
AID1508581	Antitrypanosomal activity against bloodstream trypomastigote stage of Trypanosoma cruzi Y infected in Balb/c mouse assessed as reduction in blood parasitaemia at 100 mg/kg, po qd administered for 5 consecutive days starting from day 5 post infection measu	2017	European journal of medicinal chemistry, Dec-01, Volume: 141	Structural design, synthesis and pharmacological evaluation of thiazoles against Trypanosoma cruzi.
AID1486935	Antiprotozoal activity against Leishmania mexicana MHOM/MX/ISETGS incubated for 72 hrs by Neubauer chamber based cell counting method	2017	Bioorganic & medicinal chemistry letters, 08-01, Volume: 27, Issue:15	Synthesis, in vitro and in vivo giardicidal activity of nitrothiazole-NSAID chimeras displaying broad antiprotozoal spectrum.
AID548281	Antimicrobial activity against Trypanosoma brucei NfxR1	2010	Antimicrobial agents and chemotherapy, Jul, Volume: 54, Issue:7	Cross-resistance to nitro drugs and implications for treatment of human African trypanosomiasis.
AID547247	Toxicity in mongrel dog infected with Trypanosoma cruzi Y assessed as weight loss at 12 mg/kg, po BID for 90 days started 12 to 22 days postinfection measured after 6 months	2010	Antimicrobial agents and chemotherapy, Jul, Volume: 54, Issue:7	Effects of ravuconazole treatment on parasite load and immune response in dogs experimentally infected with Trypanosoma cruzi.
AID1615021	Cytotoxicity against African green monkey Vero cells assessed as reduction in cell viability after 72 hrs by resazurin dye based assay	2019	Bioorganic & medicinal chemistry, 03-01, Volume: 27, Issue:5	Synthesis and biological evaluation of new long-chain squaramides as anti-chagasic agents in the BALB/c mouse model.
AID1294226	Selectivity index, ratio of LC50 for mouse L929 cells to IC50 for Trypanosoma cruzi CL-B5 lacZ epimastigotes in mouse L929 cells	2016	European journal of medicinal chemistry, Jun-10, Volume: 115	Antichagasic and trichomonacidal activity of 1-substituted 2-benzyl-5-nitroindazolin-3-ones and 3-alkoxy-2-benzyl-5-nitro-2H-indazoles.
AID1615052	Antitrypanosomal activity against Trypanosoma cruzi MHOM/Pe/2011/Arequipa DTU 5 trypomastigotes infected in Balb/c mouse assessed as parasite-free heart at 20 mg/kg, po pretreated once daily for 5 consecutive days starting from day 75 post infection follo	2019	Bioorganic & medicinal chemistry, 03-01, Volume: 27, Issue:5	Synthesis and biological evaluation of new long-chain squaramides as anti-chagasic agents in the BALB/c mouse model.
AID1851972	Solubility of compound in water at 0.1 M HCl at pH 1 by LC-UV analysis	2022	Journal of medicinal chemistry, 10-13, Volume: 65, Issue:19	Nitroimidazopyrazinones with Oral Activity against Tuberculosis and Chagas Disease in Mouse Models of Infection.
AID1321005	Antitrypanosomal activity against amastigote stage of Trypanosoma cruzi Y infected in human U2OS cells after 96 hrs by Draq5 staining-based high content screening assay	2016	European journal of medicinal chemistry, Oct-04, Volume: 121	Design, synthesis and antitrypanosomal activity of some nitrofurazone 1,2,4-triazolic bioisosteric analogues.
AID1686746	Selectivity index, ratio of IC50 for cytotoxicity in African green monkey Vero cells to IC50 for antitrypanosomal activity against Trypanosoma cruzi NS3 promastigote forms	2016	Journal of medicinal chemistry, 12-22, Volume: 59, Issue:24	In Vitro and in Vivo Anti-Trypanosoma cruzi Activity of New Arylamine Mannich Base-Type Derivatives.
AID1074924	Antitrypanosomal activity against Trypanosoma cruzi (IRHOD/CO/2008/SN3) infected in African green monkey Vero cells assessed as reduction in infection rate at IC25 treated for 12 hrs followed by compound-washout measured after 10 days by microscopic analy	2014	European journal of medicinal chemistry, Mar-03, Volume: 74	New perspectives on the synthesis and antichagasic activity of 3-alkoxy-1-alkyl-5-nitroindazoles.
AID1723649	Antitrypanosomal activity against Trypanosoma cruzi trypomastigotes	2020	Bioorganic & medicinal chemistry letters, 10-15, Volume: 30, Issue:20	Expanding the scope of synthetic 1,2,4-trioxanes towards Trypanosoma cruzi and Leishmania donovani.
AID1403390	Cytotoxicity activity against African green monkey Vero cells assessed as reduction in cell viability after 72 hrs by cell-titer-glo assay	2018	European journal of medicinal chemistry, Jan-20, Volume: 144	Efficacy of 2-hydroxy-3-phenylsulfanylmethyl-[1,4]-naphthoquinone derivatives against different Trypanosoma cruzi discrete type units: Identification of a promising hit compound.
AID766423	Selectivity index, ratio of LC50 for mouse NCTC-929 cells to IC50 for epimastigotes of Trypanosoma cruzi CL Brener	2013	Bioorganic & medicinal chemistry letters, Sep-01, Volume: 23, Issue:17	Selective activity of 2,4-diaryl-1,2,3,4-tetrahydroquinolines on Trypanosoma cruzi epimastigotes and amastigotes expressing β-galactosidase.
AID213643	The compound was evaluated for its inhibitory activity against Trypanosoma cruzi	2000	Bioorganic & medicinal chemistry letters, Jun-05, Volume: 10, Issue:11	Squalamine analogues as potential anti-trypanosomal and anti-leishmanial compounds.
AID669384	Selectivity index, ratio of IC50 for Balb/c mouse peritoneal macrophages to IC50 for epimastigotes of Trypanosoma cruzi	2012	Journal of natural products, May-25, Volume: 75, Issue:5	Antiprotozoal sesquiterpene pyridine alkaloids from Maytenus ilicifolia.
AID1706437	Selectivity index, ratio of IC50 for cytotoxicity against rat 3T3 cells to IC50 for antitrypanosomal activity against Trypanosoma cruzi Tulahuen strain C2C4 amastigotes infected in rat 3T3 cells	2020	European journal of medicinal chemistry, Dec-01, Volume: 207	Re-evaluating pretomanid analogues for Chagas disease: Hit-to-lead studies reveal both in vitro and in vivo trypanocidal efficacy.
AID1653747	Selectivity index, ratio of IC50 for rat L6 cells assessed as reduction in cell viability measured after 72 hrs by Alamar blue based inverted microscopy analysis to IC50 for Trypanosoma cruzi Tulahuen C4 trypomastigotes infected in rat L6 cells assessed a	2020	Bioorganic & medicinal chemistry, 01-01, Volume: 28, Issue:1	Synthesis, in-vitro antiprotozoal activity and molecular docking study of isothiocyanate derivatives.
AID1615099	Cardiotoxicity in Balb/c mouse infected with Trypanosoma cruzi MHOM/Pe/2011/Arequipa DTU 5 trypomastigotes assessed as change in ratio of creatine kinase in muscle to brain at 20 mg/kg, po once daily for 5 consecutive days starting from day 75 post infect	2019	Bioorganic & medicinal chemistry, 03-01, Volume: 27, Issue:5	Synthesis and biological evaluation of new long-chain squaramides as anti-chagasic agents in the BALB/c mouse model.
AID1613561	Hepatotoxicity in Balb/c mouse infected with Trypanosoma cruzi MHOM/Pe/2011/Arequipa DTU 5 trypomastigotes assessed as increase in total bilirubin level at 20 mg/kg, po once daily for 5 consecutive days starting from day 10 post infection measured on day	2019	European journal of medicinal chemistry, Feb-15, Volume: 164	New polyamine drugs as more effective antichagas agents than benznidazole in both the acute and chronic phases.
AID593266	Antiparasitic activity against Trypanosoma cruzi amastigotes infected in gamma-irradiated vero cells assessed as growth inhibition by fluorescence assay	2011	Bioorganic & medicinal chemistry, Apr-01, Volume: 19, Issue:7	Synthesis and biological evaluation of new 2-alkylaminoethyl-1,1-bisphosphonic acids against Trypanosoma cruzi and Toxoplasma gondii targeting farnesyl diphosphate synthase.
AID1403402	Trypanocidal activity against Trypanosoma cruzi CL trypomastigotes infected in monkey LLC-MK2 cells after 24 hrs by luminescent assay	2018	European journal of medicinal chemistry, Jan-20, Volume: 144	Efficacy of 2-hydroxy-3-phenylsulfanylmethyl-[1,4]-naphthoquinone derivatives against different Trypanosoma cruzi discrete type units: Identification of a promising hit compound.
AID1624261	Antitrypanosomal activity against nifurtimox-sensitive Trypanosoma cruzi Tulahuen CL2 harboring beta-galactosidase infected in human MRC5 cells after 7 days by resazurin dye-based assay	2019	European journal of medicinal chemistry, Feb-15, Volume: 164	Revisiting tubercidin against kinetoplastid parasites: Aromatic substitutions at position 7 improve activity and reduce toxicity.
AID756893	Antiprotozoal activity against intracellular amastigote form of Trypanosoma cruzi Tulahuen C2C4 expressing LacZ infected in rat L6 cells after 48 hrs	2013	Journal of medicinal chemistry, Jul-11, Volume: 56, Issue:13	Synthesis and antiprotozoal activity of dicationic m-terphenyl and 1,3-dipyridylbenzene derivatives.
AID766416	Antiparasitic activity against amastigotes of Trypanosoma cruzi CL Brener expressing Escherichia coli lacZ gene infected in mouse NCTC-929 cells assessed as parasite growth inhibition at 0.5 uM after 7 days by colorimetric assay	2013	Bioorganic & medicinal chemistry letters, Sep-01, Volume: 23, Issue:17	Selective activity of 2,4-diaryl-1,2,3,4-tetrahydroquinolines on Trypanosoma cruzi epimastigotes and amastigotes expressing β-galactosidase.
AID1686729	Antitrypanosomal activity against Trypanosoma cruzi Arequipa amastigote forms infected in African green monkey Vero cells incubated for 72 hrs by Giemsa staining based micrscopy	2016	Journal of medicinal chemistry, 12-22, Volume: 59, Issue:24	In Vitro and in Vivo Anti-Trypanosoma cruzi Activity of New Arylamine Mannich Base-Type Derivatives.
AID1070009	Antimicrobial activity against amastigote stage of Trypanosoma cruzi CL Brener infected in mouse NCTC-929 cells assessed as growth inhibition at 16 uM after 7 days by beta-galactosidase reporter gene assay	2014	Bioorganic & medicinal chemistry letters, Feb-15, Volume: 24, Issue:4	In vitro phenotypic screening of 7-chloro-4-amino(oxy)quinoline derivatives as putative anti-Trypanosoma cruzi agents.
AID1055181	Trypanocidal activity against amastigote form of Trypanosoma cruzi IRHOD/CO/2008/SN3 infected in African green monkey Vero cells assessed as inhibition of parasite infection rate at IC25 preincubated for 12 hrs followed by compound washout measured after	2013	European journal of medicinal chemistry, , Volume: 70	Scorpiand-like azamacrocycles prevent the chronic establishment of Trypanosoma cruzi in a murine model.
AID1603864	Toxicity in BALB/c mouse infected with Trypanosoma cruzi MHOM/Pe/2011/Arequipa;DTU 5 bloodstream trypomastigote assessed as decrease in serum creatine kinase muscle to brain ratio level in chronic phase at 20 mg/kg/day, po administered for 5 consecutive d	2019	Bioorganic & medicinal chemistry, 09-01, Volume: 27, Issue:17	Rational modification of Mannich base-type derivatives as novel antichagasic compounds: Synthesis, in vitro and in vivo evaluation.
AID1682936	Renal toxicity in BALB/c mouse infected with blood trypomastigote form of Trypanosoma cruzi strain Y assessed as creatinine level in plasma at 25 mg/kg, po administered via gavage daily for 15 days starting from 2 days post-infection and measured on 16th	2021	Bioorganic & medicinal chemistry, 01-01, Volume: 29	Trypanocidal activity of new 1,6-diphenyl-1H-pyrazolo[3,4-b]pyridine derivatives: Synthesis, in vitro and in vivo studies.
AID1198533	Trypanocidal activity against GFP expressing Trypanosoma cruzi Y C57BL/6J mouse acute model of trypanosomal infection assessed as reduction in parasitemia at 100 mg/kg/day, ip measured at 10,14 and 20 days post infection	2015	European journal of medicinal chemistry, Mar-26, Volume: 93	Computer-guided drug repurposing: identification of trypanocidal activity of clofazimine, benidipine and saquinavir.
AID1403406	Trypanocidal activity against Trypanosoma cruzi Dm28c intracellular amastigotes infected in African green monkey Vero cells after 72 hrs	2018	European journal of medicinal chemistry, Jan-20, Volume: 144	Efficacy of 2-hydroxy-3-phenylsulfanylmethyl-[1,4]-naphthoquinone derivatives against different Trypanosoma cruzi discrete type units: Identification of a promising hit compound.
AID576090	Toxicity in human patient infected with Trypanosoma cruzi assessed as occurrence of Weakness at 5 mg/kg/day for 60 days	2010	Antimicrobial agents and chemotherapy, Nov, Volume: 54, Issue:11	Tolerance of benznidazole in treatment of Chagas' disease in adults.
AID1720857	Trypanocidal activity against Trypanosoma cruzi Y strain bloodstream trypomastigotes isolated from infected Albino Swiss mouse assessed as lysis of parasite in absence of mouse blood incubated for 24 hrs by Neubauer chamber method	2020	Bioorganic & medicinal chemistry, 08-01, Volume: 28, Issue:15	Strategies towards potent trypanocidal drugs: Application of Rh-catalyzed [2 + 2 + 2] cycloadditions, sulfonyl phthalide annulation and nitroalkene reactions for the synthesis of substituted quinones and their evaluation against Trypanosoma cruzi.
AID1498263	Nephrotoxicity in Balb/c mouse infected with Trypanosoma cruzi MHOM/Pe/2011/Arequipa DTU 5 trypamastigotes assessed as decrease in urea level in serum at 20 mg/kg, po once daily for 5 consecutive days starting from day 10 post infection measured on day 12	2018	Journal of medicinal chemistry, 07-12, Volume: 61, Issue:13	Second Generation of Mannich Base-Type Derivatives with in Vivo Activity against Trypanosoma cruzi.
AID1462701	Antiparasitic activity against Trypanosoma cruzi Tulahuen C4 intracellular amastigotes infected in rat L6 cells after 96 hrs by CPRG/Nonidet reagent based photometric analysis	2017	Bioorganic & medicinal chemistry letters, 09-01, Volume: 27, Issue:17	Lead selection of antiparasitic compounds from a focused library of benzenesulfonyl derivatives of heterocycles.
AID356388	Antitrypanosomal activity against Trypanosoma cruzi	2003	Journal of natural products, Sep, Volume: 66, Issue:9	Ancistrotanzanine A, the first 5,3'-coupled naphthylisoquinoline alkaloid, and two further, 5,8'-linked related compounds from the newly described species Ancistrocladus tanzaniensis.
AID1054899	Cytotoxicity against mouse NCTC-929 cells assessed as reduction of cell viability after 24 hrs by resazurin dye-based fluorometric analysis	2013	Journal of medicinal chemistry, Nov-27, Volume: 56, Issue:22	In vitro and in vivo antileishmanial and trypanocidal studies of new N-benzene- and N-naphthalenesulfonamide derivatives.
AID1079947	Comments (NB not yet translated). [column 'COMMENTAIRES' in source]
AID1124787	Safety index, ratio of IC50 for human HepG2 cells to IC50 for epimastigote stage of Trypanosoma brucei 29-13	2014	Bioorganic & medicinal chemistry letters, Apr-01, Volume: 24, Issue:7	Synthesis and tripanocidal activity of ferrocenyl and benzyl diamines against Trypanosoma brucei and Trypanosoma cruzi.
AID1074927	Selectivity index, ratio of IC50 for African green monkey Vero cells to IC50 for Trypanosoma cruzi (IRHOD/CO/2008/SN3) epimastigotes	2014	European journal of medicinal chemistry, Mar-03, Volume: 74	New perspectives on the synthesis and antichagasic activity of 3-alkoxy-1-alkyl-5-nitroindazoles.
AID1683710	Antitrypanosomal activity against Trypanosoma cruzi TINF/CH/1956/Tulahuen (DTU VI) blood stream trypomastigote form assessed as parasite growth inhibition incubated for 24 hrs by resazurin dye based assay	2020	Journal of natural products, 12-24, Volume: 83, Issue:12	In Vivo Biological Evaluation of a Synthetic Royleanone Derivative as a Promising Fast-Acting Trypanocidal Agent by Inducing Mitochondrial-Dependent Necrosis.
AID396582	Antitrypanosomal activity against Trypanosoma cruzi Y epimastigotes	2008	European journal of medicinal chemistry, Aug, Volume: 43, Issue:8	Pyrimido[1,2-a]quinoxaline 6-oxide and phenazine 5,10-dioxide derivatives and related compounds as growth inhibitors of Trypanosoma cruzi.
AID1140926	Selectivity index, ratio of IC50 for African green monkey Vero cells to IC50 for Trypanosoma cruzi Sylvio X-10 amastigotes	2014	Journal of medicinal chemistry, May-22, Volume: 57, Issue:10	Optimization of antitrypanosomatid agents: identification of nonmutagenic drug candidates with in vivo activity.
AID1275387	Toxicity in acute chagas BALB/c mouse model infected with trypomastigotes stage of Trypanosoma cruzi strain CL Brener assessed as mortality at 50 mg/kg/day, po administered for 14 days started on day 9 post infection measured at 30 to 60 days	2016	European journal of medicinal chemistry, Feb-15, Volume: 109	New approach towards the synthesis of selenosemicarbazones, useful compounds for Chagas' disease.
AID1578093	Antitrypanosomal activity against Trypanosoma cruzi	2019	Bioorganic & medicinal chemistry letters, 10-15, Volume: 29, Issue:20	Antiprotozoal alkaloid principles of the plant family Amaryllidaceae.
AID1755138	Antitrypanosomal activity against Trypanosoma cruzi Tulahuen amastigotes infected in mouse NIH/3T3 cells assessed as parasite growth inhibition incubated for 4 days in glucose rich DMEM medium	2021	Bioorganic & medicinal chemistry letters, 09-01, Volume: 47	Synthesis, biochemical, and biological evaluation of C2 linkage derivatives of amino sugars, inhibitors of glucokinase from Trypanosoma cruzi.
AID1124785	Safety index, ratio of IC50 for human HepG2 cells to IC50 for procyclic stage of Trypanosoma brucei 427	2014	Bioorganic & medicinal chemistry letters, Apr-01, Volume: 24, Issue:7	Synthesis and tripanocidal activity of ferrocenyl and benzyl diamines against Trypanosoma brucei and Trypanosoma cruzi.
AID1615102	Cardiotoxicity in Balb/c mouse infected with Trypanosoma cruzi MHOM/Pe/2011/Arequipa DTU 5 trypomastigotes assessed as decrease in serum LDH level at 20 mg/kg, po once daily for 5 consecutive days starting from day 75 post infection measured on day 81 pos	2019	Bioorganic & medicinal chemistry, 03-01, Volume: 27, Issue:5	Synthesis and biological evaluation of new long-chain squaramides as anti-chagasic agents in the BALB/c mouse model.
AID1498327	Hepatotoxicity in Balb/c mouse infected with Trypanosoma cruzi MHOM/Pe/2011/Arequipa DTU 5 trypamastigotes assessed as change in ratio of serum ALT to GPT level at 20 mg/kg, po once daily for 5 consecutive days starting from day 75 post infection measured	2018	Journal of medicinal chemistry, 07-12, Volume: 61, Issue:13	Second Generation of Mannich Base-Type Derivatives with in Vivo Activity against Trypanosoma cruzi.
AID1493588	Antitrypanosomal activity against Trypanosoma cruzi Tulahuen amastigote forms infected in human U937 cells after 72 hrs by beta-galactosidase reporter gene assay
AID1079933	Acute liver toxicity defined via clinical observations and clear clinical-chemistry results: serum ALT or AST activity > 6 N or serum alkaline phosphatases activity > 1.7 N. This category includes cytolytic, choleostatic and mixed liver toxicity. Value is
AID1603840	Toxicity in BALB/c mouse infected with Trypanosoma cruzi MHOM/Pe/2011/Arequipa;DTU 5 bloodstream trypomastigote assessed as decrease in serum total bilirubin level in acute phase at 20 mg/kg/day, po administered for 5 consecutive days starting from day 8	2019	Bioorganic & medicinal chemistry, 09-01, Volume: 27, Issue:17	Rational modification of Mannich base-type derivatives as novel antichagasic compounds: Synthesis, in vitro and in vivo evaluation.
AID335550	Antitrypanosomal activity against Trypanosoma cruzi Tulahuen strain C2C4 containing galactosidase gene in rat L6 cells after 4 days	2002	Journal of natural products, Aug, Volume: 65, Issue:8	Ancistrocongolines A-D, new naphthylisoquinoline alkaloids from ancistrocladus congolensis.
AID1686738	Selectivity index, ratio of IC50 for cytotoxicity in African green monkey Vero cells to IC50 for antitrypanosomal activity against Trypanosoma cruzi Arequipa epimastigote forms	2016	Journal of medicinal chemistry, 12-22, Volume: 59, Issue:24	In Vitro and in Vivo Anti-Trypanosoma cruzi Activity of New Arylamine Mannich Base-Type Derivatives.
AID1154399	Antitrypanosomal activity against amastigote stage of Trypanosoma cruzi Y in BALB/c mouse peritoneal macrophages assessed as reduction of number of intracellular parasites per 100 cells after 4 days by hematoxylin/eosin staining-based optical microscopic	2014	Journal of natural products, Jun-27, Volume: 77, Issue:6	Dimeric flavonoids from Arrabidaea brachypoda and assessment of their anti-Trypanosoma cruzi activity.
AID710877	Cytotoxicity against BALB/c mouse splenocytes assessed as highest nontoxic concentration by measuring [3H]-thymidine incorporation after 24 hrs by beta-radiation counting	2012	Journal of medicinal chemistry, Dec-27, Volume: 55, Issue:24	Structural investigation of anti-Trypanosoma cruzi 2-iminothiazolidin-4-ones allows the identification of agents with efficacy in infected mice.
AID1603866	Toxicity in BALB/c mouse infected with Trypanosoma cruzi MHOM/Pe/2011/Arequipa;DTU 5 bloodstream trypomastigote assessed as increase in serum aspartate aminotransferase level in chronic phase at 20 mg/kg/day, po administered for 5 consecutive days startin	2019	Bioorganic & medicinal chemistry, 09-01, Volume: 27, Issue:17	Rational modification of Mannich base-type derivatives as novel antichagasic compounds: Synthesis, in vitro and in vivo evaluation.
AID1669166	Selectivity index, ratio of EC50 for cytotoxicity against rat H9C2 cells to EC50 for antitrypanosomal activity against Trypanosoma cruzi Y amastigotes infected in rat H9C2 cells	2020	ACS medicinal chemistry letters, Jun-11, Volume: 11, Issue:6	Development of Selective Steroid Inhibitors for the Glucose-6-phosphate Dehydrogenase from
AID1432288	Trypanocidal activity against Trypanosoma cruzi Tulahuen amastigote forms infected in human THP1 cells after 48 hrs	2017	European journal of medicinal chemistry, Mar-10, Volume: 128	Design and synthesis of a new series of 3,5-disubstituted isoxazoles active against Trypanosoma cruzi and Leishmania amazonensis.
AID1846641	Antiprotozoal activity against Trypanosoma cruzi Tulahuen C4 trypomastigote expressing beta-galactosidase infected in rat L6 cells assessed as parasite growth inhibition measured after 96 hrs in presence of CPRG/Nonidet by inverted microscopy	2021	Journal of medicinal chemistry, 05-13, Volume: 64, Issue:9	Synthesis and Biological Evaluation of Natural-Product-Inspired, Aminoalkyl-Substituted 1-Benzopyrans as Novel Antiplasmodial Agents.
AID1498174	Selectivity index, ratio of IC50 for African green monkey Vero cells to IC50 for Trypanosoma cruzi MHOM/Pe/2011/Arequipa DTU 5 epimastigotes	2018	Journal of medicinal chemistry, 07-12, Volume: 61, Issue:13	Second Generation of Mannich Base-Type Derivatives with in Vivo Activity against Trypanosoma cruzi.
AID707766	Antitrypanosomal activity against Trypanosoma cruzi IRHOD/VO/2008/SN3 metacyclic forms infected in BALB/c mouse model of acute Chagas disease assessed as reduction parasitemia at 5 mg/kg/day, ip administered for 5 consecutive days starting on day 7 post i	2012	Journal of medicinal chemistry, Nov-26, Volume: 55, Issue:22	Phthalazine derivatives containing imidazole rings behave as Fe-SOD inhibitors and show remarkable anti-T. cruzi activity in immunodeficient-mouse mode of infection.
AID1498279	Nephrotoxicity in Balb/c mouse infected with Trypanosoma cruzi MHOM/Pe/2011/Arequipa DTU 5 trypamastigotes assessed as decrease in uric acid level in serum at 20 mg/kg, po once daily for 5 consecutive days starting from day 75 post infection measured on d	2018	Journal of medicinal chemistry, 07-12, Volume: 61, Issue:13	Second Generation of Mannich Base-Type Derivatives with in Vivo Activity against Trypanosoma cruzi.
AID1687713	Anti-chagasic activity against Trypanosoma cruzi trypomastigotes infected in C3H mouse assessed as physically healthy with shiny appearance at 10 mg/kg, po treated 10 days post infection measured on day 19	2020	European journal of medicinal chemistry, Jan-15, Volume: 186	Hit-to-lead optimization of novel 2-alkylaminomethylquinoline derivatives as anti-chagas agents.
AID396007	Antimicrobial activity against Trypanosoma cruzi infected in BALB/c mouse assessed as parasitemia remaining by ELISA	2007	Antimicrobial agents and chemotherapy, Sep, Volume: 51, Issue:9	Impact of dual infections on chemotherapeutic efficacy in BALB/c mice infected with major genotypes of Trypanosoma cruzi.
AID464871	Antiparasitic activity against Trypanosoma cruzi Tulahuen C2C4 amastigotes	2010	Bioorganic & medicinal chemistry letters, Mar-15, Volume: 20, Issue:6	Discovery of novel and potent benzhydryl-tropane trypanocides highly selective for Trypanosoma cruzi.
AID1613466	Trypanocidal activity against Trypanosoma cruzi MHOM/Pe/2011/Arequipa DTU 5 epimastigotes after 48 to 72 hrs by resazurin dye based assay	2019	European journal of medicinal chemistry, Feb-15, Volume: 164	New polyamine drugs as more effective antichagas agents than benznidazole in both the acute and chronic phases.
AID1603883	Toxicity in BALB/c mouse infected with Trypanosoma cruzi MHOM/Pe/2011/Arequipa;DTU 5 bloodstream trypomastigote assessed as decrease in serum total bilirubin level in chronic phase at 20 mg/kg/day, po administered for 5 consecutive days starting from day	2019	Bioorganic & medicinal chemistry, 09-01, Volume: 27, Issue:17	Rational modification of Mannich base-type derivatives as novel antichagasic compounds: Synthesis, in vitro and in vivo evaluation.
AID1633352	Antitrypanosomal activity against Trypanosoma cruzi Y epimastigotes resazurin dye based assay
AID344434	Antiproliferative activity against Trypanosoma cruzi Y epimastigotes assessed as number of motile forms at 0.5 mM after 24 hrs by hemocytometer	2008	Journal of medicinal chemistry, Jul-24, Volume: 51, Issue:14	Complexation of the anti-Trypanosoma cruzi drug benznidazole improves solubility and efficacy.
AID1498234	Antitrypanosomal activity against Trypanosoma cruzi MHOM/Pe/2011/Arequipa DTU 5 trypamastigotes infected in Balb/c mouse assessed as reduction in parasitaemia reactivation in muscle tissue at 20 mg/kg, po pretreated once daily for 5 consecutive days start	2018	Journal of medicinal chemistry, 07-12, Volume: 61, Issue:13	Second Generation of Mannich Base-Type Derivatives with in Vivo Activity against Trypanosoma cruzi.
AID392015	Antitrypanosomal activity against Trypanosoma cruzi Tulahuen 2 infected Swiss mouse assessed as prevention of muscle inflammatory infiltrates at 200 mg/kg/day, po	2008	European journal of medicinal chemistry, Oct, Volume: 43, Issue:10	In vivo studies of 5-arylethenylbenzofuroxans in acute murine models of Chagas' disease.
AID764117	Selectivity index, ratio of IC50 for human FN1 fibroblasts to IC50 for epimastigotes of Trypanosoma cruzi Y	2013	Bioorganic & medicinal chemistry, Sep-01, Volume: 21, Issue:17	5-Nitro-2-furfuriliden derivatives as potential anti-Trypanosoma cruzi agents: design, synthesis, bioactivity evaluation, cytotoxicity and exploratory data analysis.
AID1070003	Antimicrobial activity against amastigote stage of Trypanosoma cruzi CL Brener infected in mouse NCTC-929 cells assessed as growth inhibition after 7 days by beta-galactosidase reporter gene assay	2014	Bioorganic & medicinal chemistry letters, Feb-15, Volume: 24, Issue:4	In vitro phenotypic screening of 7-chloro-4-amino(oxy)quinoline derivatives as putative anti-Trypanosoma cruzi agents.
AID1079934	Highest frequency of acute liver toxicity observed during clinical trials, expressed as a percentage. [column '% AIGUE' in source]
AID1518974	Toxicity in C3H/HeNk mouse infected with Trypanosoma cruzi K98 bloodstream form assessed as decrease in body weight at 30 mg/kg/day, po administered via gavage for 30 consecutive days starting from 90 days post infection measured at 150 days post infectio	2019	European journal of medicinal chemistry, 12-15, Volume: 184	Combined therapy with Benznidazole and repurposed drugs Clofazimine and Benidipine for chronic Chagas disease.
AID1613479	Selectivity index, ratio of IC50 for African green monkey Vero cells to IC50 for Trypanosoma cruzi IRHOD/CO/2008/SN3 DTU 1 epimastigotes	2019	European journal of medicinal chemistry, Feb-15, Volume: 164	New polyamine drugs as more effective antichagas agents than benznidazole in both the acute and chronic phases.
AID693360	Growth inhibition of epimastigote form of Trypanosoma cruzi CL-B5 after 72 hrs by lacZ reporter gene assay	2012	European journal of medicinal chemistry, Dec, Volume: 58	Synthesis, biological evaluation and chemometric analysis of indazole derivatives. 1,2-Disubstituted 5-nitroindazolinones, new prototypes of antichagasic drug.
AID1061028	Antimicrobial activity against Trypanosoma cruzi	2014	Bioorganic & medicinal chemistry, Jan-01, Volume: 22, Issue:1	New insights into molecular recognition of 1,1-bisphosphonic acids by farnesyl diphosphate synthase.
AID1070014	Antimicrobial activity against epimastigote stage of Trypanosoma cruzi CL Brener assessed as growth inhibition after 72 hrs by beta-galactosidase reporter gene assay	2014	Bioorganic & medicinal chemistry letters, Feb-15, Volume: 24, Issue:4	In vitro phenotypic screening of 7-chloro-4-amino(oxy)quinoline derivatives as putative anti-Trypanosoma cruzi agents.
AID1191155	Antitrypanosomal activity against amastigote stage of Trypanosoma cruzi	2015	European journal of medicinal chemistry, Jan-27, Volume: 90	Synthesis and biological evaluation of novel 2,3-disubstituted quinoxaline derivatives as antileishmanial and antitrypanosomal agents.
AID756892	Selectivity index, ratio of IC50 for rat L6 cells to IC50 for Trypanosoma cruzi Tulahuen C2C4	2013	Journal of medicinal chemistry, Jul-11, Volume: 56, Issue:13	Synthesis and antiprotozoal activity of dicationic m-terphenyl and 1,3-dipyridylbenzene derivatives.
AID1518968	Antitrypanosomal activity against Trypanosoma cruzi K98 bloodstream form infected in C3H/HeNk mouse assessed as change in QRS morphology at 30 mg/kg/day, po administered via gavage for 30 consecutive days starting from 90 days post infection and measured	2019	European journal of medicinal chemistry, 12-15, Volume: 184	Combined therapy with Benznidazole and repurposed drugs Clofazimine and Benidipine for chronic Chagas disease.
AID547245	Toxicity in mongrel dog infected with Trypanosoma cruzi Berenice-78 assessed as weight loss at 12 mg/kg, po BID for 90 days started 12 to 22 days postinfection measured after 1 day	2010	Antimicrobial agents and chemotherapy, Jul, Volume: 54, Issue:7	Effects of ravuconazole treatment on parasite load and immune response in dogs experimentally infected with Trypanosoma cruzi.
AID580577	Antitrypanosomal activity against Trypanosoma cruzi Y infected in C57BL/6 mouse assessed as cure rate in mouse at 100 mg/kg/day, po administered once daily for 20 consecutive days measured 60 days post infection	2009	Antimicrobial agents and chemotherapy, Jan, Volume: 53, Issue:1	Absence of CD4+ T lymphocytes, CD8+ T lymphocytes, or B lymphocytes has different effects on the efficacy of posaconazole and benznidazole in treatment of experimental acute Trypanosoma cruzi infection.
AID1062787	Antitrypanosomal activity against Trypanosoma cruzi Tulahuen 6 infected in Swiss mouse assessed as mouse survival at 100 mg/kg, po qd administered on day 8 post-infection measured on same day by microscopic analysis	2013	Journal of medicinal chemistry, Dec-27, Volume: 56, Issue:24	Two analogues of fenarimol show curative activity in an experimental model of Chagas disease.
AID1766958	Antitrypanosomal activity against trypomastigote forms of Trypanosoma cruzi Y infected in LLC-MK2 cells assessed as parasite growth inhibition by resazurin assay
AID1498194	Genotoxicity in Salmonella typhimurium TA1535 harboring pSK1002 up to 0.5 mg/ml in presence of S9 fraction by SOS/umu assay	2018	Journal of medicinal chemistry, 07-12, Volume: 61, Issue:13	Second Generation of Mannich Base-Type Derivatives with in Vivo Activity against Trypanosoma cruzi.
AID1473741	Inhibition of human MRP4 overexpressed in Sf9 cell membrane vesicles assessed as uptake of [3H]-estradiol-17beta-D-glucuronide in presence of ATP and GSH measured after 20 mins by membrane vesicle transport assay	2013	Toxicological sciences : an official journal of the Society of Toxicology, Nov, Volume: 136, Issue:1	A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.
AID764120	Selectivity index, ratio of IC50 for mouse J774 cells to IC50 for epimastigotes of Trypanosoma cruzi Y	2013	Bioorganic & medicinal chemistry, Sep-01, Volume: 21, Issue:17	5-Nitro-2-furfuriliden derivatives as potential anti-Trypanosoma cruzi agents: design, synthesis, bioactivity evaluation, cytotoxicity and exploratory data analysis.
AID1254442	Antiparasitic activity against bloodstream trypomastigote stage of Trypanosoma cruzi Y infected in BALB/c mouse assessed as reduction of parasitemia at 100 mg/kg, po qd administered for 5 days measured on day 10 post infection relative to vehicle-treated	2015	Bioorganic & medicinal chemistry, Dec-01, Volume: 23, Issue:23	Structural design, synthesis and pharmacological evaluation of 4-thiazolidinones against Trypanosoma cruzi.
AID1498276	Nephrotoxicity in Balb/c mouse infected with Trypanosoma cruzi MHOM/Pe/2011/Arequipa DTU 5 trypamastigotes assessed as change in uric acid level in serum at 20 mg/kg, po once daily for 5 consecutive days starting from day 10 post infection measured on day	2018	Journal of medicinal chemistry, 07-12, Volume: 61, Issue:13	Second Generation of Mannich Base-Type Derivatives with in Vivo Activity against Trypanosoma cruzi.
AID563565	Cytotoxicity against Swiss-Webster mouse assessed as effect on creatine kinase at 100 mg/kg/day measured after 14 days postinfection	2010	Antimicrobial agents and chemotherapy, Jul, Volume: 54, Issue:7	Arylimidamide DB766, a potential chemotherapeutic candidate for Chagas' disease treatment.
AID1501885	Selectivity index, ratio of IC50 for mouse NCTC-929 cells to IC50 for Trypanosoma cruzi Y trypomastigotes	2017	European journal of medicinal chemistry, Oct-20, Volume: 139	Efficacy of a series of alpha-pyrone derivatives against Leishmania (L.) infantum and Trypanosoma cruzi.
AID1686739	Selectivity index, ratio of IC50 for cytotoxicity in African green monkey Vero cells to IC50 for antitrypanosomal activity against Trypanosoma cruzi Arequipa amastigotes forms	2016	Journal of medicinal chemistry, 12-22, Volume: 59, Issue:24	In Vitro and in Vivo Anti-Trypanosoma cruzi Activity of New Arylamine Mannich Base-Type Derivatives.
AID396009	Antimicrobial activity against Trypanosoma cruzi infected in BALB/c mouse assessed as parasitemia remaining by FC-ALTA	2007	Antimicrobial agents and chemotherapy, Sep, Volume: 51, Issue:9	Impact of dual infections on chemotherapeutic efficacy in BALB/c mice infected with major genotypes of Trypanosoma cruzi.
AID1501891	Antitrypanosomal activity against Trypanosoma cruzi Y infected in BALB/c mouse assessed as reduction in blood parasitemia at 100 mg/kg, po administered every day starting on day 5 post infection measured on day 8 post infection	2017	European journal of medicinal chemistry, Oct-20, Volume: 139	Efficacy of a series of alpha-pyrone derivatives against Leishmania (L.) infantum and Trypanosoma cruzi.
AID1294228	Antichagasic activity against Trypanosoma cruzi Tulahuen amastigotes in mouse L929 cells assessed as growth inhibition after 96 hrs by beta galactosidase reporter gene assay	2016	European journal of medicinal chemistry, Jun-10, Volume: 115	Antichagasic and trichomonacidal activity of 1-substituted 2-benzyl-5-nitroindazolin-3-ones and 3-alkoxy-2-benzyl-5-nitro-2H-indazoles.
AID1699435	Growth inhibition of amastigote form of Trypanosoma cruzi Tulahuen C2C4 expressing LacZ infected in rat L6 cells assessed as reduction in parasitic growth incubated for 96 hra by CPRG/Nonidet reagent based inverted microscopic analysis	2020	Journal of natural products, 11-25, Volume: 83, Issue:11	Pyridine-4(1
AID710881	Antitrypanosomal activity against trypomastigotes of Trypanosoma cruzi Y infected in BALB/c mouse assessed as reduction of blood parasite level at 250 umol/kg, po qd for 5 days	2012	Journal of medicinal chemistry, Dec-27, Volume: 55, Issue:24	Structural investigation of anti-Trypanosoma cruzi 2-iminothiazolidin-4-ones allows the identification of agents with efficacy in infected mice.
AID1498295	Cardiotoxicity in Balb/c mouse infected with Trypanosoma cruzi MHOM/Pe/2011/Arequipa DTU 5 trypamastigotes assessed as change in serum LDH level at 20 mg/kg, po once daily for 5 consecutive days starting from day 10 post infection measured on day 16 post	2018	Journal of medicinal chemistry, 07-12, Volume: 61, Issue:13	Second Generation of Mannich Base-Type Derivatives with in Vivo Activity against Trypanosoma cruzi.
AID1062983	Trypanocidal activity against Trypanosoma cruzi Tulahuen amastigotes infected in mouse L929 cells assessed as parasite growth inhibition after 7 days by beta-galactosidase assay	2014	European journal of medicinal chemistry, Jan, Volume: 71	Synthesis and evaluation of the antiparasitic activity of bis-(arylmethylidene) cycloalkanones.
AID1202572	Anti-trypanosomal activity against Trypanosoma cruzi Y epimastigote forms assessed as inhibition of parasite growth after 72 hrs by microplate reader based assay	2015	European journal of medicinal chemistry, , Volume: 96	Designing and exploring active N'-[(5-nitrofuran-2-yl) methylene] substituted hydrazides against three Trypanosoma cruzi strains more prevalent in Chagas disease patients.
AID274746	Antiprotozoal activity against Trypanosoma cruzi Tulahuen C2C4 trypomastigotes in L6 cells	2007	Journal of natural products, Jan, Volume: 70, Issue:1	Limonoid orthoacetates and antiprotozoal compounds from the roots of Pseudocedrela kotschyi.
AID1074382	Antitrypanosomal activity against epimastigote stage of Trypanosoma cruzi IRHOD/CO/2008/SN3 assessed as parasite growth inhibition after 72 hrs by Neubauer hemocytometric chamber analysis	2014	Journal of medicinal chemistry, Feb-13, Volume: 57, Issue:3	Synthesis and biological evaluation of N,N'-squaramides with high in vivo efficacy and low toxicity: toward a low-cost drug against Chagas disease.
AID1498285	Cardiotoxicity in Balb/c mouse infected with Trypanosoma cruzi MHOM/Pe/2011/Arequipa DTU 5 trypamastigotes assessed as change in ratio of creatine kinase in muscle to brain at 20 mg/kg, po once daily for 5 consecutive days starting from day 10 post infect	2018	Journal of medicinal chemistry, 07-12, Volume: 61, Issue:13	Second Generation of Mannich Base-Type Derivatives with in Vivo Activity against Trypanosoma cruzi.
AID547270	Immunostimulatory activity in mongrel dog infected with Trypanosoma cruzi Berenice-78 assessed as production of antibody IgG2 at 12 mg/kg, po BID for 90 days measured up to 30 days by ELISA	2010	Antimicrobial agents and chemotherapy, Jul, Volume: 54, Issue:7	Effects of ravuconazole treatment on parasite load and immune response in dogs experimentally infected with Trypanosoma cruzi.
AID1155753	Trypanocidal activity against Trypanosoma cruzi Tulahuen C2C4 amastigotes infected in rat L6 cells after 4 days	2014	European journal of medicinal chemistry, Jul-23, Volume: 82	Design, synthesis and biological evaluation of hybrid bioisoster derivatives of N-acylhydrazone and furoxan groups with potential and selective anti-Trypanosoma cruzi activity.
AID564778	Antitrypanosomal activity against Trypanosoma cruzi Columbian bloodstream forms infected in C3H mouse assessed as decrease in parasite load at 100 mg/kg/day, ip administered 5 days postinfection for 10 consecutive days measured after 31 days	2010	Antimicrobial agents and chemotherapy, Jul, Volume: 54, Issue:7	Arylimidamide DB766, a potential chemotherapeutic candidate for Chagas' disease treatment.
AID1487117	Cytotoxicity against mouse J774 cells incubated for 24 hrs by resazurin dye based fluorescence assay	2017	Bioorganic & medicinal chemistry letters, 08-01, Volume: 27, Issue:15	Synthesis and biological evaluation of 2-methyl-1H-benzimidazole-5-carbohydrazides derivatives as modifiers of redox homeostasis of Trypanosoma cruzi.
AID564745	Toxicity in female Swiss-Webster mouse assessed as mortality at cumulative dose of 200 mg/kg, ip measured after 48 hrs	2010	Antimicrobial agents and chemotherapy, Jul, Volume: 54, Issue:7	Arylimidamide DB766, a potential chemotherapeutic candidate for Chagas' disease treatment.
AID1615115	Hepatotoxicity in Balb/c mouse infected with Trypanosoma cruzi MHOM/Pe/2011/Arequipa DTU 5 trypomastigotes assessed as increase in ratio of serum ALT to GPT level at 20 mg/kg, po once daily for 5 consecutive days starting from day 75 post infection measur	2019	Bioorganic & medicinal chemistry, 03-01, Volume: 27, Issue:5	Synthesis and biological evaluation of new long-chain squaramides as anti-chagasic agents in the BALB/c mouse model.
AID1849825	Antitrypanosomal activity against bloodstream form of Trypanosoma cruzi Y amastigotes infected in monkey LLC-MK2 cells assessed as parasite growth inhibition incubated for 5 days by Neubauer hemocytometer based fluorescence spectrophotometer method	2021	European journal of medicinal chemistry, Jan-15, Volume: 210	A comprehensive review on β-lapachone: Mechanisms, structural modifications, and therapeutic potentials.
AID563562	Antitrypanosomal activity against Trypanosoma cruzi Y bloodstream forms infected in Swiss-Webster mouse assessed as decrease in parasite load at 100 mg/kg/day, po administered 5 days postinfection for 10 alternate days measured after 31 days	2010	Antimicrobial agents and chemotherapy, Jul, Volume: 54, Issue:7	Arylimidamide DB766, a potential chemotherapeutic candidate for Chagas' disease treatment.
AID762754	Cytotoxicity against C57BL/6 mouse spleen cells after 24 hrs using propidium iodide by flow cytometry	2013	Bioorganic & medicinal chemistry letters, Aug-15, Volume: 23, Issue:16	Molecular design, synthesis and biological evaluation of 1,4-dihydro-4-oxoquinoline ribonucleosides as TcGAPDH inhibitors with trypanocidal activity.
AID214467	Compound was evaluated for anti-parasitic activity against Trypanosoma cruzi	2001	Journal of medicinal chemistry, Mar-15, Volume: 44, Issue:6	Bisphosphonates inhibit the growth of Trypanosoma brucei, Trypanosoma cruzi, Leishmania donovani, Toxoplasma gondii, and Plasmodium falciparum: a potential route to chemotherapy.
AID1603829	Antitrypanosomal activity against Trypanosoma cruzi MHOM/Pe/2011/Arequipa;DTU 5 bloodstream trypomastigote infected in BALB/c mouse assessed as parasite-free spleen in chronic phase at 20 mg/kg/day, po administered for 5 consecutive days starting from day	2019	Bioorganic & medicinal chemistry, 09-01, Volume: 27, Issue:17	Rational modification of Mannich base-type derivatives as novel antichagasic compounds: Synthesis, in vitro and in vivo evaluation.
AID564764	Antitrypanosomal activity against Trypanosoma cruzi Columbian bloodstream forms infected in C3H mouse assessed as decrease in parasite load at 100 mg/kg/day, ip administered 21 days postinfection measured on day 46	2010	Antimicrobial agents and chemotherapy, Jul, Volume: 54, Issue:7	Arylimidamide DB766, a potential chemotherapeutic candidate for Chagas' disease treatment.
AID1548466	Antitrypanosomal activity against Trypanosoma cruzi CL Brener amastigotes infected in African green monkey Vero cells assessed as reduction in parasite growth incubated for 120 hrs at 24 hrs post-infection and measured on day 6 post-infection by hemocytom
AID1278151	Cytotoxicity against mouse NCTC-929 cells assessed as cell viability after 48 hrs by MTT assay	2016	Bioorganic & medicinal chemistry letters, Feb-15, Volume: 26, Issue:4	Gibbilimbol analogues as antiparasitic agents--Synthesis and biological activity against Trypanosoma cruzi and Leishmania (L.) infantum.
AID1578097	Antitrypanosomal activity against Leishmania donovani	2019	Bioorganic & medicinal chemistry letters, 10-15, Volume: 29, Issue:20	Antiprotozoal alkaloid principles of the plant family Amaryllidaceae.
AID1254437	Selectivity index, ratio of CC50 for human J774 cells to IC50 for bloodstream trypomastigote stage of Trypanosoma cruzi Y	2015	Bioorganic & medicinal chemistry, Dec-01, Volume: 23, Issue:23	Structural design, synthesis and pharmacological evaluation of 4-thiazolidinones against Trypanosoma cruzi.
AID576832	Antitrypanosomal activity against Trypanosoma cruzi infected in african green monkey Vero cells assessed as reduction of amastigote number per infected cell at IC25 after 10 days relative to control	2011	Journal of medicinal chemistry, Feb-24, Volume: 54, Issue:4	In vivo trypanosomicidal activity of imidazole- or pyrazole-based benzo[g]phthalazine derivatives against acute and chronic phases of Chagas disease.
AID1686736	Antitrypanosomal activity against Trypanosoma cruzi SN3 trypomastigote froms infected in mouse blood incubated for 24 hrs by Neubauer chamber based assay	2016	Journal of medicinal chemistry, 12-22, Volume: 59, Issue:24	In Vitro and in Vivo Anti-Trypanosoma cruzi Activity of New Arylamine Mannich Base-Type Derivatives.
AID1062982	Cytotoxicity against mouse L929 cells after 96 hrs by Alamar blue assay	2014	European journal of medicinal chemistry, Jan, Volume: 71	Synthesis and evaluation of the antiparasitic activity of bis-(arylmethylidene) cycloalkanones.
AID576083	Toxicity in human patient infected with Trypanosoma cruzi assessed as occurrence of Palmar-plantar rash at 5 mg/kg/day for 60 days	2010	Antimicrobial agents and chemotherapy, Nov, Volume: 54, Issue:11	Tolerance of benznidazole in treatment of Chagas' disease in adults.
AID392014	Antitrypanosomal activity against Trypanosoma cruzi Tulahuen 2 infected Swiss mouse assessed as prevention of heart inflammatory infiltrates at 200 mg/kg/day, po	2008	European journal of medicinal chemistry, Oct, Volume: 43, Issue:10	In vivo studies of 5-arylethenylbenzofuroxans in acute murine models of Chagas' disease.
AID249624	Percentage delyse against amastigote forms of Y strain of Trypanosoma cruzi at 2 uM	2005	Bioorganic & medicinal chemistry letters, Jan-17, Volume: 15, Issue:2	Trypanocidal activity of (-)-cubebin derivatives against free amastigote forms of Trypanosoma cruzi.
AID1355404	Antiprotozoal activity against trypomastigote form of Trypanosoma cruzi Tulahuen C2C4 infected in rat L6 cells after 96 hrs by CPRG/Nonidet-based photometric method	2018	Journal of natural products, 06-22, Volume: 81, Issue:6	Phytochemical Study of Salvia leriifolia Roots: Rearranged Abietane Diterpenoids with Antiprotozoal Activity.
AID1361363	Trypanocidal activity against trypomastigote stage of Trypanosoma cruzi NINOA infected in NIH mouse blood assessed as reduction in parasite lysis after 24 hrs by optical microscopic method	2018	European journal of medicinal chemistry, Aug-05, Volume: 156	Synthesis, molecular docking and biological evaluation of novel phthaloyl derivatives of 3-amino-3-aryl propionic acids as inhibitors of Trypanosoma cruzi trans-sialidase.
AID1683717	Antitrypanosomal activity against Trypanosoma cruzi MHOM/Pe/2011/Arequipa(DTU V) amastigote form infected in Vero cells assessed as parasite growth inhibition incubated for 72 hrs by Giemsa-staining based assay	2020	Journal of natural products, 12-24, Volume: 83, Issue:12	In Vivo Biological Evaluation of a Synthetic Royleanone Derivative as a Promising Fast-Acting Trypanocidal Agent by Inducing Mitochondrial-Dependent Necrosis.
AID1615109	Hepatotoxicity in Balb/c mouse infected with Trypanosoma cruzi MHOM/Pe/2011/Arequipa DTU 5 trypomastigotes assessed as increase in ratio of serum AST to GOT level at 20 mg/kg, po once daily for 5 consecutive days starting from day 75 post infection measur	2019	Bioorganic & medicinal chemistry, 03-01, Volume: 27, Issue:5	Synthesis and biological evaluation of new long-chain squaramides as anti-chagasic agents in the BALB/c mouse model.
AID229349	Ratio of inhibitory concentration to that of reference drug was determined	2001	Bioorganic & medicinal chemistry letters, Oct-22, Volume: 11, Issue:20	Anti-Trypanosoma activity of some natural stilbenoids and synthetic related heterocyclic compounds.
AID707762	Antitrypanosomal activity against Trypanosoma cruzi IRHOD/VO/2008/SN3 metacyclic forms infected in BALB/c mouse model of chronic Chagas disease subjected to 3 cycles of immunosuppression with 50 mg/kg cyclophosphamide monohydrate for 3 consecutive weeks a	2012	Journal of medicinal chemistry, Nov-26, Volume: 55, Issue:22	Phthalazine derivatives containing imidazole rings behave as Fe-SOD inhibitors and show remarkable anti-T. cruzi activity in immunodeficient-mouse mode of infection.
AID564080	Antitrypanosomal activity against Trypanosoma cruzi 956 epimastigotes after 24 hrs by light microscopy	2010	Antimicrobial agents and chemotherapy, Jul, Volume: 54, Issue:7	Arylimidamide DB766, a potential chemotherapeutic candidate for Chagas' disease treatment.
AID1381726	Cytotoxicity against human WI38 cells after 48 hrs by CellTiter-Glo assay	2018	European journal of medicinal chemistry, Feb-25, Volume: 146	Aryl thiosemicarbazones for the treatment of trypanosomatidic infections.
AID1245596	Toxicity in Balb/c mouse at 13 mg/kg/day, ip	2015	Bioorganic & medicinal chemistry, Oct-01, Volume: 23, Issue:19	Discovery of potent nitrotriazole-based antitrypanosomal agents: In vitro and in vivo evaluation.
AID344431	Antiproliferative activity against Trypanosoma cruzi Y epimastigotes assessed as number of motile forms at 0.5 mM after 4 hrs by hemocytometer	2008	Journal of medicinal chemistry, Jul-24, Volume: 51, Issue:14	Complexation of the anti-Trypanosoma cruzi drug benznidazole improves solubility and efficacy.
AID613445	Trypanocidal activity against bloodstream trypomastigote form of Trypanosoma cruzi after 24 hrs	2011	European journal of medicinal chemistry, Sep, Volume: 46, Issue:9	Synthesis, trypanocidal activity and molecular modeling studies of 2-alkylaminomethylquinoline derivatives.
AID564765	Hepatotoxicity in Swiss-Webster mouse assessed as effect on GPT level at 25 mg/kg/day, ip administered 21 days postinfection measured on day 120	2010	Antimicrobial agents and chemotherapy, Jul, Volume: 54, Issue:7	Arylimidamide DB766, a potential chemotherapeutic candidate for Chagas' disease treatment.
AID266614	Antitrypanosomal activity against Trypanosoma cruzi	2006	Bioorganic & medicinal chemistry letters, Jul-15, Volume: 16, Issue:14	Design, synthesis and evaluation of novel uracil amino acid conjugates for the inhibition of Trypanosoma cruzi dUTPase.
AID1329378	Antileishmanial activity against Leishmania infantum MHOM/BR/1972/LD amastigote forms infected in BALB/c mouse peritoneal macrophages assessed as reduction in parasite viability after 120 hrs by giemsa staining based light microscopy	2016	Journal of natural products, 09-23, Volume: 79, Issue:9	Analogues of Marine Guanidine Alkaloids Are in Vitro Effective against Trypanosoma cruzi and Selectively Eliminate Leishmania (L.) infantum Intracellular Amastigotes.
AID1519002	Antitrypanosomal activity against Trypanosoma cruzi K98 bloodstream form infected in C3H/HeNk mouse assessed as effect on heart rate duration at 30 to 75 mg/kg/day, po administered via gavage for 30 consecutive days starting from 90 days post infection an	2019	European journal of medicinal chemistry, 12-15, Volume: 184	Combined therapy with Benznidazole and repurposed drugs Clofazimine and Benidipine for chronic Chagas disease.
AID1459246	Trypanocidal activity against Trypanosoma cruzi TCC epimastigotes assessed as effect on parasite motility at 1 to 15 uM supplemented with fresh medium containing compound every 9 to 10 days measured on third week	2017	European journal of medicinal chemistry, Jan-05, Volume: 125	Novel 2-arylazoimidazole derivatives as inhibitors of Trypanosoma cruzi proliferation: Synthesis and evaluation of their biological activity.
AID1351073	Antitrypanosomal activity against Trypanosoma cruzi Y Tc2 amastigotes infected in human U2OS cells after 72 hrs by Draq5 staining based HCS analysis	2018	European journal of medicinal chemistry, Jan-20, Volume: 144	Investigating the structure-activity relationships of N'-[(5-nitrofuran-2-yl) methylene] substituted hydrazides against Trypanosoma cruzi to design novel active compounds.
AID1202573	Anti-trypanosomal activity against Trypanosoma cruzi Silvio X10 cl1 epimastigote forms assessed as inhibition of parasite growth after 72 hrs by microplate reader based assay	2015	European journal of medicinal chemistry, , Volume: 96	Designing and exploring active N'-[(5-nitrofuran-2-yl) methylene] substituted hydrazides against three Trypanosoma cruzi strains more prevalent in Chagas disease patients.
AID1603737	Antitrypanosomal activity against Trypanosoma cruzi MHOM/Pe/2011/Arequipa;DTU 5 bloodstream trypomastigote infected in BALB/c mouse assessed as parasite-free adipose tissue in acute phase at 20 mg/kg/day, po administered for 5 consecutive days starting fr	2019	Bioorganic & medicinal chemistry, 09-01, Volume: 27, Issue:17	Rational modification of Mannich base-type derivatives as novel antichagasic compounds: Synthesis, in vitro and in vivo evaluation.
AID1238028	Selectivity index, ratio of EC50 for BALB/c mouse peritoneal macrophages to EC50 for Trypanosoma cruzi Y epimastigotes	2015	Bioorganic & medicinal chemistry letters, Aug-15, Volume: 25, Issue:16	Synthesis and evaluation of novel prenylated chalcone derivatives as anti-leishmanial and anti-trypanosomal compounds.
AID1584758	Antiparasitic activity against Trypanosoma cruzi Y strain bloodstream trypomastigotes infected in Swiss Webster mouse assessed as decrease in parasitemia at 100 mg/kg, po sid via gavage administered for 5 consecutive days measured at day 8 post infection	2018	Journal of medicinal chemistry, 10-25, Volume: 61, Issue:20	Discovery of Novel 7-Aryl 7-Deazapurine 3'-Deoxy-ribofuranosyl Nucleosides with Potent Activity against Trypanosoma cruzi.
AID1140993	Antitrypanosomal activity against Trypanosoma cruzi CL Brener infected in BALB/c mouse assessed as peak of maximum parasitemia at 192 umol/kg/day, po for 14 days administered in saline and tween 80 measured up to 60 days relative to control	2014	Journal of medicinal chemistry, May-22, Volume: 57, Issue:10	Optimization of antitrypanosomatid agents: identification of nonmutagenic drug candidates with in vivo activity.
AID1603948	Antitrypanosomal activity against Trypanosoma cruzi MHOM/Pe/2011/Arequipa;DTU 5 bloodstream trypomastigotes infected in BALB/c mouse assessed as reduction in serum Ig-G level in chronic phase at 20 mg/kg/day, po administered for 5 consecutive days startin	2019	Bioorganic & medicinal chemistry, 09-01, Volume: 27, Issue:17	Rational modification of Mannich base-type derivatives as novel antichagasic compounds: Synthesis, in vitro and in vivo evaluation.
AID1565132	Selectivity index, ratio of CC50 for African green monkey Vero cells to IC50 for intracellular amastigote stage of luciferase expressing Trypanosoma cruzi Dm28c infected in Vero cells	2019	European journal of medicinal chemistry, Nov-15, Volume: 182	Synthesis, structure-activity relationship and trypanocidal activity of pyrazole-imidazoline and new pyrazole-tetrahydropyrimidine hybrids as promising chemotherapeutic agents for Chagas disease.
AID1275388	Antitrypanosomal activity against trypomastigotes stage of Trypanosoma cruzi strain CL Brener infected in acute chagas BALB/c mouse model assessed as survival rate at 50 mg/kg/day, po administered for 14 days started on day 9 post infection measured at 30	2016	European journal of medicinal chemistry, Feb-15, Volume: 109	New approach towards the synthesis of selenosemicarbazones, useful compounds for Chagas' disease.
AID1074926	Selectivity index, ratio of IC50 for African green monkey Vero cells to IC50 for Trypanosoma cruzi (IRHOD/CO/2008/SN3) trypomastigotes	2014	European journal of medicinal chemistry, Mar-03, Volume: 74	New perspectives on the synthesis and antichagasic activity of 3-alkoxy-1-alkyl-5-nitroindazoles.
AID728171	Cytotoxicity against mouse NIH/3T3 cells	2013	Journal of medicinal chemistry, Mar-28, Volume: 56, Issue:6	Antitrypanosomal lead discovery: identification of a ligand-efficient inhibitor of Trypanosoma cruzi CYP51 and parasite growth.
AID632297	Antitrypanosomal activity against blood stream form of Trypanosoma cruzi Tulahuen C4 infected in rat L6 cells after 72 hrs by alamar blue assay	2011	Journal of medicinal chemistry, Dec-08, Volume: 54, Issue:23	Novel 3-nitro-1H-1,2,4-triazole-based aliphatic and aromatic amines as anti-chagasic agents.
AID1612897	Selectivity index, ratio of CC50 for human U2OS cells to EC50 for Trypanosoma cruzi Y infected in human U2OS cells	2019	European journal of medicinal chemistry, Feb-01, Volume: 163	Discovery of new potent hits against intracellular Trypanosoma cruzi by QSAR-based virtual screening.
AID582595	Antitrypanosomal activity against Trypanosoma cruzi Tulahuen C2C4 trypomastigote after 48 hrs	2009	Antimicrobial agents and chemotherapy, Sep, Volume: 53, Issue:9	Antiprotozoal activity of 1-phenethyl-4-aminopiperidine derivatives.
AID1612898	Cytotoxicity against human U2OS cells assessed as reduction in cell viability after 96 hrs	2019	European journal of medicinal chemistry, Feb-01, Volume: 163	Discovery of new potent hits against intracellular Trypanosoma cruzi by QSAR-based virtual screening.
AID548110	Antiparasitic activity against Trypanosoma cruzi T2 epimastigotes assessed as growth inhibition at 25 uM after 5 days	2010	European journal of medicinal chemistry, Dec, Volume: 45, Issue:12	Massive screening yields novel and selective Trypanosoma cruzi triosephosphate isomerase dimer-interface-irreversible inhibitors with anti-trypanosomal activity.
AID1181597	Antimicrobial activity against trypomastigote form of Trypanosoma cruzi Tulahuen C2C4 infected in rat L6 cells after 96 hrs by microscopic analysis	2014	Journal of medicinal chemistry, Aug-14, Volume: 57, Issue:15	Pyridyl benzamides as a novel class of potent inhibitors for the kinetoplastid Trypanosoma brucei.
AID1079936	Choleostatic liver toxicity, either proven histopathologically or where the ratio of maximal ALT or AST activity above normal to that of Alkaline Phosphatase is < 2 (see ACUTE). Value is number of references indexed. [column 'CHOLE' in source]
AID1683714	Antitrypanosomal activity against Trypanosoma cruzi IRHOD/CO/2008/SN3 (DTU I) epimastigote form assessed as parasite growth inhibition incubated for 48 hrs by resazurin dye based assay	2020	Journal of natural products, 12-24, Volume: 83, Issue:12	In Vivo Biological Evaluation of a Synthetic Royleanone Derivative as a Promising Fast-Acting Trypanocidal Agent by Inducing Mitochondrial-Dependent Necrosis.
AID1381692	Antileishmanial activity against Leishmania infantum amastigote form after 72 hrs by steady-Glo reagent based assay	2018	European journal of medicinal chemistry, Feb-25, Volume: 146	Aryl thiosemicarbazones for the treatment of trypanosomatidic infections.
AID1615043	Antitrypanosomal activity against Trypanosoma cruzi MHOM/Pe/2011/Arequipa DTU 5 trypomastigotes infected in Balb/c mouse assessed as parasite-free heart at 20 mg/kg, po pretreated once daily for 5 consecutive days starting from day 10 post infection follo	2019	Bioorganic & medicinal chemistry, 03-01, Volume: 27, Issue:5	Synthesis and biological evaluation of new long-chain squaramides as anti-chagasic agents in the BALB/c mouse model.
AID1486938	Cytotoxicity against African green monkey Vero cells incubated for 24 to 48 hrs by SRB assay	2017	Bioorganic & medicinal chemistry letters, 08-01, Volume: 27, Issue:15	Synthesis, in vitro and in vivo giardicidal activity of nitrothiazole-NSAID chimeras displaying broad antiprotozoal spectrum.
AID1615055	Antitrypanosomal activity against Trypanosoma cruzi MHOM/Pe/2011/Arequipa DTU 5 trypomastigotes infected in Balb/c mouse assessed as parasite-free spleen at 20 mg/kg, po pretreated once daily for 5 consecutive days starting from day 75 post infection foll	2019	Bioorganic & medicinal chemistry, 03-01, Volume: 27, Issue:5	Synthesis and biological evaluation of new long-chain squaramides as anti-chagasic agents in the BALB/c mouse model.
AID677214	Trypanosomicidal activity against Trypanosoma cruzi infected in Vero cells assessed as reduction in trypomastigotes in culture medium after 10 days by Giemsa staining method	2012	Journal of medicinal chemistry, May-10, Volume: 55, Issue:9	In vitro and in vivo trypanosomicidal activity of pyrazole-containing macrocyclic and macrobicyclic polyamines: their action on acute and chronic phases of Chagas disease.
AID1578094	Antitrypanosomal activity against Trypanosoma brucei rhodesiense after 48 hrs by [3H]-hypoxanthine incorporation assay	2019	Bioorganic & medicinal chemistry letters, 10-15, Volume: 29, Issue:20	Antiprotozoal alkaloid principles of the plant family Amaryllidaceae.
AID1415707	Octanol/water partition coefficient, log P of the compound	2017	MedChemComm, May-01, Volume: 8, Issue:5	Antitrypanosomal and antileishmanial activity of prenyl-1,2,3-triazoles.
AID1498330	Hepatotoxicity in Balb/c mouse infected with Trypanosoma cruzi MHOM/Pe/2011/Arequipa DTU 5 trypamastigotes assessed as increase in total bilirubin level at 20 mg/kg, po once daily for 5 consecutive days starting from day 10 post infection measured on day	2018	Journal of medicinal chemistry, 07-12, Volume: 61, Issue:13	Second Generation of Mannich Base-Type Derivatives with in Vivo Activity against Trypanosoma cruzi.
AID728170	Selectivity index, ratio of EC50 for mouse NIH/3T3 cells to EC50 for Trypanosoma cruzi trypomastigote	2013	Journal of medicinal chemistry, Mar-28, Volume: 56, Issue:6	Antitrypanosomal lead discovery: identification of a ligand-efficient inhibitor of Trypanosoma cruzi CYP51 and parasite growth.
AID1616182	Cytotoxicity against Swiss mouse primary cardiac cells assessed as reduction in cell viability incubated for 24 hrs by PrestoBlue dye based colorimetry	2019	Journal of medicinal chemistry, 10-10, Volume: 62, Issue:19	Discovery of Pyrrolo[2,3-
AID576939	Antimicrobial activity against Trypanosoma cruzi Tulahuen infected in Swiss mouse assessed as mouse mortality at 60 mg/kg/day, po for 6 days per week until completion of 60 compound doses administered 5 days post infection	2010	Antimicrobial agents and chemotherapy, Sep, Volume: 54, Issue:9	Hydroxymethylnitrofurazone is active in a murine model of Chagas' disease.
AID1399455	Antitrypanosomal activity against Trypanosoma cruzi Tulahuen amastigote forms infected in rat H9c2 cells assessed as reduction in infected cells after 72 hrs by DRAQ5 DNA dye based confocal microscopic analysis	2018	Bioorganic & medicinal chemistry, 08-07, Volume: 26, Issue:14	Quinoxaline derivatives as potential antitrypanosomal and antileishmanial agents.
AID1498273	Nephrotoxicity in Balb/c mouse infected with Trypanosoma cruzi MHOM/Pe/2011/Arequipa DTU 5 trypamastigotes assessed as decrease in uric acid level in serum at 20 mg/kg, po once daily for 5 consecutive days starting from day 10 post infection measured on d	2018	Journal of medicinal chemistry, 07-12, Volume: 61, Issue:13	Second Generation of Mannich Base-Type Derivatives with in Vivo Activity against Trypanosoma cruzi.
AID1517428	Antitrypanosomal activity against Trypanosoma cruzi strain Y trypomastigotes infected in human HG39 cells by TaqMan probe based RT-PCR analysis	2019	European journal of medicinal chemistry, Dec-01, Volume: 183	Discovery of a benzothiophene-flavonol halting miltefosine and antimonial drug resistance in Leishmania parasites through the application of medicinal chemistry, screening and genomics.
AID677571	Antitrypanosomal activity against bloodstream form of Trypanosoma brucei brucei Lister 427 clone 221a overexpressing tet-inducible NTR in presence of tetracycline after 3 days	2012	Journal of medicinal chemistry, Jun-14, Volume: 55, Issue:11	Novel 3-nitro-1H-1,2,4-triazole-based amides and sulfonamides as potential antitrypanosomal agents.
AID564744	Toxicity in CH3/He(H-2k) mouse assessed as mortality at cumulative dose of 200 mg/kg, ip measured after 48 hrs	2010	Antimicrobial agents and chemotherapy, Jul, Volume: 54, Issue:7	Arylimidamide DB766, a potential chemotherapeutic candidate for Chagas' disease treatment.
AID392010	Antitrypanosomal activity against Trypanosoma cruzi Tulahuen 2 infected Swiss mouse assessed as reduction in circulating trypomastigotes antibody level at 200 mg/kg/day, po after 90 days postinfection	2008	European journal of medicinal chemistry, Oct, Volume: 43, Issue:10	In vivo studies of 5-arylethenylbenzofuroxans in acute murine models of Chagas' disease.
AID1686742	Selectivity index, ratio of IC50 for cytotoxicity in African green monkey Vero cells to IC50 for antitrypanosomal activity against Trypanosoma cruzi Tulahuen amastigote forms	2016	Journal of medicinal chemistry, 12-22, Volume: 59, Issue:24	In Vitro and in Vivo Anti-Trypanosoma cruzi Activity of New Arylamine Mannich Base-Type Derivatives.
AID707774	Antitrypanosomal activity against Trypanosoma cruzi IRHOD/VO/2008/SN3 metacyclic forms infected in african green monkey Vero cells assessed as inhibition of intracellular amastigotes replication at IC25 level 0.5 to 10 days	2012	Journal of medicinal chemistry, Nov-26, Volume: 55, Issue:22	Phthalazine derivatives containing imidazole rings behave as Fe-SOD inhibitors and show remarkable anti-T. cruzi activity in immunodeficient-mouse mode of infection.
AID1603821	Antitrypanosomal activity against Trypanosoma cruzi MHOM/Pe/2011/Arequipa;DTU 5 bloodstream trypomastigote infected in BALB/c mouse assessed as parasite-free brain in chronic phase at 20 mg/kg/day, po administered for 5 consecutive days starting from day	2019	Bioorganic & medicinal chemistry, 09-01, Volume: 27, Issue:17	Rational modification of Mannich base-type derivatives as novel antichagasic compounds: Synthesis, in vitro and in vivo evaluation.
AID1381721	Inhibition of human microsomal CYP2C9 expressed in baculovirus infected BTI-TN-5B1-4 cells incubated for 30 mins by luciferase assay	2018	European journal of medicinal chemistry, Feb-25, Volume: 146	Aryl thiosemicarbazones for the treatment of trypanosomatidic infections.
AID564078	Antitrypanosomal activity against Trypanosoma cruzi 855 epimastigotes after 24 hrs by light microscopy	2010	Antimicrobial agents and chemotherapy, Jul, Volume: 54, Issue:7	Arylimidamide DB766, a potential chemotherapeutic candidate for Chagas' disease treatment.
AID547273	Immunostimulatory activity in mongrel dog infected with Trypanosoma cruzi Berenice-78 assessed as production of antibody IgG at 7 mg/kg, po BID for 90 days measured after 6 months by ELISA	2010	Antimicrobial agents and chemotherapy, Jul, Volume: 54, Issue:7	Effects of ravuconazole treatment on parasite load and immune response in dogs experimentally infected with Trypanosoma cruzi.
AID445551	Antitrypanosomal activity against Trypanosoma cruzi CL Brener epimastigotes assessed as parasite viability after 5 days by MTT assay	2009	European journal of medicinal chemistry, Dec, Volume: 44, Issue:12	Anti-trypanosomatid benzofuroxans and deoxygenated analogues: synthesis using polymer-supported triphenylphosphine, biological evaluation and mechanism of action studies.
AID1613469	Trypanocidal activity against Trypanosoma cruzi IRHOD/CO/2008/SN3 DTU 1 epimastigotes after 48 to 72 hrs by resazurin dye based assay	2019	European journal of medicinal chemistry, Feb-15, Volume: 164	New polyamine drugs as more effective antichagas agents than benznidazole in both the acute and chronic phases.
AID1312166	Antitrypanosomal activity against amastigote stage of Trypanosoma cruzi CA-I/72 infected in mouse C2C12 cells at 10 uM measured after 3 days by DAPI staining-based assay relative to control	2016	Bioorganic & medicinal chemistry, 09-15, Volume: 24, Issue:18	Design, synthesis, molecular docking and biological evaluation of thiophen-2-iminothiazolidine derivatives for use against Trypanosoma cruzi.
AID1381719	Inhibition of human ERG incubated for 2 hrs by fluorescence polarisation assay	2018	European journal of medicinal chemistry, Feb-25, Volume: 146	Aryl thiosemicarbazones for the treatment of trypanosomatidic infections.
AID1498290	Cardiotoxicity in Balb/c mouse infected with Trypanosoma cruzi MHOM/Pe/2011/Arequipa DTU 5 trypamastigotes assessed as decrease in ratio of creatine kinase in muscle to brain at 20 mg/kg, po once daily for 5 consecutive days starting from day 75 post infe	2018	Journal of medicinal chemistry, 07-12, Volume: 61, Issue:13	Second Generation of Mannich Base-Type Derivatives with in Vivo Activity against Trypanosoma cruzi.
AID1164935	Induction of apoptosis in human platelets assessed as viable cells after 10 mins using Annexin V/propidium iodide by flow cytometry (Rvb = 89.61 %)	2014	European journal of medicinal chemistry, Nov-24, Volume: 87	In vitro antiparasitic activity of new thiosemicarbazones in strains of Trypanosoma cruzi.
AID1683671	Toxicity in BALB/c mouse infected with Trypanosomal Trypanosoma cruzi MHOM/Pe/2011/Arequipa(DTU V) assessed as reduction in survival at 20 mg/kg, po administered for 5 days starting at 9 days post infection and measured up to 145 days post infection	2020	Journal of natural products, 12-24, Volume: 83, Issue:12	In Vivo Biological Evaluation of a Synthetic Royleanone Derivative as a Promising Fast-Acting Trypanocidal Agent by Inducing Mitochondrial-Dependent Necrosis.
AID753403	Cytotoxicity against peritoneal macrophage after 24 hrs by resazurin assay	2013	Bioorganic & medicinal chemistry letters, Jun-15, Volume: 23, Issue:12	Aromatic glycosyl disulfide derivatives: evaluation of their inhibitory activities against Trypanosoma cruzi.
AID1507197	Cytotoxicity against mouse NCTC-929 cells assessed as reduction in cell viability after 48 hrs by resazurin dye-based assay	2017	European journal of medicinal chemistry, Aug-18, Volume: 136	Novel Imidazo[4,5-c][1,2,6]thiadiazine 2,2-dioxides as antiproliferative trypanosoma cruzi drugs: Computational screening from neural network, synthesis and in vivo biological properties.
AID1498300	Cardiotoxicity in Balb/c mouse infected with Trypanosoma cruzi MHOM/Pe/2011/Arequipa DTU 5 trypamastigotes assessed as decrease in serum LDH level at 20 mg/kg, po once daily for 5 consecutive days starting from day 75 post infection measured on day 81 pos	2018	Journal of medicinal chemistry, 07-12, Volume: 61, Issue:13	Second Generation of Mannich Base-Type Derivatives with in Vivo Activity against Trypanosoma cruzi.
AID623721	Trypanocidal activity against intracellular amastigote form of Trypanosoma cruzi Tulahuen expressing beta-galactosidase infected in mouse L929 cells after 7 days by microplate reader analysis	2011	European journal of medicinal chemistry, Nov, Volume: 46, Issue:11	Synthesis and evaluation of the anti parasitic activity of aromatic nitro compounds.
AID660266	Trypanocidal activity against bloodstream form of Trypanosoma cruzi Y isolated from albino mouse blood after 24 hrs by neubauer chamber analysis	2012	European journal of medicinal chemistry, Jun, Volume: 52	On the search for potential anti-Trypanosoma cruzi drugs: synthesis and biological evaluation of 2-hydroxy-3-methylamino and 1,2,3-triazolic naphthoquinoidal compounds obtained by click chemistry reactions.
AID1603738	Antitrypanosomal activity against Trypanosoma cruzi MHOM/Pe/2011/Arequipa;DTU 5 bloodstream trypomastigote infected in BALB/c mouse assessed as parasite-free adipose tissue in chronic phase at 20 mg/kg/day, po administered for 5 consecutive days starting	2019	Bioorganic & medicinal chemistry, 09-01, Volume: 27, Issue:17	Rational modification of Mannich base-type derivatives as novel antichagasic compounds: Synthesis, in vitro and in vivo evaluation.
AID1615116	Hepatotoxicity in Balb/c mouse infected with Trypanosoma cruzi MHOM/Pe/2011/Arequipa DTU 5 trypomastigotes assessed as change in ratio of serum ALT to GPT level at 20 mg/kg, po once daily for 5 consecutive days starting from day 75 post infection measured	2019	Bioorganic & medicinal chemistry, 03-01, Volume: 27, Issue:5	Synthesis and biological evaluation of new long-chain squaramides as anti-chagasic agents in the BALB/c mouse model.
AID1603752	Cytotoxicity against African green monkey Vero cells measured after 72 hrs by MTT assay	2019	Bioorganic & medicinal chemistry, 09-01, Volume: 27, Issue:17	Rational modification of Mannich base-type derivatives as novel antichagasic compounds: Synthesis, in vitro and in vivo evaluation.
AID656218	Cytotoxicity against african green monkey Vero cells after 3 days	2012	Bioorganic & medicinal chemistry letters, Apr-15, Volume: 22, Issue:8	Phosphonium lipocations as antiparasitic agents.
AID1272503	Trypanocidal activity against Trypanosoma cruzi Tulahuen 2 epimastigotes after 5 days	2016	Bioorganic & medicinal chemistry letters, Feb-01, Volume: 26, Issue:3	Synthesis and biological evaluation of quinoxaline di-N-oxide derivatives with in vitro trypanocidal activity.
AID575883	Toxicity in human patient infected with Trypanosoma cruzi assessed as occurrence of hypersensitivity on day 7 to 10	2010	Antimicrobial agents and chemotherapy, Nov, Volume: 54, Issue:11	Tolerance of benznidazole in treatment of Chagas' disease in adults.
AID1498173	Cytotoxicity against African green monkey Vero cells assessed as reduction in cell viability after 72 hrs by resazurin dye based assay	2018	Journal of medicinal chemistry, 07-12, Volume: 61, Issue:13	Second Generation of Mannich Base-Type Derivatives with in Vivo Activity against Trypanosoma cruzi.
AID1498320	Hepatotoxicity in Balb/c mouse infected with Trypanosoma cruzi MHOM/Pe/2011/Arequipa DTU 5 trypamastigotes assessed as change in ratio of serum ALT to GPT level at 20 mg/kg, po once daily for 5 consecutive days starting from day 10 post infection measured	2018	Journal of medicinal chemistry, 07-12, Volume: 61, Issue:13	Second Generation of Mannich Base-Type Derivatives with in Vivo Activity against Trypanosoma cruzi.
AID1439208	Selectivity index, ratio of CC50 for human U2OS cells to EC50 for Trypanosoma cruzi Y amastigote forms infected in human U2OS cells	2017	European journal of medicinal chemistry, Mar-10, Volume: 128	Synthesis and trypanocidal activity of a library of 4-substituted 2-(1H-pyrrolo[3,2-c]pyridin-2-yl)propan-2-ols.
AID575885	Toxicity in human patient infected with Trypanosoma cruzi assessed as occurrence of myalgias	2010	Antimicrobial agents and chemotherapy, Nov, Volume: 54, Issue:11	Tolerance of benznidazole in treatment of Chagas' disease in adults.
AID1683673	Toxicity in BALB/c mouse infected with Trypanosomal Trypanosoma cruzi MHOM/Pe/2011/Arequipa(DTU V) assessed as effect on total bilirubin level at 20 mg/kg, po administered for 5 days starting at 100 days post infection and measured after 2 days post treat	2020	Journal of natural products, 12-24, Volume: 83, Issue:12	In Vivo Biological Evaluation of a Synthetic Royleanone Derivative as a Promising Fast-Acting Trypanocidal Agent by Inducing Mitochondrial-Dependent Necrosis.
AID1811310	Cytotoxicity against mouse J774.2 cells assessed as reduction in cell viability measured after 48 hrs by resazurin dye based assay	2021	Bioorganic & medicinal chemistry, 10-15, Volume: 48	In vitro, ex vivo and in vivo short-term screening of DHEA nitrate derivatives activity over Trypanosoma cruzi Ninoa and TH strains from Oaxaca State, México.
AID547278	Antitrypanosomal activity against Trypanosoma cruzi Y infected in mongrel dog assessed as reduction in IL10 production in right atrium at 12 mg/kg, po BID after 180 days by semiquantitative RT-PCR	2010	Antimicrobial agents and chemotherapy, Jul, Volume: 54, Issue:7	Effects of ravuconazole treatment on parasite load and immune response in dogs experimentally infected with Trypanosoma cruzi.
AID1074930	Antitrypanosomal activity against Trypanosoma cruzi (IRHOD/CO/2008/SN3) trypomastigotes infected in Balb/c albino mouse after 24 hrs by Neubauer chamber counting analysis	2014	European journal of medicinal chemistry, Mar-03, Volume: 74	New perspectives on the synthesis and antichagasic activity of 3-alkoxy-1-alkyl-5-nitroindazoles.
AID1501230	Antiprotozoal activity against trypomastigote form of Trypanosoma cruzi Tulahuen C2C4 infected in rat L6 cells after 96 hrs by CPRG/Nonidet-based inverted microscopy	2017	Journal of natural products, 09-22, Volume: 80, Issue:9	Antiprotozoal Linear Furanosesterterpenoids from the Marine Sponge Ircinia oros.
AID632303	Ratio of benznidazole IC50 to compound IC50 for Trypanosoma cruzi Tulahuen C4 infected in rat L6 cells after 72 hrs by alamar blue assay	2011	Journal of medicinal chemistry, Dec-08, Volume: 54, Issue:23	Novel 3-nitro-1H-1,2,4-triazole-based aliphatic and aromatic amines as anti-chagasic agents.
AID727320	Antiparasitic activity against Trypanosoma cruzi Tulahuen C2C4 expressing beta-galactosidase infected in rat L6 cells after 96 hrs	2013	Journal of medicinal chemistry, Feb-28, Volume: 56, Issue:4	Synthesis and in vitro antimalarial testing of neocryptolepines: SAR study for improved activity by introduction and modifications of side chains at C2 and C11 on indolo[2,3-b]quinolines.
AID1592301	Antitrypanosomal activity against Trypanosoma cruzi MHOM/MX/1994/INC5 epimastigotes assessed as metabolic inhibition at 10 ug/ml after 24 hrs by MTT assay relative to control
AID1079937	Severe hepatitis, defined as possibly life-threatening liver failure or through clinical observations. Value is number of references indexed. [column 'MASS' in source]
AID1683709	Cytotoxicity against African green monkey Vero cells assessed as reduction in cell viability after 48 hrs by resazurin dye based assay	2020	Journal of natural products, 12-24, Volume: 83, Issue:12	In Vivo Biological Evaluation of a Synthetic Royleanone Derivative as a Promising Fast-Acting Trypanocidal Agent by Inducing Mitochondrial-Dependent Necrosis.
AID576081	Toxicity in human patient infected with Trypanosoma cruzi assessed as occurrence of Petechial rash at 5 mg/kg/day for 60 days	2010	Antimicrobial agents and chemotherapy, Nov, Volume: 54, Issue:11	Tolerance of benznidazole in treatment of Chagas' disease in adults.
AID597248	Antitrypanosomal activity against Trypanosoma cruzi CL Brener clone infected in BALB/c mouse assessed as reduction of microbial antibody level at 50 mg/kg/day, po after 90 days by Wilconxon test	2011	Journal of medicinal chemistry, May-26, Volume: 54, Issue:10	3-Trifluoromethylquinoxaline N,N'-dioxides as anti-trypanosomatid agents. Identification of optimal anti-T. cruzi agents and mechanism of action studies.
AID1508585	Toxicity in Balb/c mouse infected with Trypanosoma cruzi Y trypomastigotes assessed as behavioral alteration at 100 mg/kg, po qd administered for 5 consecutive days starting from day 5 post infection	2017	European journal of medicinal chemistry, Dec-01, Volume: 141	Structural design, synthesis and pharmacological evaluation of thiazoles against Trypanosoma cruzi.
AID580587	Antitrypanosomal activity against Trypanosoma cruzi Y infected in CD8+ T-lymphocyte knockout C57BL/6 mouse assessed as increase in survival of mouse at 100 mg/kg/day, po administered once daily for 20 consecutive days measured 60 days post infection	2009	Antimicrobial agents and chemotherapy, Jan, Volume: 53, Issue:1	Absence of CD4+ T lymphocytes, CD8+ T lymphocytes, or B lymphocytes has different effects on the efficacy of posaconazole and benznidazole in treatment of experimental acute Trypanosoma cruzi infection.
AID1383428	Selectivity index, ratio of LC50 for mouse L929 cells by Alamarblue assay to EC50 for Trypanosoma cruzi Tulahuen trypomastigote forms	2018	European journal of medicinal chemistry, Apr-10, Volume: 149	Identification of Pyrazolo[3,4-e][1,4]thiazepin based CYP51 inhibitors as potential Chagas disease therapeutic alternative: In vitro and in vivo evaluation, binding mode prediction and SAR exploration.
AID1061026	Antimicrobial activity against Trypanosoma cruzi CL amastigotes infected in african green monkey Vero cells measured on day 3 by fluorescence assay	2014	Bioorganic & medicinal chemistry, Jan-01, Volume: 22, Issue:1	New insights into molecular recognition of 1,1-bisphosphonic acids by farnesyl diphosphate synthase.
AID1683693	Antitrypanosomal activity against Trypanosoma cruzi MHOM/Pe/2011/Arequipa(DTU V) amastigote form infected in BALB/c mouse assessed as parasite free organ tissue ratio at 20 mg/kg, po administered for 5 days starting at 9 days post infection and measured u	2020	Journal of natural products, 12-24, Volume: 83, Issue:12	In Vivo Biological Evaluation of a Synthetic Royleanone Derivative as a Promising Fast-Acting Trypanocidal Agent by Inducing Mitochondrial-Dependent Necrosis.
AID1503431	Antitrypanosomal activity against Trypanosoma cruzi Tulahuen intracellular amastigotes transfected with beta-galactosidase infected in human U937 cells incubated for 72 hrs by spectrophotometry	2017	European journal of medicinal chemistry, Dec-01, Volume: 141	Triclosan-caffeic acid hybrids: Synthesis, leishmanicidal, trypanocidal and cytotoxic activities.
AID1383439	Antitrypanosomal activity against bloodstream trypomastigote stage of Trypanosoma cruzi Y infected in Swiss Webster mouse assessed as mouse survival at 100 mg/kg, po administered daily on day 5 to 9 measured daily until 30 days post dose relative to contr	2018	European journal of medicinal chemistry, Apr-10, Volume: 149	Identification of Pyrazolo[3,4-e][1,4]thiazepin based CYP51 inhibitors as potential Chagas disease therapeutic alternative: In vitro and in vivo evaluation, binding mode prediction and SAR exploration.
AID1683679	Toxicity in BALB/c mouse infected with Trypanosomal Trypanosoma cruzi MHOM/Pe/2011/Arequipa(DTU V) assessed as effect on urea level at 20 mg/kg, po administered for 5 days starting at 100 days post infection and measured after 2 days post treatment	2020	Journal of natural products, 12-24, Volume: 83, Issue:12	In Vivo Biological Evaluation of a Synthetic Royleanone Derivative as a Promising Fast-Acting Trypanocidal Agent by Inducing Mitochondrial-Dependent Necrosis.
AID1517443	Antitrypanosomal activity against intracellular amastigote stage of Trypanosoma cruzi Y infected in human U2OS cells measured after 96 hrs by DRAQ5 dye based microscopic analysis	2019	European journal of medicinal chemistry, Dec-01, Volume: 183	Discovery of a benzothiophene-flavonol halting miltefosine and antimonial drug resistance in Leishmania parasites through the application of medicinal chemistry, screening and genomics.
AID337140	Antitrypanosomal activity against Trypanosoma cruzi 13379 CL8 after 48 hrs
AID1055168	Hepatotoxicity in BALB/c mouse infected with bloodstream trypomastigote form of Trypanosoma cruzi IRHOD/CO/2008/SN3 assessed as lymphocytic infiltration in portal tracts at 5 mg/kg/day, ip administered for 5 days measured 150 days post-infection by light	2013	European journal of medicinal chemistry, , Volume: 70	Scorpiand-like azamacrocycles prevent the chronic establishment of Trypanosoma cruzi in a murine model.
AID580588	Antitrypanosomal activity against Trypanosoma cruzi Y infected in CD8+ T-lymphocyte knockout C57BL/6 mouse assessed as mean survival time at 100 mg/kg/day, po administered once daily for 20 consecutive days measured 60 days post infection	2009	Antimicrobial agents and chemotherapy, Jan, Volume: 53, Issue:1	Absence of CD4+ T lymphocytes, CD8+ T lymphocytes, or B lymphocytes has different effects on the efficacy of posaconazole and benznidazole in treatment of experimental acute Trypanosoma cruzi infection.
AID344427	Antiproliferative activity against Trypanosoma cruzi Y epimastigotes assessed as number of motile forms at 0.1 mM after 1 hr by hemocytometer	2008	Journal of medicinal chemistry, Jul-24, Volume: 51, Issue:14	Complexation of the anti-Trypanosoma cruzi drug benznidazole improves solubility and efficacy.
AID596810	Antitrypanosomal activity against metacyclic forms of Trypanosoma cruzi infected in vero cells assessed as decrease in trypomastigotes at IC25 concentration after 12 hrs	2011	Journal of natural products, Apr-25, Volume: 74, Issue:4	In vitro and in vivo trypanocidal activity of flavonoids from Delphinium staphisagria against Chagas disease.
AID1854933	Antitrypanosomal activity against Trypanosoma cruzi Y epimastigotes assessed as parasite growth inhibition measured after 24 hrs by hemocytometer chamber based analysis	2022	European journal of medicinal chemistry, Nov-05, Volume: 241	Rational design of a trypanocidal peptide derived from Dinoponera quadriceps venom.
AID362800	Antiprotozoal activity against Trypanosoma cruzi Tulahuen C4 in rat L6 cells	2008	Journal of natural products, Sep, Volume: 71, Issue:9	Antiprotozoal activities of heterocyclic-substituted xanthones from the marine-derived fungus Chaetomium sp.
AID1234671	Antiparasitic activity against Trypanosoma cruzi strain CL Brener epimastigotes after 12 days by ELISA reader	2015	Bioorganic & medicinal chemistry, Aug-01, Volume: 23, Issue:15	Enzymatic synthesis of bile acid derivatives and biological evaluation against Trypanosoma cruzi.
AID1329376	Antitrypanosomal activity against Trypanosoma cruzi Y trypomastigote forms infected in monkey LLC-MK2 cells assessed as reduction in parasite viability after 24 hrs by resazurin assay	2016	Journal of natural products, 09-23, Volume: 79, Issue:9	Analogues of Marine Guanidine Alkaloids Are in Vitro Effective against Trypanosoma cruzi and Selectively Eliminate Leishmania (L.) infantum Intracellular Amastigotes.
AID690544	Antiprotozoal activity against intracellular Trypanosoma cruzi amastigotes in rat L6 cells	2012	Bioorganic & medicinal chemistry letters, Oct-01, Volume: 22, Issue:19	2-Alkynoic fatty acids inhibit topoisomerase IB from Leishmania donovani.
AID1603757	Selectivity index, ratio of IC50 for African green monkey Vero cells to IC50 for Trypanosoma cruzi IRHOD/CO/2008/SN3;DTU 1	2019	Bioorganic & medicinal chemistry, 09-01, Volume: 27, Issue:17	Rational modification of Mannich base-type derivatives as novel antichagasic compounds: Synthesis, in vitro and in vivo evaluation.
AID1381713	Cytotoxicity against human THP1 cells assessed as decrease in viable cells after 72 hrs by MTT assay	2018	European journal of medicinal chemistry, Feb-25, Volume: 146	Aryl thiosemicarbazones for the treatment of trypanosomatidic infections.
AID576082	Toxicity in human patient infected with Trypanosoma cruzi assessed as occurrence of Itching at 5 mg/kg/day for 60 days	2010	Antimicrobial agents and chemotherapy, Nov, Volume: 54, Issue:11	Tolerance of benznidazole in treatment of Chagas' disease in adults.
AID564076	Antitrypanosomal activity against Trypanosoma cruzi Y epimastigotes after 24 hrs by light microscopy	2010	Antimicrobial agents and chemotherapy, Jul, Volume: 54, Issue:7	Arylimidamide DB766, a potential chemotherapeutic candidate for Chagas' disease treatment.
AID1079941	Liver damage due to vascular disease: peliosis hepatitis, hepatic veno-occlusive disease, Budd-Chiari syndrome. Value is number of references indexed. [column 'VASC' in source]
AID726228	Antitrypanosomal activity against Trypanosoma cruzi Y epimastigotes at 128 uM incubated for 48 hrs by resazurin dye reduction based ELISA method	2013	Journal of medicinal chemistry, Feb-28, Volume: 56, Issue:4	Cloning, characterization, and sulfonamide and thiol inhibition studies of an α-carbonic anhydrase from Trypanosoma cruzi, the causative agent of Chagas disease.
AID341601	Antitrypanosomal activity against Trypanosoma brucei rhodesiense STIB900	2007	Antimicrobial agents and chemotherapy, Aug, Volume: 51, Issue:8	Peroxide bond-dependent antiplasmodial specificity of artemisinin and OZ277 (RBx11160).
AID1613547	Hepatotoxicity in Balb/c mouse infected with Trypanosoma cruzi MHOM/Pe/2011/Arequipa DTU 5 trypomastigotes assessed as increase in ratio of serum AST to GOT level at 20 mg/kg, po once daily for 5 consecutive days starting from day 10 post infection measur	2019	European journal of medicinal chemistry, Feb-15, Volume: 164	New polyamine drugs as more effective antichagas agents than benznidazole in both the acute and chronic phases.
AID337149	Antitrypanosomal activity against Trypanosoma cruzi R107 after 48 hrs
AID1682938	Antitrypanosomal activity against blood trypomastigote form of Trypanosoma cruzi strain Y infected in BALB/c mouse assessed as reduction in amastigote nest in host heart at 25 mg/kg, po administered via gavage daily for 15 days starting from 2 days post-i	2021	Bioorganic & medicinal chemistry, 01-01, Volume: 29	Trypanocidal activity of new 1,6-diphenyl-1H-pyrazolo[3,4-b]pyridine derivatives: Synthesis, in vitro and in vivo studies.
AID669298	Antitrypanosomal activity against Trypanosoma cruzi Y trymastigotes infected in monkey LLC-MK2 cells after 24 hrs by Brenner counter method	2012	Journal of medicinal chemistry, Apr-12, Volume: 55, Issue:7	Terpenes from Copaifera demonstrated in vitro antiparasitic and synergic activity.
AID447814	Cytotoxicity against BALB/c mouse splenocytes after 24 hrs by [3H]thymidine incorporation assay	2009	Bioorganic & medicinal chemistry, Jul-15, Volume: 17, Issue:14	Ruthenium complexes endowed with potent anti-Trypanosoma cruzi activity: Synthesis, biological characterization and structure-activity relationships.
AID1070005	Antimicrobial activity against amastigote stage of Trypanosoma cruzi CL Brener infected in mouse NCTC-929 cells assessed as growth inhibition at 1 uM after 7 days by beta-galactosidase reporter gene assay	2014	Bioorganic & medicinal chemistry letters, Feb-15, Volume: 24, Issue:4	In vitro phenotypic screening of 7-chloro-4-amino(oxy)quinoline derivatives as putative anti-Trypanosoma cruzi agents.
AID1501897	Antitrypanosomal activity against Trypanosoma cruzi Y infected in BALB/c mouse assessed as reduction in blood parasitemia at 100 mg/kg/day, ip dosed administered for 10 consecutive days starting on day 5 post infection measured on day 14 post infection re	2017	European journal of medicinal chemistry, Oct-20, Volume: 139	Efficacy of a series of alpha-pyrone derivatives against Leishmania (L.) infantum and Trypanosoma cruzi.
AID1432599	Cytotoxicity against mouse L929 cells after 96 hrs by alamar blue assay	2017	Bioorganic & medicinal chemistry, 03-15, Volume: 25, Issue:6	Synthesis and biological evaluation of potential inhibitors of the cysteine proteases cruzain and rhodesain designed by molecular simplification.
AID1124784	Antimicrobial activity against procyclic stage of Trypanosoma brucei 427 after 24 hrs by MTT assay	2014	Bioorganic & medicinal chemistry letters, Apr-01, Volume: 24, Issue:7	Synthesis and tripanocidal activity of ferrocenyl and benzyl diamines against Trypanosoma brucei and Trypanosoma cruzi.
AID1868691	Antitrypanosomal activity against nifurtimox-sensitive Tulahuen CL2 amastigotes expressing beta galactosidase infected in human MRC5 cells assessed as inhibition of parasite growth using chlorophenol red beta-D-galactopyranoside as substrate and measured	2022	European journal of medicinal chemistry, Jul-05, Volume: 237	Exploration of 6-methyl-7-(Hetero)Aryl-7-Deazapurine ribonucleosides as antileishmanial agents.
AID1682933	Reduction in inflammatory cell infiltration in heart of BALB/c mouse infected with blood trypomastigote form of Trypanosoma cruzi strain Y at 25 mg/kg, po administered via gavage daily for 15 days starting from 2 days post-infection and measured on 16th d	2021	Bioorganic & medicinal chemistry, 01-01, Volume: 29	Trypanocidal activity of new 1,6-diphenyl-1H-pyrazolo[3,4-b]pyridine derivatives: Synthesis, in vitro and in vivo studies.
AID344440	Aqueous solubility at pH 6.5	2008	Journal of medicinal chemistry, Jul-24, Volume: 51, Issue:14	Complexation of the anti-Trypanosoma cruzi drug benznidazole improves solubility and efficacy.
AID1171005	Effect on lipid composition in Trypanosoma cruzi CAI/72 amastigotes infected in mouse C2C12 cells at 5 uM incubated for 24 hrs by GC-MS method	2014	Journal of medicinal chemistry, Dec-11, Volume: 57, Issue:23	Binding mode and potency of N-indolyloxopyridinyl-4-aminopropanyl-based inhibitors targeting Trypanosoma cruzi CYP51.
AID1706436	Inhibition of Trypanosoma cruzi Tulahuen C4 strain CYP51 expressed in Escherichia coli by fluorescence based assay	2020	European journal of medicinal chemistry, Dec-01, Volume: 207	Re-evaluating pretomanid analogues for Chagas disease: Hit-to-lead studies reveal both in vitro and in vivo trypanocidal efficacy.
AID1565126	Cytotoxicity against African green monkey Vero cells assessed as reduction in cell viability by measuring ATP level after 72 hrs by Celltiter-Glo assay	2019	European journal of medicinal chemistry, Nov-15, Volume: 182	Synthesis, structure-activity relationship and trypanocidal activity of pyrazole-imidazoline and new pyrazole-tetrahydropyrimidine hybrids as promising chemotherapeutic agents for Chagas disease.
AID1603949	Antitrypanosomal activity against Trypanosoma cruzi MHOM/Pe/2011/Arequipa;DTU 5 epimastigote assessed as effect on glycerol excretion at IC50 after 72 hrs by H NMR method relative to control	2019	Bioorganic & medicinal chemistry, 09-01, Volume: 27, Issue:17	Rational modification of Mannich base-type derivatives as novel antichagasic compounds: Synthesis, in vitro and in vivo evaluation.
AID1706433	Antitrypanosomal activity against Trypanosoma cruzi Tulahuen strain C2C4 amastigotes infected in rat 3T3 cells assessed as reduction in parasite growth incubated for 48 hrs by chlorophenol red-fl-D-galactopyranoside based colorimetric analysis	2020	European journal of medicinal chemistry, Dec-01, Volume: 207	Re-evaluating pretomanid analogues for Chagas disease: Hit-to-lead studies reveal both in vitro and in vivo trypanocidal efficacy.
AID1667421	Antitrypanosomal activity against Trypanosoma cruzi	2020	Bioorganic & medicinal chemistry letters, 04-15, Volume: 30, Issue:8	Discovery of 4-((1-(1H-imidazol-2-yl)alkoxy)methyl)pyridines as a new class of Trypanosoma cruzi growth inhibitors.
AID1067358	Antimicrobial activity against epimastigote stage of Trypanosoma cruzi MHOM/MX/1994/Ninoa clinical isolate after 72 hrs by Neubauer chamber analysis	2014	Bioorganic & medicinal chemistry, Mar-01, Volume: 22, Issue:5	2-acylamino-5-nitro-1,3-thiazoles: preparation and in vitro bioevaluation against four neglected protozoan parasites.
AID1140925	Antitrypanosomal activity against Trypanosoma cruzi Sylvio X-10 amastigotes infected in African green monkey Vero cells assessed as eradication of amastigotes after 72 hrs by Giemsa staining-based assay	2014	Journal of medicinal chemistry, May-22, Volume: 57, Issue:10	Optimization of antitrypanosomatid agents: identification of nonmutagenic drug candidates with in vivo activity.
AID1281413	Trypanocidal activity against epimastigote form of Trypanosoma cruzi Dm28c after 11 days by neubauer chamber method	2016	European journal of medicinal chemistry, Mar-23, Volume: 111	Phthalimido-thiazoles as building blocks and their effects on the growth and morphology of Trypanosoma cruzi.
AID1400237	Cytotoxicity against human THP1 cells after 72 hrs by MTT assay	2018	Bioorganic & medicinal chemistry, 09-15, Volume: 26, Issue:17	Synthesis and SAR of new isoxazole-triazole bis-heterocyclic compounds as analogues of natural lignans with antiparasitic activity.
AID1615100	Cardiotoxicity in Balb/c mouse infected with Trypanosoma cruzi MHOM/Pe/2011/Arequipa DTU 5 trypomastigotes assessed as change in serum LDH level at 20 mg/kg, po once daily for 5 consecutive days starting from day 10 post infection measured on day 16 post	2019	Bioorganic & medicinal chemistry, 03-01, Volume: 27, Issue:5	Synthesis and biological evaluation of new long-chain squaramides as anti-chagasic agents in the BALB/c mouse model.
AID1498282	Nephrotoxicity in Balb/c mouse infected with Trypanosoma cruzi MHOM/Pe/2011/Arequipa DTU 5 trypamastigotes assessed as decrease in uric acid level in serum at 20 mg/kg, po once daily for 5 consecutive days starting from day 75 post infection measured on d	2018	Journal of medicinal chemistry, 07-12, Volume: 61, Issue:13	Second Generation of Mannich Base-Type Derivatives with in Vivo Activity against Trypanosoma cruzi.
AID1519004	Antitrypanosomal activity against Trypanosoma cruzi K98 bloodstream form infected in C3H/HeNk mouse assessed as reduction in parasite burden in blood at 30 to 75 mg/kg/day, po administered via gavage for 30 consecutive days starting from 90 days post infe	2019	European journal of medicinal chemistry, 12-15, Volume: 184	Combined therapy with Benznidazole and repurposed drugs Clofazimine and Benidipine for chronic Chagas disease.
AID580582	Antitrypanosomal activity against Trypanosoma cruzi Y infected in CD4+ T-lymphocyte knockout C57BL/6 mouse assessed as mean survival time at 100 mg/kg/day, po administered once daily for 20 consecutive days measured 60 days post infection	2009	Antimicrobial agents and chemotherapy, Jan, Volume: 53, Issue:1	Absence of CD4+ T lymphocytes, CD8+ T lymphocytes, or B lymphocytes has different effects on the efficacy of posaconazole and benznidazole in treatment of experimental acute Trypanosoma cruzi infection.
AID1055144	Hepatotoxicity in BALB/c mouse infected with bloodstream trypomastigote form of Trypanosoma cruzi IRHOD/CO/2008/SN3 assessed as interstitial hemorrhage at 5 mg/kg/day, ip administered for 5 days measured 150 days post-infection by light microscopic analys	2013	European journal of medicinal chemistry, , Volume: 70	Scorpiand-like azamacrocycles prevent the chronic establishment of Trypanosoma cruzi in a murine model.
AID1615037	Antitrypanosomal activity against Trypanosoma cruzi MHOM/Pe/2011/Arequipa DTU 5 trypomastigotes infected in Balb/c mouse assessed as reduction in parasitaemia reactivation at 20 mg/kg, po pretreated once daily for 5 consecutive days starting from day 10 p	2019	Bioorganic & medicinal chemistry, 03-01, Volume: 27, Issue:5	Synthesis and biological evaluation of new long-chain squaramides as anti-chagasic agents in the BALB/c mouse model.
AID726611	Inhibition of Trypanosoma cruzi farnesyl diphosphate synthase assessed as incorporation of [4-14C]IPP measured at 37 degC	2013	European journal of medicinal chemistry, Feb, Volume: 60	Design, synthesis and biological evaluation of sulfur-containing 1,1-bisphosphonic acids as antiparasitic agents.
AID1546272	Antitrypanosomal activity against Trypanosoma cruzi Tulahuen CL2 amastigotes infected in human MRC5 SV2 cells incubated for 7 days by chlorophenol red beta-D-galactopyranoside substrate based spectrophotometric assay	2020	Bioorganic & medicinal chemistry letters, 01-01, Volume: 30, Issue:1	Structure-activity relationship of 4-azaindole-2-piperidine derivatives as agents against Trypanosoma cruzi.
AID1278148	Antiparasitic activity against amastigote stage of Trypanosoma cruzi Y	2016	Bioorganic & medicinal chemistry letters, Feb-15, Volume: 26, Issue:4	Gibbilimbol analogues as antiparasitic agents--Synthesis and biological activity against Trypanosoma cruzi and Leishmania (L.) infantum.
AID1615063	Antitrypanosomal activity against Trypanosoma cruzi MHOM/Pe/2011/Arequipa DTU 5 trypomastigotes infected in Balb/c mouse assessed as reduction in splenomegaly at 20 mg/kg, po once daily for 5 consecutive days starting from day 75 post infection measured o	2019	Bioorganic & medicinal chemistry, 03-01, Volume: 27, Issue:5	Synthesis and biological evaluation of new long-chain squaramides as anti-chagasic agents in the BALB/c mouse model.
AID285208	Mortality rate in Trypanosoma cruzi Y infected IFN-gamma knock out C57BL/6 mouse Chagas disease model at 100 mg/kg, po after 20 days	2007	Antimicrobial agents and chemotherapy, Apr, Volume: 51, Issue:4	The Anti-Trypanosoma cruzi activity of posaconazole in a murine model of acute Chagas' disease is less dependent on gamma interferon than that of benznidazole.
AID1569970	Cytotoxicity against Balb/c mouse splenocyte assessed as reduction in cell viability after 24 hrs by [3H]thymidine incorporation based beta scintillation counting analysis	2019	European journal of medicinal chemistry, Oct-15, Volume: 180	2-(phenylthio)ethylidene derivatives as anti-Trypanosoma cruzi compounds: Structural design, synthesis and antiparasitic activity.
AID1174783	Selectivity index, ratio of IC50 for african green monkey Vero cells to IC50 for trypomastigote form of Trypanosoma cruzi IRHOD/CO/2008/SN3	2015	European journal of medicinal chemistry, Jan-07, Volume: 89	Prospects of an alternative treatment against Trypanosoma cruzi based on abietic acid derivatives show promising results in Balb/c mouse model.
AID1633357	Selectivity index, ratio of CC50 for mouse RAW264.7 cells to IC50 for Trypanosoma cruzi Y epimastigotes
AID710595	Antitrypanosomal activity against intracellular amastigote form of Trypanosoma cruzi Tulahuen C2C4 infected in rat L6 cells assessed as growth inhibition after 92 hrs by inverted microscopy	2012	Journal of medicinal chemistry, Dec-13, Volume: 55, Issue:23	Conjugation of quinones with natural polyamines: toward an expanded antitrypanosomatid profile.
AID1079942	Steatosis, proven histopathologically. Value is number of references indexed. [column 'STEAT' in source]
AID762346	Antitrypanosomal activity against Trypanosoma cruzi Tulahuen C2C4 amastigotes infected in rat L6 cells after 96 hrs by beta-galactosidase reporter gene assay	2013	European journal of medicinal chemistry, Aug, Volume: 66	3-(Oxazolo[4,5-b]pyridin-2-yl)anilides as a novel class of potent inhibitors for the kinetoplastid Trypanosoma brucei, the causative agent for human African trypanosomiasis.
AID1498292	Cardiotoxicity in Balb/c mouse infected with Trypanosoma cruzi MHOM/Pe/2011/Arequipa DTU 5 trypamastigotes assessed as change in ratio of creatine kinase in muscle to brain at 20 mg/kg, po once daily for 5 consecutive days starting from day 75 post infect	2018	Journal of medicinal chemistry, 07-12, Volume: 61, Issue:13	Second Generation of Mannich Base-Type Derivatives with in Vivo Activity against Trypanosoma cruzi.
AID564079	Antitrypanosomal activity against Trypanosoma cruzi 875 epimastigotes after 24 hrs by light microscopy	2010	Antimicrobial agents and chemotherapy, Jul, Volume: 54, Issue:7	Arylimidamide DB766, a potential chemotherapeutic candidate for Chagas' disease treatment.
AID1603869	Toxicity in BALB/c mouse infected with Trypanosoma cruzi MHOM/Pe/2011/Arequipa;DTU 5 bloodstream trypomastigote assessed as decrease in serum total bilirubin level in chronic phase at 20 mg/kg/day administered for 5 consecutive days starting from day 76 p	2019	Bioorganic & medicinal chemistry, 09-01, Volume: 27, Issue:17	Rational modification of Mannich base-type derivatives as novel antichagasic compounds: Synthesis, in vitro and in vivo evaluation.
AID1633351	Antitrypanosomal activity against Trypanosoma cruzi Dm28c epimastigotes after 48 hrs by resazurin dye based assay
AID344441	Antitrypanosomal activity against Trypanosoma cruzi Y infected in Swiss mouse assessed as survivality at 385 umol/kg, po after 15 consecutive days	2008	Journal of medicinal chemistry, Jul-24, Volume: 51, Issue:14	Complexation of the anti-Trypanosoma cruzi drug benznidazole improves solubility and efficacy.
AID1055187	Trypanocidal activity against intracellular amastigote form of Trypanosoma cruzi IRHOD/CO/2008/SN3 infected in African green monkey Vero cells after 72 hrs by Giemsa staining assay	2013	European journal of medicinal chemistry, , Volume: 70	Scorpiand-like azamacrocycles prevent the chronic establishment of Trypanosoma cruzi in a murine model.
AID1615062	Antitrypanosomal activity against Trypanosoma cruzi MHOM/Pe/2011/Arequipa DTU 5 trypomastigotes infected in Balb/c mouse assessed as reduction in splenomegaly at 20 mg/kg, po once daily for 5 consecutive days starting from day 10 post infection measured o	2019	Bioorganic & medicinal chemistry, 03-01, Volume: 27, Issue:5	Synthesis and biological evaluation of new long-chain squaramides as anti-chagasic agents in the BALB/c mouse model.
AID337135	Antitrypanosomal activity against Trypanosoma cruzi Z2 after 48 hrs
AID1164931	Induction of apoptosis in human monocytes assessed as viable cells using Annexin V/propidium iodide by flow cytometry (Rvb = 97.53 %)	2014	European journal of medicinal chemistry, Nov-24, Volume: 87	In vitro antiparasitic activity of new thiosemicarbazones in strains of Trypanosoma cruzi.
AID1739884	Antitrypanosomal activity against Trypanosoma cruzi (MHOM/CH/00/Tulahuen C2, lacZ) amastigotes infected in HFF-1 cells assessed as reduction in parasite growth at 150 uM incubated for 120 hrs by CPRG/Igepal substrate based photometric method relative to c	2020	European journal of medicinal chemistry, Sep-01, Volume: 201	Discovery of highly potent and selective antiparasitic new oxadiazole and hydroxy-oxindole small molecule hybrids.
AID1236979	Induction of reactive oxygen species formation in human HT1080 cells at 10 to 50 M by fluorometric analysis	2015	Bioorganic & medicinal chemistry letters, Aug-01, Volume: 25, Issue:15	Synthesis and biological evaluation of quinones derived from natural product komaroviquinone as anti-Trypanosoma cruzi agents.
AID309301	Antitrypanosomal activity against Trypanosoma cruzi after 72 hrs	2007	Bioorganic & medicinal chemistry, Nov-01, Volume: 15, Issue:21	Marine natural products from the Turkish sponge Agelas oroides that inhibit the enoyl reductases from Plasmodium falciparum, Mycobacterium tuberculosis and Escherichia coli.
AID580589	Antitrypanosomal activity against Trypanosoma cruzi Y infected in CD8+ T-lymphocyte knockout C57BL/6 mouse assessed as cure rate in mouse at 100 mg/kg/day, po administered once daily for 20 consecutive days measured 60 days post infection	2009	Antimicrobial agents and chemotherapy, Jan, Volume: 53, Issue:1	Absence of CD4+ T lymphocytes, CD8+ T lymphocytes, or B lymphocytes has different effects on the efficacy of posaconazole and benznidazole in treatment of experimental acute Trypanosoma cruzi infection.
AID1616128	Antitrypanosomal activity against Trypanosoma cruzi Tulahuen CL2 amastigotes infected in human MRC5 SV2 cells incubated for 7 days by chlorophenol red beta-D-galactopyranoside substrate based spectrophotometric assay	2019	Journal of medicinal chemistry, 10-10, Volume: 62, Issue:19	Discovery of Pyrrolo[2,3-
AID1541612	Antitrypanosomal activity against Trypanosoma cruzi Tulahuen C4 infected in rat L6 cells measured after 96 hrs by inverted microscopy analysis	2019	Journal of natural products, 12-27, Volume: 82, Issue:12	Structure, Biosynthesis, and Bioactivity of Photoditritide from
AID1616184	Antitrypanosomal activity against Trypanosoma cruzi Y amastigotes infected in Swiss mouse primary cardiac cells incubated for 168 hrs with media replenishment for every 48 hrs followed by compound washout and measured after 168 hrs by light microscopic me	2019	Journal of medicinal chemistry, 10-10, Volume: 62, Issue:19	Discovery of Pyrrolo[2,3-
AID596809	Antitrypanosomal activity against metacyclic forms of Trypanosoma cruzi infected in vero cells assessed as inhibition of infection at IC25 concentration after 12 hrs	2011	Journal of natural products, Apr-25, Volume: 74, Issue:4	In vitro and in vivo trypanocidal activity of flavonoids from Delphinium staphisagria against Chagas disease.
AID1234672	Antiparasitic activity against Trypanosoma cruzi strain CL Brener epimastigotes at 300 uM after 12 days by ELISA reader	2015	Bioorganic & medicinal chemistry, Aug-01, Volume: 23, Issue:15	Enzymatic synthesis of bile acid derivatives and biological evaluation against Trypanosoma cruzi.
AID396014	Antimicrobial activity against Trypanosoma cruzi 1 and Trypanosoma cruzi 2 dually infected in BALB/c mouse assessed as cure rate	2007	Antimicrobial agents and chemotherapy, Sep, Volume: 51, Issue:9	Impact of dual infections on chemotherapeutic efficacy in BALB/c mice infected with major genotypes of Trypanosoma cruzi.
AID547271	Immunostimulatory activity in mongrel dog infected with Trypanosoma cruzi Berenice-78 assessed as production of antibody IgG at 7 mg/kg, po BID for 90 days measured up to 30 days by ELISA	2010	Antimicrobial agents and chemotherapy, Jul, Volume: 54, Issue:7	Effects of ravuconazole treatment on parasite load and immune response in dogs experimentally infected with Trypanosoma cruzi.
AID669305	Antitrypanosomal activity against Trypanosoma cruzi Y trymastigotes infected in monkey LLC-MK2 cells after 24 hrs by Brenner counter method in presence of beta-hydroxycopalic	2012	Journal of medicinal chemistry, Apr-12, Volume: 55, Issue:7	Terpenes from Copaifera demonstrated in vitro antiparasitic and synergic activity.
AID1124786	Antimicrobial activity against epimastigote stage of Trypanosoma brucei 29-13 after 24 hrs by MTT assay	2014	Bioorganic & medicinal chemistry letters, Apr-01, Volume: 24, Issue:7	Synthesis and tripanocidal activity of ferrocenyl and benzyl diamines against Trypanosoma brucei and Trypanosoma cruzi.
AID1498359	Antitrypanosomal activity against Trypanosoma cruzi MHOM/Pe/2011/Arequipa DTU 5 epimastigotes assessed as reduction in mitochondrial membrane potential at IC25 after 72 hrs by Rho123 staining based flow cytometry relative to control	2018	Journal of medicinal chemistry, 07-12, Volume: 61, Issue:13	Second Generation of Mannich Base-Type Derivatives with in Vivo Activity against Trypanosoma cruzi.
AID1067350	Antimicrobial activity against Giardia intestinalis IMSS:0696:1 incubated for 48 hrs followed by compound washout measured after 48 hrs	2014	Bioorganic & medicinal chemistry, Mar-01, Volume: 22, Issue:5	2-acylamino-5-nitro-1,3-thiazoles: preparation and in vitro bioevaluation against four neglected protozoan parasites.
AID1613495	Antitrypanosomal activity against Trypanosoma cruzi MHOM/Pe/2011/Arequipa DTU 5 trypomastigotes infected in Balb/c mouse assessed as parasite-free adipose tissue at 20 mg/kg, po pretreated once daily for 5 consecutive days starting from day 75 post infect	2019	European journal of medicinal chemistry, Feb-15, Volume: 164	New polyamine drugs as more effective antichagas agents than benznidazole in both the acute and chronic phases.
AID707768	Antitrypanosomal activity against Trypanosoma cruzi IRHOD/VO/2008/SN3 metacyclic forms infected in BALB/c mouse model of acute Chagas disease assessed as reduction parasitemia at 5 mg/kg/day, ip administered for 5 consecutive days starting on day 7 post i	2012	Journal of medicinal chemistry, Nov-26, Volume: 55, Issue:22	Phthalazine derivatives containing imidazole rings behave as Fe-SOD inhibitors and show remarkable anti-T. cruzi activity in immunodeficient-mouse mode of infection.
AID1603822	Antitrypanosomal activity against Trypanosoma cruzi MHOM/Pe/2011/Arequipa;DTU 5 bloodstream trypomastigote infected in BALB/c mouse assessed as parasite-free oesophagus in acute phase at 20 mg/kg/day, po administered for 5 consecutive days starting from d	2019	Bioorganic & medicinal chemistry, 09-01, Volume: 27, Issue:17	Rational modification of Mannich base-type derivatives as novel antichagasic compounds: Synthesis, in vitro and in vivo evaluation.
AID1723647	Antitrypanosomal activity against Trypanosoma cruzi epimastigotes	2020	Bioorganic & medicinal chemistry letters, 10-15, Volume: 30, Issue:20	Expanding the scope of synthetic 1,2,4-trioxanes towards Trypanosoma cruzi and Leishmania donovani.
AID1062981	Selectivity index, ratio of CC50 for mouse L929 cells to IC50 for Trypanosoma cruzi Tulahuen amastigotes	2014	European journal of medicinal chemistry, Jan, Volume: 71	Synthesis and evaluation of the antiparasitic activity of bis-(arylmethylidene) cycloalkanones.
AID664488	Antitrypanosomal activity against intracellular amastigote stage of Trypanosoma cruzi Tulahuen C2C4 infected in rat L6 cells after 96 hrs by spectrophotometric analysis	2012	Journal of medicinal chemistry, Apr-12, Volume: 55, Issue:7	Synthesis, biological evaluation, and structure-activity relationships of N-benzoyl-2-hydroxybenzamides as agents active against P. falciparum (K1 strain), Trypanosomes, and Leishmania.
AID598285	Antitrypanosomal activity against Trypanosoma cruzi MHOM/MX/1994/Ninoa epimastigotes after 72 hrs by neubauer chamber	2011	Bioorganic & medicinal chemistry letters, May-15, Volume: 21, Issue:10	Synthesis of benzologues of Nitazoxanide and Tizoxanide: a comparative study of their in vitro broad-spectrum antiprotozoal activity.
AID1156606	Antiparasitic activity against Leishmania amazonensis infected in CD-1 mouse macrophages after 72 hrs by spectrophotometric analysis	2014	European journal of medicinal chemistry, Aug-18, Volume: 83	Synthesis and antiparasitic activity of new bis-arylimidamides: DB766 analogs modified in the terminal groups.
AID580667	Antitrypanosomal activity against Trypanosoma cruzi Y infected in CD4+ T-lymphocyte knockout C57BL/6 mouse assessed as reactivation of parasite in mouse at 20 mg/kg/day, po administered twice daily for 20 consecutive days measured 60 days post infection	2009	Antimicrobial agents and chemotherapy, Jan, Volume: 53, Issue:1	Absence of CD4+ T lymphocytes, CD8+ T lymphocytes, or B lymphocytes has different effects on the efficacy of posaconazole and benznidazole in treatment of experimental acute Trypanosoma cruzi infection.
AID392020	Antitrypanosomal activity against Trypanosoma cruzi Colombiana infected Swiss mouse assessed as prevention of heart inflammatory infiltrates at 120 mg/kg/day, po	2008	European journal of medicinal chemistry, Oct, Volume: 43, Issue:10	In vivo studies of 5-arylethenylbenzofuroxans in acute murine models of Chagas' disease.
AID1079939	Cirrhosis, proven histopathologically. Value is number of references indexed. [column 'CIRRH' in source]
AID1498308	Hepatotoxicity in Balb/c mouse infected with Trypanosoma cruzi MHOM/Pe/2011/Arequipa DTU 5 trypamastigotes assessed as increase in ratio of serum AST to GOT level at 20 mg/kg, po once daily for 5 consecutive days starting from day 10 post infection measur	2018	Journal of medicinal chemistry, 07-12, Volume: 61, Issue:13	Second Generation of Mannich Base-Type Derivatives with in Vivo Activity against Trypanosoma cruzi.
AID344428	Antiproliferative activity against Trypanosoma cruzi Y epimastigotes assessed as number of motile forms at 0.5 mM after 1 hr by hemocytometer	2008	Journal of medicinal chemistry, Jul-24, Volume: 51, Issue:14	Complexation of the anti-Trypanosoma cruzi drug benznidazole improves solubility and efficacy.
AID1238026	Selectivity index, ratio of EC50 for BALB/c mouse peritoneal macrophages to EC50 for Leishmania infantum MHOM/BR/72 amastigotes	2015	Bioorganic & medicinal chemistry letters, Aug-15, Volume: 25, Issue:16	Synthesis and evaluation of novel prenylated chalcone derivatives as anti-leishmanial and anti-trypanosomal compounds.
AID1254936	Antichagasic activity against firefly luciferase expressing trypamastigote forms of transgenic Trypanosoma cruzi Y infected in Balb/c mouse assessed as reduction in parasite level at 15 mg/kg/day, ip dosed for 10 days by luciferase reporter gene assay	2015	European journal of medicinal chemistry, Oct-20, Volume: 103	3-Nitrotriazole-based piperazides as potent antitrypanosomal agents.
AID1294231	Cytotoxicity against mouse Cardiomyocytes after 48 hrs by Prestoblue assay	2016	European journal of medicinal chemistry, Jun-10, Volume: 115	Antichagasic and trichomonacidal activity of 1-substituted 2-benzyl-5-nitroindazolin-3-ones and 3-alkoxy-2-benzyl-5-nitro-2H-indazoles.
AID1613484	Selectivity index, ratio of IC50 for African green monkey Vero cells to IC50 for Trypanosoma cruzi TINF/CH/1956/Tulahuen DTU 6 trypomastigotes derived from infected Balb/c albino mouse	2019	European journal of medicinal chemistry, Feb-15, Volume: 164	New polyamine drugs as more effective antichagas agents than benznidazole in both the acute and chronic phases.
AID337134	Antitrypanosomal activity against Trypanosoma cruzi Z1 after 48 hrs
AID548112	Inhibition of Trypanosoma cruzi triosephosphate isomerase at 100 uM after 2 hrs	2010	European journal of medicinal chemistry, Dec, Volume: 45, Issue:12	Massive screening yields novel and selective Trypanosoma cruzi triosephosphate isomerase dimer-interface-irreversible inhibitors with anti-trypanosomal activity.
AID1244472	Trypanocidal activity against intracellular amastigotes of Trypanosoma cruzi Tulahuen infected in human U937 cells assessed as reduction of viability of intracellular amastigotes by measuring beta-galactosidase activity after 72 hrs by spectrophotometry a	2015	European journal of medicinal chemistry, Aug-28, Volume: 101	Synthesis, leishmanicidal, trypanocidal and cytotoxic activity of quinoline-hydrazone hybrids.
AID726231	Antitrypanosomal activity against Trypanosoma cruzi DM28 epimastigotes at 256 uM incubated for 48 hrs by resazurin dye reduction based ELISA method	2013	Journal of medicinal chemistry, Feb-28, Volume: 56, Issue:4	Cloning, characterization, and sulfonamide and thiol inhibition studies of an α-carbonic anhydrase from Trypanosoma cruzi, the causative agent of Chagas disease.
AID1074931	Antitrypanosomal activity against Trypanosoma cruzi (IRHOD/CO/2008/SN3) amastigotes infected in African green monkey Vero cells after 72 hrs by Giemsa staining-based microscopic analysis	2014	European journal of medicinal chemistry, Mar-03, Volume: 74	New perspectives on the synthesis and antichagasic activity of 3-alkoxy-1-alkyl-5-nitroindazoles.
AID1383429	Antitrypanosomal activity against bloodstream trypomastigote stage of Trypanosoma cruzi Y measured after 2 hrs by light microscopic analysis	2018	European journal of medicinal chemistry, Apr-10, Volume: 149	Identification of Pyrazolo[3,4-e][1,4]thiazepin based CYP51 inhibitors as potential Chagas disease therapeutic alternative: In vitro and in vivo evaluation, binding mode prediction and SAR exploration.
AID1519013	Toxicity in C3H/HeNk mouse infected with Trypanosoma cruzi K98 bloodstream form assessed as body weight gain at 75 mg/kg/day, po administered via gavage for 30 consecutive days starting from 90 days post infection measured up to 120 days post infection	2019	European journal of medicinal chemistry, 12-15, Volume: 184	Combined therapy with Benznidazole and repurposed drugs Clofazimine and Benidipine for chronic Chagas disease.
AID1615014	Trypanocidal activity against Trypanosoma cruzi MHOM/Pe/2011/Arequipa DTU 5 trypomastigotes derived from infected Balb/c mouse after 72 hrs by resazurin dye based assay	2019	Bioorganic & medicinal chemistry, 03-01, Volume: 27, Issue:5	Synthesis and biological evaluation of new long-chain squaramides as anti-chagasic agents in the BALB/c mouse model.
AID1587047	Antitrypanosomal activity against Trypanosoma cruzi Tulahuen amastigotes infected in mouse 3T3 cells after 6 days by beta galactosidase reporter assay	2019	ACS medicinal chemistry letters, Jan-10, Volume: 10, Issue:1	Triazolopyrimidines and Imidazopyridines: Structure-Activity Relationships and in Vivo Efficacy for Trypanosomiasis.
AID1613483	Selectivity index, ratio of IC50 for African green monkey Vero cells to IC50 for Trypanosoma cruzi TINF/CH/1956/Tulahuen DTU 6 amastigotes infected in African green monkey Vero cells	2019	European journal of medicinal chemistry, Feb-15, Volume: 164	New polyamine drugs as more effective antichagas agents than benznidazole in both the acute and chronic phases.
AID547256	Antimicrobial activity against Trypanosoma cruzi Berenice-78 infected in mongrel dog assessed as survival of dog at 12 mg/kg, po BID started 12 to 22 days postinfection measured after 1 day	2010	Antimicrobial agents and chemotherapy, Jul, Volume: 54, Issue:7	Effects of ravuconazole treatment on parasite load and immune response in dogs experimentally infected with Trypanosoma cruzi.
AID1264449	Leishmanicidal activity against promastigote stage of Leishmania infantum MCAN/ES/92/BCN722 after 48 hrs by acid phosphatase based assay	2015	European journal of medicinal chemistry, Nov-13, Volume: 105	Multicomponent reaction-based synthesis and biological evaluation of tricyclic heterofused quinolines with multi-trypanosomatid activity.
AID214976	In vitro Trypanosoma cruzi (TC)	2001	Bioorganic & medicinal chemistry letters, Jul-23, Volume: 11, Issue:14	Design, synthesis, and biological evaluation of a series of simple and novel potential antimalarial compounds.
AID1851971	Solubility of compound in water at pH 7 by LC-UV analysis	2022	Journal of medicinal chemistry, 10-13, Volume: 65, Issue:19	Nitroimidazopyrazinones with Oral Activity against Tuberculosis and Chagas Disease in Mouse Models of Infection.
AID537132	Antileishmanial activity against promastigotes of Leishmania amazonensis WHO/BR/00/LT0016 after 18 hrs by MTT assay	2010	Bioorganic & medicinal chemistry, Nov-15, Volume: 18, Issue:22	Anti-leishmanial and anti-trypanosomal activities of 1,4-dihydropyridines: In vitro evaluation and structure-activity relationship study.
AID1603754	Antitrypanosomal activity against Trypanosoma cruzi MHOM/Pe/2011/Arequipa;DTU 5 epimastigotes measured after 72 hrs by Neubauer hemocytometer	2019	Bioorganic & medicinal chemistry, 09-01, Volume: 27, Issue:17	Rational modification of Mannich base-type derivatives as novel antichagasic compounds: Synthesis, in vitro and in vivo evaluation.
AID1174781	Selectivity index, ratio of IC50 for african green monkey Vero cells to IC50 for epimastigote Trypanosoma cruzi IRHOD/CO/2008/SN3	2015	European journal of medicinal chemistry, Jan-07, Volume: 89	Prospects of an alternative treatment against Trypanosoma cruzi based on abietic acid derivatives show promising results in Balb/c mouse model.
AID1603856	Toxicity in BALB/c mouse infected with Trypanosoma cruzi MHOM/Pe/2011/Arequipa;DTU 5 bloodstream trypomastigote assessed as change in serum total bilirubin level in acute phase at 20 mg/kg/day, po administered for 5 consecutive days starting from day 8 po	2019	Bioorganic & medicinal chemistry, 09-01, Volume: 27, Issue:17	Rational modification of Mannich base-type derivatives as novel antichagasic compounds: Synthesis, in vitro and in vivo evaluation.
AID580583	Antitrypanosomal activity against Trypanosoma cruzi Y infected in CD4+ T-lymphocyte knockout C57BL/6 mouse assessed as cure rate in mouse at 100 mg/kg/day, po administered once daily for 20 consecutive days measured 60 days post infection	2009	Antimicrobial agents and chemotherapy, Jan, Volume: 53, Issue:1	Absence of CD4+ T lymphocytes, CD8+ T lymphocytes, or B lymphocytes has different effects on the efficacy of posaconazole and benznidazole in treatment of experimental acute Trypanosoma cruzi infection.
AID1498258	Antitrypanosomal activity against Trypanosoma cruzi MHOM/Pe/2011/Arequipa DTU 5 trypamastigotes infected in Balb/c mouse assessed as reduction in splenomegaly at 20 mg/kg, po once daily for 5 consecutive days starting from day 10 post infection measured o	2018	Journal of medicinal chemistry, 07-12, Volume: 61, Issue:13	Second Generation of Mannich Base-Type Derivatives with in Vivo Activity against Trypanosoma cruzi.
AID323758	Antiparasitic activity against Trypanosoma cruzi Y trypomastigotes	2008	Bioorganic & medicinal chemistry, Mar-15, Volume: 16, Issue:6	Novel 1,3,4-thiadiazolium-2-phenylamine chlorides derived from natural piperine as trypanocidal agents: chemical and biological studies.
AID373285	Antitrypanosomal activity against Trypanosoma cruzi bloodstream trypomastigote infected in BALB/c mouse assessed as antibodies at 50 mg/kg, po after 60 days by colorimetric method	2009	European journal of medicinal chemistry, Mar, Volume: 44, Issue:3	In vitro and in vivo antitrypanosomatid activity of 5-nitroindazoles.
AID1683713	Antitrypanosomal activity against Trypanosoma cruzi IRHOD/CO/2008/SN3 (DTU I) blood stream trypomastigote form assessed as parasite growth inhibition incubated for 24 hrs by resazurin dye based assay	2020	Journal of natural products, 12-24, Volume: 83, Issue:12	In Vivo Biological Evaluation of a Synthetic Royleanone Derivative as a Promising Fast-Acting Trypanocidal Agent by Inducing Mitochondrial-Dependent Necrosis.
AID1518997	Antitrypanosomal activity against Trypanosoma cruzi K98 bloodstream form infected in C3H/HeNk mouse assessed as QRS morphology at 75 mg/kg/day, po administered via gavage for 30 consecutive days starting from 90 days post infection and measured at 170 day	2019	European journal of medicinal chemistry, 12-15, Volume: 184	Combined therapy with Benznidazole and repurposed drugs Clofazimine and Benidipine for chronic Chagas disease.
AID626316	Antiparasitic activity against trypomastigotes of Trypanosoma cruzi Tulahuen C2C4 expressing LacZ gene infected in rat L6 cells after 96 hrs	2011	Bioorganic & medicinal chemistry letters, Nov-01, Volume: 21, Issue:21	Biological evaluation of glycosyl-isoindigo derivatives against the pathogenic agents of tropical diseases (malaria, Chagas disease, leishmaniasis and human African trypanosomiasis).
AID1603741	Toxicity in BALB/c mouse infected with Trypanosoma cruzi MHOM/Pe/2011/Arequipa;DTU 5 bloodstream trypomastigotes assessed as decrease in serum alkaline phosphatase level in chronic phase at 20 mg/kg/day, po administered for 5 consecutive days starting fro	2019	Bioorganic & medicinal chemistry, 09-01, Volume: 27, Issue:17	Rational modification of Mannich base-type derivatives as novel antichagasic compounds: Synthesis, in vitro and in vivo evaluation.
AID265557	Antitrypanosomatid activity against Trypanosoma cruzi Y epimastigote form	2006	Journal of medicinal chemistry, Jun-01, Volume: 49, Issue:11	2H-benzimidazole 1,3-dioxide derivatives: a new family of water-soluble anti-trypanosomatid agents.
AID1470759	Trypanocidal activity against bloodstream form of Trypanosoma cruzi NINOA infected in NIH mouse assessed as reduction in parasitemia at 100 mg/kg, po measured up to 6 hrs post dose by microscopic method	2017	European journal of medicinal chemistry, May-26, Volume: 132	An in vitro and in vivo evaluation of new potential trans-sialidase inhibitors of Trypanosoma cruzi predicted by a computational drug repositioning method.
AID1196782	Inhibition of recombinant full-length Trypanosoma cruzi CYP51 assessed as molar ratio of inhibitor to enzyme which causes 2 fold decrease in enzyme activity in 5 mins by HPLC analysis	2015	Journal of medicinal chemistry, Feb-12, Volume: 58, Issue:3	Novel 3-nitrotriazole-based amides and carbinols as bifunctional antichagasic agents.
AID1669167	Antitrypanosomal activity against Trypanosoma cruzi Y amastigotes infected in rat H9C2 rat cells assessed as reduction in number of infected cells at 10 uM after 72 hrs by Hoechst 33342 staining based fluorescence microscopy	2020	ACS medicinal chemistry letters, Jun-11, Volume: 11, Issue:6	Development of Selective Steroid Inhibitors for the Glucose-6-phosphate Dehydrogenase from
AID1055179	Trypanocidal activity against trypomastigote form of Trypanosoma cruzi IRHOD/CO/2008/SN3 infected in African green monkey Vero cells assessed as inhibition of trypomastigotes released in culture medium at IC25 relative to control	2013	European journal of medicinal chemistry, , Volume: 70	Scorpiand-like azamacrocycles prevent the chronic establishment of Trypanosoma cruzi in a murine model.
AID249627	Percentage delyse against amastigote forms of Y strain of Trypanosoma cruzi at 0.5 uM	2005	Bioorganic & medicinal chemistry letters, Jan-17, Volume: 15, Issue:2	Trypanocidal activity of (-)-cubebin derivatives against free amastigote forms of Trypanosoma cruzi.
AID282993	Antiparasitic activity against Leishmania donovani MHOM/ET/67/HU3 intracellular amastigotes	2005	Journal of medicinal chemistry, Nov-17, Volume: 48, Issue:23	Irreversible inactivation of trypanothione reductase by unsaturated Mannich bases: a divinyl ketone as key intermediate.
AID677211	Selectivity index, ratio of IC50 for Vero cells to IC50 for Trypanosoma cruzi intracellular amastigote infected in Vero cells	2012	Journal of medicinal chemistry, May-10, Volume: 55, Issue:9	In vitro and in vivo trypanosomicidal activity of pyrazole-containing macrocyclic and macrobicyclic polyamines: their action on acute and chronic phases of Chagas disease.
AID1498338	Hepatotoxicity in Balb/c mouse infected with Trypanosoma cruzi MHOM/Pe/2011/Arequipa DTU 5 trypamastigotes assessed as increase in total bilirubin level at 20 mg/kg, po once daily for 5 consecutive days starting from day 75 post infection measured on day	2018	Journal of medicinal chemistry, 07-12, Volume: 61, Issue:13	Second Generation of Mannich Base-Type Derivatives with in Vivo Activity against Trypanosoma cruzi.
AID509508	Antiprotozoal activity against Trypanosoma cruzi Tulahuen C2C4 infected in rat skeletal myoblast at 4.8 ug/ml after 48 hrs	2010	European journal of medicinal chemistry, Sep, Volume: 45, Issue:9	Synthesis and preliminary bioactivity assays of 3,4-dichloro-5-(omega-hydroxyalkylamino)-2(5H)-furanones.
AID1065110	Trypanocidal activity against Trypanosoma cruzi CA-I/72 infected in BESM cells assessed as parasite re-emergence at 6.6 uM measured over 20 days of drug treatment	2014	ACS medicinal chemistry letters, Feb-13, Volume: 5, Issue:2	Diversity-oriented synthesis yields a new drug lead for treatment of chagas disease.
AID738320	Antitrypanosomal activity against amastigote form of Trypanosoma cruzi Tulahuen infected in african green monkey Vero cells assessed as decrease in number of intracellular parasites at 0.06 to 0.5 mM treated after removal of parasite on cell supernatant f	2013	Bioorganic & medicinal chemistry, Apr-01, Volume: 21, Issue:7	α-Selective glycosylation affords mucin-related GalNAc amino acids and diketopiperazines active on Trypanosoma cruzi.
AID1496043	Antitrypanosomal activity against Trypanosoma cruzi Tulahuen amastigotes infected in mouse L929 cells assessed as reduction in infection level at 10 uM after 96 hrs by beta galactosidase reporter assay relative to control	2018	Bioorganic & medicinal chemistry letters, 06-15, Volume: 28, Issue:11	Identification and preliminary structure-activity relationship studies of novel pyridyl sulfonamides as potential Chagas disease therapeutic agents.
AID1615081	Toxicity in Balb/c mouse assessed as reduction in body mass at 20 mg/kg, po once daily for 5 consecutive days starting from day 75 post infection relative to control	2019	Bioorganic & medicinal chemistry, 03-01, Volume: 27, Issue:5	Synthesis and biological evaluation of new long-chain squaramides as anti-chagasic agents in the BALB/c mouse model.
AID1254439	Antiparasitic activity against amastigote stage of Trypanosoma cruzi Y in BALB/c mouse macrophages assessed as decrease in number of infected cells at 50 uM incubated for 6 hrs by Giemsa staining-based optical microscopic analysis	2015	Bioorganic & medicinal chemistry, Dec-01, Volume: 23, Issue:23	Structural design, synthesis and pharmacological evaluation of 4-thiazolidinones against Trypanosoma cruzi.
AID396020	Antimicrobial activity against Trypanosoma cruzi genotype 39 infected in BALB/c mouse assessed as cure rate	2007	Antimicrobial agents and chemotherapy, Sep, Volume: 51, Issue:9	Impact of dual infections on chemotherapeutic efficacy in BALB/c mice infected with major genotypes of Trypanosoma cruzi.
AID362868	Cytotoxicity against human THP1 cells after 48 hrs	2008	European journal of medicinal chemistry, May, Volume: 43, Issue:5	4-nitroacetophenone-derived thiosemicarbazones and their copper(II) complexes with significant in vitro anti-trypanosomal activity.
AID1188734	Antitrypanosomal activity against trypomastigote forms of Trypanosoma cruzi Y infected in LLC-MK2 cells assessed as reduction in viable parasites after 24 hrs by Neubauer chamber counting method	2014	European journal of medicinal chemistry, Oct-30, Volume: 86	2-Pyridyl thiazoles as novel anti-Trypanosoma cruzi agents: structural design, synthesis and pharmacological evaluation.
AID1613541	Cardiotoxicity in Balb/c mouse infected with Trypanosoma cruzi MHOM/Pe/2011/Arequipa DTU 5 trypomastigotes assessed as decrease in serum LDH level at 20 mg/kg, po once daily for 5 consecutive days starting from day 75 post infection measured on day 81 pos	2019	European journal of medicinal chemistry, Feb-15, Volume: 164	New polyamine drugs as more effective antichagas agents than benznidazole in both the acute and chronic phases.
AID1603950	Antitrypanosomal activity against Trypanosoma cruzi MHOM/Pe/2011/Arequipa;DTU 5 epimastigote assessed as effect on acetate excretion at IC50 after 72 hrs by H NMR method relative to control	2019	Bioorganic & medicinal chemistry, 09-01, Volume: 27, Issue:17	Rational modification of Mannich base-type derivatives as novel antichagasic compounds: Synthesis, in vitro and in vivo evaluation.
AID1055170	Hepatotoxicity in BALB/c mouse infected with bloodstream trypomastigote form of Trypanosoma cruzi IRHOD/CO/2008/SN3 assessed as delocalized hepatic destruction at 5 mg/kg/day, ip administered for 5 days measured 150 days post-infection by light microscopi	2013	European journal of medicinal chemistry, , Volume: 70	Scorpiand-like azamacrocycles prevent the chronic establishment of Trypanosoma cruzi in a murine model.
AID576088	Toxicity in human patient infected with Trypanosoma cruzi assessed as occurrence of Mucositis at 5 mg/kg/day for 60 days	2010	Antimicrobial agents and chemotherapy, Nov, Volume: 54, Issue:11	Tolerance of benznidazole in treatment of Chagas' disease in adults.
AID285211	Effect on survival in Trypanosoma cruzi Y infected IFN-gamma knock out C57BL/6 mouse Chagas disease model assessed as mean survival time at 100 mg/kg, po after 20 days	2007	Antimicrobial agents and chemotherapy, Apr, Volume: 51, Issue:4	The Anti-Trypanosoma cruzi activity of posaconazole in a murine model of acute Chagas' disease is less dependent on gamma interferon than that of benznidazole.
AID616289	Antiparasitic activity against Trypanosoma cruzi Tulahuen C4 amastigotes stage forms incubated for 96 hrs by beta-galactosidase reporter gene assay	2011	Journal of natural products, Sep-23, Volume: 74, Issue:9	Antimalarial β-carbolines from the New Zealand ascidian Pseudodistoma opacum.
AID1498195	Toxicity in Balb/c mouse assessed as death at 20 mg/kg, po once daily for 5 consecutive days starting from day 10 post infection	2018	Journal of medicinal chemistry, 07-12, Volume: 61, Issue:13	Second Generation of Mannich Base-Type Derivatives with in Vivo Activity against Trypanosoma cruzi.
AID1612295	Antiparasitic activity against Trypanosoma cruzi Tulahuen C4 trypomastigotes infected in rat L6 cells after 96 hrs by CPRG/Nonidet reagent based photometric analysis	2018	Journal of natural products, 10-26, Volume: 81, Issue:10	Methionine-Containing Rhabdopeptide/Xenortide-like Peptides from Heterologous Expression of the Biosynthetic Gene Cluster kj12ABC in Escherichia coli.
AID1294223	Antichagasic activity against Trypanosoma cruzi CL-B5 epimastigotes in mouse L929 cells assessed as growth inhibition after 72 hrs by beta galactosidase reporter gene assay	2016	European journal of medicinal chemistry, Jun-10, Volume: 115	Antichagasic and trichomonacidal activity of 1-substituted 2-benzyl-5-nitroindazolin-3-ones and 3-alkoxy-2-benzyl-5-nitro-2H-indazoles.
AID1498198	Toxicity in Balb/c mouse assessed as reduction in body mass at 20 mg/kg, po once daily for 5 consecutive days starting from day 75 post infection relative to control	2018	Journal of medicinal chemistry, 07-12, Volume: 61, Issue:13	Second Generation of Mannich Base-Type Derivatives with in Vivo Activity against Trypanosoma cruzi.
AID1507195	Growth inhibition of Trypanosoma cruzi clone CL B5 epimastigotes at 25 uM after 72 hrs by beta-galactosidase reporter gene assay relative to control	2017	European journal of medicinal chemistry, Aug-18, Volume: 136	Novel Imidazo[4,5-c][1,2,6]thiadiazine 2,2-dioxides as antiproliferative trypanosoma cruzi drugs: Computational screening from neural network, synthesis and in vivo biological properties.
AID1603831	Antitrypanosomal activity against Trypanosoma cruzi MHOM/Pe/2011/Arequipa;DTU 5 bloodstream trypomastigotes infected in BALB/c mouse assessed as parasite-free stomach in chronic phase at 20 mg/kg/day, po administered for 5 consecutive days starting from d	2019	Bioorganic & medicinal chemistry, 09-01, Volume: 27, Issue:17	Rational modification of Mannich base-type derivatives as novel antichagasic compounds: Synthesis, in vitro and in vivo evaluation.
AID1498303	Cardiotoxicity in Balb/c mouse infected with Trypanosoma cruzi MHOM/Pe/2011/Arequipa DTU 5 trypamastigotes assessed as decrease in serum LDH level at 20 mg/kg, po once daily for 5 consecutive days starting from day 75 post infection measured on day 127 po	2018	Journal of medicinal chemistry, 07-12, Volume: 61, Issue:13	Second Generation of Mannich Base-Type Derivatives with in Vivo Activity against Trypanosoma cruzi.
AID1683659	Inhibition of nucleic acid level in Trypanosoma cruzi MHOM/Pe/2011/Arequipa(DTU V) epimastigote form at IC25 concentration after 72 hrs by Rho (FITC-A) staining based flow cytometric analysis	2020	Journal of natural products, 12-24, Volume: 83, Issue:12	In Vivo Biological Evaluation of a Synthetic Royleanone Derivative as a Promising Fast-Acting Trypanocidal Agent by Inducing Mitochondrial-Dependent Necrosis.
AID580602	Antitrypanosomal activity against Trypanosoma cruzi Y infected in CD4+ T-lymphocyte knockout C57BL/6 mouse assessed as reactivation of parasite in mouse at 100 mg/kg/day, po administered once daily for 20 consecutive days measured 11 days post infection	2009	Antimicrobial agents and chemotherapy, Jan, Volume: 53, Issue:1	Absence of CD4+ T lymphocytes, CD8+ T lymphocytes, or B lymphocytes has different effects on the efficacy of posaconazole and benznidazole in treatment of experimental acute Trypanosoma cruzi infection.
AID1403401	Trypanocidal activity against Trypanosoma cruzi Brazil trypomastigotes infected in monkey LLC-MK2 cells after 24 hrs by luminescent assay	2018	European journal of medicinal chemistry, Jan-20, Volume: 144	Efficacy of 2-hydroxy-3-phenylsulfanylmethyl-[1,4]-naphthoquinone derivatives against different Trypanosoma cruzi discrete type units: Identification of a promising hit compound.
AID1615046	Antitrypanosomal activity against Trypanosoma cruzi MHOM/Pe/2011/Arequipa DTU 5 trypomastigotes infected in Balb/c mouse assessed as parasite-free spleen at 20 mg/kg, po pretreated once daily for 5 consecutive days starting from day 10 post infection foll	2019	Bioorganic & medicinal chemistry, 03-01, Volume: 27, Issue:5	Synthesis and biological evaluation of new long-chain squaramides as anti-chagasic agents in the BALB/c mouse model.
AID1613467	Trypanocidal activity against Trypanosoma cruzi MHOM/Pe/2011/Arequipa DTU 5 amastigotes infected in African green monkey Vero cells after 72 hrs by Giemsa-staining based microscopic assay	2019	European journal of medicinal chemistry, Feb-15, Volume: 164	New polyamine drugs as more effective antichagas agents than benznidazole in both the acute and chronic phases.
AID1383426	Cytotoxicity against mouse L929 cells assessed as reduction in cell viability after 96 hrs by Alamarblue assay	2018	European journal of medicinal chemistry, Apr-10, Volume: 149	Identification of Pyrazolo[3,4-e][1,4]thiazepin based CYP51 inhibitors as potential Chagas disease therapeutic alternative: In vitro and in vivo evaluation, binding mode prediction and SAR exploration.
AID1508573	Antitrypanosomal activity against bloodstream trypomastigote stage of Trypanosoma cruzi Y infected in Balb/c mouse macrophages assessed as reduction in number of infected cells at 0.5 uM measured after 3 days by hoeschst staining based confocal microscopi	2017	European journal of medicinal chemistry, Dec-01, Volume: 141	Structural design, synthesis and pharmacological evaluation of thiazoles against Trypanosoma cruzi.
AID1713341	Anti-chagasic activity against Trypanosoma cruzi Brazil trypomastigotes expressing firefly luciferase infected in BALB/c mouse assessed as reduction in parasitemia at 15 mg/kg/day, ip measured after 10 days by bioluminescence assay	2016	European journal of medicinal chemistry, Nov-10, Volume: 123	Nitrotriazole-based acetamides and propanamides with broad spectrum antitrypanosomal activity.
AID1613554	Hepatotoxicity in Balb/c mouse infected with Trypanosoma cruzi MHOM/Pe/2011/Arequipa DTU 5 trypomastigotes assessed as change in ratio of serum ALT to GPT level at 20 mg/kg, po once daily for 5 consecutive days starting from day 10 post infection measured	2019	European journal of medicinal chemistry, Feb-15, Volume: 164	New polyamine drugs as more effective antichagas agents than benznidazole in both the acute and chronic phases.
AID1773689	Trypanocidal activity against amastigotes form of Trypanosoma cruzi CA-I/72 infected in mouse C2C12 cells assessed as inhibition of parasite replication incubated for 48 hrs by DAPI staining based microscopic analysis	2021	Journal of medicinal chemistry, 09-09, Volume: 64, Issue:17	Structure-Based Optimization of Quinazolines as Cruzain and
AID564777	Antitrypanosomal activity against Trypanosoma cruzi Columbian bloodstream forms infected in C3H mouse assessed as survival of mouse at 100 mg/kg/day, po administered 5 days postinfection for 10 consecutive days measured after 31 days	2010	Antimicrobial agents and chemotherapy, Jul, Volume: 54, Issue:7	Arylimidamide DB766, a potential chemotherapeutic candidate for Chagas' disease treatment.
AID1753480	Antitrypanosomal activity against nifurtimox-sensitive Trypanosoma cruzi Tulahuen CL2 infected in human MRC-5 SV2 cells assessed as inhibition of parasite growth measured after 7 days by spectrophotometric analysis	2021	Journal of medicinal chemistry, 04-08, Volume: 64, Issue:7	Revisiting Pyrazolo[3,4-
AID580594	Antitrypanosomal activity against Trypanosoma cruzi Y infected in B-lymphocyte knockout C57BL/6 mouse assessed as mean survival time at 100 mg/kg/day, po administered once daily for 20 consecutive days measured 60 days post infection	2009	Antimicrobial agents and chemotherapy, Jan, Volume: 53, Issue:1	Absence of CD4+ T lymphocytes, CD8+ T lymphocytes, or B lymphocytes has different effects on the efficacy of posaconazole and benznidazole in treatment of experimental acute Trypanosoma cruzi infection.
AID1739885	Antitrypanosomal activity against Trypanosoma cruzi (MHOM/CH/00/Tulahuen C2, lacZ) amastigotes infected in HFF-1 cells assessed as reduction in parasite growth at 75 uM incubated for 120 hrs by CPRG/Igepal substrate based photometric method relative to co	2020	European journal of medicinal chemistry, Sep-01, Volume: 201	Discovery of highly potent and selective antiparasitic new oxadiazole and hydroxy-oxindole small molecule hybrids.
AID738323	Antitrypanosomal activity against trypomastigote form of Trypanosoma cruzi Tulahuen expressing beta galactosidase infected in rhesus monkey LLC-MK2 cells assessed as inhibition of parasite viability treated at 24 hrs post-infection measured after 4 days b	2013	Bioorganic & medicinal chemistry, Apr-01, Volume: 21, Issue:7	α-Selective glycosylation affords mucin-related GalNAc amino acids and diketopiperazines active on Trypanosoma cruzi.
AID753401	Selectivity index, ratio of CC50 for African green monkey Vero cells to IC50 for Trypanosoma cruzi Y trypomastigotes	2013	Bioorganic & medicinal chemistry letters, Jun-15, Volume: 23, Issue:12	Aromatic glycosyl disulfide derivatives: evaluation of their inhibitory activities against Trypanosoma cruzi.
AID1687700	Antitrypanosomal activity against Trypanosoma cruzi epimastigotes measured after 72 hrs by Neubauer hemocytometer counting method	2020	European journal of medicinal chemistry, Jan-15, Volume: 186	Hit-to-lead optimization of novel 2-alkylaminomethylquinoline derivatives as anti-chagas agents.
AID576093	Toxicity in human patient infected with Trypanosoma cruzi assessed as occurrence of Arthromyalgia at 5 mg/kg/day for 60 days	2010	Antimicrobial agents and chemotherapy, Nov, Volume: 54, Issue:11	Tolerance of benznidazole in treatment of Chagas' disease in adults.
AID1615031	Trypanocidal activity against Trypanosoma cruzi MHOM/Pe/2011/Arequipa DTU 5 amastigotes infected in African green monkey Vero cells assessed as reduction in infected cells after 72 hrs by Giemsa-staining based assay	2019	Bioorganic & medicinal chemistry, 03-01, Volume: 27, Issue:5	Synthesis and biological evaluation of new long-chain squaramides as anti-chagasic agents in the BALB/c mouse model.
AID1578096	Antitrypanosomal activity against Leishmania donovani after 48 hrs by [3H]-hypoxanthine incorporation assay	2019	Bioorganic & medicinal chemistry letters, 10-15, Volume: 29, Issue:20	Antiprotozoal alkaloid principles of the plant family Amaryllidaceae.
AID1498324	Hepatotoxicity in Balb/c mouse infected with Trypanosoma cruzi MHOM/Pe/2011/Arequipa DTU 5 trypamastigotes assessed as increase in ratio of serum ALT to GPT level at 20 mg/kg, po once daily for 5 consecutive days starting from day 75 post infection measur	2018	Journal of medicinal chemistry, 07-12, Volume: 61, Issue:13	Second Generation of Mannich Base-Type Derivatives with in Vivo Activity against Trypanosoma cruzi.
AID779143	Antimicrobial activity against Trypanosoma cruzi Tulahuen C4 amastigotes infected in rat L6 cells after 96 hrs by beta-galactosidase reporter gene assay	2013	Bioorganic & medicinal chemistry, Nov-01, Volume: 21, Issue:21	Novel 3-nitro-1H-1,2,4-triazole-based piperazines and 2-amino-1,3-benzothiazoles as antichagasic agents.
AID707773	Antitrypanosomal activity against Trypanosoma cruzi IRHOD/VO/2008/SN3 metacyclic forms infected in african green monkey Vero cells assessed as inhibition of trypomastigotes level at IC25 level 0.5 to 10 days	2012	Journal of medicinal chemistry, Nov-26, Volume: 55, Issue:22	Phthalazine derivatives containing imidazole rings behave as Fe-SOD inhibitors and show remarkable anti-T. cruzi activity in immunodeficient-mouse mode of infection.
AID1687782	Cytotoxicity against human HepG2 cells assessed as reduction in cell viability measured after 24 hrs by WST1 assay	2020	European journal of medicinal chemistry, Jan-15, Volume: 186	Novel nitroimidazole derivatives evaluated for their trypanocidal, cytotoxic, and genotoxic activities.
AID341605	Antimicrobial activity against Giardia duodenalis G1	2007	Antimicrobial agents and chemotherapy, Aug, Volume: 51, Issue:8	Peroxide bond-dependent antiplasmodial specificity of artemisinin and OZ277 (RBx11160).
AID598287	Cytotoxicity against african green monkey Vero cells after 72 hrs by MTT assay	2011	Bioorganic & medicinal chemistry letters, May-15, Volume: 21, Issue:10	Synthesis of benzologues of Nitazoxanide and Tizoxanide: a comparative study of their in vitro broad-spectrum antiprotozoal activity.
AID1603749	Toxicity in BALB/c mouse infected with Trypanosoma cruzi MHOM/Pe/2011/Arequipa;DTU 5 bloodstream trypomastigote assessed as decrease in serum uric acid level in acute phase at 20 mg/kg/day, po administered for 5 consecutive days starting from day 8 post i	2019	Bioorganic & medicinal chemistry, 09-01, Volume: 27, Issue:17	Rational modification of Mannich base-type derivatives as novel antichagasic compounds: Synthesis, in vitro and in vivo evaluation.
AID1854930	Cytotoxicity against monkey LLC-MK2 cells assessed as reduction in cell viability incubated for 24 hrs by MTT assay	2022	European journal of medicinal chemistry, Nov-05, Volume: 241	Rational design of a trypanocidal peptide derived from Dinoponera quadriceps venom.
AID707780	Toxicity against african green monkey Vero cells	2012	Journal of medicinal chemistry, Nov-26, Volume: 55, Issue:22	Phthalazine derivatives containing imidazole rings behave as Fe-SOD inhibitors and show remarkable anti-T. cruzi activity in immunodeficient-mouse mode of infection.
AID1753506	Antitrypanosomal activity against Trypanosoma cruzi Y bloodstream trypomastigotes assessed as inhibition of parasite growth incubated for 24 hrs by light microscopy	2021	Journal of medicinal chemistry, 04-08, Volume: 64, Issue:7	Revisiting Pyrazolo[3,4-
AID1615016	Trypanocidal activity against Trypanosoma cruzi IRHOD/CO/2008/SN3 DTU 1 amastigotes infected in African green monkey Vero cells after 72 hrs by Giemsa-staining based microscopic assay	2019	Bioorganic & medicinal chemistry, 03-01, Volume: 27, Issue:5	Synthesis and biological evaluation of new long-chain squaramides as anti-chagasic agents in the BALB/c mouse model.
AID1616177	In vivo antitrypanosomal activity against Trypanosoma cruzi Y trypomastigotes infected in Swiss mouse assessed as mouse survival at 100 mg/kg, po administered once daily for 5 days with 2 days interval for 3 cycles and measured up to 55 days post-infectio	2019	Journal of medicinal chemistry, 10-10, Volume: 62, Issue:19	Discovery of Pyrrolo[2,3-
AID1603763	Antitrypanosomal activity against Trypanosoma cruzi TINF/CH/1956/Tulahuen;DTU 6 amastigote forms measured after 72 hrs by Giemsa staining based assay	2019	Bioorganic & medicinal chemistry, 09-01, Volume: 27, Issue:17	Rational modification of Mannich base-type derivatives as novel antichagasic compounds: Synthesis, in vitro and in vivo evaluation.
AID263376	Antitrypanosomal activity against Trypanosoma cruzi epimastigotes at 100 ug/ml	2006	Bioorganic & medicinal chemistry letters, Apr-01, Volume: 16, Issue:7	New ligand-based approach for the discovery of antitrypanosomal compounds.
AID726610	Antiparasitic activity against Trypanosoma cruzi amastigotes infected in gamma-irradiated vero cells assessed as growth inhibition measured after 3 days by fluorescence assay	2013	European journal of medicinal chemistry, Feb, Volume: 60	Design, synthesis and biological evaluation of sulfur-containing 1,1-bisphosphonic acids as antiparasitic agents.
AID1236978	Antitrypanosomal activity against trypomastigotes stage of Trypanosoma cruzi infected in human HT1080 cells assessed as inhibition of parasite growth after 24 hrs by microscopic analysis	2015	Bioorganic & medicinal chemistry letters, Aug-01, Volume: 25, Issue:15	Synthesis and biological evaluation of quinones derived from natural product komaroviquinone as anti-Trypanosoma cruzi agents.
AID1780975	Antitrypanosomal activity against Trypanosoma cruzi trymastigotes assessed as blockage of trypomastigote infectivity at >100 uM incubated for 6 hrs followed by compound washout further infected in BSR cells for 18 hrs measured after 5 hrs post infection b	2021	European journal of medicinal chemistry, Nov-05, Volume: 223	Design and synthesis of Mannich base-type derivatives containing imidazole and benzimidazole as lead compounds for drug discovery in Chagas Disease.
AID1202574	Anti-trypanosomal activity against Trypanosoma cruzi Bug 2149 cl10 epimastigote forms assessed as inhibition of parasite growth after 72 hrs by microplate reader based assay	2015	European journal of medicinal chemistry, , Volume: 96	Designing and exploring active N'-[(5-nitrofuran-2-yl) methylene] substituted hydrazides against three Trypanosoma cruzi strains more prevalent in Chagas disease patients.
AID1410114	Antiplasmodial activity against Trypanosoma cruzi Tulahuen C4 infected in rat L6 cells after 96 hrs by CPRG/Nonidet reagent based photometric analysis	2018	Journal of natural products, 04-27, Volume: 81, Issue:4	Mbandakamine-Type Naphthylisoquinoline Dimers and Related Alkaloids from the Central African Liana Ancistrocladus ealaensis with Antiparasitic and Antileukemic Activities.
AID1176976	Antitrypanosomal activity against Trypanosoma cruzi assessed as growth inhibition	2015	Bioorganic & medicinal chemistry letters, Feb-01, Volume: 25, Issue:3	Exploring in vitro and in vivo Hsp90 inhibitors activity against human protozoan parasites.
AID1459243	Trypanocidal activity against Trypanosoma cruzi TCC epimastigotes assessed as maximal parasite density at 15 uM measured after 9 to 10 days by haemocytometric method (Rvb = 45 10'6/ml)	2017	European journal of medicinal chemistry, Jan-05, Volume: 125	Novel 2-arylazoimidazole derivatives as inhibitors of Trypanosoma cruzi proliferation: Synthesis and evaluation of their biological activity.
AID563566	Hepatotoxicity against Swiss-Webster mouse assessed as GPT at 100 mg/kg/day measured after 14 days postinfection	2010	Antimicrobial agents and chemotherapy, Jul, Volume: 54, Issue:7	Arylimidamide DB766, a potential chemotherapeutic candidate for Chagas' disease treatment.
AID1245595	Antichagasic activity against trypomastigote stage of Trypanosoma cruzi Brazil infected in Balb/c mouse assessed as reduction in parasite load at 13 mg/kg/day, ip measured after 5 days by luciferase reporter gene assay	2015	Bioorganic & medicinal chemistry, Oct-01, Volume: 23, Issue:19	Discovery of potent nitrotriazole-based antitrypanosomal agents: In vitro and in vivo evaluation.
AID1329377	Antileishmanial activity against Leishmania infantum MHOM/BR/1972/LD promastigote forms infected in golden hamster assessed as reduction in parasite viability after 48 hrs by MTT assay	2016	Journal of natural products, 09-23, Volume: 79, Issue:9	Analogues of Marine Guanidine Alkaloids Are in Vitro Effective against Trypanosoma cruzi and Selectively Eliminate Leishmania (L.) infantum Intracellular Amastigotes.
AID265556	Antitrypanosomatid activity against Trypanosoma cruzi CL Brener epimastigote form	2006	Journal of medicinal chemistry, Jun-01, Volume: 49, Issue:11	2H-benzimidazole 1,3-dioxide derivatives: a new family of water-soluble anti-trypanosomatid agents.
AID341603	Antileishmanial activity against Leishmania donovani MHOM-ET-67/L82 amastigotes by axenic assay	2007	Antimicrobial agents and chemotherapy, Aug, Volume: 51, Issue:8	Peroxide bond-dependent antiplasmodial specificity of artemisinin and OZ277 (RBx11160).
AID707779	Selectivity index, ratio of IC50 for african green monkey Vero cells to IC50 for Trypanosoma cruzi IRHOD/VO/2008/SN3 epimastigotes	2012	Journal of medicinal chemistry, Nov-26, Volume: 55, Issue:22	Phthalazine derivatives containing imidazole rings behave as Fe-SOD inhibitors and show remarkable anti-T. cruzi activity in immunodeficient-mouse mode of infection.
AID1633355	Cytotoxicity against mouse RAW264.7 cells assessed as reduction in cell viability after 48 hrs by MTT assay
AID635853	Antitrypanosomal activity against trypomastigote form of Trypanosoma cruzi Tulahuen C2C4 expressing Lac Z infected in rat L6 cells after 96 hrs by spectrophotometry	2011	Bioorganic & medicinal chemistry, Dec-15, Volume: 19, Issue:24	Bis(oxyphenylene)benzimidazoles: a novel class of anti-Plasmodium falciparum agents.
AID1498244	Antitrypanosomal activity against Trypanosoma cruzi MHOM/Pe/2011/Arequipa DTU 5 trypamastigotes infected in Balb/c mouse assessed as reduction in parasitaemia reactivation in spleen tissue at 20 mg/kg, po pretreated once daily for 5 consecutive days start	2018	Journal of medicinal chemistry, 07-12, Volume: 61, Issue:13	Second Generation of Mannich Base-Type Derivatives with in Vivo Activity against Trypanosoma cruzi.
AID1613523	Nephrotoxicity in Balb/c mouse infected with Trypanosoma cruzi MHOM/Pe/2011/Arequipa DTU 5 trypomastigotes assessed as decrease in serum urea level at 20 mg/kg, po once daily for 5 consecutive days starting from day 10 post infection measured on day 127 p	2019	European journal of medicinal chemistry, Feb-15, Volume: 164	New polyamine drugs as more effective antichagas agents than benznidazole in both the acute and chronic phases.
AID677208	Cytotoxicity against African green monkey Vero cells assessed as cell viability after 72 hrs by flow cytometric analysis	2012	Journal of medicinal chemistry, May-10, Volume: 55, Issue:9	In vitro and in vivo trypanosomicidal activity of pyrazole-containing macrocyclic and macrobicyclic polyamines: their action on acute and chronic phases of Chagas disease.
AID362661	Antitrypanosomal activity against Trypanosoma cruzi Tulahuen	2008	Journal of natural products, Sep, Volume: 71, Issue:9	Benzoic acid derivatives from Piper species and their antiparasitic activity.
AID1174777	Trypanocidal activity against epimastigote Trypanosoma cruzi IRHOD/CO/2008/SN3	2015	European journal of medicinal chemistry, Jan-07, Volume: 89	Prospects of an alternative treatment against Trypanosoma cruzi based on abietic acid derivatives show promising results in Balb/c mouse model.
AID1517429	Antitrypanosomal activity against intracellular amastigote stage of Trypanosoma cruzi ARMA 13 cl1 infected in human U2OS cells measured after 96 hrs by DRAQ5 dye based microscopic analysis	2019	European journal of medicinal chemistry, Dec-01, Volume: 183	Discovery of a benzothiophene-flavonol halting miltefosine and antimonial drug resistance in Leishmania parasites through the application of medicinal chemistry, screening and genomics.
AID1616170	Toxicity in Swiss Webster mouse infected with Trypanosoma cruzi Y trypomastigotes assessed as body weight loss at 100 mg/kg, po administered once daily via gavage for 5 days starting from 5 days post-infection and measured daily up to 40 days post-infecti	2019	Journal of medicinal chemistry, 10-10, Volume: 62, Issue:19	Discovery of Pyrrolo[2,3-
AID453255	Antitrypanosomal activity against Trypanosoma cruzi	2009	Bioorganic & medicinal chemistry, Oct-15, Volume: 17, Issue:20	Structure-activity relationship of antiparasitic and cytotoxic indoloquinoline alkaloids, and their tricyclic and bicyclic analogues.
AID341602	Antitrypanosomal activity against Trypanosoma cruzi Tulahuen C4	2007	Antimicrobial agents and chemotherapy, Aug, Volume: 51, Issue:8	Peroxide bond-dependent antiplasmodial specificity of artemisinin and OZ277 (RBx11160).
AID362867	Antitrypanosomal activity against Trypanosoma cruzi Tulahuen 2 after 5 days	2008	European journal of medicinal chemistry, May, Volume: 43, Issue:5	4-nitroacetophenone-derived thiosemicarbazones and their copper(II) complexes with significant in vitro anti-trypanosomal activity.
AID1603852	Toxicity in BALB/c mouse infected with Trypanosoma cruzi MHOM/Pe/2011/Arequipa;DTU 5 bloodstream trypomastigote assessed as increase in serum aspartate aminotransferase level in acute phase at 20 mg/kg/day, po administered for 5 consecutive days starting	2019	Bioorganic & medicinal chemistry, 09-01, Volume: 27, Issue:17	Rational modification of Mannich base-type derivatives as novel antichagasic compounds: Synthesis, in vitro and in vivo evaluation.
AID580603	Antitrypanosomal activity against Trypanosoma cruzi Y infected in CD8+ T-lymphocyte knockout C57BL/6 mouse assessed as occurrence of subpatent level of parasitemia at 100 mg/kg/day, po administered once daily for 20 consecutive days measured 60 days post	2009	Antimicrobial agents and chemotherapy, Jan, Volume: 53, Issue:1	Absence of CD4+ T lymphocytes, CD8+ T lymphocytes, or B lymphocytes has different effects on the efficacy of posaconazole and benznidazole in treatment of experimental acute Trypanosoma cruzi infection.
AID1683682	Toxicity in BALB/c mouse infected with Trypanosomal Trypanosoma cruzi MHOM/Pe/2011/Arequipa(DTU V) assessed as effect on ALT/GPT level at 20 mg/kg, po administered for 5 days starting at 9 days post infection and measured after 2 days post treatment	2020	Journal of natural products, 12-24, Volume: 83, Issue:12	In Vivo Biological Evaluation of a Synthetic Royleanone Derivative as a Promising Fast-Acting Trypanocidal Agent by Inducing Mitochondrial-Dependent Necrosis.
AID564735	Antitrypanosomal activity against Trypanosoma cruzi RBVIII epimastigotes after 24 hrs by light microscopy	2010	Antimicrobial agents and chemotherapy, Jul, Volume: 54, Issue:7	Arylimidamide DB766, a potential chemotherapeutic candidate for Chagas' disease treatment.
AID1615101	Cardiotoxicity in Balb/c mouse infected with Trypanosoma cruzi MHOM/Pe/2011/Arequipa DTU 5 trypomastigotes assessed as change in serum LDH level at 20 mg/kg, po once daily for 5 consecutive days starting from day 10 post infection measured on day 127 post	2019	Bioorganic & medicinal chemistry, 03-01, Volume: 27, Issue:5	Synthesis and biological evaluation of new long-chain squaramides as anti-chagasic agents in the BALB/c mouse model.
AID1501879	Antitrypanosomal activity against Trypanosoma cruzi Y trypomastigotes assessed as parasite viability after 24 hrs by resazurin staining-based hemocytometric analysis	2017	European journal of medicinal chemistry, Oct-20, Volume: 139	Efficacy of a series of alpha-pyrone derivatives against Leishmania (L.) infantum and Trypanosoma cruzi.
AID303387	Toxicity in Trypanosoma cruzi Tulahuen 2 infected Swiss mouse model of Chagas disease at 100 mg/kg, po	2007	Journal of medicinal chemistry, Nov-29, Volume: 50, Issue:24	In vivo anti-Chagas vinylthio-, vinylsulfinyl-, and vinylsulfonylbenzofuroxan derivatives.
AID1169288	Antitrypanosomal activity against LacZ expressing Trypanosoma cruzi Tuluhaen C2C4 amastigotes	2014	Journal of natural products, Oct-24, Volume: 77, Issue:10	Antitrypanosomal quinoline alkaloids from the roots of Waltheria indica.
AID1603875	Toxicity in BALB/c mouse infected with Trypanosoma cruzi MHOM/Pe/2011/Arequipa;DTU 5 bloodstream trypomastigote assessed as decrease in serum uric acid level in chronic phase at 20 mg/kg/day, po administered for 5 consecutive days starting from day 70 pos	2019	Bioorganic & medicinal chemistry, 09-01, Volume: 27, Issue:17	Rational modification of Mannich base-type derivatives as novel antichagasic compounds: Synthesis, in vitro and in vivo evaluation.
AID1603769	Selectivity index, ratio of IC50 for African green monkey Vero cells to IC50 for Trypanosoma cruzi IRHOD/CO/2008/SN3;DTU 1 amastigote forms	2019	Bioorganic & medicinal chemistry, 09-01, Volume: 27, Issue:17	Rational modification of Mannich base-type derivatives as novel antichagasic compounds: Synthesis, in vitro and in vivo evaluation.
AID694955	Antitrypanosomal activity against trypomastigotes of Trypanosoma cruzi Y infected in rhesus monkey LLC-MK2 cells assessed parasite viability after 24 hrs	2012	Bioorganic & medicinal chemistry, Nov-01, Volume: 20, Issue:21	Optimization of anti-Trypanosoma cruzi oxadiazoles leads to identification of compounds with efficacy in infected mice.
AID547272	Immunostimulatory activity in mongrel dog infected with Trypanosoma cruzi Berenice-78 assessed as production of antibody IgG2 at 7 mg/kg, po BID for 90 days measured up to 30 days by ELISA	2010	Antimicrobial agents and chemotherapy, Jul, Volume: 54, Issue:7	Effects of ravuconazole treatment on parasite load and immune response in dogs experimentally infected with Trypanosoma cruzi.
AID1074908	Antitrypanosomal activity against Trypanosoma cruzi (IRHOD/CO/2008/SN3) epimastigotes assessed as disruption of cytoskeleton with disorganization of microtubule structure at IC25 after 96 hrs by transmission electron microscopic analysis	2014	European journal of medicinal chemistry, Mar-03, Volume: 74	New perspectives on the synthesis and antichagasic activity of 3-alkoxy-1-alkyl-5-nitroindazoles.
AID1713342	Anti-chagasic activity against Trypanosoma cruzi Brazil trypomastigotes expressing firefly luciferase infected in BALB/c mouse assessed as reduction in parasitemia at 15 mg/kg/day, ip measured after 5 days by bioluminescence assay	2016	European journal of medicinal chemistry, Nov-10, Volume: 123	Nitrotriazole-based acetamides and propanamides with broad spectrum antitrypanosomal activity.
AID1616186	In vivo antitrypanosomal activity against Trypanosoma cruzi Y trypomastigotes infected in Swiss mouse assessed as reduction in parasitemia at 100 mg/kg, po administered once daily via gavage for 5 days starting from 5 days post-infection in presence of cy	2019	Journal of medicinal chemistry, 10-10, Volume: 62, Issue:19	Discovery of Pyrrolo[2,3-
AID1879404	Toxicity in acute CD Swiss Webster mouse model infected with Trypanosoma cruzi Y strain assessed as animal survival at 100 mg/kg, po qd for 5 consecutive days measured daily for upto 30 days post-treatment	2022	European journal of medicinal chemistry, Mar-05, Volume: 231	N
AID1616180	Antitrypanosomal activity against bloodstream form of Trypanosoma cruzi Y trypomastigotes measured after 24 hrs by Neubauer chamber-based light microscopic analysis	2019	Journal of medicinal chemistry, 10-10, Volume: 62, Issue:19	Discovery of Pyrrolo[2,3-
AID1062786	Antitrypanosomal activity against Trypanosoma cruzi Tulahuen 6 infected in Swiss mouse assessed as mouse survival at 100 mg/kg, po qd administered on day 8 post-infection for 20 days followed by 10 days non-treatment period followed by three cycles of imm	2013	Journal of medicinal chemistry, Dec-27, Volume: 56, Issue:24	Two analogues of fenarimol show curative activity in an experimental model of Chagas disease.
AID396018	Antimicrobial activity against Trypanosoma cruzi genotype 19 infected in BALB/c mouse assessed as cure rate	2007	Antimicrobial agents and chemotherapy, Sep, Volume: 51, Issue:9	Impact of dual infections on chemotherapeutic efficacy in BALB/c mice infected with major genotypes of Trypanosoma cruzi.
AID693341	Growth inhibition of mouse J774 cells at 256 uM after 24 hrs by resazurin reduction assay	2012	European journal of medicinal chemistry, Dec, Volume: 58	Synthesis, biological evaluation and chemometric analysis of indazole derivatives. 1,2-Disubstituted 5-nitroindazolinones, new prototypes of antichagasic drug.
AID1613522	Nephrotoxicity in Balb/c mouse infected with Trypanosoma cruzi MHOM/Pe/2011/Arequipa DTU 5 trypomastigotes assessed as decrease in serum urea level at 20 mg/kg, po once daily for 5 consecutive days starting from day 10 post infection measured on day 16 po	2019	European journal of medicinal chemistry, Feb-15, Volume: 164	New polyamine drugs as more effective antichagas agents than benznidazole in both the acute and chronic phases.
AID637700	Trypanocidal activity against trypomastigote Trypanosoma cruzi Tulahuen C2C4 infected in L6 cells after 96 hrs by beta-galactosidase reporter gene assay	2012	European journal of medicinal chemistry, Feb, Volume: 48	Synthesis and anti-protozoal activity of novel dihydropyrrolo[3,4-d][1,2,3]triazoles.
AID1766959	Cytotoxicity against mouse NCTC clone 929 cells assessed as reduction in cell viability after 48 hrs by MTT assay
AID656215	Cytotoxicity against african green monkey Vero cells at 25 uM after 3 days	2012	Bioorganic & medicinal chemistry letters, Apr-15, Volume: 22, Issue:8	Phosphonium lipocations as antiparasitic agents.
AID1202575	Cytotoxicity against human LL24 cells assessed as inhibition of cell growth after 24 hrs by MTT assay	2015	European journal of medicinal chemistry, , Volume: 96	Designing and exploring active N'-[(5-nitrofuran-2-yl) methylene] substituted hydrazides against three Trypanosoma cruzi strains more prevalent in Chagas disease patients.
AID1851979	Antitrypanosomal activity against bioluminescent Trypanosoma cruzi CL Brener trypomastigotes infected in BALB/c mouse assessed as reduction in parasite burden at 100 mg/kg, po administered once daily for 5 days starting from 14 days post infection and mea	2022	Journal of medicinal chemistry, 10-13, Volume: 65, Issue:19	Nitroimidazopyrazinones with Oral Activity against Tuberculosis and Chagas Disease in Mouse Models of Infection.
AID1902913	Antitrypanosomal activity against amastigotes form of Trypanosoma cruzi CA-I/72 infected in mouse C2C12 cells assessed as parasite infection level by DAPI staining based microscopic analysis	2022	Journal of medicinal chemistry, 03-10, Volume: 65, Issue:5	Intramolecular Interactions Enhance the Potency of Gallinamide A Analogues against
AID580663	Antitrypanosomal activity against Trypanosoma cruzi Y infected in CD8+ T-lymphocyte knockout C57BL/6 mouse assessed as number of mouse with reactivated parasite at 100 mg/kg/day, po administered once daily for 20 consecutive days measured 60 days post inf	2009	Antimicrobial agents and chemotherapy, Jan, Volume: 53, Issue:1	Absence of CD4+ T lymphocytes, CD8+ T lymphocytes, or B lymphocytes has different effects on the efficacy of posaconazole and benznidazole in treatment of experimental acute Trypanosoma cruzi infection.
AID1757145	Antitrypanosomal activity against Trypanosoma cruzi Tulahuen CL2 infected in human MRC5 cells assessed as inhibition of parasite growth incubated for 7 days by chlorophenol red-fl-D-galactopyranoside based spectrophotometric analysis	2021	European journal of medicinal chemistry, Apr-15, Volume: 216	Synthesis and evaluation of 3'-fluorinated 7-deazapurine nucleosides as antikinetoplastid agents.
AID1500575	Antitrypanosomal activity against Trypanosoma cruzi Tulahuen C4 amastigotes infected in rat L6 cells after 96 hrs by CPRG/nonidet-based inverted microscopic analysis	2017	European journal of medicinal chemistry, Sep-29, Volume: 138	The antitrypanosomal and antitubercular activity of some nitro(triazole/imidazole)-based aromatic amines.
AID768699	Trypanocidal activity against epimastigote stage of Trypanosoma cruzi Y after 72 hrs by MTT assay	2013	European journal of medicinal chemistry, Sep, Volume: 67	Design, synthesis and biological evaluation of new aryl thiosemicarbazone as antichagasic candidates.
AID677303	Antitrypanosomal activity against Trypanosoma cruzi infected in BALB/c mouse assessed as reduction in parasitemia at 1 mg/kg, ip dosed for 5 days measured on day 30 post infection	2012	Journal of medicinal chemistry, May-10, Volume: 55, Issue:9	In vitro and in vivo trypanosomicidal activity of pyrazole-containing macrocyclic and macrobicyclic polyamines: their action on acute and chronic phases of Chagas disease.
AID1503755	Antitrypanosomal activity against Trypanosoma cruzi trypomastigote forms infected in rat L6 cells after 96 hrs by CPRG/Nonidet substrate based photometric method	2017	Journal of natural products, 10-27, Volume: 80, Issue:10	Jozilebomines A and B, Naphthylisoquinoline Dimers from the Congolese Liana Ancistrocladus ileboensis, with Antiausterity Activities against the PANC-1 Human Pancreatic Cancer Cell Line.
AID1381722	Inhibition of human microsomal CYP2C19 expressed in baculovirus infected BTI-TN-5B1-4 cells incubated for 30 mins by luciferase assay	2018	European journal of medicinal chemistry, Feb-25, Volume: 146	Aryl thiosemicarbazones for the treatment of trypanosomatidic infections.
AID1498266	Nephrotoxicity in Balb/c mouse infected with Trypanosoma cruzi MHOM/Pe/2011/Arequipa DTU 5 trypamastigotes assessed as decrease in urea level in serum at 20 mg/kg, po once daily for 5 consecutive days starting from day 75 post infection measured on day 81	2018	Journal of medicinal chemistry, 07-12, Volume: 61, Issue:13	Second Generation of Mannich Base-Type Derivatives with in Vivo Activity against Trypanosoma cruzi.
AID1164936	Induction of apoptosis in human platelets assessed as early apoptotic cells after 10 mins using Annexin V/propidium iodide by flow cytometry (Rvb = 10.30 %)	2014	European journal of medicinal chemistry, Nov-24, Volume: 87	In vitro antiparasitic activity of new thiosemicarbazones in strains of Trypanosoma cruzi.
AID1543106	Cytotoxicity in mouse NCTC-929 cells assessed as reduction in cell viability incubated for 48 hrs by MTT assay	2019	Bioorganic & medicinal chemistry letters, 06-15, Volume: 29, Issue:12	Structure-activity relationship study of antitrypanosomal chalcone derivatives using multivariate analysis.
AID1519000	Antitrypanosomal activity against Trypanosoma cruzi K98 bloodstream form infected in C3H/HeNk mouse assessed as effect on QT interval at 30 to 75 mg/kg/day, po administered via gavage for 30 consecutive days starting from 90 days post infection and measur	2019	European journal of medicinal chemistry, 12-15, Volume: 184	Combined therapy with Benznidazole and repurposed drugs Clofazimine and Benidipine for chronic Chagas disease.
AID396003	Antimicrobial activity against Trypanosoma cruzi infected in BALB/c mouse assessed as parasitemia remaining in fresh blood	2007	Antimicrobial agents and chemotherapy, Sep, Volume: 51, Issue:9	Impact of dual infections on chemotherapeutic efficacy in BALB/c mice infected with major genotypes of Trypanosoma cruzi.
AID1603746	Antitrypanosomal activity against Trypanosoma cruzi MHOM/Pe/2011/Arequipa;DTU 5 epimastigote assessed as effect on parasite glycolytic pathway by measuring change in succinate excretion after 72 hrs by H NMR method	2019	Bioorganic & medicinal chemistry, 09-01, Volume: 27, Issue:17	Rational modification of Mannich base-type derivatives as novel antichagasic compounds: Synthesis, in vitro and in vivo evaluation.
AID1055165	Hepatotoxicity in BALB/c mouse infected with bloodstream trypomastigote form of Trypanosoma cruzi IRHOD/CO/2008/SN3 assessed as presence of necrotic cells in portal space at 5 mg/kg/day, ip administered for 5 days measured 150 days post-infection by light	2013	European journal of medicinal chemistry, , Volume: 70	Scorpiand-like azamacrocycles prevent the chronic establishment of Trypanosoma cruzi in a murine model.
AID1074922	Antitrypanosomal activity against Trypanosoma cruzi (IRHOD/CO/2008/SN3) infected in BALB/c mouse assessed as reduction in parasitemia at 1 mg/kg/day, ip treated from day 5 to day 10 post-infection measured on day 14 post-infection	2014	European journal of medicinal chemistry, Mar-03, Volume: 74	New perspectives on the synthesis and antichagasic activity of 3-alkoxy-1-alkyl-5-nitroindazoles.
AID1480892	Cytotoxicity against mouse J774A.1 cells after 24 to 72 hrs by MTT assay	2017	European journal of medicinal chemistry, Apr-21, Volume: 130	Desing and synthesis of potent anti-Trypanosoma cruzi agents new thiazoles derivatives which induce apoptotic parasite death.
AID764118	Cytotoxicity against human FN1 fibroblasts after 24 hrs by MTT assay	2013	Bioorganic & medicinal chemistry, Sep-01, Volume: 21, Issue:17	5-Nitro-2-furfuriliden derivatives as potential anti-Trypanosoma cruzi agents: design, synthesis, bioactivity evaluation, cytotoxicity and exploratory data analysis.
AID1589637	Growth inhibition of trypomastigote form of Trypanosoma cruzi Y infected in human U2OS cells measured after 72 hrs by DRAQ5 DNA dye based confocal microscopic analysis	2019	Journal of medicinal chemistry, 04-25, Volume: 62, Issue:8	Enhancement of Benzothiazoles as Pteridine Reductase-1 Inhibitors for the Treatment of Trypanosomatidic Infections.
AID1079935	Cytolytic liver toxicity, either proven histopathologically or where the ratio of maximal ALT or AST activity above normal to that of Alkaline Phosphatase is > 5 (see ACUTE). Value is number of references indexed. [column 'CYTOL' in source]
AID1603761	Antitrypanosomal activity against Trypanosoma cruzi IRHOD/CO/2008/SN3;DTU 1 amastigote forms measured after 72 hrs by Giemsa staining based assay	2019	Bioorganic & medicinal chemistry, 09-01, Volume: 27, Issue:17	Rational modification of Mannich base-type derivatives as novel antichagasic compounds: Synthesis, in vitro and in vivo evaluation.
AID598282	Antiprotozoan activity against Trichomonas vaginalis GT3 trophozoites after 48 hrs	2011	Bioorganic & medicinal chemistry letters, May-15, Volume: 21, Issue:10	Synthesis of benzologues of Nitazoxanide and Tizoxanide: a comparative study of their in vitro broad-spectrum antiprotozoal activity.
AID324605	Growth inhibition of Trypanosoma cruzi Tulahuen epimastigotes assessed as drug level causing decrease in growth constant	2008	Bioorganic & medicinal chemistry, Jan-15, Volume: 16, Issue:2	Trypanosoma cruzi: activities of lapachol and alpha- and beta-lapachone derivatives against epimastigote and trypomastigote forms.
AID337132	Antitrypanosomal activity against Trypanosoma cruzi 27R27CL1 after 48 hrs
AID1074376	Antitrypanosomal activity against amastigote stage of Trypanosoma cruzi IRHOD/CO/2008/SN3 infected in African green monkey Vero cells assessed as reduction of amastigote number per cell at IC25 preincubated for 12 hrs followed by compound washout measured	2014	Journal of medicinal chemistry, Feb-13, Volume: 57, Issue:3	Synthesis and biological evaluation of N,N'-squaramides with high in vivo efficacy and low toxicity: toward a low-cost drug against Chagas disease.
AID547253	Antimicrobial activity against Trypanosoma cruzi Y infected in mongrel dog assessed as suppression of microbial proliferation at 7 mg/kg, po BID started 12 to 22 days postinfection measured after 1 day	2010	Antimicrobial agents and chemotherapy, Jul, Volume: 54, Issue:7	Effects of ravuconazole treatment on parasite load and immune response in dogs experimentally infected with Trypanosoma cruzi.
AID396011	Antimicrobial activity against Trypanosoma cruzi infected in BALB/c mouse assessed as cure rate	2007	Antimicrobial agents and chemotherapy, Sep, Volume: 51, Issue:9	Impact of dual infections on chemotherapeutic efficacy in BALB/c mice infected with major genotypes of Trypanosoma cruzi.
AID1615096	Cardiotoxicity in Balb/c mouse infected with Trypanosoma cruzi MHOM/Pe/2011/Arequipa DTU 5 trypomastigotes assessed as change in ratio of creatine kinase in muscle to brain at 20 mg/kg, po once daily for 5 consecutive days starting from day 10 post infect	2019	Bioorganic & medicinal chemistry, 03-01, Volume: 27, Issue:5	Synthesis and biological evaluation of new long-chain squaramides as anti-chagasic agents in the BALB/c mouse model.
AID1902914	Cytotoxicity against mouse C2C12 cells assessed as lethal dose	2022	Journal of medicinal chemistry, 03-10, Volume: 65, Issue:5	Intramolecular Interactions Enhance the Potency of Gallinamide A Analogues against
AID677313	Antitrypanosomal activity against Trypanosoma cruzi infected in BALB/c mouse assessed as survival rate at 1 mg/kg, ip dosed for 5 days	2012	Journal of medicinal chemistry, May-10, Volume: 55, Issue:9	In vitro and in vivo trypanosomicidal activity of pyrazole-containing macrocyclic and macrobicyclic polyamines: their action on acute and chronic phases of Chagas disease.
AID1498208	Antitrypanosomal activity against Trypanosoma cruzi MHOM/Pe/2011/Arequipa DTU 5 trypamastigotes infected in Balb/c mouse assessed as reduction in parasitaemia reactivation at 20 mg/kg, po pretreated once daily for 5 consecutive days starting from day 10 p	2018	Journal of medicinal chemistry, 07-12, Volume: 61, Issue:13	Second Generation of Mannich Base-Type Derivatives with in Vivo Activity against Trypanosoma cruzi.
AID1739879	Antitrypanosomal activity against Trypanosoma cruzi (MHOM/CH/00/Tulahuen C2, lacZ) amastigotes infected in HFF-1 cells assessed as reduction in parasite growth incubated for 120 hrs by CPRG/Igepal substrate based photometric method	2020	European journal of medicinal chemistry, Sep-01, Volume: 201	Discovery of highly potent and selective antiparasitic new oxadiazole and hydroxy-oxindole small molecule hybrids.
AID1868687	Cytotoxicity against human MRC5 cells assessed as reduction in cell viability incubated for 3 days by resazurin dye based fluorescence analysis	2022	European journal of medicinal chemistry, Jul-05, Volume: 237	Exploration of 6-methyl-7-(Hetero)Aryl-7-Deazapurine ribonucleosides as antileishmanial agents.
AID1054901	Trypanocidal activity against extracellular epimastigote stage of Trypanosoma cruzi CL-B5 assessed as reduction of parasite load after 72 hrs by resazurin dye-based fluorometric analysis	2013	Journal of medicinal chemistry, Nov-27, Volume: 56, Issue:22	In vitro and in vivo antileishmanial and trypanocidal studies of new N-benzene- and N-naphthalenesulfonamide derivatives.
AID1608321	Trypanocidal activity against Trypanosoma cruzi Y strain bloodstream trypomastigotes isolated from infected Swiss mouse infected with monkey LLC-MK2 cells after 5 days by fluorescence spectrophotometric analysis	2019	European journal of medicinal chemistry, Oct-01, Volume: 179	Synthesis of quinones with highlighted biological applications: A critical update on the strategies towards bioactive compounds with emphasis on lapachones.
AID1683686	Toxicity in BALB/c mouse infected with Trypanosomal Trypanosoma cruzi MHOM/Pe/2011/Arequipa(DTU V) assessed as effect on uric acid level at 20 mg/kg, po administered for 5 days starting at 9 days post infection and measured after 2 days post treatment	2020	Journal of natural products, 12-24, Volume: 83, Issue:12	In Vivo Biological Evaluation of a Synthetic Royleanone Derivative as a Promising Fast-Acting Trypanocidal Agent by Inducing Mitochondrial-Dependent Necrosis.
AID598283	Antiprotozoan activity against Entamoeba histolytica HM1-IMSS trophozoites after 48 hrs	2011	Bioorganic & medicinal chemistry letters, May-15, Volume: 21, Issue:10	Synthesis of benzologues of Nitazoxanide and Tizoxanide: a comparative study of their in vitro broad-spectrum antiprotozoal activity.
AID1780967	Antitrypanosomal activity against Trypanosoma cruzi trypomastigotes assessed as inhibition of cellular invasion incubated for 6 hrs in high-glucose DMEM medium followed by compound washout further infected in BSR cells measured after 72 hrs by fluorescenc	2021	European journal of medicinal chemistry, Nov-05, Volume: 223	Design and synthesis of Mannich base-type derivatives containing imidazole and benzimidazole as lead compounds for drug discovery in Chagas Disease.
AID1498333	Hepatotoxicity in Balb/c mouse infected with Trypanosoma cruzi MHOM/Pe/2011/Arequipa DTU 5 trypamastigotes assessed as increase in total bilirubin level at 20 mg/kg, po once daily for 5 consecutive days starting from day 10 post infection measured on day	2018	Journal of medicinal chemistry, 07-12, Volume: 61, Issue:13	Second Generation of Mannich Base-Type Derivatives with in Vivo Activity against Trypanosoma cruzi.
AID1603773	Trypanocidal activity against Trypanosoma cruzi trypomastigote form infected in African green monkey Vero cells measured after 48 hrs by resazurin dye based assay	2019	Bioorganic & medicinal chemistry, 09-01, Volume: 27, Issue:17	Rational modification of Mannich base-type derivatives as novel antichagasic compounds: Synthesis, in vitro and in vivo evaluation.
AID215337	In vitro inhibitory affect against Trypanosoma brucei; No data	2000	Bioorganic & medicinal chemistry letters, Jun-05, Volume: 10, Issue:11	Synthesis and evaluation of 9,9-dimethylxanthene tricyclics against trypanothione reductase, Trypanosoma brucei, Trypanosoma cruzi and Leishmania donovani.
AID576097	Toxicity in human patient infected with Trypanosoma cruzi assessed as occurrence of Epigastralgia at 5 mg/kg/day for 60 days	2010	Antimicrobial agents and chemotherapy, Nov, Volume: 54, Issue:11	Tolerance of benznidazole in treatment of Chagas' disease in adults.
AID1613494	Antitrypanosomal activity against Trypanosoma cruzi MHOM/Pe/2011/Arequipa DTU 5 trypomastigotes infected in Balb/c mouse assessed as reduction in parasitaemia level at 20 mg/kg, po once daily for 5 consecutive days starting from day 10 post infection meas	2019	European journal of medicinal chemistry, Feb-15, Volume: 164	New polyamine drugs as more effective antichagas agents than benznidazole in both the acute and chronic phases.
AID669381	Antileishmanial activity against Leishmania chagasi MHOM/BR/1974/PP75 after 72 hrs by MTT assay	2012	Journal of natural products, May-25, Volume: 75, Issue:5	Antiprotozoal sesquiterpene pyridine alkaloids from Maytenus ilicifolia.
AID1776166	Antitrypanosomal activity against amastigote form of Trypanosoma cruzi Tulahuen C4 expressing LacZ infected in rat L6 cells assessed as inhibition of parasite growth incubated for 96 hrs by CPRG/Nonidet reagent based inverted microscopic analysis	2021	Journal of natural products, 04-23, Volume: 84, Issue:4	Spirombandakamine A
AID1780963	Cytotoxicity against golden hamster BSR cells assessed as reduction in cell viability incubated for 72 hrs followed by alamar blue addition further incubated for 6 hrs	2021	European journal of medicinal chemistry, Nov-05, Volume: 223	Design and synthesis of Mannich base-type derivatives containing imidazole and benzimidazole as lead compounds for drug discovery in Chagas Disease.
AID414762	Antitrypanosomal activity against Trypanosoma cruzi Y epimastigotes assessed as parasite growth at 10 ug/ml after 24 hrs	2009	Bioorganic & medicinal chemistry, Apr-01, Volume: 17, Issue:7	Molecular modeling studies and in vitro bioactivity evaluation of a set of novel 5-nitro-heterocyclic derivatives as anti-T. cruzi agents.
AID1164938	Induction of apoptosis in human platelets assessed as necrotic cells after 10 mins using Annexin V/propidium iodide by flow cytometry (Rvb = 0.07 %)	2014	European journal of medicinal chemistry, Nov-24, Volume: 87	In vitro antiparasitic activity of new thiosemicarbazones in strains of Trypanosoma cruzi.
AID1202551	Antimicrobial activity against Leishmania mexicana MHOM/BZ/61/M379 after 24 hrs by haemocytometry	2015	European journal of medicinal chemistry, , Volume: 96	Design, synthesis and biological evaluation of quinazoline derivatives as anti-trypanosomatid and anti-plasmodial agents.
AID396023	Antimicrobial activity against Trypanosoma cruzi OPS21 cl11 and Trypanosoma cruzi MAS cl11 dually infected in BALB/c mouse assessed as cure rate	2007	Antimicrobial agents and chemotherapy, Sep, Volume: 51, Issue:9	Impact of dual infections on chemotherapeutic efficacy in BALB/c mice infected with major genotypes of Trypanosoma cruzi.
AID596806	Antitrypanosomal activity against epimastigote form of Trypanosoma cruzi assessed as inhibition of parasite growth	2011	Journal of natural products, Apr-25, Volume: 74, Issue:4	In vitro and in vivo trypanocidal activity of flavonoids from Delphinium staphisagria against Chagas disease.
AID1351069	Antitrypanosomal activity against Trypanosoma cruzi Silvio X10 cl1 Tc1 epimastigotes measured after 72 hrs	2018	European journal of medicinal chemistry, Jan-20, Volume: 144	Investigating the structure-activity relationships of N'-[(5-nitrofuran-2-yl) methylene] substituted hydrazides against Trypanosoma cruzi to design novel active compounds.
AID766428	Antiparasitic activity against amastigotes of Trypanosoma cruzi CL Brener expressing Escherichia coli lacZ gene infected in mouse NCTC-929 cells assessed as parasite growth inhibition at 2 uM after 7 days by colorimetric assay	2013	Bioorganic & medicinal chemistry letters, Sep-01, Volume: 23, Issue:17	Selective activity of 2,4-diaryl-1,2,3,4-tetrahydroquinolines on Trypanosoma cruzi epimastigotes and amastigotes expressing β-galactosidase.
AID3334	Effective dose required against Trypanosoma cruzi amastigotes in 3T3 Fibroblasts	2001	Bioorganic & medicinal chemistry letters, Jan-22, Volume: 11, Issue:2	A disubstituted NAD+ analogue is a nanomolar inhibitor of trypanosomal glyceraldehyde-3-phosphate dehydrogenase.
AID1238019	Anti-leishmanial activity against Leishmania amazonensis MPRO/BR/1972/M1841-LV-79 promastigotes assessed as parasite growth inhibition incubated for 72 hrs by MTT assay	2015	Bioorganic & medicinal chemistry letters, Aug-15, Volume: 25, Issue:16	Synthesis and evaluation of novel prenylated chalcone derivatives as anti-leishmanial and anti-trypanosomal compounds.
AID1686724	Antitrypanosomal activity against Trypanosoma cruzi infected in African green monkey Vero cells assessed as reduction in number of amastigotes per infected cell measured up to 10 days by Giemsa staining based hemocytometry	2016	Journal of medicinal chemistry, 12-22, Volume: 59, Issue:24	In Vitro and in Vivo Anti-Trypanosoma cruzi Activity of New Arylamine Mannich Base-Type Derivatives.
AID1695262	Antitrypanosomal activity against Trypanosoma cruzi infected in rat H9c2 infected with trypomastigotes from parasite-infected monkey LLC-MK2 cells measured after 72 hrs by DRAQ5 DNA dye based microscopic imaging analysis
AID1196788	Antichagasic activity against trypomastigote stage of Trypanosoma cruzi Brazil infected in Balb/c mouse assessed as parasite index at 15 mg/kg/day, ip measured after 5 days by luciferase reporter gene assay	2015	Journal of medicinal chemistry, Feb-12, Volume: 58, Issue:3	Novel 3-nitrotriazole-based amides and carbinols as bifunctional antichagasic agents.
AID677213	Trypanosomicidal activity against Trypanosoma cruzi infected in Vero cells assessed as reduction in amastigotes per infected Vero cells after 6 days by Giemsa staining method	2012	Journal of medicinal chemistry, May-10, Volume: 55, Issue:9	In vitro and in vivo trypanosomicidal activity of pyrazole-containing macrocyclic and macrobicyclic polyamines: their action on acute and chronic phases of Chagas disease.
AID1854931	Antitrypanosomal activity against Trypanosoma cruzi Y trypomastigotes infected in monkey LLC-MK2 cells assessed as reduction in cell death inducing capability incubated for 24 hrs by hemocytometer chamber based analysis	2022	European journal of medicinal chemistry, Nov-05, Volume: 241	Rational design of a trypanocidal peptide derived from Dinoponera quadriceps venom.
AID1498314	Hepatotoxicity in Balb/c mouse infected with Trypanosoma cruzi MHOM/Pe/2011/Arequipa DTU 5 trypamastigotes assessed as increase in ratio of serum AST to GOT level at 20 mg/kg, po once daily for 5 consecutive days starting from day 75 post infection measur	2018	Journal of medicinal chemistry, 07-12, Volume: 61, Issue:13	Second Generation of Mannich Base-Type Derivatives with in Vivo Activity against Trypanosoma cruzi.
AID675026	Trypanocidal activity against bloodstream trypomastigotes of Trypanosoma cruzi infected in mouse blood assessed as lytic effect after 24 hrs	2012	European journal of medicinal chemistry, Sep, Volume: 55	Synthesis and biological evaluation of some novel 1-indanone thiazolylhydrazone derivatives as anti-Trypanosoma cruzi agents.
AID1245589	Prodrug conversion assessed as Trypanosoma brucei recombinant His-tagged type-1 nitroreductase-mediated drug metabolism by measuring NADH oxidation after 5 mins by spectrophotometric analysis	2015	Bioorganic & medicinal chemistry, Oct-01, Volume: 23, Issue:19	Discovery of potent nitrotriazole-based antitrypanosomal agents: In vitro and in vivo evaluation.
AID1565127	Trypanocidal activity against Trypanosoma cruzi Y strain bloodstream trypomastigotes isolated from infected Swiss webster mouse cardiac cells assessed as reduction in parasite viability after 24 hrs by Celltiter-Glo assay	2019	European journal of medicinal chemistry, Nov-15, Volume: 182	Synthesis, structure-activity relationship and trypanocidal activity of pyrazole-imidazoline and new pyrazole-tetrahydropyrimidine hybrids as promising chemotherapeutic agents for Chagas disease.
AID1184292	Antitrypanosomal activity against intracellular Trypanosoma cruzi infected in human U2OS cells assessed as reduction in parasite count at 400 uM after 48 hrs by confocal microscopy	2014	European journal of medicinal chemistry, Sep-12, Volume: 84	Synthesis and biological evaluation of 2,3-dihydroimidazo[1,2-a]benzimidazole derivatives against Leishmania donovani and Trypanosoma cruzi.
AID1615074	Antitrypanosomal activity against Trypanosoma cruzi MHOM/Pe/2011/Arequipa DTU 5 epimastigotes assessed as reduction in DNA and RNA levels at IC25 after 72 hrs by acridine orange staining based flow cytometry relative to control	2019	Bioorganic & medicinal chemistry, 03-01, Volume: 27, Issue:5	Synthesis and biological evaluation of new long-chain squaramides as anti-chagasic agents in the BALB/c mouse model.
AID1498186	Selectivity index, ratio of IC50 for African green monkey Vero cells to IC50 for Trypanosoma cruzi IRHOD/CO/2008/SN3 DTU 1 trypamastigotes derived from infected Balb/c albino mouse	2018	Journal of medicinal chemistry, 07-12, Volume: 61, Issue:13	Second Generation of Mannich Base-Type Derivatives with in Vivo Activity against Trypanosoma cruzi.
AID669304	Antitrypanosomal activity against Trypanosoma cruzi Y trymastigotes infected in monkey LLC-MK2 cells after 24 hrs by Brenner counter method in presence of copalic	2012	Journal of medicinal chemistry, Apr-12, Volume: 55, Issue:7	Terpenes from Copaifera demonstrated in vitro antiparasitic and synergic activity.
AID1400236	Growth inhibition of Trypanosoma cruzi Tulahuen amastigote forms infected in human THP1 cells after 72 hrs by beta-galactosidase reporter gene assay	2018	Bioorganic & medicinal chemistry, 09-15, Volume: 26, Issue:17	Synthesis and SAR of new isoxazole-triazole bis-heterocyclic compounds as analogues of natural lignans with antiparasitic activity.
AID1067357	Cytotoxicity against African green monkey Vero cells assessed as cell viability after 48 hrs by SRB assay	2014	Bioorganic & medicinal chemistry, Mar-01, Volume: 22, Issue:5	2-acylamino-5-nitro-1,3-thiazoles: preparation and in vitro bioevaluation against four neglected protozoan parasites.
AID1683711	Antitrypanosomal activity against Trypanosoma cruzi TINF/CH/1956/Tulahuen (DTU VI) epimastigote form assessed as parasite growth inhibition incubated for 48 hrs by resazurin dye based assay	2020	Journal of natural products, 12-24, Volume: 83, Issue:12	In Vivo Biological Evaluation of a Synthetic Royleanone Derivative as a Promising Fast-Acting Trypanocidal Agent by Inducing Mitochondrial-Dependent Necrosis.
AID344436	Antitrypanosomal activity against Trypanosoma cruzi Y epimastigotes assessed as number of motile forms after 24 hrs by hemocytometer	2008	Journal of medicinal chemistry, Jul-24, Volume: 51, Issue:14	Complexation of the anti-Trypanosoma cruzi drug benznidazole improves solubility and efficacy.
AID1615040	Antitrypanosomal activity against Trypanosoma cruzi MHOM/Pe/2011/Arequipa DTU 5 trypomastigotes infected in Balb/c mouse assessed as parasite-free bone marrow at 20 mg/kg, po pretreated once daily for 5 consecutive days starting from day 10 post infection	2019	Bioorganic & medicinal chemistry, 03-01, Volume: 27, Issue:5	Synthesis and biological evaluation of new long-chain squaramides as anti-chagasic agents in the BALB/c mouse model.
AID1683677	Toxicity in BALB/c mouse infected with Trypanosomal Trypanosoma cruzi MHOM/Pe/2011/Arequipa(DTU V) assessed as effect on CK-MB level at 20 mg/kg, po administered for 5 days starting at 100 days post infection and measured after 2 days post treatment	2020	Journal of natural products, 12-24, Volume: 83, Issue:12	In Vivo Biological Evaluation of a Synthetic Royleanone Derivative as a Promising Fast-Acting Trypanocidal Agent by Inducing Mitochondrial-Dependent Necrosis.
AID1054900	Cytotoxicity against mouse J774 cells assessed as reduction of cell viability after 24 hrs by resazurin dye-based fluorometric analysis	2013	Journal of medicinal chemistry, Nov-27, Volume: 56, Issue:22	In vitro and in vivo antileishmanial and trypanocidal studies of new N-benzene- and N-naphthalenesulfonamide derivatives.
AID1669165	Cytotoxicity against rat H9c2 cells after 72 hrs by Hoechst 33342 staining based fluorescence microscopy	2020	ACS medicinal chemistry letters, Jun-11, Volume: 11, Issue:6	Development of Selective Steroid Inhibitors for the Glucose-6-phosphate Dehydrogenase from
AID1432598	Antitrypanosomal activity against Trypanosoma cruzi Tulahuen trypomastigote forms infected in mouse L929 cells after 96 hrs by chlorophenol red-beta-D-galactopyranoside dye based assay	2017	Bioorganic & medicinal chemistry, 03-15, Volume: 25, Issue:6	Synthesis and biological evaluation of potential inhibitors of the cysteine proteases cruzain and rhodesain designed by molecular simplification.
AID1525222	Antitrypanosomal activity against Trypanosoma cruzi trypomastigotes measured after 24 hrs by resazurin dye based assay	2019	Journal of natural products, 05-24, Volume: 82, Issue:5	Antitrypanosomal Activity of Acetogenins Isolated from the Seeds of Porcelia macrocarpa Is Associated with Alterations in Both Plasma Membrane Electric Potential and Mitochondrial Membrane Potential.
AID1592302	Antileishmanial activity against Leishmania mexicana MNYC-BZ/62/M379 promastigotes assessed as growth inhibition measured after 24 hrs by MTT assay
AID426310	Antiamnesic activity against Entamoeba histolytica HM-1:IMSS trophozoites after 48 hrs by Hill culture method	2009	European journal of medicinal chemistry, Jul, Volume: 44, Issue:7	Synthesis and in vitro trichomonicidal, giardicidal and amebicidal activity of N-acetamide(sulfonamide)-2-methyl-4-nitro-1H-imidazoles.
AID1615056	Antitrypanosomal activity against Trypanosoma cruzi MHOM/Pe/2011/Arequipa DTU 5 trypomastigotes infected in Balb/c mouse assessed as parasite-free stomach at 20 mg/kg, po pretreated once daily for 5 consecutive days starting from day 75 post infection fol	2019	Bioorganic & medicinal chemistry, 03-01, Volume: 27, Issue:5	Synthesis and biological evaluation of new long-chain squaramides as anti-chagasic agents in the BALB/c mouse model.
AID1678869	Selectivity index, ratio of LC50 for cytotoxicity against albino Swiss mouse peritoneal macrophages to IC50 for Antitrypanosomal activity against Trypanosoma cruzi Y strain bloodstream trypomastigotes assessed as lysis of parasite in absence of mouse bloo	2020	RSC medicinal chemistry, Oct-01, Volume: 11, Issue:10	Synthesis of quinone imine and sulphur-containing compounds with antitumor and trypanocidal activities: redox and biological implications.
AID1165097	Ratio of IC50 for bloodstream forms of Trypanosoma brucei brucei Lister 427 clone 221a overexpressing type I nitroreductase in absence of tetracycline to IC50 for bloodstream forms of Trypanosoma brucei brucei Lister 427 clone 221a overexpressing type I n	2014	European journal of medicinal chemistry, Nov-24, Volume: 87	Novel nitro(triazole/imidazole)-based heteroarylamides/sulfonamides as potential antitrypanosomal agents.
AID1432290	Selectivity index, ratio of CC50 for human THP1 cells to IC50 for Trypanosoma cruzi Tulahuen amastigote forms infected in human THP1 cells	2017	European journal of medicinal chemistry, Mar-10, Volume: 128	Design and synthesis of a new series of 3,5-disubstituted isoxazoles active against Trypanosoma cruzi and Leishmania amazonensis.
AID547250	Toxicity in mongrel dog infected with Trypanosoma cruzi Berenice-78 assessed as weight loss at 7 mg/kg, po BID for 90 days started 12 to 22 days postinfection measured after 6 months	2010	Antimicrobial agents and chemotherapy, Jul, Volume: 54, Issue:7	Effects of ravuconazole treatment on parasite load and immune response in dogs experimentally infected with Trypanosoma cruzi.
AID677292	Toxicity in BALB/c mouse liver infected with Trypanosoma cruzi assessed as hepatic destruction in portal tracts at 5 mg/kg, ip after 120 days postinfection by Histopathological analysis	2012	Journal of medicinal chemistry, May-10, Volume: 55, Issue:9	In vitro and in vivo trypanosomicidal activity of pyrazole-containing macrocyclic and macrobicyclic polyamines: their action on acute and chronic phases of Chagas disease.
AID1615087	Nephrotoxicity in Balb/c mouse infected with Trypanosoma cruzi MHOM/Pe/2011/Arequipa DTU 5 trypomastigotes assessed as decrease in serum urea level at 20 mg/kg, po once daily for 5 consecutive days starting from day 75 post infection measured on day 81 po	2019	Bioorganic & medicinal chemistry, 03-01, Volume: 27, Issue:5	Synthesis and biological evaluation of new long-chain squaramides as anti-chagasic agents in the BALB/c mouse model.
AID75731	In vitro inhibition of rabbit muscle GAPDH.	2001	Journal of medicinal chemistry, Jun-21, Volume: 44, Issue:13	Adenosine analogues as selective inhibitors of glyceraldehyde-3-phosphate dehydrogenase of Trypanosomatidae via structure-based drug design.
AID337145	Antitrypanosomal activity against Trypanosoma cruzi 9280CL1 after 48 hrs
AID303379	Antitrypanosomal activity against Trypanosoma cruzi CL Brener	2007	Journal of medicinal chemistry, Nov-29, Volume: 50, Issue:24	In vivo anti-Chagas vinylthio-, vinylsulfinyl-, and vinylsulfonylbenzofuroxan derivatives.
AID1498243	Antitrypanosomal activity against Trypanosoma cruzi MHOM/Pe/2011/Arequipa DTU 5 trypamastigotes infected in Balb/c mouse assessed as reduction in parasitaemia reactivation in muscle tissue at 20 mg/kg, po pretreated once daily for 5 consecutive days start	2018	Journal of medicinal chemistry, 07-12, Volume: 61, Issue:13	Second Generation of Mannich Base-Type Derivatives with in Vivo Activity against Trypanosoma cruzi.
AID753036	Antitrypanosomal activity against epimastigote stage of Trypanosoma cruzi Y assessed as parasite growth inhibition after 5 days by spectrophotometric analysis	2013	European journal of medicinal chemistry, Jun, Volume: 64	Ligand-based design, synthesis, and experimental evaluation of novel benzofuroxan derivatives as anti-Trypanosoma cruzi agents.
AID1603871	Toxicity in BALB/c mouse infected with Trypanosoma cruzi MHOM/Pe/2011/Arequipa;DTU 5 bloodstream trypomastigote assessed as change in serum alkaline phosphatase level in chronic phase at 20 mg/kg/day, po administered for 5 consecutive days starting from d	2019	Bioorganic & medicinal chemistry, 09-01, Volume: 27, Issue:17	Rational modification of Mannich base-type derivatives as novel antichagasic compounds: Synthesis, in vitro and in vivo evaluation.
AID1586759	Antitrypanosomal activity against Trypanosoma cruzi Tulahuen C4 amastigotes harboring LacZ infected in rat L6 cells after 96 hrs by CPRG/Nonidet reagent based photometric analysis	2018	Journal of natural products, 12-28, Volume: 81, Issue:12	Antiprotozoal Isoprenoids from Salvia hydrangea.
AID1613474	Trypanocidal activity against Trypanosoma cruzi TINF/CH/1956/Tulahuen DTU 6 trypomastigotes derived from infected Balb/c albino mouse after 24 hrs by resazurin dye based assay	2019	European journal of medicinal chemistry, Feb-15, Volume: 164	New polyamine drugs as more effective antichagas agents than benznidazole in both the acute and chronic phases.
AID766424	Antiparasitic activity against amastigotes of Trypanosoma cruzi CL Brener expressing Escherichia coli lacZ gene infected in mouse NCTC-929 cells assessed as parasite growth inhibition at 32 uM after 7 days by colorimetric assay	2013	Bioorganic & medicinal chemistry letters, Sep-01, Volume: 23, Issue:17	Selective activity of 2,4-diaryl-1,2,3,4-tetrahydroquinolines on Trypanosoma cruzi epimastigotes and amastigotes expressing β-galactosidase.
AID736792	Antitrypanosomal activity against Trypanosoma cruzi trypomastigotes after 24 hrs by MTT assay	2013	Bioorganic & medicinal chemistry, Feb-01, Volume: 21, Issue:3	Conjugation to 4-aminoquinoline improves the anti-trypanosomal activity of Deferiprone-type iron chelators.
AID1613562	Hepatotoxicity in Balb/c mouse infected with Trypanosoma cruzi MHOM/Pe/2011/Arequipa DTU 5 trypomastigotes assessed as increase in total bilirubin level at 20 mg/kg, po once daily for 5 consecutive days starting from day 75 post infection measured on day	2019	European journal of medicinal chemistry, Feb-15, Volume: 164	New polyamine drugs as more effective antichagas agents than benznidazole in both the acute and chronic phases.
AID1381723	Inhibition of human microsomal CYP2D6 expressed in baculovirus infected BTI-TN-5B1-4 cells incubated for 30 mins by luciferase assay	2018	European journal of medicinal chemistry, Feb-25, Volume: 146	Aryl thiosemicarbazones for the treatment of trypanosomatidic infections.
AID287715	Antitrypanosomatid activity against Trypanosoma cruzi Y epimastigotes assessed as reduction of growth after 5 days	2007	Bioorganic & medicinal chemistry, Apr-01, Volume: 15, Issue:7	Second generation of 5-ethenylbenzofuroxan derivatives as inhibitors of Trypanosoma cruzi growth: synthesis, biological evaluation, and structure-activity relationships.
AID1277887	Selectivity index, ratio of IC50 for for mouse C3H cells to IC50 for Trypanosoma cruzi Tulahuen amastigotes infected in mouse C3H cells	2016	Bioorganic & medicinal chemistry letters, Feb-15, Volume: 26, Issue:4	Semisynthesis of new aphidicolin derivatives with high activity against Trypanosoma cruzi.
AID213632	Evaluated in vitro for antitrypanosomal activity against Trypanosoma cruzi	2002	Bioorganic & medicinal chemistry letters, Dec-16, Volume: 12, Issue:24	Antitrypanosomal activities and cytotoxicity of 5-nitro-2-furancarbohydrazides.
AID1383425	Cytotoxicity against mouse L929 cells assessed as reduction in cell viability after 96 hrs by light microscopic analysis	2018	European journal of medicinal chemistry, Apr-10, Volume: 149	Identification of Pyrazolo[3,4-e][1,4]thiazepin based CYP51 inhibitors as potential Chagas disease therapeutic alternative: In vitro and in vivo evaluation, binding mode prediction and SAR exploration.
AID707778	Selectivity index, ratio of IC50 for african green monkey Vero cells to IC50 for Trypanosoma cruzi IRHOD/VO/2008/SN3 axenic amastigotes	2012	Journal of medicinal chemistry, Nov-26, Volume: 55, Issue:22	Phthalazine derivatives containing imidazole rings behave as Fe-SOD inhibitors and show remarkable anti-T. cruzi activity in immunodeficient-mouse mode of infection.
AID1196783	Inhibition of recombinant full-length Trypanosoma cruzi CYP51 assessed as molar ratio of inhibitor to enzyme which causes 2 fold decrease in enzyme activity in 1 hr by HPLC analysis	2015	Journal of medicinal chemistry, Feb-12, Volume: 58, Issue:3	Novel 3-nitrotriazole-based amides and carbinols as bifunctional antichagasic agents.
AID548108	Selectivity for Trypanosoma cruzi triosephosphate isomerase over human triosephosphate isomerase	2010	European journal of medicinal chemistry, Dec, Volume: 45, Issue:12	Massive screening yields novel and selective Trypanosoma cruzi triosephosphate isomerase dimer-interface-irreversible inhibitors with anti-trypanosomal activity.
AID1070002	Selectivity index, ratio of LC50 for mouse NCTC-929 cells to IC50 for amastigote stage of Trypanosoma cruzi CL Brener infected in mouse NCTC-929 cells	2014	Bioorganic & medicinal chemistry letters, Feb-15, Volume: 24, Issue:4	In vitro phenotypic screening of 7-chloro-4-amino(oxy)quinoline derivatives as putative anti-Trypanosoma cruzi agents.
AID1126158	Antitrypanosomal activity against trypomastigote forms of Trypanosoma cruzi Tulahuen C4	2014	Journal of natural products, Apr-25, Volume: 77, Issue:4	Antiparasitic chaiyaphumines from entomopathogenic Xenorhabdus sp. PB61.4.
AID576078	Toxicity in human patient infected with Trypanosoma cruzi assessed as occurrence of Headache at 5 mg/kg/day for 60 days	2010	Antimicrobial agents and chemotherapy, Nov, Volume: 54, Issue:11	Tolerance of benznidazole in treatment of Chagas' disease in adults.
AID766605	Antiparasitic activity against epimastigotes of Trypanosoma cruzi assessed as inhibition of parasite proliferation	2013	Bioorganic & medicinal chemistry letters, Sep-01, Volume: 23, Issue:17	Preparation and antitrypanosomal activity of secochiliolide acid derivatives.
AID1603770	Selectivity index, ratio of IC50 for African green monkey Vero cells to IC50 for Trypanosoma cruzi IRHOD/CO/2008/SN3;DTU 1 trypomastigote forms	2019	Bioorganic & medicinal chemistry, 09-01, Volume: 27, Issue:17	Rational modification of Mannich base-type derivatives as novel antichagasic compounds: Synthesis, in vitro and in vivo evaluation.
AID401651	Antitrypanosomal activity against Trypanosoma cruzi in rat L6 cells	2005	Journal of natural products, May, Volume: 68, Issue:5	ent-Dioncophylleine A and related dehydrogenated naphthylisoquinoline alkaloids, the first Asian dioncophyllaceae-type alkaloids, from the "new"plant species Ancistrocladus benomensis.
AID1638039	Anti-trypanosomal activity against Trypanosoma cruzi IRHOD/CO/2008/SN3 amastigotes infected in African green monkey Vero cells after 72 hrs by Giemsa-staining based microscopic analysis	2019	European journal of medicinal chemistry, Mar-01, Volume: 165	Design, synthesis and molecular docking studies of novel N-arylsulfonyl-benzimidazoles with anti Trypanosoma cruzi activity.
AID263382	Antitrypanosomal activity against Trypanosoma cruzi amastigotes at 100 ug/ml	2006	Bioorganic & medicinal chemistry letters, Apr-01, Volume: 16, Issue:7	New ligand-based approach for the discovery of antitrypanosomal compounds.
AID1383432	Cytotoxicity against Swiss Webster mouse cardiac cells assessed as reduction in cell viability after 24 hrs by prestoblue assay	2018	European journal of medicinal chemistry, Apr-10, Volume: 149	Identification of Pyrazolo[3,4-e][1,4]thiazepin based CYP51 inhibitors as potential Chagas disease therapeutic alternative: In vitro and in vivo evaluation, binding mode prediction and SAR exploration.
AID1615114	Hepatotoxicity in Balb/c mouse infected with Trypanosoma cruzi MHOM/Pe/2011/Arequipa DTU 5 trypomastigotes assessed as change in ratio of serum ALT to GPT level at 20 mg/kg, po once daily for 5 consecutive days starting from day 10 post infection measured	2019	Bioorganic & medicinal chemistry, 03-01, Volume: 27, Issue:5	Synthesis and biological evaluation of new long-chain squaramides as anti-chagasic agents in the BALB/c mouse model.
AID1682943	Cytotoxicity against monkey LLC-MK2 cells assessed as reduction in cell viability incubated for 72 hrs by MTT assay	2021	Bioorganic & medicinal chemistry, 01-01, Volume: 29	Trypanocidal activity of new 1,6-diphenyl-1H-pyrazolo[3,4-b]pyridine derivatives: Synthesis, in vitro and in vivo studies.
AID1603819	Antitrypanosomal activity against Trypanosoma cruzi MHOM/Pe/2011/Arequipa;DTU 5 bloodstream trypomastigote infected in BALB/c mouse assessed as parasite-free bone marrow in chronic phase at 20 mg/kg/day, po administered for 5 consecutive days starting fro	2019	Bioorganic & medicinal chemistry, 09-01, Volume: 27, Issue:17	Rational modification of Mannich base-type derivatives as novel antichagasic compounds: Synthesis, in vitro and in vivo evaluation.
AID401638	Antitrypanosomal activity against Trypanosoma cruzi	2005	Journal of natural products, May, Volume: 68, Issue:5	Isoneocryptolepine, a synthetic indoloquinoline alkaloid, as an antiplasmodial lead compound.
AID1697059	Cytotoxicity against Balb/c mouse peritoneal macrophage assessed as cell viability measured after 72 hrs by alamar blue assay	2020	Journal of natural products, 09-25, Volume: 83, Issue:9	Production of Highly Active Antiparasitic Compounds from the Controlled Halogenation of the
AID564746	Toxicity in male Swiss-Webster mouse assessed as mortality at cumulative dose of 200 mg/kg, ip measured after 48 hrs	2010	Antimicrobial agents and chemotherapy, Jul, Volume: 54, Issue:7	Arylimidamide DB766, a potential chemotherapeutic candidate for Chagas' disease treatment.
AID1329379	Cytotoxicity against mouse NCTC-929 cells assessed as decrease in cell viability after 48 hrs by MTT assay	2016	Journal of natural products, 09-23, Volume: 79, Issue:9	Analogues of Marine Guanidine Alkaloids Are in Vitro Effective against Trypanosoma cruzi and Selectively Eliminate Leishmania (L.) infantum Intracellular Amastigotes.
AID766426	Antiparasitic activity against amastigotes of Trypanosoma cruzi CL Brener expressing Escherichia coli lacZ gene infected in mouse NCTC-929 cells assessed as parasite growth inhibition at 8 uM after 7 days by colorimetric assay	2013	Bioorganic & medicinal chemistry letters, Sep-01, Volume: 23, Issue:17	Selective activity of 2,4-diaryl-1,2,3,4-tetrahydroquinolines on Trypanosoma cruzi epimastigotes and amastigotes expressing β-galactosidase.
AID419679	Antitrypanosomal activity against Trypanosoma cruzi amastigotes infected in rat L6 cells	2009	Bioorganic & medicinal chemistry letters, Jun-01, Volume: 19, Issue:11	Privileged structure-guided synthesis of quinazoline derivatives as inhibitors of trypanothione reductase.
AID344435	Antiproliferative activity against Trypanosoma cruzi Y epimastigotes assessed as number of motile forms at 1 mM after 24 hrs by hemocytometer	2008	Journal of medicinal chemistry, Jul-24, Volume: 51, Issue:14	Complexation of the anti-Trypanosoma cruzi drug benznidazole improves solubility and efficacy.
AID669299	Antitrypanosomal activity against Trypanosoma cruzi Y amastigotes infected in monkey LLC-MK2 cells after 96 hrs by Geimsa staining method	2012	Journal of medicinal chemistry, Apr-12, Volume: 55, Issue:7	Terpenes from Copaifera demonstrated in vitro antiparasitic and synergic activity.
AID547508	Immunostimulatory activity in mongrel dog infected with Trypanosoma cruzi Berenice-78 assessed as production of antibody IgG at 12 mg/kg, po BID for 90 days measured after 6 months by ELISA	2010	Antimicrobial agents and chemotherapy, Jul, Volume: 54, Issue:7	Effects of ravuconazole treatment on parasite load and immune response in dogs experimentally infected with Trypanosoma cruzi.
AID396019	Antimicrobial activity against Trypanosoma cruzi genotype 32 infected in BALB/c mouse assessed as cure rate	2007	Antimicrobial agents and chemotherapy, Sep, Volume: 51, Issue:9	Impact of dual infections on chemotherapeutic efficacy in BALB/c mice infected with major genotypes of Trypanosoma cruzi.
AID1480897	Induction of apoptosis in bloodstream trypomastigote stage of Trypanosoma cruzi Y infected in monkey LLC-MK2 cells assessed as necrotic cells at 5 uM measured after 24 hrs by Annexin-V-FITC/propidium iodide staining based flow cytometric method (Rvb = 0.0	2017	European journal of medicinal chemistry, Apr-21, Volume: 130	Desing and synthesis of potent anti-Trypanosoma cruzi agents new thiazoles derivatives which induce apoptotic parasite death.
AID1202488	Trypanosomicidal activity against epimastigote stage of Trypanosoma cruzi CL-B5 after 72 hrs by beta-galactosidase reporter gene assay	2015	European journal of medicinal chemistry, , Volume: 96	Bond-based bilinear indices for computational discovery of novel trypanosomicidal drug-like compounds through virtual screening.
AID1603860	Toxicity in BALB/c mouse infected with Trypanosoma cruzi MHOM/Pe/2011/Arequipa;DTU 5 bloodstream trypomastigote assessed as decrease in serum urea level in chronic phase at 20 mg/kg/day, po administered for 5 consecutive days starting from day 70 post inf	2019	Bioorganic & medicinal chemistry, 09-01, Volume: 27, Issue:17	Rational modification of Mannich base-type derivatives as novel antichagasic compounds: Synthesis, in vitro and in vivo evaluation.
AID1498269	Nephrotoxicity in Balb/c mouse infected with Trypanosoma cruzi MHOM/Pe/2011/Arequipa DTU 5 trypamastigotes assessed as decrease in urea level in serum at 20 mg/kg, po once daily for 5 consecutive days starting from day 75 post infection measured on day 12	2018	Journal of medicinal chemistry, 07-12, Volume: 61, Issue:13	Second Generation of Mannich Base-Type Derivatives with in Vivo Activity against Trypanosoma cruzi.
AID337136	Antitrypanosomal activity against Trypanosoma cruzi Z2CL4 after 48 hrs
AID1615106	Hepatotoxicity in Balb/c mouse infected with Trypanosoma cruzi MHOM/Pe/2011/Arequipa DTU 5 trypomastigotes assessed as increase in ratio of serum AST to GOT level at 20 mg/kg, po once daily for 5 consecutive days starting from day 10 post infection measur	2019	Bioorganic & medicinal chemistry, 03-01, Volume: 27, Issue:5	Synthesis and biological evaluation of new long-chain squaramides as anti-chagasic agents in the BALB/c mouse model.
AID1613560	Hepatotoxicity in Balb/c mouse infected with Trypanosoma cruzi MHOM/Pe/2011/Arequipa DTU 5 trypomastigotes assessed as increase in total bilirubin level at 20 mg/kg, po once daily for 5 consecutive days starting from day 10 post infection measured on day	2019	European journal of medicinal chemistry, Feb-15, Volume: 164	New polyamine drugs as more effective antichagas agents than benznidazole in both the acute and chronic phases.
AID1422886	Antitrypanosomal activity against Trypanosoma cruzi Dm28c trypomastigotes infected in African green monkey Vero cells after 24 hrs by CPRG/Nonidet reagent based beta-galactosidase reporter gene assay	2018	ACS medicinal chemistry letters, Oct-11, Volume: 9, Issue:10	Discovery of a Biologically Active Bromodomain Inhibitor by Target-Directed Dynamic Combinatorial Chemistry.
AID693343	Growth inhibition of mouse J774 cells at 128 uM after 24 hrs by resazurin reduction assay	2012	European journal of medicinal chemistry, Dec, Volume: 58	Synthesis, biological evaluation and chemometric analysis of indazole derivatives. 1,2-Disubstituted 5-nitroindazolinones, new prototypes of antichagasic drug.
AID575889	Toxicity in human patient infected with Trypanosoma cruzi assessed as occurrence of paresthesias on 4th week of treatment	2010	Antimicrobial agents and chemotherapy, Nov, Volume: 54, Issue:11	Tolerance of benznidazole in treatment of Chagas' disease in adults.
AID547258	Antimicrobial activity against Trypanosoma cruzi Berenice-78 infected in mongrel dog assessed as survival of dog at 7 mg/kg, po BID started 12 to 22 days postinfection measured after 1 day	2010	Antimicrobial agents and chemotherapy, Jul, Volume: 54, Issue:7	Effects of ravuconazole treatment on parasite load and immune response in dogs experimentally infected with Trypanosoma cruzi.
AID1312167	Antitrypanosomal activity against amastigote stage of Trypanosoma cruzi CA-I/72 infected in mouse C2C12 cells measured after 3 days by DAPI staining-based assay	2016	Bioorganic & medicinal chemistry, 09-15, Volume: 24, Issue:18	Design, synthesis, molecular docking and biological evaluation of thiophen-2-iminothiazolidine derivatives for use against Trypanosoma cruzi.
AID302066	Reduction of Leishmania amazonensis 575 infection in mouse peritoneal macrophage at 25 uM after 48 hrs	2007	Bioorganic & medicinal chemistry, Dec-15, Volume: 15, Issue:24	Synthesis and in vitro evaluation of leishmanicidal and trypanocidal activities of N-quinolin-8-yl-arylsulfonamides.
AID1294230	Antichagasic activity against Trypanosoma cruzi Y strain amastigotes in mouse cardiomyocytes assessed as growth inhibition after 48 hrs by giemsa staining based assay	2016	European journal of medicinal chemistry, Jun-10, Volume: 115	Antichagasic and trichomonacidal activity of 1-substituted 2-benzyl-5-nitroindazolin-3-ones and 3-alkoxy-2-benzyl-5-nitro-2H-indazoles.
AID1498238	Antitrypanosomal activity against Trypanosoma cruzi MHOM/Pe/2011/Arequipa DTU 5 trypamastigotes infected in Balb/c mouse assessed as reduction in parasitaemia reactivation in bone marrow tissue at 20 mg/kg, po pretreated once daily for 5 consecutive days	2018	Journal of medicinal chemistry, 07-12, Volume: 61, Issue:13	Second Generation of Mannich Base-Type Derivatives with in Vivo Activity against Trypanosoma cruzi.
AID263380	Unspecific cytotoxicity against murine J774 macrophages at 10 ug/ml	2006	Bioorganic & medicinal chemistry letters, Apr-01, Volume: 16, Issue:7	New ligand-based approach for the discovery of antitrypanosomal compounds.
AID1592305	Selectivity index, ratio of CC50 for mouse J774.A1 cells to IC50 for antileishmanial activity against Leishmania mexicana MNYC-BZ/62/M379 promastigotes
AID1055178	Trypanocidal activity against bloodstream trypomastigote form of Trypanosoma cruzi IRHOD/CO/2008/SN3 infected in BALB/c mouse assessed as reduction of circulating parasite burden at 5 mg/kg, ip administered for 5 to 10 days measured 22 to 60 days post-inf	2013	European journal of medicinal chemistry, , Volume: 70	Scorpiand-like azamacrocycles prevent the chronic establishment of Trypanosoma cruzi in a murine model.
AID1712841	Selectivity index, ratio of >90% maximum non-toxic concentration for BALB/c mouse splenocyte to IC50 for Trypanosoma cruzi Y strain trypomastigotes	2016	European journal of medicinal chemistry, Oct-04, Volume: 121	New 1,3-thiazole derivatives and their biological and ultrastructural effects on Trypanosoma cruzi.
AID1351070	Antitrypanosomal activity Trypanosoma cruzi Y Tc2 epimastigotes measured after 72 hrs	2018	European journal of medicinal chemistry, Jan-20, Volume: 144	Investigating the structure-activity relationships of N'-[(5-nitrofuran-2-yl) methylene] substituted hydrazides against Trypanosoma cruzi to design novel active compounds.
AID1498206	Antitrypanosomal activity against Trypanosoma cruzi MHOM/Pe/2011/Arequipa DTU 5 trypamastigotes infected in Balb/c mouse assessed as reduction in parasitaemia level at 20 mg/kg, po once daily for 5 consecutive days starting from day 10 post infection meas	2018	Journal of medicinal chemistry, 07-12, Volume: 61, Issue:13	Second Generation of Mannich Base-Type Derivatives with in Vivo Activity against Trypanosoma cruzi.
AID1498345	Hepatotoxicity in Balb/c mouse infected with Trypanosoma cruzi MHOM/Pe/2011/Arequipa DTU 5 trypamastigotes assessed as increase in alkaline phosphatase level at 20 mg/kg, po once daily for 5 consecutive days starting from day 75 post infection measured on	2018	Journal of medicinal chemistry, 07-12, Volume: 61, Issue:13	Second Generation of Mannich Base-Type Derivatives with in Vivo Activity against Trypanosoma cruzi.
AID1079940	Granulomatous liver disease, proven histopathologically. Value is number of references indexed. [column 'GRAN' in source]
AID1498259	Antitrypanosomal activity against Trypanosoma cruzi MHOM/Pe/2011/Arequipa DTU 5 trypamastigotes infected in Balb/c mouse assessed as reduction in splenomegaly at 20 mg/kg, po once daily for 5 consecutive days starting from day 75 post infection measured o	2018	Journal of medicinal chemistry, 07-12, Volume: 61, Issue:13	Second Generation of Mannich Base-Type Derivatives with in Vivo Activity against Trypanosoma cruzi.
AID1780962	Antiprotozoal activity against Trypanosoma cruzi epimastigotes assessed as inhibition of parasite growth incubated for 72 hrs followed by alamar blue addition further incubated for 24 hrs	2021	European journal of medicinal chemistry, Nov-05, Volume: 223	Design and synthesis of Mannich base-type derivatives containing imidazole and benzimidazole as lead compounds for drug discovery in Chagas Disease.
AID1565135	Selectivity index, ratio of CC50 for mouse cardiomyocyte infected with intracellular amastigote stage of Trypanosoma cruzi Y strain to IC50 for amastigote stage of Trypanosoma cruzi Y strain	2019	European journal of medicinal chemistry, Nov-15, Volume: 182	Synthesis, structure-activity relationship and trypanocidal activity of pyrazole-imidazoline and new pyrazole-tetrahydropyrimidine hybrids as promising chemotherapeutic agents for Chagas disease.
AID1459252	Trypanocidal activity against Trypanosoma cruzi RA tripamastigote bloodstream forms infected in Balb/c mouse assessed as mouse survival at 100 mg/kg, po administered on day 9 post infection for 5 consecutive days measured daily during compound dosing up t	2017	European journal of medicinal chemistry, Jan-05, Volume: 125	Novel 2-arylazoimidazole derivatives as inhibitors of Trypanosoma cruzi proliferation: Synthesis and evaluation of their biological activity.
AID1613564	Hepatotoxicity in Balb/c mouse infected with Trypanosoma cruzi MHOM/Pe/2011/Arequipa DTU 5 trypomastigotes assessed as increase in total bilirubin level at 20 mg/kg, po once daily for 5 consecutive days starting from day 75 post infection measured on day	2019	European journal of medicinal chemistry, Feb-15, Volume: 164	New polyamine drugs as more effective antichagas agents than benznidazole in both the acute and chronic phases.
AID1603839	Toxicity in BALB/c mouse infected with Trypanosoma cruzi MHOM/Pe/2011/Arequipa;DTU 5 bloodstream trypomastigote assessed as increase in serum alanine aminotransferase level in acute phase at 20 mg/kg/day, po administered for 5 consecutive days starting fr	2019	Bioorganic & medicinal chemistry, 09-01, Volume: 27, Issue:17	Rational modification of Mannich base-type derivatives as novel antichagasic compounds: Synthesis, in vitro and in vivo evaluation.
AID1508559	Antitrypanosomal activity against bloodstream trypomastigote stage of Trypanosoma cruzi Y infected in monkey LLC-MK2 cells assessed as reduction in parasite motility measured after 24 hrs by neubauer chamber method	2017	European journal of medicinal chemistry, Dec-01, Volume: 141	Structural design, synthesis and pharmacological evaluation of thiazoles against Trypanosoma cruzi.
AID1174796	Antiparasitic activity against trypomastigote form of Trypanosoma cruzi IRHOD/CO/2008/SN3 infected in BALB/c mouse acute chagas disease model assessed as parasite reduction in blood at 5 mg/kg, ip measured on day 40 post infection	2015	European journal of medicinal chemistry, Jan-07, Volume: 89	Prospects of an alternative treatment against Trypanosoma cruzi based on abietic acid derivatives show promising results in Balb/c mouse model.
AID598281	Antiprotozoan activity against Giardia intestinalis IMSS:0696:1 trophozoites after 48 hrs	2011	Bioorganic & medicinal chemistry letters, May-15, Volume: 21, Issue:10	Synthesis of benzologues of Nitazoxanide and Tizoxanide: a comparative study of their in vitro broad-spectrum antiprotozoal activity.
AID341599	Antiplasmodial activity against Plasmodium falciparum K1	2007	Antimicrobial agents and chemotherapy, Aug, Volume: 51, Issue:8	Peroxide bond-dependent antiplasmodial specificity of artemisinin and OZ277 (RBx11160).
AID1686756	Antitrypanosomal activity against Trypanosoma cruzi Arequipa trypomastigotes infected in BALB/c mouse assessed as reduction in parasitemia measured during acute phase (days 0 to 40 post infection) at 50 to 100 mg/kg, po dosed on alternating days (7 to 15	2016	Journal of medicinal chemistry, 12-22, Volume: 59, Issue:24	In Vitro and in Vivo Anti-Trypanosoma cruzi Activity of New Arylamine Mannich Base-Type Derivatives.
AID1613543	Cardiotoxicity in Balb/c mouse infected with Trypanosoma cruzi MHOM/Pe/2011/Arequipa DTU 5 trypomastigotes assessed as decrease in serum LDH level at 20 mg/kg, po once daily for 5 consecutive days starting from day 75 post infection measured on day 127 po	2019	European journal of medicinal chemistry, Feb-15, Volume: 164	New polyamine drugs as more effective antichagas agents than benznidazole in both the acute and chronic phases.
AID656216	Cytotoxicity against african green monkey Vero cells at 12.5 uM after 3 days	2012	Bioorganic & medicinal chemistry letters, Apr-15, Volume: 22, Issue:8	Phosphonium lipocations as antiparasitic agents.
AID1519014	Toxicity in C3H/HeNk mouse infected with Trypanosoma cruzi K98 bloodstream form assessed as body weight gain at 30 mg/kg/day, po administered via gavage for 30 consecutive days starting from 90 days post infection measured up to 120 days post infection	2019	European journal of medicinal chemistry, 12-15, Volume: 184	Combined therapy with Benznidazole and repurposed drugs Clofazimine and Benidipine for chronic Chagas disease.
AID1633356	Selectivity index, ratio of CC50 for mouse RAW264.7 cells to IC50 for Trypanosoma cruzi Dm28c epimastigotes
AID1165095	Trypanocidal activity against bloodstream forms of Trypanosoma brucei brucei Lister 427 clone 221a overexpressing type I nitroreductase assessed as inhibition of proliferation after 3 days by resazurin assay in absence of tetracycline	2014	European journal of medicinal chemistry, Nov-24, Volume: 87	Novel nitro(triazole/imidazole)-based heteroarylamides/sulfonamides as potential antitrypanosomal agents.
AID675029	Cytotoxicity against african green monkey Vero cells after 24 hrs by MTT assay	2012	European journal of medicinal chemistry, Sep, Volume: 55	Synthesis and biological evaluation of some novel 1-indanone thiazolylhydrazone derivatives as anti-Trypanosoma cruzi agents.
AID1613568	Hepatotoxicity in Balb/c mouse infected with Trypanosoma cruzi MHOM/Pe/2011/Arequipa DTU 5 trypomastigotes assessed as change in alkaline phosphatase level at 20 mg/kg, po once daily for 5 consecutive days starting from day 10 post infection measured on d	2019	European journal of medicinal chemistry, Feb-15, Volume: 164	New polyamine drugs as more effective antichagas agents than benznidazole in both the acute and chronic phases.
AID753405	Cytotoxicity against human HeLa cells after 24 hrs by resazurin assay	2013	Bioorganic & medicinal chemistry letters, Jun-15, Volume: 23, Issue:12	Aromatic glycosyl disulfide derivatives: evaluation of their inhibitory activities against Trypanosoma cruzi.
AID580660	Antitrypanosomal activity against Trypanosoma cruzi Y infected in CD8+ T-lymphocyte knockout C57BL/6 mouse assessed as occurrence of subpatent level of parasitemia at 20 mg/kg/day, po administered twice daily for 20 consecutive days measured 60 days post	2009	Antimicrobial agents and chemotherapy, Jan, Volume: 53, Issue:1	Absence of CD4+ T lymphocytes, CD8+ T lymphocytes, or B lymphocytes has different effects on the efficacy of posaconazole and benznidazole in treatment of experimental acute Trypanosoma cruzi infection.
AID1615080	Toxicity in Balb/c mouse assessed as reduction in body mass at 20 mg/kg, po once daily for 5 consecutive days starting from day 10 post infection relative to control	2019	Bioorganic & medicinal chemistry, 03-01, Volume: 27, Issue:5	Synthesis and biological evaluation of new long-chain squaramides as anti-chagasic agents in the BALB/c mouse model.
AID1455941	Antiprotozoal activity against Trypanosoma cruzi Tulahuen C4 infected in rat L6 cells after 96 hrs by beta-galactosidase reporter gene assay
AID1603828	Antitrypanosomal activity against Trypanosoma cruzi MHOM/Pe/2011/Arequipa;DTU 5 bloodstream trypomastigote infected in BALB/c mouse assessed as parasite-free spleen in acute phase at 20 mg/kg/day, po administered for 5 consecutive days starting from day 8	2019	Bioorganic & medicinal chemistry, 09-01, Volume: 27, Issue:17	Rational modification of Mannich base-type derivatives as novel antichagasic compounds: Synthesis, in vitro and in vivo evaluation.
AID1603887	Antitrypanosomal activity against Trypanosoma cruzi MHOM/Pe/2011/Arequipa;DTU 5 epimastigote assessed as depolarization of mitochondrial membrane at IC50 measured after 72 hrs by rhodamine 123 and acridine orange staining based flow cytometry relative to	2019	Bioorganic & medicinal chemistry, 09-01, Volume: 27, Issue:17	Rational modification of Mannich base-type derivatives as novel antichagasic compounds: Synthesis, in vitro and in vivo evaluation.
AID337137	Antitrypanosomal activity against Trypanosoma cruzi 13379 CL3 after 48 hrs
AID598286	Antimalarial activity against Plasmodium berghei schizonts isolated from parasitized erythrocytes infected Wistar rat measured 16 hrs post compound exposure	2011	Bioorganic & medicinal chemistry letters, May-15, Volume: 21, Issue:10	Synthesis of benzologues of Nitazoxanide and Tizoxanide: a comparative study of their in vitro broad-spectrum antiprotozoal activity.
AID1432876	Cytotoxicity against rat L6 cells assessed as growth inhibition after 72 hrs by alamar blue assay	2017	Bioorganic & medicinal chemistry, 04-01, Volume: 25, Issue:7	Synthesis and activity of nucleoside-based antiprotozoan compounds.
AID1055167	Hepatotoxicity in BALB/c mouse infected with bloodstream trypomastigote form of Trypanosoma cruzi IRHOD/CO/2008/SN3 assessed as centrilobular destruction of hepatic vein at 5 mg/kg/day, ip administered for 5 days measured 150 days post-infection by light	2013	European journal of medicinal chemistry, , Volume: 70	Scorpiand-like azamacrocycles prevent the chronic establishment of Trypanosoma cruzi in a murine model.
AID1811311	Selectivity index, ratio of CC50 for mouse J774.2 cells to IC50 for Trypanosoma cruzi MHOM/MX/1994/Ninoa	2021	Bioorganic & medicinal chemistry, 10-15, Volume: 48	In vitro, ex vivo and in vivo short-term screening of DHEA nitrate derivatives activity over Trypanosoma cruzi Ninoa and TH strains from Oaxaca State, México.
AID564077	Antitrypanosomal activity against Trypanosoma cruzi 762 epimastigotes after 24 hrs by light microscopy	2010	Antimicrobial agents and chemotherapy, Jul, Volume: 54, Issue:7	Arylimidamide DB766, a potential chemotherapeutic candidate for Chagas' disease treatment.
AID1753503	Toxicity in Swiss webster mouse infected with Trypanosoma cruzi Y trypomastigotes assessed as animal survival at 10 mg/kg, po qd for 5 days treatment started at 6 days post-infection and measured at 34 days post-infection	2021	Journal of medicinal chemistry, 04-08, Volume: 64, Issue:7	Revisiting Pyrazolo[3,4-
AID1687706	Selectivity index, ratio of CC50 African green monkey Vero cells to IC50 for Trypanosoma cruzi amastigotes	2020	European journal of medicinal chemistry, Jan-15, Volume: 186	Hit-to-lead optimization of novel 2-alkylaminomethylquinoline derivatives as anti-chagas agents.
AID337148	Antitrypanosomal activity against Trypanosoma cruzi A99CL7 after 48 hrs
AID1498254	Antitrypanosomal activity against Trypanosoma cruzi MHOM/Pe/2011/Arequipa DTU 5 trypamastigotes infected in Balb/c mouse assessed as reduction in Ig-G level in serum at 20 mg/kg, po once daily for 5 consecutive days starting from day 75 post infection mea	2018	Journal of medicinal chemistry, 07-12, Volume: 61, Issue:13	Second Generation of Mannich Base-Type Derivatives with in Vivo Activity against Trypanosoma cruzi.
AID1615079	Toxicity in Balb/c mouse assessed as death at 20 mg/kg, po once daily for 5 consecutive days starting from day 75 post infection	2019	Bioorganic & medicinal chemistry, 03-01, Volume: 27, Issue:5	Synthesis and biological evaluation of new long-chain squaramides as anti-chagasic agents in the BALB/c mouse model.
AID1712840	Cytotoxicity against BALB/c mouse splenocyte incubated for 24 hrs by [3H]-thymidine incorporation based counter beta irradiation method	2016	European journal of medicinal chemistry, Oct-04, Volume: 121	New 1,3-thiazole derivatives and their biological and ultrastructural effects on Trypanosoma cruzi.
AID1254440	Antiparasitic activity against amastigote stage of Trypanosoma cruzi Y in BALB/c mouse macrophages assessed as decrease in number of intracellular amastigotes at 50 uM incubated for 6 hrs by Giemsa staining-based optical microscopic analysis	2015	Bioorganic & medicinal chemistry, Dec-01, Volume: 23, Issue:23	Structural design, synthesis and pharmacological evaluation of 4-thiazolidinones against Trypanosoma cruzi.
AID447813	Antitrypanosomal activity against Trypanosoma cruzi Y epimastigote form after 11 days by Trypan blue exclusion method	2009	Bioorganic & medicinal chemistry, Jul-15, Volume: 17, Issue:14	Ruthenium complexes endowed with potent anti-Trypanosoma cruzi activity: Synthesis, biological characterization and structure-activity relationships.
AID669301	Toxicity in human RBC assessed as hemolysis after 3 hrs	2012	Journal of medicinal chemistry, Apr-12, Volume: 55, Issue:7	Terpenes from Copaifera demonstrated in vitro antiparasitic and synergic activity.
AID1281414	Trypanocidal activity against trypamostigote form of Trypanosoma cruzi Y infected in African green monkey Vero cells after 24 hrs by neubauer chamber method	2016	European journal of medicinal chemistry, Mar-23, Volume: 111	Phthalimido-thiazoles as building blocks and their effects on the growth and morphology of Trypanosoma cruzi.
AID1299555	Antitrypanosomal activity against trypomastigote form of Trypanosoma cruzi Tulahuen C2C4 expressing LacZ gene infected in rat L6 cells after 96 hrs by photometric method	2016	Journal of natural products, Feb-26, Volume: 79, Issue:2	Abietane-Type Diterpenoid Amides with Highly Potent and Selective Activity against Leishmania donovani and Trypanosoma cruzi.
AID730420	Antitrypanosomal activity against Trypanosoma cruzi Tulahuen TcVI extracellular trypomastigotes forms transfected with beta-galactosidase gene infected in rat L6 cells assessed as inhibition of parasite growth after 4 days	2013	Bioorganic & medicinal chemistry, Apr-01, Volume: 21, Issue:7	Design, structure-activity relationship and in vivo efficacy of piperazine analogues of fenarimol as inhibitors of Trypanosoma cruzi.
AID1254436	Cytotoxicity against mouse J774 cells assessed as cell viability after 72 hrs by Alamar Blue assay	2015	Bioorganic & medicinal chemistry, Dec-01, Volume: 23, Issue:23	Structural design, synthesis and pharmacological evaluation of 4-thiazolidinones against Trypanosoma cruzi.
AID1603825	Antitrypanosomal activity against Trypanosoma cruzi MHOM/Pe/2011/Arequipa;DTU 5 bloodstream trypomastigote infected in BALB/c mouse assessed as parasite-free heart in chronic phase at 20 mg/kg/day, po administered for 5 consecutive days starting from day	2019	Bioorganic & medicinal chemistry, 09-01, Volume: 27, Issue:17	Rational modification of Mannich base-type derivatives as novel antichagasic compounds: Synthesis, in vitro and in vivo evaluation.
AID1613550	Hepatotoxicity in Balb/c mouse infected with Trypanosoma cruzi MHOM/Pe/2011/Arequipa DTU 5 trypomastigotes assessed as increase in ratio of serum AST to GOT level at 20 mg/kg, po once daily for 5 consecutive days starting from day 75 post infection measur	2019	European journal of medicinal chemistry, Feb-15, Volume: 164	New polyamine drugs as more effective antichagas agents than benznidazole in both the acute and chronic phases.
AID447812	Antitrypanosomal activity against Trypanosoma cruzi Y trypomastigote form after 24 hrs by Trypan blue exclusion method	2009	Bioorganic & medicinal chemistry, Jul-15, Volume: 17, Issue:14	Ruthenium complexes endowed with potent anti-Trypanosoma cruzi activity: Synthesis, biological characterization and structure-activity relationships.
AID762758	Cytotoxicity against Balb-c mouse 3T3 cells by MTT assay	2013	Bioorganic & medicinal chemistry letters, Aug-15, Volume: 23, Issue:16	Molecular design, synthesis and biological evaluation of 1,4-dihydro-4-oxoquinoline ribonucleosides as TcGAPDH inhibitors with trypanocidal activity.
AID1615024	Selectivity index, ratio of IC50 for African green monkey Vero cells to IC50 for Trypanosoma cruzi MHOM/Pe/2011/Arequipa DTU 5 trypomastigotes derived from infected Balb/c mouse	2019	Bioorganic & medicinal chemistry, 03-01, Volume: 27, Issue:5	Synthesis and biological evaluation of new long-chain squaramides as anti-chagasic agents in the BALB/c mouse model.
AID253512	Inhibitory concentration against wild-type (427) Trypanosoma brucei	2005	Journal of medicinal chemistry, Aug-25, Volume: 48, Issue:17	Design and synthesis of a series of melamine-based nitroheterocycles with activity against Trypanosomatid parasites.
AID1507436	Cytotoxicity against Swiss albino mouse peritoneal macrophages after 24 hrs by PrestoBlue dye based assay	2017	European journal of medicinal chemistry, Aug-18, Volume: 136	Rhodium-catalyzed C-H bond activation for the synthesis of quinonoid compounds: Significant Anti-Trypanosoma cruzi activities and electrochemical studies of functionalized quinones.
AID1238024	Selectivity index, ratio of EC50 for BALB/c mouse peritoneal macrophages to EC50 for Leishmania infantum MHOM/BR/72 promastigotes	2015	Bioorganic & medicinal chemistry letters, Aug-15, Volume: 25, Issue:16	Synthesis and evaluation of novel prenylated chalcone derivatives as anti-leishmanial and anti-trypanosomal compounds.
AID472780	Antitrypanosomal activity against Trypanosoma cruzi tulahuen C4 trypomastigotes infected mouse assessed as decrease in parasite replication at 20 mg/kg/day, ip on days 6 to 11 days post infection after 6 days	2010	Bioorganic & medicinal chemistry, Apr-15, Volume: 18, Issue:8	Trypanoside, anti-tuberculosis, leishmanicidal, and cytotoxic activities of tetrahydrobenzothienopyrimidines.
AID1174779	Antiparasitic activity against trypomastigote form of Trypanosoma cruzi IRHOD/CO/2008/SN3 infected in BALB/c mouse acute chagas disease model assessed as parasite reduction in blood	2015	European journal of medicinal chemistry, Jan-07, Volume: 89	Prospects of an alternative treatment against Trypanosoma cruzi based on abietic acid derivatives show promising results in Balb/c mouse model.
AID1613534	Cardiotoxicity in Balb/c mouse infected with Trypanosoma cruzi MHOM/Pe/2011/Arequipa DTU 5 trypomastigotes assessed as change in ratio of creatine kinase in muscle to brain at 20 mg/kg, po once daily for 5 consecutive days starting from day 10 post infect	2019	European journal of medicinal chemistry, Feb-15, Volume: 164	New polyamine drugs as more effective antichagas agents than benznidazole in both the acute and chronic phases.
AID564756	Antitrypanosomal activity against Trypanosoma cruzi Y bloodstream forms infected in Swiss-Webster mouse assessed as decrease in parasite load at 100 mg/kg/day, po administered 8 days postinfection measured on day 2	2010	Antimicrobial agents and chemotherapy, Jul, Volume: 54, Issue:7	Arylimidamide DB766, a potential chemotherapeutic candidate for Chagas' disease treatment.
AID1264451	Selectivity index, ratio of IC50 for rat L6 cells to IC50 for promastigote stage of Leishmania infantum MCAN/ES/92/BCN722	2015	European journal of medicinal chemistry, Nov-13, Volume: 105	Multicomponent reaction-based synthesis and biological evaluation of tricyclic heterofused quinolines with multi-trypanosomatid activity.
AID1188735	Trypanocidal activity against epimastigote forms of Trypanosoma cruzi Y assessed as reduction in viable parasites after 11 days by Neubauer chamber counting method	2014	European journal of medicinal chemistry, Oct-30, Volume: 86	2-Pyridyl thiazoles as novel anti-Trypanosoma cruzi agents: structural design, synthesis and pharmacological evaluation.
AID302064	Antiprotozoal activity against Trypanosoma cruzi Y in vero cells	2007	Bioorganic & medicinal chemistry, Dec-15, Volume: 15, Issue:24	Synthesis and in vitro evaluation of leishmanicidal and trypanocidal activities of N-quinolin-8-yl-arylsulfonamides.
AID253513	Inhibitory concentration against wild-type (427) with NAC Trypanosoma brucei	2005	Journal of medicinal chemistry, Aug-25, Volume: 48, Issue:17	Design and synthesis of a series of melamine-based nitroheterocycles with activity against Trypanosomatid parasites.
AID1156603	Cytotoxicity against rat L6 cells after 3 days by Alamar blue assay	2014	European journal of medicinal chemistry, Aug-18, Volume: 83	Synthesis and antiparasitic activity of new bis-arylimidamides: DB766 analogs modified in the terminal groups.
AID1067349	Antimicrobial activity against Trichomonas vaginalis GT3 incubated for 48 hrs followed by compound washout measured after 48 hrs	2014	Bioorganic & medicinal chemistry, Mar-01, Volume: 22, Issue:5	2-acylamino-5-nitro-1,3-thiazoles: preparation and in vitro bioevaluation against four neglected protozoan parasites.
AID1184288	Antitrypanosomal activity against intracellular Trypanosoma cruzi infected in human U2OS cells after 48 hrs by confocal microscopy	2014	European journal of medicinal chemistry, Sep-12, Volume: 84	Synthesis and biological evaluation of 2,3-dihydroimidazo[1,2-a]benzimidazole derivatives against Leishmania donovani and Trypanosoma cruzi.
AID766419	Antiparasitic activity against epimastigotes of Trypanosoma cruzi CL Brener expressing Escherichia coli lacZ gene infected in mouse NCTC-929 cells assessed as parasite growth inhibition at 32 uM after 72 hrs by colorimetric assay	2013	Bioorganic & medicinal chemistry letters, Sep-01, Volume: 23, Issue:17	Selective activity of 2,4-diaryl-1,2,3,4-tetrahydroquinolines on Trypanosoma cruzi epimastigotes and amastigotes expressing β-galactosidase.
AID547246	Toxicity in mongrel dog infected with Trypanosoma cruzi Berenice-78 assessed as weight loss at 7 mg/kg, po BID for 90 days started 12 to 22 days postinfection measured after 1 day	2010	Antimicrobial agents and chemotherapy, Jul, Volume: 54, Issue:7	Effects of ravuconazole treatment on parasite load and immune response in dogs experimentally infected with Trypanosoma cruzi.
AID1480890	Antitrypanosomal activity against bloodstream trypomastigote stage of Trypanosoma cruzi Y infected in monkey LLC-MK2 cells measured after 24 hrs by neubauer chamber method	2017	European journal of medicinal chemistry, Apr-21, Volume: 130	Desing and synthesis of potent anti-Trypanosoma cruzi agents new thiazoles derivatives which induce apoptotic parasite death.
AID1403408	Trypanocidal activity against Trypanosoma cruzi Y intracellular amastigotes infected in Swiss Webster mouse cardiomyocytes after 72 hrs	2018	European journal of medicinal chemistry, Jan-20, Volume: 144	Efficacy of 2-hydroxy-3-phenylsulfanylmethyl-[1,4]-naphthoquinone derivatives against different Trypanosoma cruzi discrete type units: Identification of a promising hit compound.
AID1613556	Hepatotoxicity in Balb/c mouse infected with Trypanosoma cruzi MHOM/Pe/2011/Arequipa DTU 5 trypomastigotes assessed as increase in ratio of serum ALT to GPT level at 20 mg/kg, po once daily for 5 consecutive days starting from day 75 post infection measur	2019	European journal of medicinal chemistry, Feb-15, Volume: 164	New polyamine drugs as more effective antichagas agents than benznidazole in both the acute and chronic phases.
AID547511	Immunostimulatory activity in mongrel dog infected with Trypanosoma cruzi Y assessed as production of antibody IgG2 at 12 mg/kg, po BID for 90 days measured after 6 months by ELISA	2010	Antimicrobial agents and chemotherapy, Jul, Volume: 54, Issue:7	Effects of ravuconazole treatment on parasite load and immune response in dogs experimentally infected with Trypanosoma cruzi.
AID1238023	Anti-leishmanial activity against Leishmania infantum MHOM/BR/72 promastigotes assessed as parasite growth inhibition incubated for 72 hrs by MTT assay	2015	Bioorganic & medicinal chemistry letters, Aug-15, Volume: 25, Issue:16	Synthesis and evaluation of novel prenylated chalcone derivatives as anti-leishmanial and anti-trypanosomal compounds.
AID1351068	Antitrypanosomal activity against Trypanosoma cruzi Colombiana Tc1 epimastigotes measured after 72 hrs	2018	European journal of medicinal chemistry, Jan-20, Volume: 144	Investigating the structure-activity relationships of N'-[(5-nitrofuran-2-yl) methylene] substituted hydrazides against Trypanosoma cruzi to design novel active compounds.
AID1614019	Antiprotozoal activity against Trypanosoma cruzi CL Brener trypomastigotes infected in BALB/c mouse assessed as reduction in parasitemia at 50 mg/kg, ip bid treated for 4 consecutive days starting at 3 days post infection by bioluminescence assay relative	2019	Journal of medicinal chemistry, 02-14, Volume: 62, Issue:3	Design, Synthesis, and Biological Evaluation of New 1-(Aryl-1 H-pyrrolyl)(phenyl)methyl-1 H-imidazole Derivatives as Antiprotozoal Agents.
AID576942	Antimicrobial activity against Trypanosoma cruzi Tulahuen infected in Swiss mouse assessed as parasite DNA level at 60 mg/kg/day, po for 6 days per week until completion of 60 compound doses administered 5 days post infection measured 180 days post dose b	2010	Antimicrobial agents and chemotherapy, Sep, Volume: 54, Issue:9	Hydroxymethylnitrofurazone is active in a murine model of Chagas' disease.
AID677312	Trypanosomicidal activity against Trypanosoma cruzi epimastigotes assessed as change in L-lactate metabolite excretion after 96 hrs by NMR analysis	2012	Journal of medicinal chemistry, May-10, Volume: 55, Issue:9	In vitro and in vivo trypanosomicidal activity of pyrazole-containing macrocyclic and macrobicyclic polyamines: their action on acute and chronic phases of Chagas disease.
AID1720853	Trypanocidal activity against Trypanosoma cruzi Y strain bloodstream trypomastigotes isolated from infected Albino Swiss mouse assessed as lysis of parasite in presence of 5 % mouse blood incubated for 24 hrs by Neubauer chamber method	2020	Bioorganic & medicinal chemistry, 08-01, Volume: 28, Issue:15	Strategies towards potent trypanocidal drugs: Application of Rh-catalyzed [2 + 2 + 2] cycloadditions, sulfonyl phthalide annulation and nitroalkene reactions for the synthesis of substituted quinones and their evaluation against Trypanosoma cruzi.
AID1508561	Cytotoxicity against rat H9c2 cells assessed as reduction in cell viability after 72 hrs by alamar blue assay	2017	European journal of medicinal chemistry, Dec-01, Volume: 141	Structural design, synthesis and pharmacological evaluation of thiazoles against Trypanosoma cruzi.
AID287713	Antitrypanosomatid activity against Trypanosoma cruzi Tulahuen 2 epimastigotes assessed as reduction of growth after 5 days	2007	Bioorganic & medicinal chemistry, Apr-01, Volume: 15, Issue:7	Second generation of 5-ethenylbenzofuroxan derivatives as inhibitors of Trypanosoma cruzi growth: synthesis, biological evaluation, and structure-activity relationships.
AID1070011	Selectivity index, ratio of LC50 for mouse NCTC-929 cells to IC50 for epimastigote stage of Trypanosoma cruzi CL Brener	2014	Bioorganic & medicinal chemistry letters, Feb-15, Volume: 24, Issue:4	In vitro phenotypic screening of 7-chloro-4-amino(oxy)quinoline derivatives as putative anti-Trypanosoma cruzi agents.
AID1156608	Antiparasitic activity against Trypanosoma brucei rhodesiense STIB900 trypomastigotes after 3 days by Alamar blue assay	2014	European journal of medicinal chemistry, Aug-18, Volume: 83	Synthesis and antiparasitic activity of new bis-arylimidamides: DB766 analogs modified in the terminal groups.
AID1616163	In vivo antitrypanosomal activity against Trypanosoma cruzi Y trypomastigotes infected in Swiss mouse assessed as reduction in parasitemia at 100 mg/kg, po administered once daily via gavage for 5 days starting from 5 days post-infection and measured 8 da	2019	Journal of medicinal chemistry, 10-10, Volume: 62, Issue:19	Discovery of Pyrrolo[2,3-
AID337150	Antitrypanosomal activity against Trypanosoma cruzi TeCL2 after 48 hrs
AID1780965	Antiprotozoal activity against Trypanosoma cruzi epimastigotes assessed as decrease in parasitemia by measuring change in fluorescence intensity at >2.5 uM measured after 3 days by flourescence based analysis	2021	European journal of medicinal chemistry, Nov-05, Volume: 223	Design and synthesis of Mannich base-type derivatives containing imidazole and benzimidazole as lead compounds for drug discovery in Chagas Disease.
AID213640	In vitro inhibitory affect against Trypanosoma cruzi; (32.7 mM Sb)	2000	Bioorganic & medicinal chemistry letters, Jun-05, Volume: 10, Issue:11	Synthesis and evaluation of 9,9-dimethylxanthene tricyclics against trypanothione reductase, Trypanosoma brucei, Trypanosoma cruzi and Leishmania donovani.
AID1381736	Antitrypanosomal activity against Trypanosoma cruzi amastigote form	2018	European journal of medicinal chemistry, Feb-25, Volume: 146	Aryl thiosemicarbazones for the treatment of trypanosomatidic infections.
AID1811308	Trypanocidal activity against Trypanosoma cruzi MHOM/MX/1994/Ninoa assessed as inhibition of parasite growth measured after 48 hrs by MTT assay	2021	Bioorganic & medicinal chemistry, 10-15, Volume: 48	In vitro, ex vivo and in vivo short-term screening of DHEA nitrate derivatives activity over Trypanosoma cruzi Ninoa and TH strains from Oaxaca State, México.
AID1613482	Selectivity index, ratio of IC50 for African green monkey Vero cells to IC50 for Trypanosoma cruzi TINF/CH/1956/Tulahuen DTU 6 epimastigotes	2019	European journal of medicinal chemistry, Feb-15, Volume: 164	New polyamine drugs as more effective antichagas agents than benznidazole in both the acute and chronic phases.
AID1155754	Induction of NO release assessed as nitrite level	2014	European journal of medicinal chemistry, Jul-23, Volume: 82	Design, synthesis and biological evaluation of hybrid bioisoster derivatives of N-acylhydrazone and furoxan groups with potential and selective anti-Trypanosoma cruzi activity.
AID1439206	Cytotoxicity against human U2OS cells	2017	European journal of medicinal chemistry, Mar-10, Volume: 128	Synthesis and trypanocidal activity of a library of 4-substituted 2-(1H-pyrrolo[3,2-c]pyridin-2-yl)propan-2-ols.
AID728172	Antitrypanosomal activity against Trypanosoma cruzi trypomastigote infected in monkey LLC-MK2 cells after 96 hrs by luciferase reporter gene assay	2013	Journal of medicinal chemistry, Mar-28, Volume: 56, Issue:6	Antitrypanosomal lead discovery: identification of a ligand-efficient inhibitor of Trypanosoma cruzi CYP51 and parasite growth.
AID1498172	Trypanocidal activity against Trypanosoma cruzi TINF/CH/1956/Tulahuen DTU 6 epimastigotes after 48 hrs by resazurin dye based assay	2018	Journal of medicinal chemistry, 07-12, Volume: 61, Issue:13	Second Generation of Mannich Base-Type Derivatives with in Vivo Activity against Trypanosoma cruzi.
AID450069	Cytotoxicity against BALB/c mouse splenocyte assessed as [3H]thymidine incorporation by beta-counting	2009	Bioorganic & medicinal chemistry, Sep-15, Volume: 17, Issue:18	Design, synthesis and cruzain docking of 3-(4-substituted-aryl)-1,2,4-oxadiazole-N-acylhydrazones as anti-Trypanosoma cruzi agents.
AID527277	Trypanocidal activity against intracellular amastigotes of Trypanosoma cruzi Tulahuen C2C4 expressing LacZ gene infected in rat L6 cells after 96 hrs	2010	Bioorganic & medicinal chemistry, Nov-01, Volume: 18, Issue:21	2-Hexadecynoic acid inhibits plasmodial FAS-II enzymes and arrests erythrocytic and liver stage Plasmodium infections.
AID287514	Toxicity against Vero cells after 72 hrs	2007	Bioorganic & medicinal chemistry, Mar-01, Volume: 15, Issue:5	1,4-Bis(alkylamino)benzo[g]phthalazines able to form dinuclear complexes of Cu(II) which as free ligands behave as SOD inhibitors and show efficient in vitro activity against Trypanosoma cruzi.
AID1615041	Antitrypanosomal activity against Trypanosoma cruzi MHOM/Pe/2011/Arequipa DTU 5 trypomastigotes infected in Balb/c mouse assessed as parasite-free brain at 20 mg/kg, po pretreated once daily for 5 consecutive days starting from day 10 post infection follo	2019	Bioorganic & medicinal chemistry, 03-01, Volume: 27, Issue:5	Synthesis and biological evaluation of new long-chain squaramides as anti-chagasic agents in the BALB/c mouse model.
AID1140998	Antitrypanosomal activity against Trypanosoma cruzi CL Brener infected in BALB/c mouse assessed as mouse survival at 192 umol/kg/day, po for 14 days administered in saline and tween 80 measured up to 60 days relative to control	2014	Journal of medicinal chemistry, May-22, Volume: 57, Issue:10	Optimization of antitrypanosomatid agents: identification of nonmutagenic drug candidates with in vivo activity.
AID1254921	Activity of histidine tagged recombinant Trypanosoma brucei brucei type 1 nitroreductase assessed as NADH oxidation at 100 uM by spectrophotometry method	2015	European journal of medicinal chemistry, Oct-20, Volume: 103	3-Nitrotriazole-based piperazides as potent antitrypanosomal agents.
AID671572	Antitrypanosomal activity against trypomastigotes of Trypanosoma cruzi Tulahuen infected in Swiss mouse model of chagas disease assessed as decrease in parasite level in blood at 100 mg/kg, po administered 8 day after post infection qd for 20 days	2012	Journal of medicinal chemistry, May-10, Volume: 55, Issue:9	Analogues of fenarimol are potent inhibitors of Trypanosoma cruzi and are efficacious in a murine model of Chagas disease.
AID768692	Inhibition of Trypanosoma cruzi cruzain expressed in Escherichia coli DH5-alpha using Bz-Phe-Arg-AMC as substrate at 10 uM preincubated for 5 mins followed by substrate addition measured for 5 mins by spectrofluorimetric analysis relative to control	2013	European journal of medicinal chemistry, Sep, Volume: 67	Design, synthesis and biological evaluation of new aryl thiosemicarbazone as antichagasic candidates.
AID1199919	Antiprotozoal activity against intracellular amastigote stage of Trypanosoma cruzi Tulahuen C4 by colorimetric assay	2015	Journal of medicinal chemistry, Feb-26, Volume: 58, Issue:4	Antiprotozoal activity and DNA binding of dicationic acridones.
AID378199	Antitrypanosomal activity against galactosidase gene containing Trypanosoma cruzi Tulahuen C2C4 trypomastigotes in rat L6 cells after 4 days	2000	Journal of natural products, Nov, Volume: 63, Issue:11	Ancistroealaines A and B, two new bioactive naphthylisoquinolines, and related naphthoic acids from Ancistrocladus ealaensis.
AID1678867	Selectivity index, ratio of LC50 for cytotoxicity against albino Swiss mouse peritoneal macrophages to IC50 for Antitrypanosomal activity against Trypanosoma cruzi Y strain bloodstream trypomastigotes assessed as lysis of parasite in presence of 5 % mouse	2020	RSC medicinal chemistry, Oct-01, Volume: 11, Issue:10	Synthesis of quinone imine and sulphur-containing compounds with antitumor and trypanocidal activities: redox and biological implications.
AID396008	Antimicrobial activity against Trypanosoma cruzi genotype 19 and genotype 32 dually infected in BALB/c mouse assessed as cure rate	2007	Antimicrobial agents and chemotherapy, Sep, Volume: 51, Issue:9	Impact of dual infections on chemotherapeutic efficacy in BALB/c mice infected with major genotypes of Trypanosoma cruzi.
AID1496048	Selectivity index, ratio of LC50 for Swiss Webster mouse cardiac cells to EC50 for bloodstream trypomastigote stage of Trypanosoma cruzi Y	2018	Bioorganic & medicinal chemistry letters, 06-15, Volume: 28, Issue:11	Identification and preliminary structure-activity relationship studies of novel pyridyl sulfonamides as potential Chagas disease therapeutic agents.
AID1615090	Nephrotoxicity in Balb/c mouse infected with Trypanosoma cruzi MHOM/Pe/2011/Arequipa DTU 5 trypomastigotes assessed as serum uric acid level at 20 mg/kg, po once daily for 5 consecutive days starting from day 10 post infection measured on day 127 post inf	2019	Bioorganic & medicinal chemistry, 03-01, Volume: 27, Issue:5	Synthesis and biological evaluation of new long-chain squaramides as anti-chagasic agents in the BALB/c mouse model.
AID547257	Antimicrobial activity against Trypanosoma cruzi Y infected in mongrel dog assessed as survival of dog at 7 mg/kg, po BID started 12 to 22 days postinfection measured after 1 day	2010	Antimicrobial agents and chemotherapy, Jul, Volume: 54, Issue:7	Effects of ravuconazole treatment on parasite load and immune response in dogs experimentally infected with Trypanosoma cruzi.
AID753408	Trypanocidal activity against Trypanosoma cruzi Y trypomastigotes infected in human HeLa cells at 37 degC after 18 hrs by resazurin assay	2013	Bioorganic & medicinal chemistry letters, Jun-15, Volume: 23, Issue:12	Aromatic glycosyl disulfide derivatives: evaluation of their inhibitory activities against Trypanosoma cruzi.
AID613448	Selectivity index, ratio of CC50 for african green monkey COS7 cells to IC50 for bloodstream trypomastigote form of Trypanosoma cruzi	2011	European journal of medicinal chemistry, Sep, Volume: 46, Issue:9	Synthesis, trypanocidal activity and molecular modeling studies of 2-alkylaminomethylquinoline derivatives.
AID1603888	Antitrypanosomal activity against Trypanosoma cruzi MHOM/Pe/2011/Arequipa;DTU 5 epimastigote assessed as inhibition of DNA and RNA levels at IC50 measured after 72 hrs by by acridine orange staining based flow cytometry relative to control	2019	Bioorganic & medicinal chemistry, 09-01, Volume: 27, Issue:17	Rational modification of Mannich base-type derivatives as novel antichagasic compounds: Synthesis, in vitro and in vivo evaluation.
AID1254916	Antichagasic activity against amastigote forms of Trypanosoma cruzi Tulahuen C4 assessed as inhibition of growth	2015	European journal of medicinal chemistry, Oct-20, Volume: 103	3-Nitrotriazole-based piperazides as potent antitrypanosomal agents.
AID1074380	Cytotoxicity against African green monkey Vero cells assessed as cell viability after 72 hrs by propidium iodide/fluorescein diacetate staining-based flow cytometric analysis	2014	Journal of medicinal chemistry, Feb-13, Volume: 57, Issue:3	Synthesis and biological evaluation of N,N'-squaramides with high in vivo efficacy and low toxicity: toward a low-cost drug against Chagas disease.
AID726609	Inhibition of Toxoplasma gondii farnesyl diphosphate synthase assessed as incorporation of [4-14C]IPP measured at 37 degC	2013	European journal of medicinal chemistry, Feb, Volume: 60	Design, synthesis and biological evaluation of sulfur-containing 1,1-bisphosphonic acids as antiparasitic agents.
AID1432878	Antitrypanosomal activity against Trypanosoma cruzi Tulahuen strain C2C4 amastigote forms harboring LacZ infected in rat L6 cells after 96 hrs by CPRG/Nonidet reagent based photometric method	2017	Bioorganic & medicinal chemistry, 04-01, Volume: 25, Issue:7	Synthesis and activity of nucleoside-based antiprotozoan compounds.
AID580600	Antitrypanosomal activity against Trypanosoma cruzi Y infected in CD4+ T-lymphocyte knockout C57BL/6 mouse assessed as occurrence of subpatent parasitemia level in mouse at 100 mg/kg/day, po administered once daily for 20 consecutive days measured 4 to 24	2009	Antimicrobial agents and chemotherapy, Jan, Volume: 53, Issue:1	Absence of CD4+ T lymphocytes, CD8+ T lymphocytes, or B lymphocytes has different effects on the efficacy of posaconazole and benznidazole in treatment of experimental acute Trypanosoma cruzi infection.
AID756886	Cytotoxicity against rat L6 cells after 72 hrs by Alamar Blue assay	2013	Journal of medicinal chemistry, Jul-11, Volume: 56, Issue:13	Synthesis and antiprotozoal activity of dicationic m-terphenyl and 1,3-dipyridylbenzene derivatives.
AID1613538	Cardiotoxicity in Balb/c mouse infected with Trypanosoma cruzi MHOM/Pe/2011/Arequipa DTU 5 trypomastigotes assessed as change in serum LDH level at 20 mg/kg, po once daily for 5 consecutive days starting from day 10 post infection measured on day 16 post	2019	European journal of medicinal chemistry, Feb-15, Volume: 164	New polyamine drugs as more effective antichagas agents than benznidazole in both the acute and chronic phases.
AID537131	Antileishmanial activity against amastigotes of Leishmania chagasi MHOM/BR/1972/LD after 24 hrs by MTT assay	2010	Bioorganic & medicinal chemistry, Nov-15, Volume: 18, Issue:22	Anti-leishmanial and anti-trypanosomal activities of 1,4-dihydropyridines: In vitro evaluation and structure-activity relationship study.
AID1074379	Selectivity index, ratio of IC50 for African green monkey Vero cells to IC50 for epimastigote stage of Trypanosoma cruzi IRHOD/CO/2008/SN3	2014	Journal of medicinal chemistry, Feb-13, Volume: 57, Issue:3	Synthesis and biological evaluation of N,N'-squaramides with high in vivo efficacy and low toxicity: toward a low-cost drug against Chagas disease.
AID1615015	Trypanocidal activity against Trypanosoma cruzi IRHOD/CO/2008/SN3 DTU 1 epimastigotes after 72 hrs by resazurin dye based assay	2019	Bioorganic & medicinal chemistry, 03-01, Volume: 27, Issue:5	Synthesis and biological evaluation of new long-chain squaramides as anti-chagasic agents in the BALB/c mouse model.
AID1854935	Antitrypanosomal activity against Trypanosoma cruzi Y epimastigotes assessed as parasite growth inhibition measured after 72 hrs by hemocytometer chamber based analysis	2022	European journal of medicinal chemistry, Nov-05, Volume: 241	Rational design of a trypanocidal peptide derived from Dinoponera quadriceps venom.
AID1456724	Antiparasitic activity against Trypanosoma cruzi infected in human assessed as cure rate under acute condition	2017	Journal of medicinal chemistry, 09-28, Volume: 60, Issue:18	Nitroimidazoles: Molecular Fireworks That Combat a Broad Spectrum of Infectious Diseases.
AID1603873	Toxicity in BALB/c mouse infected with Trypanosoma cruzi MHOM/Pe/2011/Arequipa;DTU 5 bloodstream trypomastigote assessed as decrease in serum urea level in chronic phase at 20 mg/kg/day, po administered for 5 consecutive days starting from day 70 post inf	2019	Bioorganic & medicinal chemistry, 09-01, Volume: 27, Issue:17	Rational modification of Mannich base-type derivatives as novel antichagasic compounds: Synthesis, in vitro and in vivo evaluation.
AID1420624	Trypanocidal activity against Trypanosoma cruzi Tulahuen trypomastigotes infected in human THP1 cells assessed as growth inhibition after 48 hrs by chlorophenolred-beta-d-galactopyranoside/Nonidet P-40 reagent-based assay	2018	Bioorganic & medicinal chemistry letters, 11-01, Volume: 28, Issue:20	Synthesis and biological evaluation of isoxazolyl-sulfonamides: A non-cytotoxic scaffold active against Trypanosoma cruzi, Leishmania amazonensis and Herpes Simplex Virus.
AID576104	Toxicity in human patient infected with Trypanosoma cruzi assessed as occurrence of Aphthous stomatitis at 5 mg/kg/day for 60 days	2010	Antimicrobial agents and chemotherapy, Nov, Volume: 54, Issue:11	Tolerance of benznidazole in treatment of Chagas' disease in adults.
AID576089	Toxicity in human patient infected with Trypanosoma cruzi assessed as occurrence of Anorexia at 5 mg/kg/day for 60 days	2010	Antimicrobial agents and chemotherapy, Nov, Volume: 54, Issue:11	Tolerance of benznidazole in treatment of Chagas' disease in adults.
AID1682937	Cardiac toxicity in BALB/c mouse infected with blood trypomastigote form of Trypanosoma cruzi strain Y assessed as CK-MB level in plasma at 25 mg/kg, po administered via gavage daily for 15 days starting from 2 days post-infection and measured on 16th day	2021	Bioorganic & medicinal chemistry, 01-01, Volume: 29	Trypanocidal activity of new 1,6-diphenyl-1H-pyrazolo[3,4-b]pyridine derivatives: Synthesis, in vitro and in vivo studies.
AID1254024	Antiparasitic activity against trypomastigote form of Trypanosoma cruzi Y strain assessed as parasite viability at 62.5 to 500 uM incubated for 24 hrs	2015	Bioorganic & medicinal chemistry, Nov-01, Volume: 23, Issue:21	1,2,3-Triazole-based analogue of benznidazole displays remarkable activity against Trypanosoma cruzi.
AID1361364	Trypanocidal activity against trypomastigote stage of Trypanosoma cruzi INC-5 infected in NIH mouse blood assessed as parasite lysis at 10 ug/ml after 24 hrs by optical microscopic method relative to control	2018	European journal of medicinal chemistry, Aug-05, Volume: 156	Synthesis, molecular docking and biological evaluation of novel phthaloyl derivatives of 3-amino-3-aryl propionic acids as inhibitors of Trypanosoma cruzi trans-sialidase.
AID1615124	Hepatotoxicity in Balb/c mouse infected with Trypanosoma cruzi MHOM/Pe/2011/Arequipa DTU 5 trypomastigotes assessed as increase in alkaline phosphatase level at 20 mg/kg, po once daily for 5 consecutive days starting from day 10 post infection measured on	2019	Bioorganic & medicinal chemistry, 03-01, Volume: 27, Issue:5	Synthesis and biological evaluation of new long-chain squaramides as anti-chagasic agents in the BALB/c mouse model.
AID537130	Antileishmanial activity against promastigotes of Leishmania chagasi MHOM/BR/1972/LD after 18 hrs by MTT assay	2010	Bioorganic & medicinal chemistry, Nov-15, Volume: 18, Issue:22	Anti-leishmanial and anti-trypanosomal activities of 1,4-dihydropyridines: In vitro evaluation and structure-activity relationship study.
AID1687704	Selectivity index, ratio of CC50 African green monkey Vero cells to IC50 for Trypanosoma cruzi epimastigotes	2020	European journal of medicinal chemistry, Jan-15, Volume: 186	Hit-to-lead optimization of novel 2-alkylaminomethylquinoline derivatives as anti-chagas agents.
AID1290516	Cytotoxicity against human THP1 cells assessed as cell viability after 72 hrs by MTT assay	2016	Bioorganic & medicinal chemistry letters, Apr-01, Volume: 26, Issue:7	Individual and combined antiparasitic effect of six plant metabolites against Leishmania amazonensis and Trypanosoma cruzi.
AID1616175	In vivo antitrypanosomal activity against Trypanosoma cruzi Y trypomastigotes infected in Swiss mouse assessed as reduction in parasitemia at 100 mg/kg, po administered once daily for 5 days with 2 days interval for 3 cycles and measured up to 30 days pos	2019	Journal of medicinal chemistry, 10-10, Volume: 62, Issue:19	Discovery of Pyrrolo[2,3-
AID1519009	Antitrypanosomal activity against Trypanosoma cruzi K98 bloodstream form infected in C3H/HeNk mouse assessed as adipocytes replacement in skeletal muscle by measuring number of adipocyte at 30 mg/kg/day, po administered via gavage for 30 consecutive days	2019	European journal of medicinal chemistry, 12-15, Volume: 184	Combined therapy with Benznidazole and repurposed drugs Clofazimine and Benidipine for chronic Chagas disease.
AID284136	Trypanocidal activity in Swiss albino mouse inoculated with Trypanosoma cruzi Y blood trypomastigotes assessed as parasitaemia reduction administered after 7th day of inoculation at 250 mg/kg, po after 4 hrs relative to control	2007	Bioorganic & medicinal chemistry, Jan-01, Volume: 15, Issue:1	Synthesis and trypanocidal activity of ent-kaurane glycosides.
AID1603951	Antitrypanosomal activity against Trypanosoma cruzi MHOM/Pe/2011/Arequipa;DTU 5 epimastigote assessed as effect on L-alanine excretion at IC50 after 72 hrs by H NMR method relative to control	2019	Bioorganic & medicinal chemistry, 09-01, Volume: 27, Issue:17	Rational modification of Mannich base-type derivatives as novel antichagasic compounds: Synthesis, in vitro and in vivo evaluation.
AID710590	Selectivity index, ratio of IC50 for rat L6 cells to IC50 for intracellular amastigote form of Trypanosoma cruzi Tulahuen strain C2C4	2012	Journal of medicinal chemistry, Dec-13, Volume: 55, Issue:23	Conjugation of quinones with natural polyamines: toward an expanded antitrypanosomatid profile.
AID1712839	Antiparasitic activity against Trypanosoma cruzi Y strain trypomastigotes assessed as reduction in parasite viability after 24 hrs by Neubauer chamber counting method	2016	European journal of medicinal chemistry, Oct-04, Volume: 121	New 1,3-thiazole derivatives and their biological and ultrastructural effects on Trypanosoma cruzi.
AID603333	Antitrypanosomal activity against bloodstream trypomastigote form of Trypanosoma cruzi Y isolated from albino mouse blood after 24 hrs	2011	European journal of medicinal chemistry, Jul, Volume: 46, Issue:7	Synthesis and anti-Trypanosoma cruzi activity of β-lapachone analogues.
AID1054891	Trypanocidal activity against intracellular amastigote stage of Trypanosoma cruzi CL-B5 infected in mouse NCTC-929 cells assessed as reduction of parasite load after 7 days by resazurin dye-based fluorometric analysis	2013	Journal of medicinal chemistry, Nov-27, Volume: 56, Issue:22	In vitro and in vivo antileishmanial and trypanocidal studies of new N-benzene- and N-naphthalenesulfonamide derivatives.
AID1498185	Selectivity index, ratio of IC50 for African green monkey Vero cells to IC50 for Trypanosoma cruzi IRHOD/CO/2008/SN3 DTU 1 amastigotes infected in African green monkey Vero cells	2018	Journal of medicinal chemistry, 07-12, Volume: 61, Issue:13	Second Generation of Mannich Base-Type Derivatives with in Vivo Activity against Trypanosoma cruzi.
AID1615026	Selectivity index, ratio of IC50 for African green monkey Vero cells to IC50 for Trypanosoma cruzi IRHOD/CO/2008/SN3 DTU 1 amastigotes infected in African green monkey Vero cells	2019	Bioorganic & medicinal chemistry, 03-01, Volume: 27, Issue:5	Synthesis and biological evaluation of new long-chain squaramides as anti-chagasic agents in the BALB/c mouse model.
AID1584761	Trypanocidal activity against Trypanosoma cruzi Y strain bloodstream trypomastigotes isolated from infected Swiss mouse cardiac cells assessed as parasite death after 24 hrs by neubauer chamber based light microscopy	2018	Journal of medicinal chemistry, 10-25, Volume: 61, Issue:20	Discovery of Novel 7-Aryl 7-Deazapurine 3'-Deoxy-ribofuranosyl Nucleosides with Potent Activity against Trypanosoma cruzi.
AID1683718	Antitrypanosomal activity against Trypanosoma cruzi MHOM/Pe/2011/Arequipa(DTU V) epimastigote form assessed as parasite growth inhibition incubated for 48 hrs by resazurin dye based assay	2020	Journal of natural products, 12-24, Volume: 83, Issue:12	In Vivo Biological Evaluation of a Synthetic Royleanone Derivative as a Promising Fast-Acting Trypanocidal Agent by Inducing Mitochondrial-Dependent Necrosis.
AID693340	Growth inhibition of epimastigote form of Trypanosoma cruzi CL-B5 at 128 uM after 72 hrs by lacZ reporter gene assay	2012	European journal of medicinal chemistry, Dec, Volume: 58	Synthesis, biological evaluation and chemometric analysis of indazole derivatives. 1,2-Disubstituted 5-nitroindazolinones, new prototypes of antichagasic drug.
AID1687714	Anti-chagasic activity against Trypanosoma cruzi trypomastigotes infected in C3H mouse assessed as well-groomed fur and alert at 10 mg/kg, po treated 10 days post infection measured on day 19	2020	European journal of medicinal chemistry, Jan-15, Volume: 186	Hit-to-lead optimization of novel 2-alkylaminomethylquinoline derivatives as anti-chagas agents.
AID1198535	Trypanocidal activity against GFP expressing Trypanosoma cruzi Y C57BL/6J mouse acute model of trypanosomal infection assessed as reduction in cardiac amastigote nests counts at 100 mg/kg/day, ip measured at 10,14 and 20 days post infection by HE staining	2015	European journal of medicinal chemistry, Mar-26, Volume: 93	Computer-guided drug repurposing: identification of trypanocidal activity of clofazimine, benidipine and saquinavir.
AID1615078	Toxicity in Balb/c mouse assessed as death at 20 mg/kg, po once daily for 5 consecutive days starting from day 10 post infection	2019	Bioorganic & medicinal chemistry, 03-01, Volume: 27, Issue:5	Synthesis and biological evaluation of new long-chain squaramides as anti-chagasic agents in the BALB/c mouse model.
AID675025	Trypanocidal activity against epimastigotes of Trypanosoma cruzi Tulahuen 2 assessed as inhibition of parasite growth after 4 days by trypan blue staining	2012	European journal of medicinal chemistry, Sep, Volume: 55	Synthesis and biological evaluation of some novel 1-indanone thiazolylhydrazone derivatives as anti-Trypanosoma cruzi agents.
AID396580	Antitrypanosomal activity against Trypanosoma cruzi Tulahuen 2 epimastigotes	2008	European journal of medicinal chemistry, Aug, Volume: 43, Issue:8	Pyrimido[1,2-a]quinoxaline 6-oxide and phenazine 5,10-dioxide derivatives and related compounds as growth inhibitors of Trypanosoma cruzi.
AID558399	Antiprotozoal activity against Trypanosoma cruzi Tulahuen C2C4 amastigotes	2009	Antimicrobial agents and chemotherapy, Jul, Volume: 53, Issue:7	Trypanothione reductase high-throughput screening campaign identifies novel classes of inhibitors with antiparasitic activity.
AID677293	Toxicity in BALB/c mouse liver infected with Trypanosoma cruzi assessed as necrotic cells in portal tracts at 5 mg/kg, ip after 120 days postinfection by Histopathological analysis	2012	Journal of medicinal chemistry, May-10, Volume: 55, Issue:9	In vitro and in vivo trypanosomicidal activity of pyrazole-containing macrocyclic and macrobicyclic polyamines: their action on acute and chronic phases of Chagas disease.
AID1578098	Antitrypanosomal activity against Trypanosoma brucei rhodesiense	2019	Bioorganic & medicinal chemistry letters, 10-15, Volume: 29, Issue:20	Antiprotozoal alkaloid principles of the plant family Amaryllidaceae.
AID1196784	Antichagasic activity against trypomastigote stage of Trypanosoma cruzi Brazil infected in Balb/c mouse assessed as reduction of parasite index at 15 mg/kg/day, ip measured after 10 days by luciferase reporter gene assay relative to control	2015	Journal of medicinal chemistry, Feb-12, Volume: 58, Issue:3	Novel 3-nitrotriazole-based amides and carbinols as bifunctional antichagasic agents.
AID1565128	Trypanocidal activity against luciferase expressing Trypanosoma cruzi Dm28c trypomastigotes isolated from infected Vero cells assessed as reduction in parasite viability after 24 hrs by luciferase-luminescence assay	2019	European journal of medicinal chemistry, Nov-15, Volume: 182	Synthesis, structure-activity relationship and trypanocidal activity of pyrazole-imidazoline and new pyrazole-tetrahydropyrimidine hybrids as promising chemotherapeutic agents for Chagas disease.
AID577156	Antimicrobial activity against Trypanosoma cruzi Tulahuen infected in Swiss mouse assessed as reduction in reduction in parasite induced histopathological changes in skeletal muscle at 60 mg/kg/day, po for 6 days per week until completion of 60 compound d	2010	Antimicrobial agents and chemotherapy, Sep, Volume: 54, Issue:9	Hydroxymethylnitrofurazone is active in a murine model of Chagas' disease.
AID677575	Selectivity ratio of IC50 for Trypanosoma brucei brucei Lister 427 clone 221a overexpressing tet-inducible NTR in presence of tetracycline to IC50 for Trypanosoma brucei brucei overexpressing tet-inducible NTR in absence of tetracyclin	2012	Journal of medicinal chemistry, Jun-14, Volume: 55, Issue:11	Novel 3-nitro-1H-1,2,4-triazole-based amides and sulfonamides as potential antitrypanosomal agents.
AID1616188	In vivo antitrypanosomal activity against Trypanosoma cruzi Y trypomastigotes infected in Swiss mouse assessed as reduction in parasitemia at 100 mg/kg, po administered once daily for 5 days with 2 days interval for 3 cycles in presence of cyclophosphamid	2019	Journal of medicinal chemistry, 10-10, Volume: 62, Issue:19	Discovery of Pyrrolo[2,3-
AID730419	Cytotoxicity against rat L6 cells after 72 hrs by Alamar Blue assay	2013	Bioorganic & medicinal chemistry, Apr-01, Volume: 21, Issue:7	Design, structure-activity relationship and in vivo efficacy of piperazine analogues of fenarimol as inhibitors of Trypanosoma cruzi.
AID1487118	Selectivity index, ratio of CC50 for cytotoxicity against mouse J774 cells to IC50 for antitrypanosomal activity against Trypanosoma cruzi Queretaro epimastigotes	2017	Bioorganic & medicinal chemistry letters, 08-01, Volume: 27, Issue:15	Synthesis and biological evaluation of 2-methyl-1H-benzimidazole-5-carbohydrazides derivatives as modifiers of redox homeostasis of Trypanosoma cruzi.
AID396024	Antimicrobial activity against Trypanosoma cruzi Bug2148 cl1 and Trypanosoma cruzi MAS cl11 dually infected in BALB/c mouse assessed as cure rate	2007	Antimicrobial agents and chemotherapy, Sep, Volume: 51, Issue:9	Impact of dual infections on chemotherapeutic efficacy in BALB/c mice infected with major genotypes of Trypanosoma cruzi.
AID1254441	Antiparasitic activity against amastigote stage of Trypanosoma cruzi Y in BALB/c mouse macrophages assessed as decrease in number of intracellular amastigotes incubated for 6 hrs by Giemsa staining-based optical microscopic analysis	2015	Bioorganic & medicinal chemistry, Dec-01, Volume: 23, Issue:23	Structural design, synthesis and pharmacological evaluation of 4-thiazolidinones against Trypanosoma cruzi.
AID597236	Antitrypanosomal activity against Trypanosoma cruzi Y infected in Swiss albino mouse assessed as increase of mouse survival days at 50 mg/kg/day, po relative to control	2011	Journal of medicinal chemistry, May-26, Volume: 54, Issue:10	3-Trifluoromethylquinoxaline N,N'-dioxides as anti-trypanosomatid agents. Identification of optimal anti-T. cruzi agents and mechanism of action studies.
AID677291	Toxicity in BALB/c mouse liver infected with Trypanosoma cruzi assessed as intestinal hemorrhage at 5 mg/kg, ip after 120 days postinfection by Histopathological analysis	2012	Journal of medicinal chemistry, May-10, Volume: 55, Issue:9	In vitro and in vivo trypanosomicidal activity of pyrazole-containing macrocyclic and macrobicyclic polyamines: their action on acute and chronic phases of Chagas disease.
AID1272502	Trypanocidal activity against Trypanosoma cruzi Tulahuen 2 epimastigotes at 25 uM after 5 days	2016	Bioorganic & medicinal chemistry letters, Feb-01, Volume: 26, Issue:3	Synthesis and biological evaluation of quinoxaline di-N-oxide derivatives with in vitro trypanocidal activity.
AID1603815	Genotoxicity in Salmonella typhimurium TA1535 harboring pSK1002 assessed as survival in presence of Sprague-Dawley rat liver S9 fraction metabolic activation by SOS/umu assay	2019	Bioorganic & medicinal chemistry, 09-01, Volume: 27, Issue:17	Rational modification of Mannich base-type derivatives as novel antichagasic compounds: Synthesis, in vitro and in vivo evaluation.
AID1238022	Selectivity index, ratio of EC50 for BALB/c mouse peritoneal macrophages to EC50 for Leishmania amazonensis MPRO/BR/1972/M1841-LV-79 amastigotes	2015	Bioorganic & medicinal chemistry letters, Aug-15, Volume: 25, Issue:16	Synthesis and evaluation of novel prenylated chalcone derivatives as anti-leishmanial and anti-trypanosomal compounds.
AID1615022	Selectivity index, ratio of IC50 for African green monkey Vero cells to IC50 for Trypanosoma cruzi MHOM/Pe/2011/Arequipa DTU 5 epimastigotes	2019	Bioorganic & medicinal chemistry, 03-01, Volume: 27, Issue:5	Synthesis and biological evaluation of new long-chain squaramides as anti-chagasic agents in the BALB/c mouse model.
AID1603755	Antitrypanosomal activity against Trypanosoma cruzi IRHOD/CO/2008/SN3;DTU 1 epimastigotes measured after 72 hrs by Neubauer hemocytometer	2019	Bioorganic & medicinal chemistry, 09-01, Volume: 27, Issue:17	Rational modification of Mannich base-type derivatives as novel antichagasic compounds: Synthesis, in vitro and in vivo evaluation.
AID1518994	Toxicity in C3H/HeNk mouse infected with Trypanosoma cruzi K98 bloodstream form assessed as decrease in body weight at 75 mg/kg/day, po administered via gavage for 30 consecutive days starting from 90 days post infection measured at 150 days post infectio	2019	European journal of medicinal chemistry, 12-15, Volume: 184	Combined therapy with Benznidazole and repurposed drugs Clofazimine and Benidipine for chronic Chagas disease.
AID1773690	Cytotoxicity against mouse C2C12 cells	2021	Journal of medicinal chemistry, 09-09, Volume: 64, Issue:17	Structure-Based Optimization of Quinazolines as Cruzain and
AID1686732	Antitrypanosomal activity against Trypanosoma cruzi Tulahuen amastigote forms infected in African green monkey Vero cells incubated for 72 hrs by Giemsa staining based micrscopy	2016	Journal of medicinal chemistry, 12-22, Volume: 59, Issue:24	In Vitro and in Vivo Anti-Trypanosoma cruzi Activity of New Arylamine Mannich Base-Type Derivatives.
AID1422890	Selectivity index, ratio of IC50 for African green monkey Vero cells to IC50 for Trypanosoma cruzi Dm28c trypomastigotes infected in African green monkey Vero cells	2018	ACS medicinal chemistry letters, Oct-11, Volume: 9, Issue:10	Discovery of a Biologically Active Bromodomain Inhibitor by Target-Directed Dynamic Combinatorial Chemistry.
AID1695264	Cytotoxicity against rat H9c2 cells assessed as reduction in cell viability
AID1638042	Selectivity index, ratio of IC50 for African green monkey Vero cells to IC50 for Trypanosoma cruzi IRHOD/CO/2008/SN3 amastigotes infected in African green monkey Vero cells	2019	European journal of medicinal chemistry, Mar-01, Volume: 165	Design, synthesis and molecular docking studies of novel N-arylsulfonyl-benzimidazoles with anti Trypanosoma cruzi activity.
AID1613480	Selectivity index, ratio of IC50 for African green monkey Vero cells to IC50 for Trypanosoma cruzi IRHOD/CO/2008/SN3 DTU 1 amastigotes infected in African green monkey Vero cells	2019	European journal of medicinal chemistry, Feb-15, Volume: 164	New polyamine drugs as more effective antichagas agents than benznidazole in both the acute and chronic phases.
AID1498245	Antitrypanosomal activity against Trypanosoma cruzi MHOM/Pe/2011/Arequipa DTU 5 trypamastigotes infected in Balb/c mouse assessed as reduction in parasitaemia reactivation in stomach tissue at 20 mg/kg, po pretreated once daily for 5 consecutive days star	2018	Journal of medicinal chemistry, 07-12, Volume: 61, Issue:13	Second Generation of Mannich Base-Type Derivatives with in Vivo Activity against Trypanosoma cruzi.
AID1507198	Selectivity index, ratio of IC50 for mouse NCTC-929 cells to IC50 for Trypanosoma cruzi clone CL B5 epimastigotes	2017	European journal of medicinal chemistry, Aug-18, Volume: 136	Novel Imidazo[4,5-c][1,2,6]thiadiazine 2,2-dioxides as antiproliferative trypanosoma cruzi drugs: Computational screening from neural network, synthesis and in vivo biological properties.
AID1565131	Selectivity index, ratio of CC50 for African green monkey Vero cells to IC50 for luciferase expressing Trypanosoma cruzi Dm28c trypomastigotes isolated from infected Vero cells	2019	European journal of medicinal chemistry, Nov-15, Volume: 182	Synthesis, structure-activity relationship and trypanocidal activity of pyrazole-imidazoline and new pyrazole-tetrahydropyrimidine hybrids as promising chemotherapeutic agents for Chagas disease.
AID1202576	Selectivity index, ratio of IC50 for human LL24 cells to IC50 for Trypanosoma cruzi Y epimastigote forms	2015	European journal of medicinal chemistry, , Volume: 96	Designing and exploring active N'-[(5-nitrofuran-2-yl) methylene] substituted hydrazides against three Trypanosoma cruzi strains more prevalent in Chagas disease patients.
AID1518993	Antitrypanosomal activity against Trypanosoma cruzi K98 bloodstream form infected in C3H/HeNk mouse assessed as reduction in parasite burden in cardiac muscle at 30 to 75 mg/kg/day, po administered via gavage for 30 consecutive days starting from 90 days	2019	European journal of medicinal chemistry, 12-15, Volume: 184	Combined therapy with Benznidazole and repurposed drugs Clofazimine and Benidipine for chronic Chagas disease.
AID1584763	Cytotoxicity against Swiss mouse embryonic cardiomyocytes assessed as reduction in cell viability after 24 hrs by prestoblue-staining based colorimetry	2018	Journal of medicinal chemistry, 10-25, Volume: 61, Issue:20	Discovery of Novel 7-Aryl 7-Deazapurine 3'-Deoxy-ribofuranosyl Nucleosides with Potent Activity against Trypanosoma cruzi.
AID601812	Trypanocidal activity against Trypanosoma cruzi Y epimastigotes after 72 hrs by MTT assay	2011	Journal of natural products, May-27, Volume: 74, Issue:5	Absolute configuration and selective trypanocidal activity of gaudichaudianic acid enantiomers.
AID1683694	Antitrypanosomal activity against Trypanosoma cruzi MHOM/Pe/2011/Arequipa(DTU V) amastigote form infected in BALB/c mouse assessed as reactivation parasitaemia at 20 mg/kg, po administered for 5 days starting at 100 days post infection and measured up to	2020	Journal of natural products, 12-24, Volume: 83, Issue:12	In Vivo Biological Evaluation of a Synthetic Royleanone Derivative as a Promising Fast-Acting Trypanocidal Agent by Inducing Mitochondrial-Dependent Necrosis.
AID1615088	Nephrotoxicity in Balb/c mouse infected with Trypanosoma cruzi MHOM/Pe/2011/Arequipa DTU 5 trypomastigotes assessed as decrease in serum urea level at 20 mg/kg, po once daily for 5 consecutive days starting from day 75 post infection measured on day 127 p	2019	Bioorganic & medicinal chemistry, 03-01, Volume: 27, Issue:5	Synthesis and biological evaluation of new long-chain squaramides as anti-chagasic agents in the BALB/c mouse model.
AID1383435	Antitrypanosomal activity against bloodstream trypomastigote stage of Trypanosoma cruzi Y infected in Swiss Webster mouse assessed as reduction in parasitemia at 100 mg/kg, po administered daily on day 5 to 9 post infection relative to control	2018	European journal of medicinal chemistry, Apr-10, Volume: 149	Identification of Pyrazolo[3,4-e][1,4]thiazepin based CYP51 inhibitors as potential Chagas disease therapeutic alternative: In vitro and in vivo evaluation, binding mode prediction and SAR exploration.
AID1439205	Antitrypanosomal activity against Trypanosoma cruzi Y amastigote forms infected in human U2OS cells after 96 hrs by Draq5 staining-based high content analysis	2017	European journal of medicinal chemistry, Mar-10, Volume: 128	Synthesis and trypanocidal activity of a library of 4-substituted 2-(1H-pyrrolo[3,2-c]pyridin-2-yl)propan-2-ols.
AID576096	Toxicity in human patient infected with Trypanosoma cruzi assessed as occurrence of Gastrointestinal disorders at 5 mg/kg/day for 60 days	2010	Antimicrobial agents and chemotherapy, Nov, Volume: 54, Issue:11	Tolerance of benznidazole in treatment of Chagas' disease in adults.
AID1686757	Antitrypanosomal activity against Trypanosoma cruzi Arequipa trypomastigotes infected in BALB/c mouse assessed as reduction in mouse mortality measured during acute phase (days 0 to 40 post infection) at 50 to 100 mg/kg, po dosed on alternating days (7 to	2016	Journal of medicinal chemistry, 12-22, Volume: 59, Issue:24	In Vitro and in Vivo Anti-Trypanosoma cruzi Activity of New Arylamine Mannich Base-Type Derivatives.
AID1403403	Trypanocidal activity against Trypanosoma cruzi Dm28c trypomastigotes infected in monkey LLC-MK2 cells after 24 hrs by luminescent assay	2018	European journal of medicinal chemistry, Jan-20, Volume: 144	Efficacy of 2-hydroxy-3-phenylsulfanylmethyl-[1,4]-naphthoquinone derivatives against different Trypanosoma cruzi discrete type units: Identification of a promising hit compound.
AID344433	Antiproliferative activity against Trypanosoma cruzi Y epimastigotes assessed as number of motile forms at 0.1 mM after 24 hrs by hemocytometer	2008	Journal of medicinal chemistry, Jul-24, Volume: 51, Issue:14	Complexation of the anti-Trypanosoma cruzi drug benznidazole improves solubility and efficacy.
AID337147	Antitrypanosomal activity against Trypanosoma cruzi Y after 48 hrs
AID1615048	Antitrypanosomal activity against Trypanosoma cruzi MHOM/Pe/2011/Arequipa DTU 5 trypomastigotes infected in Balb/c mouse assessed as parasite-free adipose tissue at 20 mg/kg, po pretreated once daily for 5 consecutive days starting from day 75 post infect	2019	Bioorganic & medicinal chemistry, 03-01, Volume: 27, Issue:5	Synthesis and biological evaluation of new long-chain squaramides as anti-chagasic agents in the BALB/c mouse model.
AID1616183	Cytotoxicity against mouse L929 cells assessed as reduction in cell viability	2019	Journal of medicinal chemistry, 10-10, Volume: 62, Issue:19	Discovery of Pyrrolo[2,3-
AID1615018	Trypanocidal activity against Trypanosoma cruzi TINF/CH/1956/Tulahuen DTU 6 epimastigotes after 72 hrs by resazurin dye based assay	2019	Bioorganic & medicinal chemistry, 03-01, Volume: 27, Issue:5	Synthesis and biological evaluation of new long-chain squaramides as anti-chagasic agents in the BALB/c mouse model.
AID373283	Antitrypanosomal activity against Trypanosoma cruzi bloodstream trypomastigote infected in BALB/c mouse assessed as antibodies at 50 mg/kg, po after 30 days by colorimetric method	2009	European journal of medicinal chemistry, Mar, Volume: 44, Issue:3	In vitro and in vivo antitrypanosomatid activity of 5-nitroindazoles.
AID1480891	Antitrypanosomal activity against Trypanosoma cruzi Dm28c epimastigotes measured after 4 to 5 days by neubauer chamber method	2017	European journal of medicinal chemistry, Apr-21, Volume: 130	Desing and synthesis of potent anti-Trypanosoma cruzi agents new thiazoles derivatives which induce apoptotic parasite death.
AID1687777	Antitrypanosomal activity against bloodstream form of Trypanosoma cruzi Y trypomastigotes infected in African green monkey Vero cells assessed as increase in parasite lysis measured after 24 hrs by Neubauer chamber method	2020	European journal of medicinal chemistry, Jan-15, Volume: 186	Novel nitroimidazole derivatives evaluated for their trypanocidal, cytotoxic, and genotoxic activities.
AID1498209	Antitrypanosomal activity against Trypanosoma cruzi MHOM/Pe/2011/Arequipa DTU 5 trypamastigotes infected in Balb/c mouse assessed as reduction in parasitaemia reactivation at 20 mg/kg, po pretreated once daily for 5 consecutive days starting from day 75 p	2018	Journal of medicinal chemistry, 07-12, Volume: 61, Issue:13	Second Generation of Mannich Base-Type Derivatives with in Vivo Activity against Trypanosoma cruzi.
AID1290518	Selectivity index, ratio of CC50 for human THP1 cells to IC50 for Trypanosoma cruzi Tulahuen	2016	Bioorganic & medicinal chemistry letters, Apr-01, Volume: 26, Issue:7	Individual and combined antiparasitic effect of six plant metabolites against Leishmania amazonensis and Trypanosoma cruzi.
AID547510	Immunostimulatory activity in mongrel dog infected with Trypanosoma cruzi Y assessed as production of antibody IgG at 12 mg/kg, po BID for 90 days measured after 6 months by ELISA	2010	Antimicrobial agents and chemotherapy, Jul, Volume: 54, Issue:7	Effects of ravuconazole treatment on parasite load and immune response in dogs experimentally infected with Trypanosoma cruzi.
AID382236	Trypanocidal activity against Trypanosoma cruzi Y blood stream trypomastigotes after 24 hrs	2008	Bioorganic & medicinal chemistry, May-01, Volume: 16, Issue:9	Synthesis and anti-Trypanosoma cruzi activity of derivatives from nor-lapachones and lapachones.
AID776295	Antimicrobial activity against Trypanosoma cruzi RA amastigotes infected in African green monkey Vero cells assessed as growth inhibition at 1 ug/ml after 72 hrs by Giemsa staining-based light microscopy	2013	European journal of medicinal chemistry, Nov, Volume: 69	Synthesis, physicochemical properties of allopurinol derivatives and their biological activity against Trypanosoma cruzi.
AID317066	Antiparasitic activity against Trypanosoma cruzi epimastigotes after 72 hrs	2008	Journal of medicinal chemistry, Mar-27, Volume: 51, Issue:6	Efficient inhibition of iron superoxide dismutase and of Trypanosoma cruzi growth by benzo[g]phthalazine derivatives functionalized with one or two imidazole rings.
AID1459245	Trypanocidal activity against Trypanosoma cruzi TCC epimastigotes assessed as maximal parasite density at 1 to 15 uM supplemented with fresh medium containing compound every 9 to 10 days measured on third week by haemocytometric method	2017	European journal of medicinal chemistry, Jan-05, Volume: 125	Novel 2-arylazoimidazole derivatives as inhibitors of Trypanosoma cruzi proliferation: Synthesis and evaluation of their biological activity.
AID1498251	Antitrypanosomal activity against Trypanosoma cruzi MHOM/Pe/2011/Arequipa DTU 5 trypamastigotes infected in Balb/c mouse assessed as reduction in Ig-G level in serum at 20 mg/kg, po once daily for 5 consecutive days starting from day 10 post infection mea	2018	Journal of medicinal chemistry, 07-12, Volume: 61, Issue:13	Second Generation of Mannich Base-Type Derivatives with in Vivo Activity against Trypanosoma cruzi.
AID1683672	Toxicity in BALB/c mouse infected with Trypanosomal Trypanosoma cruzi MHOM/Pe/2011/Arequipa(DTU V) assessed as effect on ALP level at 20 mg/kg, po administered for 5 days starting at 100 days post infection and measured after 2 days post treatment	2020	Journal of natural products, 12-24, Volume: 83, Issue:12	In Vivo Biological Evaluation of a Synthetic Royleanone Derivative as a Promising Fast-Acting Trypanocidal Agent by Inducing Mitochondrial-Dependent Necrosis.
AID1851973	Antitrypanosomal activity against Trypanosoma cruzi Tulahuen amastigotes infected in mouse 3T3 cells assessed as inhibition of parasite growth incubated for 48 hrs by Hoechst 3348 staining based analysis	2022	Journal of medicinal chemistry, 10-13, Volume: 65, Issue:19	Nitroimidazopyrazinones with Oral Activity against Tuberculosis and Chagas Disease in Mouse Models of Infection.
AID1244469	Trypanocidal activity against intracellular amastigotes of Trypanosoma cruzi Tulahuen infected in human U937 cells assessed as reduction of viability of intracellular amastigotes by measuring beta-galactosidase activity at 20 ug/ml after 72 hrs by spectro	2015	European journal of medicinal chemistry, Aug-28, Volume: 101	Synthesis, leishmanicidal, trypanocidal and cytotoxic activity of quinoline-hydrazone hybrids.
AID1633353	Antitrypanosomal activity against Trypanosoma cruzi Dm28c epimastigotes assessed as reduction in epimastigotes number after 48 hrs by resazurin dye based spectrophotometric method
AID576086	Toxicity in human patient infected with Trypanosoma cruzi assessed as occurrence of Hyperpigmentation at 5 mg/kg/day for 60 days	2010	Antimicrobial agents and chemotherapy, Nov, Volume: 54, Issue:11	Tolerance of benznidazole in treatment of Chagas' disease in adults.
AID323757	Antiparasitic activity against Trypanosoma cruzi Y epimastigote	2008	Bioorganic & medicinal chemistry, Mar-15, Volume: 16, Issue:6	Novel 1,3,4-thiadiazolium-2-phenylamine chlorides derived from natural piperine as trypanocidal agents: chemical and biological studies.
AID669302	Selectivity ratio of CC50 for monkey LLC-MK2 cells to IC50 for Trypanosoma cruzi Y amastigotes	2012	Journal of medicinal chemistry, Apr-12, Volume: 55, Issue:7	Terpenes from Copaifera demonstrated in vitro antiparasitic and synergic activity.
AID1287595	Antiparasitic activity against nifurtimox-sensitive amastigote stage of Trypanosoma cruzi tulahuen CL2 infected in human MRC5 cells	2016	European journal of medicinal chemistry, May-04, Volume: 113	In vitro screening of 2-(1H-imidazol-1-yl)-1-phenylethanol derivatives as antiprotozoal agents and docking studies on Trypanosoma cruzi CYP51.
AID1496047	Cytotoxicity against Swiss Webster mouse cardiomyocyte assessed as reduction in cell viability after 24 hrs by PrestoBlue assay	2018	Bioorganic & medicinal chemistry letters, 06-15, Volume: 28, Issue:11	Identification and preliminary structure-activity relationship studies of novel pyridyl sulfonamides as potential Chagas disease therapeutic agents.
AID1633354	Antitrypanosomal activity against Trypanosoma cruzi Y epimastigotes assessed as reduction in epimastigotes resazurin dye based spectrophotometric method assay
AID1294229	Antichagasic activity against Trypanosoma cruzi Y strain epimastigotes in mouse cardiomyocytes assessed as growth inhibition after 48 hrs by resazurin assay	2016	European journal of medicinal chemistry, Jun-10, Volume: 115	Antichagasic and trichomonacidal activity of 1-substituted 2-benzyl-5-nitroindazolin-3-ones and 3-alkoxy-2-benzyl-5-nitro-2H-indazoles.
AID1278152	Selectivity index, ratio of CC50 for mouse NCTC-292 cells to IC50 for Trypanosoma cruzi Y trypomastigotes	2016	Bioorganic & medicinal chemistry letters, Feb-15, Volume: 26, Issue:4	Gibbilimbol analogues as antiparasitic agents--Synthesis and biological activity against Trypanosoma cruzi and Leishmania (L.) infantum.
AID1613477	Selectivity index, ratio of IC50 for African green monkey Vero cells to IC50 for Trypanosoma cruzi MHOM/Pe/2011/Arequipa DTU 5 amastigotes infected in African green monkey Vero cells	2019	European journal of medicinal chemistry, Feb-15, Volume: 164	New polyamine drugs as more effective antichagas agents than benznidazole in both the acute and chronic phases.
AID753409	Trypanocidal activity against Trypanosoma cruzi Y trypomastigotes infected in human HeLa cells at 4 degC after 18 hrs by hemocytometric analysis	2013	Bioorganic & medicinal chemistry letters, Jun-15, Volume: 23, Issue:12	Aromatic glycosyl disulfide derivatives: evaluation of their inhibitory activities against Trypanosoma cruzi.
AID1498317	Hepatotoxicity in Balb/c mouse infected with Trypanosoma cruzi MHOM/Pe/2011/Arequipa DTU 5 trypamastigotes assessed as increase in ratio of serum ALT to GPT level at 20 mg/kg, po once daily for 5 consecutive days starting from day 10 post infection measur	2018	Journal of medicinal chemistry, 07-12, Volume: 61, Issue:13	Second Generation of Mannich Base-Type Derivatives with in Vivo Activity against Trypanosoma cruzi.
AID1156610	Antiparasitic activity against chloroquine-resistant Plasmodium falciparum K1 after 3 days by [3H]-hypoxanthine incorporation assay	2014	European journal of medicinal chemistry, Aug-18, Volume: 83	Synthesis and antiparasitic activity of new bis-arylimidamides: DB766 analogs modified in the terminal groups.
AID1615060	Antitrypanosomal activity against Trypanosoma cruzi MHOM/Pe/2011/Arequipa DTU 5 trypomastigotes infected in Balb/c mouse assessed as reduction in Ig-G level in serum at 20 mg/kg, po once daily for 5 consecutive days starting from day 75 post infection mea	2019	Bioorganic & medicinal chemistry, 03-01, Volume: 27, Issue:5	Synthesis and biological evaluation of new long-chain squaramides as anti-chagasic agents in the BALB/c mouse model.
AID1074923	Antitrypanosomal activity against Trypanosoma cruzi (IRHOD/CO/2008/SN3) infected in African green monkey Vero cells assessed as reduction in number of trypomastigotes at IC25 treated for 12 hrs followed by compound-washout measured after 10 days by micros	2014	European journal of medicinal chemistry, Mar-03, Volume: 74	New perspectives on the synthesis and antichagasic activity of 3-alkoxy-1-alkyl-5-nitroindazoles.
AID1191152	Antitrypanosomal activity against epimastigote stage of Trypanosoma cruzi Y after 96 hrs by hemocytometry	2015	European journal of medicinal chemistry, Jan-27, Volume: 90	Synthesis and biological evaluation of novel 2,3-disubstituted quinoxaline derivatives as antileishmanial and antitrypanosomal agents.
AID302069	Reduction of Trypanosoma cruzi Y amastigotes infection in Vero cells at 25 uM after 48 hrs	2007	Bioorganic & medicinal chemistry, Dec-15, Volume: 15, Issue:24	Synthesis and in vitro evaluation of leishmanicidal and trypanocidal activities of N-quinolin-8-yl-arylsulfonamides.
AID726226	Antitrypanosomal activity against Trypanosoma cruzi Y epimastigotes at 32 uM incubated for 48 hrs by resazurin dye reduction based ELISA method	2013	Journal of medicinal chemistry, Feb-28, Volume: 56, Issue:4	Cloning, characterization, and sulfonamide and thiol inhibition studies of an α-carbonic anhydrase from Trypanosoma cruzi, the causative agent of Chagas disease.
AID155965	Cytotoxicity against peritoneal macrophages of female CD1 mice culturing amastigote stages of Leishmania donovani; no data	2000	Bioorganic & medicinal chemistry letters, Jun-05, Volume: 10, Issue:11	Synthesis and evaluation of 9,9-dimethylxanthene tricyclics against trypanothione reductase, Trypanosoma brucei, Trypanosoma cruzi and Leishmania donovani.
AID576087	Toxicity in human patient infected with Trypanosoma cruzi assessed as occurrence of Erythema nodosum at 5 mg/kg/day for 60 days	2010	Antimicrobial agents and chemotherapy, Nov, Volume: 54, Issue:11	Tolerance of benznidazole in treatment of Chagas' disease in adults.
AID1603880	Toxicity in BALB/c mouse infected with Trypanosoma cruzi MHOM/Pe/2011/Arequipa;DTU 5 bloodstream trypomastigote assessed as change in serum aspartate aminotransferase level in chronic phase at 20 mg/kg/day, po administered for 5 consecutive days starting	2019	Bioorganic & medicinal chemistry, 09-01, Volume: 27, Issue:17	Rational modification of Mannich base-type derivatives as novel antichagasic compounds: Synthesis, in vitro and in vivo evaluation.
AID666684	Cytotoxicity against mouse J774 cells after 18 hrs by MTT assay	2012	European journal of medicinal chemistry, Aug, Volume: 54	Design and synthesis of new (E)-cinnamic N-acylhydrazones as potent antitrypanosomal agents.
AID1420626	Selectivity index, ratio of CC50 for human THP1 cells to G150 for Trypanosoma cruzi Tulahuen trypomastigotes	2018	Bioorganic & medicinal chemistry letters, 11-01, Volume: 28, Issue:20	Synthesis and biological evaluation of isoxazolyl-sulfonamides: A non-cytotoxic scaffold active against Trypanosoma cruzi, Leishmania amazonensis and Herpes Simplex Virus.
AID1603823	Antitrypanosomal activity against Trypanosoma cruzi MHOM/Pe/2011/Arequipa;DTU 5 bloodstream trypomastigote infected in BALB/c mouse assessed as parasite-free oesophagus in chronic phase at 20 mg/kg/day, po administered for 5 consecutive days starting from	2019	Bioorganic & medicinal chemistry, 09-01, Volume: 27, Issue:17	Rational modification of Mannich base-type derivatives as novel antichagasic compounds: Synthesis, in vitro and in vivo evaluation.
AID1682934	Hepatotoxicity in BALB/c mouse infected with blood trypomastigote form of Trypanosoma cruzi strain Y assessed as AST level in plasma at 25 mg/kg, po administered via gavage daily for 15 days starting from 2 days post-infection and measured on 16th day pos	2021	Bioorganic & medicinal chemistry, 01-01, Volume: 29	Trypanocidal activity of new 1,6-diphenyl-1H-pyrazolo[3,4-b]pyridine derivatives: Synthesis, in vitro and in vivo studies.
AID263378	Antitrypanosomal activity against Trypanosoma cruzi epimastigotes at 1 ug/ml	2006	Bioorganic & medicinal chemistry letters, Apr-01, Volume: 16, Issue:7	New ligand-based approach for the discovery of antitrypanosomal compounds.
AID728167	Antitrypanosomal activity against Trypanosoma cruzi Tulahuen infected in monkey LLC-MK2 cells after 48 to 72 hrs by beta-galactosidase reporter gene assay	2013	Journal of medicinal chemistry, Mar-28, Volume: 56, Issue:6	Antitrypanosomal lead discovery: identification of a ligand-efficient inhibitor of Trypanosoma cruzi CYP51 and parasite growth.
AID1480893	Selectivity index, ratio of highest non-cytotoxic concentration for mouse J774A.1 cells to CC50 for bloodstream trypomastigote stage of Trypanosoma cruzi Y infected in monkey LLC-MK2 cells	2017	European journal of medicinal chemistry, Apr-21, Volume: 130	Desing and synthesis of potent anti-Trypanosoma cruzi agents new thiazoles derivatives which induce apoptotic parasite death.
AID1244585	Antiparasitic activity against trypomastigotes of Trypanosoma cruzi Y assessed as induction of parasite death at 5 uM after 24 hrs using propidium iodide staining after 24 hrs by flow cytometry analysis	2015	European journal of medicinal chemistry, Aug-28, Volume: 101	Synthesis and structure-activity relationship study of a new series of antiparasitic aryloxyl thiosemicarbazones inhibiting Trypanosoma cruzi cruzain.
AID694793	Antitrypanosomal activity against trypomastigotes of Trypanosoma cruzi Y infected in BALB/c mouse assessed as reduction of parasite level in blood at 100 mg/kg, po administered after 5 days of postinfection qd for 5 days	2012	Bioorganic & medicinal chemistry, Nov-01, Volume: 20, Issue:21	Optimization of anti-Trypanosoma cruzi oxadiazoles leads to identification of compounds with efficacy in infected mice.
AID564081	Antitrypanosomal activity against Trypanosoma cruzi 958 epimastigotes after 24 hrs by light microscopy	2010	Antimicrobial agents and chemotherapy, Jul, Volume: 54, Issue:7	Arylimidamide DB766, a potential chemotherapeutic candidate for Chagas' disease treatment.
AID1608335	Anti-parasitic activity against trypomastigotes form of Trypanosoma cruzi after 24 hrs	2019	European journal of medicinal chemistry, Oct-01, Volume: 179	Synthesis of quinones with highlighted biological applications: A critical update on the strategies towards bioactive compounds with emphasis on lapachones.
AID596807	Cytotoxicity against african green monkey Vero cells assessed as cell viability after 72 hrs by FACS analysis	2011	Journal of natural products, Apr-25, Volume: 74, Issue:4	In vitro and in vivo trypanocidal activity of flavonoids from Delphinium staphisagria against Chagas disease.
AID644366	Antiprotozoal activity against Trypanosoma cruzi Tulahuen C2C4 amastigotes infected in rat L6 myoblasts after 96 hrs by CPRG/Nonidet-based spectrophotometry	2012	Bioorganic & medicinal chemistry, Feb-15, Volume: 20, Issue:4	Synthesis and antimalarial and antituberculosis activities of a series of natural and unnatural 4-methoxy-6-styryl-pyran-2-ones, dihydro analogues and photo-dimers.
AID1613548	Hepatotoxicity in Balb/c mouse infected with Trypanosoma cruzi MHOM/Pe/2011/Arequipa DTU 5 trypomastigotes assessed as increase in ratio of serum AST to GOT level at 20 mg/kg, po once daily for 5 consecutive days starting from day 75 post infection measur	2019	European journal of medicinal chemistry, Feb-15, Volume: 164	New polyamine drugs as more effective antichagas agents than benznidazole in both the acute and chronic phases.
AID313539	Antitrypanosomal activity against Trypanosoma cruzi Tulahuen epimastigotes after 72 hrs	2008	Bioorganic & medicinal chemistry letters, Jan-01, Volume: 18, Issue:1	Leishmanicidal and trypanocidal activities of 2-aminocyclohexanol and 1,2-cyclohexanediamine derivatives.
AID671576	Antitrypanosomal activity against trypomastigotes of Trypanosoma cruzi Tulahuen infected immunosuppressed Swiss mouse assessed as level of parasite in blood at 100 mg/kg, po administered 8 day after post infection qd for 20 days measured after 3 cycles of	2012	Journal of medicinal chemistry, May-10, Volume: 55, Issue:9	Analogues of fenarimol are potent inhibitors of Trypanosoma cruzi and are efficacious in a murine model of Chagas disease.
AID1079948	Times to onset, minimal and maximal, observed in the indexed observations. [column 'DELAI' in source]
AID1687707	Anti-chagasic activity against Trypanosoma cruzi trypomastigotes infected in C3H mouse assessed as reduction in parasitemia at 10 mg/kg, po treated 10 days post infection for 7 consecutive days by Neubauer chamber counting method relative to control	2020	European journal of medicinal chemistry, Jan-15, Volume: 186	Hit-to-lead optimization of novel 2-alkylaminomethylquinoline derivatives as anti-chagas agents.
AID1400238	Selectivity index, ratio of CC50 for human THP1 cells to GI50 for Trypanosoma cruzi Tulahuen amastigote forms infected in human THP1 cells	2018	Bioorganic & medicinal chemistry, 09-15, Volume: 26, Issue:17	Synthesis and SAR of new isoxazole-triazole bis-heterocyclic compounds as analogues of natural lignans with antiparasitic activity.
AID1614009	Cytotoxicity against rat L6 cels assessed as reduction in cell viability after 72 hrs by Alamar Blue dye-based fluorometric analysis	2019	Journal of medicinal chemistry, 02-14, Volume: 62, Issue:3	Design, Synthesis, and Biological Evaluation of New 1-(Aryl-1 H-pyrrolyl)(phenyl)methyl-1 H-imidazole Derivatives as Antiprotozoal Agents.
AID1613526	Nephrotoxicity in Balb/c mouse infected with Trypanosoma cruzi MHOM/Pe/2011/Arequipa DTU 5 trypomastigotes assessed as decrease in serum urea level at 20 mg/kg, po once daily for 5 consecutive days starting from day 75 post infection measured on day 127 p	2019	European journal of medicinal chemistry, Feb-15, Volume: 164	New polyamine drugs as more effective antichagas agents than benznidazole in both the acute and chronic phases.
AID1706426	Antitrypanosomal activity against bloodstream trypomastigotes form of Trypanosoma cruzi CL Brener infected in BALB/c mouse assessed as reduction in parasitemia at 100 mg/kg, po qd administered for 5 days starting from day 114 post infection followed by cy	2020	European journal of medicinal chemistry, Dec-01, Volume: 207	Re-evaluating pretomanid analogues for Chagas disease: Hit-to-lead studies reveal both in vitro and in vivo trypanocidal efficacy.
AID1154402	Antitrypanosomal activity against trypomastigote stage of Trypanosoma cruzi Y infected in BALB/c mouse peritoneal macrophages assessed as inhibition of host cell invasion at 10 uM after 2 hrs by hematoxylin/eosin staining-based optical microscopic analysi	2014	Journal of natural products, Jun-27, Volume: 77, Issue:6	Dimeric flavonoids from Arrabidaea brachypoda and assessment of their anti-Trypanosoma cruzi activity.
AID247798	Trypanocidal activity against amastigote forms of Y strain of Trypanosoma cruzi	2005	Bioorganic & medicinal chemistry letters, Jan-17, Volume: 15, Issue:2	Trypanocidal activity of (-)-cubebin derivatives against free amastigote forms of Trypanosoma cruzi.
AID1683674	Toxicity in BALB/c mouse infected with Trypanosomal Trypanosoma cruzi MHOM/Pe/2011/Arequipa(DTU V) assessed as effect on ALT/GPT level at 20 mg/kg, po administered for 5 days starting at 100 days post infection and measured after 2 days post treatment	2020	Journal of natural products, 12-24, Volume: 83, Issue:12	In Vivo Biological Evaluation of a Synthetic Royleanone Derivative as a Promising Fast-Acting Trypanocidal Agent by Inducing Mitochondrial-Dependent Necrosis.
AID373281	Toxicity in BALB/c mouse assessed as survival fraction at 50 mg/kg, po after 9 weeks	2009	European journal of medicinal chemistry, Mar, Volume: 44, Issue:3	In vitro and in vivo antitrypanosomatid activity of 5-nitroindazoles.
AID564747	Toxicity in male Swiss-Webster mouse assessed as weight loss at cumulative dose of 200 mg/kg, ip measured after 48 hrs	2010	Antimicrobial agents and chemotherapy, Jul, Volume: 54, Issue:7	Arylimidamide DB766, a potential chemotherapeutic candidate for Chagas' disease treatment.
AID669382	Antitrypanosomal activity against epimastigotes of Trypanosoma cruzi after 72 hrs by MTT assay	2012	Journal of natural products, May-25, Volume: 75, Issue:5	Antiprotozoal sesquiterpene pyridine alkaloids from Maytenus ilicifolia.
AID1070012	Cytotoxicity against mouse NCTC-929 cells after 48 hrs by resazurin staining-based fluorescence assay	2014	Bioorganic & medicinal chemistry letters, Feb-15, Volume: 24, Issue:4	In vitro phenotypic screening of 7-chloro-4-amino(oxy)quinoline derivatives as putative anti-Trypanosoma cruzi agents.
AID1687778	Antitrypanosomal activity against Trypanosoma cruzi Y axenic amastigotes infected in African green monkey Vero cells after 24 hrs by MTT assay	2020	European journal of medicinal chemistry, Jan-15, Volume: 186	Novel nitroimidazole derivatives evaluated for their trypanocidal, cytotoxic, and genotoxic activities.
AID1496044	Antitrypanosomal activity against Trypanosoma cruzi Tulahuen amastigotes infected in mouse L929 cells after 96 hrs by beta galactosidase reporter assay	2018	Bioorganic & medicinal chemistry letters, 06-15, Volume: 28, Issue:11	Identification and preliminary structure-activity relationship studies of novel pyridyl sulfonamides as potential Chagas disease therapeutic agents.
AID575890	Toxicity in human patient infected with Trypanosoma cruzi assessed as occurrence of polyneuritis on 4th week of treatment	2010	Antimicrobial agents and chemotherapy, Nov, Volume: 54, Issue:11	Tolerance of benznidazole in treatment of Chagas' disease in adults.
AID1612899	Antimicrobial activity against Trypanosoma cruzi Y infected in human U2OS cells after 96 hrs by HCS assay	2019	European journal of medicinal chemistry, Feb-01, Volume: 163	Discovery of new potent hits against intracellular Trypanosoma cruzi by QSAR-based virtual screening.
AID1678866	Cytotoxicity against albino Swiss mouse peritoneal macrophages assessed as reduction in cell viability incubated for 24 hrs by Presto blue assay	2020	RSC medicinal chemistry, Oct-01, Volume: 11, Issue:10	Synthesis of quinone imine and sulphur-containing compounds with antitumor and trypanocidal activities: redox and biological implications.
AID1569975	Selectivity index, ratio of maximum non-toxic concentration for Balb/c mouse splenocyte to IC50 for bloodstream form of Trypanosoma cruzi trypomastigotes	2019	European journal of medicinal chemistry, Oct-15, Volume: 180	2-(phenylthio)ethylidene derivatives as anti-Trypanosoma cruzi compounds: Structural design, synthesis and antiparasitic activity.
AID1687701	Antitrypanosomal activity against bloodstream Trypanosoma cruzi trypomastigotes measured after 24 hrs by Neubauer chamber method	2020	European journal of medicinal chemistry, Jan-15, Volume: 186	Hit-to-lead optimization of novel 2-alkylaminomethylquinoline derivatives as anti-chagas agents.
AID1498177	Trypanocidal activity against Trypanosoma cruzi MHOM/Pe/2011/Arequipa DTU 5 amastigotes infected in African green monkey Vero cells after 72 hrs by Giemsa-staining based microscopic assay	2018	Journal of medicinal chemistry, 07-12, Volume: 61, Issue:13	Second Generation of Mannich Base-Type Derivatives with in Vivo Activity against Trypanosoma cruzi.
AID576079	Toxicity in human patient infected with Trypanosoma cruzi assessed as occurrence of Dermatological disorder at 5 mg/kg/day for 60 days	2010	Antimicrobial agents and chemotherapy, Nov, Volume: 54, Issue:11	Tolerance of benznidazole in treatment of Chagas' disease in adults.
AID564757	Antitrypanosomal activity against Trypanosoma cruzi Y bloodstream forms infected in Swiss-Webster mouse assessed as survival of mouse at 100 mg/kg/day, ip administered 8 days postinfection measured on day 120	2010	Antimicrobial agents and chemotherapy, Jul, Volume: 54, Issue:7	Arylimidamide DB766, a potential chemotherapeutic candidate for Chagas' disease treatment.
AID1615047	Antitrypanosomal activity against Trypanosoma cruzi MHOM/Pe/2011/Arequipa DTU 5 trypomastigotes infected in Balb/c mouse assessed as parasite-free stomach at 20 mg/kg, po pretreated once daily for 5 consecutive days starting from day 10 post infection fol	2019	Bioorganic & medicinal chemistry, 03-01, Volume: 27, Issue:5	Synthesis and biological evaluation of new long-chain squaramides as anti-chagasic agents in the BALB/c mouse model.
AID677311	Trypanosomicidal activity against Trypanosoma cruzi epimastigotes assessed as change in succinate metabolite excretion after 96 hrs by NMR analysis	2012	Journal of medicinal chemistry, May-10, Volume: 55, Issue:9	In vitro and in vivo trypanosomicidal activity of pyrazole-containing macrocyclic and macrobicyclic polyamines: their action on acute and chronic phases of Chagas disease.
AID1498205	Antitrypanosomal activity against Trypanosoma cruzi MHOM/Pe/2011/Arequipa DTU 5 trypamastigotes infected in Balb/c mouse assessed as reduction in parasitaemia level at 20 mg/kg, po once daily for 5 consecutive days starting from day 10 post infection meas	2018	Journal of medicinal chemistry, 07-12, Volume: 61, Issue:13	Second Generation of Mannich Base-Type Derivatives with in Vivo Activity against Trypanosoma cruzi.
AID1403394	Therapeutic index, ratio of CC50 for African green monkey Vero cells to IC50 for infected Swiss Webster mouse derived bloodstream form of Trypanosoma cruzi Y	2018	European journal of medicinal chemistry, Jan-20, Volume: 144	Efficacy of 2-hydroxy-3-phenylsulfanylmethyl-[1,4]-naphthoquinone derivatives against different Trypanosoma cruzi discrete type units: Identification of a promising hit compound.
AID1624251	Cytotoxicity against human MRC5 cells assessed as reduction in cell viability after 3 days by resazurin dye-based assay	2019	European journal of medicinal chemistry, Feb-15, Volume: 164	Revisiting tubercidin against kinetoplastid parasites: Aromatic substitutions at position 7 improve activity and reduce toxicity.
AID1683681	Toxicity in BALB/c mouse infected with Trypanosomal Trypanosoma cruzi MHOM/Pe/2011/Arequipa(DTU V) assessed as effect on total bilirubin level at 20 mg/kg, po administered for 5 days starting at 9 days post infection and measured after 2 days post treatme	2020	Journal of natural products, 12-24, Volume: 83, Issue:12	In Vivo Biological Evaluation of a Synthetic Royleanone Derivative as a Promising Fast-Acting Trypanocidal Agent by Inducing Mitochondrial-Dependent Necrosis.
AID1687705	Selectivity index, ratio of CC50 African green monkey Vero cells to IC50 for Trypanosoma cruzi trypomastigotes	2020	European journal of medicinal chemistry, Jan-15, Volume: 186	Hit-to-lead optimization of novel 2-alkylaminomethylquinoline derivatives as anti-chagas agents.
AID1633361	Selectivity index, ratio of CC50 for African green monkey Vero cells to IC50 for Trypanosoma cruzi Dm28c trypomastigotes infected in African green monkey Vero cells
AID1669164	Antitrypanosomal activity against Trypanosoma cruzi Y amastigotes infected in rat H9C2 cells after 72 hrs by Hoechst 33342 staining based fluorescence microscopy	2020	ACS medicinal chemistry letters, Jun-11, Volume: 11, Issue:6	Development of Selective Steroid Inhibitors for the Glucose-6-phosphate Dehydrogenase from
AID1615095	Cardiotoxicity in Balb/c mouse infected with Trypanosoma cruzi MHOM/Pe/2011/Arequipa DTU 5 trypomastigotes assessed as change in ratio of creatine kinase in muscle to brain at 20 mg/kg, po once daily for 5 consecutive days starting from day 10 post infect	2019	Bioorganic & medicinal chemistry, 03-01, Volume: 27, Issue:5	Synthesis and biological evaluation of new long-chain squaramides as anti-chagasic agents in the BALB/c mouse model.
AID1070013	Cytotoxicity against mouse NCTC-929 cells at 256 uM after 48 hrs by resazurin staining-based fluorescence assay	2014	Bioorganic & medicinal chemistry letters, Feb-15, Volume: 24, Issue:4	In vitro phenotypic screening of 7-chloro-4-amino(oxy)quinoline derivatives as putative anti-Trypanosoma cruzi agents.
AID1603882	Toxicity in BALB/c mouse infected with Trypanosoma cruzi MHOM/Pe/2011/Arequipa;DTU 5 bloodstream trypomastigote assessed as change in serum alanine aminotransferase level in chronic phase at 20 mg/kg/day, po administered for 5 consecutive days starting fr	2019	Bioorganic & medicinal chemistry, 09-01, Volume: 27, Issue:17	Rational modification of Mannich base-type derivatives as novel antichagasic compounds: Synthesis, in vitro and in vivo evaluation.
AID677212	Trypanosomicidal activity against Trypanosoma cruzi infected in Vero cells assessed as reduction in rate of infection after 10 days by Giemsa staining method	2012	Journal of medicinal chemistry, May-10, Volume: 55, Issue:9	In vitro and in vivo trypanosomicidal activity of pyrazole-containing macrocyclic and macrobicyclic polyamines: their action on acute and chronic phases of Chagas disease.
AID536029	Antitrypanosomal activity against epimastigotes of Trypanosoma cruzi Y assessed as viability at 40 uM after 7 days by trypan blue exclusion assay	2010	Bioorganic & medicinal chemistry, Nov-15, Volume: 18, Issue:22	Studies toward the structural optimization of novel thiazolylhydrazone-based potent antitrypanosomal agents.
AID710878	Antitrypanosomal activity against epimastigotes of Trypanosoma cruzi Y infected in LLC-MK2 cells assessed as parasite motility after 11 days	2012	Journal of medicinal chemistry, Dec-27, Volume: 55, Issue:24	Structural investigation of anti-Trypanosoma cruzi 2-iminothiazolidin-4-ones allows the identification of agents with efficacy in infected mice.
AID1686740	Selectivity index, ratio of IC50 for cytotoxicity in African green monkey Vero cells to IC50 for antitrypanosomal activity against Trypanosoma cruzi Arequipa trypomastigote forms	2016	Journal of medicinal chemistry, 12-22, Volume: 59, Issue:24	In Vitro and in Vivo Anti-Trypanosoma cruzi Activity of New Arylamine Mannich Base-Type Derivatives.
AID576098	Toxicity in human patient infected with Trypanosoma cruzi assessed as occurrence of Nausea at 5 mg/kg/day for 60 days	2010	Antimicrobial agents and chemotherapy, Nov, Volume: 54, Issue:11	Tolerance of benznidazole in treatment of Chagas' disease in adults.
AID1613532	Cardiotoxicity in Balb/c mouse infected with Trypanosoma cruzi MHOM/Pe/2011/Arequipa DTU 5 trypomastigotes assessed as change in ratio of creatine kinase in muscle to brain at 20 mg/kg, po once daily for 5 consecutive days starting from day 10 post infect	2019	European journal of medicinal chemistry, Feb-15, Volume: 164	New polyamine drugs as more effective antichagas agents than benznidazole in both the acute and chronic phases.
AID1603838	Toxicity in BALB/c mouse infected with Trypanosoma cruzi MHOM/Pe/2011/Arequipa;DTU 5 bloodstream trypomastigote assessed as increase in serum aspartate aminotransferase level in acute phase at 20 mg/kg/day, po administered for 5 consecutive days starting	2019	Bioorganic & medicinal chemistry, 09-01, Volume: 27, Issue:17	Rational modification of Mannich base-type derivatives as novel antichagasic compounds: Synthesis, in vitro and in vivo evaluation.
AID576080	Toxicity in human patient infected with Trypanosoma cruzi assessed as occurrence of Urticaria at 5 mg/kg/day for 60 days	2010	Antimicrobial agents and chemotherapy, Nov, Volume: 54, Issue:11	Tolerance of benznidazole in treatment of Chagas' disease in adults.
AID707776	Selectivity index, ratio of IC50 for african green monkey Vero cells to IC50 for Trypanosoma cruzi IRHOD/VO/2008/SN3 blood trypomastigotes	2012	Journal of medicinal chemistry, Nov-26, Volume: 55, Issue:22	Phthalazine derivatives containing imidazole rings behave as Fe-SOD inhibitors and show remarkable anti-T. cruzi activity in immunodeficient-mouse mode of infection.
AID1074381	Antitrypanosomal activity against amastigote stage of Trypanosoma cruzi IRHOD/CO/2008/SN3 infected in African green monkey Vero cells assessed as parasite growth inhibition after 72 hrs by Giemsa staining-based microscopic analysis	2014	Journal of medicinal chemistry, Feb-13, Volume: 57, Issue:3	Synthesis and biological evaluation of N,N'-squaramides with high in vivo efficacy and low toxicity: toward a low-cost drug against Chagas disease.
AID575886	Toxicity in human patient infected with Trypanosoma cruzi assessed as occurrence of arthralgias	2010	Antimicrobial agents and chemotherapy, Nov, Volume: 54, Issue:11	Tolerance of benznidazole in treatment of Chagas' disease in adults.
AID1615027	Selectivity index, ratio of IC50 for African green monkey Vero cells to IC50 for Trypanosoma cruzi IRHOD/CO/2008/SN3 DTU 1 trypomastigotes derived from infected Balb/c mouse	2019	Bioorganic & medicinal chemistry, 03-01, Volume: 27, Issue:5	Synthesis and biological evaluation of new long-chain squaramides as anti-chagasic agents in the BALB/c mouse model.
AID1498188	Selectivity index, ratio of IC50 for African green monkey Vero cells to IC50 for Trypanosoma cruzi TINF/CH/1956/Tulahuen DTU 6 trypamastigotes derived from infected Balb/c albino mouse	2018	Journal of medicinal chemistry, 07-12, Volume: 61, Issue:13	Second Generation of Mannich Base-Type Derivatives with in Vivo Activity against Trypanosoma cruzi.
AID1508574	Antitrypanosomal activity against bloodstream trypomastigote stage of Trypanosoma cruzi Y infected in Balb/c mouse macrophages assessed as reduction in number of intracellular amastigotes at 0.5 uM measured after 3 days by hoeschst staining based confocal	2017	European journal of medicinal chemistry, Dec-01, Volume: 141	Structural design, synthesis and pharmacological evaluation of thiazoles against Trypanosoma cruzi.
AID1739883	Antitrypanosomal activity against Trypanosoma cruzi (MHOM/CH/00/Tulahuen C2, lacZ) amastigotes infected in HFF-1 cells assessed as reduction in parasite growth at 300 uM incubated for 120 hrs by CPRG/Igepal substrate based photometric method relative to c	2020	European journal of medicinal chemistry, Sep-01, Volume: 201	Discovery of highly potent and selective antiparasitic new oxadiazole and hydroxy-oxindole small molecule hybrids.
AID1753504	Toxicity in Swiss webster mouse infected with Trypanosoma cruzi Y trypomastigotes assessed as animal survival at 100 mg/kg, po qd for 5 days treatment started at 6 days post-infection and measured at 34 days post-infection	2021	Journal of medicinal chemistry, 04-08, Volume: 64, Issue:7	Revisiting Pyrazolo[3,4-
AID1507199	Antitrypanosomal activity against Trypanosoma cruzi clone CL B5 amastigotes harboring lacZ infected in mouse NCTC-929 cells after 7 days by beta-galactosidase reporter gene assay	2017	European journal of medicinal chemistry, Aug-18, Volume: 136	Novel Imidazo[4,5-c][1,2,6]thiadiazine 2,2-dioxides as antiproliferative trypanosoma cruzi drugs: Computational screening from neural network, synthesis and in vivo biological properties.
AID1165090	Antiparasitic activity against trypomastigote forms of Trypanosoma cruzi Tulahuen C2C4 infected in rat L6 cells assessed as inhibition of growth after 96 hrs by inverted microscopy	2014	European journal of medicinal chemistry, Nov-24, Volume: 87	Novel nitro(triazole/imidazole)-based heteroarylamides/sulfonamides as potential antitrypanosomal agents.
AID392023	Toxicity against Trypanosoma cruzi Colombiana infected Swiss mouse assessed as mouse survival at 120 mg/kg/day, po after 25 days	2008	European journal of medicinal chemistry, Oct, Volume: 43, Issue:10	In vivo studies of 5-arylethenylbenzofuroxans in acute murine models of Chagas' disease.
AID1603835	Toxicity in BALB/c mouse infected with Trypanosoma cruzi MHOM/Pe/2011/Arequipa;DTU 5 bloodstream trypomastigote assessed as decrease in serum uric acid level in acute phase at 20 mg/kg/day, po administered for 5 consecutive days starting from day 8 post i	2019	Bioorganic & medicinal chemistry, 09-01, Volume: 27, Issue:17	Rational modification of Mannich base-type derivatives as novel antichagasic compounds: Synthesis, in vitro and in vivo evaluation.
AID1543107	Selectivity index, ratio of CC50 for cytotoxicity in mouse NCTC-929 cells to EC50 for Antitrypanosomal activity against Trypanosoma cruzi trypomastigotes infected in LLC-MK2-ATCC CCL7 cells	2019	Bioorganic & medicinal chemistry letters, 06-15, Volume: 29, Issue:12	Structure-activity relationship study of antitrypanosomal chalcone derivatives using multivariate analysis.
AID1740563	Cytotoxicity against human THP-1 cells assessed as reduction in cell viability after 72 hrs by MTT assay	2020	European journal of medicinal chemistry, Sep-15, Volume: 202	8-Alkynyl-3-nitroimidazopyridines display potent antitrypanosomal activity against both T. b. brucei and cruzi.
AID1498180	Trypanocidal activity against Trypanosoma cruzi IRHOD/CO/2008/SN3 DTU 1 trypamastigotes derived from infected Balb/c albino mouse after 24 hrs by resazurin dye based assay	2018	Journal of medicinal chemistry, 07-12, Volume: 61, Issue:13	Second Generation of Mannich Base-Type Derivatives with in Vivo Activity against Trypanosoma cruzi.
AID1503433	Selectivity index, ratio of LC50 for cytotoxicity in human U937 cells to EC50 for antitrypanosomal activity against Trypanosoma cruzi Tulahuen intracellular amastigotes transfected with beta-galactosidase infected in human U937 cells	2017	European journal of medicinal chemistry, Dec-01, Volume: 141	Triclosan-caffeic acid hybrids: Synthesis, leishmanicidal, trypanocidal and cytotoxic activities.
AID1518996	Antitrypanosomal activity against Trypanosoma cruzi K98 bloodstream form infected in C3H/HeNk mouse assessed as change in QRS morphology at 30 mg/kg/day, po administered via gavage for 30 consecutive days starting from 90 days post infection and measured	2019	European journal of medicinal chemistry, 12-15, Volume: 184	Combined therapy with Benznidazole and repurposed drugs Clofazimine and Benidipine for chronic Chagas disease.
AID1254025	Antiparasitic activity against amastigote form of Trypanosoma cruzi Y strain infected in bone marrow macrophage cells assessed as amastigote viability incubated for 4 days by rapid panoptic stain based microscopy method	2015	Bioorganic & medicinal chemistry, Nov-01, Volume: 23, Issue:21	1,2,3-Triazole-based analogue of benznidazole displays remarkable activity against Trypanosoma cruzi.
AID1603739	Genotoxicity in Salmonella typhimurium TA1535 harboring pSK1002 assessed as umu gene induction in absence of Sprague-Dawley rat liver S9 fraction metabolic activation by SOS/umu assay	2019	Bioorganic & medicinal chemistry, 09-01, Volume: 27, Issue:17	Rational modification of Mannich base-type derivatives as novel antichagasic compounds: Synthesis, in vitro and in vivo evaluation.
AID1603767	Selectivity index, ratio of IC50 for African green monkey Vero cells to IC50 for Trypanosoma cruzi MHOM/Pe/2011/Arequipa; DTU 5 amastigote forms	2019	Bioorganic & medicinal chemistry, 09-01, Volume: 27, Issue:17	Rational modification of Mannich base-type derivatives as novel antichagasic compounds: Synthesis, in vitro and in vivo evaluation.
AID1375932	Parasiticidal activity against amastigote stage of Trypanosoma cruzi Tulahuen infected in mouse brain fibroblast assessed as time duration of effect at 9.6 microM preincubated for 5 days followed by another 10 days incubation with fresh compound	2018	Journal of medicinal chemistry, 06-14, Volume: 61, Issue:11	NMR Biochemical Assay for Oxidosqualene Cyclase: Evaluation of Inhibitor Activities on Trypanosoma cruzi and Human Enzymes.
AID343557	Antitrypanosomal activity against epimastigotes of Trypanosoma cruzi Tulahuen 2	2008	Bioorganic & medicinal chemistry, Jul-15, Volume: 16, Issue:14	New trypanocidal hybrid compounds from the association of hydrazone moieties and benzofuroxan heterocycle.
AID1228663	Antitrypanosomal activity against trypomastigote stage of Trypanosoma cruzi Y assessed as inhibition of cell viability after 24 hrs by MTT assay	2015	Journal of natural products, May-22, Volume: 78, Issue:5	Anti-parasitic Guanidine and Pyrimidine Alkaloids from the Marine Sponge Monanchora arbuscula.
AID1615119	Hepatotoxicity in Balb/c mouse infected with Trypanosoma cruzi MHOM/Pe/2011/Arequipa DTU 5 trypomastigotes assessed as increase in total bilirubin level at 20 mg/kg, po once daily for 5 consecutive days starting from day 10 post infection measured on day	2019	Bioorganic & medicinal chemistry, 03-01, Volume: 27, Issue:5	Synthesis and biological evaluation of new long-chain squaramides as anti-chagasic agents in the BALB/c mouse model.
AID252103	In vivo percent inhibition of compound at a dose of 45 mg/kg, p.o., for 5 doses in rodent model with Trypanosoma brucei brucei STIB 795 strain [ND = not determined]	2005	Journal of medicinal chemistry, Aug-25, Volume: 48, Issue:17	Design and synthesis of a series of melamine-based nitroheterocycles with activity against Trypanosomatid parasites.
AID564734	Antitrypanosomal activity against Trypanosoma cruzi MS1523 epimastigotes after 24 hrs by light microscopy	2010	Antimicrobial agents and chemotherapy, Jul, Volume: 54, Issue:7	Arylimidamide DB766, a potential chemotherapeutic candidate for Chagas' disease treatment.
AID1603827	Antitrypanosomal activity against Trypanosoma cruzi MHOM/Pe/2011/Arequipa;DTU 5 bloodstream trypomastigote infected in BALB/c mouse assessed as parasite-free muscle in chronic phase at 20 mg/kg/day, po administered for 5 consecutive days starting from day	2019	Bioorganic & medicinal chemistry, 09-01, Volume: 27, Issue:17	Rational modification of Mannich base-type derivatives as novel antichagasic compounds: Synthesis, in vitro and in vivo evaluation.
AID392018	Antitrypanosomal activity against Trypanosoma cruzi Tulahuen 2 infected Swiss mouse assessed as prevention of liver congestion at 200 mg/kg/day, po	2008	European journal of medicinal chemistry, Oct, Volume: 43, Issue:10	In vivo studies of 5-arylethenylbenzofuroxans in acute murine models of Chagas' disease.
AID1615057	Antitrypanosomal activity against Trypanosoma cruzi MHOM/Pe/2011/Arequipa DTU 5 trypomastigotes infected in Balb/c mouse assessed as reduction in Ig-G level in serum at 20 mg/kg, po once daily for 5 consecutive days starting from day 10 post infection mea	2019	Bioorganic & medicinal chemistry, 03-01, Volume: 27, Issue:5	Synthesis and biological evaluation of new long-chain squaramides as anti-chagasic agents in the BALB/c mouse model.
AID597246	Antitrypanosomal activity against Trypanosoma cruzi Y infected in Swiss albino mouse assessed as reduction of microbial antibody level at 50 mg/kg/day, po by Wilconxon test	2011	Journal of medicinal chemistry, May-26, Volume: 54, Issue:10	3-Trifluoromethylquinoxaline N,N'-dioxides as anti-trypanosomatid agents. Identification of optimal anti-T. cruzi agents and mechanism of action studies.
AID1683687	Toxicity in BALB/c mouse infected with Trypanosomal Trypanosoma cruzi MHOM/Pe/2011/Arequipa(DTU V) assessed as effect on urea level at 20 mg/kg, po administered for 5 days starting at 9 days post infection and measured after 2 days post treatment	2020	Journal of natural products, 12-24, Volume: 83, Issue:12	In Vivo Biological Evaluation of a Synthetic Royleanone Derivative as a Promising Fast-Acting Trypanocidal Agent by Inducing Mitochondrial-Dependent Necrosis.
AID1578095	Antitrypanosomal activity against Trypanosoma cruzi after 48 hrs by [3H]-hypoxanthine incorporation assay	2019	Bioorganic & medicinal chemistry letters, 10-15, Volume: 29, Issue:20	Antiprotozoal alkaloid principles of the plant family Amaryllidaceae.
AID563559	Antitrypanosomal activity against Trypanosoma cruzi Y infected in Swiss-Webster mouse assessed as decrease in parasite-induced weight loss at 100 mg/kg/day, ip administered 5 days post-infection for 10 consecutive days measured on day 120	2010	Antimicrobial agents and chemotherapy, Jul, Volume: 54, Issue:7	Arylimidamide DB766, a potential chemotherapeutic candidate for Chagas' disease treatment.
AID564767	Hepatotoxicity in Swiss-Webster mouse assessed as increased GPT level at 100 mg/kg/day, ip administered 21 days postinfection measured on day 120	2010	Antimicrobial agents and chemotherapy, Jul, Volume: 54, Issue:7	Arylimidamide DB766, a potential chemotherapeutic candidate for Chagas' disease treatment.
AID1603766	Trypanocidal activity against Trypanosoma cruzi trypomastigote form infected in African green monkey Vero cells assessed as ratio of infected cells at 25 uM measured after 72 hrs by Giemsa staining based assay relative to control	2019	Bioorganic & medicinal chemistry, 09-01, Volume: 27, Issue:17	Rational modification of Mannich base-type derivatives as novel antichagasic compounds: Synthesis, in vitro and in vivo evaluation.
AID1811312	Selectivity index, ratio of CC50 for mouse J774.2 cells to IC50 for Trypanosoma cruzi ITRI/MX/2018/TH	2021	Bioorganic & medicinal chemistry, 10-15, Volume: 48	In vitro, ex vivo and in vivo short-term screening of DHEA nitrate derivatives activity over Trypanosoma cruzi Ninoa and TH strains from Oaxaca State, México.
AID677205	Trypanosomicidal activity against Trypanosoma cruzi SN3 epimastigote after 72 hrs by hemocytometric analysis	2012	Journal of medicinal chemistry, May-10, Volume: 55, Issue:9	In vitro and in vivo trypanosomicidal activity of pyrazole-containing macrocyclic and macrobicyclic polyamines: their action on acute and chronic phases of Chagas disease.
AID1851974	Antitrypanosomal activity against Trypanosoma cruzi Tulahuen amastigotes infected in mouse 3T3 cells assessed as reduction in parasite growth at Emax concentration incubated for 48 hrs by Hoechst 3348 staining based analysis	2022	Journal of medicinal chemistry, 10-13, Volume: 65, Issue:19	Nitroimidazopyrazinones with Oral Activity against Tuberculosis and Chagas Disease in Mouse Models of Infection.
AID1603743	Antitrypanosomal activity against Trypanosoma cruzi MHOM/Pe/2011/Arequipa;DTU 5 bloodstream trypomastigote infected in BALB/c mouse assessed as parasitemia reactivation in chronic phase at 20 mg/kg/day, po administered for 5 consecutive days starting from	2019	Bioorganic & medicinal chemistry, 09-01, Volume: 27, Issue:17	Rational modification of Mannich base-type derivatives as novel antichagasic compounds: Synthesis, in vitro and in vivo evaluation.
AID548280	Antimicrobial activity against Trypanosoma brucei	2010	Antimicrobial agents and chemotherapy, Jul, Volume: 54, Issue:7	Cross-resistance to nitro drugs and implications for treatment of human African trypanosomiasis.
AID1536892	Antitrypanosomal activity against beta-galactosidase expressing nifurtimox-sensitive Trypanosoma cruzi Tulahuen CL2 infected in human MRC5 SV2 cells assessed as reduction in parasite burden after 168 hrs by CPRG and Nonidet based spectrophotometric analys	2019	Bioorganic & medicinal chemistry, 02-15, Volume: 27, Issue:4	Synthesis and antimicrobial activities of N
AID726227	Antitrypanosomal activity against Trypanosoma cruzi Y epimastigotes at 64 uM incubated for 48 hrs by resazurin dye reduction based ELISA method	2013	Journal of medicinal chemistry, Feb-28, Volume: 56, Issue:4	Cloning, characterization, and sulfonamide and thiol inhibition studies of an α-carbonic anhydrase from Trypanosoma cruzi, the causative agent of Chagas disease.
AID1697062	Selectivity index, ratio of CC50 for mouse peritoneal macrophages to IC50 for Trypanosoma cruzi amastigotes infected in BALB/c mouse peritoneal macrophages	2020	Journal of natural products, 09-25, Volume: 83, Issue:9	Production of Highly Active Antiparasitic Compounds from the Controlled Halogenation of the
AID1403389	Cytotoxicity activity against Swiss Webster mouse primary hepatocytes assessed as reduction in cell viability after 72 hrs by cell-titer-glo assay	2018	European journal of medicinal chemistry, Jan-20, Volume: 144	Efficacy of 2-hydroxy-3-phenylsulfanylmethyl-[1,4]-naphthoquinone derivatives against different Trypanosoma cruzi discrete type units: Identification of a promising hit compound.
AID576835	Antitrypanosomal activity against trypomastigote of Trypanosoma cruzi infected in BALB/c mouse assessed as increase of host survival at 1 mg/kg, ip for 5 days administered 7 days after infection	2011	Journal of medicinal chemistry, Feb-24, Volume: 54, Issue:4	In vivo trypanosomicidal activity of imidazole- or pyrazole-based benzo[g]phthalazine derivatives against acute and chronic phases of Chagas disease.
AID1615050	Antitrypanosomal activity against Trypanosoma cruzi MHOM/Pe/2011/Arequipa DTU 5 trypomastigotes infected in Balb/c mouse assessed as parasite-free brain at 20 mg/kg, po pretreated once daily for 5 consecutive days starting from day 75 post infection follo	2019	Bioorganic & medicinal chemistry, 03-01, Volume: 27, Issue:5	Synthesis and biological evaluation of new long-chain squaramides as anti-chagasic agents in the BALB/c mouse model.
AID344438	Antitrypanosomal activity against Trypanosoma cruzi Y infected in Swiss mouse assessed as decrease in parasitemia at 385 umol/kg, po after 15 consecutive days	2008	Journal of medicinal chemistry, Jul-24, Volume: 51, Issue:14	Complexation of the anti-Trypanosoma cruzi drug benznidazole improves solubility and efficacy.
AID580668	Antitrypanosomal activity against Trypanosoma cruzi Y infected in CD4+ T-lymphocyte knockout C57BL/6 mouse assessed as reactivation of parasite in mouse at 100 mg/kg/day, po administered once daily for 20 consecutive days measured 60 days post infection	2009	Antimicrobial agents and chemotherapy, Jan, Volume: 53, Issue:1	Absence of CD4+ T lymphocytes, CD8+ T lymphocytes, or B lymphocytes has different effects on the efficacy of posaconazole and benznidazole in treatment of experimental acute Trypanosoma cruzi infection.
AID1329380	Selectivity index, ratio of CC50 for mouse NCTC-929 cells to IC50 for Leishmania infantum MHOM/BR/1972/LD amastigote forms infected in BALB/c mouse macrophages	2016	Journal of natural products, 09-23, Volume: 79, Issue:9	Analogues of Marine Guanidine Alkaloids Are in Vitro Effective against Trypanosoma cruzi and Selectively Eliminate Leishmania (L.) infantum Intracellular Amastigotes.
AID753407	Trypanocidal activity against Trypanosoma cruzi H510 trypomastigotes infected in human HeLa cells at 37 degC after 18 hrs by resazurin assay	2013	Bioorganic & medicinal chemistry letters, Jun-15, Volume: 23, Issue:12	Aromatic glycosyl disulfide derivatives: evaluation of their inhibitory activities against Trypanosoma cruzi.
AID1615044	Antitrypanosomal activity against Trypanosoma cruzi MHOM/Pe/2011/Arequipa DTU 5 trypomastigotes infected in Balb/c mouse assessed as parasite-free lungs at 20 mg/kg, po pretreated once daily for 5 consecutive days starting from day 10 post infection follo	2019	Bioorganic & medicinal chemistry, 03-01, Volume: 27, Issue:5	Synthesis and biological evaluation of new long-chain squaramides as anti-chagasic agents in the BALB/c mouse model.
AID1070015	Antimicrobial activity against epimastigote stage of Trypanosoma cruzi CL Brener assessed as growth inhibition at 256 uM after 72 hrs by beta-galactosidase reporter gene assay	2014	Bioorganic & medicinal chemistry letters, Feb-15, Volume: 24, Issue:4	In vitro phenotypic screening of 7-chloro-4-amino(oxy)quinoline derivatives as putative anti-Trypanosoma cruzi agents.
AID1603816	Genotoxicity in Salmonella typhimurium TA1535 harboring pSK1002 assessed as survival in absence of Sprague-Dawley rat liver S9 fraction metabolic activation by SOS/umu assay	2019	Bioorganic & medicinal chemistry, 09-01, Volume: 27, Issue:17	Rational modification of Mannich base-type derivatives as novel antichagasic compounds: Synthesis, in vitro and in vivo evaluation.
AID714975	Antitrypanosomal activity against bloodstream trypomastigote form of Trypanosoma cruzi NINOA isolated from infected mouse at the peak of parasitemia assessed as reduction in parasite motility at 5 to 50 ug/ml after 24 hrs	2012	Bioorganic & medicinal chemistry, Apr-15, Volume: 20, Issue:8	Identification of benzoylisoquinolines as potential anti-Chagas agents.
AID1686745	Selectivity index, ratio of IC50 for cytotoxicity in African green monkey Vero cells to IC50 for antitrypanosomal activity against Trypanosoma cruzi NS3 amastigote forms	2016	Journal of medicinal chemistry, 12-22, Volume: 59, Issue:24	In Vitro and in Vivo Anti-Trypanosoma cruzi Activity of New Arylamine Mannich Base-Type Derivatives.
AID1613478	Selectivity index, ratio of IC50 for African green monkey Vero cells to IC50 for Trypanosoma cruzi MHOM/Pe/2011/Arequipa DTU 5 trypomastigotes derived from infected Balb/c albino mouse	2019	European journal of medicinal chemistry, Feb-15, Volume: 164	New polyamine drugs as more effective antichagas agents than benznidazole in both the acute and chronic phases.
AID1613496	Antitrypanosomal activity against Trypanosoma cruzi MHOM/Pe/2011/Arequipa DTU 5 trypomastigotes infected in Balb/c mouse assessed as parasite-free bone marrow at 20 mg/kg, po pretreated once daily for 5 consecutive days starting from day 75 post infection	2019	European journal of medicinal chemistry, Feb-15, Volume: 164	New polyamine drugs as more effective antichagas agents than benznidazole in both the acute and chronic phases.
AID337141	Antitrypanosomal activity against Trypanosoma cruzi C8 CL1 after 48 hrs
AID693344	Growth inhibition of epimastigote form of Trypanosoma cruzi CL-B5 at 64 uM after 72 hrs by lacZ reporter gene assay	2012	European journal of medicinal chemistry, Dec, Volume: 58	Synthesis, biological evaluation and chemometric analysis of indazole derivatives. 1,2-Disubstituted 5-nitroindazolinones, new prototypes of antichagasic drug.
AID1613471	Trypanocidal activity against Trypanosoma cruzi IRHOD/CO/2008/SN3 DTU 1 trypomastigotes derived from infected Balb/c albino mouse after 24 hrs by resazurin dye based assay	2019	European journal of medicinal chemistry, Feb-15, Volume: 164	New polyamine drugs as more effective antichagas agents than benznidazole in both the acute and chronic phases.
AID1615020	Trypanocidal activity against Trypanosoma cruzi TINF/CH/1956/Tulahuen DTU 6 trypomastigotes derived from infected Balb/c mouse after 72 hrs by resazurin dye based assay	2019	Bioorganic & medicinal chemistry, 03-01, Volume: 27, Issue:5	Synthesis and biological evaluation of new long-chain squaramides as anti-chagasic agents in the BALB/c mouse model.
AID1383423	Antitrypanosomal activity against Trypanosoma cruzi Tulahuen trypomastigote forms infected in mouse L929 cells assessed as reduction in parasite load after 96 hrs by beta-galactosidase reporter gene assay	2018	European journal of medicinal chemistry, Apr-10, Volume: 149	Identification of Pyrazolo[3,4-e][1,4]thiazepin based CYP51 inhibitors as potential Chagas disease therapeutic alternative: In vitro and in vivo evaluation, binding mode prediction and SAR exploration.
AID1613527	Nephrotoxicity in Balb/c mouse infected with Trypanosoma cruzi MHOM/Pe/2011/Arequipa DTU 5 trypomastigotes assessed as decrease in serum uric acid level at 20 mg/kg, po once daily for 5 consecutive days starting from day 10 post infection measured on day	2019	European journal of medicinal chemistry, Feb-15, Volume: 164	New polyamine drugs as more effective antichagas agents than benznidazole in both the acute and chronic phases.
AID396581	Antitrypanosomal activity against Trypanosoma cruzi CL Brener epimastigotes	2008	European journal of medicinal chemistry, Aug, Volume: 43, Issue:8	Pyrimido[1,2-a]quinoxaline 6-oxide and phenazine 5,10-dioxide derivatives and related compounds as growth inhibitors of Trypanosoma cruzi.
AID1454628	Antitrypanosomal activity against bioluminescent PpyRE9h expressing Trypanosoma cruzi Tulahuen tryptomastigotes infected subcutaneously in BALB/c mouse assessed as suppression of Trypanosoma cruzi infection at 100 mg/kg, po qd administered for 5 days meas	2017	ACS medicinal chemistry letters, Jul-13, Volume: 8, Issue:7	New Class of Antitrypanosomal Agents Based on Imidazopyridines.
AID576101	Toxicity in human patient infected with Trypanosoma cruzi assessed as occurrence of Heartburn at 5 mg/kg/day for 60 days	2010	Antimicrobial agents and chemotherapy, Nov, Volume: 54, Issue:11	Tolerance of benznidazole in treatment of Chagas' disease in adults.
AID324607	Effect on oxygen uptake per mg of protein in Trypanosoma cruzi Tulahuen epimastigotes relative to control	2008	Bioorganic & medicinal chemistry, Jan-15, Volume: 16, Issue:2	Trypanosoma cruzi: activities of lapachol and alpha- and beta-lapachone derivatives against epimastigote and trypomastigote forms.
AID324608	Effect on oxygen redox cycling in Trypanosoma cruzi Tulahuen assessed as oxygen consumption per mg of protein relative to control	2008	Bioorganic & medicinal chemistry, Jan-15, Volume: 16, Issue:2	Trypanosoma cruzi: activities of lapachol and alpha- and beta-lapachone derivatives against epimastigote and trypomastigote forms.
AID1517431	Antitrypanosomal activity against intracellular amastigote stage of Trypanosoma cruzi CL Brener infected in human U2OS cells measured after 96 hrs by DRAQ5 dye based microscopic analysis	2019	European journal of medicinal chemistry, Dec-01, Volume: 183	Discovery of a benzothiophene-flavonol halting miltefosine and antimonial drug resistance in Leishmania parasites through the application of medicinal chemistry, screening and genomics.
AID1613570	Hepatotoxicity in Balb/c mouse infected with Trypanosoma cruzi MHOM/Pe/2011/Arequipa DTU 5 trypomastigotes assessed as increase in alkaline phosphatase level at 20 mg/kg, po once daily for 5 consecutive days starting from day 75 post infection measured on	2019	European journal of medicinal chemistry, Feb-15, Volume: 164	New polyamine drugs as more effective antichagas agents than benznidazole in both the acute and chronic phases.
AID1507435	Antitrypanosomal activity against bloodstream forms of Trypanosoma cruzi Y isolated from parasite infected Albino Swiss mouse assessed as induction of parasite lysis incubated for 24 hrs by Neubauer chamber based cell counting method	2017	European journal of medicinal chemistry, Aug-18, Volume: 136	Rhodium-catalyzed C-H bond activation for the synthesis of quinonoid compounds: Significant Anti-Trypanosoma cruzi activities and electrochemical studies of functionalized quinones.
AID1615039	Antitrypanosomal activity against Trypanosoma cruzi MHOM/Pe/2011/Arequipa DTU 5 trypomastigotes infected in Balb/c mouse assessed as parasite-free adipose tissue at 20 mg/kg, po pretreated once daily for 5 consecutive days starting from day 10 post infect	2019	Bioorganic & medicinal chemistry, 03-01, Volume: 27, Issue:5	Synthesis and biological evaluation of new long-chain squaramides as anti-chagasic agents in the BALB/c mouse model.
AID1079944	Benign tumor, proven histopathologically. Value is number of references indexed. [column 'T.BEN' in source]
AID1351071	Antitrypanosomal activity Trypanosoma cruzi Bug 2149 cl10 Tc5 epimastigotes measured after 72 hrs	2018	European journal of medicinal chemistry, Jan-20, Volume: 144	Investigating the structure-activity relationships of N'-[(5-nitrofuran-2-yl) methylene] substituted hydrazides against Trypanosoma cruzi to design novel active compounds.
AID1244578	Antitrypanosomal activity against amastigote and trypomastigote forms of Trypanosoma cruzi Tulahuen expressing beta-galactosidase gene infected in mouse L-929 cells assessed as inhibition of parasite growth after 7 days by colorimetric betagalactosidase a	2015	European journal of medicinal chemistry, Aug-28, Volume: 101	Synthesis and structure-activity relationship study of a new series of antiparasitic aryloxyl thiosemicarbazones inhibiting Trypanosoma cruzi cruzain.
AID1277886	Antitrypanosomal activity against Trypanosoma cruzi Tulahuen amastigotes infected in mouse C3H cells after 72 hrs by microplate reader analysis	2016	Bioorganic & medicinal chemistry letters, Feb-15, Volume: 26, Issue:4	Semisynthesis of new aphidicolin derivatives with high activity against Trypanosoma cruzi.
AID1264450	Selectivity index, ratio of IC50 for rat L6 cells to IC50 for epimastigote stage of Trypanosoma cruzi MHOM/ES/2203/BCN590	2015	European journal of medicinal chemistry, Nov-13, Volume: 105	Multicomponent reaction-based synthesis and biological evaluation of tricyclic heterofused quinolines with multi-trypanosomatid activity.
AID1587053	Antitrypanosomal activity against Trypanosoma cruzi Tulahuen amastigotes infected in mouse 3T3 cells assessed as relapse time at 25 times EC50 supplemented with fresh medium containing compound every 4 days for 16 days followed by compound washout and mea	2019	ACS medicinal chemistry letters, Jan-10, Volume: 10, Issue:1	Triazolopyrimidines and Imidazopyridines: Structure-Activity Relationships and in Vivo Efficacy for Trypanosomiasis.
AID404373	Antitrypanosomal activity against Trypanosoma cruzi Tulahuen C2C4	2008	Journal of medicinal chemistry, Jun-26, Volume: 51, Issue:12	Synthesis and in vitro antiprotozoal activities of water-soluble, inexpensive 3,7-bis(dialkylamino)phenoxazin-5-ium derivatives.
AID707782	Antitrypanosomal activity against Trypanosoma cruzi IRHOD/VO/2008/SN3 intracellular amastigotes infected in african green monkey Vero cells incubated for 72 hrs	2012	Journal of medicinal chemistry, Nov-26, Volume: 55, Issue:22	Phthalazine derivatives containing imidazole rings behave as Fe-SOD inhibitors and show remarkable anti-T. cruzi activity in immunodeficient-mouse mode of infection.
AID564733	Antitrypanosomal activity against Trypanosoma cruzi 960 epimastigotes after 24 hrs by light microscopy	2010	Antimicrobial agents and chemotherapy, Jul, Volume: 54, Issue:7	Arylimidamide DB766, a potential chemotherapeutic candidate for Chagas' disease treatment.
AID1615051	Antitrypanosomal activity against Trypanosoma cruzi MHOM/Pe/2011/Arequipa DTU 5 trypomastigotes infected in Balb/c mouse assessed as parasite-free oesophagus at 20 mg/kg, po pretreated once daily for 5 consecutive days starting from day 75 post infection	2019	Bioorganic & medicinal chemistry, 03-01, Volume: 27, Issue:5	Synthesis and biological evaluation of new long-chain squaramides as anti-chagasic agents in the BALB/c mouse model.
AID1498193	Genotoxicity in Salmonella typhimurium TA1535 harboring pSK1002 up to 0.5 mg/ml by SOS/umu assay	2018	Journal of medicinal chemistry, 07-12, Volume: 61, Issue:13	Second Generation of Mannich Base-Type Derivatives with in Vivo Activity against Trypanosoma cruzi.
AID1615129	Hepatotoxicity in Balb/c mouse infected with Trypanosoma cruzi MHOM/Pe/2011/Arequipa DTU 5 trypomastigotes assessed as increase in alkaline phosphatase level at 20 mg/kg, po once daily for 5 consecutive days starting from day 75 post infection measured on	2019	Bioorganic & medicinal chemistry, 03-01, Volume: 27, Issue:5	Synthesis and biological evaluation of new long-chain squaramides as anti-chagasic agents in the BALB/c mouse model.
AID1174782	Selectivity index, ratio of IC50 for african green monkey Vero cells to IC50 for intracellular amastigote form of Trypanosoma cruzi IRHOD/CO/2008/SN3	2015	European journal of medicinal chemistry, Jan-07, Volume: 89	Prospects of an alternative treatment against Trypanosoma cruzi based on abietic acid derivatives show promising results in Balb/c mouse model.
AID1849823	Antitrypanosomal activity against bloodstream form of Trypanosoma cruzi Y trypomastigotes infected in Swiss Webster mouse assessed as reduction in viable parasite in blood incubated for 24 hrs by Neubauer counting chamber based light microscopic analysis	2021	European journal of medicinal chemistry, Jan-15, Volume: 210	A comprehensive review on β-lapachone: Mechanisms, structural modifications, and therapeutic potentials.
AID1140922	Antitrypanosomal activity against Trypanosoma cruzi Tulahuen 2 epimastigotes assessed as growth inhibition after 5 days	2014	Journal of medicinal chemistry, May-22, Volume: 57, Issue:10	Optimization of antitrypanosomatid agents: identification of nonmutagenic drug candidates with in vivo activity.
AID287513	Inhibition of Trypanosoma cruzi Maracay epimastigotes after 72 hrs	2007	Bioorganic & medicinal chemistry, Mar-01, Volume: 15, Issue:5	1,4-Bis(alkylamino)benzo[g]phthalazines able to form dinuclear complexes of Cu(II) which as free ligands behave as SOD inhibitors and show efficient in vitro activity against Trypanosoma cruzi.
AID1615036	Antitrypanosomal activity against Trypanosoma cruzi MHOM/Pe/2011/Arequipa DTU 5 trypomastigotes infected in Balb/c mouse assessed as reduction in parasitaemia level at 20 mg/kg, po once daily for 5 consecutive days starting from day 10 post infection meas	2019	Bioorganic & medicinal chemistry, 03-01, Volume: 27, Issue:5	Synthesis and biological evaluation of new long-chain squaramides as anti-chagasic agents in the BALB/c mouse model.
AID1154400	Cytotoxicity against BALB/c mouse peritoneal macrophages after 72 hrs by AlamarBlue assay	2014	Journal of natural products, Jun-27, Volume: 77, Issue:6	Dimeric flavonoids from Arrabidaea brachypoda and assessment of their anti-Trypanosoma cruzi activity.
AID1613572	Hepatotoxicity in Balb/c mouse infected with Trypanosoma cruzi MHOM/Pe/2011/Arequipa DTU 5 trypomastigotes assessed as increase in alkaline phosphatase level at 20 mg/kg, po once daily for 5 consecutive days starting from day 75 post infection measured on	2019	European journal of medicinal chemistry, Feb-15, Volume: 164	New polyamine drugs as more effective antichagas agents than benznidazole in both the acute and chronic phases.
AID1683712	Antitrypanosomal activity against Trypanosoma cruzi TINF/CH/1956/Tulahuen (DTU VI) amastigote form infected in Vero cells assessed as parasite growth inhibition incubated for 72 hrs by Giemsa-staining based assay	2020	Journal of natural products, 12-24, Volume: 83, Issue:12	In Vivo Biological Evaluation of a Synthetic Royleanone Derivative as a Promising Fast-Acting Trypanocidal Agent by Inducing Mitochondrial-Dependent Necrosis.
AID1275380	Antitrypanosomal activity against epimastigote stage of Trypanosoma cruzi Dm28c after 72 hrs by resazurin dye based microplate reader analysis	2016	European journal of medicinal chemistry, Feb-15, Volume: 109	New approach towards the synthesis of selenosemicarbazones, useful compounds for Chagas' disease.
AID1383431	Cytotoxicity against Swiss Webster mouse cardiac cells assessed as reduction in cell viability after 24 hrs by light microscopic analysis	2018	European journal of medicinal chemistry, Apr-10, Volume: 149	Identification of Pyrazolo[3,4-e][1,4]thiazepin based CYP51 inhibitors as potential Chagas disease therapeutic alternative: In vitro and in vivo evaluation, binding mode prediction and SAR exploration.
AID1361012	Antiparasitic activity against trypomastigote form of Trypanosoma cruzi assessed as parasite lysis after 24 hrs by Pizzi-Brener method	2018	European journal of medicinal chemistry, Jul-15, Volume: 155	Symmetrical and unsymmetrical substituted 2,5-diarylidene cyclohexanones as anti-parasitic compounds.
AID1879401	Antitrypanosomal activity against Trypanosoma cruzi Y strain infected in acute CD Swiss Webster mouse model assessed as reduction in parasitemia at 100 mg/kg, po qd for 5 consecutive days by light microscopy relative to control	2022	European journal of medicinal chemistry, Mar-05, Volume: 231	N
AID547277	Antitrypanosomal activity against Trypanosoma cruzi Y infected in mongrel dog assessed as reduction in INFgamma production in right atrium at 12 mg/kg, po BID after 180 days by semiquantitative RT-PCR	2010	Antimicrobial agents and chemotherapy, Jul, Volume: 54, Issue:7	Effects of ravuconazole treatment on parasite load and immune response in dogs experimentally infected with Trypanosoma cruzi.
AID1498235	Antitrypanosomal activity against Trypanosoma cruzi MHOM/Pe/2011/Arequipa DTU 5 trypamastigotes infected in Balb/c mouse assessed as reduction in parasitaemia reactivation in spleen tissue at 20 mg/kg, po pretreated once daily for 5 consecutive days start	2018	Journal of medicinal chemistry, 07-12, Volume: 61, Issue:13	Second Generation of Mannich Base-Type Derivatives with in Vivo Activity against Trypanosoma cruzi.
AID656217	Cytotoxicity against african green monkey Vero cells at 6.25 uM after 3 days	2012	Bioorganic & medicinal chemistry letters, Apr-15, Volume: 22, Issue:8	Phosphonium lipocations as antiparasitic agents.
AID1498298	Cardiotoxicity in Balb/c mouse infected with Trypanosoma cruzi MHOM/Pe/2011/Arequipa DTU 5 trypamastigotes assessed as change in serum LDH level at 20 mg/kg, po once daily for 5 consecutive days starting from day 10 post infection measured on day 127 post	2018	Journal of medicinal chemistry, 07-12, Volume: 61, Issue:13	Second Generation of Mannich Base-Type Derivatives with in Vivo Activity against Trypanosoma cruzi.
AID1074921	Antitrypanosomal activity against Trypanosoma cruzi (IRHOD/CO/2008/SN3) infected in BALB/c mouse assessed as reduction in parasitemia at 1 mg/kg/day, ip treated from day 5 to day 10 post-infection measured on day 30 post-infection relative to control	2014	European journal of medicinal chemistry, Mar-03, Volume: 74	New perspectives on the synthesis and antichagasic activity of 3-alkoxy-1-alkyl-5-nitroindazoles.
AID1074373	Trypanocidal activity against metacyclic trypomastigote stage of Trypanosoma cruzi infected in BALB/c albino mouse acute chagas disease model assessed as reduction of parasite burden at 25 mg/kg, ip administered on day 7 to 12 post-infection measured on d	2014	Journal of medicinal chemistry, Feb-13, Volume: 57, Issue:3	Synthesis and biological evaluation of N,N'-squaramides with high in vivo efficacy and low toxicity: toward a low-cost drug against Chagas disease.
AID576107	Toxicity in human patient infected with Trypanosoma cruzi assessed as occurrence of degree 1 esophagopathy at 5 mg/kg/day for 60 days	2010	Antimicrobial agents and chemotherapy, Nov, Volume: 54, Issue:11	Tolerance of benznidazole in treatment of Chagas' disease in adults.
AID1070008	Antimicrobial activity against amastigote stage of Trypanosoma cruzi CL Brener infected in mouse NCTC-929 cells assessed as growth inhibition at 8 uM after 7 days by beta-galactosidase reporter gene assay	2014	Bioorganic & medicinal chemistry letters, Feb-15, Volume: 24, Issue:4	In vitro phenotypic screening of 7-chloro-4-amino(oxy)quinoline derivatives as putative anti-Trypanosoma cruzi agents.
AID344424	Antitrypanosomal activity against bloodstream trypomastigote of Trypanosoma cruzi Y assessed as number of motile forms after 1 hr by hemocytometer	2008	Journal of medicinal chemistry, Jul-24, Volume: 51, Issue:14	Complexation of the anti-Trypanosoma cruzi drug benznidazole improves solubility and efficacy.
AID1486932	Antiprotozoal activity against Giardia intestinalis IMSS:0696:1 (genotype A) trophozoites incubated for 48 hrs	2017	Bioorganic & medicinal chemistry letters, 08-01, Volume: 27, Issue:15	Synthesis, in vitro and in vivo giardicidal activity of nitrothiazole-NSAID chimeras displaying broad antiprotozoal spectrum.
AID1277885	Cytotoxicity against mouse C3H cells after 72 hrs by MTS assay	2016	Bioorganic & medicinal chemistry letters, Feb-15, Volume: 26, Issue:4	Semisynthesis of new aphidicolin derivatives with high activity against Trypanosoma cruzi.
AID548283	Selectivity ratio of EC50 for Trypanosoma brucei NfxR1 to EC50 for Trypanosoma brucei	2010	Antimicrobial agents and chemotherapy, Jul, Volume: 54, Issue:7	Cross-resistance to nitro drugs and implications for treatment of human African trypanosomiasis.
AID3375	Effective concentration required to inhibit the growth of murine 3T3 fibroblasts	2001	Journal of medicinal chemistry, Jun-21, Volume: 44, Issue:13	Adenosine analogues as selective inhibitors of glyceraldehyde-3-phosphate dehydrogenase of Trypanosomatidae via structure-based drug design.
AID706518	Antitrypanosomal activity against Trypanosoma cruzi IRHOD/VO/2008/SN3 axenic amastigotes infected in african green monkey Vero cells incubated for 72 hrs	2012	Journal of medicinal chemistry, Nov-26, Volume: 55, Issue:22	Phthalazine derivatives containing imidazole rings behave as Fe-SOD inhibitors and show remarkable anti-T. cruzi activity in immunodeficient-mouse mode of infection.
AID1638040	Cytotoxicity against African green monkey Vero cells after 72 hrs by propidium iodide/fluorescein diacetate staining based flow cytometry	2019	European journal of medicinal chemistry, Mar-01, Volume: 165	Design, synthesis and molecular docking studies of novel N-arylsulfonyl-benzimidazoles with anti Trypanosoma cruzi activity.
AID396017	Antimicrobial activity against Trypanosoma cruzi genotype 20 infected in BALB/c mouse assessed as cure rate	2007	Antimicrobial agents and chemotherapy, Sep, Volume: 51, Issue:9	Impact of dual infections on chemotherapeutic efficacy in BALB/c mice infected with major genotypes of Trypanosoma cruzi.
AID1686730	Antitrypanosomal activity against Trypanosoma cruzi Arequipa trypomastigote froms infected in mouse blood incubated for 24 hrs by Neubauer chamber based assay	2016	Journal of medicinal chemistry, 12-22, Volume: 59, Issue:24	In Vitro and in Vivo Anti-Trypanosoma cruzi Activity of New Arylamine Mannich Base-Type Derivatives.
AID1603818	Antitrypanosomal activity against Trypanosoma cruzi MHOM/Pe/2011/Arequipa;DTU 5 bloodstream trypomastigote infected in BALB/c mouse assessed as parasite-free bone marrow in acute phase at 20 mg/kg/day, po administered for 5 consecutive days starting from	2019	Bioorganic & medicinal chemistry, 09-01, Volume: 27, Issue:17	Rational modification of Mannich base-type derivatives as novel antichagasic compounds: Synthesis, in vitro and in vivo evaluation.
AID580599	Antitrypanosomal activity against Trypanosoma cruzi Y infected in CD4+ T-lymphocyte knockout C57BL/6 mouse assessed as occurrence of subpatent parasitemia level in mouse at 20 mg/kg/day, po administered twice daily for 20 consecutive days measured 4 to 24	2009	Antimicrobial agents and chemotherapy, Jan, Volume: 53, Issue:1	Absence of CD4+ T lymphocytes, CD8+ T lymphocytes, or B lymphocytes has different effects on the efficacy of posaconazole and benznidazole in treatment of experimental acute Trypanosoma cruzi infection.
AID1055166	Hepatotoxicity in BALB/c mouse infected with bloodstream trypomastigote form of Trypanosoma cruzi IRHOD/CO/2008/SN3 assessed as hepatic destruction in portal space at 5 mg/kg/day, ip administered for 5 days measured 150 days post-infection by light micros	2013	European journal of medicinal chemistry, , Volume: 70	Scorpiand-like azamacrocycles prevent the chronic establishment of Trypanosoma cruzi in a murine model.
AID707777	Selectivity index, ratio of IC50 for african green monkey Vero cells to IC50 for Trypanosoma cruzi IRHOD/VO/2008/SN3 intracellular amastigotes	2012	Journal of medicinal chemistry, Nov-26, Volume: 55, Issue:22	Phthalazine derivatives containing imidazole rings behave as Fe-SOD inhibitors and show remarkable anti-T. cruzi activity in immunodeficient-mouse mode of infection.
AID580595	Antitrypanosomal activity against Trypanosoma cruzi Y infected in B-lymphocyte knockout C57BL/6 mouse assessed as cure rate in mouse at 100 mg/kg/day, po administered once daily for 20 consecutive days measured 60 days post infection	2009	Antimicrobial agents and chemotherapy, Jan, Volume: 53, Issue:1	Absence of CD4+ T lymphocytes, CD8+ T lymphocytes, or B lymphocytes has different effects on the efficacy of posaconazole and benznidazole in treatment of experimental acute Trypanosoma cruzi infection.
AID1278147	Antiparasitic activity against trypomastigote stage of Trypanosoma cruzi Y assessed as parasite viability after 24 hrs by MTT assay	2016	Bioorganic & medicinal chemistry letters, Feb-15, Volume: 26, Issue:4	Gibbilimbol analogues as antiparasitic agents--Synthesis and biological activity against Trypanosoma cruzi and Leishmania (L.) infantum.
AID1615089	Nephrotoxicity in Balb/c mouse infected with Trypanosoma cruzi MHOM/Pe/2011/Arequipa DTU 5 trypomastigotes assessed as decrease in serum uric acid level at 20 mg/kg, po once daily for 5 consecutive days starting from day 10 post infection measured on day	2019	Bioorganic & medicinal chemistry, 03-01, Volume: 27, Issue:5	Synthesis and biological evaluation of new long-chain squaramides as anti-chagasic agents in the BALB/c mouse model.
AID1603826	Antitrypanosomal activity against Trypanosoma cruzi MHOM/Pe/2011/Arequipa;DTU 5 bloodstream trypomastigote infected in BALB/c mouse assessed as parasite-free muscle in acute phase at 20 mg/kg/day, po administered for 5 consecutive days starting from day 8	2019	Bioorganic & medicinal chemistry, 09-01, Volume: 27, Issue:17	Rational modification of Mannich base-type derivatives as novel antichagasic compounds: Synthesis, in vitro and in vivo evaluation.
AID344430	Antiproliferative activity against Trypanosoma cruzi Y epimastigotes assessed as number of motile forms at 0.1 mM after 4 hrs by hemocytometer	2008	Journal of medicinal chemistry, Jul-24, Volume: 51, Issue:14	Complexation of the anti-Trypanosoma cruzi drug benznidazole improves solubility and efficacy.
AID1432289	Cytotoxicity against human THP1 cells assessed as reduction in cell viability after 72 hrs by MTT assay	2017	European journal of medicinal chemistry, Mar-10, Volume: 128	Design and synthesis of a new series of 3,5-disubstituted isoxazoles active against Trypanosoma cruzi and Leishmania amazonensis.
AID1603952	Antitrypanosomal activity against Trypanosoma cruzi MHOM/Pe/2011/Arequipa;DTU 5 epimastigote assessed as effect on D-lactate excretion at IC50 after 72 hrs by H NMR method relative to control	2019	Bioorganic & medicinal chemistry, 09-01, Volume: 27, Issue:17	Rational modification of Mannich base-type derivatives as novel antichagasic compounds: Synthesis, in vitro and in vivo evaluation.
AID106020	In Vitro cytotoxicity on MRC-5 cells	2000	Journal of medicinal chemistry, Jul-13, Volume: 43, Issue:14	Antimalarial, antitrypanosomal, and antileishmanial activities and cytotoxicity of bis(9-amino-6-chloro-2-methoxyacridines): influence of the linker.
AID1555445	Cytotoxicity against mouse NCTC-929 cells assessed as reduction in cell viability incubated for 48 hrs by MTT assay	2019	European journal of medicinal chemistry, Aug-15, Volume: 176	Dehydrodieugenol B derivatives as antiparasitic agents: Synthesis and biological activity against Trypanosoma cruzi.
AID1074375	Antitrypanosomal activity against trypomastigote stage of Trypanosoma cruzi IRHOD/CO/2008/SN3 assessed as reduction of trypomastigote number per mililiter of culture medium at IC25 preincubated for 12 hrs followed by compound washout measured every 48 hrs	2014	Journal of medicinal chemistry, Feb-13, Volume: 57, Issue:3	Synthesis and biological evaluation of N,N'-squaramides with high in vivo efficacy and low toxicity: toward a low-cost drug against Chagas disease.
AID1420625	Trypanocidal activity against Trypanosoma cruzi Tulahuen trypomastigotes infected in human THP1 cells at 20 uM after 48 hrs by chlorophenolred-beta-d-galactopyranoside/Nonidet P-40 reagent-based assay	2018	Bioorganic & medicinal chemistry letters, 11-01, Volume: 28, Issue:20	Synthesis and biological evaluation of isoxazolyl-sulfonamides: A non-cytotoxic scaffold active against Trypanosoma cruzi, Leishmania amazonensis and Herpes Simplex Virus.
AID1498181	Trypanocidal activity against Trypanosoma cruzi TINF/CH/1956/Tulahuen DTU 6 amastigotes infected in African green monkey Vero cells after 72 hrs by Giemsa-staining based microscopic assay	2018	Journal of medicinal chemistry, 07-12, Volume: 61, Issue:13	Second Generation of Mannich Base-Type Derivatives with in Vivo Activity against Trypanosoma cruzi.
AID1615054	Antitrypanosomal activity against Trypanosoma cruzi MHOM/Pe/2011/Arequipa DTU 5 trypomastigotes infected in Balb/c mouse assessed as parasite-free muscle at 20 mg/kg, po pretreated once daily for 5 consecutive days starting from day 75 post infection foll	2019	Bioorganic & medicinal chemistry, 03-01, Volume: 27, Issue:5	Synthesis and biological evaluation of new long-chain squaramides as anti-chagasic agents in the BALB/c mouse model.
AID1603848	Toxicity in BALB/c mouse infected with Trypanosoma cruzi MHOM/Pe/2011/Arequipa;DTU 5 bloodstream trypomastigote assessed as change in serum creatine kinase muscle to brain ratio level in acute phase at 20 mg/kg/day, po administered for 5 consecutive days	2019	Bioorganic & medicinal chemistry, 09-01, Volume: 27, Issue:17	Rational modification of Mannich base-type derivatives as novel antichagasic compounds: Synthesis, in vitro and in vivo evaluation.
AID337151	Antitrypanosomal activity against Trypanosoma cruzi 31R16CL1 after 48 hrs
AID677288	Toxicity in BALB/c mouse liver infected with Trypanosoma cruzi assessed as delocalized hepatic destruction at 5 mg/kg, ip after 120 days postinfection by Histopathological analysis	2012	Journal of medicinal chemistry, May-10, Volume: 55, Issue:9	In vitro and in vivo trypanosomicidal activity of pyrazole-containing macrocyclic and macrobicyclic polyamines: their action on acute and chronic phases of Chagas disease.
AID766418	Selectivity index, ratio of LC50 for mouse NCTC-929 cells to IC50 for amastigotes of Trypanosoma cruzi CL Brener	2013	Bioorganic & medicinal chemistry letters, Sep-01, Volume: 23, Issue:17	Selective activity of 2,4-diaryl-1,2,3,4-tetrahydroquinolines on Trypanosoma cruzi epimastigotes and amastigotes expressing β-galactosidase.
AID1400235	Growth inhibition of Trypanosoma cruzi Tulahuen amastigote forms infected in human THP1 cells at 20 uM after 72 hrs by beta-galactosidase reporter gene assay relative to control	2018	Bioorganic & medicinal chemistry, 09-15, Volume: 26, Issue:17	Synthesis and SAR of new isoxazole-triazole bis-heterocyclic compounds as analogues of natural lignans with antiparasitic activity.
AID753406	Trypanocidal activity against Trypanosoma cruzi strain CL trypomastigotes infected in human HeLa cells at 37 degC after 18 hrs by resazurin assay	2013	Bioorganic & medicinal chemistry letters, Jun-15, Volume: 23, Issue:12	Aromatic glycosyl disulfide derivatives: evaluation of their inhibitory activities against Trypanosoma cruzi.
AID564766	Hepatotoxicity in Swiss-Webster mouse assessed as effect on GPT level at 50 mg/kg/day, ip administered 21 days postinfection measured on day 120	2010	Antimicrobial agents and chemotherapy, Jul, Volume: 54, Issue:7	Arylimidamide DB766, a potential chemotherapeutic candidate for Chagas' disease treatment.
AID1638038	Anti-trypanosomal activity against Trypanosoma cruzi IRHOD/CO/2008/SN3 epimastigotes after 72 hrs by Neubauer hemocytometric method	2019	European journal of medicinal chemistry, Mar-01, Volume: 165	Design, synthesis and molecular docking studies of novel N-arylsulfonyl-benzimidazoles with anti Trypanosoma cruzi activity.
AID1503429	Cytotoxicity in human U937 cells assessed as reduction in cell viability incubated for 72 hrs by MTT assay	2017	European journal of medicinal chemistry, Dec-01, Volume: 141	Triclosan-caffeic acid hybrids: Synthesis, leishmanicidal, trypanocidal and cytotoxic activities.
AID1294225	Antichagasic activity against Trypanosoma cruzi CL-B5 intracellular amastigotes in mouse L929 cells assessed as growth inhibition after 7 days by beta galactosidase reporter gene assay	2016	European journal of medicinal chemistry, Jun-10, Volume: 115	Antichagasic and trichomonacidal activity of 1-substituted 2-benzyl-5-nitroindazolin-3-ones and 3-alkoxy-2-benzyl-5-nitro-2H-indazoles.
AID1470751	Trypanocidal activity against trypomastigote stage of Trypanosoma cruzi INC-5 infected in NIH mouse blood assessed as parasite lysis at 50 ug/ml after 24 hrs by optical microscopic method relative to control	2017	European journal of medicinal chemistry, May-26, Volume: 132	An in vitro and in vivo evaluation of new potential trans-sialidase inhibitors of Trypanosoma cruzi predicted by a computational drug repositioning method.
AID373279	Antitrypanosomal activity against Trypanosoma cruzi bloodstream trypomastigote infected in BALB/c mouse assessed as parasitemia at 50 mg/kg, po after 60 days by colorimetric method	2009	European journal of medicinal chemistry, Mar, Volume: 44, Issue:3	In vitro and in vivo antitrypanosomatid activity of 5-nitroindazoles.
AID1486933	Antiprotozoal activity against Trichomonas vaginalis GT3 trophozoites incubated for 48 hrs	2017	Bioorganic & medicinal chemistry letters, 08-01, Volume: 27, Issue:15	Synthesis, in vitro and in vivo giardicidal activity of nitrothiazole-NSAID chimeras displaying broad antiprotozoal spectrum.
AID1697061	Antiparasitic activity against intracellular Trypanosoma cruzi amastigotes infected in mouse peritoneal macrophage measured after 72 hrs	2020	Journal of natural products, 09-25, Volume: 83, Issue:9	Production of Highly Active Antiparasitic Compounds from the Controlled Halogenation of the
AID449387	Inhibition of Mitochondrial dehydrogenase in Trypanosoma cruzi Y epimastigotes at 20 uM after 30 to 240 mins by MTT dye reduction assay in relative to control	2009	European journal of medicinal chemistry, Nov, Volume: 44, Issue:11	Second generation of 2H-benzimidazole 1,3-dioxide derivatives as anti-trypanosomatid agents: synthesis, biological evaluation, and mode of action studies.
AID1480898	Induction of apoptosis in bloodstream trypomastigote stage of Trypanosoma cruzi Y infected in monkey LLC-MK2 cells assessed as necrotic cells at 25 uM measured after 24 hrs by Annexin-V-FITC/propidium iodide staining based flow cytometric method (Rvb = 0.	2017	European journal of medicinal chemistry, Apr-21, Volume: 130	Desing and synthesis of potent anti-Trypanosoma cruzi agents new thiazoles derivatives which induce apoptotic parasite death.
AID547248	Toxicity in mongrel dog infected with Trypanosoma cruzi Y assessed as weight loss at 7 mg/kg, po BID for 90 days started 12 to 22 days postinfection measured after 6 months	2010	Antimicrobial agents and chemotherapy, Jul, Volume: 54, Issue:7	Effects of ravuconazole treatment on parasite load and immune response in dogs experimentally infected with Trypanosoma cruzi.
AID1065866	Antitrypanosomal activity against Trypanosoma cruzi Y epimastigotes after 5 days by resazurin dye-based assay	2014	Journal of medicinal chemistry, Jan-23, Volume: 57, Issue:2	Design, synthesis, and evaluation of hydroxamic acid derivatives as promising agents for the management of Chagas disease.
AID1584733	Cytotoxicity against human MRC5 SV2 cells assessed as reduction in cell viability after 3 days resazurin-based fluorimetric assay	2018	Journal of medicinal chemistry, 10-25, Volume: 61, Issue:20	Discovery of Novel 7-Aryl 7-Deazapurine 3'-Deoxy-ribofuranosyl Nucleosides with Potent Activity against Trypanosoma cruzi.
AID337146	Antitrypanosomal activity against Trypanosoma cruzi CL after 48 hrs
AID1780973	Trypanocidal activity against Trypanosoma cruzi CL-Luc-Neon amastigotes infected in BSR cells assessed as inhibition of parasite growth at 20 times IC50 incubated for 20 days measured after 30 days of compound wash out by epifluorescence microscopy analys	2021	European journal of medicinal chemistry, Nov-05, Volume: 223	Design and synthesis of Mannich base-type derivatives containing imidazole and benzimidazole as lead compounds for drug discovery in Chagas Disease.
AID753035	Selectivity index, ratio of IC50 for human fibroblasts to GI50 for epimastigote stage of Trypanosoma cruzi Y	2013	European journal of medicinal chemistry, Jun, Volume: 64	Ligand-based design, synthesis, and experimental evaluation of novel benzofuroxan derivatives as anti-Trypanosoma cruzi agents.
AID1496045	Cytotoxicity against mouse L929 cells assessed as reduction in cell viability after 96 hrs by alamar blue assay	2018	Bioorganic & medicinal chemistry letters, 06-15, Volume: 28, Issue:11	Identification and preliminary structure-activity relationship studies of novel pyridyl sulfonamides as potential Chagas disease therapeutic agents.
AID1615092	Nephrotoxicity in Balb/c mouse infected with Trypanosoma cruzi MHOM/Pe/2011/Arequipa DTU 5 trypomastigotes assessed as decrease in serum uric acid level at 20 mg/kg, po once daily for 5 consecutive days starting from day 75 post infection measured on day	2019	Bioorganic & medicinal chemistry, 03-01, Volume: 27, Issue:5	Synthesis and biological evaluation of new long-chain squaramides as anti-chagasic agents in the BALB/c mouse model.
AID1603858	Toxicity in BALB/c mouse infected with Trypanosoma cruzi MHOM/Pe/2011/Arequipa;DTU 5 bloodstream trypomastigote assessed as change in serum alkaline phosphatase level in acute phase at 20 mg/kg/day, po administered for 5 consecutive days and measured on d	2019	Bioorganic & medicinal chemistry, 09-01, Volume: 27, Issue:17	Rational modification of Mannich base-type derivatives as novel antichagasic compounds: Synthesis, in vitro and in vivo evaluation.
AID1683683	Toxicity in BALB/c mouse infected with Trypanosomal Trypanosoma cruzi MHOM/Pe/2011/Arequipa(DTU V) assessed as effect on AST/GOT level at 20 mg/kg, po administered for 5 days starting at 9 days post infection and measured after 2 days post treatment	2020	Journal of natural products, 12-24, Volume: 83, Issue:12	In Vivo Biological Evaluation of a Synthetic Royleanone Derivative as a Promising Fast-Acting Trypanocidal Agent by Inducing Mitochondrial-Dependent Necrosis.
AID1565133	Trypanocidal activity against intracellular amastigote stage of Trypanosoma cruzi Y strain infected in Swiss webster cardiac cells assessed as reduction in parasite viability after 24 hrs by Celltiter-Glo assay	2019	European journal of medicinal chemistry, Nov-15, Volume: 182	Synthesis, structure-activity relationship and trypanocidal activity of pyrazole-imidazoline and new pyrazole-tetrahydropyrimidine hybrids as promising chemotherapeutic agents for Chagas disease.
AID1638041	Selectivity index, ratio of IC50 for African green monkey Vero cells to IC50 for Trypanosoma cruzi IRHOD/CO/2008/SN3 epimastigotes	2019	European journal of medicinal chemistry, Mar-01, Volume: 165	Design, synthesis and molecular docking studies of novel N-arylsulfonyl-benzimidazoles with anti Trypanosoma cruzi activity.
AID1074932	Antitrypanosomal activity against Trypanosoma cruzi (IRHOD/CO/2008/SN3) epimastigotes after 72 hrs by Neubauer chamber counting analysis	2014	European journal of medicinal chemistry, Mar-03, Volume: 74	New perspectives on the synthesis and antichagasic activity of 3-alkoxy-1-alkyl-5-nitroindazoles.
AID1603837	Toxicity in BALB/c mouse infected with Trypanosoma cruzi MHOM/Pe/2011/Arequipa;DTU 5 bloodstream trypomastigote assessed as decrease in serum creatine kinase muscle to brain ratio level in acute phase at 20 mg/kg/day, po administered for 5 consecutive day	2019	Bioorganic & medicinal chemistry, 09-01, Volume: 27, Issue:17	Rational modification of Mannich base-type derivatives as novel antichagasic compounds: Synthesis, in vitro and in vivo evaluation.
AID1614006	Antiprotozoal activity against Trypanosoma cruzi Tulahuen C2C4 amastigotes infected in rat L6 cells after 96 hrs by inverted microscopic analysis	2019	Journal of medicinal chemistry, 02-14, Volume: 62, Issue:3	Design, Synthesis, and Biological Evaluation of New 1-(Aryl-1 H-pyrrolyl)(phenyl)methyl-1 H-imidazole Derivatives as Antiprotozoal Agents.
AID1686733	Antitrypanosomal activity against Trypanosoma cruzi Tulahuen trypomastigote froms infected in mouse blood incubated for 24 hrs by Neubauer chamber based assay	2016	Journal of medicinal chemistry, 12-22, Volume: 59, Issue:24	In Vitro and in Vivo Anti-Trypanosoma cruzi Activity of New Arylamine Mannich Base-Type Derivatives.
AID249626	Percentage delyse against amastigote forms of Y strain of Trypanosoma cruzi at 32 uM	2005	Bioorganic & medicinal chemistry letters, Jan-17, Volume: 15, Issue:2	Trypanocidal activity of (-)-cubebin derivatives against free amastigote forms of Trypanosoma cruzi.
AID1613468	Trypanocidal activity against Trypanosoma cruzi MHOM/Pe/2011/Arequipa DTU 5 trypomastigotes derived from infected Balb/c albino mouse after 24 hrs by resazurin dye based assay	2019	European journal of medicinal chemistry, Feb-15, Volume: 164	New polyamine drugs as more effective antichagas agents than benznidazole in both the acute and chronic phases.
AID396016	Antimicrobial activity against Trypanosoma cruzi 1 dually infected in BALB/c mouse assessed as cure rate	2007	Antimicrobial agents and chemotherapy, Sep, Volume: 51, Issue:9	Impact of dual infections on chemotherapeutic efficacy in BALB/c mice infected with major genotypes of Trypanosoma cruzi.
AID1399456	Antitrypanosomal activity against Trypanosoma cruzi Tulahuen amastigote forms infected in rat H9c2 cells assessed as reduction in amastigote number per cell after 72 hrs by DRAQ5 DNA dye based confocal microscopic analysis	2018	Bioorganic & medicinal chemistry, 08-07, Volume: 26, Issue:14	Quinoxaline derivatives as potential antitrypanosomal and antileishmanial agents.
AID1592303	Antitrypanosomal activity against Trypanosoma cruzi MHOM/MX/1994/INC5 epimastigotes assessed as growth inhibition measured after 24 hrs by MTT assay
AID1065867	Antitrypanosomal activity against Trypanosoma cruzi Y epimastigotes assessed as growth inhibition at 32 uM after 5 days by Neubauer chamber counting analysis relative to control	2014	Journal of medicinal chemistry, Jan-23, Volume: 57, Issue:2	Design, synthesis, and evaluation of hydroxamic acid derivatives as promising agents for the management of Chagas disease.
AID1615025	Selectivity index, ratio of IC50 for African green monkey Vero cells to IC50 for Trypanosoma cruzi IRHOD/CO/2008/SN3 DTU 1 epimastigotes	2019	Bioorganic & medicinal chemistry, 03-01, Volume: 27, Issue:5	Synthesis and biological evaluation of new long-chain squaramides as anti-chagasic agents in the BALB/c mouse model.
AID1860609	Antitrypanosomal activity against Trypanosoma cruzi infected in Vero cells assessed as relapse day after washout at 50 times EC50 for 8 days followed by washout by microscopic analysis	2022	European journal of medicinal chemistry, Aug-05, Volume: 238	Identification and development of a series of disubstituted piperazines for the treatment of Chagas disease.
AID1686725	Antitrypanosomal activity against Trypanosoma cruzi infected in African green monkey Vero cells assessed as reduction in infection rate measured up to 10 days by Giemsa staining based hemocytometry	2016	Journal of medicinal chemistry, 12-22, Volume: 59, Issue:24	In Vitro and in Vivo Anti-Trypanosoma cruzi Activity of New Arylamine Mannich Base-Type Derivatives.
AID1686735	Antitrypanosomal activity against Trypanosoma cruzi SN3 amastigote forms infected in African green monkey Vero cells incubated for 72 hrs by Giemsa staining based micrscopy	2016	Journal of medicinal chemistry, 12-22, Volume: 59, Issue:24	In Vitro and in Vivo Anti-Trypanosoma cruzi Activity of New Arylamine Mannich Base-Type Derivatives.
AID598284	Antileishmanial activity against Leishmania mexicana MHOM/MX/ISETGS promastigotes after 72 hrs by neubauer chamber	2011	Bioorganic & medicinal chemistry letters, May-15, Volume: 21, Issue:10	Synthesis of benzologues of Nitazoxanide and Tizoxanide: a comparative study of their in vitro broad-spectrum antiprotozoal activity.
AID1361011	Antiparasitic activity against epimastigote form of Trypanosoma cruzi Y assessed as parasite growth inhibition after 96 hrs by Neubauer hemocytometer	2018	European journal of medicinal chemistry, Jul-15, Volume: 155	Symmetrical and unsymmetrical substituted 2,5-diarylidene cyclohexanones as anti-parasitic compounds.
AID1498236	Antitrypanosomal activity against Trypanosoma cruzi MHOM/Pe/2011/Arequipa DTU 5 trypamastigotes infected in Balb/c mouse assessed as reduction in parasitaemia reactivation in stomach tissue at 20 mg/kg, po pretreated once daily for 5 consecutive days star	2018	Journal of medicinal chemistry, 07-12, Volume: 61, Issue:13	Second Generation of Mannich Base-Type Derivatives with in Vivo Activity against Trypanosoma cruzi.
AID575884	Toxicity in human patient infected with Trypanosoma cruzi assessed as occurrence of dermatitis with cutaneous eruptions on day 7 to 10	2010	Antimicrobial agents and chemotherapy, Nov, Volume: 54, Issue:11	Tolerance of benznidazole in treatment of Chagas' disease in adults.
AID728165	Antitrypanosomal activity against Trypanosoma cruzi Y infected in monkey LLC-MK2 cells after 48 to 72 hrs by luciferase reporter gene assay	2013	Journal of medicinal chemistry, Mar-28, Volume: 56, Issue:6	Antitrypanosomal lead discovery: identification of a ligand-efficient inhibitor of Trypanosoma cruzi CYP51 and parasite growth.
AID1381717	Cytotoxicity against human A549 cells after 48 hrs by CellTiter-Glo assay	2018	European journal of medicinal chemistry, Feb-25, Volume: 146	Aryl thiosemicarbazones for the treatment of trypanosomatidic infections.
AID1613472	Trypanocidal activity against Trypanosoma cruzi TINF/CH/1956/Tulahuen DTU 6 epimastigotes after 48 to 72 hrs by resazurin dye based assay	2019	European journal of medicinal chemistry, Feb-15, Volume: 164	New polyamine drugs as more effective antichagas agents than benznidazole in both the acute and chronic phases.
AID1616181	Antitrypanosomal activity against Trypanosoma cruzi Y amastigotes infected in Swiss mouse primary cardiac cells replenished for every 48 hrs for 168 hrs by geimsa staining based assay	2019	Journal of medicinal chemistry, 10-10, Volume: 62, Issue:19	Discovery of Pyrrolo[2,3-
AID677210	Selectivity index, ratio of IC50 for Vero cells to IC50 for Trypanosoma cruzi anexic amastigote	2012	Journal of medicinal chemistry, May-10, Volume: 55, Issue:9	In vitro and in vivo trypanosomicidal activity of pyrazole-containing macrocyclic and macrobicyclic polyamines: their action on acute and chronic phases of Chagas disease.
AID706519	Antitrypanosomal activity against Trypanosoma cruzi IRHOD/VO/2008/SN3 epimastigotes infected in african green monkey Vero cells incubated for 72 hrs	2012	Journal of medicinal chemistry, Nov-26, Volume: 55, Issue:22	Phthalazine derivatives containing imidazole rings behave as Fe-SOD inhibitors and show remarkable anti-T. cruzi activity in immunodeficient-mouse mode of infection.
AID1498343	Hepatotoxicity in Balb/c mouse infected with Trypanosoma cruzi MHOM/Pe/2011/Arequipa DTU 5 trypamastigotes assessed as change in alkaline phosphatase level at 20 mg/kg, po once daily for 5 consecutive days starting from day 10 post infection measured on d	2018	Journal of medicinal chemistry, 07-12, Volume: 61, Issue:13	Second Generation of Mannich Base-Type Derivatives with in Vivo Activity against Trypanosoma cruzi.
AID396015	Antimicrobial activity against Trypanosoma cruzi 1 and Trypanosoma cruzi dually infected in BALB/c mouse assessed as cure rate	2007	Antimicrobial agents and chemotherapy, Sep, Volume: 51, Issue:9	Impact of dual infections on chemotherapeutic efficacy in BALB/c mice infected with major genotypes of Trypanosoma cruzi.
AID392021	Antitrypanosomal activity against Trypanosoma cruzi Colombiana infected Swiss mouse assessed as prevention of skeletal muscle inflammatory infiltrates at 120 mg/kg/day, po	2008	European journal of medicinal chemistry, Oct, Volume: 43, Issue:10	In vivo studies of 5-arylethenylbenzofuroxans in acute murine models of Chagas' disease.
AID576105	Toxicity in human patient infected with Trypanosoma cruzi assessed as occurrence of Hearing impairment at 5 mg/kg/day for 60 days	2010	Antimicrobial agents and chemotherapy, Nov, Volume: 54, Issue:11	Tolerance of benznidazole in treatment of Chagas' disease in adults.
AID1603745	Antitrypanosomal activity against Trypanosoma cruzi MHOM/Pe/2011/Arequipa;DTU 5 bloodstream trypomastigotes infected in BALB/c mouse assessed as reduction in serum Ig-G level in acute phase at 20 mg/kg/day, po administered for 5 consecutive days starting	2019	Bioorganic & medicinal chemistry, 09-01, Volume: 27, Issue:17	Rational modification of Mannich base-type derivatives as novel antichagasic compounds: Synthesis, in vitro and in vivo evaluation.
AID1155759	Cytotoxicity against human HepG2 cells after 24 hrs by XTT assay	2014	European journal of medicinal chemistry, Jul-23, Volume: 82	Design, synthesis and biological evaluation of hybrid bioisoster derivatives of N-acylhydrazone and furoxan groups with potential and selective anti-Trypanosoma cruzi activity.
AID1507190	Growth inhibition of Trypanosoma cruzi clone CL B5 amastigotes harboring lacZ derived from infected mouse NCTC-929 cells at 25 uM after 7 days by beta-galactosidase reporter gene assay relative to control	2017	European journal of medicinal chemistry, Aug-18, Volume: 136	Novel Imidazo[4,5-c][1,2,6]thiadiazine 2,2-dioxides as antiproliferative trypanosoma cruzi drugs: Computational screening from neural network, synthesis and in vivo biological properties.
AID1615086	Nephrotoxicity in Balb/c mouse infected with Trypanosoma cruzi MHOM/Pe/2011/Arequipa DTU 5 trypomastigotes assessed as decrease in serum urea level at 20 mg/kg, po once daily for 5 consecutive days starting from day 10 post infection measured on day 127 p	2019	Bioorganic & medicinal chemistry, 03-01, Volume: 27, Issue:5	Synthesis and biological evaluation of new long-chain squaramides as anti-chagasic agents in the BALB/c mouse model.
AID1603740	Genotoxicity in Salmonella typhimurium TA1535 harboring pSK1002 assessed as umu gene induction in presence of Sprague-Dawley rat liver S9 fraction metabolic activation by SOS/umu assay	2019	Bioorganic & medicinal chemistry, 09-01, Volume: 27, Issue:17	Rational modification of Mannich base-type derivatives as novel antichagasic compounds: Synthesis, in vitro and in vivo evaluation.
AID214326	In Vitro inhibition concentration against Trypomastigote form of Trypanosoma cruzi	2000	Journal of medicinal chemistry, Jul-13, Volume: 43, Issue:14	Antimalarial, antitrypanosomal, and antileishmanial activities and cytotoxicity of bis(9-amino-6-chloro-2-methoxyacridines): influence of the linker.
AID1779354	Antitrypanosomal activity against Trypanosoma cruzi Tulahuen C4 strain amastigotes infected in rat L6 cells measured after 96 hrs by inverted microscopy analysis	2021	European journal of medicinal chemistry, Oct-05, Volume: 221	Synthesis, in vitro antiprotozoal activity, molecular docking and molecular dynamics studies of some new monocationic guanidinobenzimidazoles.
AID1254435	Antiparasitic activity against bloodstream trypomastigote stage of Trypanosoma cruzi Y assessed as parasite viability after 24 hrs by Neubauer chamber analysis	2015	Bioorganic & medicinal chemistry, Dec-01, Volume: 23, Issue:23	Structural design, synthesis and pharmacological evaluation of 4-thiazolidinones against Trypanosoma cruzi.
AID1605625	Antitrypanosomal activity against Trypanosoma cruzi Tulahuen strain C2C4 trypomastigotes infected in rat L6 cells incubated for 96 hrs by photometric method based assay	2020	Journal of medicinal chemistry, 03-26, Volume: 63, Issue:6	Discovery and Optimization of a Compound Series Active against
AID576095	Toxicity in human patient infected with Trypanosoma cruzi assessed as occurrence of Paresthesia at 5 mg/kg/day for 60 days	2010	Antimicrobial agents and chemotherapy, Nov, Volume: 54, Issue:11	Tolerance of benznidazole in treatment of Chagas' disease in adults.
AID1498261	Nephrotoxicity in Balb/c mouse infected with Trypanosoma cruzi MHOM/Pe/2011/Arequipa DTU 5 trypamastigotes assessed as decrease in urea level in serum at 20 mg/kg, po once daily for 5 consecutive days starting from day 10 post infection measured on day 16	2018	Journal of medicinal chemistry, 07-12, Volume: 61, Issue:13	Second Generation of Mannich Base-Type Derivatives with in Vivo Activity against Trypanosoma cruzi.
AID1381727	Cytotoxicity against human 786-O cells assessed as decrease in mitochondrial viability after 6 hrs by CMXRos staining based assay	2018	European journal of medicinal chemistry, Feb-25, Volume: 146	Aryl thiosemicarbazones for the treatment of trypanosomatidic infections.
AID1456550	Cytotoxicity against human U937 cells after 72 hrs by MTT assay
AID710592	Cytotoxicity against rat L6 cells assessed as growth inhibition after 72 hrs by inverted microscopy	2012	Journal of medicinal chemistry, Dec-13, Volume: 55, Issue:23	Conjugation of quinones with natural polyamines: toward an expanded antitrypanosomatid profile.
AID576940	Antimicrobial activity against Trypanosoma cruzi Tulahuen infected in Swiss mouse assessed as parasite DNA level at 60 mg/kg/day, po for 6 days per week until completion of 60 compound doses administered 5 days post infection measured 30 days post dose by	2010	Antimicrobial agents and chemotherapy, Sep, Volume: 54, Issue:9	Hydroxymethylnitrofurazone is active in a murine model of Chagas' disease.
AID1156605	Selectivity index, ratio of IC50 for rat L6 cells to IC50 for Trypanosoma cruzi Tulahen LacZ/C4 amastigotes	2014	European journal of medicinal chemistry, Aug-18, Volume: 83	Synthesis and antiparasitic activity of new bis-arylimidamides: DB766 analogs modified in the terminal groups.
AID1454607	Antitrypanosomal activity against Trypanosoma cruzi Tulahuen amastigotes infected in mouse 3T3 cells after 6 days by beta galactosidase reporter asay	2017	ACS medicinal chemistry letters, Jul-13, Volume: 8, Issue:7	New Class of Antitrypanosomal Agents Based on Imidazopyridines.
AID1740562	Antitrypanosomal activity against Trypanosoma cruzi trypomastigotes infected in African green monkey Vero cells incubated for 120 hrs measured on day 6 cells followed by trypomastigotes release by haemocytometer-based light microscopy	2020	European journal of medicinal chemistry, Sep-15, Volume: 202	8-Alkynyl-3-nitroimidazopyridines display potent antitrypanosomal activity against both T. b. brucei and cruzi.
AID213787	Inhibitory concentration against Epimastigotes (Tulahuen strain) of Trypanosoma cruzi	2001	Bioorganic & medicinal chemistry letters, Oct-22, Volume: 11, Issue:20	Anti-Trypanosoma activity of some natural stilbenoids and synthetic related heterocyclic compounds.
AID1517430	Antitrypanosomal activity against intracellular amastigote stage of Trypanosoma cruzi 92.80 cl2 infected in human U2OS cells measured after 96 hrs by DRAQ5 dye based microscopic analysis	2019	European journal of medicinal chemistry, Dec-01, Volume: 183	Discovery of a benzothiophene-flavonol halting miltefosine and antimonial drug resistance in Leishmania parasites through the application of medicinal chemistry, screening and genomics.
AID1154398	Antitrypanosomal activity against trypomastigote stage of Trypanosoma cruzi Y assessed as living parasites level after 24 hrs by Neubauer chamber analysis	2014	Journal of natural products, Jun-27, Volume: 77, Issue:6	Dimeric flavonoids from Arrabidaea brachypoda and assessment of their anti-Trypanosoma cruzi activity.
AID748436	Antitrypanosomal activity against Trypanosoma cruzi Tulahuen C2C4 amastigotes infected in rat L6 cells after 96 hrs by photometric analysis	2013	ACS medicinal chemistry letters, Jun-13, Volume: 4, Issue:6	New Promising Compounds with in Vitro Nanomolar Activity against Trypanosoma cruzi.
AID1854934	Antitrypanosomal activity against Trypanosoma cruzi Y epimastigotes assessed as parasite growth inhibition measured after 48 hrs by hemocytometer chamber based analysis	2022	European journal of medicinal chemistry, Nov-05, Volume: 241	Rational design of a trypanocidal peptide derived from Dinoponera quadriceps venom.
AID1587074	Antitrypanosomal activity against Trypanosoma cruzi Tulahuen amastigotes infected in Balb/c mouse assessed as reduction in infection at 100 mg/kg, po administered once daily for 5 days starting from day 7 post-infection measured on day 13, 17 and 24	2019	ACS medicinal chemistry letters, Jan-10, Volume: 10, Issue:1	Triazolopyrimidines and Imidazopyridines: Structure-Activity Relationships and in Vivo Efficacy for Trypanosomiasis.
AID768695	Mutagenicity in Swiss albino mouse at 100 mg/kg after 30 hrs by micronucleus test	2013	European journal of medicinal chemistry, Sep, Volume: 67	Design, synthesis and biological evaluation of new aryl thiosemicarbazone as antichagasic candidates.
AID1202578	Selectivity index, ratio of IC50 for human LL24 cells to IC50 for Trypanosoma cruzi Bug 2149 cl10	2015	European journal of medicinal chemistry, , Volume: 96	Designing and exploring active N'-[(5-nitrofuran-2-yl) methylene] substituted hydrazides against three Trypanosoma cruzi strains more prevalent in Chagas disease patients.
AID1518995	Antitrypanosomal activity against Trypanosoma cruzi K98 bloodstream form infected in C3H/HeNk mouse assessed as change in QRS morphology at 75 mg/kg/day, po administered via gavage for 30 consecutive days starting from 90 days post infection and measured	2019	European journal of medicinal chemistry, 12-15, Volume: 184	Combined therapy with Benznidazole and repurposed drugs Clofazimine and Benidipine for chronic Chagas disease.
AID287714	Antitrypanosomatid activity against Trypanosoma cruzi CL Brener epimastigotes assessed as reduction of growth after 5 days	2007	Bioorganic & medicinal chemistry, Apr-01, Volume: 15, Issue:7	Second generation of 5-ethenylbenzofuroxan derivatives as inhibitors of Trypanosoma cruzi growth: synthesis, biological evaluation, and structure-activity relationships.
AID1616169	In vivo antitrypanosomal activity against Trypanosoma cruzi Y trypomastigotes infected in Swiss mouse assessed as mouse survival at 100 mg/kg, po administered once daily via gavage for 5 days starting from 5 days post-infection and measured daily up to 40	2019	Journal of medicinal chemistry, 10-10, Volume: 62, Issue:19	Discovery of Pyrrolo[2,3-
AID327492	Antitrypanosomal activity against Trypanosoma cruzi Y infected in human LLC-MK2 cells after 24 hrs by MTT assay	2008	Journal of natural products, Mar, Volume: 71, Issue:3	Antiparasitic, antineuroinflammatory, and cytotoxic polyketides from the marine sponge Plakortis angulospiculatus collected in Brazil.
AID1432600	Selectivity index, ratio of CC50 for mouse L929 cells to IC50 for Trypanosoma cruzi Tulahuen trypomastigote forms infected in mouse L929 cells	2017	Bioorganic & medicinal chemistry, 03-15, Volume: 25, Issue:6	Synthesis and biological evaluation of potential inhibitors of the cysteine proteases cruzain and rhodesain designed by molecular simplification.
AID1498182	Trypanocidal activity against Trypanosoma cruzi TINF/CH/1956/Tulahuen DTU 6 trypamastigotes derived from infected Balb/c albino mouse after 24 hrs by resazurin dye based assay	2018	Journal of medicinal chemistry, 07-12, Volume: 61, Issue:13	Second Generation of Mannich Base-Type Derivatives with in Vivo Activity against Trypanosoma cruzi.
AID1383441	Antitrypanosomal activity against bloodstream trypomastigote stage of Trypanosoma cruzi Y infected in Swiss Webster mouse assessed as reduction in parasitemia at 100 mg/kg, po administered daily measured at day 8 post infection	2018	European journal of medicinal chemistry, Apr-10, Volume: 149	Identification of Pyrazolo[3,4-e][1,4]thiazepin based CYP51 inhibitors as potential Chagas disease therapeutic alternative: In vitro and in vivo evaluation, binding mode prediction and SAR exploration.
AID613447	Cytotoxicity against african green monkey COS7 cells after 24 hrs by MTT assay	2011	European journal of medicinal chemistry, Sep, Volume: 46, Issue:9	Synthesis, trypanocidal activity and molecular modeling studies of 2-alkylaminomethylquinoline derivatives.
AID382468	Therapeutic index, ratio of IC50 for rat L6 cells to IC50 for Plasmodium falciparum K1	2008	European journal of medicinal chemistry, Jan, Volume: 43, Issue:1	Synthesis and antiprotozoal activities of simplified analogs of naphthylisoquinoline alkaloids.
AID728164	Antitrypanosomal activity against Trypanosoma cruzi trypomastigote infected in mouse NIH/3T3 cells at 9.5 uM incubated for 3 days post infection by DAPI-staining based immunofluorescence assay	2013	Journal of medicinal chemistry, Mar-28, Volume: 56, Issue:6	Antitrypanosomal lead discovery: identification of a ligand-efficient inhibitor of Trypanosoma cruzi CYP51 and parasite growth.
AID1381691	Antitrypanosomal activity against Trypanosoma brucei Lister 427 bloodstream form after 72 hrs by SYBR Green assay	2018	European journal of medicinal chemistry, Feb-25, Volume: 146	Aryl thiosemicarbazones for the treatment of trypanosomatidic infections.
AID1074372	Trypanocidal activity against metacyclic trypomastigote stage of Trypanosoma cruzi infected in BALB/c albino mouse acute chagas disease model assessed as inhibition of parasitemia at 25 mg/kg, ip administered on day 7 to 12 post-infection measured every 2	2014	Journal of medicinal chemistry, Feb-13, Volume: 57, Issue:3	Synthesis and biological evaluation of N,N'-squaramides with high in vivo efficacy and low toxicity: toward a low-cost drug against Chagas disease.
AID362866	Antitrypanosomal activity against Trypanosoma cruzi Tulahuen 2 at 25 uM after 5 days	2008	European journal of medicinal chemistry, May, Volume: 43, Issue:5	4-nitroacetophenone-derived thiosemicarbazones and their copper(II) complexes with significant in vitro anti-trypanosomal activity.
AID1070004	Antimicrobial activity against amastigote stage of Trypanosoma cruzi CL Brener infected in mouse NCTC-929 cells assessed as growth inhibition at 0.5 uM after 7 days by beta-galactosidase reporter gene assay	2014	Bioorganic & medicinal chemistry letters, Feb-15, Volume: 24, Issue:4	In vitro phenotypic screening of 7-chloro-4-amino(oxy)quinoline derivatives as putative anti-Trypanosoma cruzi agents.
AID282995	Antiparasitic activity against Trypanosoma cruzi MHOM/CL/00/Tulahuan-LacZ intracellular amastigotes	2005	Journal of medicinal chemistry, Nov-17, Volume: 48, Issue:23	Irreversible inactivation of trypanothione reductase by unsaturated Mannich bases: a divinyl ketone as key intermediate.
AID263383	Antitrypanosomal activity against Trypanosoma cruzi amastigotes at 10 ug/ml	2006	Bioorganic & medicinal chemistry letters, Apr-01, Volume: 16, Issue:7	New ligand-based approach for the discovery of antitrypanosomal compounds.
AID575887	Toxicity in human patient infected with Trypanosoma cruzi assessed as occurrence of lymphadenopathy	2010	Antimicrobial agents and chemotherapy, Nov, Volume: 54, Issue:11	Tolerance of benznidazole in treatment of Chagas' disease in adults.
AID1498252	Antitrypanosomal activity against Trypanosoma cruzi MHOM/Pe/2011/Arequipa DTU 5 trypamastigotes infected in Balb/c mouse assessed as reduction in Ig-G level in serum at 20 mg/kg, po once daily for 5 consecutive days starting from day 10 post infection mea	2018	Journal of medicinal chemistry, 07-12, Volume: 61, Issue:13	Second Generation of Mannich Base-Type Derivatives with in Vivo Activity against Trypanosoma cruzi.
AID1254922	Activity of histidine tagged recombinant Trypanosoma cruzi type 1 nitroreductase assessed as NADH oxidation at 100 uM by spectrophotometry method	2015	European journal of medicinal chemistry, Oct-20, Volume: 103	3-Nitrotriazole-based piperazides as potent antitrypanosomal agents.
AID1498229	Antitrypanosomal activity against Trypanosoma cruzi MHOM/Pe/2011/Arequipa DTU 5 trypamastigotes infected in Balb/c mouse assessed as reduction in parasitaemia reactivation in bone marrow tissue at 20 mg/kg, po pretreated once daily for 5 consecutive days	2018	Journal of medicinal chemistry, 07-12, Volume: 61, Issue:13	Second Generation of Mannich Base-Type Derivatives with in Vivo Activity against Trypanosoma cruzi.
AID1055188	Trypanocidal activity against extracellular epimastigote form of Trypanosoma cruzi IRHOD/CO/2008/SN3 after 72 hrs by Neubauer hemocytometric analysis	2013	European journal of medicinal chemistry, , Volume: 70	Scorpiand-like azamacrocycles prevent the chronic establishment of Trypanosoma cruzi in a murine model.
AID766415	Antiparasitic activity against amastigotes of Trypanosoma cruzi CL Brener expressing Escherichia coli lacZ gene infected in mouse NCTC-929 cells assessed as parasite growth inhibition at 1 uM after 7 days by colorimetric assay	2013	Bioorganic & medicinal chemistry letters, Sep-01, Volume: 23, Issue:17	Selective activity of 2,4-diaryl-1,2,3,4-tetrahydroquinolines on Trypanosoma cruzi epimastigotes and amastigotes expressing β-galactosidase.
AID1244580	Selectivity index, ratio of CC50 for mouse L929 cells to IC50 for amastigote and trypomastigote forms of Trypanosoma cruzi Tulahuen	2015	European journal of medicinal chemistry, Aug-28, Volume: 101	Synthesis and structure-activity relationship study of a new series of antiparasitic aryloxyl thiosemicarbazones inhibiting Trypanosoma cruzi cruzain.
AID1124788	Antimicrobial activity against epimastigote stage of Trypanosoma cruzi Y after 72 hrs by MTT assay	2014	Bioorganic & medicinal chemistry letters, Apr-01, Volume: 24, Issue:7	Synthesis and tripanocidal activity of ferrocenyl and benzyl diamines against Trypanosoma brucei and Trypanosoma cruzi.
AID1613528	Nephrotoxicity in Balb/c mouse infected with Trypanosoma cruzi MHOM/Pe/2011/Arequipa DTU 5 trypomastigotes assessed as serum uric acid level at 20 mg/kg, po once daily for 5 consecutive days starting from day 10 post infection measured on day 127 post inf	2019	European journal of medicinal chemistry, Feb-15, Volume: 164	New polyamine drugs as more effective antichagas agents than benznidazole in both the acute and chronic phases.
AID1683695	Antitrypanosomal activity against Trypanosoma cruzi MHOM/Pe/2011/Arequipa(DTU V) amastigote form infected in BALB/c mouse assessed as reactivation parasitaemia at 20 mg/kg, po administered for 5 days starting at 9 days post infection and measured up to 14	2020	Journal of natural products, 12-24, Volume: 83, Issue:12	In Vivo Biological Evaluation of a Synthetic Royleanone Derivative as a Promising Fast-Acting Trypanocidal Agent by Inducing Mitochondrial-Dependent Necrosis.
AID1196804	Activity of his-tagged recombinant Trypanosoma cruzi type-1 nitroreductase assessed as oxidized NADH level per mg of protein after 5 mins by absorption spectrum analysis	2015	Journal of medicinal chemistry, Feb-12, Volume: 58, Issue:3	Novel 3-nitrotriazole-based amides and carbinols as bifunctional antichagasic agents.
AID1473738	Inhibition of human BSEP overexpressed in Sf9 cell membrane vesicles assessed as uptake of [3H]-taurocholate in presence of ATP measured after 15 to 20 mins by membrane vesicle transport assay	2013	Toxicological sciences : an official journal of the Society of Toxicology, Nov, Volume: 136, Issue:1	A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.
AID1683699	Antitrypanosomal activity against Trypanosoma cruzi MHOM/Pe/2011/Arequipa(DTU V) amastigote form infected in Vero cells assessed as parasite growth inhibition at 50 uM incubated for 72 hrs by Giemsa-staining based assay relative to control	2020	Journal of natural products, 12-24, Volume: 83, Issue:12	In Vivo Biological Evaluation of a Synthetic Royleanone Derivative as a Promising Fast-Acting Trypanocidal Agent by Inducing Mitochondrial-Dependent Necrosis.
AID1683685	Toxicity in BALB/c mouse infected with Trypanosomal Trypanosoma cruzi MHOM/Pe/2011/Arequipa(DTU V) assessed as effect on CK-MB level at 20 mg/kg, po administered for 5 days starting at 9 days post infection and measured after 2 days post treatment	2020	Journal of natural products, 12-24, Volume: 83, Issue:12	In Vivo Biological Evaluation of a Synthetic Royleanone Derivative as a Promising Fast-Acting Trypanocidal Agent by Inducing Mitochondrial-Dependent Necrosis.
AID1555444	Antitrypanosomal activity against Trypanosoma cruzi amastigotes infected in BALB/c mouse peritoneal macrophages assessed as decrease in parasitic load with in the cell incubated for 48 hrs by Giemsa staining based light microscopy	2019	European journal of medicinal chemistry, Aug-15, Volume: 176	Dehydrodieugenol B derivatives as antiparasitic agents: Synthesis and biological activity against Trypanosoma cruzi.
AID707767	Toxicity in Trypanosoma cruzi IRHOD/VO/2008/SN3 metacyclic forms infected BALB/c mouse model of acute Chagas disease assessed as mortality incidence at 5 mg/kg/day, ip administered for 5 consecutive days starting on day 7 post infection until day 12 post	2012	Journal of medicinal chemistry, Nov-26, Volume: 55, Issue:22	Phthalazine derivatives containing imidazole rings behave as Fe-SOD inhibitors and show remarkable anti-T. cruzi activity in immunodeficient-mouse mode of infection.
AID1486937	Antiprotozoal activity against Trypanosoma cruzi MHOM/MX/1994/Ninoa incubated for 72 hrs by Neubauer chamber based cell counting method	2017	Bioorganic & medicinal chemistry letters, 08-01, Volume: 27, Issue:15	Synthesis, in vitro and in vivo giardicidal activity of nitrothiazole-NSAID chimeras displaying broad antiprotozoal spectrum.
AID1518969	Antitrypanosomal activity against Trypanosoma cruzi K98 bloodstream form infected in C3H/HeNk mouse assessed as reduction in cardiac tissue inflammation at 30 to 75 mg/kg/day, po administered via gavage for 30 consecutive days starting from 90 days post i	2019	European journal of medicinal chemistry, 12-15, Volume: 184	Combined therapy with Benznidazole and repurposed drugs Clofazimine and Benidipine for chronic Chagas disease.
AID1555446	Selectivity index, ratio of CC50 for mouse NCTC-929 cells to IC50 for Trypanosoma cruzi amastigotes infected in BA;B/c mouse peritoneal macrophages	2019	European journal of medicinal chemistry, Aug-15, Volume: 176	Dehydrodieugenol B derivatives as antiparasitic agents: Synthesis and biological activity against Trypanosoma cruzi.
AID764119	Cytotoxicity against mouse J774 cells after 48 hrs by MTT assay	2013	Bioorganic & medicinal chemistry, Sep-01, Volume: 21, Issue:17	5-Nitro-2-furfuriliden derivatives as potential anti-Trypanosoma cruzi agents: design, synthesis, bioactivity evaluation, cytotoxicity and exploratory data analysis.
AID337142	Antitrypanosomal activity against Trypanosoma cruzi A98CL5 after 48 hrs
AID249625	Percentage delyse against amastigote forms of Y strain of Trypanosoma cruzi at 8 uM	2005	Bioorganic & medicinal chemistry letters, Jan-17, Volume: 15, Issue:2	Trypanocidal activity of (-)-cubebin derivatives against free amastigote forms of Trypanosoma cruzi.
AID669380	Antileishmanial activity against Leishmania amazonensis MPRO/BR/1972/M1841-LV-79 after 72 hrs by MTT assay	2012	Journal of natural products, May-25, Volume: 75, Issue:5	Antiprotozoal sesquiterpene pyridine alkaloids from Maytenus ilicifolia.
AID323759	Antiparasitic activity against Trypanosoma cruzi Y amastigotes	2008	Bioorganic & medicinal chemistry, Mar-15, Volume: 16, Issue:6	Novel 1,3,4-thiadiazolium-2-phenylamine chlorides derived from natural piperine as trypanocidal agents: chemical and biological studies.
AID1501883	Cytotoxicity against mouse NCTC-929 cells after 72 hrs by MTT assay	2017	European journal of medicinal chemistry, Oct-20, Volume: 139	Efficacy of a series of alpha-pyrone derivatives against Leishmania (L.) infantum and Trypanosoma cruzi.
AID1459251	Trypanocidal activity against Trypanosoma cruzi RA tripamastigote bloodstream forms infected in Balb/c mouse assessed as reduction in parasitaemia at 100 mg/kg, po administered on day 9 post infection for 5 consecutive days measured on day 35 post infecti	2017	European journal of medicinal chemistry, Jan-05, Volume: 125	Novel 2-arylazoimidazole derivatives as inhibitors of Trypanosoma cruzi proliferation: Synthesis and evaluation of their biological activity.
AID439873	Antimicrobial activity against Trypanosoma cruzi Tulahuen C2C4 amastigote forms infected in rat L6 cells	2009	Journal of medicinal chemistry, Nov-12, Volume: 52, Issue:21	Searching for new cures for tuberculosis: design, synthesis, and biological evaluation of 2-methylbenzothiazoles.
AID1518992	Antitrypanosomal activity against Trypanosoma cruzi K98 bloodstream form infected in C3H/HeNk mouse assessed as reduction in parasite burden in skeletal muscle at 30 to 75 mg/kg/day, po administered via gavage for 30 consecutive days starting from 90 days	2019	European journal of medicinal chemistry, 12-15, Volume: 184	Combined therapy with Benznidazole and repurposed drugs Clofazimine and Benidipine for chronic Chagas disease.
AID449369	Antitrypanosomal activity against Trypanosoma cruzi Tulahuen 2 epimastigotes assessed as inhibition of parasite growth after 5 days	2009	European journal of medicinal chemistry, Nov, Volume: 44, Issue:11	Second generation of 2H-benzimidazole 1,3-dioxide derivatives as anti-trypanosomatid agents: synthesis, biological evaluation, and mode of action studies.
AID1202550	Antimicrobial activity against bloodstream trypomastigote stage of Trypanosoma cruzi INC-5 after 24 hrs by Brener method	2015	European journal of medicinal chemistry, , Volume: 96	Design, synthesis and biological evaluation of quinazoline derivatives as anti-trypanosomatid and anti-plasmodial agents.
AID1773692	Antitrypanosomal activity against Trypanosoma brucei brucei Lister 427 bloodstream forms measured after 72 hrs by SYBR green dye based assay	2021	Journal of medicinal chemistry, 09-09, Volume: 64, Issue:17	Structure-Based Optimization of Quinazolines as Cruzain and
AID1613509	Antitrypanosomal activity against Trypanosoma cruzi MHOM/Pe/2011/Arequipa DTU 5 trypomastigotes infected in Balb/c mouse assessed as reduction in splenomegaly at 20 mg/kg, po once daily for 5 consecutive days starting from day 10 post infection measured o	2019	European journal of medicinal chemistry, Feb-15, Volume: 164	New polyamine drugs as more effective antichagas agents than benznidazole in both the acute and chronic phases.
AID1196799	Antitrypanosomal activity against amastigote stage of Trypanosoma cruzi Tulahuen C4 infected in rat L6 cells assessed as parasite growth inhibition after 96 hrs by colorimetric analysis	2015	Journal of medicinal chemistry, Feb-12, Volume: 58, Issue:3	Novel 3-nitrotriazole-based amides and carbinols as bifunctional antichagasic agents.
AID766427	Antiparasitic activity against amastigotes of Trypanosoma cruzi CL Brener expressing Escherichia coli lacZ gene infected in mouse NCTC-929 cells assessed as parasite growth inhibition at 4 uM after 7 days by colorimetric assay	2013	Bioorganic & medicinal chemistry letters, Sep-01, Volume: 23, Issue:17	Selective activity of 2,4-diaryl-1,2,3,4-tetrahydroquinolines on Trypanosoma cruzi epimastigotes and amastigotes expressing β-galactosidase.
AID1501893	Toxicity in BALB/c mouse infected with Trypanosoma cruzi Y assessed as mortality at 100 mg/kg/day, po administered for 10 consecutive days starting on day 5 post infection measured during compound dosing	2017	European journal of medicinal chemistry, Oct-20, Volume: 139	Efficacy of a series of alpha-pyrone derivatives against Leishmania (L.) infantum and Trypanosoma cruzi.
AID1405635	Antitrypanosomal activity against luciferase-expressing Trypanosoma cruzi CL Brener infected in Balb/c mouse assessed as reduction in parasitemia at 50 mg/kg, ip bid for 4 days by bioluminescence assay relative to control	2018	European journal of medicinal chemistry, Aug-05, Volume: 156	Biological evaluation and structure-activity relationships of imidazole-based compounds as antiprotozoal agents.
AID1603945	Antitrypanosomal activity against Trypanosoma cruzi MHOM/Pe/2011/Arequipa;DTU 5 epimastigote assessed as change in RNA level at IC50 measured after 72 hrs by acridine orange staining based flow cytometry relative to control	2019	Bioorganic & medicinal chemistry, 09-01, Volume: 27, Issue:17	Rational modification of Mannich base-type derivatives as novel antichagasic compounds: Synthesis, in vitro and in vivo evaluation.
AID1498170	Trypanocidal activity against Trypanosoma cruzi MHOM/Pe/2011/Arequipa DTU 5 epimastigotes after 48 hrs by resazurin dye based assay	2018	Journal of medicinal chemistry, 07-12, Volume: 61, Issue:13	Second Generation of Mannich Base-Type Derivatives with in Vivo Activity against Trypanosoma cruzi.
AID1811313	Antitrypanosomal activity against Trypanosoma cruzi MHOM/MX/1994/Ninoa infected in animal assessed as reduction in viable parasite in blood measured after 24 hrs by neubauer chamber assay	2021	Bioorganic & medicinal chemistry, 10-15, Volume: 48	In vitro, ex vivo and in vivo short-term screening of DHEA nitrate derivatives activity over Trypanosoma cruzi Ninoa and TH strains from Oaxaca State, México.
AID1329381	Selectivity index, ratio of CC50 for mouse NCTC-929 cells to IC50 for Trypanosoma cruzi Y trypomastigote form infected in monkey LLC-MK2 cells	2016	Journal of natural products, 09-23, Volume: 79, Issue:9	Analogues of Marine Guanidine Alkaloids Are in Vitro Effective against Trypanosoma cruzi and Selectively Eliminate Leishmania (L.) infantum Intracellular Amastigotes.
AID1254444	Antiparasitic activity against bloodstream trypomastigote stage of Trypanosoma cruzi Y infected in BALB/c mouse assessed as increase in survival rate by measuring mortality at 100 mg/kg, po qd administered for 5 days measured until 30 days	2015	Bioorganic & medicinal chemistry, Dec-01, Volume: 23, Issue:23	Structural design, synthesis and pharmacological evaluation of 4-thiazolidinones against Trypanosoma cruzi.
AID1055171	Hepatotoxicity in BALB/c mouse infected with bloodstream trypomastigote form of Trypanosoma cruzi IRHOD/CO/2008/SN3 assessed as granuloma with lymphocytic infiltrate at 5 mg/kg/day, ip administered for 5 days measured 150 days post-infection by light micr	2013	European journal of medicinal chemistry, , Volume: 70	Scorpiand-like azamacrocycles prevent the chronic establishment of Trypanosoma cruzi in a murine model.
AID1613552	Hepatotoxicity in Balb/c mouse infected with Trypanosoma cruzi MHOM/Pe/2011/Arequipa DTU 5 trypomastigotes assessed as increase in serum ALT to GPT level at 20 mg/kg, po once daily for 5 consecutive days starting from day 10 post infection measured on day	2019	European journal of medicinal chemistry, Feb-15, Volume: 164	New polyamine drugs as more effective antichagas agents than benznidazole in both the acute and chronic phases.
AID1753511	Antitrypanosomal activity against nifurtimox-sensitive Trypanosoma cruzi Tulahuen CL2 infected in Swiss mouse peritoneal macrophages assessed as inhibition of parasite growth measured after 7 days by spectrophotometric analysis	2021	Journal of medicinal chemistry, 04-08, Volume: 64, Issue:7	Revisiting Pyrazolo[3,4-
AID575888	Toxicity in human patient infected with Trypanosoma cruzi assessed as occurrence of polyneuropathy on 4th week of treatment	2010	Antimicrobial agents and chemotherapy, Nov, Volume: 54, Issue:11	Tolerance of benznidazole in treatment of Chagas' disease in adults.
AID725217	Antiprotozoal activity against Trypanosoma cruzi Tulahuen C4 amastigotes after 96 hrs	2013	Bioorganic & medicinal chemistry letters, Jan-15, Volume: 23, Issue:2	Discovery and preliminary structure-activity relationship analysis of 1,14-sperminediphenylacetamides as potent and selective antimalarial lead compounds.
AID1244462	Cytotoxicity against human U937 cells assessed as cell viability after 72 hrs by MTT assay	2015	European journal of medicinal chemistry, Aug-28, Volume: 101	Synthesis, leishmanicidal, trypanocidal and cytotoxic activity of quinoline-hydrazone hybrids.
AID547249	Toxicity in mongrel dog infected with Trypanosoma cruzi Berenice-78 assessed as weight loss at 12 mg/kg, po BID for 90 days started 12 to 22 days postinfection measured after 6 months	2010	Antimicrobial agents and chemotherapy, Jul, Volume: 54, Issue:7	Effects of ravuconazole treatment on parasite load and immune response in dogs experimentally infected with Trypanosoma cruzi.
AID1184289	Cytotoxicity against human U2OS cells infected with intracellular Trypanosoma cruzi	2014	European journal of medicinal chemistry, Sep-12, Volume: 84	Synthesis and biological evaluation of 2,3-dihydroimidazo[1,2-a]benzimidazole derivatives against Leishmania donovani and Trypanosoma cruzi.
AID1202549	Antimicrobial activity against bloodstream trypomastigote stage of Trypanosoma cruzi NINOA after 24 hrs by Brener method	2015	European journal of medicinal chemistry, , Volume: 96	Design, synthesis and biological evaluation of quinazoline derivatives as anti-trypanosomatid and anti-plasmodial agents.
AID445550	Antitrypanosomal activity against Trypanosoma cruzi Tulahuen 2 epimastigotes assessed as parasite growth inhibition after 5 days	2009	European journal of medicinal chemistry, Dec, Volume: 44, Issue:12	Anti-trypanosomatid benzofuroxans and deoxygenated analogues: synthesis using polymer-supported triphenylphosphine, biological evaluation and mechanism of action studies.
AID401526	Antitrypanosomal activity against Trypanosoma cruzi	2004	Journal of natural products, May, Volume: 67, Issue:5	Ancistrotanzanine C and related 5,1'- and 7,3'-coupled naphthylisoquinoline alkaloids from Ancistrocladus tanzaniensis.
AID343556	Antitrypanosomal activity against epimastigotes of Trypanosoma cruzi Tulahuen 2 at 25 uM relative to control	2008	Bioorganic & medicinal chemistry, Jul-15, Volume: 16, Issue:14	New trypanocidal hybrid compounds from the association of hydrazone moieties and benzofuroxan heterocycle.
AID1177592	Antiparasitic activity against Trypanosoma cruzi Tulahuen C4	2014	Journal of natural products, Aug-22, Volume: 77, Issue:8	Xenortide Biosynthesis by Entomopathogenic Xenorhabdus nematophila.
AID1228665	Cytotoxicity against rhesus monkey LLC-MK2 cells assessed as inhibition of cell viability after 48 hrs by MTT assay	2015	Journal of natural products, May-22, Volume: 78, Issue:5	Anti-parasitic Guanidine and Pyrimidine Alkaloids from the Marine Sponge Monanchora arbuscula.
AID1584732	Antiparasitic activity against Trypanosoma cruzi Tulahuen CL2 intracellular amastigotes expressing beta-galactosidase infected in human MRC5 SV2 cells after 7 days by chlorophenol red beta-D-galactopyranoside-based spectrophotometric analysis	2018	Journal of medicinal chemistry, 10-25, Volume: 61, Issue:20	Discovery of Novel 7-Aryl 7-Deazapurine 3'-Deoxy-ribofuranosyl Nucleosides with Potent Activity against Trypanosoma cruzi.
AID1586958	Antitrypanosomal activity against Trypanosoma cruzi MHOM/BR/78/Silvio cloneX10/7A epimastigotes measured after 4 days by resazurin dye based fluorescence assay	2019	ACS medicinal chemistry letters, Jan-10, Volume: 10, Issue:1	Nongenotoxic 3-Nitroimidazo[1,2-
AID1281433	Induction of apoptosis in trypamostigote form of Trypanosoma cruzi Y assessed as necrotic cells at 25 uM after 24 hrs by Annexin V-FITC/propidium iodide staining based flow cytometry relative to untreated control	2016	European journal of medicinal chemistry, Mar-23, Volume: 111	Phthalimido-thiazoles as building blocks and their effects on the growth and morphology of Trypanosoma cruzi.
AID1498305	Hepatotoxicity in Balb/c mouse infected with Trypanosoma cruzi MHOM/Pe/2011/Arequipa DTU 5 trypamastigotes assessed as increase in ratio of serum AST to GOT level at 20 mg/kg, po once daily for 5 consecutive days starting from day 10 post infection measur	2018	Journal of medicinal chemistry, 07-12, Volume: 61, Issue:13	Second Generation of Mannich Base-Type Derivatives with in Vivo Activity against Trypanosoma cruzi.
AID497467	Trypanocidal activity against trypomastigote form of Trypanosoma cruzi Tulahuen infected in rat L6 cells after 96 hrs	2010	Journal of natural products, Aug-27, Volume: 73, Issue:8	Antiprotozoal steroidal saponins from the marine sponge Pandaros acanthifolium.
AID1156604	Antiparasitic activity against Trypanosoma cruzi Tulahen LacZ/C4 amastigotes after 4 days by beta-galactosidase reporter gene assay	2014	European journal of medicinal chemistry, Aug-18, Volume: 83	Synthesis and antiparasitic activity of new bis-arylimidamides: DB766 analogs modified in the terminal groups.
AID1498190	Trypanocidal activity against Trypanosoma cruzi MHOM/Pe/2011/Arequipa DTU 5 amastigotes infected in African green monkey Vero cells assessed as infected cells at 50 uM after 72 hrs by Giemsa-staining based microscopic assay relative to control	2018	Journal of medicinal chemistry, 07-12, Volume: 61, Issue:13	Second Generation of Mannich Base-Type Derivatives with in Vivo Activity against Trypanosoma cruzi.
AID1174780	Cytotoxicity against african green monkey Vero cells after 72 hrs	2015	European journal of medicinal chemistry, Jan-07, Volume: 89	Prospects of an alternative treatment against Trypanosoma cruzi based on abietic acid derivatives show promising results in Balb/c mouse model.
AID1613537	Cardiotoxicity in Balb/c mouse infected with Trypanosoma cruzi MHOM/Pe/2011/Arequipa DTU 5 trypomastigotes assessed as change in ratio of creatine kinase in muscle to brain at 20 mg/kg, po once daily for 5 consecutive days starting from day 75 post infect	2019	European journal of medicinal chemistry, Feb-15, Volume: 164	New polyamine drugs as more effective antichagas agents than benznidazole in both the acute and chronic phases.
AID1403407	Therapeutic index, ratio of CC50 for African green monkey Vero cells to IC50 for Trypanosoma cruzi Dm28c intracellular amastigotes infected in African green monkey Vero cells	2018	European journal of medicinal chemistry, Jan-20, Volume: 144	Efficacy of 2-hydroxy-3-phenylsulfanylmethyl-[1,4]-naphthoquinone derivatives against different Trypanosoma cruzi discrete type units: Identification of a promising hit compound.
AID1851975	Cytotoxicity against mouse 3T3 cells	2022	Journal of medicinal chemistry, 10-13, Volume: 65, Issue:19	Nitroimidazopyrazinones with Oral Activity against Tuberculosis and Chagas Disease in Mouse Models of Infection.
AID1860608	Antitrypanosomal activity against Trypanosoma cruzi infected in Vero cells assessed as relapse day after washout at 12.5 times EC50 for 8 days followed by washout by microscopic analysis	2022	European journal of medicinal chemistry, Aug-05, Volume: 238	Identification and development of a series of disubstituted piperazines for the treatment of Chagas disease.
AID1613475	Cytotoxicity against African green monkey Vero cells assessed as reduction in cell viability after 48 to 72 hrs by resazurin dye based assay	2019	European journal of medicinal chemistry, Feb-15, Volume: 164	New polyamine drugs as more effective antichagas agents than benznidazole in both the acute and chronic phases.
AID1245580	Antiparasitic activity against amastigote stage of Trypanosoma cruzi Tulahuen C4 infected in rat L6 cells assessed as parasite growth inhibition after 96 hrs by beta-galactosidase reporter gene assay	2015	Bioorganic & medicinal chemistry, Oct-01, Volume: 23, Issue:19	Discovery of potent nitrotriazole-based antitrypanosomal agents: In vitro and in vivo evaluation.
AID744593	Antiprotozoal activity against trypomastigote form of Trypanosoma cruzi Colombian infected in BALB/c mouse assessed as decrease in parasitemia at 100 mg/kg, po administered for 1 week followed by weekly administration measured after 8 months	2013	Bioorganic & medicinal chemistry letters, May-01, Volume: 23, Issue:9	New antiprotozoal agents: their synthesis and biological evaluations.
AID1615058	Antitrypanosomal activity against Trypanosoma cruzi MHOM/Pe/2011/Arequipa DTU 5 trypomastigotes infected in Balb/c mouse assessed as reduction in Ig-G level in serum at 20 mg/kg, po once daily for 5 consecutive days starting from day 10 post infection mea	2019	Bioorganic & medicinal chemistry, 03-01, Volume: 27, Issue:5	Synthesis and biological evaluation of new long-chain squaramides as anti-chagasic agents in the BALB/c mouse model.
AID537136	Cytotoxicity against rhesus monkey LLC-MK2 cells after 48 hrs by MTT assay	2010	Bioorganic & medicinal chemistry, Nov-15, Volume: 18, Issue:22	Anti-leishmanial and anti-trypanosomal activities of 1,4-dihydropyridines: In vitro evaluation and structure-activity relationship study.
AID1615059	Antitrypanosomal activity against Trypanosoma cruzi MHOM/Pe/2011/Arequipa DTU 5 trypomastigotes infected in Balb/c mouse assessed as reduction in Ig-G level in serum at 20 mg/kg, po pretreated once daily for 5 consecutive days starting from day 10 post in	2019	Bioorganic & medicinal chemistry, 03-01, Volume: 27, Issue:5	Synthesis and biological evaluation of new long-chain squaramides as anti-chagasic agents in the BALB/c mouse model.
AID1240908	Cytotoxicity against rat L6 cells after 72 hrs by alamar blue assay	2015	Journal of medicinal chemistry, Aug-27, Volume: 58, Issue:16	2-Phenoxy-1,4-naphthoquinones: From a Multitarget Antitrypanosomal to a Potential Antitumor Profile.
AID1603830	Antitrypanosomal activity against Trypanosoma cruzi MHOM/Pe/2011/Arequipa;DTU 5 bloodstream trypomastigotes infected in BALB/c mouse assessed as parasite-free stomach in acute phase at 20 mg/kg/day, po administered for 5 consecutive days starting from day	2019	Bioorganic & medicinal chemistry, 09-01, Volume: 27, Issue:17	Rational modification of Mannich base-type derivatives as novel antichagasic compounds: Synthesis, in vitro and in vivo evaluation.
AID596811	Antitrypanosomal activity against blood trypomastigote forms of Trypanosoma cruzi infected in BALB/c mouse assessed as mouse survival rate at 1 mg/kg, ip administered 7 days postinfection once daily for 5 days	2011	Journal of natural products, Apr-25, Volume: 74, Issue:4	In vitro and in vivo trypanocidal activity of flavonoids from Delphinium staphisagria against Chagas disease.
AID1070007	Antimicrobial activity against amastigote stage of Trypanosoma cruzi CL Brener infected in mouse NCTC-929 cells assessed as growth inhibition at 4 uM after 7 days by beta-galactosidase reporter gene assay	2014	Bioorganic & medicinal chemistry letters, Feb-15, Volume: 24, Issue:4	In vitro phenotypic screening of 7-chloro-4-amino(oxy)quinoline derivatives as putative anti-Trypanosoma cruzi agents.
AID595452	Antiparasitic activity against intracellular amastigotes of Trypanosoma cruzi Tulahuen C2C4 expressing LacZ gene infected in rat L6 cells after 96 hrs by photometrically	2011	Journal of natural products, Apr-25, Volume: 74, Issue:4	Didemnidines A and B, indole spermidine alkaloids from the New Zealand ascidian Didemnum sp.
AID299531	Inhibition of Trypanosoma cruzi	2007	Bioorganic & medicinal chemistry letters, Aug-01, Volume: 17, Issue:15	Synthesis and in vitro protozoocidal activity of diazabicyclic benzotropolone derivatives.
AID1683668	Toxicity in BALB/c mouse infected with Trypanosomal Trypanosoma cruzi MHOM/Pe/2011/Arequipa(DTU V) assessed as reduction in weight at 20 mg/kg, po administered for 5 days starting at 100 days post infection and measured up to 145 days post infection	2020	Journal of natural products, 12-24, Volume: 83, Issue:12	In Vivo Biological Evaluation of a Synthetic Royleanone Derivative as a Promising Fast-Acting Trypanocidal Agent by Inducing Mitochondrial-Dependent Necrosis.
AID1615121	Hepatotoxicity in Balb/c mouse infected with Trypanosoma cruzi MHOM/Pe/2011/Arequipa DTU 5 trypomastigotes assessed as increase in total bilirubin level at 20 mg/kg, po once daily for 5 consecutive days starting from day 75 post infection measured on day	2019	Bioorganic & medicinal chemistry, 03-01, Volume: 27, Issue:5	Synthesis and biological evaluation of new long-chain squaramides as anti-chagasic agents in the BALB/c mouse model.
AID580661	Antitrypanosomal activity against Trypanosoma cruzi Y infected in CD8+ T-lymphocyte knockout C57BL/6 mouse assessed as occurrence of low level of circulating parasites at 100 mg/kg/day, po administered once daily for 20 consecutive days measured 15 days p	2009	Antimicrobial agents and chemotherapy, Jan, Volume: 53, Issue:1	Absence of CD4+ T lymphocytes, CD8+ T lymphocytes, or B lymphocytes has different effects on the efficacy of posaconazole and benznidazole in treatment of experimental acute Trypanosoma cruzi infection.
AID1498231	Antitrypanosomal activity against Trypanosoma cruzi MHOM/Pe/2011/Arequipa DTU 5 trypamastigotes infected in Balb/c mouse assessed as reduction in parasitaemia reactivation in esophagus tissue at 20 mg/kg, po pretreated once daily for 5 consecutive days st	2018	Journal of medicinal chemistry, 07-12, Volume: 61, Issue:13	Second Generation of Mannich Base-Type Derivatives with in Vivo Activity against Trypanosoma cruzi.
AID1079945	Animal toxicity known. [column 'TOXIC' in source]
AID396589	Antitrypanosomal activity against Trypanosoma cruzi CL-B5 amastigotes infected in mouse NCTC-929 fibroblast after 7 days by colorimetric method	2008	European journal of medicinal chemistry, Sep, Volume: 43, Issue:9	Activity of a hydroxybibenzyl bryophyte constituent against Leishmania spp. and Trypanosoma cruzi: in silico, in vitro and in vivo activity studies.
AID392005	Antitrypanosomal activity against Trypanosoma cruzi Colombiana infected Swiss mouse assessed as reduction in circulating trypomastigotes antibody level at 120 mg/kg/day, po after 44 days postinfection	2008	European journal of medicinal chemistry, Oct, Volume: 43, Issue:10	In vivo studies of 5-arylethenylbenzofuroxans in acute murine models of Chagas' disease.
AID1074925	Antitrypanosomal activity against Trypanosoma cruzi (IRHOD/CO/2008/SN3) infected in African green monkey Vero cells assessed as reduction in number of amastigotes at IC25 treated for 12 hrs followed by compound-washout measured after 10 days by microscopi	2014	European journal of medicinal chemistry, Mar-03, Volume: 74	New perspectives on the synthesis and antichagasic activity of 3-alkoxy-1-alkyl-5-nitroindazoles.
AID382467	Antiplasmodial activity against Plasmodium falciparum K1 infected human erythrocytes after 48 hrs as [3H]hypoxanthine uptake	2008	European journal of medicinal chemistry, Jan, Volume: 43, Issue:1	Synthesis and antiprotozoal activities of simplified analogs of naphthylisoquinoline alkaloids.
AID1687780	Selectivity index, ratio of GI50 for mouse RAW264.7 cells assessed as reduction in cell viability measured after 24 hrs by WST1 assay to IC50 for antitrypanosomal activity against Trypanosoma cruzi Y axenic amastigotes infected in African green monkey Ver	2020	European journal of medicinal chemistry, Jan-15, Volume: 186	Novel nitroimidazole derivatives evaluated for their trypanocidal, cytotoxic, and genotoxic activities.
AID1074929	Cytotoxicity against African green monkey Vero cells assessed as cell viability after 72 hrs by propidium iodide staining-based flow cytometric analysis	2014	European journal of medicinal chemistry, Mar-03, Volume: 74	New perspectives on the synthesis and antichagasic activity of 3-alkoxy-1-alkyl-5-nitroindazoles.
AID155967	Cytotoxicity against peritoneal macrophages of female CD1 mice culturing amastigote stages of Trypanosoma cruzi; no data	2000	Bioorganic & medicinal chemistry letters, Jun-05, Volume: 10, Issue:11	Synthesis and evaluation of 9,9-dimethylxanthene tricyclics against trypanothione reductase, Trypanosoma brucei, Trypanosoma cruzi and Leishmania donovani.
AID613446	Trypanocidal activity against intracellular amastigotes form of Trypanosoma cruzi expressing beta-galactosidase infected in mouse J774 cells on day 7	2011	European journal of medicinal chemistry, Sep, Volume: 46, Issue:9	Synthesis, trypanocidal activity and molecular modeling studies of 2-alkylaminomethylquinoline derivatives.
AID344425	Cytotoxicity against chinese hamster V79 cells	2008	Journal of medicinal chemistry, Jul-24, Volume: 51, Issue:14	Complexation of the anti-Trypanosoma cruzi drug benznidazole improves solubility and efficacy.
AID1498239	Antitrypanosomal activity against Trypanosoma cruzi MHOM/Pe/2011/Arequipa DTU 5 trypamastigotes infected in Balb/c mouse assessed as reduction in parasitaemia reactivation in brain tissue at 20 mg/kg, po pretreated once daily for 5 consecutive days starti	2018	Journal of medicinal chemistry, 07-12, Volume: 61, Issue:13	Second Generation of Mannich Base-Type Derivatives with in Vivo Activity against Trypanosoma cruzi.
AID1462695	Antiparasitic activity against Trypanosoma cruzi Tulahuen C4 intracellular amastigotes infected in rat L6 cells assessed as growth inhibition at 4.8 ug/ml after 96 hrs by CPRG/Nonidet reagent based photometric analysis relative to control	2017	Bioorganic & medicinal chemistry letters, 09-01, Volume: 27, Issue:17	Lead selection of antiparasitic compounds from a focused library of benzenesulfonyl derivatives of heterocycles.
AID1498360	Induction of mitochondrial membrane potential disruption in Trypanosoma cruzi MHOM/Pe/2011/Arequipa DTU 5 epimastigotes assessed as inhibition of DNA replication and RNA synthesis at IC25 after 72 hrs by acridine orange staining based flow cytometry relat	2018	Journal of medicinal chemistry, 07-12, Volume: 61, Issue:13	Second Generation of Mannich Base-Type Derivatives with in Vivo Activity against Trypanosoma cruzi.
AID1616127	Cytotoxicity against human MRC5 SV2 cells assessed as reduction in cell viability incubated for 3 days by resazurin dye based assay	2019	Journal of medicinal chemistry, 10-10, Volume: 62, Issue:19	Discovery of Pyrrolo[2,3-
AID766422	Cytotoxicity against mouse NCTC-929 cells after 48 hrs by resazurin based fluorescence assay	2013	Bioorganic & medicinal chemistry letters, Sep-01, Volume: 23, Issue:17	Selective activity of 2,4-diaryl-1,2,3,4-tetrahydroquinolines on Trypanosoma cruzi epimastigotes and amastigotes expressing β-galactosidase.
AID575891	Toxicity in human patient infected with Trypanosoma cruzi assessed as occurrence of thrombopenic purpura after 2nd week of treatment	2010	Antimicrobial agents and chemotherapy, Nov, Volume: 54, Issue:11	Tolerance of benznidazole in treatment of Chagas' disease in adults.
AID1459247	Trypanocidal activity against Trypanosoma cruzi TCC epimastigotes assessed as effect on parasite viability at 1 to 15 uM supplemented with fresh medium containing compound every 9 to 10 days measured on third week by maximal parasite density	2017	European journal of medicinal chemistry, Jan-05, Volume: 125	Novel 2-arylazoimidazole derivatives as inhibitors of Trypanosoma cruzi proliferation: Synthesis and evaluation of their biological activity.
AID537133	Antileishmanial activity against promastigotes of Leishmania major MHOM/1L/80/Fredlin after 18 hrs by MTT assay	2010	Bioorganic & medicinal chemistry, Nov-15, Volume: 18, Issue:22	Anti-leishmanial and anti-trypanosomal activities of 1,4-dihydropyridines: In vitro evaluation and structure-activity relationship study.
AID677209	Selectivity index, ratio of IC50 for Vero cells to IC50 for Trypanosoma cruzi epimastigote	2012	Journal of medicinal chemistry, May-10, Volume: 55, Issue:9	In vitro and in vivo trypanosomicidal activity of pyrazole-containing macrocyclic and macrobicyclic polyamines: their action on acute and chronic phases of Chagas disease.
AID1245590	Prodrug conversion assessed as Trypanosoma cruzi recombinant type-1 nitroreductase-mediated drug metabolism by measuring NADH oxidation after 5 mins by spectrophotometric analysis	2015	Bioorganic & medicinal chemistry, Oct-01, Volume: 23, Issue:19	Discovery of potent nitrotriazole-based antitrypanosomal agents: In vitro and in vivo evaluation.
AID1079943	Malignant tumor, proven histopathologically. Value is number of references indexed. [column 'T.MAL' in source]
AID547276	Immunostimulatory activity in mongrel dog infected with Trypanosoma cruzi Y assessed as production of antibody IgG2 at 7 mg/kg, po BID for 90 days measured after 6 months by ELISA	2010	Antimicrobial agents and chemotherapy, Jul, Volume: 54, Issue:7	Effects of ravuconazole treatment on parasite load and immune response in dogs experimentally infected with Trypanosoma cruzi.
AID1603764	Trypanocidal activity against Trypanosoma cruzi TINF/CH/1956/Tulahuen;DTU 6 trypomastigote forms infected in BALB/c albino mouse measured after 10 mins by Neubauer chamber method	2019	Bioorganic & medicinal chemistry, 09-01, Volume: 27, Issue:17	Rational modification of Mannich base-type derivatives as novel antichagasic compounds: Synthesis, in vitro and in vivo evaluation.
AID1079931	Moderate liver toxicity, defined via clinical-chemistry results: ALT or AST serum activity 6 times the normal upper limit (N) or alkaline phosphatase serum activity of 1.7 N. Value is number of references indexed. [column 'BIOL' in source]
AID213667	In vitro growth inhibition of amastigotes of Trypanosoma cruzi	2004	Bioorganic & medicinal chemistry letters, Jul-05, Volume: 14, Issue:13	Toxic effects of natural piperine and its derivatives on epimastigotes and amastigotes of Trypanosoma cruzi.
AID1238021	Anti-leishmanial activity against Leishmania amazonensis MPRO/BR/1972/M1841-LV-79 amastigotes infected in BALB/c mouse peritoneal macrophages assessed as reduction in the infection index incubated for 24 hrs by Giemsa staining method	2015	Bioorganic & medicinal chemistry letters, Aug-15, Volume: 25, Issue:16	Synthesis and evaluation of novel prenylated chalcone derivatives as anti-leishmanial and anti-trypanosomal compounds.
AID1351075	Selectivity index, ratio of CC50 for cytotoxicity against human U2OS cells to IC50 for Trypanosoma cruzi Y Tc2 amastigotes infected in human U2OS cells	2018	European journal of medicinal chemistry, Jan-20, Volume: 144	Investigating the structure-activity relationships of N'-[(5-nitrofuran-2-yl) methylene] substituted hydrazides against Trypanosoma cruzi to design novel active compounds.
AID1163253	Trypanocidal activity against nifurtimox-sensitive Trypanosoma cruzi Tulahuen CL2 infected in human MRC5 SV2 cells assessed as parasite growth inhibition after 168 hrs by beta-galactosidase assay	2014	Bioorganic & medicinal chemistry, Oct-01, Volume: 22, Issue:19	From human immunodeficiency virus non-nucleoside reverse transcriptase inhibitors to potent and selective antitrypanosomal compounds.
AID576108	Toxicity in human patient infected with Trypanosoma cruzi assessed as occurrence of dolichocolon at 5 mg/kg/day for 60 days	2010	Antimicrobial agents and chemotherapy, Nov, Volume: 54, Issue:11	Tolerance of benznidazole in treatment of Chagas' disease in adults.
AID1498176	Selectivity index, ratio of IC50 for African green monkey Vero cells to IC50 for Trypanosoma cruzi TINF/CH/1956/Tulahuen DTU 6 epimastigotes	2018	Journal of medicinal chemistry, 07-12, Volume: 61, Issue:13	Second Generation of Mannich Base-Type Derivatives with in Vivo Activity against Trypanosoma cruzi.
AID1254020	Antiparasitic activity against trypomastigote form of Trypanosoma cruzi Tulahuen-lacZ infected in LLC-MK2 ATCC cells assessed as parasite viability incubated for 4 days at 37 degC by chlorophenol beta-D-galactopyranose substrate based trypanocidal assay	2015	Bioorganic & medicinal chemistry, Nov-01, Volume: 23, Issue:21	1,2,3-Triazole-based analogue of benznidazole displays remarkable activity against Trypanosoma cruzi.
AID1849827	Antitrypanosomal activity against bloodstream form of Trypanosoma cruzi Y trypomastigotes infected in albino mouse assessed as reduction in viable parasite in blood by Neubauer counting chamber method	2021	European journal of medicinal chemistry, Jan-15, Volume: 210	A comprehensive review on β-lapachone: Mechanisms, structural modifications, and therapeutic potentials.
AID677572	Antitrypanosomal activity against bloodstream form of Trypanosoma brucei brucei Lister 427 clone 221a overexpressing tet-inducible NTR in absence of tetracycline after 3 days	2012	Journal of medicinal chemistry, Jun-14, Volume: 55, Issue:11	Novel 3-nitro-1H-1,2,4-triazole-based amides and sulfonamides as potential antitrypanosomal agents.
AID548109	Antiparasitic activity against Trypanosoma cruzi T2 epimastigotes assessed as growth inhibition	2010	European journal of medicinal chemistry, Dec, Volume: 45, Issue:12	Massive screening yields novel and selective Trypanosoma cruzi triosephosphate isomerase dimer-interface-irreversible inhibitors with anti-trypanosomal activity.
AID672967	Cytotoxicity against african green monkey Vero cells after 72 hrs by spectrophotometric analysis	2012	Bioorganic & medicinal chemistry, Aug-15, Volume: 20, Issue:16	New oxirane derivatives of 1,4-naphthoquinones and their evaluation against T. cruzi epimastigote forms.
AID1055186	Trypanocidal activity against extracellular trypomastigote form of Trypanosoma cruzi IRHOD/CO/2008/SN3 after 24 hrs by Neubauer hemocytometric analysis	2013	European journal of medicinal chemistry, , Volume: 70	Scorpiand-like azamacrocycles prevent the chronic establishment of Trypanosoma cruzi in a murine model.
AID1682939	Antitrypanosomal activity against blood trypomastigote form of Trypanosoma cruzi strain Y infected in BALB/c mouse assessed as reduction in parasite DNA load in host heart at 25 mg/kg, po administered via gavage daily for 15 days starting from 2 days post	2021	Bioorganic & medicinal chemistry, 01-01, Volume: 29	Trypanocidal activity of new 1,6-diphenyl-1H-pyrazolo[3,4-b]pyridine derivatives: Synthesis, in vitro and in vivo studies.
AID1498187	Selectivity index, ratio of IC50 for African green monkey Vero cells to IC50 for Trypanosoma cruzi TINF/CH/1956/Tulahuen DTU 6 amastigotes infected in African green monkey Vero cells	2018	Journal of medicinal chemistry, 07-12, Volume: 61, Issue:13	Second Generation of Mannich Base-Type Derivatives with in Vivo Activity against Trypanosoma cruzi.
AID710861	Antitrypanosomal activity against trypomastigotes of Trypanosoma cruzi Y infected in mouse peritoneal macrophages assessed as reduction of intracellular parasite level at 10 uM after 4 days	2012	Journal of medicinal chemistry, Dec-27, Volume: 55, Issue:24	Structural investigation of anti-Trypanosoma cruzi 2-iminothiazolidin-4-ones allows the identification of agents with efficacy in infected mice.
AID1498340	Hepatotoxicity in Balb/c mouse infected with Trypanosoma cruzi MHOM/Pe/2011/Arequipa DTU 5 trypamastigotes assessed as increase in alkaline phosphatase level at 20 mg/kg, po once daily for 5 consecutive days starting from day 10 post infection measured on	2018	Journal of medicinal chemistry, 07-12, Volume: 61, Issue:13	Second Generation of Mannich Base-Type Derivatives with in Vivo Activity against Trypanosoma cruzi.
AID285210	Effect on survival in Trypanosoma cruzi Y infected C57BL/6 mouse Chagas disease model assessed as mean survival time at 100 mg/kg, po after 20 days	2007	Antimicrobial agents and chemotherapy, Apr, Volume: 51, Issue:4	The Anti-Trypanosoma cruzi activity of posaconazole in a murine model of acute Chagas' disease is less dependent on gamma interferon than that of benznidazole.
AID1496049	Antitrypanosomal activity against bloodstream trypomastigote stage of Trypanosoma cruzi Y infected in Swiss Webster mouse cardiac cells after 24 hrs	2018	Bioorganic & medicinal chemistry letters, 06-15, Volume: 28, Issue:11	Identification and preliminary structure-activity relationship studies of novel pyridyl sulfonamides as potential Chagas disease therapeutic agents.
AID1498240	Antitrypanosomal activity against Trypanosoma cruzi MHOM/Pe/2011/Arequipa DTU 5 trypamastigotes infected in Balb/c mouse assessed as reduction in parasitaemia reactivation in esophagus tissue at 20 mg/kg, po pretreated once daily for 5 consecutive days st	2018	Journal of medicinal chemistry, 07-12, Volume: 61, Issue:13	Second Generation of Mannich Base-Type Derivatives with in Vivo Activity against Trypanosoma cruzi.
AID396006	Antimicrobial activity against Trypanosoma cruzi infected in BALB/c mouse assessed as parasitemia remaining by PCR method	2007	Antimicrobial agents and chemotherapy, Sep, Volume: 51, Issue:9	Impact of dual infections on chemotherapeutic efficacy in BALB/c mice infected with major genotypes of Trypanosoma cruzi.
AID576837	Antitrypanosomal activity against trypomastigote of Trypanosoma cruzi infected in BALB/c mouse assessed as reduction of anti-Trypanosoma cruzi antibody level at 1 mg/kg, ip qd for 5 days measured after 120 days postinfection by ELISA	2011	Journal of medicinal chemistry, Feb-24, Volume: 54, Issue:4	In vivo trypanosomicidal activity of imidazole- or pyrazole-based benzo[g]phthalazine derivatives against acute and chronic phases of Chagas disease.
AID106021	Tested for cytotoxicity towards human MRC-5 cells	2002	Bioorganic & medicinal chemistry letters, Dec-16, Volume: 12, Issue:24	Antitrypanosomal activities and cytotoxicity of 5-nitro-2-furancarbohydrazides.
AID1615122	Hepatotoxicity in Balb/c mouse infected with Trypanosoma cruzi MHOM/Pe/2011/Arequipa DTU 5 trypomastigotes assessed as increase in total bilirubin level at 20 mg/kg, po once daily for 5 consecutive days starting from day 75 post infection measured on day	2019	Bioorganic & medicinal chemistry, 03-01, Volume: 27, Issue:5	Synthesis and biological evaluation of new long-chain squaramides as anti-chagasic agents in the BALB/c mouse model.
AID1780969	Selectivity index, ratio of cytotoxicity against golden hamster BSR cells to IC50 for antitrypanosomal activity against Trypanosoma cruzi trypomastigotes	2021	European journal of medicinal chemistry, Nov-05, Volume: 223	Design and synthesis of Mannich base-type derivatives containing imidazole and benzimidazole as lead compounds for drug discovery in Chagas Disease.
AID439776	Antitrypanosomal activity against Trypanosoma cruzi trypomastigotes	2009	Journal of medicinal chemistry, Dec-10, Volume: 52, Issue:23	Neglected tropical diseases: multi-target-directed ligands in the search for novel lead candidates against Trypanosoma and Leishmania.
AID1196810	Binding affinity to recombinant full-length Trypanosoma cruzi CYP51 by UV-spectrophotometric analysis	2015	Journal of medicinal chemistry, Feb-12, Volume: 58, Issue:3	Novel 3-nitrotriazole-based amides and carbinols as bifunctional antichagasic agents.
AID613444	Trypanocidal activity against epimastigote form of Trypanosoma cruzi assessed as [3H]thymidine uptake after 72 hrs by liquid scintillation counter	2011	European journal of medicinal chemistry, Sep, Volume: 46, Issue:9	Synthesis, trypanocidal activity and molecular modeling studies of 2-alkylaminomethylquinoline derivatives.
AID1321006	Cytotoxicity against human U2OS cells infected with amastigote stage of Trypanosoma cruzi Y assessed as decrease in number of cells after 96 hrs by Draq5 staining-based high content screening assay	2016	European journal of medicinal chemistry, Oct-04, Volume: 121	Design, synthesis and antitrypanosomal activity of some nitrofurazone 1,2,4-triazolic bioisosteric analogues.
AID1498228	Antitrypanosomal activity against Trypanosoma cruzi MHOM/Pe/2011/Arequipa DTU 5 trypamastigotes infected in Balb/c mouse assessed as reduction in parasitaemia reactivation in adipose tissue at 20 mg/kg, po pretreated once daily for 5 consecutive days star	2018	Journal of medicinal chemistry, 07-12, Volume: 61, Issue:13	Second Generation of Mannich Base-Type Derivatives with in Vivo Activity against Trypanosoma cruzi.
AID766421	Cytotoxicity against mouse NCTC-929 cells at 256 uM after 48 hrs by resazurin based fluorescence assay	2013	Bioorganic & medicinal chemistry letters, Sep-01, Volume: 23, Issue:17	Selective activity of 2,4-diaryl-1,2,3,4-tetrahydroquinolines on Trypanosoma cruzi epimastigotes and amastigotes expressing β-galactosidase.
AID344439	Antitrypanosomal activity against Trypanosoma cruzi Y infected in Swiss mouse assessed as survivality at 385 umol/kg, po for 1 day after 15 days	2008	Journal of medicinal chemistry, Jul-24, Volume: 51, Issue:14	Complexation of the anti-Trypanosoma cruzi drug benznidazole improves solubility and efficacy.
AID1456723	Antiparasitic activity against Trypanosoma cruzi infected in human assessed as cure rate under chronic condition	2017	Journal of medicinal chemistry, 09-28, Volume: 60, Issue:18	Nitroimidazoles: Molecular Fireworks That Combat a Broad Spectrum of Infectious Diseases.
AID1191151	Antitrypanosomal activity against trypomastigote stage of Trypanosoma cruzi Y infected in monkey LLC-MK2 cells after 24 hrs by Pizzi-Brener method	2015	European journal of medicinal chemistry, Jan-27, Volume: 90	Synthesis and biological evaluation of novel 2,3-disubstituted quinoxaline derivatives as antileishmanial and antitrypanosomal agents.
AID1687703	Cytotoxicity against African green monkey Vero cells assessed as reduction in cell viability measured after 24 hrs by MTT assay	2020	European journal of medicinal chemistry, Jan-15, Volume: 186	Hit-to-lead optimization of novel 2-alkylaminomethylquinoline derivatives as anti-chagas agents.
AID1682944	Antitrypanosomal activity against intracellular amastigote form of Trypanosoma cruzi Tulahuen strain infected in monkey LLC-MK2 cells assessed as reduction in parasite viability incubated for 72 hrs by beta-galactosidase reporter gene assay	2021	Bioorganic & medicinal chemistry, 01-01, Volume: 29	Trypanocidal activity of new 1,6-diphenyl-1H-pyrazolo[3,4-b]pyridine derivatives: Synthesis, in vitro and in vivo studies.
AID1238025	Anti-leishmanial activity against Leishmania infantum MHOM/BR/72 amastigotes infected in BALB/c mouse peritoneal macrophages assessed as reduction in the infection index incubated for 24 hrs by Giemsa staining method	2015	Bioorganic & medicinal chemistry letters, Aug-15, Volume: 25, Issue:16	Synthesis and evaluation of novel prenylated chalcone derivatives as anti-leishmanial and anti-trypanosomal compounds.
AID1633359	Antitrypanosomal activity against Trypanosoma cruzi Dm28c intracellular amastigotes infected in African green monkey Vero cells incubated for 24 hrs by luciferase-luminescence based assay
AID547280	Antitrypanosomal activity against Trypanosoma cruzi Y infected in mongrel dog assessed as reduction in IL10 production in right atrium at 7 mg/kg, po BID after 180 days by semiquantitative RT-PCR	2010	Antimicrobial agents and chemotherapy, Jul, Volume: 54, Issue:7	Effects of ravuconazole treatment on parasite load and immune response in dogs experimentally infected with Trypanosoma cruzi.
AID576947	Antimicrobial activity against Trypanosoma cruzi Tulahuen infected in Swiss mouse assessed as reduction in blood parasite load at 60 mg/kg/day, po for 6 days per week until completion of 60 compound doses administered 5 days post infection	2010	Antimicrobial agents and chemotherapy, Sep, Volume: 54, Issue:9	Hydroxymethylnitrofurazone is active in a murine model of Chagas' disease.
AID1686731	Antitrypanosomal activity against Trypanosoma cruzi Tulahuen epimastigote forms incubated for 72 hrs by hemocytometry	2016	Journal of medicinal chemistry, 12-22, Volume: 59, Issue:24	In Vitro and in Vivo Anti-Trypanosoma cruzi Activity of New Arylamine Mannich Base-Type Derivatives.
AID1498230	Antitrypanosomal activity against Trypanosoma cruzi MHOM/Pe/2011/Arequipa DTU 5 trypamastigotes infected in Balb/c mouse assessed as reduction in parasitaemia reactivation in brain tissue at 20 mg/kg, po pretreated once daily for 5 consecutive days starti	2018	Journal of medicinal chemistry, 07-12, Volume: 61, Issue:13	Second Generation of Mannich Base-Type Derivatives with in Vivo Activity against Trypanosoma cruzi.
AID1615013	Trypanocidal activity against Trypanosoma cruzi MHOM/Pe/2011/Arequipa DTU 5 amastigotes infected in African green monkey Vero cells after 72 hrs by Giemsa-staining based microscopic assay	2019	Bioorganic & medicinal chemistry, 03-01, Volume: 27, Issue:5	Synthesis and biological evaluation of new long-chain squaramides as anti-chagasic agents in the BALB/c mouse model.
AID1683692	Antitrypanosomal activity against Trypanosoma cruzi MHOM/Pe/2011/Arequipa(DTU V) amastigote form infected in BALB/c mouse assessed as parasite free organ tissue ratio at 20 mg/kg, po administered for 5 days starting at 100 days post infection and measured	2020	Journal of natural products, 12-24, Volume: 83, Issue:12	In Vivo Biological Evaluation of a Synthetic Royleanone Derivative as a Promising Fast-Acting Trypanocidal Agent by Inducing Mitochondrial-Dependent Necrosis.
AID547251	Antimicrobial activity against Trypanosoma cruzi Y infected in mongrel dog assessed as suppression of microbial proliferation at 12 mg/kg, po BID started 12 to 22 days postinfection measured after 1 day	2010	Antimicrobial agents and chemotherapy, Jul, Volume: 54, Issue:7	Effects of ravuconazole treatment on parasite load and immune response in dogs experimentally infected with Trypanosoma cruzi.
AID1375934	Parasiticidal activity against amastigote stage of Trypanosoma cruzi Tulahuen infected in mouse brain fibroblast assessed as time duration of effect at 19.2 microM preincubated for 5 days followed by another 10 days incubation with fresh compound	2018	Journal of medicinal chemistry, 06-14, Volume: 61, Issue:11	NMR Biochemical Assay for Oxidosqualene Cyclase: Evaluation of Inhibitor Activities on Trypanosoma cruzi and Human Enzymes.
AID344437	Antitrypanosomal activity against Trypanosoma cruzi Y infected in Swiss mouse assessed as survivality at 100 nmol/kg, ip after 15 consecutive days	2008	Journal of medicinal chemistry, Jul-24, Volume: 51, Issue:14	Complexation of the anti-Trypanosoma cruzi drug benznidazole improves solubility and efficacy.
AID1613525	Nephrotoxicity in Balb/c mouse infected with Trypanosoma cruzi MHOM/Pe/2011/Arequipa DTU 5 trypomastigotes assessed as decrease in serum urea level at 20 mg/kg, po once daily for 5 consecutive days starting from day 75 post infection measured on day 81 po	2019	European journal of medicinal chemistry, Feb-15, Volume: 164	New polyamine drugs as more effective antichagas agents than benznidazole in both the acute and chronic phases.
AID1498179	Trypanocidal activity against Trypanosoma cruzi IRHOD/CO/2008/SN3 DTU 1 amastigotes infected in African green monkey Vero cells after 72 hrs by Giemsa-staining based microscopic assay	2018	Journal of medicinal chemistry, 07-12, Volume: 61, Issue:13	Second Generation of Mannich Base-Type Derivatives with in Vivo Activity against Trypanosoma cruzi.
AID548284	Selectivity ratio of EC50 for Trypanosoma brucei NfxR2 to EC50 for Trypanosoma brucei	2010	Antimicrobial agents and chemotherapy, Jul, Volume: 54, Issue:7	Cross-resistance to nitro drugs and implications for treatment of human African trypanosomiasis.
AID1367742	Antitrypanosomal activity against tdTomato red labeled trypomastigote stage of Trypanosoma cruzi infected in gamma-irradiated African green monkey Vero cells after 3 days by fluorescence assay	2017	Bioorganic & medicinal chemistry, 12-15, Volume: 25, Issue:24	Selenium-containing analogues of WC-9 are extremely potent inhibitors of Trypanosoma cruzi proliferation.
AID677290	Toxicity in BALB/c mouse liver infected with Trypanosoma cruzi assessed as lymphocytic infiltrations in portal tracts at 5 mg/kg, ip after 120 days postinfection Histopathological analysis	2012	Journal of medicinal chemistry, May-10, Volume: 55, Issue:9	In vitro and in vivo trypanosomicidal activity of pyrazole-containing macrocyclic and macrobicyclic polyamines: their action on acute and chronic phases of Chagas disease.
AID1290514	Antiprotozoan activity against intracellular amastigote stage of Trypanosoma cruzi Tulahuen infected in human THP1 cells assessed as reduction in parasite viability after 48 hrs by microplate based assay	2016	Bioorganic & medicinal chemistry letters, Apr-01, Volume: 26, Issue:7	Individual and combined antiparasitic effect of six plant metabolites against Leishmania amazonensis and Trypanosoma cruzi.
AID414763	Antitrypanosomal activity against Trypanosoma cruzi Y epimastigotes assessed as parasite growth at 20 ug/ml after 24 hrs	2009	Bioorganic & medicinal chemistry, Apr-01, Volume: 17, Issue:7	Molecular modeling studies and in vitro bioactivity evaluation of a set of novel 5-nitro-heterocyclic derivatives as anti-T. cruzi agents.
AID1198737	Antitrypanosomal activity against amastigote stage of Trypanosoma cruzi Tulahuen infected in human U937 cells assessed as parasite growth inhibition at 20 ug/mL after 72 hrs by beta-galactosidase reporter gene assay relative to control	2015	European journal of medicinal chemistry, Mar-26, Volume: 93	An efficient synthesis of new caffeine-based chalcones, pyrazolines and pyrazolo[3,4-b][1,4]diazepines as potential antimalarial, antitrypanosomal and antileishmanial agents.
AID1079932	Highest frequency of moderate liver toxicity observed during clinical trials, expressed as a percentage. [column '% BIOL' in source]
AID317067	Toxicity in african green monkey Vero cells after 72 hrs	2008	Journal of medicinal chemistry, Mar-27, Volume: 51, Issue:6	Efficient inhibition of iron superoxide dismutase and of Trypanosoma cruzi growth by benzo[g]phthalazine derivatives functionalized with one or two imidazole rings.
AID1608322	Selectivity index, ratio of CC50 for monkey LLC-MK2 cells to IC50 for Trypanosoma cruzi Y strain bloodstream trypomastigotes	2019	European journal of medicinal chemistry, Oct-01, Volume: 179	Synthesis of quinones with highlighted biological applications: A critical update on the strategies towards bioactive compounds with emphasis on lapachones.
AID547255	Antimicrobial activity against Trypanosoma cruzi Y infected in mongrel dog assessed as survival of dog at 12 mg/kg, po BID started 12 to 22 days postinfection measured after 1 day	2010	Antimicrobial agents and chemotherapy, Jul, Volume: 54, Issue:7	Effects of ravuconazole treatment on parasite load and immune response in dogs experimentally infected with Trypanosoma cruzi.
AID1498241	Antitrypanosomal activity against Trypanosoma cruzi MHOM/Pe/2011/Arequipa DTU 5 trypamastigotes infected in Balb/c mouse assessed as reduction in parasitaemia reactivation in heart tissue at 20 mg/kg, po pretreated once daily for 5 consecutive days starti	2018	Journal of medicinal chemistry, 07-12, Volume: 61, Issue:13	Second Generation of Mannich Base-Type Derivatives with in Vivo Activity against Trypanosoma cruzi.
AID576829	Cytotoxicity against african green monkey Vero cells after 72 hrs by trypan blue assay	2011	Journal of medicinal chemistry, Feb-24, Volume: 54, Issue:4	In vivo trypanosomicidal activity of imidazole- or pyrazole-based benzo[g]phthalazine derivatives against acute and chronic phases of Chagas disease.
AID677206	Trypanosomicidal activity against Trypanosoma cruzi SN3 anexic amastigote after 48 hrs by hemocytometric analysis	2012	Journal of medicinal chemistry, May-10, Volume: 55, Issue:9	In vitro and in vivo trypanosomicidal activity of pyrazole-containing macrocyclic and macrobicyclic polyamines: their action on acute and chronic phases of Chagas disease.
AID1496046	Selectivity index, ratio of LC50 for mouse L929 cells to EC50 for Trypanosoma cruzi Tulahuen amastigotes	2018	Bioorganic & medicinal chemistry letters, 06-15, Volume: 28, Issue:11	Identification and preliminary structure-activity relationship studies of novel pyridyl sulfonamides as potential Chagas disease therapeutic agents.
AID285214	Antimicrobial activity against Trypanosoma cruzi Y infected IFN-gamma knock out C57BL/6 mouse Chagas disease model assessed as percent of cured mouse at 100 mg/kg, po after 20 days	2007	Antimicrobial agents and chemotherapy, Apr, Volume: 51, Issue:4	The Anti-Trypanosoma cruzi activity of posaconazole in a murine model of acute Chagas' disease is less dependent on gamma interferon than that of benznidazole.
AID547264	Antimicrobial activity against Trypanosoma cruzi Berenice-78 infected in mongrel dog assessed as parasite level in blood of dog at 7 mg/kg, po BID started 12 to 22 days postinfection measured after 30 days by PCR analysis	2010	Antimicrobial agents and chemotherapy, Jul, Volume: 54, Issue:7	Effects of ravuconazole treatment on parasite load and immune response in dogs experimentally infected with Trypanosoma cruzi.
AID1603762	Antitrypanosomal activity against bloodstream trypomastigote stage of Trypanosoma cruzi IRHOD/CO/2008/SN3;DTU 1 isolated from parasite infected BALB/c Albino mouse cardiac cells after 24 hrs by Neubauer chamber based cell counting method	2019	Bioorganic & medicinal chemistry, 09-01, Volume: 27, Issue:17	Rational modification of Mannich base-type derivatives as novel antichagasic compounds: Synthesis, in vitro and in vivo evaluation.
AID596808	Selectivity index, ratio of IC50 for african green monkey Vero cells to IC50 for epimastigote form of Trypanosoma cruzi	2011	Journal of natural products, Apr-25, Volume: 74, Issue:4	In vitro and in vivo trypanocidal activity of flavonoids from Delphinium staphisagria against Chagas disease.
AID726232	Inhibition of Trypanosoma cruzi CL Brener recombinant alpha-carbonic anhydrase expressed in insect Sf9 cell Baculovirus system by stopped flow CO2 hydration assay	2013	Journal of medicinal chemistry, Feb-28, Volume: 56, Issue:4	Cloning, characterization, and sulfonamide and thiol inhibition studies of an α-carbonic anhydrase from Trypanosoma cruzi, the causative agent of Chagas disease.
AID766425	Antiparasitic activity against amastigotes of Trypanosoma cruzi CL Brener expressing Escherichia coli lacZ gene infected in mouse NCTC-929 cells assessed as parasite growth inhibition at 16 uM after 7 days by colorimetric assay	2013	Bioorganic & medicinal chemistry letters, Sep-01, Volume: 23, Issue:17	Selective activity of 2,4-diaryl-1,2,3,4-tetrahydroquinolines on Trypanosoma cruzi epimastigotes and amastigotes expressing β-galactosidase.
AID1613540	Cardiotoxicity in Balb/c mouse infected with Trypanosoma cruzi MHOM/Pe/2011/Arequipa DTU 5 trypomastigotes assessed as change in serum LDH level at 20 mg/kg, po once daily for 5 consecutive days starting from day 10 post infection measured on day 127 post	2019	European journal of medicinal chemistry, Feb-15, Volume: 164	New polyamine drugs as more effective antichagas agents than benznidazole in both the acute and chronic phases.
AID1312163	Antitrypanosomal activity against trypomastigote stage of Trypanosoma cruzi Y measured after 24 hrs using propidium iodide by neubauer chamber method	2016	Bioorganic & medicinal chemistry, 09-15, Volume: 24, Issue:18	Design, synthesis, molecular docking and biological evaluation of thiophen-2-iminothiazolidine derivatives for use against Trypanosoma cruzi.
AID1584770	Antiparasitic activity against Trypanosoma cruzi Y strain bloodstream trypomastigotes infected in Swiss Webster mouse at 100 mg/kg, po sid via gavage administered for 5 consecutive days starting from day 5 post infection followed by cyclophosphamide-induc	2018	Journal of medicinal chemistry, 10-25, Volume: 61, Issue:20	Discovery of Novel 7-Aryl 7-Deazapurine 3'-Deoxy-ribofuranosyl Nucleosides with Potent Activity against Trypanosoma cruzi.
AID214501	The compound was evaluated for its in vitro inhibitory affect against trypanothione reductase; No data	2000	Bioorganic & medicinal chemistry letters, Jun-05, Volume: 10, Issue:11	Synthesis and evaluation of 9,9-dimethylxanthene tricyclics against trypanothione reductase, Trypanosoma brucei, Trypanosoma cruzi and Leishmania donovani.
AID626321	Selectivity index, ratio of IC50 for rat L6 cells to IC50 for Trypanosoma cruzi Tulahuen C2C4 trypomastigotes	2011	Bioorganic & medicinal chemistry letters, Nov-01, Volume: 21, Issue:21	Biological evaluation of glycosyl-isoindigo derivatives against the pathogenic agents of tropical diseases (malaria, Chagas disease, leishmaniasis and human African trypanosomiasis).
AID1244586	Antiparasitic activity against trypomastigotes of Trypanosoma cruzi Y assessed as induction of parasite death at 25 uM after 24 hrs using propidium iodide staining after 24 hrs by flow cytometry analysis	2015	European journal of medicinal chemistry, Aug-28, Volume: 101	Synthesis and structure-activity relationship study of a new series of antiparasitic aryloxyl thiosemicarbazones inhibiting Trypanosoma cruzi cruzain.
AID333757	Antitrypanosomal activity against Trypanosoma cruzi	2004	Journal of natural products, Dec, Volume: 67, Issue:12	Ancistrobenomine a, the first naphthylisoquinoline oxygenated at Me-3, and related 5,1'-coupled alkaloids, from the "new" plant species ancistrocladusbenomensis.
AID677307	Trypanosomicidal activity against Trypanosoma cruzi epimastigotes assessed as inhibition of acetate metabolite excretion after 96 hrs by NMR analysis	2012	Journal of medicinal chemistry, May-10, Volume: 55, Issue:9	In vitro and in vivo trypanosomicidal activity of pyrazole-containing macrocyclic and macrobicyclic polyamines: their action on acute and chronic phases of Chagas disease.
AID1165096	Trypanocidal activity against bloodstream forms of Trypanosoma brucei brucei Lister 427 clone 221a overexpressing type I nitroreductase assessed as inhibition of proliferation after 3 days by resazurin assay in presence of tetracycline	2014	European journal of medicinal chemistry, Nov-24, Volume: 87	Novel nitro(triazole/imidazole)-based heteroarylamides/sulfonamides as potential antitrypanosomal agents.
AID1487116	Antitrypanosomal activity against Trypanosoma cruzi Queretaro epimastigotes assessed as reduction in parasite viability incubated for 24 hrs by Neubauer hematocytometery	2017	Bioorganic & medicinal chemistry letters, 08-01, Volume: 27, Issue:15	Synthesis and biological evaluation of 2-methyl-1H-benzimidazole-5-carbohydrazides derivatives as modifiers of redox homeostasis of Trypanosoma cruzi.
AID597239	Antitrypanosomal activity against Trypanosoma cruzi CL Brener clone infected in BALB/c mouse assessed as increase of mouse survival days at 50 mg/kg/day, po relative to control	2011	Journal of medicinal chemistry, May-26, Volume: 54, Issue:10	3-Trifluoromethylquinoxaline N,N'-dioxides as anti-trypanosomatid agents. Identification of optimal anti-T. cruzi agents and mechanism of action studies.
AID343558	Antitrypanosomal activity against epimastigotes of Trypanosoma cruzi CL Brener	2008	Bioorganic & medicinal chemistry, Jul-15, Volume: 16, Issue:14	New trypanocidal hybrid compounds from the association of hydrazone moieties and benzofuroxan heterocycle.
AID1281416	Selectivity index, ratio of MNTD90 for cytotoxicity against BALB/c mouse splenocytes to IC50 for trypamostigote form of Trypanosoma cruzi Y infected in African green monkey Vero cells	2016	European journal of medicinal chemistry, Mar-23, Volume: 111	Phthalimido-thiazoles as building blocks and their effects on the growth and morphology of Trypanosoma cruzi.
AID1155760	Selectivity index, ratio of IC50 for human HepG2 cells to IC50 for Trypanosoma cruzi Tulahuen C2C4	2014	European journal of medicinal chemistry, Jul-23, Volume: 82	Design, synthesis and biological evaluation of hybrid bioisoster derivatives of N-acylhydrazone and furoxan groups with potential and selective anti-Trypanosoma cruzi activity.
AID537139	Cytotoxicity in BALB/c mouse erythrocytes assessed as hemolysis at 50 uM after 3 hrs	2010	Bioorganic & medicinal chemistry, Nov-15, Volume: 18, Issue:22	Anti-leishmanial and anti-trypanosomal activities of 1,4-dihydropyridines: In vitro evaluation and structure-activity relationship study.
AID1615017	Trypanocidal activity against Trypanosoma cruzi IRHOD/CO/2008/SN3 DTU 1 trypomastigotes derived from infected Balb/c mouse after 72 hrs by resazurin dye based assay	2019	Bioorganic & medicinal chemistry, 03-01, Volume: 27, Issue:5	Synthesis and biological evaluation of new long-chain squaramides as anti-chagasic agents in the BALB/c mouse model.
AID1164932	Induction of apoptosis in human monocytes assessed as early apoptotic cells using Annexin V/propidium iodide by flow cytometry (Rvb = 2.18 %)	2014	European journal of medicinal chemistry, Nov-24, Volume: 87	In vitro antiparasitic activity of new thiosemicarbazones in strains of Trypanosoma cruzi.
AID1683716	Antitrypanosomal activity against Trypanosoma cruzi MHOM/Pe/2011/Arequipa(DTU V) blood stream trypomastigote form assessed as parasite growth inhibition incubated for 24 hrs by resazurin dye based assay	2020	Journal of natural products, 12-24, Volume: 83, Issue:12	In Vivo Biological Evaluation of a Synthetic Royleanone Derivative as a Promising Fast-Acting Trypanocidal Agent by Inducing Mitochondrial-Dependent Necrosis.
AID1198739	Antitrypanosomal activity against amastigote stage of Trypanosoma cruzi Tulahuen infected in human U937 cells assessed as parasite growth inhibition after 72 hrs by beta-galactosidase reporter gene assay	2015	European journal of medicinal chemistry, Mar-26, Volume: 93	An efficient synthesis of new caffeine-based chalcones, pyrazolines and pyrazolo[3,4-b][1,4]diazepines as potential antimalarial, antitrypanosomal and antileishmanial agents.
AID1603834	Toxicity in BALB/c mouse infected with Trypanosoma cruzi MHOM/Pe/2011/Arequipa;DTU 5 bloodstream trypomastigote assessed as decrease in serum urea level in acute phase at 20 mg/kg/day, po administered for 5 consecutive days starting from day 8 post infect	2019	Bioorganic & medicinal chemistry, 09-01, Volume: 27, Issue:17	Rational modification of Mannich base-type derivatives as novel antichagasic compounds: Synthesis, in vitro and in vivo evaluation.
AID536030	Toxicity in Swiss mouse assessed as mortality at 100 mg/kg, ip after 72 hrs	2010	Bioorganic & medicinal chemistry, Nov-15, Volume: 18, Issue:22	Studies toward the structural optimization of novel thiazolylhydrazone-based potent antitrypanosomal agents.
AID1064593	Antiparasitic activity against trypomastigote form of Trypanosoma cruzi Y infected in LLCMK2 cells assessed as parasite lysis after 24 hrs by Pizzi-Brener method	2014	Bioorganic & medicinal chemistry, Feb-01, Volume: 22, Issue:3	Unsymmetrical 1,5-diaryl-3-oxo-1,4-pentadienyls and their evaluation as antiparasitic agents.
AID303380	Antitrypanosomal activity against Trypanosoma cruzi Y	2007	Journal of medicinal chemistry, Nov-29, Volume: 50, Issue:24	In vivo anti-Chagas vinylthio-, vinylsulfinyl-, and vinylsulfonylbenzofuroxan derivatives.
AID1613470	Trypanocidal activity against Trypanosoma cruzi IRHOD/CO/2008/SN3 DTU 1 amastigotes infected in African green monkey Vero cells after 72 hrs by Giemsa-staining based microscopic assay	2019	European journal of medicinal chemistry, Feb-15, Volume: 164	New polyamine drugs as more effective antichagas agents than benznidazole in both the acute and chronic phases.
AID1498184	Selectivity index, ratio of IC50 for African green monkey Vero cells to IC50 for Trypanosoma cruzi MHOM/Pe/2011/Arequipa DTU 5 trypamastigotes derived from infected Balb/c albino mouse	2018	Journal of medicinal chemistry, 07-12, Volume: 61, Issue:13	Second Generation of Mannich Base-Type Derivatives with in Vivo Activity against Trypanosoma cruzi.
AID1592304	Cytotoxicity against mouse J774.A1 cells assessed as reduction in cell viability measured after 20 hrs by MTT assay
AID677309	Trypanosomicidal activity against Trypanosoma cruzi epimastigotes assessed as change in L-alanine metabolite excretion after 96 hrs by NMR analysis	2012	Journal of medicinal chemistry, May-10, Volume: 55, Issue:9	In vitro and in vivo trypanosomicidal activity of pyrazole-containing macrocyclic and macrobicyclic polyamines: their action on acute and chronic phases of Chagas disease.
AID1608332	Anti-parasitic activity against amastigote form of Trypanosoma cruzi after 24 hrs	2019	European journal of medicinal chemistry, Oct-01, Volume: 179	Synthesis of quinones with highlighted biological applications: A critical update on the strategies towards bioactive compounds with emphasis on lapachones.
AID1615053	Antitrypanosomal activity against Trypanosoma cruzi MHOM/Pe/2011/Arequipa DTU 5 trypomastigotes infected in Balb/c mouse assessed as parasite-free lungs at 20 mg/kg, po pretreated once daily for 5 consecutive days starting from day 75 post infection follo	2019	Bioorganic & medicinal chemistry, 03-01, Volume: 27, Issue:5	Synthesis and biological evaluation of new long-chain squaramides as anti-chagasic agents in the BALB/c mouse model.
AID272980	Antitrypanosomal activity against Trypanosoma cruzi trypomastigotes in CD1 mouse macrophage	2006	Journal of medicinal chemistry, Oct-05, Volume: 49, Issue:20	Evaluation of azasterols as anti-parasitics.
AID1351077	Antitrypanosomal activity against Trypanosoma cruzi Y Tc2 amastigotes infected in human U2OS cells at 1.56 uM after 72 hrs by Draq5 staining based HCS analysis	2018	European journal of medicinal chemistry, Jan-20, Volume: 144	Investigating the structure-activity relationships of N'-[(5-nitrofuran-2-yl) methylene] substituted hydrazides against Trypanosoma cruzi to design novel active compounds.
AID597234	Antitrypanosomal activity against Trypanosoma cruzi CL Brener clone infected in Swiss albino mouse assessed as increase of mouse survival days at 50 mg/kg/day, po relative to control	2011	Journal of medicinal chemistry, May-26, Volume: 54, Issue:10	3-Trifluoromethylquinoxaline N,N'-dioxides as anti-trypanosomatid agents. Identification of optimal anti-T. cruzi agents and mechanism of action studies.
AID1470753	Trypanocidal activity against trypomastigote stage of Trypanosoma cruzi NINOA infected in NIH mouse blood assessed as parasite lysis at 50 ug/ml after 24 hrs by optical microscopic method relative to control	2017	European journal of medicinal chemistry, May-26, Volume: 132	An in vitro and in vivo evaluation of new potential trans-sialidase inhibitors of Trypanosoma cruzi predicted by a computational drug repositioning method.
AID677289	Toxicity in BALB/c mouse liver infected with Trypanosoma cruzi assessed as blood vessels with thickened walls at 5 mg/kg, ip after 120 days postinfection by Histopathological analysis	2012	Journal of medicinal chemistry, May-10, Volume: 55, Issue:9	In vitro and in vivo trypanosomicidal activity of pyrazole-containing macrocyclic and macrobicyclic polyamines: their action on acute and chronic phases of Chagas disease.
AID344429	Antiproliferative activity against Trypanosoma cruzi Y epimastigotes assessed as number of motile forms at 1 mM after 1 hr by hemocytometer	2008	Journal of medicinal chemistry, Jul-24, Volume: 51, Issue:14	Complexation of the anti-Trypanosoma cruzi drug benznidazole improves solubility and efficacy.
AID1459242	Trypanocidal activity against Trypanosoma cruzi TCC epimastigotes assessed as parasite duplication time at 15 uM measured after 9 to 10 days (Rvb = 2 day)	2017	European journal of medicinal chemistry, Jan-05, Volume: 125	Novel 2-arylazoimidazole derivatives as inhibitors of Trypanosoma cruzi proliferation: Synthesis and evaluation of their biological activity.
AID1686737	Cytotoxicity in African green monkey Vero cells incubated for 72 hrs	2016	Journal of medicinal chemistry, 12-22, Volume: 59, Issue:24	In Vitro and in Vivo Anti-Trypanosoma cruzi Activity of New Arylamine Mannich Base-Type Derivatives.
AID285207	Mortality rate in Trypanosoma cruzi Y infected wild type C57BL/6 mouse Chagas disease model at 100 mg/kg, po after 20 days	2007	Antimicrobial agents and chemotherapy, Apr, Volume: 51, Issue:4	The Anti-Trypanosoma cruzi activity of posaconazole in a murine model of acute Chagas' disease is less dependent on gamma interferon than that of benznidazole.
AID1615093	Nephrotoxicity in Balb/c mouse infected with Trypanosoma cruzi MHOM/Pe/2011/Arequipa DTU 5 trypomastigotes assessed as decrease in serum uric acid level at 20 mg/kg, po once daily for 5 consecutive days starting from day 75 post infection measured on day	2019	Bioorganic & medicinal chemistry, 03-01, Volume: 27, Issue:5	Synthesis and biological evaluation of new long-chain squaramides as anti-chagasic agents in the BALB/c mouse model.
AID1603947	Antitrypanosomal activity against Trypanosoma cruzi MHOM/Pe/2011/Arequipa;DTU 5 bloodstream trypomastigotes infected in BALB/c mouse assessed as reduction in serum Ig-G level in acute phase at 20 mg/kg/day, po administered for 5 consecutive days starting	2019	Bioorganic & medicinal chemistry, 09-01, Volume: 27, Issue:17	Rational modification of Mannich base-type derivatives as novel antichagasic compounds: Synthesis, in vitro and in vivo evaluation.
AID1074906	Antitrypanosomal activity against Trypanosoma cruzi (IRHOD/CO/2008/SN3) epimastigotes assessed as plasma membrane with scalloped appearance with undulations and discontinuities at IC25 after 96 hrs by transmission electron microscopic analysis	2014	European journal of medicinal chemistry, Mar-03, Volume: 74	New perspectives on the synthesis and antichagasic activity of 3-alkoxy-1-alkyl-5-nitroindazoles.
AID1868700	Selectivity index, ratio of CC50 for cytotoxicity against human MRC5 cells to EC50 for Trypanosoma cruzi Tulahuen CL2 amastigotes expressing beta galactosidase infected in human MRC5 cells	2022	European journal of medicinal chemistry, Jul-05, Volume: 237	Exploration of 6-methyl-7-(Hetero)Aryl-7-Deazapurine ribonucleosides as antileishmanial agents.
AID1244579	Cytotoxicity against mouse L929 cells assessed as cell viability after 96 hrs by alamarBlue assay	2015	European journal of medicinal chemistry, Aug-28, Volume: 101	Synthesis and structure-activity relationship study of a new series of antiparasitic aryloxyl thiosemicarbazones inhibiting Trypanosoma cruzi cruzain.
AID1603850	Toxicity in BALB/c mouse infected with Trypanosoma cruzi MHOM/Pe/2011/Arequipa;DTU 5 bloodstream trypomastigote assessed as increase in serum lactate dehydrogenase level in acute phase at 20 mg/kg/day, po administered for 5 consecutive days starting from	2019	Bioorganic & medicinal chemistry, 09-01, Volume: 27, Issue:17	Rational modification of Mannich base-type derivatives as novel antichagasic compounds: Synthesis, in vitro and in vivo evaluation.
AID1639039	Cytotoxicity against African green monkey Vero cells after 72 hrs by Alamar Blue assay	2019	Bioorganic & medicinal chemistry, 04-01, Volume: 27, Issue:7	Further insights of selenium-containing analogues of WC-9 against Trypanosoma cruzi.
AID672965	Antitrypanosomal activity against Trypanosoma cruzi Y epimastigotes assessed as cell death at 50 uM after 72 hrs by propidium iodide staining-based flow cytometric analysis	2012	Bioorganic & medicinal chemistry, Aug-15, Volume: 20, Issue:16	New oxirane derivatives of 1,4-naphthoquinones and their evaluation against T. cruzi epimastigote forms.
AID1687783	Cytotoxicity against mouse RAW264.7 cells assessed as reduction in cell viability measured after 24 hrs by WST1 assay	2020	European journal of medicinal chemistry, Jan-15, Volume: 186	Novel nitroimidazole derivatives evaluated for their trypanocidal, cytotoxic, and genotoxic activities.
AID1264448	Trypanocidal activity against epimastigote stage of Trypanosoma cruzi MHOM/ES/2203/BCN590 after 72 hrs by cell counting analysis	2015	European journal of medicinal chemistry, Nov-13, Volume: 105	Multicomponent reaction-based synthesis and biological evaluation of tricyclic heterofused quinolines with multi-trypanosomatid activity.
AID1498196	Toxicity in Balb/c mouse assessed as death at 20 mg/kg, po once daily for 5 consecutive days starting from day 75 post infection	2018	Journal of medicinal chemistry, 07-12, Volume: 61, Issue:13	Second Generation of Mannich Base-Type Derivatives with in Vivo Activity against Trypanosoma cruzi.
AID263379	Unspecific cytotoxicity against murine J774 macrophages at 100 ug/ml	2006	Bioorganic & medicinal chemistry letters, Apr-01, Volume: 16, Issue:7	New ligand-based approach for the discovery of antitrypanosomal compounds.
AID1067348	Antimicrobial activity against promastigote stage of Leishmania amazonensis IFLA/BR/67/PH-8 clinical isolate after 72 hrs by Neubauer chamber analysis	2014	Bioorganic & medicinal chemistry, Mar-01, Volume: 22, Issue:5	2-acylamino-5-nitro-1,3-thiazoles: preparation and in vitro bioevaluation against four neglected protozoan parasites.
AID1615019	Trypanocidal activity against Trypanosoma cruzi TINF/CH/1956/Tulahuen DTU 6 amastigotes infected in African green monkey Vero cells after 72 hrs by Giemsa-staining based microscopic assay	2019	Bioorganic & medicinal chemistry, 03-01, Volume: 27, Issue:5	Synthesis and biological evaluation of new long-chain squaramides as anti-chagasic agents in the BALB/c mouse model.
AID396013	Antimicrobial activity against Trypanosoma cruzi and Trypanosoma cruzi 2 dually infected in BALB/c mouse assessed as cure rate	2007	Antimicrobial agents and chemotherapy, Sep, Volume: 51, Issue:9	Impact of dual infections on chemotherapeutic efficacy in BALB/c mice infected with major genotypes of Trypanosoma cruzi.
AID576106	Toxicity in human patient infected with Trypanosoma cruzi assessed as occurrence of cardiac disorders at 5 mg/kg/day for 60 days	2010	Antimicrobial agents and chemotherapy, Nov, Volume: 54, Issue:11	Tolerance of benznidazole in treatment of Chagas' disease in adults.
AID1164934	Induction of apoptosis in human monocytes assessed as necrotic cells using Annexin V/propidium iodide by flow cytometry (Rvb = 0.02 %)	2014	European journal of medicinal chemistry, Nov-24, Volume: 87	In vitro antiparasitic activity of new thiosemicarbazones in strains of Trypanosoma cruzi.
AID693345	Growth inhibition of mouse J774 cells at 64 uM after 24 hrs by resazurin reduction assay	2012	European journal of medicinal chemistry, Dec, Volume: 58	Synthesis, biological evaluation and chemometric analysis of indazole derivatives. 1,2-Disubstituted 5-nitroindazolinones, new prototypes of antichagasic drug.
AID1613481	Selectivity index, ratio of IC50 for African green monkey Vero cells to IC50 for Trypanosoma cruzi IRHOD/CO/2008/SN3 DTU 1 trypomastigotes derived from infected Balb/c albino mouse	2019	European journal of medicinal chemistry, Feb-15, Volume: 164	New polyamine drugs as more effective antichagas agents than benznidazole in both the acute and chronic phases.
AID1055169	Hepatotoxicity in BALB/c mouse infected with bloodstream trypomastigote form of Trypanosoma cruzi IRHOD/CO/2008/SN3 assessed as vessels with thickened walls at 5 mg/kg/day, ip administered for 5 days measured 150 days post-infection by light microscopic a	2013	European journal of medicinal chemistry, , Volume: 70	Scorpiand-like azamacrocycles prevent the chronic establishment of Trypanosoma cruzi in a murine model.
AID1615073	Antitrypanosomal activity against Trypanosoma cruzi MHOM/Pe/2011/Arequipa DTU 5 epimastigotes assessed as change in mitochondrial membrane potential at IC25 after 72 hrs by Rho123 staining based flow cytometry relative to control	2019	Bioorganic & medicinal chemistry, 03-01, Volume: 27, Issue:5	Synthesis and biological evaluation of new long-chain squaramides as anti-chagasic agents in the BALB/c mouse model.
AID672966	Antitrypanosomal activity against Trypanosoma cruzi Y epimastigotes after 72 hrs by Neubauer counter-based microscopic analysis	2012	Bioorganic & medicinal chemistry, Aug-15, Volume: 20, Issue:16	New oxirane derivatives of 1,4-naphthoquinones and their evaluation against T. cruzi epimastigote forms.
AID762752	Selectivity index, ratio of C57BL/6 mouse spleen cells to trypomastigotes forms of Trypanosoma cruzi Tulahuen infected in monkey LLC-MK2 cells	2013	Bioorganic & medicinal chemistry letters, Aug-15, Volume: 23, Issue:16	Molecular design, synthesis and biological evaluation of 1,4-dihydro-4-oxoquinoline ribonucleosides as TcGAPDH inhibitors with trypanocidal activity.
AID1079938	Chronic liver disease either proven histopathologically, or through a chonic elevation of serum amino-transferase activity after 6 months. Value is number of references indexed. [column 'CHRON' in source]
AID1613545	Hepatotoxicity in Balb/c mouse infected with Trypanosoma cruzi MHOM/Pe/2011/Arequipa DTU 5 trypomastigotes assessed as increase in ratio of serum AST to GOT level at 20 mg/kg, po once daily for 5 consecutive days starting from day 10 post infection measur	2019	European journal of medicinal chemistry, Feb-15, Volume: 164	New polyamine drugs as more effective antichagas agents than benznidazole in both the acute and chronic phases.
AID1422887	Antitrypanosomal activity against Trypanosoma cruzi Dm28c amastigotes infected in African green monkey Vero cells after 48 hrs by CPRG/Nonidet reagent based beta-galactosidase reporter gene assay	2018	ACS medicinal chemistry letters, Oct-11, Volume: 9, Issue:10	Discovery of a Biologically Active Bromodomain Inhibitor by Target-Directed Dynamic Combinatorial Chemistry.
AID337139	Antitrypanosomal activity against Trypanosoma cruzi 13379 CL6 after 48 hrs
AID1624262	Selectivity index, ratio of EC50 for human MRC5 cells to EC50 for nifurtimox-sensitive Trypanosoma cruzi Tulahuen CL2 harboring beta-galactosidase	2019	European journal of medicinal chemistry, Feb-15, Volume: 164	Revisiting tubercidin against kinetoplastid parasites: Aromatic substitutions at position 7 improve activity and reduce toxicity.
AID1498183	Selectivity index, ratio of IC50 for African green monkey Vero cells to IC50 for Trypanosoma cruzi MHOM/Pe/2011/Arequipa DTU 5 amastigotes infected in African green monkey Vero cells	2018	Journal of medicinal chemistry, 07-12, Volume: 61, Issue:13	Second Generation of Mannich Base-Type Derivatives with in Vivo Activity against Trypanosoma cruzi.
AID762753	Trypanocidal activity against trypomastigotes forms of Trypanosoma cruzi Tulahuen infected in monkey LLC-MK2 cells after 24 hrs by beta-galactosidase reporter assay	2013	Bioorganic & medicinal chemistry letters, Aug-15, Volume: 23, Issue:16	Molecular design, synthesis and biological evaluation of 1,4-dihydro-4-oxoquinoline ribonucleosides as TcGAPDH inhibitors with trypanocidal activity.
AID1683670	Toxicity in BALB/c mouse infected with Trypanosomal Trypanosoma cruzi MHOM/Pe/2011/Arequipa(DTU V) assessed as reduction in survival at 20 mg/kg, po administered for 5 days starting at 100 days post infection and measured up to 145 days post infection	2020	Journal of natural products, 12-24, Volume: 83, Issue:12	In Vivo Biological Evaluation of a Synthetic Royleanone Derivative as a Promising Fast-Acting Trypanocidal Agent by Inducing Mitochondrial-Dependent Necrosis.
AID548282	Antimicrobial activity against Trypanosoma brucei NfxR2	2010	Antimicrobial agents and chemotherapy, Jul, Volume: 54, Issue:7	Cross-resistance to nitro drugs and implications for treatment of human African trypanosomiasis.
AID1498189	Trypanocidal activity against Trypanosoma cruzi MHOM/Pe/2011/Arequipa DTU 5 amastigotes infected in African green monkey Vero cells assessed as reduction in infected cells after 72 hrs by Giemsa-staining based microscopic assay	2018	Journal of medicinal chemistry, 07-12, Volume: 61, Issue:13	Second Generation of Mannich Base-Type Derivatives with in Vivo Activity against Trypanosoma cruzi.
AID341600	Antiplasmodial activity against Plasmodium falciparum NF54	2007	Antimicrobial agents and chemotherapy, Aug, Volume: 51, Issue:8	Peroxide bond-dependent antiplasmodial specificity of artemisinin and OZ277 (RBx11160).
AID1613473	Trypanocidal activity against Trypanosoma cruzi TINF/CH/1956/Tulahuen DTU 6 amastigotes infected in African green monkey Vero cells after 72 hrs by Giemsa-staining based microscopic assay	2019	European journal of medicinal chemistry, Feb-15, Volume: 164	New polyamine drugs as more effective antichagas agents than benznidazole in both the acute and chronic phases.
AID100286	In vitro inhibitory affect against Leishmania donovani; No data	2000	Bioorganic & medicinal chemistry letters, Jun-05, Volume: 10, Issue:11	Synthesis and evaluation of 9,9-dimethylxanthene tricyclics against trypanothione reductase, Trypanosoma brucei, Trypanosoma cruzi and Leishmania donovani.
AID1383433	Selectivity index, ratio of LC50 for Swiss Webster mouse cardiac cells by light microscopic analysis to EC50 for bloodstream trypomastigote stage of Trypanosoma cruzi Y measured after 24 hrs	2018	European journal of medicinal chemistry, Apr-10, Volume: 149	Identification of Pyrazolo[3,4-e][1,4]thiazepin based CYP51 inhibitors as potential Chagas disease therapeutic alternative: In vitro and in vivo evaluation, binding mode prediction and SAR exploration.
AID1124789	Safety index, ratio of IC50 for human HepG2 cells to IC50 for epimastigote stage of Trypanosoma cruzi Y	2014	Bioorganic & medicinal chemistry letters, Apr-01, Volume: 24, Issue:7	Synthesis and tripanocidal activity of ferrocenyl and benzyl diamines against Trypanosoma brucei and Trypanosoma cruzi.
AID547254	Antimicrobial activity against Trypanosoma cruzi Berenice-78 infected in mongrel dog assessed as suppression of microbial proliferation at 7 mg/kg, po BID started 12 to 22 days postinfection measured after 1 day	2010	Antimicrobial agents and chemotherapy, Jul, Volume: 54, Issue:7	Effects of ravuconazole treatment on parasite load and immune response in dogs experimentally infected with Trypanosoma cruzi.
AID1866580	Inhibition of Trypanosoma cruzi G6PD	2022	Journal of medicinal chemistry, 03-24, Volume: 65, Issue:6	Boosting the Discovery of Small Molecule Inhibitors of Glucose-6-Phosphate Dehydrogenase for the Treatment of Cancer, Infectious Diseases, and Inflammation.
AID1614011	Selectivity index, ratio of CC50 for rat L6 cels to IC50 for Trypanosoma brucei Tulahuen C2C4 amastigotes	2019	Journal of medicinal chemistry, 02-14, Volume: 62, Issue:3	Design, Synthesis, and Biological Evaluation of New 1-(Aryl-1 H-pyrrolyl)(phenyl)methyl-1 H-imidazole Derivatives as Antiprotozoal Agents.
AID1565129	Trypanocidal activity against intracellular amastigote stage of luciferase expressing Trypanosoma cruzi Dm28c infected in Vero cells assessed as reduction in parasite viability after 72 hrs in presence of luciferin by Giemsa staining based optical microsc	2019	European journal of medicinal chemistry, Nov-15, Volume: 182	Synthesis, structure-activity relationship and trypanocidal activity of pyrazole-imidazoline and new pyrazole-tetrahydropyrimidine hybrids as promising chemotherapeutic agents for Chagas disease.
AID1603824	Antitrypanosomal activity against Trypanosoma cruzi MHOM/Pe/2011/Arequipa;DTU 5 bloodstream trypomastigote infected in BALB/c mouse assessed as parasite-free heart in acute phase at 20 mg/kg/day, po administered for 5 consecutive days starting from day 8	2019	Bioorganic & medicinal chemistry, 09-01, Volume: 27, Issue:17	Rational modification of Mannich base-type derivatives as novel antichagasic compounds: Synthesis, in vitro and in vivo evaluation.
AID1462694	Antiparasitic activity against Trypanosoma cruzi Tulahuen C4 intracellular amastigotes infected in rat L6 cells assessed as growth inhibition at 0.8 ug/ml after 96 hrs by CPRG/Nonidet reagent based photometric analysis relative to control	2017	Bioorganic & medicinal chemistry letters, 09-01, Volume: 27, Issue:17	Lead selection of antiparasitic compounds from a focused library of benzenesulfonyl derivatives of heterocycles.
AID341606	Antimicrobial activity against Babesia divergens 1903B	2007	Antimicrobial agents and chemotherapy, Aug, Volume: 51, Issue:8	Peroxide bond-dependent antiplasmodial specificity of artemisinin and OZ277 (RBx11160).
AID1518998	Antitrypanosomal activity against Trypanosoma cruzi K98 bloodstream form infected in C3H/HeNk mouse assessed as effect on RR interval at 30 to 75 mg/kg/day, po administered via gavage for 30 consecutive days starting from 90 days post infection and measur	2019	European journal of medicinal chemistry, 12-15, Volume: 184	Combined therapy with Benznidazole and repurposed drugs Clofazimine and Benidipine for chronic Chagas disease.
AID1517424	Antitrypanosomal activity against intracellular amastigote stage of Trypanosoma cruzi Silvio X10/1 infected in human U2OS cells measured after 96 hrs by DRAQ5 dye based microscopic analysis	2019	European journal of medicinal chemistry, Dec-01, Volume: 183	Discovery of a benzothiophene-flavonol halting miltefosine and antimonial drug resistance in Leishmania parasites through the application of medicinal chemistry, screening and genomics.
AID577157	Antimicrobial activity against Trypanosoma cruzi Tulahuen infected in Swiss mouse assessed as reduction in reduction in parasite induced histopathological changes in liver at 60 mg/kg/day, po for 6 days per week until completion of 60 compound doses admin	2010	Antimicrobial agents and chemotherapy, Sep, Volume: 54, Issue:9	Hydroxymethylnitrofurazone is active in a murine model of Chagas' disease.
AID1074920	Toxicity in BALB/c mouse assessed as survival at 1 mg/kg/day, ip relative to control	2014	European journal of medicinal chemistry, Mar-03, Volume: 74	New perspectives on the synthesis and antichagasic activity of 3-alkoxy-1-alkyl-5-nitroindazoles.
AID1403409	Cytotoxicity against Swiss Webster mouse cardiomyocytes after 72 hrs	2018	European journal of medicinal chemistry, Jan-20, Volume: 144	Efficacy of 2-hydroxy-3-phenylsulfanylmethyl-[1,4]-naphthoquinone derivatives against different Trypanosoma cruzi discrete type units: Identification of a promising hit compound.
AID1547543	Trypanosomacidal activity against Trypanosoma cruzi strain Y trypomastigotes assessed as reduction in number of infected cells at faster rate at 20 uM measured for 24 to 96 hrs by Hoechst 33342 staining based fluorescence imaging assay	2020	ACS medicinal chemistry letters, Mar-12, Volume: 11, Issue:3	Discovery of Potent
AID677305	Antitrypanosomal activity against Trypanosoma cruzi infected in BALB/c mouse assessed as reduction in anti-organism antibody at 1 mg/kg, ip dosed for 5 days measured on day 40 to 120 post infection	2012	Journal of medicinal chemistry, May-10, Volume: 55, Issue:9	In vitro and in vivo trypanosomicidal activity of pyrazole-containing macrocyclic and macrobicyclic polyamines: their action on acute and chronic phases of Chagas disease.
AID666682	Antitrypanosomal activity against Trypanosoma cruzi Tulahuen C2C4 intracellular amastigotes infected in rat L6 cells after 4 days by photometry	2012	European journal of medicinal chemistry, Aug, Volume: 54	Design and synthesis of new (E)-cinnamic N-acylhydrazones as potent antitrypanosomal agents.
AID1128397	Antitrypanosomal activity against amastigote stage of lacZ expressing Trypanosoma cruzi Tulahuen after 72 hrs	2014	Journal of medicinal chemistry, Mar-27, Volume: 57, Issue:6	Synthesis, biological evaluation, and structure-activity relationships of potent noncovalent and nonpeptidic cruzain inhibitors as anti-Trypanosoma cruzi agents.
AID378742	Antitrypanosomal activity against Trypanosoma cruzi Y trypomastigotes infected in Swiss albino mouse assessed as reduction in parasitaemia at 500 mg/kg, po after 6 hrs	1999	Journal of natural products, Feb, Volume: 62, Issue:2	Biological activities of 7-epiclusianone.
AID656214	Antitrypanosomal activity against Trypanosoma cruzi Tulahuen 2 infected in african green monkey Vero cells expressing red fluorescent protein after 3 days by fluorescence analysis	2012	Bioorganic & medicinal chemistry letters, Apr-15, Volume: 22, Issue:8	Phosphonium lipocations as antiparasitic agents.
AID396022	Antimicrobial activity against Trypanosoma cruzi genotype 39 and genotype 32 dually infected in BALB/c mouse assessed as cure rate	2007	Antimicrobial agents and chemotherapy, Sep, Volume: 51, Issue:9	Impact of dual infections on chemotherapeutic efficacy in BALB/c mice infected with major genotypes of Trypanosoma cruzi.
AID1683684	Toxicity in BALB/c mouse infected with Trypanosomal Trypanosoma cruzi MHOM/Pe/2011/Arequipa(DTU V) assessed as effect on LDH level at 20 mg/kg, po administered for 5 days starting at 9 days post infection and measured after 2 days post treatment	2020	Journal of natural products, 12-24, Volume: 83, Issue:12	In Vivo Biological Evaluation of a Synthetic Royleanone Derivative as a Promising Fast-Acting Trypanocidal Agent by Inducing Mitochondrial-Dependent Necrosis.
AID1686734	Antitrypanosomal activity against Trypanosoma cruzi SN3 epimastigote forms incubated for 72 hrs by hemocytometry	2016	Journal of medicinal chemistry, 12-22, Volume: 59, Issue:24	In Vitro and in Vivo Anti-Trypanosoma cruzi Activity of New Arylamine Mannich Base-Type Derivatives.
AID1569972	Antitrypanosomal activity against Trypanosoma cruzi Dm28c epimastigotes after 5 days by Neubauer chamber method	2019	European journal of medicinal chemistry, Oct-15, Volume: 180	2-(phenylthio)ethylidene derivatives as anti-Trypanosoma cruzi compounds: Structural design, synthesis and antiparasitic activity.
AID1603953	Antitrypanosomal activity against Trypanosoma cruzi MHOM/Pe/2011/Arequipa;DTU 5 epimastigote assessed as effect on ethanol excretion at IC50 after 72 hrs by H NMR method relative to control	2019	Bioorganic & medicinal chemistry, 09-01, Volume: 27, Issue:17	Rational modification of Mannich base-type derivatives as novel antichagasic compounds: Synthesis, in vitro and in vivo evaluation.
AID1381693	Antitrypanosomal activity against Trypanosoma cruzi amastigote form infected in human U2OS cells assessed as parasite growth inhibition after 72 hrs	2018	European journal of medicinal chemistry, Feb-25, Volume: 146	Aryl thiosemicarbazones for the treatment of trypanosomatidic infections.
AID1613519	Induction of mitochondrial membrane potential disruption Trypanosoma cruzi MHOM/Pe/2011/Arequipa DTU 5 epimastigotes assessed as inhibition of DNA and RNA levels at IC25 after 72 hrs by acridine orange staining based flow cytometry relative to control	2019	European journal of medicinal chemistry, Feb-15, Volume: 164	New polyamine drugs as more effective antichagas agents than benznidazole in both the acute and chronic phases.
AID1381725	Inhibition of recombinant full-length human aurora B kinase expressed in baculovirus system using MBP as substrate incubated for 45 mins by ADP-glo kinase assay	2018	European journal of medicinal chemistry, Feb-25, Volume: 146	Aryl thiosemicarbazones for the treatment of trypanosomatidic infections.
AID1361365	Trypanocidal activity against trypomastigote stage of Trypanosoma cruzi INC-5 infected in NIH mouse blood assessed as parasite lysis after 24 hrs by optical microscopic method	2018	European journal of medicinal chemistry, Aug-05, Volume: 156	Synthesis, molecular docking and biological evaluation of novel phthaloyl derivatives of 3-amino-3-aryl propionic acids as inhibitors of Trypanosoma cruzi trans-sialidase.
AID1240905	Selectivity index, ratio of IC50 for rat L6 cells to IC50 for trypomastigote forms of Trypanosoma cruzi Tulahuen C4	2015	Journal of medicinal chemistry, Aug-27, Volume: 58, Issue:16	2-Phenoxy-1,4-naphthoquinones: From a Multitarget Antitrypanosomal to a Potential Antitumor Profile.
AID536028	Antitrypanosomal activity against epimastigotes of Trypanosoma cruzi Y assessed as viability at 40 uM after 15 hrs by trypan blue exclusion assay	2010	Bioorganic & medicinal chemistry, Nov-15, Volume: 18, Issue:22	Studies toward the structural optimization of novel thiazolylhydrazone-based potent antitrypanosomal agents.
AID392022	Antitrypanosomal activity against Trypanosoma cruzi Colombiana infected Swiss mouse assessed as prevention of liver congestion at 120 mg/kg/day, po	2008	European journal of medicinal chemistry, Oct, Volume: 43, Issue:10	In vivo studies of 5-arylethenylbenzofuroxans in acute murine models of Chagas' disease.
AID1615112	Hepatotoxicity in Balb/c mouse infected with Trypanosoma cruzi MHOM/Pe/2011/Arequipa DTU 5 trypomastigotes assessed as increase in serum ALT to GPT level at 20 mg/kg, po once daily for 5 consecutive days starting from day 10 post infection measured on day	2019	Bioorganic & medicinal chemistry, 03-01, Volume: 27, Issue:5	Synthesis and biological evaluation of new long-chain squaramides as anti-chagasic agents in the BALB/c mouse model.
AID1379739	Antitrypanosomal activity against Trypanosoma cruzi Tulahuen trypomastigotes expressing beta-galactosidase gene incubated for 4 days by beta-galactosidase mediated CPRG substrate hydrolysis assay	2017	European journal of medicinal chemistry, Nov-10, Volume: 140	Synthesis and 2D-QSAR studies of neolignan-based diaryl-tetrahydrofuran and -furan analogues with remarkable activity against Trypanosoma cruzi and assessment of the trypanothione reductase activity.
AID537135	Antitrypanosomal activity against trypomastigotes of Trypanosoma cruzi infected in rhesus monkey LLC-MK2 cells after 48 hrs by MTT assay	2010	Bioorganic & medicinal chemistry, Nov-15, Volume: 18, Issue:22	Anti-leishmanial and anti-trypanosomal activities of 1,4-dihydropyridines: In vitro evaluation and structure-activity relationship study.
AID1055184	Selectivity index, ratio of IC50 for African green monkey Vero cells to IC50 for extracellular epimastigote form of Trypanosoma cruzi IRHOD/CO/2008/SN3	2013	European journal of medicinal chemistry, , Volume: 70	Scorpiand-like azamacrocycles prevent the chronic establishment of Trypanosoma cruzi in a murine model.
AID1422885	Antitrypanosomal activity against Trypanosoma cruzi Dm28c epimastigotes infected in African green monkey Vero cells after 72 hrs by CPRG/Nonidet reagent based beta-galactosidase reporter gene assay	2018	ACS medicinal chemistry letters, Oct-11, Volume: 9, Issue:10	Discovery of a Biologically Active Bromodomain Inhibitor by Target-Directed Dynamic Combinatorial Chemistry.
AID726224	Antitrypanosomal activity against Trypanosoma cruzi Y epimastigotes at 8 uM incubated for 48 hrs by resazurin dye reduction based ELISA method	2013	Journal of medicinal chemistry, Feb-28, Volume: 56, Issue:4	Cloning, characterization, and sulfonamide and thiol inhibition studies of an α-carbonic anhydrase from Trypanosoma cruzi, the causative agent of Chagas disease.
AID1686744	Selectivity index, ratio of IC50 for cytotoxicity in African green monkey Vero cells to IC50 for antitrypanosomal activity against Trypanosoma cruzi NS3 epimastigote forms	2016	Journal of medicinal chemistry, 12-22, Volume: 59, Issue:24	In Vitro and in Vivo Anti-Trypanosoma cruzi Activity of New Arylamine Mannich Base-Type Derivatives.
AID563555	Toxicity in CH3/He(H-2k) mouse assessed as effect on creatine kinase level at 100 mg/kg/day, po	2010	Antimicrobial agents and chemotherapy, Jul, Volume: 54, Issue:7	Arylimidamide DB766, a potential chemotherapeutic candidate for Chagas' disease treatment.
AID1498288	Cardiotoxicity in Balb/c mouse infected with Trypanosoma cruzi MHOM/Pe/2011/Arequipa DTU 5 trypamastigotes assessed as change in ratio of creatine kinase in muscle to brain at 20 mg/kg, po once daily for 5 consecutive days starting from day 10 post infect	2018	Journal of medicinal chemistry, 07-12, Volume: 61, Issue:13	Second Generation of Mannich Base-Type Derivatives with in Vivo Activity against Trypanosoma cruzi.
AID547263	Antimicrobial activity against Trypanosoma cruzi Y infected in mongrel dog assessed as parasite level in blood of dog at 7 mg/kg, po BID started 12 to 22 days postinfection measured after 30 days by PCR analysis	2010	Antimicrobial agents and chemotherapy, Jul, Volume: 54, Issue:7	Effects of ravuconazole treatment on parasite load and immune response in dogs experimentally infected with Trypanosoma cruzi.
AID1615029	Selectivity index, ratio of IC50 for African green monkey Vero cells to IC50 for Trypanosoma cruzi TINF/CH/1956/Tulahuen DTU 6 amastigotes infected in African green monkey Vero cells	2019	Bioorganic & medicinal chemistry, 03-01, Volume: 27, Issue:5	Synthesis and biological evaluation of new long-chain squaramides as anti-chagasic agents in the BALB/c mouse model.
AID251290	In vivo activity at a dose of 45 mg/kg, p.o., for 5 doses in in rodent model with Trypanosoma brucei brucei STIB 795 strain, measured as survival days (control 13 days)	2005	Journal of medicinal chemistry, Aug-25, Volume: 48, Issue:17	Design and synthesis of a series of melamine-based nitroheterocycles with activity against Trypanosomatid parasites.
AID1603772	Selectivity index, ratio of IC50 for African green monkey Vero cells to IC50 for Trypanosoma cruzi TINF/CH/1956/Tulahuen;DTU 6 trypomastigote forms	2019	Bioorganic & medicinal chemistry, 09-01, Volume: 27, Issue:17	Rational modification of Mannich base-type derivatives as novel antichagasic compounds: Synthesis, in vitro and in vivo evaluation.
AID1055177	Trypanocidal activity against bloodstream trypomastigote form of Trypanosoma cruzi IRHOD/CO/2008/SN3 infected in BALB/c mouse assessed as reduction of anti-parasitic Ig-G level in serum at 5 mg/kg/day, ip administered for 5 days measured over 40 to 120 da	2013	European journal of medicinal chemistry, , Volume: 70	Scorpiand-like azamacrocycles prevent the chronic establishment of Trypanosoma cruzi in a murine model.
AID1065109	Trypanocidal activity against Trypanosoma cruzi CA-I/72 infected in BESM cells assessed as parasite re-emergence at 6.6 uM treated for 20 days measured after 37 days	2014	ACS medicinal chemistry letters, Feb-13, Volume: 5, Issue:2	Diversity-oriented synthesis yields a new drug lead for treatment of chagas disease.
AID302065	Cytotoxicity against Vero cells by MTT assay	2007	Bioorganic & medicinal chemistry, Dec-15, Volume: 15, Issue:24	Synthesis and in vitro evaluation of leishmanicidal and trypanocidal activities of N-quinolin-8-yl-arylsulfonamides.
AID396012	Antimicrobial activity against Trypanosoma cruzi 2 infected in BALB/c mouse assessed as cure rate	2007	Antimicrobial agents and chemotherapy, Sep, Volume: 51, Issue:9	Impact of dual infections on chemotherapeutic efficacy in BALB/c mice infected with major genotypes of Trypanosoma cruzi.
AID1470754	Trypanocidal activity against trypomastigote stage of Trypanosoma cruzi NINOA infected in NIH mouse blood after 24 hrs by optical microscopic method	2017	European journal of medicinal chemistry, May-26, Volume: 132	An in vitro and in vivo evaluation of new potential trans-sialidase inhibitors of Trypanosoma cruzi predicted by a computational drug repositioning method.
AID1507196	Antitrypanosomal activity against Trypanosoma cruzi clone CL B5 epimastigotes at 25 uM after 72 hrs by beta-galactosidase reporter gene assay	2017	European journal of medicinal chemistry, Aug-18, Volume: 136	Novel Imidazo[4,5-c][1,2,6]thiadiazine 2,2-dioxides as antiproliferative trypanosoma cruzi drugs: Computational screening from neural network, synthesis and in vivo biological properties.
AID548113	Inhibition of Trypanosoma cruzi triosephosphate isomerase at 400 uM after 2 hrs	2010	European journal of medicinal chemistry, Dec, Volume: 45, Issue:12	Massive screening yields novel and selective Trypanosoma cruzi triosephosphate isomerase dimer-interface-irreversible inhibitors with anti-trypanosomal activity.
AID1653741	Antitrypanosomal activity against Trypanosoma cruzi Tulahuen C4 trypomastigotes infected in rat L6 cells assessed as parasite growth inhibition measured after 96 hrs by inverted microscopy analysis	2020	Bioorganic & medicinal chemistry, 01-01, Volume: 28, Issue:1	Synthesis, in-vitro antiprotozoal activity and molecular docking study of isothiocyanate derivatives.
AID630656	Antitrypanosomal activity against epimastigote form of Trypanosoma cruzi Y after 5 days by spectrophotometer analysis	2011	Bioorganic & medicinal chemistry, Nov-01, Volume: 19, Issue:21	Synthesis, molecular modeling and preliminary biological evaluation of a set of 3-acetyl-2,5-disubstituted-2,3-dihydro-1,3,4-oxadiazole as potential antibacterial, anti-Trypanosoma cruzi and antifungal agents.
AID1525223	Antitrypanosomal activity against Trypanosoma cruzi amastigotes infected in peritoneal macrophages (unknown origin) measured after 48 hrs by resazurin dye based assay	2019	Journal of natural products, 05-24, Volume: 82, Issue:5	Antitrypanosomal Activity of Acetogenins Isolated from the Seeds of Porcelia macrocarpa Is Associated with Alterations in Both Plasma Membrane Electric Potential and Mitochondrial Membrane Potential.
AID1615035	Antitrypanosomal activity against Trypanosoma cruzi MHOM/Pe/2011/Arequipa DTU 5 trypomastigotes infected in Balb/c mouse assessed as reduction in parasitaemia level at 20 mg/kg, po once daily for 5 consecutive days starting from day 10 post infection meas	2019	Bioorganic & medicinal chemistry, 03-01, Volume: 27, Issue:5	Synthesis and biological evaluation of new long-chain squaramides as anti-chagasic agents in the BALB/c mouse model.
AID1603854	Toxicity in BALB/c mouse infected with Trypanosoma cruzi MHOM/Pe/2011/Arequipa;DTU 5 bloodstream trypomastigote assessed as change in serum alanine aminotransferase level in acute phase at 20 mg/kg/day, po administered for 5 consecutive days starting from	2019	Bioorganic & medicinal chemistry, 09-01, Volume: 27, Issue:17	Rational modification of Mannich base-type derivatives as novel antichagasic compounds: Synthesis, in vitro and in vivo evaluation.
AID1633360	Cytotoxicity against African green monkey Vero cells 72 hrs by CellTiter-Glo assay
AID1615028	Selectivity index, ratio of IC50 for African green monkey Vero cells to IC50 for Trypanosoma cruzi TINF/CH/1956/Tulahuen DTU 6 epimastigotes	2019	Bioorganic & medicinal chemistry, 03-01, Volume: 27, Issue:5	Synthesis and biological evaluation of new long-chain squaramides as anti-chagasic agents in the BALB/c mouse model.
AID263377	Antitrypanosomal activity against Trypanosoma cruzi epimastigotes at 10 ug/ml	2006	Bioorganic & medicinal chemistry letters, Apr-01, Volume: 16, Issue:7	New ligand-based approach for the discovery of antitrypanosomal compounds.
AID669297	Antitrypanosomal activity against Trypanosoma cruzi Y epimastigotes after 96 hrs by neubauer chamber	2012	Journal of medicinal chemistry, Apr-12, Volume: 55, Issue:7	Terpenes from Copaifera demonstrated in vitro antiparasitic and synergic activity.
AID1683678	Toxicity in BALB/c mouse infected with Trypanosomal Trypanosoma cruzi MHOM/Pe/2011/Arequipa(DTU V) assessed as effect on uric acid level at 20 mg/kg, po administered for 5 days starting at 100 days post infection and measured after 2 days post treatment	2020	Journal of natural products, 12-24, Volume: 83, Issue:12	In Vivo Biological Evaluation of a Synthetic Royleanone Derivative as a Promising Fast-Acting Trypanocidal Agent by Inducing Mitochondrial-Dependent Necrosis.
AID1687790	Selectivity index, ratio of GI50 for human HepG2 cells assessed as reduction in cell viability measured after 24 hrs by WST1 assay to IC50 for antitrypanosomal activity against Trypanosoma cruzi Y axenic amastigotes infected in African green monkey Vero c	2020	European journal of medicinal chemistry, Jan-15, Volume: 186	Novel nitroimidazole derivatives evaluated for their trypanocidal, cytotoxic, and genotoxic activities.
AID1519010	Antitrypanosomal activity against Trypanosoma cruzi K98 bloodstream form infected in C3H/HeNk mouse assessed as adipocytes replacement in skeletal muscle by measuring number of adipocyte at 75 mg/kg/day, po administered via gavage for 30 consecutive days	2019	European journal of medicinal chemistry, 12-15, Volume: 184	Combined therapy with Benznidazole and repurposed drugs Clofazimine and Benidipine for chronic Chagas disease.
AID1615085	Nephrotoxicity in Balb/c mouse infected with Trypanosoma cruzi MHOM/Pe/2011/Arequipa DTU 5 trypomastigotes assessed as decrease in serum urea level at 20 mg/kg, po once daily for 5 consecutive days starting from day 10 post infection measured on day 16 po	2019	Bioorganic & medicinal chemistry, 03-01, Volume: 27, Issue:5	Synthesis and biological evaluation of new long-chain squaramides as anti-chagasic agents in the BALB/c mouse model.
AID1254443	Antiparasitic activity against bloodstream trypomastigote stage of Trypanosoma cruzi Y infected in BALB/c mouse assessed as reduction of parasitemia at 100 mg/kg, po qd administered for 5 days measured on day 12 post infection relative to vehicle-treated	2015	Bioorganic & medicinal chemistry, Dec-01, Volume: 23, Issue:23	Structural design, synthesis and pharmacological evaluation of 4-thiazolidinones against Trypanosoma cruzi.
AID1603744	Antitrypanosomal activity against Trypanosoma cruzi MHOM/Pe/2011/Arequipa;DTU 5 bloodstream trypomastigote infected in BALB/c mouse assessed as parasitemia reactivation in acute phase at 20 mg/kg/day, po administered for 5 consecutive days starting from d	2019	Bioorganic & medicinal chemistry, 09-01, Volume: 27, Issue:17	Rational modification of Mannich base-type derivatives as novel antichagasic compounds: Synthesis, in vitro and in vivo evaluation.
AID1616171	Toxicity in Swiss Webster mouse infected with Trypanosoma cruzi Y trypomastigotes assessed as appearance of clinical symptoms at 100 mg/kg, po administered once daily via gavage for 5 days starting from 5 days post-infection and measured daily up to 40 da	2019	Journal of medicinal chemistry, 10-10, Volume: 62, Issue:19	Discovery of Pyrrolo[2,3-
AID1687715	Anti-chagasic activity against Trypanosoma cruzi trypomastigotes infected in C3H mouse assessed as active behaviour at 10 mg/kg, po treated 10 days post infection measured on day 19	2020	European journal of medicinal chemistry, Jan-15, Volume: 186	Hit-to-lead optimization of novel 2-alkylaminomethylquinoline derivatives as anti-chagas agents.
AID1486934	Antiprotozoal activity against Leishmania amazonensis IFLA/BR/67/PH-8 incubated for 72 hrs by Neubauer chamber based cell counting method	2017	Bioorganic & medicinal chemistry letters, 08-01, Volume: 27, Issue:15	Synthesis, in vitro and in vivo giardicidal activity of nitrothiazole-NSAID chimeras displaying broad antiprotozoal spectrum.
AID337130	Antitrypanosomal activity against Trypanosoma cruzi Tulahuen after 48 hrs
AID1174798	Antiparasitic activity against trypomastigote form of Trypanosoma cruzi IRHOD/CO/2008/SN3 infected in BALB/c mouse acute chagas disease model assessed as parasitemia reactivation at 5 mg/kg, ip after 60 days immunosuppressed with cyclophosphamide monohydr	2015	European journal of medicinal chemistry, Jan-07, Volume: 89	Prospects of an alternative treatment against Trypanosoma cruzi based on abietic acid derivatives show promising results in Balb/c mouse model.
AID575180	Antimicrobial activity against Trypanosoma cruzi infected in rat L6E9 myoblasts assessed as inhibition of [3H]uracil incorporation by giemsa staining	2010	Antimicrobial agents and chemotherapy, Sep, Volume: 54, Issue:9	Chemical validation of phosphodiesterase C as a chemotherapeutic target in Trypanosoma cruzi, the etiological agent of Chagas' disease.
AID1439207	Antitrypanosomal activity against Trypanosoma cruzi Y amastigote forms infected in human U2OS cells after 96 hrs by Draq5 staining-based high content analysis relative to control	2017	European journal of medicinal chemistry, Mar-10, Volume: 128	Synthesis and trypanocidal activity of a library of 4-substituted 2-(1H-pyrrolo[3,2-c]pyridin-2-yl)propan-2-ols.
AID1565134	Cytotoxicity against mouse cardiomyocytes infected with intracellular amastigote stage of Trypanosoma cruzi Y strain assessed as reduction in cardiomyocyte viability after 72 hrs by Celltiter-Glo assay	2019	European journal of medicinal chemistry, Nov-15, Volume: 182	Synthesis, structure-activity relationship and trypanocidal activity of pyrazole-imidazoline and new pyrazole-tetrahydropyrimidine hybrids as promising chemotherapeutic agents for Chagas disease.
AID1613529	Nephrotoxicity in Balb/c mouse infected with Trypanosoma cruzi MHOM/Pe/2011/Arequipa DTU 5 trypomastigotes assessed as decrease in serum uric acid level at 20 mg/kg, po once daily for 5 consecutive days starting from day 75 post infection measured on day	2019	European journal of medicinal chemistry, Feb-15, Volume: 164	New polyamine drugs as more effective antichagas agents than benznidazole in both the acute and chronic phases.
AID213635	Effective concentration required to inhibit the growth of mammalian stage of Trypanosoma cruzi grown in murine 3T3 fibroblasts	2001	Journal of medicinal chemistry, Jun-21, Volume: 44, Issue:13	Adenosine analogues as selective inhibitors of glyceraldehyde-3-phosphate dehydrogenase of Trypanosomatidae via structure-based drug design.
AID536024	Antitrypanosomal activity against epimastigotes of Trypanosoma cruzi Y assessed as viability at 40 uM after 11 days by trypan blue exclusion assay	2010	Bioorganic & medicinal chemistry, Nov-15, Volume: 18, Issue:22	Studies toward the structural optimization of novel thiazolylhydrazone-based potent antitrypanosomal agents.
AID1498237	Antitrypanosomal activity against Trypanosoma cruzi MHOM/Pe/2011/Arequipa DTU 5 trypamastigotes infected in Balb/c mouse assessed as reduction in parasitaemia reactivation in adipose tissue at 20 mg/kg, po pretreated once daily for 5 consecutive days star	2018	Journal of medicinal chemistry, 07-12, Volume: 61, Issue:13	Second Generation of Mannich Base-Type Derivatives with in Vivo Activity against Trypanosoma cruzi.
AID1603865	Toxicity in BALB/c mouse infected with Trypanosoma cruzi MHOM/Pe/2011/Arequipa;DTU 5 bloodstream trypomastigote assessed as decrease in serum lactate dehydrogenase level in chronic phase at 20 mg/kg/day, po administered for 5 consecutive days starting fro	2019	Bioorganic & medicinal chemistry, 09-01, Volume: 27, Issue:17	Rational modification of Mannich base-type derivatives as novel antichagasic compounds: Synthesis, in vitro and in vivo evaluation.
AID1613558	Hepatotoxicity in Balb/c mouse infected with Trypanosoma cruzi MHOM/Pe/2011/Arequipa DTU 5 trypomastigotes assessed as change in ratio of serum ALT to GPT level at 20 mg/kg, po once daily for 5 consecutive days starting from day 75 post infection measured	2019	European journal of medicinal chemistry, Feb-15, Volume: 164	New polyamine drugs as more effective antichagas agents than benznidazole in both the acute and chronic phases.
AID621152	Antiprotozoal activity against Trypanosoma cruzi Tulahuen C4 at pH 7.4 by microplate assay	2011	Bioorganic & medicinal chemistry letters, Oct-01, Volume: 21, Issue:19	Synthesis and in vitro antiprotozoal activities of 5-phenyliminobenzo[a]phenoxazine derivatives.
AID303378	Antitrypanosomal activity against Trypanosoma cruzi Tulahuen 2	2007	Journal of medicinal chemistry, Nov-29, Volume: 50, Issue:24	In vivo anti-Chagas vinylthio-, vinylsulfinyl-, and vinylsulfonylbenzofuroxan derivatives.
AID576100	Toxicity in human patient infected with Trypanosoma cruzi assessed as occurrence of Abdominal bloating at 5 mg/kg/day for 60 days	2010	Antimicrobial agents and chemotherapy, Nov, Volume: 54, Issue:11	Tolerance of benznidazole in treatment of Chagas' disease in adults.
AID1403393	Therapeutic index, ratio of CC50 for African green monkey Vero cells to IC50 for Trypanosoma cruzi Y trypomastigotes infected in monkey LLC-MK2 cells	2018	European journal of medicinal chemistry, Jan-20, Volume: 144	Efficacy of 2-hydroxy-3-phenylsulfanylmethyl-[1,4]-naphthoquinone derivatives against different Trypanosoma cruzi discrete type units: Identification of a promising hit compound.
AID707781	Antitrypanosomal activity against Trypanosoma cruzi IRHOD/VO/2008/SN3 isolated from mouse blood trypomastigotes incubated for 24 hrs	2012	Journal of medicinal chemistry, Nov-26, Volume: 55, Issue:22	Phthalazine derivatives containing imidazole rings behave as Fe-SOD inhibitors and show remarkable anti-T. cruzi activity in immunodeficient-mouse mode of infection.
AID1254447	Toxicity in BALB/c mouse infected with bloodstream trypomastigote stage of Trypanosoma cruzi Y assessed as body weight loss at 100 mg/kg, po qd administered for 5 days	2015	Bioorganic & medicinal chemistry, Dec-01, Volume: 23, Issue:23	Structural design, synthesis and pharmacological evaluation of 4-thiazolidinones against Trypanosoma cruzi.
AID1687702	Antitrypanosomal activity against bloodstream Trypanosoma cruzi amastigotes expressing beta-galactosidase infected in african green monkey VERO cells incubated for 5 days measured by microplate reader assay	2020	European journal of medicinal chemistry, Jan-15, Volume: 186	Hit-to-lead optimization of novel 2-alkylaminomethylquinoline derivatives as anti-chagas agents.
AID576085	Toxicity in human patient infected with Trypanosoma cruzi assessed as occurrence of Dyshidrosis at 5 mg/kg/day for 60 days	2010	Antimicrobial agents and chemotherapy, Nov, Volume: 54, Issue:11	Tolerance of benznidazole in treatment of Chagas' disease in adults.
AID1498255	Antitrypanosomal activity against Trypanosoma cruzi MHOM/Pe/2011/Arequipa DTU 5 trypamastigotes infected in Balb/c mouse assessed as reduction in Ig-G level in serum at 20 mg/kg, po pretreated once daily for 5 consecutive days starting from day 75 post in	2018	Journal of medicinal chemistry, 07-12, Volume: 61, Issue:13	Second Generation of Mannich Base-Type Derivatives with in Vivo Activity against Trypanosoma cruzi.
AID1615104	Cardiotoxicity in Balb/c mouse infected with Trypanosoma cruzi MHOM/Pe/2011/Arequipa DTU 5 trypomastigotes assessed as decrease in serum LDH level at 20 mg/kg, po once daily for 5 consecutive days starting from day 75 post infection measured on day 127 po	2019	Bioorganic & medicinal chemistry, 03-01, Volume: 27, Issue:5	Synthesis and biological evaluation of new long-chain squaramides as anti-chagasic agents in the BALB/c mouse model.
AID710864	Antitrypanosomal activity against trypomastigotes of Trypanosoma cruzi Y infected in mouse peritoneal macrophages assessed as reduction of intracellular parasite level after 4 days	2012	Journal of medicinal chemistry, Dec-27, Volume: 55, Issue:24	Structural investigation of anti-Trypanosoma cruzi 2-iminothiazolidin-4-ones allows the identification of agents with efficacy in infected mice.
AID1184293	Antitrypanosomal activity against intracellular Trypanosoma cruzi infected in human U2OS cells assessed as reduction in parasite count at 12.5 uM after 48 hrs by confocal microscopy	2014	European journal of medicinal chemistry, Sep-12, Volume: 84	Synthesis and biological evaluation of 2,3-dihydroimidazo[1,2-a]benzimidazole derivatives against Leishmania donovani and Trypanosoma cruzi.
AID1780964	Selectivity index, ratio of IC50 for cytotoxicity against golden hamster BSR cells to IC50 for antiprotozoal activity against Trypanosoma cruzi epimastigotes	2021	European journal of medicinal chemistry, Nov-05, Volume: 223	Design and synthesis of Mannich base-type derivatives containing imidazole and benzimidazole as lead compounds for drug discovery in Chagas Disease.
AID1508560	Cytotoxicity against mouse J774 cells assessed as reduction in cell viability after 72 hrs by alamar blue assay	2017	European journal of medicinal chemistry, Dec-01, Volume: 141	Structural design, synthesis and pharmacological evaluation of thiazoles against Trypanosoma cruzi.
AID1473740	Inhibition of human MRP3 overexpressed in Sf9 insect cell membrane vesicles assessed as uptake of [3H]-estradiol-17beta-D-glucuronide in presence of ATP and GSH measured after 10 mins by membrane vesicle transport assay	2013	Toxicological sciences : an official journal of the Society of Toxicology, Nov, Volume: 136, Issue:1	A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.
AID1615110	Hepatotoxicity in Balb/c mouse infected with Trypanosoma cruzi MHOM/Pe/2011/Arequipa DTU 5 trypomastigotes assessed as increase in ratio of serum AST to GOT level at 20 mg/kg, po once daily for 5 consecutive days starting from day 75 post infection measur	2019	Bioorganic & medicinal chemistry, 03-01, Volume: 27, Issue:5	Synthesis and biological evaluation of new long-chain squaramides as anti-chagasic agents in the BALB/c mouse model.
AID1164939	Activation of human platelets assessed as CD62P expression at 3.9 ug/ml by flow cytometry relative to control	2014	European journal of medicinal chemistry, Nov-24, Volume: 87	In vitro antiparasitic activity of new thiosemicarbazones in strains of Trypanosoma cruzi.
AID694953	Antitrypanosomal activity against epimastigotes of Trypanosoma cruzi Y after 5 days	2012	Bioorganic & medicinal chemistry, Nov-01, Volume: 20, Issue:21	Optimization of anti-Trypanosoma cruzi oxadiazoles leads to identification of compounds with efficacy in infected mice.
AID563560	Cardiotoxicity in CH3/He(H-2k) mouse assessed as effect on heart rate level at 100 mg/kg/day, po	2010	Antimicrobial agents and chemotherapy, Jul, Volume: 54, Issue:7	Arylimidamide DB766, a potential chemotherapeutic candidate for Chagas' disease treatment.
AID1603845	Toxicity in BALB/c mouse infected with Trypanosoma cruzi MHOM/Pe/2011/Arequipa;DTU 5 bloodstream trypomastigote assessed as decrease in serum urea level in acute phase at 20 mg/kg/day, po administered for 5 consecutive days starting from day 8 post infect	2019	Bioorganic & medicinal chemistry, 09-01, Volume: 27, Issue:17	Rational modification of Mannich base-type derivatives as novel antichagasic compounds: Synthesis, in vitro and in vivo evaluation.
AID311644	Antiparasitic activity against Trypanosoma cruzi	2007	Journal of natural products, Oct, Volume: 70, Issue:10	Antiprotozoal polyacetylenes from the Tanzanian medicinal plant Cussonia zimmermannii.
AID1508583	Antitrypanosomal activity against bloodstream trypomastigote stage of Trypanosoma cruzi Y infected in Balb/c mouse assessed as protection against mouse mortality at 100 mg/kg, po qd administered for 5 consecutive days starting from day 5 post infection me	2017	European journal of medicinal chemistry, Dec-01, Volume: 141	Structural design, synthesis and pharmacological evaluation of thiazoles against Trypanosoma cruzi.
AID1615126	Hepatotoxicity in Balb/c mouse infected with Trypanosoma cruzi MHOM/Pe/2011/Arequipa DTU 5 trypomastigotes assessed as change in alkaline phosphatase level at 20 mg/kg, po once daily for 5 consecutive days starting from day 10 post infection measured on d	2019	Bioorganic & medicinal chemistry, 03-01, Volume: 27, Issue:5	Synthesis and biological evaluation of new long-chain squaramides as anti-chagasic agents in the BALB/c mouse model.
AID1541165	Antiprotozoal activity against Trypanosoma cruzi Tulahuen C4 amastigotes infected in rat L6 cells assessed as growth inhibition after 96 by photometric analysis
AID265555	Antitrypanosomatid activity against Trypanosoma cruzi Tulahuen 2 epimastigote form	2006	Journal of medicinal chemistry, Jun-01, Volume: 49, Issue:11	2H-benzimidazole 1,3-dioxide derivatives: a new family of water-soluble anti-trypanosomatid agents.
AID1713352	Trypanocidal activity against Trypanosoma cruzi Tulahuen C4 amastigotes intra-peritoneally infected in BALB/C mouse assessed as reduction in spleen trypomastigotes treated day 4 postinfection for 20 days	2016	European journal of medicinal chemistry, Nov-10, Volume: 123	Nitrotriazole-based acetamides and propanamides with broad spectrum antitrypanosomal activity.
AID547269	Immunostimulatory activity in mongrel dog infected with Trypanosoma cruzi Berenice-78 assessed as production of antibody IgG at 12 mg/kg, po BID for 90 days measured up to 30 days by ELISA	2010	Antimicrobial agents and chemotherapy, Jul, Volume: 54, Issue:7	Effects of ravuconazole treatment on parasite load and immune response in dogs experimentally infected with Trypanosoma cruzi.
AID1653744	Cytotoxicity against rat L6 cells assessed as reduction in cell viability measured after 72 hrs by Alamar blue based inverted microscopy analysis	2020	Bioorganic & medicinal chemistry, 01-01, Volume: 28, Issue:1	Synthesis, in-vitro antiprotozoal activity and molecular docking study of isothiocyanate derivatives.
AID1383427	Selectivity index, ratio of LC50 for mouse L929 cells by light microscopic analysis to EC50 for Trypanosoma cruzi Tulahuen trypomastigote forms	2018	European journal of medicinal chemistry, Apr-10, Volume: 149	Identification of Pyrazolo[3,4-e][1,4]thiazepin based CYP51 inhibitors as potential Chagas disease therapeutic alternative: In vitro and in vivo evaluation, binding mode prediction and SAR exploration.
AID677287	Toxicity in BALB/c mouse liver infected with Trypanosoma cruzi assessed as granulomas with limphocitic infiltration at 5 mg/kg, ip after 120 days postinfection by Histopathological analysis	2012	Journal of medicinal chemistry, May-10, Volume: 55, Issue:9	In vitro and in vivo trypanosomicidal activity of pyrazole-containing macrocyclic and macrobicyclic polyamines: their action on acute and chronic phases of Chagas disease.
AID1070010	Antimicrobial activity against amastigote stage of Trypanosoma cruzi CL Brener infected in mouse NCTC-929 cells assessed as growth inhibition at 32 uM after 7 days by beta-galactosidase reporter gene assay	2014	Bioorganic & medicinal chemistry letters, Feb-15, Volume: 24, Issue:4	In vitro phenotypic screening of 7-chloro-4-amino(oxy)quinoline derivatives as putative anti-Trypanosoma cruzi agents.
AID726608	Antiparasitic activity against Toxoplasma gondii tachyzoite expressing red fluorescence protein assessed as growth inhibition by fluorescence plate reader	2013	European journal of medicinal chemistry, Feb, Volume: 60	Design, synthesis and biological evaluation of sulfur-containing 1,1-bisphosphonic acids as antiparasitic agents.
AID536026	Antitrypanosomal activity against trypomastigotes of Trypanosoma cruzi Y assessed as viability after 24 hrs by trypan blue exclusion assay	2010	Bioorganic & medicinal chemistry, Nov-15, Volume: 18, Issue:22	Studies toward the structural optimization of novel thiazolylhydrazone-based potent antitrypanosomal agents.
AID1383430	Antitrypanosomal activity against bloodstream trypomastigote stage of Trypanosoma cruzi Y measured after 24 hrs by light microscopic analysis	2018	European journal of medicinal chemistry, Apr-10, Volume: 149	Identification of Pyrazolo[3,4-e][1,4]thiazepin based CYP51 inhibitors as potential Chagas disease therapeutic alternative: In vitro and in vivo evaluation, binding mode prediction and SAR exploration.
AID1415704	Antitrypanosomal activity against Trypanosoma cruzi strain CL Brener epimastigotes measured after 72 hrs by Neubauer chamber based cell counting method	2017	MedChemComm, May-01, Volume: 8, Issue:5	Antitrypanosomal and antileishmanial activity of prenyl-1,2,3-triazoles.
AID1456554	Antitrypanosomal activity against Trypanosoma cruzi Tulahuen intracellular amastigote harboring LacZ infected in human U937 cells after 72 hrs by CPRG/Nonidet reagent based spectrophotometric method
AID576833	Antitrypanosomal activity against Trypanosoma cruzi infected in african green monkey Vero cells assessed as reduction of trypomastigote number per infected cell at IC25 after 10 days relative to control	2011	Journal of medicinal chemistry, Feb-24, Volume: 54, Issue:4	In vivo trypanosomicidal activity of imidazole- or pyrazole-based benzo[g]phthalazine derivatives against acute and chronic phases of Chagas disease.
AID1780966	Antitrypanosomal activity against Trypanosoma cruzi amastigotes infected in BSR cells assessed as inhibition of replication of intracellular amastigotes incubated for 72 hrs by fluorescence based analysis	2021	European journal of medicinal chemistry, Nov-05, Volume: 223	Design and synthesis of Mannich base-type derivatives containing imidazole and benzimidazole as lead compounds for drug discovery in Chagas Disease.
AID1555442	Antitrypanosomal activity against Trypanosoma cruzi strain Y trypomastigotes maintained in Rhesus monkey LLC-MK1 cells assessed as decrease in trypomastigotes cell viability incubated for 24 hrs by resazurin dye based colorimetric assay	2019	European journal of medicinal chemistry, Aug-15, Volume: 176	Dehydrodieugenol B derivatives as antiparasitic agents: Synthesis and biological activity against Trypanosoma cruzi.
AID1399457	Cytotoxicity against rat H9c2 cells infected with Trypanosoma cruzi Tulahuen amastigote forms assessed as reduction in cell number after 72 hrs by DRAQ5 DNA dye based confocal microscopic analysis	2018	Bioorganic & medicinal chemistry, 08-07, Volume: 26, Issue:14	Quinoxaline derivatives as potential antitrypanosomal and antileishmanial agents.
AID536809	Antitrypanosomal activity against clone C4 Trypanosoma cruzi Tulahuen expressing LacZ	2010	European journal of medicinal chemistry, Nov, Volume: 45, Issue:11	QSAR guided synthesis of simplified antiplasmodial analogs of naphthylisoquinoline alkaloids.
AID1072681	Cytotoxicity against BALB/c mouse splenocytes assessed as cell viability after 24 hrs by [3H]thymidine incorporation assay	2014	European journal of medicinal chemistry, Mar-21, Volume: 75	Conformational restriction of aryl thiosemicarbazones produces potent and selective anti-Trypanosoma cruzi compounds which induce apoptotic parasite death.
AID1244576	Antiparasitic activity against trypomastigotes of Trypanosoma cruzi Y assessed as reduction of parasite count after 24 hrs	2015	European journal of medicinal chemistry, Aug-28, Volume: 101	Synthesis and structure-activity relationship study of a new series of antiparasitic aryloxyl thiosemicarbazones inhibiting Trypanosoma cruzi cruzain.
AID1682942	Selectivity index, ratio of CC50 for monkey LLC-MK2 cells to IC50 for antitrypanosomal activity against intracellular amastigote form of Trypanosoma cruzi Tulahuen strain infected in monkey LLC-MK2 cells	2021	Bioorganic & medicinal chemistry, 01-01, Volume: 29	Trypanocidal activity of new 1,6-diphenyl-1H-pyrazolo[3,4-b]pyridine derivatives: Synthesis, in vitro and in vivo studies.
AID1470752	Trypanocidal activity against trypomastigote stage of Trypanosoma cruzi INC-5 infected in NIH mouse blood after 24 hrs by optical microscopic method	2017	European journal of medicinal chemistry, May-26, Volume: 132	An in vitro and in vivo evaluation of new potential trans-sialidase inhibitors of Trypanosoma cruzi predicted by a computational drug repositioning method.
AID576092	Toxicity in human patient infected with Trypanosoma cruzi assessed as occurrence of Articular involvement at 5 mg/kg/day for 60 days	2010	Antimicrobial agents and chemotherapy, Nov, Volume: 54, Issue:11	Tolerance of benznidazole in treatment of Chagas' disease in adults.
AID1603836	Toxicity in BALB/c mouse infected with Trypanosoma cruzi MHOM/Pe/2011/Arequipa;DTU 5 bloodstream trypomastigote assessed as decrease in serum lactate dehydrogenase level in acute phase at 20 mg/kg/day,po administered for 5 consecutive days starting from d	2019	Bioorganic & medicinal chemistry, 09-01, Volume: 27, Issue:17	Rational modification of Mannich base-type derivatives as novel antichagasic compounds: Synthesis, in vitro and in vivo evaluation.
AID1381720	Inhibition of human microsomal CYP1A2 expressed in baculovirus infected BTI-TN-5B1-4 cells incubated for 30 mins by luciferase assay	2018	European journal of medicinal chemistry, Feb-25, Volume: 146	Aryl thiosemicarbazones for the treatment of trypanosomatidic infections.
AID1613518	Antitrypanosomal activity against Trypanosoma cruzi MHOM/Pe/2011/Arequipa DTU 5 epimastigotes assessed as change in mitochondrial membrane potential at IC25 after 72 hrs by Rho123 staining based flow cytometry relative to control	2019	European journal of medicinal chemistry, Feb-15, Volume: 164	New polyamine drugs as more effective antichagas agents than benznidazole in both the acute and chronic phases.
AID726225	Antitrypanosomal activity against Trypanosoma cruzi Y epimastigotes at 16 uM incubated for 48 hrs by resazurin dye reduction based ELISA method	2013	Journal of medicinal chemistry, Feb-28, Volume: 56, Issue:4	Cloning, characterization, and sulfonamide and thiol inhibition studies of an α-carbonic anhydrase from Trypanosoma cruzi, the causative agent of Chagas disease.
AID1633362	Selectivity index, ratio of CC50 for African green monkey Vero cells to IC50 for Trypanosoma cruzi Dm28c intracellular amastigotes infected in African green monkey Vero cells
AID1177051	Antiprotozoan activity against Trypanosoma cruzi Tulahuen C4 amastigotes	2015	Bioorganic & medicinal chemistry letters, Feb-01, Volume: 25, Issue:3	Hydroxamic acid based histone deacetylase inhibitors with confirmed activity against the malaria parasite.
AID1565130	Selectivity index, ratio of CC50 for African green monkey Vero cells to IC50 for Trypanosoma cruzi Y strain bloodstream trypomastigotes isolated from infected Swiss webster mouse cardiac cells	2019	European journal of medicinal chemistry, Nov-15, Volume: 182	Synthesis, structure-activity relationship and trypanocidal activity of pyrazole-imidazoline and new pyrazole-tetrahydropyrimidine hybrids as promising chemotherapeutic agents for Chagas disease.
AID1686728	Antitrypanosomal activity against Trypanosoma cruzi Arequipa epimastigote forms incubated for 72 hrs by hemocytometry	2016	Journal of medicinal chemistry, 12-22, Volume: 59, Issue:24	In Vitro and in Vivo Anti-Trypanosoma cruzi Activity of New Arylamine Mannich Base-Type Derivatives.
AID547279	Antitrypanosomal activity against Trypanosoma cruzi Y infected in mongrel dog assessed as reduction in INFgamma production in right atrium at 7 mg/kg, po BID after 180 days by semiquantitative RT-PCR	2010	Antimicrobial agents and chemotherapy, Jul, Volume: 54, Issue:7	Effects of ravuconazole treatment on parasite load and immune response in dogs experimentally infected with Trypanosoma cruzi.
AID1653748	Selectivity index, ratio of IC50 for rat L6 cells assessed as reduction in cell viability measured after 72 hrs by Alamar blue based inverted microscopy analysis to IC50 for Leishmania donovani MHOM-ET-67/L82 axenic amastigotes assessed as parasite growth	2020	Bioorganic & medicinal chemistry, 01-01, Volume: 28, Issue:1	Synthesis, in-vitro antiprotozoal activity and molecular docking study of isothiocyanate derivatives.
AID621157	Selectivity index, ratio of IC50 for rat L6 cells to IC50 for Trypanosoma cruzi Tulahuen C4	2011	Bioorganic & medicinal chemistry letters, Oct-01, Volume: 21, Issue:19	Synthesis and in vitro antiprotozoal activities of 5-phenyliminobenzo[a]phenoxazine derivatives.
AID1615042	Antitrypanosomal activity against Trypanosoma cruzi MHOM/Pe/2011/Arequipa DTU 5 trypomastigotes infected in Balb/c mouse assessed as parasite-free oesophagus at 20 mg/kg, po pretreated once daily for 5 consecutive days starting from day 10 post infection	2019	Bioorganic & medicinal chemistry, 03-01, Volume: 27, Issue:5	Synthesis and biological evaluation of new long-chain squaramides as anti-chagasic agents in the BALB/c mouse model.
AID1686770	Antitrypanosomal activity against Trypanosoma cruzi Arequipa trypomastigotes infected in BALB/c mouse assessed as reduction in splenomegaly by measuring weight percent of spleens measured during acute phase (days 0 to 40 post infection) at 100 mg/kg, po d	2016	Journal of medicinal chemistry, 12-22, Volume: 59, Issue:24	In Vitro and in Vivo Anti-Trypanosoma cruzi Activity of New Arylamine Mannich Base-Type Derivatives.
AID1055180	Trypanocidal activity against amastigote form of Trypanosoma cruzi IRHOD/CO/2008/SN3 infected in African green monkey Vero cells assessed as inhibition of amastigotes load per cell at IC25 preincubated for 12 hrs followed by compound washout measured afte	2013	European journal of medicinal chemistry, , Volume: 70	Scorpiand-like azamacrocycles prevent the chronic establishment of Trypanosoma cruzi in a murine model.
AID1383424	Antitrypanosomal activity against Trypanosoma cruzi Tulahuen trypomastigote forms infected in mouse L929 cells assessed as reduction in infection level at 10 to 12 uM after 96 hrs by beta-galactosidase reporter gene assay relative to control	2018	European journal of medicinal chemistry, Apr-10, Volume: 149	Identification of Pyrazolo[3,4-e][1,4]thiazepin based CYP51 inhibitors as potential Chagas disease therapeutic alternative: In vitro and in vivo evaluation, binding mode prediction and SAR exploration.
AID537134	Antileishmanial activity against promastigotes of Leishmania braziliensis MHO/BR/75/M2903 after 18 hrs by MTT assay	2010	Bioorganic & medicinal chemistry, Nov-15, Volume: 18, Issue:22	Anti-leishmanial and anti-trypanosomal activities of 1,4-dihydropyridines: In vitro evaluation and structure-activity relationship study.
AID677207	Trypanosomicidal activity against Trypanosoma cruzi SN3 amastigote infected in Vero cells after 72 hrs by Giemsa staining method	2012	Journal of medicinal chemistry, May-10, Volume: 55, Issue:9	In vitro and in vivo trypanosomicidal activity of pyrazole-containing macrocyclic and macrobicyclic polyamines: their action on acute and chronic phases of Chagas disease.
AID671573	Antitrypanosomal activity against trypomastigotes of Trypanosoma cruzi Tulahuen infected in Swiss mouse model of chagas disease assessed as increase in host survival at 100 mg/kg, po administered 8 day after post infection qd for 20 days	2012	Journal of medicinal chemistry, May-10, Volume: 55, Issue:9	Analogues of fenarimol are potent inhibitors of Trypanosoma cruzi and are efficacious in a murine model of Chagas disease.
AID1753499	Antitrypanosomal activity against Trypanosoma cruzi strain Y bloodstream trypomastigotes infected in Swiss Webster mouse assessed as reduction in parasitemia at 100 mg/kg, po qd for 5 days treatment started at 6 days post-infection and measured at 8 days	2021	Journal of medicinal chemistry, 04-08, Volume: 64, Issue:7	Revisiting Pyrazolo[3,4-
AID450068	Antitrypanosomal activity against Trypanosoma cruzi trypomastigote Y strain after 24 hrs by trypan blue exclusion assay	2009	Bioorganic & medicinal chemistry, Sep-15, Volume: 17, Issue:18	Design, synthesis and cruzain docking of 3-(4-substituted-aryl)-1,2,4-oxadiazole-N-acylhydrazones as anti-Trypanosoma cruzi agents.
AID1526367	Antitrypanosomal activity against Trypanosoma cruzi amastigote stage forms infected in mouse C2C12 cells incubated for 3 days by 4',6-diamidino-2-phenylindole staining based microscopy
AID396010	Antimicrobial activity against Trypanosoma cruzi 1 infected in BALB/c mouse assessed as cure rate	2007	Antimicrobial agents and chemotherapy, Sep, Volume: 51, Issue:9	Impact of dual infections on chemotherapeutic efficacy in BALB/c mice infected with major genotypes of Trypanosoma cruzi.
AID1300852	Antitrypanosomal activity against amastigote stage of Trypanosoma cruzi Tulahuen C4 infected in rat L6 cells assessed as inhibition of parasite growth using CPRG/Nonidet as substrate after 96 hrs by beta-galactosidase reporter gene assay	2016	European journal of medicinal chemistry, Jul-19, Volume: 117	Antitrypanosomal activity of 5-nitro-2-aminothiazole-based compounds.
AID576091	Toxicity in human patient infected with Trypanosoma cruzi assessed as occurrence of Fever at 5 mg/kg/day for 60 days	2010	Antimicrobial agents and chemotherapy, Nov, Volume: 54, Issue:11	Tolerance of benznidazole in treatment of Chagas' disease in adults.
AID764122	Antitrypanosomal activity against epimastigotes of Trypanosoma cruzi Y assessed as parasite growth inhibition after 5 days by spectrophotometric analysis	2013	Bioorganic & medicinal chemistry, Sep-01, Volume: 21, Issue:17	5-Nitro-2-furfuriliden derivatives as potential anti-Trypanosoma cruzi agents: design, synthesis, bioactivity evaluation, cytotoxicity and exploratory data analysis.
AID1854944	Induction of cell death in Trypanosoma cruzi Y epimastigotes assessed as dead cells at 125 uM incubated for 24 hrs by Annexin V/7-AAD staining based flow cytometric analysis (Rvb = 1.13 %)	2022	European journal of medicinal chemistry, Nov-05, Volume: 241	Rational design of a trypanocidal peptide derived from Dinoponera quadriceps venom.
AID1244575	Antiparasitic activity against epimastigotes of Trypanosoma cruzi Dm28c assessed as reduction of parasite count after 5 days	2015	European journal of medicinal chemistry, Aug-28, Volume: 101	Synthesis and structure-activity relationship study of a new series of antiparasitic aryloxyl thiosemicarbazones inhibiting Trypanosoma cruzi cruzain.
AID1851976	Selectivity index, ratio of CC50 for cytotoxicity against mouse 3T3 cells to IC50 for antitrypanosomal activity against Trypanosoma cruzi Tulahuen amastigotes infected in mouse 3T3 cells	2022	Journal of medicinal chemistry, 10-13, Volume: 65, Issue:19	Nitroimidazopyrazinones with Oral Activity against Tuberculosis and Chagas Disease in Mouse Models of Infection.
AID1615117	Hepatotoxicity in Balb/c mouse infected with Trypanosoma cruzi MHOM/Pe/2011/Arequipa DTU 5 trypomastigotes assessed as increase in total bilirubin level at 20 mg/kg, po once daily for 5 consecutive days starting from day 10 post infection measured on day	2019	Bioorganic & medicinal chemistry, 03-01, Volume: 27, Issue:5	Synthesis and biological evaluation of new long-chain squaramides as anti-chagasic agents in the BALB/c mouse model.
AID1405621	Antitrypanosomal activity against Trypanosoma cruzi Tulahuen strain C2C4 amastigote forms infected in rat L6 cells after 96 hrs by CPRG/Nonidet reagent based photometric method	2018	European journal of medicinal chemistry, Aug-05, Volume: 156	Biological evaluation and structure-activity relationships of imidazole-based compounds as antiprotozoal agents.
AID1780968	Selectivity index, ratio of cytotoxicity against golden hamster BSR cells to IC50 for antitrypanosomal activity against Trypanosoma cruzi amastigotes infected in BSR cells	2021	European journal of medicinal chemistry, Nov-05, Volume: 223	Design and synthesis of Mannich base-type derivatives containing imidazole and benzimidazole as lead compounds for drug discovery in Chagas Disease.
AID1617100	Antiprotozoal activity against Trypanosoma cruzi Tulahuen C4 amastigotes infected in rat L6 cells incubated for 96 hrs by beta-galactosidase reporter gene assay	2019	Journal of natural products, 11-22, Volume: 82, Issue:11	Ealamines A-H, a Series of Naphthylisoquinolines with the Rare 7,8'-Coupling Site, from the Congolese Liana
AID1603943	Antitrypanosomal activity against Trypanosoma cruzi MHOM/Pe/2011/Arequipa;DTU 5 bloodstream trypomastigotes infected in BALB/c mouse assessed as reduction in serum Ig-G level in acute phase at 20 mg/kg/day, po administered for 5 consecutive days starting	2019	Bioorganic & medicinal chemistry, 09-01, Volume: 27, Issue:17	Rational modification of Mannich base-type derivatives as novel antichagasic compounds: Synthesis, in vitro and in vivo evaluation.
AID1196803	Activity of his-tagged recombinant Trypanosoma brucei type-1 nitroreductase assessed as oxidized NADH level per mg of protein after 5 mins by absorption spectrum analysis	2015	Journal of medicinal chemistry, Feb-12, Volume: 58, Issue:3	Novel 3-nitrotriazole-based amides and carbinols as bifunctional antichagasic agents.
AID1074377	Antitrypanosomal activity against amastigote stage of Trypanosoma cruzi IRHOD/CO/2008/SN3 infected in African green monkey Vero cells assessed as decrease in infection rate at IC25 preincubated for 12 hrs followed by compound washout measured every 48 hrs	2014	Journal of medicinal chemistry, Feb-13, Volume: 57, Issue:3	Synthesis and biological evaluation of N,N'-squaramides with high in vivo efficacy and low toxicity: toward a low-cost drug against Chagas disease.
AID753404	Cytotoxicity against African green monkey Vero cells after 24 hrs by resazurin assay	2013	Bioorganic & medicinal chemistry letters, Jun-15, Volume: 23, Issue:12	Aromatic glycosyl disulfide derivatives: evaluation of their inhibitory activities against Trypanosoma cruzi.
AID285213	Antimicrobial activity against Trypanosoma cruzi Y infected wild type C57BL/6 mouse Chagas disease model assessed as percent of cured mouse at 100 mg/kg, po after 20 days	2007	Antimicrobial agents and chemotherapy, Apr, Volume: 51, Issue:4	The Anti-Trypanosoma cruzi activity of posaconazole in a murine model of acute Chagas' disease is less dependent on gamma interferon than that of benznidazole.
AID1603877	Toxicity in BALB/c mouse infected with Trypanosoma cruzi MHOM/Pe/2011/Arequipa;DTU 5 bloodstream trypomastigote assessed as decrease in serum creatine kinase muscle to brain ratio level in chronic phase at 20 mg/kg/day, po administered for 5 consecutive d	2019	Bioorganic & medicinal chemistry, 09-01, Volume: 27, Issue:17	Rational modification of Mannich base-type derivatives as novel antichagasic compounds: Synthesis, in vitro and in vivo evaluation.
AID1493586	Cytotoxicity against human U937 cells after 72 hrs by MTT assay
AID1321007	Selectivity index, ratio of CC50 for human U2OS cells infected with amastigote stage of Trypanosoma cruzi Y to EC50 for amastigote stage of Trypanosoma cruzi Y	2016	European journal of medicinal chemistry, Oct-04, Volume: 121	Design, synthesis and antitrypanosomal activity of some nitrofurazone 1,2,4-triazolic bioisosteric analogues.
AID536027	Cytotoxicity against BALB/c mouse Splenocyte assessed as non-cytotoxic concentration after 24 hrs by [3H]-thymidine incorporation assay relative to control	2010	Bioorganic & medicinal chemistry, Nov-15, Volume: 18, Issue:22	Studies toward the structural optimization of novel thiazolylhydrazone-based potent antitrypanosomal agents.
AID504749	qHTS profiling for inhibitors of Plasmodium falciparum proliferation	2011	Science (New York, N.Y.), Aug-05, Volume: 333, Issue:6043	Chemical genomic profiling for antimalarial therapies, response signatures, and molecular targets.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Timeframe	Studies, This Drug (%)	All Drugs %
pre-1990	89 (7.30)	18.7374
1990's	65 (5.33)	18.2507
2000's	229 (18.77)	29.6817
2010's	652 (53.44)	24.3611
2020's	185 (15.16)	2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Publication Type	This drug (%)	All Drugs (%)
Trials	51 (3.88%)	5.53%
Reviews	92 (7.00%)	6.00%
Case Studies	67 (5.10%)	4.05%
Observational	9 (0.68%)	0.25%
Other	1,095 (83.33%)	84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Trial	Phase	Enrollment	Study Type	Start Date	Status
Phase 2 Proof-of-Activity Study of Oral Posaconazole in the Treatment of Asymptomatic Chronic Chagas Disease (Phase 2, Protocol No. P05267) [NCT01377480]	Phase 2	120 participants (Actual)	Interventional	2011-07-06	Completed
Etiologic Treatment With Benznidazole in Adult Patients With Chronic Chagas Disease. A Randomized Double Blind Clinical Trial [NCT02386358]	Phase 3	910 participants (Actual)	Interventional	1999-03-31	Completed
Cardiovascular Health Investigation and Collaboration From Countries of America to Assess the Markers and Outcomes of Chagas Disease (CHICAMOCHA-3) - EQUITY (Equivalence of Usual Interventions for Trypanosomiasis) [NCT02369978]	Phase 2/Phase 3	500 participants (Anticipated)	Interventional	2015-08-31	Recruiting
A Phase 1 Pharmacokinetic Drug-Drug Interaction Study of Benznidazole and E1224 in Healthy Male Volunteers [NCT03892213]	Phase 1	28 participants (Actual)	Interventional	2014-10-31	Completed
A Phase I, Open-label, Study of the Absorption, Metabolism and Excretion, of [14C]-Benznidazole (BNZ) Following a Single Oral Dose in Healthy Male Subjects [NCT03739541]	Phase 1	6 participants (Actual)	Interventional	2018-07-16	Completed
PROTOCOL FOR PHASE II CLINICAL TRIAL, RANDOMIZED AND OPEN FOR ETIOLOGICAL TREATMENT OF CHRONIC CHAGAS DISEASE WITH POSACONAZOLE AND BENZNIDAZOLE [NCT01162967]	Phase 2	78 participants (Actual)	Interventional	2010-09-30	Completed
Population Pharmacokinetics Study of Benznidazole in Children With Chagas Disease [NCT00699387]		37 participants (Actual)	Interventional	2007-04-30	Completed
Phase 2 Randomized, Multicenter, Placebo-controlled, Safety and Efficacy Study to Evaluate Three Oral E1224 Dosing Regimens and Benznidazole for the Treatment of Adult Patients With Chronic Indeterminate Chagas Disease [NCT01489228]	Phase 2	230 participants (Anticipated)	Interventional	2011-06-30	Recruiting
Population Pharmacokinetics Study of Benznidazole in Children With Chagas'Disease [NCT01549236]	Phase 4	80 participants (Actual)	Interventional	2011-05-31	Completed
Benznidazole Evaluation for Interrupting Trypanosomiasis - The BENEFIT Trial [NCT00123916]	Phase 3	2,854 participants (Actual)	Interventional	2004-11-30	Completed
A Phase 1 Non-Randomized Open Label Study of ICM20 [NCT05523596]	Phase 1	24 participants (Anticipated)	Interventional	2022-12-20	Recruiting
Phase II Clinical Trial for the Evaluation of Different Benznidazole Regimens for the Treatment of Chronic Chagas Disease in Adult Patients. Berenice Project [NCT03191162]	Phase 2	238 participants (Actual)	Interventional	2017-04-21	Completed
Evolution of Serologic Biomarkers and Diastolic Function and Segmentary Contractility Determined by Echocardiography After Treatment in Chagas Diseases [NCT01755377]		63 participants (Actual)	Observational	2012-12-31	Completed
Population Pharmacokinetics in Benznidazole-treated Adults With Chronic Chagas Disease. Benznidazole Pharmacokinetics and Adverse Reactions Relationship. [NCT01755403]	Phase 4	52 participants (Actual)	Interventional	2012-12-31	Completed
New Chemotherapy Regimens and Biomarkers for Chagas Disease [NCT03981523]	Phase 2	450 participants (Anticipated)	Interventional	2019-12-18	Active, not recruiting
Prospective, Single-arm, Multicentre Study, Using a Historical Control, to Evaluate the Efficacy/Safety and Population Pharmacokinetics of Benznidazole in Children With Chronic Indeterminate Chagas Disease [NCT04024163]	Phase 3	178 participants (Actual)	Interventional	2019-09-19	Active, not recruiting
Short-course Benznidazole Treatment to Reduce Trypanosoma Cruzi Parasitic Load in Women of Reproductive Age: A Non-inferiority Randomized Controlled Trial [NCT03672487]	Phase 3	600 participants (Anticipated)	Interventional	2019-06-01	Recruiting
Optimization of Sampling Procedure for PCR Technique to Assess Parasitological Response for Patients With Chronic Chagas Disease Treated With Benznidazole in Aiquile, Bolivia [NCT01678599]	Phase 4	220 participants (Actual)	Interventional	2011-04-30	Completed
Phase 2 Randomized, Multicenter, Safety and Efficacy Trial to Evaluate Different Oral Benznidazole Monotherapy and Benznidazole/E1224 Combination Regimens for the Treatment of Adult Patients With Chronic Indeterminate Chagas Disease [NCT03378661]	Phase 2	210 participants (Actual)	Interventional	2016-11-30	Active, not recruiting
Phase III Randomized,Multicenter Non-inferiority Study to Evaluate the Efficacy and Safety of Shorter Benznidazole Regimens Compared to the Standard Regimen to Treat Adult Patients With Chronic Chagas Disease [NCT04897516]	Phase 3	300 participants (Anticipated)	Interventional	2021-07-28	Recruiting
[information is prepared from clinicaltrials.gov, extracted Sep-2024]

Trial	Outcome
NCT01377480 (1) [back to overview]	Percentage of Participants With a Successful Response as Measured by Qualitative Polymerase Chain Reaction

Intervention	Percentage of participants (Number)
Posaconazole	15.6
Placebo	10.0
Posaconazole + Benznidazole	82.1
Benznidazole + Placebo	86.7

Substance	Relationship Strength	Studies	Trials	Classes	Roles
adenine [no description available]	2.06	1	0	6-aminopurines; purine nucleobase	Daphnia magna metabolite; Escherichia coli metabolite; human metabolite; mouse metabolite; Saccharomyces cerevisiae metabolite
quinacrine Quinacrine: An acridine derivative formerly widely used as an antimalarial but superseded by chloroquine in recent years. It has also been used as an anthelmintic and in the treatment of giardiasis and malignant effusions. It is used in cell biological experiments as an inhibitor of phospholipase A2.. quinacrine : A member of the class of acridines that is acridine substituted by a chloro group at position 6, a methoxy group at position 2 and a [5-(diethylamino)pentan-2-yl]nitrilo group at position 9.	3.01	4	0	acridines; aromatic ether; organochlorine compound; tertiary amino compound	antimalarial; EC 1.8.1.12 (trypanothione-disulfide reductase) inhibitor
benzene [no description available]	2.21	1	0	aromatic annulene; benzenes; volatile organic compound	carcinogenic agent; environmental contaminant; non-polar solvent
carbamates [no description available]	1.98	1	0	amino-acid anion
carbon monoxide Carbon Monoxide: Carbon monoxide (CO). A poisonous colorless, odorless, tasteless gas. It combines with hemoglobin to form carboxyhemoglobin, which has no oxygen carrying capacity. The resultant oxygen deprivation causes headache, dizziness, decreased pulse and respiratory rates, unconsciousness, and death. (From Merck Index, 11th ed). carbon monoxide : A one-carbon compound in which the carbon is joined only to a single oxygen. It is a colourless, odourless, tasteless, toxic gas.	1.97	1	0	carbon oxide; gas molecular entity; one-carbon compound	biomarker; EC 1.9.3.1 (cytochrome c oxidase) inhibitor; human metabolite; ligand; metabolite; mitochondrial respiratory-chain inhibitor; mouse metabolite; neurotoxin; neurotransmitter; P450 inhibitor; probe; signalling molecule; vasodilator agent
aminooxyacetic acid Aminooxyacetic Acid: A compound that inhibits aminobutyrate aminotransferase activity in vivo, thereby raising the level of gamma-aminobutyric acid in tissues.. (aminooxy)acetic acid : A member of the class of hydroxylamines that is acetic acid substituted at postion 2 by an aminooxy group. It is a compound which inhibits aminobutyrate aminotransferase activity in vivo, resulting in increased levels of gamma-aminobutyric acid in tissues.	2.05	1	0	amino acid; hydroxylamines; monocarboxylic acid	anticonvulsant; EC 2.6.1.19 (4-aminobutyrate--2-oxoglutarate transaminase) inhibitor; EC 4.2.1.22 (cystathionine beta-synthase) inhibitor; nootropic agent
aminocaproic acid Aminocaproic Acid: An antifibrinolytic agent that acts by inhibiting plasminogen activators which have fibrinolytic properties.. 6-aminohexanoic acid : An epsilon-amino acid comprising hexanoic acid carrying an amino substituent at position C-6. Used to control postoperative bleeding, and to treat overdose effects of the thrombolytic agents streptokinase and tissue plasminogen activator.	2.05	1	0	amino acid zwitterion; epsilon-amino acid; omega-amino fatty acid	antifibrinolytic drug; hematologic agent; metabolite
dimethyl sulfoxide Dimethyl Sulfoxide: A highly polar organic liquid, that is used widely as a chemical solvent. Because of its ability to penetrate biological membranes, it is used as a vehicle for topical application of pharmaceuticals. It is also used to protect tissue during CRYOPRESERVATION. Dimethyl sulfoxide shows a range of pharmacological activity including analgesia and anti-inflammation.. dimethyl sulfoxide : A 2-carbon sulfoxide in which the sulfur atom has two methyl substituents.	2.44	2	0	sulfoxide; volatile organic compound	alkylating agent; antidote; Escherichia coli metabolite; geroprotector; MRI contrast agent; non-narcotic analgesic; polar aprotic solvent; radical scavenger
hydrogen Hydrogen: The first chemical element in the periodic table with atomic symbol H, and atomic number 1. Protium (atomic weight 1) is by far the most common hydrogen isotope. Hydrogen also exists as the stable isotope DEUTERIUM (atomic weight 2) and the radioactive isotope TRITIUM (atomic weight 3). Hydrogen forms into a diatomic molecule at room temperature and appears as a highly flammable colorless and odorless gas.. dihydrogen : An elemental molecule consisting of two hydrogens joined by a single bond.	2.15	1	0	elemental hydrogen; elemental molecule; gas molecular entity	antioxidant; electron donor; food packaging gas; fuel; human metabolite
hydroquinone [no description available]	2.11	1	0	benzenediol; hydroquinones	antioxidant; carcinogenic agent; cofactor; Escherichia coli metabolite; human xenobiotic metabolite; mouse metabolite; skin lightening agent
hydroxylamine amino alcohol : An alcohol containing an amino functional group in addition to the alcohol-defining hydroxy group.	2.07	1	0	hydroxylamines	algal metabolite; bacterial xenobiotic metabolite; EC 1.1.3.13 (alcohol oxidase) inhibitor; EC 4.2.1.22 (cystathionine beta-synthase) inhibitor; EC 4.3.1.10 (serine-sulfate ammonia-lyase) inhibitor; nitric oxide donor; nucleophilic reagent
imidazole imidazole: RN given refers to parent cpd. 1H-imidazole : An imidazole tautomer which has the migrating hydrogen at position 1.	4.04	1	0	imidazole
thioctic acid Thioctic Acid: An octanoic acid bridged with two sulfurs so that it is sometimes also called a pentanoic acid in some naming schemes. It is biosynthesized by cleavage of LINOLEIC ACID and is a coenzyme of oxoglutarate dehydrogenase (KETOGLUTARATE DEHYDROGENASE COMPLEX). It is used in DIETARY SUPPLEMENTS.	4.84	4	2	dithiolanes; heterocyclic fatty acid; thia fatty acid	fundamental metabolite; geroprotector
melatonin [no description available]	2.08	1	0	acetamides; tryptamines	anticonvulsant; central nervous system depressant; geroprotector; hormone; human metabolite; immunological adjuvant; mouse metabolite; radical scavenger
niacin Niacin: A water-soluble vitamin of the B complex occurring in various animal and plant tissues. It is required by the body for the formation of coenzymes NAD and NADP. It has PELLAGRA-curative, vasodilating, and antilipemic properties.. vitamin B3 : Any member of a group of vitamers that belong to the chemical structural class called pyridines that exhibit biological activity against vitamin B3 deficiency. Vitamin B3 deficiency causes a condition known as pellagra whose symptoms include depression, dermatitis and diarrhea. The vitamers include nicotinic acid and nicotinamide (and their ionized and salt forms).. nicotinic acid : A pyridinemonocarboxylic acid that is pyridine in which the hydrogen at position 3 is replaced by a carboxy group.	3.31	1	0	pyridine alkaloid; pyridinemonocarboxylic acid; vitamin B3	antidote; antilipemic drug; EC 3.5.1.19 (nicotinamidase) inhibitor; Escherichia coli metabolite; human urinary metabolite; metabolite; mouse metabolite; plant metabolite; vasodilator agent
nitrites Nitrites: Salts of nitrous acid or compounds containing the group NO2-. The inorganic nitrites of the type MNO2 (where M=metal) are all insoluble, except the alkali nitrites. The organic nitrites may be isomeric, but not identical with the corresponding nitro compounds. (Grant & Hackh's Chemical Dictionary, 5th ed)	2.71	3	0	monovalent inorganic anion; nitrogen oxoanion; reactive nitrogen species	human metabolite
oxamic acid Oxamic Acid: Amino-substituted glyoxylic acid derivative.. oxamic acid : A dicarboxylic acid monoamide resulting from the formal condensation of one of the carboxy groups of oxalic acid with ammonia.	2.95	4	0	dicarboxylic acid monoamide	Escherichia coli metabolite
palmitic acid Palmitic Acid: A common saturated fatty acid found in fats and waxes including olive oil, palm oil, and body lipids.. hexadecanoic acid : A straight-chain, sixteen-carbon, saturated long-chain fatty acid.	2.47	2	0	long-chain fatty acid; straight-chain saturated fatty acid	algal metabolite; Daphnia magna metabolite; EC 1.1.1.189 (prostaglandin-E2 9-reductase) inhibitor; plant metabolite
phosphorylcholine Phosphorylcholine: Calcium and magnesium salts used therapeutically in hepatobiliary dysfunction.. phosphocholine : The phosphate of choline; and the parent compound of the phosphocholine family.	3.17	5	0	phosphocholines	allergen; epitope; hapten; human metabolite; mouse metabolite
phthalic acid phthalic acid: RN given refers to parent cpd; structure in Merck Index, 9th ed, #7178. phthalic acid : A benzenedicarboxylic acid cosisting of two carboxy groups at ortho positions.	2.31	1	0	benzenedicarboxylic acid	human xenobiotic metabolite
propylene glycol Propylene Glycol: A clear, colorless, viscous organic solvent and diluent used in pharmaceutical preparations.. propane-1,2-diol : The simplest member of the class of propane-1,2-diols, consisting of propane in which a hydrogen at position 1 and a hydrogen at position 2 are substituted by hydroxy groups. A colourless, viscous, hygroscopic, low-melting (-59degreeC) and high-boiling (188degreeC) liquid with low toxicity, it is used as a solvent, emulsifying agent, and antifreeze.	2.15	1	0	glycol; propane-1,2-diols	allergen; human xenobiotic metabolite; mouse metabolite; protic solvent
putrescine [no description available]	2.13	1	0	alkane-alpha,omega-diamine	antioxidant; fundamental metabolite
pyrazinamide pyrazinecarboxamide : A monocarboxylic acid amide resulting from the formal condensation of the carboxy group of pyrazinoic acid (pyrazine-2-carboxylic acid) with ammonia. A prodrug for pyrazinoic acid, pyrazinecarboxamide is used as part of multidrug regimens for the treatment of tuberculosis.	2.08	1	0	monocarboxylic acid amide; N-acylammonia; pyrazines	antitubercular agent; prodrug
spermidine [no description available]	3.29	6	0	polyazaalkane; triamine	autophagy inducer; fundamental metabolite; geroprotector
taurine [no description available]	2.03	1	0	amino sulfonic acid; zwitterion	antioxidant; Escherichia coli metabolite; glycine receptor agonist; human metabolite; mouse metabolite; nutrient; radical scavenger; Saccharomyces cerevisiae metabolite
uracil 2,4-dihydroxypyrimidine: a urinary biomarker for bipolar disorder	1.99	1	0	pyrimidine nucleobase; pyrimidone	allergen; Daphnia magna metabolite; Escherichia coli metabolite; human metabolite; mouse metabolite; prodrug; Saccharomyces cerevisiae metabolite
vanillin Vanilla: A plant genus of the family ORCHIDACEAE that is the source of the familiar flavoring used in foods and medicines (FLAVORING AGENTS).	2.17	1	0	benzaldehydes; monomethoxybenzene; phenols	anti-inflammatory agent; anticonvulsant; antioxidant; flavouring agent; plant metabolite
1-(3-chlorophenyl)piperazine 1-(3-chlorophenyl)piperazine: supposed metabolite of TRAZODONE; RN given refers to parent cpd; structure. 1-(3-chlorophenyl)piperazine : A N-arylpiperazine that is piperazine carrying a 3-chlorophenyl substituent at position 1. It is a metabolite of the antidepressant drug trazodone.	2.08	1	0	monochlorobenzenes; N-arylpiperazine	drug metabolite; environmental contaminant; serotonergic agonist; xenobiotic
17-octadecynoic acid octadec-17-ynoic acid : An acetylenic fatty acid that is octadecanoi acid (stearic acid) which has been doubly dehydrogenated at positions 17 and 18 to give the corresponding alkynoic acid.	2.07	1	0	acetylenic fatty acid; long-chain fatty acid; monounsaturated fatty acid; terminal acetylenic compound	EC 1.14.14.94 (leukotriene-B4 20-monooxygenase) inhibitor; EC 1.14.15.3 (alkane 1-monooxygenase) inhibitor; P450 inhibitor
3-methylcholanthrene Methylcholanthrene: A carcinogen that is often used in experimental cancer studies.. 3-methylcholanthrene : A pentacyclic ortho- and peri-fused polycyclic arene consisting of a dihydrocyclopenta[ij]tetraphene ring system with a methyl substituent at the 3-position.	1.96	1	0	ortho- and peri-fused polycyclic arene	aryl hydrocarbon receptor agonist; carcinogenic agent
4-phenyl-3-furoxancarbonitrile 4-phenyl-3-furoxancarbonitrile: structure given in first source. 4-phenyl-3-furoxancarbonitrile : A 1,2,5-oxadiazole substituted by an oxido, cyano and phenyl groups at positions 2, 3 and 4, respectively. It is a vasodilator and inhibitor of platelet aggregation.	2.04	1	0	1,2,5-oxadiazole; benzenes; N-oxide; nitrile	geroprotector; nitric oxide donor; platelet aggregation inhibitor; soluble guanylate cyclase activator; vasodilator agent
phenytoin [no description available]	2.05	1	0	imidazolidine-2,4-dione	anticonvulsant; drug allergen; sodium channel blocker; teratogenic agent
tacrine Tacrine: A cholinesterase inhibitor that crosses the blood-brain barrier. Tacrine has been used to counter the effects of muscle relaxants, as a respiratory stimulant, and in the treatment of Alzheimer's disease and other central nervous system disorders.. tacrine : A member of the class of acridines that is 1,2,3,4-tetrahydroacridine substituted by an amino group at position 9. It is used in the treatment of Alzheimer's disease.	2.08	1	0	acridines; aromatic amine	EC 3.1.1.7 (acetylcholinesterase) inhibitor
ro 48-8071 Ro 48-8071: a cholesterol synthesis inhibitor; structure in first source. Ro 48-8071 : An aromatic ketone that is 2-fluoro-4'-bromobenzophenone in which the hydrogen at position 4 (meta to the fluoro group) is replaced by a 6-[methyl(prop-2-en-1-yl)amino]hexyl}oxy group. An inhibitor of lanosterol synthase.	2.17	1	0	aromatic ether; aromatic ketone; bromobenzenes; monofluorobenzenes; olefinic compound; tertiary amino compound	antineoplastic agent; EC 5.4.99.7 (lanosterol synthase) inhibitor
acebutolol Acebutolol: A cardioselective beta-1 adrenergic antagonist with little effect on the bronchial receptors. The drug has stabilizing and quinidine-like effects on cardiac rhythm, as well as weak inherent sympathomimetic action.. acebutolol : An ether that is the 2-acetyl-4-(butanoylamino)phenyl ether of the primary hydroxy group of 3-(propan-2-ylamino)propane-1,2-diol.	2.05	1	0	aromatic amide; ethanolamines; ether; monocarboxylic acid amide; propanolamine; secondary amino compound	anti-arrhythmia drug; antihypertensive agent; beta-adrenergic antagonist; sympathomimetic agent
acetaminophen Acetaminophen: Analgesic antipyretic derivative of acetanilide. It has weak anti-inflammatory properties and is used as a common analgesic, but may cause liver, blood cell, and kidney damage.. paracetamol : A member of the class of phenols that is 4-aminophenol in which one of the hydrogens attached to the amino group has been replaced by an acetyl group.	2.47	2	0	acetamides; phenols	antipyretic; cyclooxygenase 1 inhibitor; cyclooxygenase 2 inhibitor; cyclooxygenase 3 inhibitor; environmental contaminant; ferroptosis inducer; geroprotector; hepatotoxic agent; human blood serum metabolite; non-narcotic analgesic; non-steroidal anti-inflammatory drug; xenobiotic
acetazolamide Acetazolamide: One of the CARBONIC ANHYDRASE INHIBITORS that is sometimes effective against absence seizures. It is sometimes useful also as an adjunct in the treatment of tonic-clonic, myoclonic, and atonic seizures, particularly in women whose seizures occur or are exacerbated at specific times in the menstrual cycle. However, its usefulness is transient often because of rapid development of tolerance. Its antiepileptic effect may be due to its inhibitory effect on brain carbonic anhydrase, which leads to an increased transneuronal chloride gradient, increased chloride current, and increased inhibition. (From Smith and Reynard, Textbook of Pharmacology, 1991, p337)	2.77	3	0	monocarboxylic acid amide; sulfonamide; thiadiazoles	anticonvulsant; diuretic; EC 4.2.1.1 (carbonic anhydrase) inhibitor
acetohydroxamic acid acetohydroxamic acid: urease inhibitor. oxime : Compounds of structure R2C=NOH derived from condensation of aldehydes or ketones with hydroxylamine. Oximes from aldehydes may be called aldoximes; those from ketones may be called ketoximes.. N-hydroxyacetimidic acid : A carbohydroximic acid consisting of acetimidic acid having a hydroxy group attached to the imide nitrogen.. acetohydroxamic acid : A member of the class of acetohydroxamic acids that is acetamide in which one of the amino hydrogens has been replaced by a hydroxy group.	2.05	1	0	acetohydroxamic acids; carbohydroximic acid	algal metabolite; EC 3.5.1.5 (urease) inhibitor
albendazole [no description available]	2.46	2	0	aryl sulfide; benzimidazoles; benzimidazolylcarbamate fungicide; carbamate ester	anthelminthic drug; microtubule-destabilising agent; tubulin modulator
albuterol Albuterol: A short-acting beta-2 adrenergic agonist that is primarily used as a bronchodilator agent to treat ASTHMA. Albuterol is prepared as a racemic mixture of R(-) and S(+) stereoisomers. The stereospecific preparation of R(-) isomer of albuterol is referred to as levalbuterol.. albuterol : A member of the class of phenylethanolamines that is 4-(2-amino-1-hydroxyethyl)-2-(hydroxymethyl)phenol having a tert-butyl group attached to the nirogen atom. It acts as a beta-adrenergic agonist used in the treatment of asthma and chronic obstructive pulmonary disease (COPD).	2.47	2	0	phenols; phenylethanolamines; secondary amino compound	beta-adrenergic agonist; bronchodilator agent; environmental contaminant; xenobiotic
alendronate alendronic acid : A 1,1-bis(phosphonic acid) that is methanebis(phosphonic acid) in which the two methylene hydrogens are replaced by hydroxy and 3-aminopropyl groups.	2.43	2	0	1,1-bis(phosphonic acid); primary amino compound	bone density conservation agent; EC 2.5.1.1 (dimethylallyltranstransferase) inhibitor
alprazolam Alprazolam: A triazolobenzodiazepine compound with antianxiety and sedative-hypnotic actions, that is efficacious in the treatment of PANIC DISORDERS, with or without AGORAPHOBIA, and in generalized ANXIETY DISORDERS. (From AMA Drug Evaluations Annual, 1994, p238). alprazolam : A member of the class of triazolobenzodiazepines that is 4H-[1,2,4]triazolo[4,3-a][1,4]benzodiazepine carrying methyl, phenyl and chloro substituents at positions 1, 6 and 8 respectively. Alprazolam is only found in individuals that have taken this drug.	2.05	1	0	organochlorine compound; triazolobenzodiazepine	anticonvulsant; anxiolytic drug; GABA agonist; muscle relaxant; sedative; xenobiotic
alprenolol Alprenolol: One of the ADRENERGIC BETA-ANTAGONISTS used as an antihypertensive, anti-anginal, and anti-arrhythmic agent.. alprenolol : A secondary alcohol that is propan-2-ol substituted by a 2-allylphenoxy group at position 1 and an isopropylamino group at position 3. It is a beta-adrenergic antagonist used as a antihypertensive, anti-arrhythmia and a sympatholytic agent.	2.08	1	0	secondary alcohol; secondary amino compound	anti-arrhythmia drug; antihypertensive agent; beta-adrenergic antagonist; sympatholytic agent
diatrizoic acid Diatrizoate: A commonly used x-ray contrast medium. As DIATRIZOATE MEGLUMINE and as Diatrizoate sodium, it is used for gastrointestinal studies, angiography, and urography.. amidotrizoic acid : A member of the class of benzoic acids that is benzoic acid having iodo substituents at the 2-, 4- and 6-positions and acetamido substituents at the 3- and 5-positions. It is used, mainly as its N-methylglucamine and sodium salts, as an X-ray contrast medium in gastrointestinal studies, angiography, and urography.	2.08	1	0	acetamides; benzoic acids; organoiodine compound	environmental contaminant; radioopaque medium; xenobiotic
aminoglutethimide Aminoglutethimide: An aromatase inhibitor that is used in the treatment of advanced BREAST CANCER.. aminoglutethimide : A dicarboximide that is a six-membered cyclic compound having ethyl and 4-aminophenyl substituents at the 3-position.	2.47	2	0	dicarboximide; piperidones; substituted aniline	adrenergic agent; anticonvulsant; antineoplastic agent; EC 1.14.14.14 (aromatase) inhibitor
theophylline [no description available]	2.47	2	0	dimethylxanthine	adenosine receptor antagonist; anti-asthmatic drug; anti-inflammatory agent; bronchodilator agent; drug metabolite; EC 3.1.4.* (phosphoric diester hydrolase) inhibitor; fungal metabolite; human blood serum metabolite; immunomodulator; muscle relaxant; vasodilator agent
amiodarone Amiodarone: An antianginal and class III antiarrhythmic drug. It increases the duration of ventricular and atrial muscle action by inhibiting POTASSIUM CHANNELS and VOLTAGE-GATED SODIUM CHANNELS. There is a resulting decrease in heart rate and in vascular resistance.. amiodarone : A member of the class of 1-benzofurans that is 1-benzofuran substituted by a butyl group at position 2 and a 4-[2-(diethylamino)ethoxy]-3,5-diiodobenzoyl group at position 3. It is a cardiovascular drug used for the treatment of cardiac dysrhythmias.	3.21	5	0	1-benzofurans; aromatic ketone; organoiodine compound; tertiary amino compound	cardiovascular drug
dan 2163 [no description available]	2.08	1	0	aromatic amide; aromatic amine; benzamides; pyrrolidines; sulfone	environmental contaminant; second generation antipsychotic; xenobiotic
amitriptyline Amitriptyline: Tricyclic antidepressant with anticholinergic and sedative properties. It appears to prevent the re-uptake of norepinephrine and serotonin at nerve terminals, thus potentiating the action of these neurotransmitters. Amitriptyline also appears to antagonize cholinergic and alpha-1 adrenergic responses to bioactive amines.. amitriptyline : An organic tricyclic compound that is 10,11-dihydro-5H-dibenzo[a,d][7]annulene substituted by a 3-(dimethylamino)propylidene group at position 5.	2.47	2	0	carbotricyclic compound; tertiary amine	adrenergic uptake inhibitor; antidepressant; environmental contaminant; tropomyosin-related kinase B receptor agonist; xenobiotic
amlexanox amlexanox: SRA-A antagonist;structure given in first source. amlexanox : A pyridochromene-derived monocarboxylic acid having an amino substituent at the 2-position, an oxo substituent at the 5-position and an isopropyl substituent at the 7-position.	2.08	1	0	monocarboxylic acid; pyridochromene	anti-allergic agent; anti-ulcer drug; non-steroidal anti-inflammatory drug
amlodipine Amlodipine: A long-acting dihydropyridine calcium channel blocker. It is effective in the treatment of ANGINA PECTORIS and HYPERTENSION.. amlodipine : A fully substituted dialkyl 1,4-dihydropyridine-3,5-dicarboxylate derivative, which is used for the treatment of hypertension, chronic stable angina and confirmed or suspected vasospastic angina.	2.76	3	0	dihydropyridine; ethyl ester; methyl ester; monochlorobenzenes; primary amino compound	antihypertensive agent; calcium channel blocker; vasodilator agent
amoxapine Amoxapine: The N-demethylated derivative of the antipsychotic agent LOXAPINE that works by blocking the reuptake of norepinephrine, serotonin, or both; it also blocks dopamine receptors. Amoxapine is used for the treatment of depression.. amoxapine : A dibenzooxazepine compound having a chloro substituent at the 2-position and a piperazin-1-yl group at the 11-position.	2.08	1	0	dibenzooxazepine	adrenergic uptake inhibitor; antidepressant; dopaminergic antagonist; geroprotector; serotonin uptake inhibitor
amsacrine Amsacrine: An aminoacridine derivative that intercalates into DNA and is used as an antineoplastic agent.. amsacrine : A sulfonamide that is N-phenylmethanesulfonamide substituted by a methoxy group at position 3 and an acridin-9-ylamino group at position 4. It exhibits antineoplastic activity.	2.08	1	0	acridines; aromatic ether; sulfonamide	antineoplastic agent; EC 5.99.1.3 [DNA topoisomerase (ATP-hydrolysing)] inhibitor
anastrozole [no description available]	2.08	1	0	nitrile; triazoles	antineoplastic agent; EC 1.14.14.14 (aromatase) inhibitor
anthralin Anthralin: An anthracene derivative that disrupts MITOCHONDRIA function and structure and is used for the treatment of DERMATOSES, especially PSORIASIS. It may cause FOLLICULITIS.. anthralin : An anthracene compound derived by the substitution of -OH groups for hydrogen at C-1 and C-8, and with an oxo group at C-9.	2.08	1	0	anthracenes	antipsoriatic
antipyrine Antipyrine: An analgesic and antipyretic that has been given by mouth and as ear drops. Antipyrine is often used in testing the effects of other drugs or diseases on drug-metabolizing enzymes in the liver. (From Martindale, The Extra Pharmacopoeia, 30th ed, p29). antipyrine : A pyrazolone derivative that is 1,2-dihydropyrazol-3-one substituted with methyl groups at N-1 and C-5 and with a phenyl group at N-2.	2.08	1	0	pyrazolone	antipyretic; cyclooxygenase 3 inhibitor; environmental contaminant; non-narcotic analgesic; non-steroidal anti-inflammatory drug; xenobiotic
aprindine Aprindine: A class Ib anti-arrhythmia agent used to manage ventricular and supraventricular arrhythmias.	2.05	1	0	indanes
aspirin Aspirin: The prototypical analgesic used in the treatment of mild to moderate pain. It has anti-inflammatory and antipyretic properties and acts as an inhibitor of cyclooxygenase which results in the inhibition of the biosynthesis of prostaglandins. Aspirin also inhibits platelet aggregation and is used in the prevention of arterial and venous thrombosis. (From Martindale, The Extra Pharmacopoeia, 30th ed, p5). acetylsalicylate : A benzoate that is the conjugate base of acetylsalicylic acid, arising from deprotonation of the carboxy group.. acetylsalicylic acid : A member of the class of benzoic acids that is salicylic acid in which the hydrogen that is attached to the phenolic hydroxy group has been replaced by an acetoxy group. A non-steroidal anti-inflammatory drug with cyclooxygenase inhibitor activity.	3.2	5	0	benzoic acids; phenyl acetates; salicylates	anticoagulant; antipyretic; cyclooxygenase 1 inhibitor; cyclooxygenase 2 inhibitor; drug allergen; EC 1.1.1.188 (prostaglandin-F synthase) inhibitor; geroprotector; non-narcotic analgesic; non-steroidal anti-inflammatory drug; plant activator; platelet aggregation inhibitor; prostaglandin antagonist; teratogenic agent
astemizole Astemizole: Antihistamine drug now withdrawn from the market in many countries because of rare but potentially fatal side effects.. astemizole : A piperidine compound having a 2-(4-methoxyphenyl)ethyl group at the 1-position and an N-[(4-fluorobenzyl)benzimidazol-2-yl]amino group at the 4-position.	2.08	1	0	benzimidazoles; piperidines	anti-allergic agent; anticoronaviral agent; H1-receptor antagonist
atenolol Atenolol: A cardioselective beta-1 adrenergic blocker possessing properties and potency similar to PROPRANOLOL, but without a negative inotropic effect.. atenolol : An ethanolamine compound having a (4-carbamoylmethylphenoxy)methyl group at the 1-position and an N-isopropyl substituent.	3	4	0	ethanolamines; monocarboxylic acid amide; propanolamine	anti-arrhythmia drug; antihypertensive agent; beta-adrenergic antagonist; environmental contaminant; sympatholytic agent; xenobiotic
azathioprine Azathioprine: An immunosuppressive agent used in combination with cyclophosphamide and hydroxychloroquine in the treatment of rheumatoid arthritis. According to the Fourth Annual Report on Carcinogens (NTP 85-002, 1985), this substance has been listed as a known carcinogen. (Merck Index, 11th ed). azathioprine : A thiopurine that is 6-mercaptopurine in which the mercapto hydrogen is replaced by a 1-methyl-4-nitroimidazol-5-yl group. It is a prodrug for mercaptopurine and is used as an immunosuppressant, prescribed for the treatment of inflammatory conditions and after organ transplantation and also for treatment of Crohn's didease and MS.	2.95	4	0	aryl sulfide; C-nitro compound; imidazoles; thiopurine	antimetabolite; antineoplastic agent; carcinogenic agent; DNA synthesis inhibitor; hepatotoxic agent; immunosuppressive agent; prodrug
baclofen [no description available]	2.08	1	0	amino acid zwitterion; gamma-amino acid; monocarboxylic acid; monochlorobenzenes; primary amino compound	central nervous system depressant; GABA agonist; muscle relaxant
benzbromarone Benzbromarone: Uricosuric that acts by increasing uric acid clearance. It is used in the treatment of gout.. benzbromarone : 1-Benzofuran substituted at C-2 and C-3 by an ethyl group and a 3,5-dibromo-4-hydroxybenzoyl group respectively. An inhibitor of CYP2C9, it is used as an anti-gout medication.	2.08	1	0	1-benzofurans; aromatic ketone	uricosuric drug
benzo(a)pyrene Benzo(a)pyrene: A potent mutagen and carcinogen. It is a public health concern because of its possible effects on industrial workers, as an environmental pollutant, an as a component of tobacco smoke.. benzo[a]pyrene : An ortho- and peri-fused polycyclic arene consisting of five fused benzene rings.	2.25	1	0	ortho- and peri-fused polycyclic arene	carcinogenic agent; mouse metabolite
benzocaine Benzocaine: A surface anesthetic that acts by preventing transmission of impulses along NERVE FIBERS and at NERVE ENDINGS.. dextran sulfate sodium : An organic sodium salt of dextran sulfate. It induces colitis in mice.. benzocaine : A benzoate ester having 4-aminobenzoic acid as the acid component and ethanol as the alcohol component. A surface anaesthetic, it is used to suppress the gag reflex, and as a lubricant and topical anaesthetic on the larynx, mouth, nasal cavity, respiratory tract, oesophagus, rectum, urinary tract, and vagina.	2.08	1	0	benzoate ester; substituted aniline	allergen; antipruritic drug; sensitiser; topical anaesthetic
benzyl isothiocyanate benzyl isothiocyanate: inhibits carcinogen-induced neoplasia; structure in Negwer, 5th ed, #715; also promotes urinary bladder carcinoma	2.25	1	0	benzenes; isothiocyanate	antibacterial drug
bepridil Bepridil: A long-acting calcium-blocking agent with significant anti-anginal activity. The drug produces significant coronary vasodilation and modest peripheral effects. It has antihypertensive and selective anti-arrhythmia activities and acts as a calmodulin antagonist.. bepridil : A tertiary amine in which the substituents on nitrogen are benzyl, phenyl and 3-(2-methylpropoxy)-2-(pyrrolidin-1-yl)propyl.	2.05	1	0	pyrrolidines; tertiary amine	anti-arrhythmia drug; antihypertensive agent; calcium channel blocker; vasodilator agent
diminazene Diminazene: An effective trypanocidal agent.. diminazene : A triazene derivative that is triazene in which each of the terminal nitrogens is substituted by a 4-carbamimidoylphenyl group.	2.43	2	0	carboxamidine; triazene derivative	antiparasitic agent; trypanocidal drug
bicalutamide bicalutamide: approved for treatment of advanced prostate cancer. N-[4-cyano-3-(trifluoromethyl)phenyl]-3-[(4-fluorophenyl)sulfonyl]-2-hydroxy-2-methylpropanamide : A member of the class of (trifluoromethyl)benzenes that is 4-amino-2-(trifluoromethyl)benzonitrile in which one of the amino hydrogens is substituted by a 3-[(4-fluorophenyl)sulfonyl]-2-hydroxy-2-methylpropanoyl group.. bicalutamide : A racemate comprising of equal amounts of (R)-bicalutamide and (S)-bicalutamide. It is an oral non-steroidal antiandrogen used in the treatment of prostate cancer and hirsutism.	2.08	1	0	(trifluoromethyl)benzenes; monocarboxylic acid amide; monofluorobenzenes; nitrile; sulfone; tertiary alcohol
bay h 4502 bifonazole : A racemate comprising equimolar amounts of R- and S-bifonazole. It is a broad spectrum antifungal drug used for the treatment of fungal skin and nail infections.. 1-[biphenyl-4-yl(phenyl)methyl]imidazole : A member of the class of imidazoles carrying an alpha-(biphenyl-4-yl)benzyl substituent at position 1.	2.08	1	0	biphenyls; imidazoles
bisacodyl Bisacodyl: A diphenylmethane stimulant laxative used for the treatment of CONSTIPATION and for bowel evacuation. (From Martindale, The Extra Pharmacopoeia, 30th ed, p871)	2.08	1	0	diarylmethane
bisoprolol Bisoprolol: A cardioselective beta-1 adrenergic blocker. It is effective in the management of HYPERTENSION and ANGINA PECTORIS.	2.05	1	0	secondary alcohol; secondary amine	anti-arrhythmia drug; antihypertensive agent; beta-adrenergic antagonist; sympatholytic agent
bretylium bretylium: RN given refers to parent cpd. bretylium : A quaternary ammonium cation having 2-bromobenzyl, ethyl and two methyl groups attached to the nitrogen. It blocks noradrenaline release from the peripheral sympathetic nervous system, and is used in emergency medicine, cardiology, and other specialties for the acute management of ventricular tachycardia and ventricular fibrillation.	2.05	1	0	quaternary ammonium ion	adrenergic antagonist; anti-arrhythmia drug; antihypertensive agent
bromhexine Bromhexine: A mucolytic agent used in the treatment of respiratory disorders associated with viscid or excessive mucus. (From Martindale, The Extra Pharmacopoeia, 30th ed, p744). bromhexine : A substituted aniline that is 2,4-dibromoaniline which is substituted at position 6 by a [cyclohexyl(methyl)amino]methyl group. It is used (as the monohydrochloride salt) as a mucolytic for the treatment of respiratory disorders associated with productive cough (i.e. a cough characterised by the production of sputum).	2.05	1	0	organobromine compound; substituted aniline; tertiary amino compound	mucolytic
bromopride bromopride: RN given refers to parent cpd; structure	2.08	1	0	benzamides
bronopol [no description available]	2.08	1	0	nitro compound
bumetanide [no description available]	2.47	2	0	amino acid; benzoic acids; sulfonamide	diuretic; EC 3.6.3.49 (channel-conductance-controlling ATPase) inhibitor
busulfan [no description available]	2.08	1	0	methanesulfonate ester	alkylating agent; antineoplastic agent; carcinogenic agent; insect sterilant; teratogenic agent
caffeine [no description available]	2.08	1	0	purine alkaloid; trimethylxanthine	adenosine A2A receptor antagonist; adenosine receptor antagonist; adjuvant; central nervous system stimulant; diuretic; EC 2.7.11.1 (non-specific serine/threonine protein kinase) inhibitor; EC 3.1.4.* (phosphoric diester hydrolase) inhibitor; environmental contaminant; food additive; fungal metabolite; geroprotector; human blood serum metabolite; mouse metabolite; mutagen; plant metabolite; psychotropic drug; ryanodine receptor agonist; xenobiotic
verapamil Verapamil: A calcium channel blocker that is a class IV anti-arrhythmia agent.. verapamil : A racemate comprising equimolar amounts of dexverapamil and (S)-verapamil. An L-type calcium channel blocker of the phenylalkylamine class, it is used (particularly as the hydrochloride salt) in the treatment of hypertension, angina pectoris and cardiac arrhythmia, and as a preventive medication for migraine.. 2-(3,4-dimethoxyphenyl)-5-{[2-(3,4-dimethoxyphenyl)ethyl](methyl)amino}-2-(propan-2-yl)pentanenitrile : A tertiary amino compound that is 3,4-dimethoxyphenylethylamine in which the hydrogens attached to the nitrogen are replaced by a methyl group and a 4-cyano-4-(3,4-dimethoxyphenyl)-5-methylhexyl group.	3.71	9	0	aromatic ether; nitrile; polyether; tertiary amino compound
carbamazepine Carbamazepine: A dibenzazepine that acts as a sodium channel blocker. It is used as an anticonvulsant for the treatment of grand mal and psychomotor or focal SEIZURES. It may also be used in the management of BIPOLAR DISORDER, and has analgesic properties.. carbamazepine : A dibenzoazepine that is 5H-dibenzo[b,f]azepine carrying a carbamoyl substituent at the azepine nitrogen, used as an anticonvulsant.	2.47	2	0	dibenzoazepine; ureas	analgesic; anticonvulsant; antimanic drug; drug allergen; EC 3.5.1.98 (histone deacetylase) inhibitor; environmental contaminant; glutamate transporter activator; mitogen; non-narcotic analgesic; sodium channel blocker; xenobiotic
carmustine Carmustine: A cell-cycle phase nonspecific alkylating antineoplastic agent. It is used in the treatment of brain tumors and various other malignant neoplasms. (From Martindale, The Extra Pharmacopoeia, 30th ed, p462) This substance may reasonably be anticipated to be a carcinogen according to the Fourth Annual Report on Carcinogens (NTP 85-002, 1985). (From Merck Index, 11th ed). carmustine : A member of the class of N-nitrosoureas that is 1,3-bis(2-chloroethyl)urea in which one of the nitrogens is substituted by a nitroso group.	2.94	4	0	N-nitrosoureas; organochlorine compound	alkylating agent; antineoplastic agent
carprofen carprofen: RN given refers to cpd without isomeric designation. carprofen : Propanoic acid in which one of the methylene hydrogens is substituted by a 6-chloro-9H-carbazol-2-yl group. A non-steroidal anti-inflammatory drug, it is no longer used in human medicine but is still used for treatment of arthritis in elderly dogs.	2.08	1	0	carbazoles; organochlorine compound	EC 1.14.99.1 (prostaglandin-endoperoxide synthase) inhibitor; non-steroidal anti-inflammatory drug; photosensitizing agent
carteolol Carteolol: A beta-adrenergic antagonist used as an anti-arrhythmia agent, an anti-angina agent, an antihypertensive agent, and an antiglaucoma agent.	2.05	1	0	quinolone; secondary alcohol	anti-arrhythmia drug; antiglaucoma drug; antihypertensive agent; beta-adrenergic antagonist; sympatholytic agent
carvedilol [no description available]	2.52	2	0	carbazoles; secondary alcohol; secondary amino compound	alpha-adrenergic antagonist; antihypertensive agent; beta-adrenergic antagonist; cardiovascular drug; vasodilator agent
carbonyl cyanide m-chlorophenyl hydrazone Carbonyl Cyanide m-Chlorophenyl Hydrazone: A proton ionophore. It is commonly used as an uncoupling agent and inhibitor of photosynthesis because of its effects on mitochondrial and chloroplast membranes.. CCCP : A member of the class of monochlorobenzenes that is benzene substituted by 2-(1,3-dinitrilopropan-2-ylidene)hydrazinyl and chloro groups at positions 1 and 3, respectively. It is a mitochondrial depolarizing agent that induces reactive oxygen species mediated cell death.	2.21	1	0	hydrazone; monochlorobenzenes; nitrile	antibacterial agent; geroprotector; ionophore
celecoxib [no description available]	2.49	2	0	organofluorine compound; pyrazoles; sulfonamide; toluenes	cyclooxygenase 2 inhibitor; geroprotector; non-narcotic analgesic; non-steroidal anti-inflammatory drug
chlorambucil Chlorambucil: A nitrogen mustard alkylating agent used as antineoplastic for chronic lymphocytic leukemia, Hodgkin's disease, and others. Although it is less toxic than most other nitrogen mustards, it has been listed as a known carcinogen in the Fourth Annual Report on Carcinogens (NTP 85-002, 1985). (Merck Index, 11th ed). chlorambucil : A monocarboxylic acid that is butanoic acid substituted at position 4 by a 4-[bis(2-chloroethyl)amino]phenyl group. A chemotherapy drug that can be used in combination with the antibody obinutuzumab for the treatment of chronic lymphocytic leukemia.	2.08	1	0	aromatic amine; monocarboxylic acid; nitrogen mustard; organochlorine compound; tertiary amino compound	alkylating agent; antineoplastic agent; carcinogenic agent; drug allergen; immunosuppressive agent
chlordiazepoxide Chlordiazepoxide: An anxiolytic benzodiazepine derivative with anticonvulsant, sedative, and amnesic properties. It has also been used in the symptomatic treatment of alcohol withdrawal.. chlordiazepoxide : A benzodiazepine that is 3H-1,4-benzodiazepine 4-oxide substituted by a chloro group at position 7, a phenyl group at position 5 and a methylamino group at position 2.	2.47	2	0	benzodiazepine
chloroquine Chloroquine: The prototypical antimalarial agent with a mechanism that is not well understood. It has also been used to treat rheumatoid arthritis, systemic lupus erythematosus, and in the systemic therapy of amebic liver abscesses.. chloroquine : An aminoquinoline that is quinoline which is substituted at position 4 by a [5-(diethylamino)pentan-2-yl]amino group at at position 7 by chlorine. It is used for the treatment of malaria, hepatic amoebiasis, lupus erythematosus, light-sensitive skin eruptions, and rheumatoid arthritis.	5.81	83	0	aminoquinoline; organochlorine compound; secondary amino compound; tertiary amino compound	anticoronaviral agent; antimalarial; antirheumatic drug; autophagy inhibitor; dermatologic drug
chlorpheniramine Chlorpheniramine: A histamine H1 antagonist used in allergic reactions, hay fever, rhinitis, urticaria, and asthma. It has also been used in veterinary applications. One of the most widely used of the classical antihistaminics, it generally causes less drowsiness and sedation than PROMETHAZINE.. chlorphenamine : A tertiary amino compound that is propylamine which is substituted at position 3 by a pyridin-2-yl group and a p-chlorophenyl group and in which the hydrogens attached to the nitrogen are replaced by methyl groups. A histamine H1 antagonist, it is used to relieve the symptoms of hay fever, rhinitis, urticaria, and asthma.	2.08	1	0	monochlorobenzenes; pyridines; tertiary amino compound	anti-allergic agent; antidepressant; antipruritic drug; H1-receptor antagonist; histamine antagonist; serotonin uptake inhibitor
chlorpromazine Chlorpromazine: The prototypical phenothiazine antipsychotic drug. Like the other drugs in this class chlorpromazine's antipsychotic actions are thought to be due to long-term adaptation by the brain to blocking DOPAMINE RECEPTORS. Chlorpromazine has several other actions and therapeutic uses, including as an antiemetic and in the treatment of intractable hiccup.. chlorpromazine : A substituted phenothiazine in which the ring nitrogen at position 10 is attached to C-3 of an N,N-dimethylpropanamine moiety.	2.47	2	0	organochlorine compound; phenothiazines; tertiary amine	anticoronaviral agent; antiemetic; dopaminergic antagonist; EC 3.4.21.26 (prolyl oligopeptidase) inhibitor; phenothiazine antipsychotic drug
chlorpropamide Chlorpropamide: A sulfonylurea hypoglycemic agent used in the treatment of non-insulin-dependent diabetes mellitus not responding to dietary modification. (From Martindale, The Extra Pharmacopoeia, 30th ed, p277). chlorpropamide : An N-sulfonylurea that is urea in which a hydrogen attached to one of the nitrogens is substituted by 4-chlorobenzenesulfonyl group and a hydrogen attached to the other nitrogen is substituted by propyl group. Chlorpropamide is a hypoglycaemic agent used in the treatment of type 2 (non-insulin-dependent) diabetes mellitus not responding to dietary modification.	2.47	2	0	monochlorobenzenes; N-sulfonylurea	hypoglycemic agent; insulin secretagogue
chlorthalidone Chlorthalidone: A benzenesulfonamide-phthalimidine that tautomerizes to a BENZOPHENONES form. It is considered a thiazide-like diuretic.	2.47	2	0	isoindoles; monochlorobenzenes; sulfonamide
chlorzoxazone Chlorzoxazone: A centrally acting central muscle relaxant with sedative properties. It is claimed to inhibit muscle spasm by exerting an effect primarily at the level of the spinal cord and subcortical areas of the brain. (From Martindale, The Extra Pharmacopoea, 30th ed, p1202). chlorzoxazone : A member of the class of 1,3-benzoxazoles that is 1,3-benzoxazol-2-ol in which the hydrogen atom at position 5 is substituted by chlorine. A centrally acting muscle relaxant with sedative properties, it is used for the symptomatic treatment of painful muscle spasm.	2.08	1	0	1,3-benzoxazoles; heteroaryl hydroxy compound; organochlorine compound	muscle relaxant; sedative
cifenline [no description available]	2.08	1	0	diarylmethane
ciclopirox [no description available]	2.08	1	0	cyclic hydroxamic acid; hydroxypyridone antifungal drug; pyridone	antibacterial agent; antiseborrheic
ciglitazone ciglitazone: structure given in second source; PPAR agonist used for type II diabetes. ciglitazone : An aromatic ether that consists of 1,3-thiazolidine-2,4-dione with position 5 substituted by a 4-[(1-methylcyclohexyl)methoxy]benzyl group. A selective PPARgamma agonist.	2.08	1	0	aromatic ether; thiazolidinone	antineoplastic agent; insulin-sensitizing drug
cilostazol [no description available]	2.08	1	0	lactam; tetrazoles	anticoagulant; bronchodilator agent; EC 3.1.4.17 (3',5'-cyclic-nucleotide phosphodiesterase) inhibitor; fibrin modulating drug; neuroprotective agent; platelet aggregation inhibitor; vasodilator agent
cimetidine Cimetidine: A histamine congener, it competitively inhibits HISTAMINE binding to HISTAMINE H2 RECEPTORS. Cimetidine has a range of pharmacological actions. It inhibits GASTRIC ACID secretion, as well as PEPSIN and GASTRIN output.. cimetidine : A member of the class of guanidines that consists of guanidine carrying a methyl substituent at position 1, a cyano group at position 2 and a 2-{[(5-methyl-1H-imidazol-4-yl)methyl]sulfanyl}ethyl group at position 3. It is a H2-receptor antagonist that inhibits the production of acid in stomach.	2.77	3	0	aliphatic sulfide; guanidines; imidazoles; nitrile	adjuvant; analgesic; anti-ulcer drug; H2-receptor antagonist; P450 inhibitor
ciprofibrate [no description available]	2.08	1	0	cyclopropanes; monocarboxylic acid; organochlorine compound	antilipemic drug
ciprofloxacin Ciprofloxacin: A broad-spectrum antimicrobial carboxyfluoroquinoline.. ciprofloxacin : A quinolone that is quinolin-4(1H)-one bearing cyclopropyl, carboxylic acid, fluoro and piperazin-1-yl substituents at positions 1, 3, 6 and 7, respectively.	2.47	2	0	aminoquinoline; cyclopropanes; fluoroquinolone antibiotic; N-arylpiperazine; quinolinemonocarboxylic acid; quinolone antibiotic; quinolone; zwitterion	antibacterial drug; antiinfective agent; antimicrobial agent; DNA synthesis inhibitor; EC 5.99.1.3 [DNA topoisomerase (ATP-hydrolysing)] inhibitor; environmental contaminant; topoisomerase IV inhibitor; xenobiotic
citalopram Citalopram: A furancarbonitrile that is one of the serotonin uptake inhibitors used as an antidepressant. The drug is also effective in reducing ethanol uptake in alcoholics and is used in depressed patients who also suffer from TARDIVE DYSKINESIA in preference to tricyclic antidepressants, which aggravate dyskinesia.. citalopram : A racemate comprising equimolar amounts of (R)-citalopram and its enantiomer, escitalopram. It is used as an antidepressant, although only escitalopram is active.. 1-[3-(dimethylamino)propyl]-1-(4-fluorophenyl)-1,3-dihydro-2-benzofuran-5-carbonitrile : A nitrile that is 1,3-dihydro-2-benzofuran-5-carbonitrile in which one of the hydrogens at position 1 is replaced by a p-fluorophenyl group, while the other is replaced by a 3-(dimethylamino)propyl group.	2.47	2	0	2-benzofurans; cyclic ether; nitrile; organofluorine compound; tertiary amino compound
clenbuterol Clenbuterol: A substituted phenylaminoethanol that has beta-2 adrenomimetic properties at very low doses. It is used as a bronchodilator in asthma.. clenbuterol : A substituted aniline that is 2,6-dichloroaniline in which the hydrogen at position 4 has been replaced by a 2-(tert-butylamino)-1-hydroxyethyl group.	2.05	1	0	amino alcohol; dichlorobenzene; ethanolamines; primary arylamine; secondary amino compound; substituted aniline	beta-adrenergic agonist; bronchodilator agent; sympathomimetic agent
clioquinol Clioquinol: A potentially neurotoxic 8-hydroxyquinoline derivative long used as a topical anti-infective, intestinal antiamebic, and vaginal trichomonacide. The oral preparation has been shown to cause subacute myelo-optic neuropathy and has been banned worldwide.. 5-chloro-7-iodoquinolin-8-ol : A monohydroxyquinoline that is quinolin-8-ol in which the hydrogens at positions 5 and 7 are replaced by chlorine and iodine, respectively. It has antibacterial and atifungal properties, and is used in creams for the treatment of skin infections. It has also been investigated as a chelator of copper and zinc ions for the possible treatment of Alzheimer's disease.	2.47	2	0	monohydroxyquinoline; organochlorine compound; organoiodine compound	antibacterial agent; antifungal agent; antimicrobial agent; antineoplastic agent; antiprotozoal drug; chelator; copper chelator
clobazam Clobazam: A benzodiazepine derivative that is a long-acting GABA-A RECEPTOR agonist. It is used as an antiepileptic in the treatment of SEIZURES, including seizures associated with LENNOX-GASTAUT SYNDROME. It is also used as an anxiolytic, for the short-term treatment of acute ANXIETY.. clobazam : 7-Chloro-1H-1,5-benzodiazepine-2,4(3H,5H)-dione in which the hydrogen attached to the nitrogen at position 1 is substituted by a methyl group, whilst that attached to the other nitrogen is substituted by a phenyl group. It is used for the short-term management of acute anxiety and as an adjunct in the treatment of epilepsy in association with other antiepileptics.	2.08	1	0	1,4-benzodiazepinone; organochlorine compound	anticonvulsant; anxiolytic drug; GABA modulator
clofazimine Clofazimine: A fat-soluble riminophenazine dye used for the treatment of leprosy. It has been used investigationally in combination with other antimycobacterial drugs to treat Mycobacterium avium infections in AIDS patients. Clofazimine also has a marked anti-inflammatory effect and is given to control the leprosy reaction, erythema nodosum leprosum. (From AMA Drug Evaluations Annual, 1993, p1619). clofazimine : 3-Isopropylimino-3,5-dihydro-phenazine in which the hydrogen at position 5 is substituted substituted by a 4-chlorophenyl group, and that at position 2 is substituted by a (4-chlorophenyl)amino group. A dark red crystalline solid, clofazimine is an antimycobacterial and is one of the main drugs used for the treatment of multi-bacillary leprosy. However, it can cause red/brown discolouration of the skin, so other treatments are often preferred in light-skinned patients.	2.81	3	0	monochlorobenzenes; phenazines	dye; leprostatic drug; non-steroidal anti-inflammatory drug
clofibrate angiokapsul: contains clofibrate & insoitolnicotinate	2.47	2	0	aromatic ether; ethyl ester; monochlorobenzenes	anticholesteremic drug; antilipemic drug; geroprotector; PPARalpha agonist
clomiphene [no description available]	2.08	1	0	tertiary amine	estrogen antagonist; estrogen receptor modulator
clomipramine Clomipramine: A tricyclic antidepressant similar to IMIPRAMINE that selectively inhibits the uptake of serotonin in the brain. It is readily absorbed from the gastrointestinal tract and demethylated in the liver to form its primary active metabolite, desmethylclomipramine.. clomipramine : A dibenzoazepine that is 10,11-dihydro-5H-dibenzo[b,f]azepine which is substituted by chlorine at position 3 and in which the hydrogen attached to the nitrogen is replaced by a 3-(dimethylamino)propyl group. One of the more sedating tricyclic antidepressants, it is used as the hydrochloride salt for the treatment of depression as well as obsessive-compulsive disorder and phobias.	3.78	10	0	dibenzoazepine	anticoronaviral agent; antidepressant; EC 1.8.1.12 (trypanothione-disulfide reductase) inhibitor; serotonergic antagonist; serotonergic drug; serotonin uptake inhibitor
clonidine Clonidine: An imidazoline sympatholytic agent that stimulates ALPHA-2 ADRENERGIC RECEPTORS and central IMIDAZOLINE RECEPTORS. It is commonly used in the management of HYPERTENSION.. clonidine (amino form) : A clonidine that is 4,5-dihydro-1H-imidazol-2-amine in which one of the amino hydrogens is replaced by a 2,6-dichlorophenyl group.	2.48	2	0	clonidine; imidazoline
4-chloro-N-(2,6-dimethyl-1-piperidinyl)-3-sulfamoylbenzamide [no description available]	2.08	1	0	sulfonamide
chlorazepate clorazepic acid : A 1,4-benzodiazepinone in which the oxo group is at position 2, and which is substituted at positions 3, 5, and 7 by carboxy, phenyl and chloro groups, respectively.	2.05	1	0	1,4-benzodiazepinone	anticonvulsant; anxiolytic drug; GABA modulator; prodrug
damnacanthal damnacanthal: structure given in first source; isolated from the stem bark and roots of Morinda lucida; a selective inhibitor of p56(lck) tyrosine kinase activity	2.13	1	0	aldehyde; monohydroxyanthraquinone
dapsone [no description available]	2.47	2	0	substituted aniline; sulfone	anti-inflammatory drug; antiinfective agent; antimalarial; leprostatic drug
debrisoquin Debrisoquin: An adrenergic neuron-blocking drug similar in effects to GUANETHIDINE. It is also noteworthy in being a substrate for a polymorphic cytochrome P-450 enzyme. Persons with certain isoforms of this enzyme are unable to properly metabolize this and many other clinically important drugs. They are commonly referred to as having a debrisoquin 4-hydroxylase polymorphism.	2.05	1	0	carboxamidine; isoquinolines	adrenergic agent; antihypertensive agent; human metabolite; sympatholytic agent
deferiprone Deferiprone: A pyridone derivative and iron chelator that is used in the treatment of IRON OVERLOAD in patients with THALASSEMIA.. deferiprone : A member of the class of 4-pyridones that is pyridin-4(1H)-one substituted at positions 1 and 2 by methyl groups and at position 3 by a hydroxy group. A lipid-soluble iron-chelator used for treatment of thalassaemia.	2.08	1	0	4-pyridones	iron chelator; protective agent
deferoxamine Deferoxamine: Natural product isolated from Streptomyces pilosus. It forms iron complexes and is used as a chelating agent, particularly in the mesylate form.. desferrioxamine B : An acyclic desferrioxamine that is butanedioic acid in which one of the carboxy groups undergoes formal condensation with the primary amino group of N-(5-aminopentyl)-N-hydroxyacetamide and the second carboxy group undergoes formal condensation with the hydroxyamino group of N(1)-(5-aminopentyl)-N(1)-hydroxy-N(4)-[5-(hydroxyamino)pentyl]butanediamide. It is a siderophore native to Streptomyces pilosus biosynthesised by the DesABCD enzyme cluster as a high affinity Fe(III) chelator.	2.46	2	0	acyclic desferrioxamine	bacterial metabolite; ferroptosis inhibitor; iron chelator; siderophore
desipramine Desipramine: A tricyclic dibenzazepine compound that potentiates neurotransmission. Desipramine selectively blocks reuptake of norepinephrine from the neural synapse, and also appears to impair serotonin transport. This compound also possesses minor anticholinergic activity, through its affinity to muscarinic receptors.. desipramine : A dibenzoazepine consisting of 10,11-dihydro-5H-dibenzo[b,f]azepine substituted on nitrogen with a 3-(methylamino)propyl group.	2.77	3	0	dibenzoazepine; secondary amino compound	adrenergic uptake inhibitor; alpha-adrenergic antagonist; antidepressant; cholinergic antagonist; drug allergen; EC 3.1.4.12 (sphingomyelin phosphodiesterase) inhibitor; EC 3.4.21.26 (prolyl oligopeptidase) inhibitor; H1-receptor antagonist; serotonin uptake inhibitor
eflornithine Eflornithine: An inhibitor of ORNITHINE DECARBOXYLASE, the rate limiting enzyme of the polyamine biosynthetic pathway.. eflornithine : A fluoroamino acid that is ornithine substituted by a difluoromethyl group at position 2.	2.95	4	0	alpha-amino acid; fluoroamino acid	trypanocidal drug
diazepam Diazepam: A benzodiazepine with anticonvulsant, anxiolytic, sedative, muscle relaxant, and amnesic properties and a long duration of action. Its actions are mediated by enhancement of GAMMA-AMINOBUTYRIC ACID activity.. diazepam : A 1,4-benzodiazepinone that is 1,3-dihydro-2H-1,4-benzodiazepin-2-one substituted by a chloro group at position 7, a methyl group at position 1 and a phenyl group at position 5.	2.47	2	0	1,4-benzodiazepinone; organochlorine compound	anticonvulsant; anxiolytic drug; environmental contaminant; sedative; xenobiotic
diazoxide Diazoxide: A benzothiadiazine derivative that is a peripheral vasodilator used for hypertensive emergencies. It lacks diuretic effect, apparently because it lacks a sulfonamide group.. diazoxide : A benzothiadiazine that is the S,S-dioxide of 2H-1,2,4-benzothiadiazine which is substituted at position 3 by a methyl group and at position 7 by chlorine. A peripheral vasodilator, it increases the concentration of glucose in the plasma and inhibits the secretion of insulin by the beta- cells of the pancreas. It is used orally in the management of intractable hypoglycaemia and intravenously in the management of hypertensive emergencies.	2.47	2	0	benzothiadiazine; organochlorine compound; sulfone	antihypertensive agent; beta-adrenergic agonist; bronchodilator agent; cardiotonic drug; diuretic; K-ATP channel agonist; sodium channel blocker; sympathomimetic agent; vasodilator agent
diclofenac Diclofenac: A non-steroidal anti-inflammatory agent (NSAID) with antipyretic and analgesic actions. It is primarily available as the sodium salt.. diclofenac : A monocarboxylic acid consisting of phenylacetic acid having a (2,6-dichlorophenyl)amino group at the 2-position.	3.02	4	0	amino acid; aromatic amine; dichlorobenzene; monocarboxylic acid; secondary amino compound	antipyretic; drug allergen; EC 1.14.99.1 (prostaglandin-endoperoxide synthase) inhibitor; environmental contaminant; non-narcotic analgesic; non-steroidal anti-inflammatory drug; xenobiotic
dichlorphenamide Dichlorphenamide: A carbonic anhydrase inhibitor that is used in the treatment of glaucoma.. diclofenamide : A sulfonamide that is benzene-1,3-disulfonamide in which the hydrogens at positions 4 and 5 are substituted by chlorine. An oral carbonic anhydrase inhibitor, it partially suppresses the secretion (inflow) of aqueous humor in the eye and so reduces intraocular pressure. It is used for the treatment of glaucoma.	2.08	1	0	dichlorobenzene; sulfonamide	antiglaucoma drug; EC 4.2.1.1 (carbonic anhydrase) inhibitor; ophthalmology drug
3,4-dihydroxybenzohydroxamic acid [no description available]	2.05	1	0	benzoic acids
diflunisal Diflunisal: A salicylate derivative and anti-inflammatory analgesic with actions and side effects similar to those of ASPIRIN.. diflunisal : An organofluorine compound comprising salicylic acid having a 2,4-difluorophenyl group at the 5-position.	2.05	1	0	monohydroxybenzoic acid; organofluorine compound	non-narcotic analgesic; non-steroidal anti-inflammatory drug
dimercaprol Dimercaprol: An anti-gas warfare agent that is effective against Lewisite (dichloro(2-chlorovinyl)arsine) and formerly known as British Anti-Lewisite or BAL. It acts as a chelating agent and is used in the treatment of arsenic, gold, and other heavy metal poisoning.. dimercaprol : A dithiol that is propane-1,2-dithiol in which one of the methyl hydrogens is replaced by a hydroxy group. a chelating agent originally developed during World War II as an experimental antidote against the arsenic-based poison gas Lewisite, it has been used clinically since 1949 for the treatment of poisoning by arsenic, mercury and gold. It can also be used for treatment of poisoning by antimony, bismuth and possibly thallium, and (with sodium calcium edetate) in cases of acute leaad poisoning. Administration is by (painful) intramuscular injection of a suspension of dimercaprol in peanut oil, typically every 4 hours for 2-10 days depending on the toxicity. In the past, dimercaprol was also used for the treatment of Wilson's disease, a severely debilitating genetic disorder in which the body tends to retain copper, with resultant liver and brain injury.	2.05	1	0	dithiol; primary alcohol	chelator
dipyridamole Dipyridamole: A phosphodiesterase inhibitor that blocks uptake and metabolism of adenosine by erythrocytes and vascular endothelial cells. Dipyridamole also potentiates the antiaggregating action of prostacyclin. (From AMA Drug Evaluations Annual, 1994, p752). dipyridamole : A pyrimidopyrimidine that is 2,2',2'',2'''-(pyrimido[5,4-d]pyrimidine-2,6-diyldinitrilo)tetraethanol substituted by piperidin-1-yl groups at positions 4 and 8 respectively. A vasodilator agent, it inhibits the formation of blood clots.	2.08	1	0	piperidines; pyrimidopyrimidine; tertiary amino compound; tetrol	adenosine phosphodiesterase inhibitor; EC 3.5.4.4 (adenosine deaminase) inhibitor; platelet aggregation inhibitor; vasodilator agent
disopyramide Disopyramide: A class I anti-arrhythmic agent (one that interferes directly with the depolarization of the cardiac membrane and thus serves as a membrane-stabilizing agent) with a depressant action on the heart similar to that of guanidine. It also possesses some anticholinergic and local anesthetic properties.. disopyramide : A monocarboxylic acid amide that is butanamide substituted by a diisopropylamino group at position 4, a phenyl group at position 2 and a pyridin-2-yl group at position 2. It is used as a anti-arrhythmia drug.	2.08	1	0	monocarboxylic acid amide; pyridines; tertiary amino compound	anti-arrhythmia drug
disulfiram [no description available]	2.75	3	0	organic disulfide; organosulfur acaricide	angiogenesis inhibitor; antineoplastic agent; apoptosis inducer; EC 1.2.1.3 [aldehyde dehydrogenase (NAD(+))] inhibitor; EC 3.1.1.1 (carboxylesterase) inhibitor; EC 3.1.1.8 (cholinesterase) inhibitor; EC 5.99.1.2 (DNA topoisomerase) inhibitor; ferroptosis inducer; fungicide; NF-kappaB inhibitor
domperidone Domperidone: A specific blocker of dopamine receptors. It speeds gastrointestinal peristalsis, causes prolactin release, and is used as antiemetic and tool in the study of dopaminergic mechanisms.. domperidone : 1-[3-(Piperidin-1-yl)propyl]-1,3-dihydro-2H-benzimidazol-2-one in which the 4-position of the piperidine ring is substituted by a 5-chloro-1,3-dihydro-2H-benzimidazol-2-on-1-yl group. A dopamine antagonist, it is used as an antiemetic for the short-term treatment of nausea and vomiting, and to control gastrointestinal effects of dopaminergic drugs given in the management of parkinsonism. The free base is used in oral suspensions, while the maleate salt is used in tablet preparations.	2.47	2	0	benzimidazoles; heteroarylpiperidine	antiemetic; dopaminergic antagonist
donepezil Donepezil: An indan and piperidine derivative that acts as a selective and reversible inhibitor of ACETYLCHOLINESTERASE. Donepezil is highly selective for the central nervous system and is used in the management of mild to moderate DEMENTIA in ALZHEIMER DISEASE.. donepezil : A racemate comprising equimolar amounts of (R)- and (S)-donepezil. A centrally acting reversible acetylcholinesterase inhibitor, its main therapeutic use is in the treatment of Alzheimer's disease where it is used to increase cortical acetylcholine.. 2-[(1-benzylpiperidin-4-yl)methyl]-5,6-dimethoxyindan-1-one : A member of the class of indanones that is 5,6-dimethoxyindan-1-one which is substituted at position 2 by an (N-benzylpiperidin-4-yl)methyl group.	2.08	1	0	aromatic ether; indanones; piperidines; racemate	EC 3.1.1.7 (acetylcholinesterase) inhibitor; EC 3.1.1.8 (cholinesterase) inhibitor; nootropic agent
doxepin Doxepin: A dibenzoxepin tricyclic compound. It displays a range of pharmacological actions including maintaining adrenergic innervation. Its mechanism of action is not fully understood, but it appears to block reuptake of monoaminergic neurotransmitters into presynaptic terminals. It also possesses anticholinergic activity and modulates antagonism of histamine H(1)- and H(2)-receptors.. doxepin : A dibenzooxepine that is 6,11-dihydrodibenzo[b,e]oxepine substituted by a 3-(dimethylamino)propylidene group at position 11. It is used as an antidepressant drug.	2.08	1	0	dibenzooxepine; tertiary amino compound	antidepressant
ebastine [no description available]	2.08	1	0	organic molecular entity
enoxacin Enoxacin: A broad-spectrum 6-fluoronaphthyridinone antibacterial agent that is structurally related to NALIDIXIC ACID.. enoxacin : A 1,8-naphthyridine derivative that is 1,4-dihydro-1,8-naphthyridine with an ethyl group at the 1 position, a carboxy group at the 3-position, an oxo sustituent at the 4-position, a fluoro substituent at the 5-position and a piperazin-1-yl group at the 7 position. An antibacterial, it is used in the treatment of urinary-tract infections and gonorrhoea.	2.08	1	0	1,8-naphthyridine derivative; amino acid; fluoroquinolone antibiotic; monocarboxylic acid; N-arylpiperazine; quinolone antibiotic	antibacterial drug; DNA synthesis inhibitor
etanidazole Etanidazole: A nitroimidazole that sensitizes hypoxic tumor cells that are normally resistant to radiation therapy.. etanidazole : A monocarboxylic acid amide obtained by formal condensation of the carboxy group of (2-nitro-1H-imidazol-1-yl)acetic acid with the amino group of ethanolamine. Used as a radiosensitising agent for hypoxic tumour cells.	4.85	2	1	C-nitro compound; imidazoles; monocarboxylic acid amide	alkylating agent; antineoplastic agent; prodrug; radiosensitizing agent
ethacrynic acid Ethacrynic Acid: A compound that inhibits symport of sodium, potassium, and chloride primarily in the ascending limb of Henle, but also in the proximal and distal tubules. This pharmacological action results in excretion of these ions, increased urinary output, and reduction in extracellular fluid. This compound has been classified as a loop or high ceiling diuretic.. etacrynic acid : An aromatic ether that is phenoxyacetic acid in which the phenyl ring is substituted by chlorines at positions 2 and 3, and by a 2-methylidenebutanoyl group at position 4. It is a loop diuretic used to treat high blood pressure resulting from diseases such as congestive heart failure, liver failure, and kidney failure. It is also a glutathione S-transferase (EC 2.5.1.18) inhibitor.	2.47	2	0	aromatic ether; aromatic ketone; dichlorobenzene; monocarboxylic acid	EC 2.5.1.18 (glutathione transferase) inhibitor; ion transport inhibitor; loop diuretic
ethosuximide Ethosuximide: An anticonvulsant especially useful in the treatment of absence seizures unaccompanied by other types of seizures.. ethosuximide : A dicarboximide that is pyrrolidine-2,5-dione in which the hydrogens at position 3 are substituted by one methyl and one ethyl group. An antiepileptic, it is used in the treatment of absence seizures and may be used for myoclonic seizures, but is ineffective against tonic-clonic seizures.	2.47	2	0	dicarboximide; pyrrolidinone	anticonvulsant; geroprotector; T-type calcium channel blocker
ethoxzolamide Ethoxzolamide: A carbonic anhydrase inhibitor used as diuretic and in glaucoma. It may cause hypokalemia.. ethoxzolamide : A sulfonamide that is 1,3-benzothiazole-2-sulfonamide which is substituted by an ethoxy group at position 6. A carbonic anhydrase inhibitor, it has been used in the treatment of glaucoma, and as a diuretic.	2.08	1	0	aromatic ether; benzothiazoles; sulfonamide	antiglaucoma drug; diuretic; EC 4.2.1.1 (carbonic anhydrase) inhibitor
ethyl loflazepate ethyl loflazepate: structure given in first source	2.05	1	0	organic molecular entity
brl 42810 [no description available]	2.08	1	0	2-aminopurines; acetate ester	antiviral drug; prodrug
carbonyl cyanide p-trifluoromethoxyphenylhydrazone Carbonyl Cyanide p-Trifluoromethoxyphenylhydrazone: A proton ionophore that is commonly used as an uncoupling agent in biochemical studies.. carbonyl cyanide p-trifluoromethoxyphenylhydrazone : A hydrazone that is hydrazonomalononitrile in which one of the hydrazine hydrogens is substituted by a p-trifluoromethoxyphenyl group.	2.15	1	0	aromatic ether; hydrazone; nitrile; organofluorine compound	ATP synthase inhibitor; geroprotector; ionophore
4-biphenylylacetic acid biphenyl-4-ylacetic acid : A monocarboxylic acid in which one of the alpha-hydrogens is substituted by a biphenyl-4-yl group. An active metabolite of fenbufen, it is used as a topical medicine to treat muscle inflammation and arthritis.	2.08	1	0	biphenyls; monocarboxylic acid	non-steroidal anti-inflammatory drug
felodipine Felodipine: A dihydropyridine calcium antagonist with positive inotropic effects. It lowers blood pressure by reducing peripheral vascular resistance through a highly selective action on smooth muscle in arteriolar resistance vessels.. felodipine : The mixed (methyl, ethyl) diester of 4-(2,3-dichlorophenyl)-2,6-dimethyl-1,4-dihydropyridine-3,5-dicarboxylic acid. A calcium-channel blocker, it lowers blood pressure by reducing peripheral vascular resistance through a highly selective action on smooth muscle in arteriolar resistance vessels. It is used in the management of hypertension and angina pectoris.	2.47	2	0	dichlorobenzene; dihydropyridine; ethyl ester; methyl ester	anti-arrhythmia drug; antihypertensive agent; calcium channel blocker; vasodilator agent
fenofibrate Pharmavit: a polyvitamin product, comprising vitamins A, D2, B1, B2, B6, C, E, nicotinamide, & calcium pantothene; may be a promising agent for application to human populations exposed to carcinogenic and genetic hazards of ionizing radiation; RN from CHEMLINE	2.52	2	0	aromatic ether; chlorobenzophenone; isopropyl ester; monochlorobenzenes	antilipemic drug; environmental contaminant; geroprotector; xenobiotic
berotek Fenoterol: A synthetic adrenergic beta-2 agonist that is used as a bronchodilator and tocolytic.. fenoterol : A member of the class resorcinols that is 5-(1-hydroxyethyl)benzene-1,3-diol in which one of the methyl hydrogens is replaced by a 1-(4-hydroxyphenyl)propan-2-amino group. A beta2-adrenergic agonist, it is used (as the hydrobromide salt) as a bronchodilator in the management of reversible airway obstruction.	2.05	1	0	resorcinols; secondary alcohol; secondary amino compound	beta-adrenergic agonist; bronchodilator agent; sympathomimetic agent; tocolytic agent
fentanyl Fentanyl: A potent narcotic analgesic, abuse of which leads to habituation or addiction. It is primarily a mu-opioid agonist. Fentanyl is also used as an adjunct to general anesthetics, and as an anesthetic for induction and maintenance. (From Martindale, The Extra Pharmacopoeia, 30th ed, p1078). fentanyl : A monocarboxylic acid amide resulting from the formal condensation of the aryl amino group of N-phenyl-1-(2-phenylethyl)piperidin-4-amine with propanoic acid.	2.05	1	0	anilide; monocarboxylic acid amide; piperidines	adjuvant; anaesthesia adjuvant; anaesthetic; intravenous anaesthetic; mu-opioid receptor agonist; opioid analgesic
flecainide Flecainide: A potent anti-arrhythmia agent, effective in a wide range of ventricular and atrial ARRHYTHMIAS and TACHYCARDIAS.. flecainide : A monocarboxylic acid amide obtained by formal condensation of the carboxy group of 2,5-bis(2,2,2-trifluoroethoxy)benzoic acid with the primary amino group of piperidin-2-ylmethylamine. An antiarrhythmic agent used (in the form of its acetate salt) to prevent and treat tachyarrhythmia (abnormal fast rhythm of the heart).	2.05	1	0	aromatic ether; monocarboxylic acid amide; organofluorine compound; piperidines	anti-arrhythmia drug
fleroxacin Fleroxacin: A broad-spectrum antimicrobial fluoroquinolone. The drug strongly inhibits the DNA-supercoiling activity of DNA GYRASE.. fleroxacin : A fluoroquinolone antibiotic that is 4-oxo-1,4-dihydroquinoline which is substituted at positions 1, 3, 6, 7 and 8 by 2-fluoroethyl, carboxy, fluoro, 4-methylpiperazin-1-yl and fluoro groups, respectively. It is active against many Gram-positive and Gram-negative bacteria.	2.08	1	0	difluorobenzene; fluoroquinolone antibiotic; monocarboxylic acid; N-alkylpiperazine; quinolines	antibacterial drug; EC 5.99.1.3 [DNA topoisomerase (ATP-hydrolysing)] inhibitor; topoisomerase IV inhibitor
fluconazole Fluconazole: Triazole antifungal agent that is used to treat oropharyngeal CANDIDIASIS and cryptococcal MENINGITIS in AIDS.. fluconazole : A member of the class of triazoles that is propan-2-ol substituted at position 1 and 3 by 1H-1,2,4-triazol-1-yl groups and at position 2 by a 2,4-difluorophenyl group. It is an antifungal drug used for the treatment of mucosal candidiasis and for systemic infections including systemic candidiasis, coccidioidomycosis, and cryptococcosis.	3.58	8	0	conazole antifungal drug; difluorobenzene; tertiary alcohol; triazole antifungal drug	environmental contaminant; P450 inhibitor; xenobiotic
flucytosine Flucytosine: A fluorinated cytosine analog that is used as an antifungal agent.. flucytosine : An organofluorine compound that is cytosine that is substituted at position 5 by a fluorine. A prodrug for the antifungal 5-fluorouracil, it is used for the treatment of systemic fungal infections.	2.53	2	0	aminopyrimidine; nucleoside analogue; organofluorine compound; pyrimidine antifungal drug; pyrimidone	prodrug
fluphenazine [no description available]	2.05	1	0	N-alkylpiperazine; organofluorine compound; phenothiazines	anticoronaviral agent; dopaminergic antagonist; phenothiazine antipsychotic drug
flumazenil Flumazenil: A potent benzodiazepine receptor antagonist. Since it reverses the sedative and other actions of benzodiazepines, it has been suggested as an antidote to benzodiazepine overdoses.. flumazenil : An organic heterotricyclic compound that is 5,6-dihydro-4H-imidazo[1,5-a][1,4]benzodiazepine which is substituted at positions 3, 5, 6, and 8 by ethoxycarbonyl, methyl, oxo, and fluoro groups, respectively. It is used as an antidote to benzodiazepine overdose.	2.08	1	0	ethyl ester; imidazobenzodiazepine; organofluorine compound	antidote to benzodiazepine poisoning; GABA antagonist
fluorescite fluorescein (acid form) : A xanthene dye that is highly fluorescent and commonly used as a fluorescent tracer.	2.08	1	0	benzoic acids; cyclic ketone; hydroxy monocarboxylic acid; organic heterotricyclic compound; phenols; xanthene dye	fluorescent dye; radioopaque medium
fluorouracil Fluorouracil: A pyrimidine analog that is an antineoplastic antimetabolite. It interferes with DNA synthesis by blocking the THYMIDYLATE SYNTHETASE conversion of deoxyuridylic acid to thymidylic acid.. 5-fluorouracil : A nucleobase analogue that is uracil in which the hydrogen at position 5 is replaced by fluorine. It is an antineoplastic agent which acts as an antimetabolite - following conversion to the active deoxynucleotide, it inhibits DNA synthesis (by blocking the conversion of deoxyuridylic acid to thymidylic acid by the cellular enzyme thymidylate synthetase) and so slows tumour growth.	2.47	2	0	nucleobase analogue; organofluorine compound	antimetabolite; antineoplastic agent; environmental contaminant; immunosuppressive agent; radiosensitizing agent; xenobiotic
fluoxetine Fluoxetine: The first highly specific serotonin uptake inhibitor. It is used as an antidepressant and often has a more acceptable side-effects profile than traditional antidepressants.. fluoxetine : A racemate comprising equimolar amounts of (R)- and (S)-fluoxetine. A selective serotonin reuptake inhibitor (SSRI), it is used (generally as the hydrochloride salt) for the treatment of depression (and the depressive phase of bipolar disorder), bullimia nervosa, and obsessive-compulsive disorder.. N-methyl-3-phenyl-3-[4-(trifluoromethyl)phenoxy]propan-1-amine : An aromatic ether consisting of 4-trifluoromethylphenol in which the hydrogen of the phenolic hydroxy group is replaced by a 3-(methylamino)-1-phenylpropyl group.	2.76	3	0	(trifluoromethyl)benzenes; aromatic ether; secondary amino compound
flurbiprofen Flurbiprofen: An anti-inflammatory analgesic and antipyretic of the phenylalkynoic acid series. It has been shown to reduce bone resorption in periodontal disease by inhibiting CARBONIC ANHYDRASE.. flurbiprofen : A monocarboxylic acid that is a 2-fluoro-[1,1'-biphenyl-4-yl] moiety linked to C-2 of propionic acid. A non-steroidal anti-inflammatory, analgesic and antipyretic, it is used as a pre-operative anti-miotic as well as orally for arthritis or dental pain.	2.05	1	0	fluorobiphenyl; monocarboxylic acid	antipyretic; EC 1.14.99.1 (prostaglandin-endoperoxide synthase) inhibitor; non-narcotic analgesic; non-steroidal anti-inflammatory drug
flutamide Flutamide: An antiandrogen with about the same potency as cyproterone in rodent and canine species.	2.47	2	0	(trifluoromethyl)benzenes; monocarboxylic acid amide	androgen antagonist; antineoplastic agent
furafylline [no description available]	2.21	1	0	oxopurine
furosemide Furosemide: A benzoic-sulfonamide-furan. It is a diuretic with fast onset and short duration that is used for EDEMA and chronic RENAL INSUFFICIENCY.. furosemide : A chlorobenzoic acid that is 4-chlorobenzoic acid substituted by a (furan-2-ylmethyl)amino and a sulfamoyl group at position 2 and 5 respectively. It is a diuretic used in the treatment of congestive heart failure.	2.75	3	0	chlorobenzoic acid; furans; sulfonamide	environmental contaminant; loop diuretic; xenobiotic
gemfibrozil [no description available]	2.08	1	0	aromatic ether	antilipemic drug
2,5-dihydroxybenzoic acid 2,5-dihydroxybenzoic acid: RN given refers to parent cpd; a oxidative product of saligenin. 2,5-dihydroxybenzoic acid : A dihydroxybenzoic acid having the two hydroxy groups at the 2- and 5-positions.	2.11	1	0	dihydroxybenzoic acid	EC 1.13.11.33 (arachidonate 15-lipoxygenase) inhibitor; fungal metabolite; human metabolite; MALDI matrix material; mouse metabolite
gliclazide Gliclazide: An oral sulfonylurea hypoglycemic agent which stimulates insulin secretion.	2.08	1	0	N-sulfonylurea	hypoglycemic agent; insulin secretagogue; radical scavenger
glimepiride glimepiride: structure given in first source	2.08	1	0	sulfonamide
glipizide Glipizide: An oral hypoglycemic agent which is rapidly absorbed and completely metabolized.. glipizide : An N-sulfonylurea that is glyburide in which the (5-chloro-2-methoxybenzoyl group is replaced by a (5-methylpyrazin-2-yl)carbonyl group. An oral hypoglycemic agent, it is used in the treatment of type 2 diabetes mellitus.	2.08	1	0	aromatic amide; monocarboxylic acid amide; N-sulfonylurea; pyrazines	EC 2.7.1.33 (pantothenate kinase) inhibitor; hypoglycemic agent; insulin secretagogue
glutethimide Glutethimide: A hypnotic and sedative. Its use has been largely superseded by other drugs.	2.05	1	0	piperidines
glyburide Glyburide: An antidiabetic sulfonylurea derivative with actions like those of chlorpropamide. glyburide : An N-sulfonylurea that is acetohexamide in which the acetyl group is replaced by a 2-(5-chloro-2-methoxybenzamido)ethyl group.	2.08	1	0	monochlorobenzenes; N-sulfonylurea	anti-arrhythmia drug; EC 2.7.1.33 (pantothenate kinase) inhibitor; EC 3.6.3.49 (channel-conductance-controlling ATPase) inhibitor; hypoglycemic agent
guanethidine Guanethidine: An antihypertensive agent that acts by inhibiting selectively transmission in post-ganglionic adrenergic nerves. It is believed to act mainly by preventing the release of norepinephrine at nerve endings and causes depletion of norepinephrine in peripheral sympathetic nerve terminals as well as in tissues.. guanethidine : A member of the class of guanidines in which one of the hydrogens of the amino group has been replaced by a 2-azocan-1-ylethyl group.. guanethidine sulfate : A organic sulfate salt composed of two molecules of guanethidine and one of sulfuric acid.	2.05	1	0	azocanes; guanidines	adrenergic antagonist; antihypertensive agent; sympatholytic agent
guanfacine Guanfacine: A centrally acting antihypertensive agent with specificity towards ADRENERGIC ALPHA-2 RECEPTORS.	2.08	1	0	acetamides
haloperidol Haloperidol: A phenyl-piperidinyl-butyrophenone that is used primarily to treat SCHIZOPHRENIA and other PSYCHOSES. It is also used in schizoaffective disorder, DELUSIONAL DISORDERS, ballism, and TOURETTE SYNDROME (a drug of choice) and occasionally as adjunctive therapy in INTELLECTUAL DISABILITY and the chorea of HUNTINGTON DISEASE. It is a potent antiemetic and is used in the treatment of intractable HICCUPS. (From AMA Drug Evaluations Annual, 1994, p279). haloperidol : A compound composed of a central piperidine structure with hydroxy and p-chlorophenyl substituents at position 4 and an N-linked p-fluorobutyrophenone moiety.	2.08	1	0	aromatic ketone; hydroxypiperidine; monochlorobenzenes; organofluorine compound; tertiary alcohol	antidyskinesia agent; antiemetic; dopaminergic antagonist; first generation antipsychotic; serotonergic antagonist
miltefosine miltefosine: hexadecyl phosphocholine derivative of cisplatin; did not substantially activate HIV long terminal repeat; less toxic than cisplatin. miltefosine : A phospholipid that is the hexadecyl monoester of phosphocholine.	7.7	108	0	phosphocholines; phospholipid	anti-inflammatory agent; anticoronaviral agent; antifungal agent; antineoplastic agent; antiprotozoal drug; apoptosis inducer; immunomodulator; protein kinase inhibitor
ethidium Ethidium: A trypanocidal agent and possible antiviral agent that is widely used in experimental cell biology and biochemistry. Ethidium has several experimentally useful properties including binding to nucleic acids, noncompetitive inhibition of nicotinic acetylcholine receptors, and fluorescence among others. It is most commonly used as the bromide.. ethidium : The fluorescent compound widely used in experimental cell biology and biochemistry to reveal double-stranded DNA and RNA.	1.98	1	0	phenanthridines	fluorochrome; intercalator
hydrochlorothiazide Hydrochlorothiazide: A thiazide diuretic often considered the prototypical member of this class. It reduces the reabsorption of electrolytes from the renal tubules. This results in increased excretion of water and electrolytes, including sodium, potassium, chloride, and magnesium. It is used in the treatment of several disorders including edema, hypertension, diabetes insipidus, and hypoparathyroidism.. hydrochlorothiazide : A benzothiadiazine that is 3,4-dihydro-2H-1,2,4-benzothiadiazine 1,1-dioxide substituted by a chloro group at position 6 and a sulfonamide at 7. It is diuretic used for the treatment of hypertension and congestive heart failure.	2.77	3	0	benzothiadiazine; organochlorine compound; sulfonamide	antihypertensive agent; diuretic; environmental contaminant; xenobiotic
hydroflumethiazide Hydroflumethiazide: A thiazide diuretic with actions and uses similar to those of HYDROCHLOROTHIAZIDE. (From Martindale, The Extra Pharmacopoeia, 30th ed, p822). hydroflumethiazide : A benzothiadiazine consisting of a 3,4-dihydro-HH-1,2,4-benzothiadiazine bicyclic system dioxygenated on sulfur and carrying trifluoromethyl and aminosulfonyl groups at positions 6 and 7 respectively. A diuretic with actions and uses similar to those of hydrochlorothiazide.	2.08	1	0	benzothiadiazine; thiazide	antihypertensive agent; diuretic
hydroxyurea [no description available]	2.47	2	0	one-carbon compound; ureas	antimetabolite; antimitotic; antineoplastic agent; DNA synthesis inhibitor; EC 1.17.4.1 (ribonucleoside-diphosphate reductase) inhibitor; genotoxin; immunomodulator; radical scavenger; teratogenic agent
hydroxyzine Hydroxyzine: A histamine H1 receptor antagonist that is effective in the treatment of chronic urticaria, dermatitis, and histamine-mediated pruritus. Unlike its major metabolite CETIRIZINE, it does cause drowsiness. It is also effective as an antiemetic, for relief of anxiety and tension, and as a sedative.. hydroxyzine : A N-alkylpiperazine that is piperzine in which the nitrogens atoms are substituted by 2-(2-hydroxyethoxy)ethyl and (4-chlorophenyl)(phenyl)methyl groups respectively.	2.05	1	0	hydroxyether; monochlorobenzenes; N-alkylpiperazine	anticoronaviral agent; antipruritic drug; anxiolytic drug; dermatologic drug; H1-receptor antagonist
ibuprofen Midol: combination of cinnamedrine, phenacetin, aspirin & caffeine	2.48	2	0	monocarboxylic acid	antipyretic; cyclooxygenase 1 inhibitor; cyclooxygenase 2 inhibitor; drug allergen; environmental contaminant; geroprotector; non-narcotic analgesic; non-steroidal anti-inflammatory drug; radical scavenger; xenobiotic
phenelzine Phenelzine: One of the MONOAMINE OXIDASE INHIBITORS used to treat DEPRESSION; PHOBIC DISORDERS; and PANIC.	2.05	1	0	primary amine
lidocaine Lidocaine: A local anesthetic and cardiac depressant used as an antiarrhythmia agent. Its actions are more intense and its effects more prolonged than those of PROCAINE but its duration of action is shorter than that of BUPIVACAINE or PRILOCAINE.. lidocaine : The monocarboxylic acid amide resulting from the formal condensation of N,N-diethylglycine with 2,6-dimethylaniline.	2.47	2	0	benzenes; monocarboxylic acid amide; tertiary amino compound	anti-arrhythmia drug; drug allergen; environmental contaminant; local anaesthetic; xenobiotic
ifosfamide [no description available]	2.08	1	0	ifosfamides	alkylating agent; antineoplastic agent; environmental contaminant; immunosuppressive agent; xenobiotic
imipramine Imipramine: The prototypical tricyclic antidepressant. It has been used in major depression, dysthymia, bipolar depression, attention-deficit disorders, agoraphobia, and panic disorders. It has less sedative effect than some other members of this therapeutic group.. imipramine : A dibenzoazepine that is 5H-dibenzo[b,f]azepine substituted by a 3-(dimethylamino)propyl group at the nitrogen atom.	2.77	3	0	dibenzoazepine	adrenergic uptake inhibitor; antidepressant; EC 3.4.21.26 (prolyl oligopeptidase) inhibitor
amrinone Amrinone: A positive inotropic cardiotonic (CARDIOTONIC AGENTS) with vasodilator properties, phosphodiesterase 3 inhibitory activity, and the ability to stimulate calcium ion influx into the cardiac cell.. amrinone : A 3,4'-bipyridine substituted at positions 5 and 6 by an amino group and a keto function respectively. A pyridine phosphodiesterase 3 inhibitor, it is a drug that may improve the prognosis in patients with congestive heart failure.	2.47	2	0	bipyridines	EC 3.1.4.* (phosphoric diester hydrolase) inhibitor
incadronate [no description available]	2.51	2	0	1,1-bis(phosphonic acid)
indapamide Indapamide: A benzamide-sulfonamide-indole derived DIURETIC that functions by inhibiting SODIUM CHLORIDE SYMPORTERS.. indapamide : A sulfonamide formed by condensation of the carboxylic group of 4-chloro-3-sulfamoylbenzoic acid with the amino group of 2-methyl-2,3-dihydro-1H-indol-1-amine.	2.47	2	0	indoles; organochlorine compound; sulfonamide	antihypertensive agent; diuretic
indomethacin Indomethacin: A non-steroidal anti-inflammatory agent (NSAID) that inhibits CYCLOOXYGENASE, which is necessary for the formation of PROSTAGLANDINS and other AUTACOIDS. It also inhibits the motility of POLYMORPHONUCLEAR LEUKOCYTES.. indometacin : A member of the class of indole-3-acetic acids that is indole-3-acetic acid in which the indole ring is substituted at positions 1, 2 and 5 by p-chlorobenzoyl, methyl, and methoxy groups, respectively. A non-steroidal anti-inflammatory drug, it is used in the treatment of musculoskeletal and joint disorders including osteoarthritis, rheumatoid arthritis, gout, bursitis and tendinitis.	2.47	2	0	aromatic ether; indole-3-acetic acids; monochlorobenzenes; N-acylindole	analgesic; drug metabolite; EC 1.14.99.1 (prostaglandin-endoperoxide synthase) inhibitor; environmental contaminant; gout suppressant; non-steroidal anti-inflammatory drug; xenobiotic metabolite; xenobiotic
iohexol Iohexol: An effective non-ionic, water-soluble contrast agent which is used in myelography, arthrography, nephroangiography, arteriography, and other radiographic procedures. Its low systemic toxicity is the combined result of low chemotoxicity and low osmolality.. iohexol : A benzenedicarboxamide compound having N-(2,3-dihydroxypropyl)carbamoyl groups at the 1- and 3-positions, iodo substituents at the 2-, 4- and 6-positions and an N-(2,3-dihydroxypropyl)acetamido group at the 5-position.	2.08	1	0	benzenedicarboxamide; organoiodine compound	environmental contaminant; radioopaque medium; xenobiotic
iproniazid [no description available]	2.08	1	0	carbohydrazide; pyridines
avapro Irbesartan: A spiro compound, biphenyl and tetrazole derivative that acts as an angiotensin II type 1 receptor antagonist. It is used in the management of HYPERTENSION, and in the treatment of kidney disease.. irbesartan : A biphenylyltetrazole that is an angiotensin II receptor antagonist used mainly for the treatment of hypertension.	2.08	1	0	azaspiro compound; biphenylyltetrazole	angiotensin receptor antagonist; antihypertensive agent; environmental contaminant; xenobiotic
isoniazid Hydra: A genus of freshwater polyps in the family Hydridae, order Hydroida, class HYDROZOA. They are of special interest because of their complex organization and because their adult organization corresponds roughly to the gastrula of higher animals.. hydrazide : Compounds derived from oxoacids RkE(=O)l(OH)m (l =/= 0) by replacing -OH by -NRNR2 (R groups are commonly H). (IUPAC).	3.37	6	0	carbohydrazide	antitubercular agent; drug allergen
isradipine Isradipine: A potent antagonist of CALCIUM CHANNELS that is highly selective for VASCULAR SMOOTH MUSCLE. It is effective in the treatment of chronic stable angina pectoris, hypertension, and congestive cardiac failure.	2.47	2	0	benzoxadiazole; dihydropyridine; isopropyl ester; methyl ester
itraconazole [no description available]	3.65	2	0	piperazines
juglone juglone: structure. juglone : A hydroxy-1,4-naphthoquinone that is 1,4-naphthoquinone in which the hydrogen at position 5 has been replaced by a hydroxy group. A plant-derived 1,4-naphthoquinone with confirmed antibacterial and antitumor activities.	2.15	1	0	hydroxy-1,4-naphthoquinone	geroprotector; herbicide; reactive oxygen species generator
nsc 664704 kenpaullone: inhibits CDK1/cyclin B; structure in first source. kenpaullone : An indolobenzazepine that is paullone in which the hydrogen at position 9 is replaced by a bromo substituent. It is an ATP-competitive inhibitor of cyclin-dependent kinases (CDKs) and glycogen synthase kinase 3beta (GSK3beta).	2.05	1	0	indolobenzazepine; lactam; organobromine compound	cardioprotective agent; EC 2.7.11.22 (cyclin-dependent kinase) inhibitor; EC 2.7.11.26 (tau-protein kinase) inhibitor; geroprotector
ketamine Ketamine: A cyclohexanone derivative used for induction of anesthesia. Its mechanism of action is not well understood, but ketamine can block NMDA receptors (RECEPTORS, N-METHYL-D-ASPARTATE) and may interact with sigma receptors.. ketamine : A member of the class of cyclohexanones in which one of the hydrogens at position 2 is substituted by a 2-chlorophenyl group, while the other is substituted by a methylamino group.	2.47	2	0	cyclohexanones; monochlorobenzenes; secondary amino compound	analgesic; environmental contaminant; intravenous anaesthetic; neurotoxin; NMDA receptor antagonist; xenobiotic
ketanserin Ketanserin: A selective serotonin receptor antagonist with weak adrenergic receptor blocking properties. The drug is effective in lowering blood pressure in essential hypertension. It also inhibits platelet aggregation. It is well tolerated and is particularly effective in older patients.. ketanserin : A member of the class of quinazolines that is quinazoline-2,4(1H,3H)-dione which is substituted at position 3 by a 2-[4-(p-fluorobenzoyl)piperidin-1-yl]ethyl group.	2.47	2	0	aromatic ketone; organofluorine compound; piperidines; quinazolines	alpha-adrenergic antagonist; antihypertensive agent; cardiovascular drug; EC 3.4.21.26 (prolyl oligopeptidase) inhibitor; serotonergic antagonist
ketoconazole 1-acetyl-4-(4-{[2-(2,4-dichlorophenyl)-2-(1H-imidazol-1-ylmethyl)-1,3-dioxolan-4-yl]methoxy}phenyl)piperazine : A dioxolane that is 1,3-dioxolane which is substituted at positions 2, 2, and 4 by imidazol-1-ylmethyl, 2,4-dichlorophenyl, and [para-(4-acetylpiperazin-1-yl)phenoxy]methyl groups, respectively.	3.73	10	0	dichlorobenzene; dioxolane; ether; imidazoles; N-acylpiperazine; N-arylpiperazine
ketoprofen Ketoprofen: An IBUPROFEN-type anti-inflammatory analgesic and antipyretic. It is used in the treatment of rheumatoid arthritis and osteoarthritis.. ketoprofen : An oxo monocarboxylic acid that consists of propionic acid substituted by a 3-benzoylphenyl group at position 2.	2.05	1	0	benzophenones; oxo monocarboxylic acid	antipyretic; drug allergen; EC 1.14.99.1 (prostaglandin-endoperoxide synthase) inhibitor; environmental contaminant; non-steroidal anti-inflammatory drug; xenobiotic
ketotifen Ketotifen: A cycloheptathiophene blocker of histamine H1 receptors and release of inflammatory mediators. It has been proposed for the treatment of asthma, rhinitis, skin allergies, and anaphylaxis.. ketotifen : An organic heterotricyclic compound that is 4,9-dihydro-10H-benzo[4,5]cyclohepta[1,2-b]thiophen-10-one which is substituted at position 4 by a 1-methylpiperidin-4-ylidene group. A blocker of histamine H1 receptors with a stabilising action on mast cells, it is used (usually as its hydrogen fumarate salt) for the treatment of asthma, where it may take several weeks to exert its full effect.	2.05	1	0	cyclic ketone; olefinic compound; organic heterotricyclic compound; organosulfur heterocyclic compound; piperidines; tertiary amino compound	anti-asthmatic drug; H1-receptor antagonist
labetalol Labetalol: A salicylamide derivative that is a non-cardioselective blocker of BETA-ADRENERGIC RECEPTORS and ALPHA-1 ADRENERGIC RECEPTORS.. labetalol : A diastereoisomeric mixture of approximately equal amounts of all four possible stereoisomers ((R,S)-labetolol, (S,R)-labetolol, (S,S)-labetalol and (R,R)-labetalol). It is an adrenergic antagonist used to treat high blood pressure.. 2-hydroxy-5-{1-hydroxy-2-[(4-phenylbutan-2-yl)amino]ethyl}benzamide : A member of the class of benzamides that is benzamide substituted by a hydroxy group at position 2 and by a 1-hydroxy-2-[(4-phenylbutan-2-yl)amino]ethyl group at position 5.	2.05	1	0	benzamides; benzenes; phenols; primary carboxamide; salicylamides; secondary alcohol; secondary amino compound
lamotrigine [no description available]	2.08	1	0	1,2,4-triazines; dichlorobenzene; primary arylamine	anticonvulsant; antidepressant; antimanic drug; calcium channel blocker; EC 3.4.21.26 (prolyl oligopeptidase) inhibitor; environmental contaminant; excitatory amino acid antagonist; geroprotector; non-narcotic analgesic; xenobiotic
lansoprazole Lansoprazole: A 2,2,2-trifluoroethoxypyridyl derivative of timoprazole that is used in the therapy of STOMACH ULCERS and ZOLLINGER-ELLISON SYNDROME. The drug inhibits H(+)-K(+)-EXCHANGING ATPASE which is found in GASTRIC PARIETAL CELLS. Lansoprazole is a racemic mixture of (R)- and (S)-isomers.	2.47	2	0	benzimidazoles; pyridines; sulfoxide	anti-ulcer drug; EC 3.6.3.10 (H(+)/K(+)-exchanging ATPase) inhibitor
lapachol lapachol : A hydroxy-1,4-naphthoquinone that is 1,4-naphthoquinone substituted by hydroxy and 3-methylbut-2-en-1-yl groups at positions 2 and 3, respectively. It is a natural compound that exhibits antibacterial and anticancer properties, first isolated in 1882 from the bark of Tabebuia avellanedae.	2.74	3	0
beta-lapachone beta-lapachone: antineoplastic inhibitor of reverse transcriptase, DNA topoisomerase, and DNA polymerase. beta-lapachone : A benzochromenone that is 3,4-dihydro-2H-benzo[h]chromene-5,6-dione substituted by geminal methyl groups at position 2. Isolated from Tabebuia avellanedae, it exhibits antineoplastic and anti-inflammatory activities.	5.36	10	0	benzochromenone; orthoquinones	anti-inflammatory agent; antineoplastic agent; plant metabolite
leflunomide Leflunomide: An isoxazole derivative that inhibits dihydroorotate dehydrogenase, the fourth enzyme in the pyrimidine biosynthetic pathway. It is used an immunosuppressive agent in the treatment of RHEUMATOID ARTHRITIS and PSORIATIC ARTHRITIS.. leflunomide : A monocarboxylic acid amide obtained by formal condensation of the carboxy group of 5-methyl-1,2-oxazole-4-carboxylic acid with the anilino group of 4-(trifluoromethyl)aniline. The prodrug of teriflunomide.	2.08	1	0	(trifluoromethyl)benzenes; isoxazoles; monocarboxylic acid amide	antineoplastic agent; antiparasitic agent; EC 1.3.98.1 [dihydroorotate oxidase (fumarate)] inhibitor; EC 3.1.3.16 (phosphoprotein phosphatase) inhibitor; hepatotoxic agent; immunosuppressive agent; non-steroidal anti-inflammatory drug; prodrug; pyrimidine synthesis inhibitor; tyrosine kinase inhibitor
letrozole [no description available]	2.08	1	0	nitrile; triazoles	antineoplastic agent; EC 1.14.14.14 (aromatase) inhibitor
lofepramine Lofepramine: A psychotropic IMIPRAMINE derivative that acts as a tricyclic antidepressant and possesses few anticholinergic properties. It is metabolized to DESIPRAMINE.	2.47	2	0	aromatic ketone; dibenzoazepine; monochlorobenzenes; tertiary amino compound	antidepressant
lomefloxacin lomefloxacin: structure given in first source. lomefloxacin : A fluoroquinolone antibiotic, used (generally as the hydrochloride salt) to treat bacterial infections including bronchitis and urinary tract infections. It is also used to prevent urinary tract infections prior to surgery.	2.48	2	0	fluoroquinolone antibiotic; N-arylpiperazine; quinolinemonocarboxylic acid; quinolone antibiotic; quinolone	antimicrobial agent; antitubercular agent; photosensitizing agent
lomustine [no description available]	5.79	12	2	N-nitrosoureas; organochlorine compound	alkylating agent; antineoplastic agent
loratadine Loratadine: A second-generation histamine H1 receptor antagonist used in the treatment of allergic rhinitis and urticaria. Unlike most classical antihistamines (HISTAMINE H1 ANTAGONISTS) it lacks central nervous system depressing effects such as drowsiness.. loratadine : A benzocycloheptapyridine that is 6,11-dihydro-5H-benzo[5,6]cyclohepta[1,2-b]pyridine substituted by a chloro group at position 8 and a 1-(ethoxycarbonyl)piperidin-4-ylidene group at position 11. It is a H1-receptor antagonist commonly employed in the treatment of allergic disorders.	2.08	1	0	benzocycloheptapyridine; ethyl ester; N-acylpiperidine; organochlorine compound; tertiary carboxamide	anti-allergic agent; cholinergic antagonist; geroprotector; H1-receptor antagonist
lorazepam Lorazepam: A benzodiazepine used as an anti-anxiety agent with few side effects. It also has hypnotic, anticonvulsant, and considerable sedative properties and has been proposed as a preanesthetic agent.	2.05	1	0	benzodiazepine
2-(4-morpholinyl)-8-phenyl-4h-1-benzopyran-4-one 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one: specific inhibitor of phosphatidylinositol 3-kinase; structure in first source	2.31	1	0	chromones; morpholines; organochlorine compound	autophagy inhibitor; EC 2.7.1.137 (phosphatidylinositol 3-kinase) inhibitor; geroprotector
mafenide Mafenide: A sulfonamide that inhibits the enzyme CARBONIC ANHYDRASE and is used as a topical anti-bacterial agent, especially in burn therapy.	2.08	1	0	aromatic amine
maprotiline Maprotiline: A bridged-ring tetracyclic antidepressant that is both mechanistically and functionally similar to the tricyclic antidepressants, including side effects associated with its use.	2.47	2	0	anthracenes
mazindol Mazindol: Tricyclic anorexigenic agent unrelated to and less toxic than AMPHETAMINE, but with some similar side effects. It inhibits uptake of catecholamines and blocks the binding of cocaine to the dopamine uptake transporter.	2.05	1	0	organic molecular entity
mebendazole Mebendazole: A benzimidazole that acts by interfering with CARBOHYDRATE METABOLISM and inhibiting polymerization of MICROTUBULES.. mebendazole : A carbamate ester that is methyl 1H-benzimidazol-2-ylcarbamate substituted by a benzoyl group at position 5.	2.08	1	0	aromatic ketone; benzimidazoles; carbamate ester	antinematodal drug; microtubule-destabilising agent; tubulin modulator
mechlorethamine nitrogen mustard : Compounds having two beta-haloalkyl groups bound to a nitrogen atom, as in (X-CH2-CH2)2NR.	2.05	1	0	nitrogen mustard; organochlorine compound	alkylating agent
mefenamic acid Mefenamic Acid: A non-steroidal anti-inflammatory agent with analgesic, anti-inflammatory, and antipyretic properties. It is an inhibitor of cyclooxygenase.. mefenamic acid : An aminobenzoic acid that is anthranilic acid in which one of the hydrogens attached to the nitrogen is replaced by a 2,3-dimethylphenyl group. Although classed as a non-steroidal anti-inflammatory drug, its anti-inflammatory properties are considered to be minor. It is used to relieve mild to moderate pain, including headaches, dental pain, osteoarthritis and rheumatoid arthritis.	2.08	1	0	aminobenzoic acid; secondary amino compound	analgesic; antipyretic; antirheumatic drug; EC 1.14.99.1 (prostaglandin-endoperoxide synthase) inhibitor; environmental contaminant; non-steroidal anti-inflammatory drug; xenobiotic
mefloquine hydrochloride [2,8-bis(trifluoromethyl)quinolin-4-yl]-(2-piperidyl)methanol : An organofluorine compound that consists of quinoline bearing trifluoromethyl substituents at positions 2 and 8 as well as a (2-piperidinyl)hydroxymethyl substituent at position 4.	2.43	2	0	organofluorine compound; piperidines; quinolines; secondary alcohol
vitamin k 3 Vitamin K 3: A synthetic naphthoquinone without the isoprenoid side chain and biological activity, but can be converted to active vitamin K2, menaquinone, after alkylation in vivo.	2.41	1	0	1,4-naphthoquinones; vitamin K	angiogenesis inhibitor; antineoplastic agent; EC 3.4.22.69 (SARS coronavirus main proteinase) inhibitor; human urinary metabolite; nutraceutical
mephenytoin Mephenytoin: An anticonvulsant effective in tonic-clonic epilepsy (EPILEPSY, TONIC-CLONIC). It may cause blood dyscrasias.. mephenytoin : An imidazolidine-2,4-dione (hydantoin) in which the imidazolidine nucleus carries a methyl group at N-3 and has ethyl and phenyl substituents at C-5. An anticonvulsant, it is no longer available in the USA or the UK but is still studied largely because of its interesting hydroxylation polymorphism.	2.05	1	0	imidazolidine-2,4-dione	anticonvulsant
metformin Metformin: A biguanide hypoglycemic agent used in the treatment of non-insulin-dependent diabetes mellitus not responding to dietary modification. Metformin improves glycemic control by improving insulin sensitivity and decreasing intestinal absorption of glucose. (From Martindale, The Extra Pharmacopoeia, 30th ed, p289). metformin : A member of the class of guanidines that is biguanide the carrying two methyl substituents at position 1.	2.08	1	0	guanidines	environmental contaminant; geroprotector; hypoglycemic agent; xenobiotic
methazolamide Methazolamide: A carbonic anhydrase inhibitor that is used as a diuretic and in the treatment of glaucoma.	2.08	1	0	sulfonamide; thiadiazoles
methoxyamine methoxyamine: analytical reagent for aldehydes and ketones; strong irritant, can probably produce methemoglobinemia; RN given refers to parent cpd; structure	2.05	1	0	organooxygen compound
methoxyflurane Methoxyflurane: An inhalation anesthetic. Currently, methoxyflurane is rarely used for surgical, obstetric, or dental anesthesia. If so employed, it should be administered with NITROUS OXIDE to achieve a relatively light level of anesthesia, and a neuromuscular blocking agent given concurrently to obtain the desired degree of muscular relaxation. (From AMA Drug Evaluations Annual, 1994, p180). methoxyflurane : An ether in which the two groups attached to the central oxygen atom are methyl and 2,2-dichloro-1,1-difluoroethyl.	2.05	1	0	ether; organochlorine compound; organofluorine compound	hepatotoxic agent; inhalation anaesthetic; nephrotoxic agent; non-narcotic analgesic
methyl methanesulfonate [no description available]	2.31	1	0	methanesulfonate ester	alkylating agent; apoptosis inducer; carcinogenic agent; genotoxin; mutagen
methylphenidate Methylphenidate: A central nervous system stimulant used most commonly in the treatment of ATTENTION DEFICIT DISORDER in children and for NARCOLEPSY. Its mechanisms appear to be similar to those of DEXTROAMPHETAMINE. The d-isomer of this drug is referred to as DEXMETHYLPHENIDATE HYDROCHLORIDE.. methylphenidate : A racemate comprising equimolar amounts of the two threo isomers of methyl phenyl(piperidin-2-yl)acetate. A central stimulant and indirect-acting sympathomimetic, is used (generally as the hydrochloride salt) in the treatment of hyperactivity disorders in children and for the treatment of narcolepsy.. methyl phenyl(piperidin-2-yl)acetate : A amino acid ester that is methyl phenylacetate in which one of the hydrogens alpha to the carbonyl group is replaced by a piperidin-2-yl group.	2.05	1	0	beta-amino acid ester; methyl ester; piperidines
metoclopramide Metoclopramide: A dopamine D2 antagonist that is used as an antiemetic.. metoclopramide : A member of the class of benzamides resulting from the formal condensation of 4-amino-5-chloro-2-methoxybenzoic acid with the primary amino group of N,N-diethylethane-1,2-diamine.	2.47	2	0	benzamides; monochlorobenzenes; substituted aniline; tertiary amino compound	antiemetic; dopaminergic antagonist; environmental contaminant; gastrointestinal drug; xenobiotic
metoprolol Metoprolol: A selective adrenergic beta-1 blocking agent that is commonly used to treat ANGINA PECTORIS; HYPERTENSION; and CARDIAC ARRHYTHMIAS.. metoprolol : A propanolamine that is 1-(propan-2-ylamino)propan-2-ol substituted by a 4-(2-methoxyethyl)phenoxy group at position 1.	2.08	1	0	aromatic ether; propanolamine; secondary alcohol; secondary amino compound	antihypertensive agent; beta-adrenergic antagonist; environmental contaminant; geroprotector; xenobiotic
metronidazole Metronidazole: A nitroimidazole used to treat AMEBIASIS; VAGINITIS; TRICHOMONAS INFECTIONS; GIARDIASIS; ANAEROBIC BACTERIA; and TREPONEMAL INFECTIONS.. metronidazole : A member of the class of imidazoles substituted at C-1, -2 and -5 with 2-hydroxyethyl, nitro and methyl groups respectively. It has activity against anaerobic bacteria and protozoa, and has a radiosensitising effect on hypoxic tumour cells. It may be given by mouth in tablets, or as the benzoate in an oral suspension. The hydrochloride salt can be used in intravenous infusions. Metronidazole is a prodrug and is selective for anaerobic bacteria due to their ability to intracellularly reduce the nitro group of metronidazole to give nitroso-containing intermediates. These can covalently bind to DNA, disrupting its helical structure, inducing DNA strand breaks and inhibiting bacterial nucleic acid synthesis, ultimately resulting in bacterial cell death.	7.79	21	1	C-nitro compound; imidazoles; primary alcohol	antiamoebic agent; antibacterial drug; antimicrobial agent; antiparasitic agent; antitrichomonal drug; environmental contaminant; prodrug; radiosensitizing agent; xenobiotic
mexiletine Mexiletine: Antiarrhythmic agent pharmacologically similar to LIDOCAINE. It may have some anticonvulsant properties.. mexiletine : An aromatic ether which is 2,6-dimethylphenyl ether of 2-aminopropan-1-ol.	2.47	2	0	aromatic ether; primary amino compound	anti-arrhythmia drug
mianserin Mianserin: A tetracyclic compound with antidepressant effects. It may cause drowsiness and hematological problems. Its mechanism of therapeutic action is not well understood, although it apparently blocks alpha-adrenergic, histamine H1, and some types of serotonin receptors.. mianserin : A dibenzoazepine (specifically 1,2,3,4,10,14b-hexahydrodibenzo[c,f]pyrazino[1,2-a]azepine) methyl-substituted on N-2. Closely related to (and now mostly superseded by) the tetracyclic antidepressant mirtazapinean, it is an atypical antidepressant used in the treatment of depression throughout Europe and elsewhere.	2.05	1	0	dibenzoazepine	adrenergic uptake inhibitor; alpha-adrenergic antagonist; antidepressant; EC 3.4.21.26 (prolyl oligopeptidase) inhibitor; geroprotector; H1-receptor antagonist; histamine agonist; sedative; serotonergic antagonist
midazolam Midazolam: A short-acting hypnotic-sedative drug with anxiolytic and amnestic properties. It is used in dentistry, cardiac surgery, endoscopic procedures, as preanesthetic medication, and as an adjunct to local anesthesia. The short duration and cardiorespiratory stability makes it useful in poor-risk, elderly, and cardiac patients. It is water-soluble at pH less than 4 and lipid-soluble at physiological pH.. midazolam : An imidazobenzodiazepine that is 4H-imidazo[1,5-a][1,4]benzodiazepine which is substituted by a methyl, 2-fluorophenyl and chloro groups at positions 1, 6 and 8, respectively.	2.08	1	0	imidazobenzodiazepine; monofluorobenzenes; organochlorine compound	anticonvulsant; antineoplastic agent; anxiolytic drug; apoptosis inducer; central nervous system depressant; GABAA receptor agonist; general anaesthetic; muscle relaxant; sedative
minoxidil Minoxidil: A potent direct-acting peripheral vasodilator (VASODILATOR AGENTS) that reduces peripheral resistance and produces a fall in BLOOD PRESSURE. (From Martindale, The Extra Pharmacopoeia, 30th ed, p371). minoxidil : A pyrimidine N-oxide that is pyrimidine-2,4-diamine 3-oxide substituted by a piperidin-1-yl group at position 6.	2.47	2	0	dialkylarylamine; tertiary amino compound
mirtazapine Mirtazapine: A piperazinoazepine tetracyclic compound that enhances the release of NOREPINEPHRINE and SEROTONIN through blockage of presynaptic ALPHA-2 ADRENERGIC RECEPTORS. It also blocks both 5-HT2 and 5-HT3 serotonin receptors and is a potent HISTAMINE H1 RECEPTOR antagonist. It is used for the treatment of depression, and may also be useful for the treatment of anxiety disorders.	2.08	1	0	benzazepine; tetracyclic antidepressant	alpha-adrenergic antagonist; anxiolytic drug; H1-receptor antagonist; histamine antagonist; oneirogen; serotonergic antagonist
moclobemide Moclobemide: A reversible inhibitor of monoamine oxidase type A; (RIMA); (see MONOAMINE OXIDASE INHIBITORS) that has antidepressive properties.. moclobemide : A member of the class of benzamides that is benzamide substituted by a chloro group at position 4 and a 2-(morpholin-4-yl)ethyl group at the nitrogen atom. It acts as a reversible monoamine oxidase inhibitor and is used in the treatment of depression.	2.08	1	0	benzamides; monochlorobenzenes; morpholines	antidepressant; environmental contaminant; xenobiotic
acecainide Acecainide: A major metabolite of PROCAINAMIDE. Its anti-arrhythmic action may cause cardiac toxicity in kidney failure.. N-acetylprocainamide : A benzamide obtained via formal condensation of 4-acetamidobenzoic acid and 2-(diethylamino)ethylamine.	2.08	1	0	acetamides; benzamides	anti-arrhythmia drug
nabumetone Nabumetone: A butanone non-steroidal anti-inflammatory drug and cyclooxygenase-2 (COX2) inhibitor that is used in the management of pain associated with OSTEOARTHRITIS and RHEUMATOID ARTHRITIS.. nabumetone : A methyl ketone that is 2-butanone in which one of the methyl hydrogens at position 4 is replaced by a 6-methoxy-2-naphthyl group. A prodrug that is converted to the active metabolite, 6-methoxy-2-naphthylacetic acid, following oral administration. It is shown to have a slightly lower risk of gastrointestinal side effects than most other non-steroidal anti-inflammatory drugs.	2.05	1	0	methoxynaphthalene; methyl ketone	cyclooxygenase 2 inhibitor; non-narcotic analgesic; non-steroidal anti-inflammatory drug; prodrug
nadolol [no description available]	2.08	1	0	tetralins
nalidixic acid [no description available]	2.47	2	0	1,8-naphthyridine derivative; monocarboxylic acid; quinolone antibiotic	antibacterial drug; antimicrobial agent; DNA synthesis inhibitor
nefazodone nefazodone: may be useful as an opiate adjunct	2.08	1	0	aromatic ether; monochlorobenzenes; N-alkylpiperazine; N-arylpiperazine; triazoles	alpha-adrenergic antagonist; analgesic; antidepressant; serotonergic antagonist; serotonin uptake inhibitor
nefopam Nefopam: Non-narcotic analgesic chemically similar to ORPHENADRINE. Its mechanism of action is unclear. It is used for the relief of acute and chronic pain. (From Martindale, The Extra Pharmacopoeia, 30th ed, p26). nefopam : A racemate comprising equal amounts of (R)- and (S)-nefopam. The hydrochloride is a centrally acting non-opiate analgesic commonly used for the treatment of moderate to severe pain.. 5-methyl-1-phenyl-3,4,5,6-tetrahydro-1H-2,5-benzoxazocine : A member of the class of benzoxazocines that is 3,4,5,6-tetrahydro-1H-2,5-benzoxazocine substituted by phenyl and methyl groups at positions 1 and 5 respectively.	2.08	1	0	benzoxazocine; tertiary amino compound
neostigmine Neostigmine: A cholinesterase inhibitor used in the treatment of myasthenia gravis and to reverse the effects of muscle relaxants such as gallamine and tubocurarine. Neostigmine, unlike PHYSOSTIGMINE, does not cross the blood-brain barrier.. neostigmine : A quaternary ammonium ion comprising an anilinium ion core having three methyl substituents on the aniline nitrogen, and a 3-[(dimethylcarbamoyl)oxy] substituent at position 3. It is a parasympathomimetic which acts as a reversible acetylcholinesterase inhibitor.	2.08	1	0	quaternary ammonium ion	antidote to curare poisoning; EC 3.1.1.7 (acetylcholinesterase) inhibitor
nevirapine Nevirapine: A potent, non-nucleoside reverse transcriptase inhibitor used in combination with nucleoside analogues for treatment of HIV INFECTIONS and AIDS.. nevirapine : A dipyridodiazepine that is 5,11-dihydro-6H-dipyrido[3,2-b:2',3'-e][1,4]diazepine which is substituted by methyl, oxo, and cyclopropyl groups at positions 4, 6, and 11, respectively. A non-nucleoside reverse transcriptase inhibitor with activity against HIV-1, it is used in combination with other antiretrovirals for the treatment of HIV infection.	2.49	2	0	cyclopropanes; dipyridodiazepine	antiviral drug; HIV-1 reverse transcriptase inhibitor
nicardipine Nicardipine: A potent calcium channel blockader with marked vasodilator action. It has antihypertensive properties and is effective in the treatment of angina and coronary spasms without showing cardiodepressant effects. It has also been used in the treatment of asthma and enhances the action of specific antineoplastic agents.. nicardipine : A racemate comprising equimolar amounts of (R)- and (S)-nicardipine. It is a calcium channel blocker which is used to treat hypertension.. 2-[benzyl(methyl)amino]ethyl methyl 2,6-dimethyl-4-(3-nitrophenyl)-1,4-dihydropyridine-3,5-dicarboxylate : A dihydropyridine that is 1,4-dihydropyridine substituted by a methyl, {2-[benzyl(methyl)amino]ethoxy}carbonyl, 3-nitrophenyl, methoxycarbonyl and methyl groups at positions 2, 3, 4, 5 and 6, respectively.	2.47	2	0	benzenes; C-nitro compound; diester; dihydropyridine; methyl ester; tertiary amino compound
nifedipine Nifedipine: A potent vasodilator agent with calcium antagonistic action. It is a useful anti-anginal agent that also lowers blood pressure.	2.76	3	0	C-nitro compound; dihydropyridine; methyl ester	calcium channel blocker; human metabolite; tocolytic agent; vasodilator agent
nimesulide nimesulide: structure. nimesulide : An aromatic ether having phenyl and 2-methylsulfonamido-5-nitrophenyl as the two aryl groups.	2.08	1	0	aromatic ether; C-nitro compound; sulfonamide	cyclooxygenase 2 inhibitor; non-steroidal anti-inflammatory drug
nimodipine Nimodipine: A calcium channel blockader with preferential cerebrovascular activity. It has marked cerebrovascular dilating effects and lowers blood pressure.. nimodipine : A dihydropyridine that is 1,4-dihydropyridine which is substituted by methyl groups at positions 2 and 6, a (2-methoxyethoxy)carbonyl group at position 3, a m-nitrophenyl group at position 4, and an isopropoxycarbonyl group at position 5. An L-type calcium channel blocker, it acts particularly on cerebral circulation, and is used both orally and intravenously for the prevention and treatment of subarachnoid hemorrhage from ruptured intracranial aneurysm.	2.47	2	0	2-methoxyethyl ester; C-nitro compound; dicarboxylic acids and O-substituted derivatives; diester; dihydropyridine; isopropyl ester	antihypertensive agent; calcium channel blocker; cardiovascular drug; vasodilator agent
nisoldipine Nisoldipine: A dihydropyridine calcium channel antagonist that acts as a potent arterial vasodilator and antihypertensive agent. It is also effective in patients with cardiac failure and angina.. nisoldipine : A racemate consisting of equimolar amounts of (R)- and (S)-nisoldipine. A calcium channel blocker, it is used in the treatment of hypertension and angina pectoris.. methyl 2-methylpropyl 2,6-dimethyl-4-(2-nitrophenyl)-1,4-dihydropyridine-3,5-dicarboxylate : A dihydropyridine that is 1,4-dihydropyridine which is substituted by methyl groups at positions 2 and 6, a methoxycarbonyl group at position 3, an o-nitrophenyl group at position 4, and an isobutoxycarbonyl group at position 5. The racemate, a calcium channel blocker, is used in the treatment of hypertension and angina pectoris.	2.08	1	0	C-nitro compound; dicarboxylic acids and O-substituted derivatives; diester; dihydropyridine; methyl ester
nitrazepam Nitrazepam: A benzodiazepine derivative used as an anticonvulsant and hypnotic.. nitrazepam : A 1,4-benzodiazepinone that is 1,3-dihydro-2H-1,4-benzodiazepin-2-one which is substituted at positions 5 and 7 by phenyl and nitro groups, respectively. It is used as a hypnotic for the short-term management of insomnia and for the treatment of epileptic spasms in infants (West's syndrome).	2.08	1	0	1,4-benzodiazepinone; C-nitro compound	anticonvulsant; antispasmodic drug; drug metabolite; GABA modulator; sedative
nitrendipine Nitrendipine: A calcium channel blocker with marked vasodilator action. It is an effective antihypertensive agent and differs from other calcium channel blockers in that it does not reduce glomerular filtration rate and is mildly natriuretic, rather than sodium retentive.. nitrendipine : A dihydropyridine that is 1,4-dihydropyridine substituted by methyl groups at positions 2 and 6, a 3-nitrophenyl group at position 4, a ethoxycarbonyl group at position 3 and a methoxycarbonyl group at position 5. It is a calcium-channel blocker used in the treatment of hypertension.	2.76	3	0	C-nitro compound; dicarboxylic acids and O-substituted derivatives; diester; dihydropyridine; ethyl ester; methyl ester	antihypertensive agent; calcium channel blocker; geroprotector; vasodilator agent
nitroglycerin Nitroglycerin: A volatile vasodilator which relieves ANGINA PECTORIS by stimulating GUANYLATE CYCLASE and lowering cytosolic calcium. It is also sometimes used for TOCOLYSIS and explosives.. nitroglycerol : A nitrate ester that is glycerol in which nitro group(s) replace the hydrogen(s) attached to one or more of the hydroxy groups.. nitroglycerin : A nitroglycerol that is glycerol in which the hydrogen atoms of all three hydroxy groups are replaced by nitro groups. It acts as a prodrug, releasing nitric oxide to open blood vessels and so alleviate heart pain.	2.05	1	0	nitroglycerol	explosive; muscle relaxant; nitric oxide donor; prodrug; tocolytic agent; vasodilator agent; xenobiotic
nomifensine Nomifensine: An isoquinoline derivative that prevents dopamine reuptake into synaptosomes. The maleate was formerly used in the treatment of depression. It was withdrawn worldwide in 1986 due to the risk of acute hemolytic anemia with intravascular hemolysis resulting from its use. In some cases, renal failure also developed. (From Martindale, The Extra Pharmacopoeia, 30th ed, p266). nomifensine : An N-methylated tetrahydroisoquinoline carrying phenyl and amino substituents at positions C-4 and C-8, respectively.	2.05	1	0	isoquinolines	dopamine uptake inhibitor
norfloxacin Norfloxacin: A synthetic fluoroquinolone (FLUOROQUINOLONES) with broad-spectrum antibacterial activity against most gram-negative and gram-positive bacteria. Norfloxacin inhibits bacterial DNA GYRASE.. norfloxacin : A quinolinemonocarboxylic acid with broad-spectrum antibacterial activity against most gram-negative and gram-positive bacteria. Norfloxacin is bactericidal and its mode of action depends on blocking of bacterial DNA replication by binding itself to an enzyme called DNA gyrase.	2.77	3	0	fluoroquinolone antibiotic; N-arylpiperazine; quinolinemonocarboxylic acid; quinolone antibiotic; quinolone	antibacterial drug; DNA synthesis inhibitor; environmental contaminant; xenobiotic
nortriptyline Nortriptyline: A metabolite of AMITRIPTYLINE that is also used as an antidepressive agent. Nortriptyline is used in major depression, dysthymia, and atypical depressions.. nortriptyline : An organic tricyclic compound that is 10,11-dihydro-5H-dibenzo[a,d][7]annulene substituted by a 3-(methylamino)propylidene group at position 5. It is an active metabolite of amitriptyline.	2.47	2	0	organic tricyclic compound; secondary amine	adrenergic uptake inhibitor; analgesic; antidepressant; antineoplastic agent; apoptosis inducer; drug metabolite
ofloxacin Ofloxacin: A synthetic fluoroquinolone antibacterial agent that inhibits the supercoiling activity of bacterial DNA GYRASE, halting DNA REPLICATION.. 9-fluoro-3-methyl-10-(4-methylpiperazin-1-yl)-7-oxo-2,3-dihydro-7H-[1,4]oxazino[2,3,4-ij]quinoline-6-carboxylic acid : An oxazinoquinoline that is 2,3-dihydro-7H-[1,4]oxazino[2,3,4-ij]quinolin-7-one substituted by methyl, carboxy, fluoro, and 4-methylpiperazin-1-yl groups at positions 3, 6, 9, and 10, respectively.. ofloxacin : A racemate comprising equimolar amounts of levofloxacin and dextrofloxacin. It is a synthetic fluoroquinolone antibacterial agent which inhibits the supercoiling activity of bacterial DNA gyrase, halting DNA replication.	2.74	3	0	3-oxo monocarboxylic acid; N-arylpiperazine; N-methylpiperazine; organofluorine compound; oxazinoquinoline
olomoucine olomoucine: inhibits protein P34CDC2. olomoucine : A 9H-purine that is substituted by a (2-hydroxyethyl)nitrilo, benzylnitrilo and a methyl group at positions 2,6 and 9, respectively. It is a cyclin-dependent kinase inhibitor.	2.05	1	0	2,6-diaminopurines; ethanolamines	EC 2.7.11.22 (cyclin-dependent kinase) inhibitor
omeprazole Omeprazole: A 4-methoxy-3,5-dimethylpyridyl, 5-methoxybenzimidazole derivative of timoprazole that is used in the therapy of STOMACH ULCERS and ZOLLINGER-ELLISON SYNDROME. The drug inhibits an H(+)-K(+)-EXCHANGING ATPASE which is found in GASTRIC PARIETAL CELLS.. omeprazole : A racemate comprising equimolar amounts of (R)- and (S)-omeprazole.. 5-methoxy-2-{[(4-methoxy-3,5-dimethylpyridin-2-yl)methyl]sulfinyl}-1H-benzimidazole : A member of the class of benzimidazoles that is 1H-benzimidazole which is substituted by a [4-methoxy-3,5-dimethylpyridin-2-yl)methyl]sulfinyl group at position 2 and a methoxy group at position 5.	2.47	2	0	aromatic ether; benzimidazoles; pyridines; sulfoxide
ondansetron Ondansetron: A competitive serotonin type 3 receptor antagonist. It is effective in the treatment of nausea and vomiting caused by cytotoxic chemotherapy drugs, including cisplatin, and has reported anxiolytic and neuroleptic properties.	2.08	1	0	carbazoles
oxamniquine Oxamniquine: An anthelmintic with schistosomicidal activity against Schistosoma mansoni, but not against other Schistosoma spp. Oxamniquine causes worms to shift from the mesenteric veins to the liver where the male worms are retained; the female worms return to the mesentery, but can no longer release eggs. (From Martindale, The Extra Pharmacopoeia, 31st ed, p121). oxamniquine : A racemate comprising equimolar amounts of (R)- and (S)-oxamniquine. An anthelmintic, it is administered orally for the treatment of schistomiasis caused by Schistosoma mansoni (but not by other Schistosoma species); intramuscular administration is no longer used as it causes severe pain at the injection site.. {2-[(isopropylamino)methyl]-7-nitro-1,2,3,4-tetrahydroquinolin-6-yl}methanol : A member of the class of quinolines that is 1,2,3,4-tetrahydroquinoline which is substituted at positions 2, 6, and 7 by (isopropylamino)methyl, hydroxymethyl, and nitro groups, respectively.	1.97	1	0	aromatic primary alcohol; C-nitro compound; quinolines; secondary amino compound
oxaprozin Oxaprozin: An oxazole-propionic acid derivative, cyclooxygenase inhibitor, and non-steroidal anti-inflammatory drug that is used in the treatment of pain and inflammation associated with of OSTEOARTHRITIS; RHEUMATOID ARTHRITIS; and ARTHRITIS, JUVENILE.. oxaprozin : A monocarboxylic acid that is a propionic acid derivative having a 4,5-diphenyl-1,3-oxazol-2-yl substituent at position 3. It is non-steroidal anti-inflammatory drug commonly used to relieve the pain and inflammatory responses associated with osteoarthritis and rheumatoid arthritis.	2.08	1	0	1,3-oxazoles; monocarboxylic acid	analgesic; non-steroidal anti-inflammatory drug
oxatomide oxatomide: structure; an anti-allergic & an anti-asthmatic. oxatomide : A member of the class of benzimidazoles that is 1,3-dihydro-2H-benzimidazol-2-one substituted by a 3-[4-(diphenylmethyl)piperazin-1-yl]propyl group at position 1. It is an anti-allergic drug.	2.05	1	0	benzimidazoles; diarylmethane; N-alkylpiperazine	anti-allergic agent; anti-inflammatory agent; geroprotector; H1-receptor antagonist; serotonergic antagonist
oxazepam Oxazepam: A benzodiazepine used in the treatment of anxiety, alcohol withdrawal, and insomnia.. oxazepam : A 1,4-benzodiazepinone that is 1,3-dihydro-2H-1,4-benzodiazepin-2-one substituted by a chloro group at position 7, a hydroxy group at position 3 and phenyl group at position 5.	2.05	1	0	1,4-benzodiazepinone; organochlorine compound	anxiolytic drug; environmental contaminant; xenobiotic
oxprenolol Oxprenolol: A beta-adrenergic antagonist used in the treatment of hypertension, angina pectoris, arrhythmias, and anxiety.	2.05	1	0	aromatic ether
oxybutynin oxybutynin: RN given refers to parent cpd. oxybutynin : A racemate comprising equimolar amounts of (R)-oxybutynin and esoxybutynin. An antispasmodic used for the treatment of overactive bladder.	2.08	1	0	acetylenic compound; carboxylic ester; racemate; tertiary alcohol; tertiary amino compound	antispasmodic drug; calcium channel blocker; local anaesthetic; muscarinic antagonist; muscle relaxant; parasympatholytic
oxyphenbutazone Oxyphenbutazone: A non-steroidal anti-inflammatory drug. Oxyphenbutazone eyedrops have been used abroad in the management of postoperative ocular inflammation, superficial eye injuries, and episcleritis. (From AMA, Drug Evaluations Annual, 1994, p2000) It had been used by mouth in rheumatic disorders such as ankylosing spondylitis, osteoarthritis, and rheumatoid arthritis but such use is no longer considered justified owing to the risk of severe hematological adverse effects. (From Martindale, The Extra Pharmacopoeia, 30th ed, p27). oxyphenbutazone : A metabolite of phenylbutazone obtained by hydroxylation at position 4 of one of the phenyl rings. Commonly used (as its hydrate) to treat pain, swelling and stiffness associated with arthritis and gout, it was withdrawn from the market 1984 following association with blood dyscrasis and Stevens-Johnson syndrome.	2.05	1	0	phenols; pyrazolidines	antimicrobial agent; antineoplastic agent; antipyretic; drug metabolite; gout suppressant; non-narcotic analgesic; non-steroidal anti-inflammatory drug; xenobiotic metabolite
aminosalicylic acid Aminosalicylic Acid: An antitubercular agent often administered in association with ISONIAZID. The sodium salt of the drug is better tolerated than the free acid.. 4-aminosalicylic acid : An aminobenzoic acid that is salicylic acid substituted by an amino group at position 4.	2.05	1	0	aminobenzoic acid; phenols	antitubercular agent
pamidronate [no description available]	2.43	2	0	phosphonoacetic acid
pantoprazole Pantoprazole: 2-pyridinylmethylsulfinylbenzimidazole proton pump inhibitor that is used in the treatment of GASTROESOPHAGEAL REFLUX and PEPTIC ULCER.. pantoprazole : A member of the class of benzimidazoles that is 1H-benzimidazole substituted by a difluoromethoxy group at position 5 and a [(3,4-dimethoxypyridin-2-yl)methyl]sulfinyl group at position 2.	2.05	1	0	aromatic ether; benzimidazoles; organofluorine compound; pyridines; sulfoxide	anti-ulcer drug; EC 3.6.3.10 (H(+)/K(+)-exchanging ATPase) inhibitor; environmental contaminant; xenobiotic
papaverine Papaverine: An alkaloid found in opium but not closely related to the other opium alkaloids in its structure or pharmacological actions. It is a direct-acting smooth muscle relaxant used in the treatment of impotence and as a vasodilator, especially for cerebral vasodilation. The mechanism of its pharmacological actions is not clear, but it apparently can inhibit phosphodiesterases and it may have direct actions on calcium channels.. papaverine : A benzylisoquinoline alkaloid that is isoquinoline substituted by methoxy groups at positions 6 and 7 and a 3,4-dimethoxybenzyl group at position 1. It has been isolated from Papaver somniferum.	2.47	2	0	benzylisoquinoline alkaloid; dimethoxybenzene; isoquinolines	antispasmodic drug; vasodilator agent
pemoline Pemoline: A central nervous system stimulant used in fatigue and depressive states and to treat hyperkinetic disorders in children.. pemoline : A member of the class of 1,3-oxazoles that is 1,3-oxazol-4(5H)-one which is substituted by an amino group at position 2 and by a phenyl group at position 5. A central nervous system stimulant, it was used to treat hyperactivity disorders in children, but withdrawn from use following reports of serious hepatotoxicity.	2.08	1	0	1,3-oxazoles	central nervous system stimulant
pentamidine Pentamidine: Antiprotozoal agent effective in trypanosomiasis, leishmaniasis, and some fungal infections; used in treatment of PNEUMOCYSTIS pneumonia in HIV-infected patients. It may cause diabetes mellitus, central nervous system damage, and other toxic effects.. pentamidine : A diether consisting of pentane-1,5-diol in which both hydroxyl hydrogens have been replaced by 4-amidinophenyl groups. A trypanocidal drug that is used for treatment of cutaneous leishmaniasis and Chagas disease.	6.83	46	0	aromatic ether; carboxamidine; diether	anti-inflammatory agent; antifungal agent; calmodulin antagonist; chemokine receptor 5 antagonist; EC 2.3.1.48 (histone acetyltransferase) inhibitor; NMDA receptor antagonist; S100 calcium-binding protein B inhibitor; trypanocidal drug; xenobiotic
pentobarbital Pentobarbital: A short-acting barbiturate that is effective as a sedative and hypnotic (but not as an anti-anxiety) agent and is usually given orally. It is prescribed more frequently for sleep induction than for sedation but, like similar agents, may lose its effectiveness by the second week of continued administration. (From AMA Drug Evaluations Annual, 1994, p236). pentobarbital : A member of the class of barbiturates, the structure of which is that of barbituric acid substituted at C-5 by ethyl and sec-pentyl groups.	2.37	2	0	barbiturates	GABAA receptor agonist
pentoxifylline [no description available]	3.25	5	0	oxopurine
perphenazine Perphenazine: An antipsychotic phenothiazine derivative with actions and uses similar to those of CHLORPROMAZINE.. perphenazine : A phenothiazine derivative in which the phenothiazine tricycle carries a chloro substituent at the 2-position and a 3-[4-(2-hydroxyethyl)piperazin-1-yl]propyl group at N-10.	2.47	2	0	N-(2-hydroxyethyl)piperazine; N-alkylpiperazine; organochlorine compound; phenothiazines	antiemetic; dopaminergic antagonist; phenothiazine antipsychotic drug
phenacetin Saridon: contains phenacetin, caffeine, propyphenazone & pyrithyldione	2.47	2	0	acetamides; aromatic ether	cyclooxygenase 3 inhibitor; non-narcotic analgesic; peripheral nervous system drug
phenindione Phenindione: An indandione that has been used as an anticoagulant. Phenindione has actions similar to WARFARIN, but it is now rarely employed because of its higher incidence of severe adverse effects. (From Martindale, The Extra Pharmacopoeia, 30th ed, p234)	2.05	1	0	aromatic ketone; beta-diketone	anticoagulant
phenobarbital Phenobarbital: A barbituric acid derivative that acts as a nonselective central nervous system depressant. It potentiates GAMMA-AMINOBUTYRIC ACID action on GABA-A RECEPTORS, and modulates chloride currents through receptor channels. It also inhibits glutamate induced depolarizations.. phenobarbital : A member of the class of barbiturates, the structure of which is that of barbituric acid substituted at C-5 by ethyl and phenyl groups.	1.96	1	0	barbiturates	anticonvulsant; drug allergen; excitatory amino acid antagonist; sedative
phentermine Phentermine: A central nervous system stimulant and sympathomimetic with actions and uses similar to those of DEXTROAMPHETAMINE. It has been used most frequently in the treatment of obesity.	2.05	1	0	primary amine	adrenergic agent; appetite depressant; central nervous system drug; central nervous system stimulant; dopaminergic agent; sympathomimetic agent
phenylbutazone Phenylbutazone: A butyl-diphenyl-pyrazolidinedione that has anti-inflammatory, antipyretic, and analgesic activities. It has been used in ANKYLOSING SPONDYLITIS; RHEUMATOID ARTHRITIS; and REACTIVE ARTHRITIS.. phenylbutazone : A member of the class of pyrazolidines that is 1,2-diphenylpyrazolidine-3,5-dione carrying a butyl group at the 4-position.	2.05	1	0	pyrazolidines	antirheumatic drug; EC 1.1.1.184 [carbonyl reductase (NADPH)] inhibitor; metabolite; non-narcotic analgesic; non-steroidal anti-inflammatory drug; peripheral nervous system drug
pindolol Pindolol: A moderately lipophilic beta blocker (ADRENERGIC BETA-ANTAGONISTS). It is non-cardioselective and has intrinsic sympathomimetic actions, but little membrane-stabilizing activity. (From Martindale, The Extra Pharmocopoeia, 30th ed, p638). pindolol : A member of the class of indols which is the 2-hydroxy-3-(isopropylamino)propyl ether derivative of 1H-indol-4-ol.	2.08	1	0	indoles; secondary amine	antiglaucoma drug; antihypertensive agent; beta-adrenergic antagonist; serotonergic antagonist; vasodilator agent
pioglitazone Pioglitazone: A thiazolidinedione and PPAR GAMMA agonist that is used in the treatment of TYPE 2 DIABETES MELLITUS.. pioglitazone : A member of the class of thiazolidenediones that is 1,3-thiazolidine-2,4-dione substituted by a benzyl group at position 5 which in turn is substituted by a 2-(5-ethylpyridin-2-yl)ethoxy group at position 4 of the phenyl ring. It exhibits hypoglycemic activity.	2.08	1	0	aromatic ether; pyridines; thiazolidinediones	antidepressant; cardioprotective agent; EC 2.7.1.33 (pantothenate kinase) inhibitor; EC 6.2.1.3 (long-chain-fatty-acid--CoA ligase) inhibitor; ferroptosis inhibitor; geroprotector; hypoglycemic agent; insulin-sensitizing drug; PPARgamma agonist; xenobiotic
piracetam Piracetam: A compound suggested to be both a nootropic and a neuroprotective agent.	2.08	1	0	organonitrogen compound; organooxygen compound
piribedil Piribedil: A dopamine D2 agonist. It is used in the treatment of parkinson disease, particularly for alleviation of tremor. It has also been used for circulatory disorders and in other applications as a D2 agonist.	2.08	1	0	N-arylpiperazine
ono 1078 pranlukast: SRS-A antagonist; leukotriene D4 receptor antagonist	2.08	1	0	chromones
pyranoprofen pyranoprofen: RN given refers to unlabled parent cpd; structure given in first source	2.08	1	0	pyridochromene
praziquantel azinox: Russian drug	2.73	3	0	isoquinolines
prazosin Prazosin: A selective adrenergic alpha-1 antagonist used in the treatment of HEART FAILURE; HYPERTENSION; PHEOCHROMOCYTOMA; RAYNAUD DISEASE; PROSTATIC HYPERTROPHY; and URINARY RETENTION.. prazosin : A member of the class of piperazines that is piperazine substituted by a furan-2-ylcarbonyl group and a 4-amino-6,7-dimethoxyquinazolin-2-yl group at positions 1 and 4 respectively.	2.08	1	0	aromatic ether; furans; monocarboxylic acid amide; piperazines; quinazolines	alpha-adrenergic antagonist; antihypertensive agent; EC 3.4.21.26 (prolyl oligopeptidase) inhibitor
primaquine Primaquine: An aminoquinoline that is given by mouth to produce a radical cure and prevent relapse of vivax and ovale malarias following treatment with a blood schizontocide. It has also been used to prevent transmission of falciparum malaria by those returning to areas where there is a potential for re-introduction of malaria. Adverse effects include anemias and GI disturbances. (From Martindale, The Extra Pharmacopeia, 30th ed, p404). primaquine : An N-substituted diamine that is pentane-1,4-diamine substituted by a 6-methoxyquinolin-8-yl group at the N(4) position. It is a drug used in the treatment of malaria and Pneumocystis pneumonia.	2.47	2	0	aminoquinoline; aromatic ether; N-substituted diamine	antimalarial
primidone Primidone: A barbiturate derivative that acts as a GABA modulator and anti-epileptic agent. It is partly metabolized to PHENOBARBITAL in the body and owes some of its actions to this metabolite.. primidone : A pyrimidone that is dihydropyrimidine-4,6(1H,5H)-dione substituted by an ethyl and a phenyl group at position 5. It is used as an anticonvulsant for treatment of various types of seizures.	2.08	1	0	pyrimidone	anticonvulsant; environmental contaminant; xenobiotic
probenecid Probenecid: The prototypical uricosuric agent. It inhibits the renal excretion of organic anions and reduces tubular reabsorption of urate. Probenecid has also been used to treat patients with renal impairment, and, because it reduces the renal tubular excretion of other drugs, has been used as an adjunct to antibacterial therapy.. probenecid : A sulfonamide in which the nitrogen of 4-sulfamoylbenzoic acid is substituted with two propyl groups.	2.08	1	0	benzoic acids; sulfonamide	uricosuric drug
procainamide Procainamide: A class Ia antiarrhythmic drug that is structurally-related to PROCAINE.. procainamide : A benzamide that is 4-aminobenzamide substituted on the amide N by a 2-(diethylamino)ethyl group. It is a pharmaceutical antiarrhythmic agent used for the medical treatment of cardiac arrhythmias.	2.47	2	0	benzamides	anti-arrhythmia drug; platelet aggregation inhibitor; sodium channel blocker
procaine Procaine: A local anesthetic of the ester type that has a slow onset and a short duration of action. It is mainly used for infiltration anesthesia, peripheral nerve block, and spinal block. (From Martindale, The Extra Pharmacopoeia, 30th ed, p1016).. procaine : A benzoate ester, formally the result of esterification of 4-aminobenzoic acid with 2-diethylaminoethanol but formed experimentally by reaction of ethyl 4-aminobenzoate with 2-diethylaminoethanol.	2.05	1	0	benzoate ester; substituted aniline; tertiary amino compound	central nervous system depressant; drug allergen; local anaesthetic; peripheral nervous system drug
procarbazine Procarbazine: An antineoplastic agent used primarily in combination with mechlorethamine, vincristine, and prednisone (the MOPP protocol) in the treatment of Hodgkin's disease.. procarbazine : A benzamide obtained by formal condensation of the carboxy group of 4-[(2-methylhydrazino)methyl]benzoic acid with the amino group of isopropylamine. An antineoplastic chemotherapy drug used for treatment of Hodgkin's lymphoma. Metabolism yields azo-procarbazine and hydrogen peroxide, which results in the breaking of DNA strands.	2.05	1	0	benzamides; hydrazines	antineoplastic agent
prochlorperazine Prochlorperazine: A phenothiazine antipsychotic used principally in the treatment of NAUSEA; VOMITING; and VERTIGO. It is more likely than CHLORPROMAZINE to cause EXTRAPYRAMIDAL DISORDERS. (From Martindale, The Extra Pharmacopoeia, 30th ed, p612). prochlorperazine : A member of the class of phenothiazines that is 10H-phenothiazine having a chloro substituent at the 2-position and a 3-(4-methylpiperazin-1-yl)propyl group at the N-10 position.	2.08	1	0	N-alkylpiperazine; N-methylpiperazine; organochlorine compound; phenothiazines	alpha-adrenergic antagonist; antiemetic; cholinergic antagonist; dopamine receptor D2 antagonist; dopaminergic antagonist; EC 3.4.21.26 (prolyl oligopeptidase) inhibitor; first generation antipsychotic
procyclidine Procyclidine: A muscarinic antagonist that crosses the blood-brain barrier and is used in the treatment of drug-induced extrapyramidal disorders and in parkinsonism.. procyclidine : A tertiary alcohol that consists of propan-1-ol substituted by a cyclohexyl and a phenyl group at position 1 and a pyrrolidin-1-yl group at position 3.	2.08	1	0	pyrrolidines; tertiary alcohol	antidyskinesia agent; antiparkinson drug; muscarinic antagonist
promazine Promazine: A phenothiazine with actions similar to CHLORPROMAZINE but with less antipsychotic activity. It is primarily used in short-term treatment of disturbed behavior and as an antiemetic.. promazine : A phenothiazine deriative in which the phenothiazine tricycle has a 3-(dimethylaminopropyl) group at the N-10 position.	2.11	1	0	phenothiazines; tertiary amine	antiemetic; dopaminergic antagonist; EC 3.4.21.26 (prolyl oligopeptidase) inhibitor; H1-receptor antagonist; muscarinic antagonist; phenothiazine antipsychotic drug; serotonergic antagonist
promethazine Promethazine: A phenothiazine derivative with histamine H1-blocking, antimuscarinic, and sedative properties. It is used as an antiallergic, in pruritus, for motion sickness and sedation, and also in animals.. promethazine : A tertiary amine that is a substituted phenothiazine in which the ring nitrogen at position 10 is attached to C-3 of an N,N-dimethylpropan-2-amine moiety.	2.47	2	0	phenothiazines; tertiary amine	anti-allergic agent; anticoronaviral agent; antiemetic; antipruritic drug; H1-receptor antagonist; local anaesthetic; sedative
propafenone Propafenone: An antiarrhythmia agent that is particularly effective in ventricular arrhythmias. It also has weak beta-blocking activity.. propafenone : An aromatic ketone that is 3-(propylamino)propane-1,2-diol in which the hydrogen of the primary hydroxy group is replaced by a 2-(3-phenylpropanoyl)phenyl group. It is a class 1C antiarrhythmic drug with local anesthetic effects, and is used as the hydrochloride salt in the management of supraventricular and ventricular arrhythmias.	2.08	1	0	aromatic ketone; secondary alcohol; secondary amino compound	anti-arrhythmia drug
propidium Propidium: Quaternary ammonium analog of ethidium; an intercalating dye with a specific affinity to certain forms of DNA and, used as diiodide, to separate them in density gradients; also forms fluorescent complexes with cholinesterase which it inhibits.	2.13	1	0	phenanthridines; quaternary ammonium ion	fluorochrome; intercalator
propranolol Propranolol: A widely used non-cardioselective beta-adrenergic antagonist. Propranolol has been used for MYOCARDIAL INFARCTION; ARRHYTHMIA; ANGINA PECTORIS; HYPERTENSION; HYPERTHYROIDISM; MIGRAINE; PHEOCHROMOCYTOMA; and ANXIETY but adverse effects instigate replacement by newer drugs.. propranolol : A propanolamine that is propan-2-ol substituted by a propan-2-ylamino group at position 1 and a naphthalen-1-yloxy group at position 3.	3.19	5	0	naphthalenes; propanolamine; secondary amine	anti-arrhythmia drug; antihypertensive agent; anxiolytic drug; beta-adrenergic antagonist; environmental contaminant; human blood serum metabolite; vasodilator agent; xenobiotic
protopine [no description available]	3.31	1	0	dibenzazecine alkaloid	plant metabolite
pyrimethamine Maloprim: contains above 2 cpds	2.8	3	0	aminopyrimidine; monochlorobenzenes	antimalarial; antiprotozoal drug; EC 1.5.1.3 (dihydrofolate reductase) inhibitor
rabeprazole Rabeprazole: A 4-(3-methoxypropoxy)-3-methylpyridinyl derivative of timoprazole that is used in the therapy of STOMACH ULCERS and ZOLLINGER-ELLISON SYNDROME. The drug inhibits H(+)-K(+)-EXCHANGING ATPASE which is found in GASTRIC PARIETAL CELLS.	2.54	2	0	benzimidazoles; pyridines; sulfoxide	anti-ulcer drug; EC 3.6.3.10 (H(+)/K(+)-exchanging ATPase) inhibitor
ranitidine [no description available]	2.77	3	0	aralkylamine
riluzole Riluzole: A glutamate antagonist (RECEPTORS, GLUTAMATE) used as an anticonvulsant (ANTICONVULSANTS) and to prolong the survival of patients with AMYOTROPHIC LATERAL SCLEROSIS.	2.53	2	0	benzothiazoles
risperidone Risperidone: A selective blocker of DOPAMINE D2 RECEPTORS and SEROTONIN 5-HT2 RECEPTORS that acts as an atypical antipsychotic agent. It has been shown to improve both positive and negative symptoms in the treatment of SCHIZOPHRENIA.. risperidone : A member of the class of pyridopyrimidines that is 2-methyl-6,7,8,9-tetrahydropyrido[1,2-a]pyrimidin-4-one carrying an additional 2-[4-(6-fluoro-1,2-benzoxazol-3-yl)piperidin-1-yl]ethyl group at position 2.	2.08	1	0	1,2-benzoxazoles; heteroarylpiperidine; organofluorine compound; pyridopyrimidine	alpha-adrenergic antagonist; dopaminergic antagonist; EC 3.4.21.26 (prolyl oligopeptidase) inhibitor; H1-receptor antagonist; psychotropic drug; second generation antipsychotic; serotonergic antagonist
rofecoxib [no description available]	2.08	1	0	butenolide; sulfone	analgesic; cyclooxygenase 2 inhibitor; non-steroidal anti-inflammatory drug
saccharin Saccharin: Flavoring agent and non-nutritive sweetener.. saccharin : A 1,2-benzisothiazole having a keto-group at the 3-position and two oxo substituents at the 1-position. It is used as an artificial sweetening agent.	2.08	1	0	1,2-benzisothiazole; N-sulfonylcarboxamide	environmental contaminant; sweetening agent; xenobiotic
semustine Semustine: 4-Methyl derivative of LOMUSTINE; (CCNU). An antineoplastic agent which functions as an alkylating agent.. semustine : An organochlorine compound that is urea in which the two hydrogens on one of the amino groups are replaced by nitroso and 2-chloroethyl groups and one hydrogen from the other amino group is replaced by a 4-methylcyclohexyl group.	1.96	1	0	N-nitrosoureas; organochlorine compound	alkylating agent; antineoplastic agent; carcinogenic agent
sulfadiazine Sulfadiazine: One of the short-acting SULFONAMIDES used in combination with PYRIMETHAMINE to treat toxoplasmosis in patients with acquired immunodeficiency syndrome and in newborns with congenital infections.. sulfadiazine : A sulfonamide consisting of pyrimidine with a 4-aminobenzenesulfonamido group at the 2-position.. diazine : The parent structure of the diazines.	2.08	1	0	pyrimidines; substituted aniline; sulfonamide antibiotic; sulfonamide	antiinfective agent; antimicrobial agent; antiprotozoal drug; coccidiostat; drug allergen; EC 1.1.1.153 [sepiapterin reductase (L-erythro-7,8-dihydrobiopterin forming)] inhibitor; EC 2.5.1.15 (dihydropteroate synthase) inhibitor; environmental contaminant; xenobiotic
risedronic acid Risedronic Acid: A pyridine and diphosphonic acid derivative that acts as a CALCIUM CHANNEL BLOCKER and inhibits BONE RESORPTION.	3.15	5	0	pyridines
sotalol Sotalol: An adrenergic beta-antagonist that is used in the treatment of life-threatening arrhythmias.. sotalol : A sulfonamide that is N-phenylmethanesulfonamide in which the phenyl group is substituted at position 4 by a 1-hydroxy-2-(isopropylamino)ethyl group. It has both beta-adrenoreceptor blocking (Vaughan Williams Class II) and cardiac action potential duration prolongation (Vaughan Williams Class III) antiarrhythmic properties. It is used (usually as the hydrochloride salt) for the management of ventricular and supraventricular arrhythmias.	2.08	1	0	ethanolamines; secondary alcohol; secondary amino compound; sulfonamide	anti-arrhythmia drug; beta-adrenergic antagonist; environmental contaminant; xenobiotic
stearic acid octadecanoic acid : A C18 straight-chain saturated fatty acid component of many animal and vegetable lipids. As well as in the diet, it is used in hardening soaps, softening plastics and in making cosmetics, candles and plastics.	2.21	1	0	long-chain fatty acid; saturated fatty acid; straight-chain saturated fatty acid	algal metabolite; Daphnia magna metabolite; human metabolite; plant metabolite
imatinib [no description available]	2.08	1	0	aromatic amine; benzamides; N-methylpiperazine; pyridines; pyrimidines	antineoplastic agent; apoptosis inducer; tyrosine kinase inhibitor
vorinostat Vorinostat: A hydroxamic acid and anilide derivative that acts as a HISTONE DEACETYLASE inhibitor. It is used in the treatment of CUTANEOUS T-CELL LYMPHOMA and SEZARY SYNDROME.. vorinostat : A dicarboxylic acid diamide comprising suberic (octanedioic) acid coupled to aniline and hydroxylamine. A histone deacetylase inhibitor, it is marketed under the name Zolinza for the treatment of cutaneous T cell lymphoma (CTCL).	2.5	2	0	dicarboxylic acid diamide; hydroxamic acid	antineoplastic agent; apoptosis inducer; EC 3.5.1.98 (histone deacetylase) inhibitor
sulfamethoxazole Sulfamethoxazole: A bacteriostatic antibacterial agent that interferes with folic acid synthesis in susceptible bacteria. Its broad spectrum of activity has been limited by the development of resistance. (From Martindale, The Extra Pharmacopoeia, 30th ed, p208). sulfamethoxazole : An isoxazole (1,2-oxazole) compound having a methyl substituent at the 5-position and a 4-aminobenzenesulfonamido group at the 3-position.	2.57	2	0	isoxazoles; substituted aniline; sulfonamide antibiotic; sulfonamide	antibacterial agent; antiinfective agent; antimicrobial agent; drug allergen; EC 1.1.1.153 [sepiapterin reductase (L-erythro-7,8-dihydrobiopterin forming)] inhibitor; EC 2.5.1.15 (dihydropteroate synthase) inhibitor; environmental contaminant; epitope; P450 inhibitor; xenobiotic
sulfanilamide [no description available]	2.08	1	0	substituted aniline; sulfonamide antibiotic; sulfonamide	antibacterial agent; drug allergen; EC 4.2.1.1 (carbonic anhydrase) inhibitor
sulfanitran [no description available]	2.08	1	0	sulfonamide
sulfasalazine Sulfasalazine: A drug that is used in the management of inflammatory bowel diseases. Its activity is generally considered to lie in its metabolic breakdown product, 5-aminosalicylic acid (see MESALAMINE) released in the colon. (From Martindale, The Extra Pharmacopoeia, 30th ed, p907). sulfasalazine : An azobenzene consisting of diphenyldiazene having a carboxy substituent at the 4-position, a hydroxy substituent at the 3-position and a 2-pyridylaminosulphonyl substituent at the 4'-position.	2.52	2	0
sulfisoxazole Sulfisoxazole: A short-acting sulfonamide antibacterial with activity against a wide range of gram- negative and gram-positive organisms.. sulfisoxazole : A sulfonamide antibacterial with an oxazole substituent. It has antibiotic activity against a wide range of gram-negative and gram-positive organisms.	2.08	1	0	isoxazoles; sulfonamide antibiotic; sulfonamide	antibacterial drug; drug allergen
sulforaphane sulforaphane: from Cardaria draba L.. sulforaphane : An isothiocyanate having a 4-(methylsulfinyl)butyl group attached to the nitrogen.	2.05	1	0	isothiocyanate; sulfoxide	antineoplastic agent; antioxidant; EC 3.5.1.98 (histone deacetylase) inhibitor; plant metabolite
sulpiride Sulpiride: A dopamine D2-receptor antagonist. It has been used therapeutically as an antidepressant, antipsychotic, and as a digestive aid. (From Merck Index, 11th ed). sulpiride : A member of the class of benzamides obtained from formal condensation between the carboxy group of 2-methoxy-5-sulfamoylbenzoic acid and the primary amino group of (1-ethylpyrrolidin-2-yl)methylamine.	2.08	1	0	benzamides; N-alkylpyrrolidine; sulfonamide	antidepressant; antiemetic; antipsychotic agent; dopaminergic antagonist
sulthiame sulthiame: was heading 1964-94 (see under THIAZINES 1964-90); use THIAZINES to search SULTHIAME 1966-94	2.08	1	0	organic molecular entity
sumatriptan Sumatriptan: A serotonin agonist that acts selectively at 5HT1 receptors. It is used in the treatment of MIGRAINE DISORDERS.. sumatriptan : A sulfonamide that consists of N,N-dimethyltryptamine bearing an additional (N-methylsulfamoyl)methyl substituent at position 5. Selective agonist for a vascular 5-HT1 receptor subtype (probably a member of the 5-HT1D family). Used (in the form of its succinate salt) for the acute treatment of migraine with or without aura in adults.	2.08	1	0	sulfonamide; tryptamines	serotonergic agonist; vasoconstrictor agent
suramin Suramin: A polyanionic compound with an unknown mechanism of action. It is used parenterally in the treatment of African trypanosomiasis and it has been used clinically with diethylcarbamazine to kill the adult Onchocerca. (From AMA Drug Evaluations Annual, 1992, p1643) It has also been shown to have potent antineoplastic properties.. suramin : A member of the class of phenylureas that is urea in which each of the amino groups has been substituted by a 3-({2-methyl-5-[(4,6,8-trisulfo-1-naphthyl)carbamoyl]phenyl}carbamoyl)phenyl group. An activator of both the rabbit skeletal muscle RyR1 and sheep cardiac RyR2 isoform ryanodine receptor channels, it has been used for the treatment of human African trypanosomiasis for over 100 years.	4.24	5	0	naphthalenesulfonic acid; phenylureas; secondary carboxamide	angiogenesis inhibitor; antinematodal drug; antineoplastic agent; apoptosis inhibitor; EC 2.7.11.13 (protein kinase C) inhibitor; GABA antagonist; GABA-gated chloride channel antagonist; purinergic receptor P2 antagonist; ryanodine receptor agonist; trypanocidal drug
gatifloxacin Gatifloxacin: A fluoroquinolone antibacterial agent and DNA TOPOISOMERASE II inhibitor that is used as an ophthalmic solution for the treatment of BACTERIAL CONJUNCTIVITIS.. gatifloxacin : A monocarboxylic acid that is 4-oxo-1,4-dihydroquinoline-3-carboxylic acid which is substituted on the nitrogen by a cyclopropyl group and at positions 6, 7, and 8 by fluoro, 3-methylpiperazin-1-yl, and methoxy groups, respectively. Gatifloxacin is an antibiotic of the fourth-generation fluoroquinolone family, that like other members of that family, inhibits the bacterial topoisomerase type-II enzymes.	2.08	1	0	N-arylpiperazine; organofluorine compound; quinolinemonocarboxylic acid; quinolone antibiotic; quinolone	antiinfective agent; antimicrobial agent; EC 5.99.1.3 [DNA topoisomerase (ATP-hydrolysing)] inhibitor
tazarotene tazarotene: a topical acetylenic retinoid; a topical kerytolytic. tazarotene : The ethyl ester of tazarotenic acid. A prodrug for tazarotenic acid, it is used for the treatment of psoriasis, acne, and sun-damaged skin.	2.08	1	0	acetylenic compound; ethyl ester; pyridines; retinoid; thiochromane	keratolytic drug; prodrug; teratogenic agent
temozolomide [no description available]	2.08	1	0	imidazotetrazine; monocarboxylic acid amide; triazene derivative	alkylating agent; antineoplastic agent; prodrug
terazosin Terazosin: induces decreased blood pressure; used in the treatment of benign prostatic hyperplasia	2.08	1	0	furans; piperazines; primary amino compound; quinazolines	alpha-adrenergic antagonist; antihypertensive agent; antineoplastic agent
terbutaline Terbutaline: A selective beta-2 adrenergic agonist used as a bronchodilator and tocolytic.. terbutaline : A member of the class of phenylethanolamines that is catechol substituted at position 5 by a 2-(tert-butylamino)-1-hydroxyethyl group.	2.47	2	0	phenylethanolamines; resorcinols	anti-asthmatic drug; beta-adrenergic agonist; bronchodilator agent; EC 3.1.1.7 (acetylcholinesterase) inhibitor; hypoglycemic agent; sympathomimetic agent; tocolytic agent
terfenadine Terfenadine: A selective histamine H1-receptor antagonist devoid of central nervous system depressant activity. The drug was used for ALLERGY but withdrawn due to causing LONG QT SYNDROME.	2.78	3	0	diarylmethane
thioridazine Thioridazine: A phenothiazine antipsychotic used in the management of PHYCOSES, including SCHIZOPHRENIA.. thioridazine : A phenothiazine derivative having a methylsulfanyl subsitituent at the 2-position and a (1-methylpiperidin-2-yl)ethyl] group at the N-10 position.	2.77	3	0	phenothiazines; piperidines	alpha-adrenergic antagonist; dopaminergic antagonist; EC 1.8.1.12 (trypanothione-disulfide reductase) inhibitor; EC 3.4.21.26 (prolyl oligopeptidase) inhibitor; first generation antipsychotic; H1-receptor antagonist; serotonergic antagonist
thiotepa Thiotepa: A very toxic alkylating antineoplastic agent also used as an insect sterilant. It causes skin, gastrointestinal, CNS, and bone marrow damage. According to the Fourth Annual Report on Carcinogens (NTP 85-002, 1985), thiotepa may reasonably be anticipated to be a carcinogen (Merck Index, 11th ed).	2.08	1	0	aziridines
tiapride [no description available]	2.08	1	0	benzamides
ticlopidine Ticlopidine: An effective inhibitor of platelet aggregation commonly used in the placement of STENTS in CORONARY ARTERIES.. ticlopidine : A thienopyridine that is 4,5,6,7-tetrahydrothieno[3,2-c]pyridine in which the hydrogen attached to the nitrogen is replaced by an o-chlorobenzyl group.	2.05	1	0	monochlorobenzenes; thienopyridine	anticoagulant; fibrin modulating drug; hematologic agent; P2Y12 receptor antagonist; platelet aggregation inhibitor
tilorone Tilorone: An antiviral agent used as its hydrochloride. It is the first recognized synthetic, low-molecular-weight compound that is an orally active interferon inducer, and is also reported to have antineoplastic and anti-inflammatory actions.. tilorone : A member of the class of fluoren-9-ones that is 9H-fluoren-9-one which is substituted by a 2-(diethylamino)ethoxy group at positions 2 and 7. It is an interferon inducer and a selective alpha7 nicotinic acetylcholine receptor (alpha7 nAChR) agonist. Its hydrochloride salt is used as an antiviral drug.	2.08	1	0	aromatic ether; diether; fluoren-9-ones; tertiary amino compound	anti-inflammatory agent; antineoplastic agent; antiviral agent; interferon inducer; nicotinic acetylcholine receptor agonist
tinidazole Tinidazole: A nitroimidazole alkylating agent that is used as an antitrichomonal agent against TRICHOMONAS VAGINALIS; ENTAMOEBA HISTOLYTICA; and GIARDIA LAMBLIA infections. It also acts as an antibacterial agent for the treatment of BACTERIAL VAGINOSIS and anaerobic bacterial infections.. tinidazole : 1H-imidazole substituted at C-1 by a (2-ethylsulfonyl)ethyl group, at C-2 by a methyl group and at C-5 by a nitro group. It is used as an antiprotozoal, antibacterial agent.	3.61	2	0	imidazoles	antiamoebic agent; antibacterial drug; antiparasitic agent; antiprotozoal drug
tizanidine tizanidine: RN given refers to parent cpd; structure. tizanidine : 2,1,3-Benzothiadiazole substituted at C-4 by a Delta(1)-imidazolin-2-ylamino group and at C-4 by a chloro group. It is an agonist at alpha2-adrenergic receptor sites.	2.08	1	0	benzothiadiazole; imidazoles	alpha-adrenergic agonist; muscle relaxant
nikethamide Nikethamide: A central nervous system stimulant. It was formerly used in the treatment of barbiturate overdose but is now considered to be of no value for such purposes and may be dangerous. (From Martindale, The Extra Pharmacopoeia, 30th ed, p1229)	2.08	1	0	pyridinecarboxamide
tolbutamide Tolbutamide: A sulphonylurea hypoglycemic agent with actions and uses similar to those of CHLORPROPAMIDE. (From Martindale, The Extra Pharmacopoeia, 30th ed, p290). tolbutamide : An N-sulfonylurea that consists of 1-butylurea having a tosyl group attached at the 3-position.	2.47	2	0	N-sulfonylurea	human metabolite; hypoglycemic agent; insulin secretagogue; potassium channel blocker
tolnaftate [no description available]	2.08	1	0	monothiocarbamic ester	antifungal drug
trazodone Trazodone: A serotonin uptake inhibitor that is used as an antidepressive agent. It has been shown to be effective in patients with major depressive disorders and other subsets of depressive disorders. It is generally more useful in depressive disorders associated with insomnia and anxiety. This drug does not aggravate psychotic symptoms in patients with schizophrenia or schizoaffective disorders. (From AMA Drug Evaluations Annual, 1994, p309). trazodone : An N-arylpiperazine in which one nitrogen is substituted by a 3-chlorophenyl group, while the other is substituted by a 3-(3-oxo[1,2,4]triazolo[4,3-a]pyridin-2(3H)-yl)propyl group.	2.08	1	0	monochlorobenzenes; N-alkylpiperazine; N-arylpiperazine; triazolopyridine	adrenergic antagonist; antidepressant; anxiolytic drug; H1-receptor antagonist; sedative; serotonin uptake inhibitor
triamterene Triamterene: A pteridinetriamine compound that inhibits SODIUM reabsorption through SODIUM CHANNELS in renal EPITHELIAL CELLS.. triamterene : Pteridine substituted at positions 2, 4 and 7 with amino groups and at position 6 with a phenyl group. A sodium channel blocker, it is used as a diuretic in the treatment of hypertension and oedema.	2.47	2	0	pteridines	diuretic; sodium channel blocker
triazolam Triazolam: A short-acting benzodiazepine used in the treatment of insomnia. Some countries temporarily withdrew triazolam from the market because of concerns about adverse reactions, mostly psychological, associated with higher dose ranges. Its use at lower doses with appropriate care and labeling has been reaffirmed by the FDA and most other countries.	2.05	1	0	triazolobenzodiazepine	sedative
triclosan [no description available]	2.76	3	0	aromatic ether; dichlorobenzene; monochlorobenzenes; phenols	antibacterial agent; antimalarial; drug allergen; EC 1.3.1.9 [enoyl-[acyl-carrier-protein] reductase (NADH)] inhibitor; EC 1.5.1.3 (dihydrofolate reductase) inhibitor; fungicide; persistent organic pollutant; xenobiotic
trifluoperazine [no description available]	2.05	1	0	N-alkylpiperazine; N-methylpiperazine; organofluorine compound; phenothiazines	antiemetic; calmodulin antagonist; dopaminergic antagonist; EC 1.8.1.12 (trypanothione-disulfide reductase) inhibitor; EC 5.3.3.5 (cholestenol Delta-isomerase) inhibitor; phenothiazine antipsychotic drug
trifluralin Trifluralin: A microtubule-disrupting pre-emergence herbicide.. trifluralin : A substituted aniline that is N,N-dipropylaniline substituted by a nitro groups at positions 2 and 6 and a trifluoromethyl group at position 4. It is an agrochemical used as a pre-emergence herbicide.	2.7	3	0	(trifluoromethyl)benzenes; C-nitro compound; substituted aniline	agrochemical; environmental contaminant; herbicide; xenobiotic
trimethadione Trimethadione: An anticonvulsant effective in absence seizures, but generally reserved for refractory cases because of its toxicity. (From AMA Drug Evaluations Annual, 1994, p378). trimethadione : An oxazolidinone that is 1,3-oxazolidine-2,4-dione substituted by methyl groups at positions 3, 5 and 5. It is an antiepileptic agent.	2.05	1	0	oxazolidinone	anticonvulsant; geroprotector
trimethoprim Trimethoprim: A pyrimidine inhibitor of dihydrofolate reductase, it is an antibacterial related to PYRIMETHAMINE. It is potentiated by SULFONAMIDES and the TRIMETHOPRIM, SULFAMETHOXAZOLE DRUG COMBINATION is the form most often used. It is sometimes used alone as an antimalarial. TRIMETHOPRIM RESISTANCE has been reported.. trimethoprim : An aminopyrimidine antibiotic whose structure consists of pyrimidine 2,4-diamine and 1,2,3-trimethoxybenzene moieties linked by a methylene bridge.	2.47	2	0	aminopyrimidine; methoxybenzenes	antibacterial drug; diuretic; drug allergen; EC 1.5.1.3 (dihydrofolate reductase) inhibitor; environmental contaminant; xenobiotic
troglitazone Troglitazone: A chroman and thiazolidinedione derivative that acts as a PEROXISOME PROLIFERATOR-ACTIVATED RECEPTORS (PPAR) agonist. It was formerly used in the treatment of TYPE 2 DIABETES MELLITUS, but has been withdrawn due to hepatotoxicity.	2.08	1	0	chromanes; thiazolidinone	anticoagulant; anticonvulsant; antineoplastic agent; antioxidant; EC 6.2.1.3 (long-chain-fatty-acid--CoA ligase) inhibitor; ferroptosis inhibitor; hypoglycemic agent; platelet aggregation inhibitor; vasodilator agent
thenoyltrifluoroacetone Thenoyltrifluoroacetone: Chelating agent and inhibitor of cellular respiration.	2.08	1	0
delavirdine Delavirdine: A potent, non-nucleoside reverse transcriptase inhibitor with activity specific for HIV-1.. delavirdine : The amide resulting from the formal condensation of 5-[(methylsulfonyl)amino]-1H-indole-2-carboxylic acid and 4-amino group of 1-[3-(isopropylamino)pyridin-2-yl]piperazine, delavirdine is a non-nucleoside reverse transcriptase inhibitor with activity specific for HIV-1. Viral resistance emerges rapidly when delavirdine is used alone, so it is therefore used (as the methanesulfonic acid salt) with other antiretrovirals for combination therapy of HIV infection.	2.1	1	0	aminopyridine; indolecarboxamide; N-acylpiperazine; sulfonamide	antiviral drug; HIV-1 reverse transcriptase inhibitor
undecylenic acid undecylenic acid: a fatty acid with a terminal double bond. 10-undecenoic acid : An undecenoic acid having its double bond in the 10-position. It is derived from castor oil and is used for the treatment of skin problems.. undecenoic acid : A C11, straight-chain fatty acid carrying a C=C double bond at any position.	2.08	1	0	undecenoic acid	antifungal drug; plant metabolite
urapidil [no description available]	2.08	1	0	piperazines
venlafaxine venlafaxine : A tertiary amino compound that is N,N-dimethylethanamine substituted at position 1 by a 1-hydroxycyclohexyl and 4-methoxyphenyl group.	2.08	1	0	cyclohexanols; monomethoxybenzene; tertiary alcohol; tertiary amino compound	adrenergic uptake inhibitor; analgesic; antidepressant; dopamine uptake inhibitor; environmental contaminant; serotonin uptake inhibitor; xenobiotic
vigabatrin [no description available]	2.08	1	0	gamma-amino acid	anticonvulsant; EC 2.6.1.19 (4-aminobutyrate--2-oxoglutarate transaminase) inhibitor
pirinixic acid pirinixic acid: structure	2.08	1	0	aryl sulfide; organochlorine compound; pyrimidines
ici 204,219 zafirlukast: a leukotriene D4 receptor antagonist	2.08	1	0	carbamate ester; indoles; N-sulfonylcarboxamide	anti-asthmatic agent; leukotriene antagonist
zaleplon zaleplon: an azabicyclo(4.3.0)nonane; a nonbenzodiazepine; one of the so-called of Z drugs (zopiclone, eszopiclone, zolpidem, and zaleplon) for which there is some correlation with tumors; a hypnotic with less marked effect on psychomotor functions compared to lorazepam. zaleplon : A pyrazolo[1,5-a]pyrimidine having a nitrile group at position 3 and a 3-(N-ethylacetamido)phenyl substituent at the 7-position.	2.08	1	0	nitrile; pyrazolopyrimidine	anticonvulsant; anxiolytic drug; central nervous system depressant; sedative
zonisamide Zonisamide: A benzisoxazole and sulfonamide derivative that acts as a CALCIUM CHANNEL blocker. It is used primarily as an adjunctive antiepileptic agent for the treatment of PARTIAL SEIZURES, with or without secondary generalization.. zonisamide : A 1,2-benzoxazole compound having a sulfamoylmethyl substituent at the 3-position.	2.49	2	0	1,2-benzoxazoles; sulfonamide	anticonvulsant; antioxidant; central nervous system drug; protective agent; T-type calcium channel blocker
zopiclone zopiclone: S(+)-enantiomer of racemic zopiclone; azabicyclo(4.3.0)nonane; a nonbenzodiazepine; one of the so-called of Z drugs (zopiclone, eszopiclone, zolpidem, and zaleplon) for which there is some correlation with tumors; was term of zopiclone 2004-2007. zopiclone : A pyrrolo[3,4-b]pyrazine compound having a 4-methylpiperazine-1-carboxyl group at the 5-position, a 5-chloropyridin-2-yl group at the 6-position and an oxo-substituent at the 7-position.	2.47	2	0	monochloropyridine; pyrrolopyrazine	central nervous system depressant; sedative
mitomycin Mitomycin: An antineoplastic antibiotic produced by Streptomyces caespitosus. It is one of the bi- or tri-functional ALKYLATING AGENTS causing cross-linking of DNA and inhibition of DNA synthesis.. mitomycin : A family of aziridine-containing natural products isolated from Streptomyces caespitosus or Streptomyces lavendulae.	2.21	1	0	mitomycin	alkylating agent; antineoplastic agent
corticosterone [no description available]	2.11	1	0	11beta-hydroxy steroid; 20-oxo steroid; 21-hydroxy steroid; 3-oxo-Delta(4) steroid; C21-steroid; glucocorticoid; primary alpha-hydroxy ketone	human metabolite; mouse metabolite
prednisolone Prednisolone: A glucocorticoid with the general properties of the corticosteroids. It is the drug of choice for all conditions in which routine systemic corticosteroid therapy is indicated, except adrenal deficiency states.. prednisolone : A glucocorticoid that is prednisone in which the oxo group at position 11 has been reduced to the corresponding beta-hydroxy group. It is a drug metabolite of prednisone.	2.08	1	0	11beta-hydroxy steroid; 17alpha-hydroxy steroid; 20-oxo steroid; 21-hydroxy steroid; 3-oxo-Delta(1),Delta(4)-steroid; C21-steroid; glucocorticoid; primary alpha-hydroxy ketone; tertiary alpha-hydroxy ketone	adrenergic agent; anti-inflammatory drug; antineoplastic agent; drug metabolite; environmental contaminant; immunosuppressive agent; xenobiotic
reserpine Reserpine: An alkaloid found in the roots of Rauwolfia serpentina and R. vomitoria. Reserpine inhibits the uptake of norepinephrine into storage vesicles resulting in depletion of catecholamines and serotonin from central and peripheral axon terminals. It has been used as an antihypertensive and an antipsychotic as well as a research tool, but its adverse effects limit its clinical use.. reserpine : An alkaloid found in the roots of Rauwolfia serpentina and R. vomitoria.	2.47	2	0	alkaloid ester; methyl ester; yohimban alkaloid	adrenergic uptake inhibitor; antihypertensive agent; EC 3.4.21.26 (prolyl oligopeptidase) inhibitor; environmental contaminant; first generation antipsychotic; plant metabolite; xenobiotic
thymidine [no description available]	2.41	2	0	pyrimidine 2'-deoxyribonucleoside	Escherichia coli metabolite; human metabolite; metabolite; mouse metabolite
penicillamine Penicillamine: 3-Mercapto-D-valine. The most characteristic degradation product of the penicillin antibiotics. It is used as an antirheumatic and as a chelating agent in Wilson's disease.. penicillamine : An alpha-amino acid having the structure of valine substituted at the beta position with a sulfanyl group.	2.08	1	0	non-proteinogenic alpha-amino acid; penicillamine	antirheumatic drug; chelator; copper chelator; drug allergen
prednisone Prednisone: A synthetic anti-inflammatory glucocorticoid derived from CORTISONE. It is biologically inert and converted to PREDNISOLONE in the liver.. prednisone : A synthetic glucocorticoid drug that is particularly effective as an immunosuppressant, and affects virtually all of the immune system. Prednisone is a prodrug that is converted by the liver into prednisolone (a beta-hydroxy group instead of the oxo group at position 11), which is the active drug and also a steroid.	1.98	1	0	11-oxo steroid; 17alpha-hydroxy steroid; 20-oxo steroid; 21-hydroxy steroid; 3-oxo-Delta(1),Delta(4)-steroid; C21-steroid; glucocorticoid; primary alpha-hydroxy ketone; tertiary alpha-hydroxy ketone	adrenergic agent; anti-inflammatory drug; antineoplastic agent; immunosuppressive agent; prodrug
paramethasone Paramethasone: A glucocorticoid with the general properties of corticosteroids. It has been used by mouth in the treatment of all conditions in which corticosteroid therapy is indicated except adrenal-deficiency states for which its lack of sodium-retaining properties makes it less suitable than HYDROCORTISONE with supplementary FLUDROCORTISONE. (From Martindale, The Extra Pharmacopoeia, 30th ed, p737)	2.05	1	0	fluorinated steroid
dehydroepiandrosterone Dehydroepiandrosterone: A major C19 steroid produced by the ADRENAL CORTEX. It is also produced in small quantities in the TESTIS and the OVARY. Dehydroepiandrosterone (DHEA) can be converted to TESTOSTERONE; ANDROSTENEDIONE; ESTRADIOL; and ESTRONE. Most of DHEA is sulfated (DEHYDROEPIANDROSTERONE SULFATE) before secretion.. dehydroepiandrosterone : An androstanoid that is androst-5-ene substituted by a beta-hydroxy group at position 3 and an oxo group at position 17. It is a naturally occurring steroid hormone produced by the adrenal glands.	3.86	2	0	17-oxo steroid; 3beta-hydroxy-Delta(5)-steroid; androstanoid	androgen; human metabolite; mouse metabolite
carbon tetrachloride Carbon Tetrachloride: A solvent for oils, fats, lacquers, varnishes, rubber waxes, and resins, and a starting material in the manufacturing of organic compounds. Poisoning by inhalation, ingestion or skin absorption is possible and may be fatal. (Merck Index, 11th ed). tetrachloromethane : A chlorocarbon that is methane in which all the hydrogens have been replaced by chloro groups.	2.4	2	0	chlorocarbon; chloromethanes	hepatotoxic agent; refrigerant
chloramphenicol Amphenicol: Chloramphenicol and its derivatives.	3.96	3	0	C-nitro compound; carboxamide; diol; organochlorine compound	antibacterial drug; antimicrobial agent; Escherichia coli metabolite; geroprotector; Mycoplasma genitalium metabolite; protein synthesis inhibitor
cetrimonium bromide cetyltrimethylammonium bromide : The organic bromide salt that is the bromide salt of cetyltrimethylammonium; one of the components of the topical antiseptic cetrimide.	2.05	1	0	organic bromide salt; quaternary ammonium salt	detergent; surfactant
ethinyl estradiol Ethinyl Estradiol: A semisynthetic alkylated ESTRADIOL with a 17-alpha-ethinyl substitution. It has high estrogenic potency when administered orally, and is often used as the estrogenic component in ORAL CONTRACEPTIVES.. 17alpha-ethynylestradiol : A 3-hydroxy steroid that is estradiol substituted by a ethynyl group at position 17. It is a xenoestrogen synthesized from estradiol and has been shown to exhibit high estrogenic potency on oral administration.	2.08	1	0	17-hydroxy steroid; 3-hydroxy steroid; terminal acetylenic compound	xenoestrogen
tubocurarine Tubocurarine: A neuromuscular blocker and active ingredient in CURARE; plant based alkaloid of Menispermaceae.. tubocurarine : A benzylisoquinoline alkaloid muscle relaxant which constitutes the active component of curare.. isoquinoline alkaloid : Any alkaloid that has a structure based on an isoquinoline nucleus. They are derived from the amino acids like tyrosine and phenylalanine.	2.08	1	0	bisbenzylisoquinoline alkaloid	drug allergen; muscle relaxant; nicotinic antagonist
apomorphine Apomorphine: A derivative of morphine that is a dopamine D2 agonist. It is a powerful emetic and has been used for that effect in acute poisoning. It has also been used in the diagnosis and treatment of parkinsonism, but its adverse effects limit its use.	2.08	1	0	aporphine alkaloid	alpha-adrenergic drug; antidyskinesia agent; antiparkinson drug; dopamine agonist; emetic; serotonergic drug
puromycin aminonucleoside 3'-amino-3'-deoxy-N(6),N(6)-dimethyladenosine: structure in first source. 3'-amino-3'-deoxy-N(6),N(6)-dimethyladenosine : Puromycin derivative that lacks the methoxyphenylalanyl group on the amine of the sugar ring.	2.17	1	0	3'-deoxyribonucleoside; adenosines
adenosine diphosphate Adenosine Diphosphate: Adenosine 5'-(trihydrogen diphosphate). An adenine nucleotide containing two phosphate groups esterified to the sugar moiety at the 5'-position.	2.1	1	0	adenosine 5'-phosphate; purine ribonucleoside 5'-diphosphate	fundamental metabolite; human metabolite
2,3,4,6-tetrachlorophenol 2,3,4,6-tetrachlorophenol: RN given refers to parent cpd; see also record for tetrachlorophenol with locants for chloro groups not specified. 2,3,4,6-tetrachlorophenol : A tetrachlorophenol in which the chlorines are located at positions 2, 3, 4, and 6.	2.02	1	0	tetrachlorophenol	xenobiotic metabolite
uridine [no description available]	1.96	1	0	uridines	drug metabolite; fundamental metabolite; human metabolite
kanamycin a Kanamycin: Antibiotic complex produced by Streptomyces kanamyceticus from Japanese soil. Comprises 3 components: kanamycin A, the major component, and kanamycins B and C, the minor components.. kanamycin : Kanamycin is a naturally occurring antibiotic complex from Streptomyces kanamyceticus that consists of several components: kanamycin A, the major component (also usually designated as kanamycin), and kanamycins B, C, D and X the minor components.	2.08	1	0	kanamycins	bacterial metabolite
bromodeoxyuridine Bromodeoxyuridine: A nucleoside that substitutes for thymidine in DNA and thus acts as an antimetabolite. It causes breaks in chromosomes and has been proposed as an antiviral and antineoplastic agent. It has been given orphan drug status for use in the treatment of primary brain tumors.	2.04	1	0	pyrimidine 2'-deoxyribonucleoside	antimetabolite; antineoplastic agent
carbostyril Quinolones: A group of derivatives of naphthyridine carboxylic acid, quinoline carboxylic acid, or NALIDIXIC ACID.. quinolin-2(1H)-one : A quinolone that is 1,2-dihydroquinoline substituted by an oxo group at position 2.	2.46	2	0	monohydroxyquinoline; quinolone	bacterial xenobiotic metabolite
levodopa Levodopa: The naturally occurring form of DIHYDROXYPHENYLALANINE and the immediate precursor of DOPAMINE. Unlike dopamine itself, it can be taken orally and crosses the blood-brain barrier. It is rapidly taken up by dopaminergic neurons and converted to DOPAMINE. It is used for the treatment of PARKINSONIAN DISORDERS and is usually given with agents that inhibit its conversion to dopamine outside of the central nervous system.. L-dopa : An optically active form of dopa having L-configuration. Used to treat the stiffness, tremors, spasms, and poor muscle control of Parkinson's disease	2.47	2	0	amino acid zwitterion; dopa; L-tyrosine derivative; non-proteinogenic L-alpha-amino acid	allelochemical; antidyskinesia agent; antiparkinson drug; dopaminergic agent; hapten; human metabolite; mouse metabolite; neurotoxin; plant growth retardant; plant metabolite; prodrug
tyrosine Tyrosine: A non-essential amino acid. In animals it is synthesized from PHENYLALANINE. It is also the precursor of EPINEPHRINE; THYROID HORMONES; and melanin.. tyrosine : An alpha-amino acid that is phenylalanine bearing a hydroxy substituent at position 4 on the phenyl ring.	2.1	1	0	amino acid zwitterion; erythrose 4-phosphate/phosphoenolpyruvate family amino acid; L-alpha-amino acid; proteinogenic amino acid; tyrosine	EC 1.3.1.43 (arogenate dehydrogenase) inhibitor; fundamental metabolite; micronutrient; nutraceutical
niridazole Niridazole: An antischistosomal agent that has become obsolete.	3.06	1	0	1,3-thiazoles; C-nitro compound
methylene blue Methylene Blue: A compound consisting of dark green crystals or crystalline powder, having a bronze-like luster. Solutions in water or alcohol have a deep blue color. Methylene blue is used as a bacteriologic stain and as an indicator. It inhibits GUANYLATE CYCLASE, and has been used to treat cyanide poisoning and to lower levels of METHEMOGLOBIN.. methylene blue : An organic chloride salt having 3,7-bis(dimethylamino)phenothiazin-5-ium as the counterion. A commonly used dye that also exhibits antioxidant, antimalarial, antidepressant and cardioprotective properties.	2.21	1	0	organic chloride salt	acid-base indicator; antidepressant; antimalarial; antimicrobial agent; antioxidant; cardioprotective agent; EC 1.4.3.4 (monoamine oxidase) inhibitor; EC 3.1.1.8 (cholinesterase) inhibitor; EC 4.6.1.2 (guanylate cyclase) inhibitor; fluorochrome; histological dye; neuroprotective agent; physical tracer
leucine Leucine: An essential branched-chain amino acid important for hemoglobin formation.. leucine : A branched-chain amino acid that consists of glycine in which one of the hydrogens attached to the alpha-carbon is substituted by an isobutyl group.	1.96	1	0	amino acid zwitterion; L-alpha-amino acid; leucine; proteinogenic amino acid; pyruvate family amino acid	algal metabolite; Escherichia coli metabolite; human metabolite; mouse metabolite; plant metabolite; Saccharomyces cerevisiae metabolite
lactose Lactose: A disaccharide of GLUCOSE and GALACTOSE in human and cow milk. It is used in pharmacy for tablets, in medicine as a nutrient, and in industry.. lactose : A glycosylglucose disaccharide, found most notably in milk, that consists of D-galactose and D-glucose fragments bonded through a beta-1->4 glycosidic linkage. The glucose fragment can be in either the alpha- or beta-pyranose form, whereas the galactose fragment can only have the beta-pyranose form.. beta-lactose : The beta-anomer of lactose.	2.6	1	0	lactose
colchicine (S)-colchicine : A colchicine that has (S)-configuration. It is a secondary metabolite, has anti-inflammatory properties and is used to treat gout, crystal-induced joint inflammation, familial Mediterranean fever, and many other conditions.	2.08	1	0	alkaloid; colchicine	anti-inflammatory agent; gout suppressant; mutagen
cycloheximide Cycloheximide: Antibiotic substance isolated from streptomycin-producing strains of Streptomyces griseus. It acts by inhibiting elongation during protein synthesis.. cycloheximide : A dicarboximide that is 4-(2-hydroxyethyl)piperidine-2,6-dione in which one of the hydrogens attached to the carbon bearing the hydroxy group is replaced by a 3,5-dimethyl-2-oxocyclohexyl group. It is an antibiotic produced by the bacterium Streptomyces griseus.	1.99	1	0	antibiotic fungicide; cyclic ketone; dicarboximide; piperidine antibiotic; piperidones; secondary alcohol	anticoronaviral agent; bacterial metabolite; ferroptosis inhibitor; neuroprotective agent; protein synthesis inhibitor
fluocinolone acetonide Fluocinolone Acetonide: A glucocorticoid derivative used topically in the treatment of various skin disorders. It is usually employed as a cream, gel, lotion, or ointment. It has also been used topically in the treatment of inflammatory eye, ear, and nose disorders. (From Martindale, The Extra Pharmacopoeia, 30th ed, p732). fluocinolone acetonide : A fluorinated steroid that is flunisolide in which the hydrogen at position 9 is replaced by fluorine. A corticosteroid with glucocorticoid activity, it is used (both as the anhydrous form and as the dihydrate) in creams, gels and ointments for the treatment of various skin disorders.	2.05	1	0	11beta-hydroxy steroid; 20-oxo steroid; 21-hydroxy steroid; 3-oxo-Delta(1),Delta(4)-steroid; cyclic ketal; fluorinated steroid; glucocorticoid; organic heteropentacyclic compound; primary alpha-hydroxy ketone	anti-inflammatory drug; antipruritic drug
triamcinolone diacetate triamcinolone diacetate: lysyl oxidase antagonist; Polcortolon may also refers to triamcinolone	2.08	1	0	corticosteroid hormone
tubercidin Tubercidin: An antibiotic purine ribonucleoside that readily substitutes for adenosine in the biological system, but its incorporation into DNA and RNA has an inhibitory effect on the metabolism of these nucleic acids.. tubercidin : An N-glycosylpyrrolopyrimidine that is adenosine in which the in the 5-membered ring that is not attached to the ribose moiety is replaced by a carbon. Tubercidin is produced in the culture broth of Streptomyces tubericidus.	3.21	4	0	antibiotic antifungal agent; N-glycosylpyrrolopyrimidine; ribonucleoside	antimetabolite; antineoplastic agent; bacterial metabolite
ampicillin Ampicillin: Semi-synthetic derivative of penicillin that functions as an orally active broad-spectrum antibiotic.. ampicillin : A penicillin in which the substituent at position 6 of the penam ring is a 2-amino-2-phenylacetamido group.	2.52	2	0	beta-lactam antibiotic; penicillin allergen; penicillin	antibacterial drug
mannitol [no description available]	2.05	1	0	mannitol	allergen; antiglaucoma drug; compatible osmolytes; Escherichia coli metabolite; food anticaking agent; food bulking agent; food humectant; food stabiliser; food thickening agent; hapten; metabolite; osmotic diuretic; sweetening agent
cytarabine [no description available]	2.47	2	0	beta-D-arabinoside; monosaccharide derivative; pyrimidine nucleoside	antimetabolite; antineoplastic agent; antiviral agent; immunosuppressive agent
4-toluenesulfonamide 4-toluenesulfonamide: RN given refers to parent cpd. toluene-4-sulfonamide : A sulfonamide that is benzenesulfonamide bearing a methyl group at position 4.	2.08	1	0	sulfonamide
medroxyprogesterone acetate [no description available]	2.08	1	0	20-oxo steroid; 3-oxo-Delta(4) steroid; acetate ester; corticosteroid; steroid ester	adjuvant; androgen; antineoplastic agent; antioxidant; female contraceptive drug; inhibitor; progestin; synthetic oral contraceptive
sulfobromophthalein sodium bromosulfophthalein sodium : An organic sodium salt that is the disodium salt of bromosulfophthalein.. bromosulfophthalein : An organosulfonic acid that consists of phthalide bearing four bromo substituents at positions 4, 5, 6 and 7 as well as two 4-hydroxy-3-sulfophenyl groups both located at position 1.	2.05	1	0	organic sodium salt	dye
cordycepin [no description available]	2.17	1	0	3'-deoxyribonucleoside; adenosines	antimetabolite; nucleoside antibiotic
triamcinolone acetonide Triamcinolone Acetonide: An esterified form of TRIAMCINOLONE. It is an anti-inflammatory glucocorticoid used topically in the treatment of various skin disorders. Intralesional, intramuscular, and intra-articular injections are also administered under certain conditions.. triamcinolone acetonide : A synthetic glucocorticoid that is the 16,17-acetonide of triamcinolone. Used to treat various skin infections.	2.08	1	0	11beta-hydroxy steroid; 20-oxo steroid; 21-hydroxy steroid; 3-oxo-Delta(4) steroid; cyclic ketal; fluorinated steroid; glucocorticoid; primary alpha-hydroxy ketone	anti-allergic agent; anti-inflammatory drug
methylprednisolone Methylprednisolone: A PREDNISOLONE derivative with similar anti-inflammatory action.. 6alpha-methylprednisolone : The 6alpha-stereoisomer of 6-methylprednisolone.	2.47	2	0	6-methylprednisolone; primary alpha-hydroxy ketone; tertiary alpha-hydroxy ketone	adrenergic agent; anti-inflammatory drug; antiemetic; environmental contaminant; neuroprotective agent; xenobiotic
lawsone lawsone: a molluscacide from leaves of Lawsonia inermis L. topical sunscreening agent; structure; powdered leaves of Lawsonia inermis(Lythraceae) used as brown hair dye. lawsone : 1,4-Naphthoquinone carrying a hydroxy function at C-2. It is obtained from the leaves of Lawsonia inermis.	2.52	2	0
rotenone Derris: A plant genus of the family FABACEAE. The root is a source of rotenoids (ROTENONE) and flavonoids. Some species of Pongamia have been reclassified to this genus and some to MILLETTIA. Some species of Deguelia have been reclassified to this genus.. rotenoid : Members of the class of tetrahydrochromenochromene that consists of a cis-fused tetrahydrochromeno[3,4-b]chromene skeleton and its substituted derivatives. The term was originally restricted to natural products, but is now also used to describe semi-synthetic and fully synthetic compounds.	2.08	1	0	organic heteropentacyclic compound; rotenones	antineoplastic agent; metabolite; mitochondrial NADH:ubiquinone reductase inhibitor; phytogenic insecticide; piscicide; toxin
fluorene [no description available]	2.21	1	0	ortho-fused polycyclic arene; ortho-fused tricyclic hydrocarbon
n-vinyl-2-pyrrolidinone N-vinyl-2-pyrrolidinone: monomer of POVIDONE; structure given in first source	2.78	3	0	pyrrolidin-2-ones
pseudoephedrine Pseudoephedrine: A phenethylamine that is an isomer of EPHEDRINE which has less central nervous system effects and usage is mainly for respiratory tract decongestion.. pseudoephedrine : A member of the class of the class of phenylethanolamines that is (1S)-2-(methylamino)-1-phenylethan-1-ol in which the pro-S hydrogen at position 2 is replaced by a methyl group.	2.05	1	0	phenylethanolamines; secondary alcohol; secondary amino compound	anti-asthmatic drug; bronchodilator agent; central nervous system drug; nasal decongestant; plant metabolite; sympathomimetic agent; vasoconstrictor agent; xenobiotic
quinoxalines quinoxaline : A naphthyridine in which the nitrogens are at positions 1 and 4.	2.1	1	0	mancude organic heterobicyclic parent; naphthyridine; ortho-fused heteroarene
tolonium chloride Tolonium Chloride: A phenothiazine that has been used as a hemostatic, a biological stain, and a dye for wool and silk. Tolonium chloride has also been used as a diagnostic aid for oral and gastric neoplasms and in the identification of the parathyroid gland in thyroid surgery.. tolonium chloride : An organic chloride salt having 3-amino-7-(dimethylamino)-2-methylphenothiazin-5-ium (tolonium) as the counterion. It is a blue nuclear counterstain that can be used to demonstrate Nissl substance and is also useful for staining mast cell granules, both in metachromatic and orthochromatic techniques.	2.21	1	0
xanthenes Xanthenes: Compounds with three aromatic rings in linear arrangement with an OXYGEN in the center ring.	2.03	1	0	xanthene
phenothiazine 10H-phenothiazine : The 10H-tautomer of phenothiazine.	2.25	1	0	phenothiazine	ferroptosis inhibitor; plant metabolite; radical scavenger
butylparaben [no description available]	2.13	1	0	organic molecular entity
4-butyrolactone 4-Butyrolactone: One of the FURANS with a carbonyl thereby forming a cyclic lactone. It is an endogenous compound made from gamma-aminobutyrate and is the precursor of gamma-hydroxybutyrate. It is also used as a pharmacological agent and solvent.. tetrahydrofuranone : Any oxolane having an oxo- substituent at any position on the tetrahydrofuran ring.. gamma-butyrolactone : A butan-4-olide that is tetrahydrofuran substituted by an oxo group at position 2.	2.08	1	0	butan-4-olide	metabolite; neurotoxin
2-hydroxy-2-phenylacetic acid (1,2,2,6-tetramethyl-4-piperidinyl) ester [no description available]	2.41	1	0	piperidines
acetoacetanilide N-phenylacetoacetamide: structure in first source	2.05	1	0
glyoxal [no description available]	2.07	1	0	dialdehyde	agrochemical; allergen; pesticide; plant growth regulator
pentane Pentanes: Five-carbon saturated hydrocarbon group of the methane series. Include isomers and derivatives.. pentane : A straight chain alkane consisting of 5 carbon atoms.	1.96	1	0	alkane; volatile organic compound	non-polar solvent; refrigerant
pyrroles 1H-pyrrole : A tautomer of pyrrole that has the double bonds at positions 2 and 4.. pyrrole : A five-membered monocyclic heteroarene comprising one NH and four CH units which forms the parent compound of the pyrrole group of compounds. Its five-membered ring structure has three tautomers. A 'closed class'.. azole : Any monocyclic heteroarene consisting of a five-membered ring containing nitrogen. Azoles can also contain one or more other non-carbon atoms, such as nitrogen, sulfur or oxygen.	2.15	1	0	pyrrole; secondary amine
thiophenes Thiophenes: A monocyclic heteroarene furan in which the oxygen atom is replaced by a sulfur.. thiophenes : Compounds containing at least one thiophene ring.	2.13	1	0	mancude organic heteromonocyclic parent; monocyclic heteroarene; thiophenes; volatile organic compound	non-polar solvent
phenformin Phenformin: A biguanide hypoglycemic agent with actions and uses similar to those of METFORMIN. Although it is generally considered to be associated with an unacceptably high incidence of lactic acidosis, often fatal, it is still available in some countries. (From Martindale, The Extra Pharmacopoeia, 30th ed, p290). phenformin : A member of the class of biguanides that is biguanide in which one of the terminal nitrogen atoms is substituted by a 2-phenylethyl group. It was used as an anti-diabetic drug but was later withdrawn from the market due to potential risk of lactic acidosis.	2.47	2	0	biguanides	antineoplastic agent; geroprotector; hypoglycemic agent
dichlone dichlone: structure	2.48	2	0
framycetin Framycetin: A component of NEOMYCIN that is produced by Streptomyces fradiae. On hydrolysis it yields neamine and neobiosamine B. (From Merck Index, 11th ed). framycetin : A tetracyclic antibacterial agent derived from neomycin, being a glycoside ester of neamine and neobiosamine B.	1.96	1	0	aminoglycoside	allergen; antibacterial drug; Escherichia coli metabolite
2-amino-5-nitrothiazole 2-amino-5-nitrothiazole: RN given refers to cpd without isomeric designation	2.1	1	0	C-nitro compound; thiazoles
carzenide [no description available]	2.08	1	0	sulfonamide
nithiamide [no description available]	2.1	1	0	acetamides; aromatic amide
sterogenol hexadecylpyridinium bromide: structure in first source. cetylpyridinium bromide : A pyridinium salt that has N-hexadecylpyridinium as the cation and bromide as the anion.	2.05	1	0	bromide salt; pyridinium salt	antiseptic drug; EC 2.7.11.18 (myosin-light-chain kinase) inhibitor; surfactant
potassium cyanide [no description available]	2.25	1	0	cyanide salt; one-carbon compound; potassium salt	EC 1.15.1.1 (superoxide dismutase) inhibitor; EC 1.9.3.1 (cytochrome c oxidase) inhibitor; neurotoxin
cycloguanil cycloguanil: the active metabolite of proguanil; antifolate drug; structure in first source. cycloguanil : A triazine in which a 1,6-dihydro-1,3,5-triazine ring is substituted at N-1 by a 4-chlorophenyl group, at C-2 and -4 by amino groups and at C-6 by gem-dimethyl groups. A dihydrofolate reductase inhibitor, it is a metabolite of the antimalarial drug proguanil.	2.05	1	0	triazines	antifolate; antiinfective agent; antimalarial; antiparasitic agent; antiprotozoal drug; EC 1.5.1.3 (dihydrofolate reductase) inhibitor
diazooxonorleucine Diazooxonorleucine: An amino acid that inhibits phosphate-activated glutaminase and interferes with glutamine metabolism. It is an antineoplastic antibiotic produced by an unidentified species of Streptomyces from Peruvian soil. (From Merck Index, 11th ed). 6-diazo-5-oxo-L-norleucine : A non-proteinogenic L-alpha-amino acid that is L-norleucine which is substituted at position 5 by an oxo group and at position 6 by a diazo group. It is as inhibitor of various glutamine-utilising enzymes.	1.97	1	0	amino acid zwitterion; diazo compound; ketone; non-proteinogenic L-alpha-amino acid	analgesic; antibacterial agent; antimetabolite; antineoplastic agent; antiviral agent; apoptosis inducer; bacterial metabolite; EC 2.4.2.14 (amidophosphoribosyltransferase) inhibitor; EC 3.5.1.2 (glutaminase) inhibitor; EC 6.3.4.2 [CTP synthase (glutamine hydrolyzing)] inhibitor; EC 6.3.5.1 [NAD(+) synthase (glutamine-hydrolysing)] inhibitor; EC 6.3.5.2 [GMP synthase (glutamine-hydrolysing)] inhibitor; EC 6.3.5.3 (phosphoribosylformylglycinamidine synthase) inhibitor; EC 6.3.5.4 [asparagine synthase (glutamine-hydrolysing)] inhibitor; EC 6.3.5.5 [carbamoyl-phosphate synthase (glutamine-hydrolysing)] inhibitor; glutamine antagonist
quinazolines Quinazolines: A group of aromatic heterocyclic compounds that contain a bicyclic structure with two fused six-membered aromatic rings, a benzene ring and a pyrimidine ring.. quinazoline : A mancude organic heterobicyclic parent that is naphthalene in which the carbon atoms at positions 1 and 3 have been replaced by nitrogen atoms.. quinazolines : Any organic heterobicyclic compound based on a quinazoline skeleton and its substituted derivatives.	2.47	2	0	azaarene; mancude organic heterobicyclic parent; ortho-fused heteroarene; quinazolines
indazoles Indazoles: A group of heterocyclic aromatic organic compounds consisting of the fusion of BENZENE and PYRAZOLES.	4.12	4	0	indazole
isoxazoles Isoxazoles: Azoles with an OXYGEN and a NITROGEN next to each other at the 1,2 positions, in contrast to OXAZOLES that have nitrogens at the 1,3 positions.. isoxazole : A monocyclic heteroarene with a structure consisting of a 5-membered ring containing three carbon atoms and an oxygen and nitrogen atom adjacent to each other. It is the parent of the class of isoxazoles.. isoxazoles : Oxazoles in which the N and O atoms are adjacent.	2.6	1	0	isoxazoles; mancude organic heteromonocyclic parent; monocyclic heteroarene
thiazoles [no description available]	7.63	8	3	1,3-thiazoles; mancude organic heteromonocyclic parent; monocyclic heteroarene
hydrazine diamine : Any polyamine that contains two amino groups.	2.21	1	0	azane; hydrazines	EC 4.3.1.10 (serine-sulfate ammonia-lyase) inhibitor
aminophylline Aminophylline: A drug combination that contains THEOPHYLLINE and ethylenediamine. It is more soluble in water than theophylline but has similar pharmacologic actions. It's most common use is in bronchial asthma, but it has been investigated for several other applications.. aminophylline : A mixture comprising of theophylline and ethylenediamine in a 2:1 ratio.	2.08	1	0	mixture	bronchodilator agent; cardiotonic drug
galantamine Galantamine: A benzazepine derived from norbelladine. It is found in GALANTHUS and other AMARYLLIDACEAE. It is a cholinesterase inhibitor that has been used to reverse the muscular effects of GALLAMINE TRIETHIODIDE and TUBOCURARINE and has been studied as a treatment for ALZHEIMER DISEASE and other central nervous system disorders.. galanthamine : A benzazepine alkaloid isolated from certain species of daffodils.	3.63	2	0	benzazepine alkaloid fundamental parent; benzazepine alkaloid; organic heterotetracyclic compound; tertiary amino compound	antidote to curare poisoning; cholinergic drug; EC 3.1.1.7 (acetylcholinesterase) inhibitor; EC 3.1.1.8 (cholinesterase) inhibitor; plant metabolite
procarbazine hydrochloride procarbazine hydrochloride : A hydrochloride obtained by combining procarbazine with one equivalent of hydrochloric acid. An antineoplastic chemotherapy drug used for treatment of Hodgkin's lymphoma. Metabolism yields azo-procarbazine and hydrogen peroxide, which results in the breaking of DNA strands.	2.08	1	0	hydrochloride	antineoplastic agent
betamethasone Betamethasone: A glucocorticoid given orally, parenterally, by local injection, by inhalation, or applied topically in the management of various disorders in which corticosteroids are indicated. Its lack of mineralocorticoid properties makes betamethasone particularly suitable for treating cerebral edema and congenital adrenal hyperplasia. (From Martindale, The Extra Pharmacopoeia, 30th ed, p724)	2.47	2	0	11beta-hydroxy steroid; 17alpha-hydroxy steroid; 20-oxo steroid; 21-hydroxy steroid; 3-oxo-Delta(1),Delta(4)-steroid; fluorinated steroid; glucocorticoid; primary alpha-hydroxy ketone; tertiary alpha-hydroxy ketone	anti-asthmatic agent; anti-inflammatory drug; immunosuppressive agent
dextropropoxyphene Dextropropoxyphene: A narcotic analgesic structurally related to METHADONE. Only the dextro-isomer has an analgesic effect; the levo-isomer appears to exert an antitussive effect.. propoxyphene : A racemate of the (1R,2R)- and (1S,2R)- diastereoisomers.. dextropropoxyphene : The (1S,2R)-(+)-diastereoisomer of propoxyphene.	2.05	1	0	1-benzyl-3-(dimethylamino)-2-methyl-1-phenylpropyl propanoate	mu-opioid receptor agonist; opioid analgesic
limestone Calcium Carbonate: Carbonic acid calcium salt (CaCO3). An odorless, tasteless powder or crystal that occurs in nature. It is used therapeutically as a phosphate buffer in hemodialysis patients and as a calcium supplement.. calcium carbonate : A calcium salt with formula CCaO3.	2.17	1	0	calcium salt; carbonate salt; inorganic calcium salt; one-carbon compound	antacid; fertilizer; food colouring; food firming agent
chenodeoxycholic acid Chenodeoxycholic Acid: A bile acid, usually conjugated with either glycine or taurine. It acts as a detergent to solubilize fats for intestinal absorption and is reabsorbed by the small intestine. It is used as cholagogue, a choleretic laxative, and to prevent or dissolve gallstones.. chenodeoxycholic acid : A dihydroxy-5beta-cholanic acid that is (5beta)-cholan-24-oic acid substituted by hydroxy groups at positions 3 and 7 respectively.. chenodeoxycholate : Conjugate base of chenodeoxycholic acid; major species at pH 7.3.	2.11	1	0	bile acid; C24-steroid; dihydroxy-5beta-cholanic acid	human metabolite; mouse metabolite
indirubin [no description available]	2.17	1	0
plumbagin plumbagin: a superoxide anion generator. plumbagin : A hydroxy-1,4-naphthoquinone that is 1,4-naphthoquinone in which the hydrogens at positions 2 and 5 are substituted by methyl and hydroxy groups, respectively.	2.15	1	0	hydroxy-1,4-naphthoquinone; phenols	anticoagulant; antineoplastic agent; immunological adjuvant; metabolite
cepharanthine cepharanthine: isoquinoline alkaloid from tubers of STEPHANIA; stimulates recovery of immunologic function in lymphatic system after administration of antineoplastic agents or x-irradiation. cepharanthine : A bisbenzylisoquinoline alkaloid from tubers of Stephania; stimulates recovery of immunologic function in lymphatic system after administration of antineoplastic agents or x-irradiation.	2	1	0	bisbenzylisoquinoline alkaloid; isoquinolines
emetine Emetine: The principal alkaloid of ipecac, from the ground roots of Uragoga (or Cephaelis) ipecacuanha or U. acuminata, of the Rubiaceae. It is used as an amebicide in many different preparations and may cause serious cardiac, hepatic, or renal damage and violent diarrhea and vomiting. Emetine inhibits protein synthesis in EUKARYOTIC CELLS but not PROKARYOTIC CELLS.. emetine : A pyridoisoquinoline comprising emetam having methoxy substituents at the 6'-, 7'-, 10- and 11-positions. It is an antiprotozoal agent and emetic. It inhibits SARS-CoV2, Zika and Ebola virus replication and displays antimalarial, antineoplastic and antiamoebic properties.	2.47	2	0	isoquinoline alkaloid; pyridoisoquinoline	antiamoebic agent; anticoronaviral agent; antiinfective agent; antimalarial; antineoplastic agent; antiprotozoal drug; antiviral agent; autophagy inhibitor; emetic; expectorant; plant metabolite; protein synthesis inhibitor
melarsoprol Melarsoprol: Arsenical used in trypanosomiases. It may cause fatal encephalopathy and other undesirable side effects.	7.48	89	0	triazines
benzohydroxamic acid [no description available]	2.05	1	0
thiazolidines Thiazolidines: Reduced (protonated) form of THIAZOLES. They can be oxidized to THIAZOLIDINEDIONES.	2.11	1	0	thiazolidine
oleanolic acid [no description available]	2.08	1	0	hydroxy monocarboxylic acid; pentacyclic triterpenoid	plant metabolite
podophyllotoxin Podophyllum: A genus of poisonous American herbs, family BERBERIDACEAE. The roots yield PODOPHYLLOTOXIN and other pharmacologically important agents. The plant was formerly used as a cholagogue and cathartic. It is different from the European mandrake, MANDRAGORA.	6.72	68	0	furonaphthodioxole; lignan; organic heterotetracyclic compound	antimitotic; antineoplastic agent; keratolytic drug; microtubule-destabilising agent; plant metabolite; tubulin modulator
medroxyprogesterone [no description available]	2.05	1	0	17alpha-hydroxy steroid; 20-oxo steroid; 3-oxo-Delta(4) steroid; tertiary alpha-hydroxy ketone	contraceptive drug; progestin; synthetic oral contraceptive
androstenediol Androstenediol: An intermediate in TESTOSTERONE biosynthesis, found in the TESTIS or the ADRENAL GLANDS. Androstenediol, derived from DEHYDROEPIANDROSTERONE by the reduction of the 17-keto group (17-HYDROXYSTEROID DEHYDROGENASES), is converted to TESTOSTERONE by the oxidation of the 3-beta hydroxyl group to a 3-keto group (3-HYDROXYSTEROID DEHYDROGENASES).. androst-5-ene-3beta,17beta-diol : A 3beta-hydroxy-Delta(5)-steroid that is 3beta-hydroxyandrost-5-ene carrying an additional hydroxy group at position 17beta.	2.31	1	0	17beta-hydroxy steroid; 3beta-hydroxy-Delta(5)-steroid	androgen; human metabolite; mouse metabolite; radiation protective agent
dimenhydrinate gravinol: has antioxidant and ant-inflammatory activities; structure in first source	2.08	1	0	diarylmethane
flavone flavone: RN given refers to unlabeled cpd; structure given in first source. flavone : The simplest member of the class of flavones that consists of 4H-chromen-4-one bearing a phenyl substituent at position 2.	2.05	1	0	flavones	metabolite; nematicide
azomycin azomycin: RN given refers to parent cpd with specified locant; structure	22.27	874	49	C-nitro compound; imidazoles	antitubercular agent
malondialdehyde Malondialdehyde: The dialdehyde of malonic acid.. malonaldehyde : A dialdehyde that is propane substituted by two oxo groups at the terminal carbon atoms respectively. A biomarker of oxidative damage to lipids caused by smoking, it exists in vivo mainly in the enol form.	1.96	1	0	dialdehyde	biomarker
violacein [no description available]	2.21	1	0
gentian violet Gentian Violet: A dye that is a mixture of violet rosanilinis with antibacterial, antifungal, and anthelmintic properties.. crystal violet : An organic chloride salt that is the monochloride salt of crystal violet cation. It has been used in creams for the topical treatment of bacterial and fungal infections, being effective against some Gram-positive bacteria (notably Staphylococcus species) and some pathogenic fungi (including Candida species) but use declined following reports of animal carcinogenicity. It has also been used for dying wood, silk, and paper, as well as a histological stain.	6.38	21	0	organic chloride salt	anthelminthic drug; antibacterial agent; antifungal agent; antiseptic drug; histological dye
resazurin resazurin: used as indicator in detection of hyposulfite (sulfoxylate); in food research (reductase test); structure	2.03	1	0	phenoxazine
1-naphthylisothiocyanate 1-Naphthylisothiocyanate: A tool for the study of liver damage which causes bile stasis and hyperbilirubinemia acutely and bile duct hyperplasia and biliary cirrhosis chronically, with changes in hepatocyte function. It may cause skin and kidney damage.	2.08	1	0	isothiocyanate	insecticide
docusate Dioctyl Sulfosuccinic Acid: All-purpose surfactant, wetting agent, and solubilizer used in the drug, cosmetics, and food industries. It has also been used in laxatives and as cerumenolytics. It is usually administered as either the calcium, potassium, or sodium salt.	2.03	1	0	diester; organosulfonic acid
megestrol acetate [no description available]	2.47	2	0	20-oxo steroid; 3-oxo-Delta(4) steroid; acetate ester; steroid ester	antineoplastic agent; appetite enhancer; contraceptive drug; progestin; synthetic oral contraceptive
erythromycin Erythromycin: A bacteriostatic antibiotic macrolide produced by Streptomyces erythreus. Erythromycin A is considered its major active component. In sensitive organisms, it inhibits protein synthesis by binding to 50S ribosomal subunits. This binding process inhibits peptidyl transferase activity and interferes with translocation of amino acids during translation and assembly of proteins.. erythromycin : Any of several wide-spectrum macrolide antibiotics obtained from actinomycete Saccharopolyspora erythraea (formerly known as Streptomyces erythraeus).. erythromycin A : An erythromycin that consists of erythronolide A having 2,6-dideoxy-3-C-methyl-3-O-methyl-alpha-L-ribo-hexopyranosyl and 3,4,6-trideoxy-3-(dimethylamino)-beta-D-xylo-hexopyranosyl residues attahced at positions 4 and 6 respectively.	2.47	2	0	cyclic ketone; erythromycin
5-nitro-2-furoic acid 5-nitro-2-furoic acid: structure given in first source	2.01	1	0
dehydroepiandrosterone sulfate Dehydroepiandrosterone Sulfate: The circulating form of a major C19 steroid produced primarily by the ADRENAL CORTEX. DHEA sulfate serves as a precursor for TESTOSTERONE; ANDROSTENEDIONE; ESTRADIOL; and ESTRONE.. dehydroepiandrosterone sulfate : A steroid sulfate that is the 3-sulfooxy derivative of dehydroepiandrosterone.	2.05	1	0	17-oxo steroid; steroid sulfate	EC 2.7.1.33 (pantothenate kinase) inhibitor; human metabolite; mouse metabolite
hydroxychloroquine sulfate [no description available]	2.08	1	0
levonorgestrel Levonorgestrel: A synthetic progestational hormone with actions similar to those of PROGESTERONE and about twice as potent as its racemic or (+-)-isomer (NORGESTREL). It is used for contraception, control of menstrual disorders, and treatment of endometriosis.	2.08	1	0	17beta-hydroxy steroid; 3-oxo-Delta(4) steroid; terminal acetylenic compound	contraceptive drug; female contraceptive drug; progestin; synthetic oral contraceptive
vinblastine [no description available]	2.06	1	0
2-chloro-1,4-naphthoquinone 2-chloro-1,4-naphthoquinone: Vitamin K dependent carboxylase antagonist	2.07	1	0	1,4-naphthoquinones; organochlorine compound
ethambutol hydrochloride ethambutol dihydrochloride : The dihydrchloride salt of ethambutol. A bacteriostatic antimycobacterial drug, it is effective against Mycobacterium tuberculosis and some other mycobacteria. It is used in combination with other antituberculous drugs in the treatment of pulmonary and extrapulmonary tuberculosis; resistant strains of M. tuberculosis are readily produced if ethambutol dihydrochloride is used alone.	2.08	1	0	hydrochloride	antitubercular agent
ethambutol Ethambutol: An antitubercular agent that inhibits the transfer of mycolic acids into the cell wall of the tubercle bacillus. It may also inhibit the synthesis of spermidine in mycobacteria. The action is usually bactericidal, and the drug can penetrate human cell membranes to exert its lethal effect. (From Smith and Reynard, Textbook of Pharmacology, 1992, p863). ethambutol : An ethylenediamine derivative that is ethane-1,2-diamine in which one hydrogen attached to each of the nitrogens is sutstituted by a 1-hydroxybutan-2-yl group (S,S-configuration). It is a bacteriostatic antimycobacterial drug, effective against Mycobacterium tuberculosis and some other mycobacteria. It is used (as the dihydrochloride salt) in combination with other antituberculous drugs in the treatment of pulmonary and extrapulmonary tuberculosis; resistant strains of M. tuberculosis are readily produced if ethambutol is used alone.	2.05	1	0	ethanolamines; ethylenediamine derivative	antitubercular agent; environmental contaminant; xenobiotic
nicotinamide mononucleotide Nicotinamide Mononucleotide: 3-Carbamoyl-1-beta-D-ribofuranosyl pyridinium hydroxide-5'phosphate, inner salt. A nucleotide in which the nitrogenous base, nicotinamide, is in beta-N-glycosidic linkage with the C-1 position of D-ribose. Synonyms: Nicotinamide Ribonucleotide; NMN.	2	1	0	nicotinamide mononucleotide	Escherichia coli metabolite; mouse metabolite
antimycin a [no description available]	2.08	1	0	benzamides; formamides; macrodiolide; phenols	antifungal agent; mitochondrial respiratory-chain inhibitor; piscicide
vancomycin Vancomycin: Antibacterial obtained from Streptomyces orientalis. It is a glycopeptide related to RISTOCETIN that inhibits bacterial cell wall assembly and is toxic to kidneys and the inner ear.. vancomycin : A complex glycopeptide from Streptomyces orientalis. It inhibits a specific step in the synthesis of the peptidoglycan layer in the Gram-positive bacteria Staphylococcus aureus and Clostridium difficile.	2.06	1	0	glycopeptide	antibacterial drug; antimicrobial agent; bacterial metabolite
d-alpha tocopherol Vitamin E: A generic descriptor for all TOCOPHEROLS and TOCOTRIENOLS that exhibit ALPHA-TOCOPHEROL activity. By virtue of the phenolic hydrogen on the 2H-1-benzopyran-6-ol nucleus, these compounds exhibit varying degree of antioxidant activity, depending on the site and number of methyl groups and the type of ISOPRENOIDS.. tocopherol : A collective name for a group of closely related lipids that contain a chroman-6-ol nucleus substituted at position 2 by a methyl group and by a saturated hydrocarbon chain consisting of three isoprenoid units. They are designated as alpha-, beta-, gamma-, and delta-tocopherol depending on the number and position of additional methyl substituents on the aromatic ring. Tocopherols occur in vegetable oils and vegetable oil products, almost exclusively with R,R,R configuration. Tocotrienols differ from tocopherols only in having three double bonds in the hydrocarbon chain.. vitamin E : Any member of a group of fat-soluble chromanols that exhibit biological activity against vitamin E deficiency. The vitamers in this class consists of a chroman-6-ol core which is substituted at position 2 by a methyl group and (also at position 2) either a saturated or a triply-unsaturated hydrocarbon chain consisting of three isoprenoid units. The major function of vitamin E is to act as a natural antioxidant by scavenging free radicals and molecular oxygen.. (R,R,R)-alpha-tocopherol : An alpha-tocopherol that has R,R,R configuration. The naturally occurring stereoisomer of alpha-tocopherol, it is found particularly in sunflower and olive oils.	2.72	3	0	alpha-tocopherol	algal metabolite; antiatherogenic agent; anticoagulant; antioxidant; antiviral agent; EC 2.7.11.13 (protein kinase C) inhibitor; immunomodulator; micronutrient; nutraceutical; plant metabolite
pregnenolone carbonitrile Pregnenolone Carbonitrile: A catatoxic steroid and microsomal enzyme inducer having significant effects on the induction of cytochrome P450. It has also demonstrated the potential for protective capability against acetaminophen-induced liver damage.	2.08	1	0	aliphatic nitrile
metylperon metylperon: RN given refers to parent cpd	2.08	1	0	aromatic ketone
2-amino-6-methoxybenzothiazole 2-amino-6-methoxybenzothiazole: RN given refers to parent cpd	2.21	1	0
methionine sulfoximine methionine sulfoximine : A non-proteinogenic alpha-amino acid that is the sulfoximine derivative of methionine .	1.97	1	0	methionine derivative; non-proteinogenic alpha-amino acid; sulfoximide
2-methoxy-1,4-naphthoquinone 2-methoxy-1,4-naphthoquinone: isolated from Swertia calycina; structure in first source. 2-methoxy-1,4-naphthoquinone : A naphthoquinone that is naphthalene-1,4-dione substituted by a methoxy group at position 2. It has been isolated from the roots of Rubia yunnanensis.	2.07	1	0	1,4-naphthoquinones; enol ether	antimicrobial agent; metabolite; plant metabolite
sulfadoxine Sulfadoxine: A long acting sulfonamide that is used, usually in combination with other drugs, for respiratory, urinary tract, and malarial infections.. sulfadoxine : A sulfonamide consisting of pyrimidine having methoxy substituents at the 5- and 6-positions and a 4-aminobenzenesulfonamido group at the 4-position. In combination with the antiprotozoal pyrimethamine (CHEBI:8673) it is used as an antimalarial.	2.05	1	0	pyrimidines; sulfonamide	antibacterial drug; antimalarial
acetophenazine acetophenazine: major descriptor (73-85); minor descriptor (64-72); on-line search PHENOTHIAZINES (64-85); Index Medicus search PHENOTHIAZINES (64-72); ACETOPHENAZINE (73-85); RN given refers to parent cpd. acetophenazine : A member of the class of phenothiazines that is 10H-phenothiazine substituted by a 3-[4-(2-hydroxyethyl)piperazin-1-yl]propyl group at the nitogen atom and an acetyl group at position 2.	2.05	1	0	N-(2-hydroxyethyl)piperazine; N-alkylpiperazine; phenothiazines	phenothiazine antipsychotic drug
4-nitroimidazole 5-nitroimidazole : A C-nitro compound that is imidazole bearing a nitro substituent at position 5.	1.97	1	0	C-nitro compound; imidazoles
stavudine Stavudine: A dideoxynucleoside analog that inhibits reverse transcriptase and has in vitro activity against HIV.. stavudine : A nucleoside analogue obtained by formal dehydration across positions 2 and 3 of thymidine. An inhibitor of HIV-1 reverse transcriptase	2.08	1	0	dihydrofuran; nucleoside analogue; organic molecular entity	antimetabolite; antiviral agent; EC 2.7.7.49 (RNA-directed DNA polymerase) inhibitor
dicloxacillin Dicloxacillin: One of the PENICILLINS which is resistant to PENICILLINASE.. dicloxacillin : A penicillin that is 6-aminopenicillanic acid in which one of the amino hydrogens is replaced by a 3-(2,6-dichlorophenyl)-5-methyl-1,2-oxazol-4-yl]formyl group.	2.08	1	0	dichlorobenzene; penicillin	antibacterial drug
benzolamide Benzolamide: Selective renal carbonic anhydrase inhibitor. It may also be of use in certain cases of respiratory failure.	2.08	1	0
cladribine [no description available]	2.08	1	0	organochlorine compound; purine 2'-deoxyribonucleoside	antineoplastic agent; immunosuppressive agent
5-amino-1h-tetrazole [no description available]	3.31	1	0
beclomethasone [no description available]	2.05	1	0	11beta-hydroxy steroid; 17alpha-hydroxy steroid; 20-oxo steroid; 21-hydroxy steroid; 3-oxo-Delta(1),Delta(4)-steroid; chlorinated steroid; corticosteroid; glucocorticoid; primary alpha-hydroxy ketone; tertiary alpha-hydroxy ketone	anti-asthmatic drug; anti-inflammatory drug
pyrodifenium bromide pyrodifenium bromide: was heading 1976-94 (see under PYRROLIDINES 1976-90); PRIFINIUM BROMIDE was see PYRODIFENIUM BROMIDE 1976-94: use PYRROLIDINES to search PYRODIFENIUM BROMIDE 1976-94; quaternary ammonium anticholinergic agent more specific for the gastrointestinal tract than atropine	2.05	1	0	organic molecular entity
buthionine sulfoximine Buthionine Sulfoximine: A synthetic amino acid that depletes glutathione by irreversibly inhibiting gamma-glutamylcysteine synthetase. Inhibition of this enzyme is a critical step in glutathione biosynthesis. It has been shown to inhibit the proliferative response in human T-lymphocytes and inhibit macrophage activation. (J Biol Chem 1995;270(33):1945-7). 2-amino-4-(S-butylsulfonimidoyl)butanoic acid : A non-proteinogenic alpha-amino acid that is homocysteine in which the thiol group carries an oxo, imino and butyl groups.. S-butyl-DL-homocysteine (S,R)-sulfoximine : A sulfoximide that is the sulfoximine derivative of an analogue of DL-methionine in which the S-methyl group is replaced by S-butyl.	3.11	5	0	diastereoisomeric mixture; homocysteines; non-proteinogenic alpha-amino acid; sulfoximide	EC 6.3.2.2 (glutamate--cysteine ligase) inhibitor; ferroptosis inducer
metocurine metocurine: from Chinese herb Cyclea hainanensis Mrr	2.08	1	0	isoquinolines
5-nitroindazole [no description available]	2.51	2	0
nimorazole Nimorazole: An antitrichomonal agent which is effective either topically or orally and whose urinary metabolites are also trichomonicidal.	4.45	1	1	C-nitro compound; imidazoles
helenalin helenalin: toxic principle of Helenium microcephalum (smallhead sneezeweed); structure. helenalin : A sesquiterpene lactone that is 3,3a,4,4a,7a,8,9,9a-octahydroazuleno[6,5-b]furan-2,5-dione substituted by a hydroxy group at position 4, methyl groups at positions 4a and 8 and a methylidene group at position 3 (the 3aS,4S,4aR,7aR,8R,9aR stereoisomer).. NF-kappaB inhibitor : An inhibitor of NF-kappaB (nuclear factor kappa-light-chain-enhancer of activated B cells), a protein complex involved in the transcription of DNA.	2.46	2	0	cyclic ketone; gamma-lactone; organic heterotricyclic compound; secondary alcohol; sesquiterpene lactone	anti-inflammatory agent; antineoplastic agent; metabolite; plant metabolite
2-toluanilide 2-toluanilide: structure given in first source	2.1	1	0	benzamides; benzanilide fungicide
etidronate disodium etidronate disodium : An organic sodium salt resulting from the replacement of two protons from etidronic acid (one from from each of the phosphonic acid groups) by sodium ions.	2.08	1	0	organic sodium salt	antineoplastic agent; bone density conservation agent; chelator
palladium Palladium: A chemical element having an atomic weight of 106.4, atomic number of 46, and the symbol Pd. It is a white, ductile metal resembling platinum, and following it in abundance and importance of applications. It is used in dentistry in the form of gold, silver, and copper alloys.. palladium : Chemical element (nickel group element atom) with atomic number 46.	2.05	1	0	metal allergen; nickel group element atom; platinum group metal atom
ruthenium Ruthenium: A hard, brittle, grayish-white rare earth metal with an atomic symbol Ru, atomic number 44, and atomic weight 101.07. It is used as a catalyst and hardener for PLATINUM and PALLADIUM.	2.51	2	0	iron group element atom; platinum group metal atom
technetium Technetium: The first artificially produced element and a radioactive fission product of URANIUM. Technetium has the atomic symbol Tc, and atomic number 43. All technetium isotopes are radioactive. Technetium 99m (m=metastable) which is the decay product of Molybdenum 99, has a half-life of about 6 hours and is used diagnostically as a radioactive imaging agent. Technetium 99 which is a decay product of technetium 99m, has a half-life of 210,000 years.	2.05	1	0	manganese group element atom
zalcitabine Zalcitabine: A dideoxynucleoside compound in which the 3'-hydroxy group on the sugar moiety has been replaced by a hydrogen. This modification prevents the formation of phosphodiester linkages which are needed for the completion of nucleic acid chains. The compound is a potent inhibitor of HIV replication at low concentrations, acting as a chain-terminator of viral DNA by binding to reverse transcriptase. Its principal toxic side effect is axonal degeneration resulting in peripheral neuropathy.. zalcitabine : A pyrimidine 2',3'-dideoxyribonucleoside compound having cytosine as the nucleobase.	2.08	1	0	pyrimidine 2',3'-dideoxyribonucleoside	antimetabolite; antiviral drug; HIV-1 reverse transcriptase inhibitor
camptothecin NSC 100880: carboxylate (opened lactone) form of camptothecin; RN refers to (S)-isomer; structure given in first source	2.48	2	0	delta-lactone; pyranoindolizinoquinoline; quinoline alkaloid; tertiary alcohol	antineoplastic agent; EC 5.99.1.2 (DNA topoisomerase) inhibitor; genotoxin; plant metabolite
potassium persulfate [no description available]	1.96	1	0
barium sulfate Barium Sulfate: A compound used as an x-ray contrast medium that occurs in nature as the mineral barite. It is also used in various manufacturing applications and mixed into heavy concrete to serve as a radiation shield.. barium sulfate : A metal sulfate with formula BaO4S. Virtually insoluble in water at room temperature, it is mostly used as a component in oil well drilling fluid it occurs naturally as the mineral barite.	2.07	1	0	barium salt; inorganic barium salt; metal sulfate	radioopaque medium
amopyroquine amopyroquine: RN given refers to parent cpd; structure	2.05	1	0
mafenide acetate [no description available]	2.08	1	0	carboxylic acid
misonidazole Misonidazole: A nitroimidazole that sensitizes normally radio-resistant hypoxic cells to radiation. It may also be directly cytotoxic to hypoxic cells and has been proposed as an antineoplastic.	6.32	12	1
desmethylmisonidazole [no description available]	5.54	5	1
diacerein diacerein: chelates with bivalent metals; a quinone which possesses redox properties; metabolized to active rhein; proposed mechanisms include inhibiting IL1 and metalloproteinases; called a slow acting symptomatic drug in osteoarthritis; no effect of cyclooxygenase;	2.08	1	0	anthraquinone
xipamide Xipamide: A sulfamoylbenzamide analog of CLOPAMIDE. It is diuretic and saluretic with antihypertensive activity. It is bound to PLASMA PROTEINS, thus has a delayed onset and prolonged action.	2.05	1	0	benzamides
selegiline hydrochloride, (r)-isomer [no description available]	2.08	1	0	hydrochloride; terminal acetylenic compound	antiparkinson drug; dopaminergic agent; EC 1.4.3.4 (monoamine oxidase) inhibitor
levamisole Levamisole: An antihelminthic drug that has been tried experimentally in rheumatic disorders where it apparently restores the immune response by increasing macrophage chemotaxis and T-lymphocyte function. Paradoxically, this immune enhancement appears to be beneficial in rheumatoid arthritis where dermatitis, leukopenia, and thrombocytopenia, and nausea and vomiting have been reported as side effects. (From Smith and Reynard, Textbook of Pharmacology, 1991, p435-6). levamisole : A 6-phenyl-2,3,5,6-tetrahydroimidazo[2,1-b][1,3]thiazole that has S configuration. It is used (generally as the monohydrochloride salt) to treat parasitic worm infections in pigs, sheep and cattle and was formerly used in humans as an adjuvant to chemotherapy for the treatment of various cancers. It is also widely used as an adulterant to coccaine.	2.51	2	0	6-phenyl-2,3,5,6-tetrahydroimidazo[2,1-b][1,3]thiazole	antinematodal drug; antirheumatic drug; EC 3.1.3.1 (alkaline phosphatase) inhibitor; immunological adjuvant; immunomodulator
thiamphenicol [no description available]	2.08	1	0	monocarboxylic acid amide; sulfone	antimicrobial agent; immunosuppressive agent
pancuronium bromide pancuronium bromide : A bromide salt consisting of two bromide ions and one pancuronium dication.	2.08	1	0	bromide salt	cholinergic antagonist; muscle relaxant; nicotinic antagonist
ornidazole Ornidazole: A nitroimidazole antiprotozoal agent used in ameba and trichomonas infections. It is partially plasma-bound and also has radiation-sensitizing action.. ornidazole : A C-nitro compound that is 5-nitroimidazole in which the hydrogens at positions 1 and 2 are replaced by 3-chloro-2-hydroxypropyl and methyl groups, respectively. It is used in the treatment of susceptible protozoal infections and for the treatment of anaerobic bacterial infections.	4.57	4	0	C-nitro compound; imidazoles; organochlorine compound; secondary alcohol	antiamoebic agent; antibacterial drug; antiinfective agent; antiprotozoal drug; antitrichomonal drug; epitope
danazol Danazol: A synthetic steroid with antigonadotropic and anti-estrogenic activities that acts as an anterior pituitary suppressant by inhibiting the pituitary output of gonadotropins. It possesses some androgenic properties. Danazol has been used in the treatment of endometriosis and some benign breast disorders.	2.47	2	0	17beta-hydroxy steroid; terminal acetylenic compound	anti-estrogen; estrogen antagonist; geroprotector
cl 64855 [no description available]	4.35	6	0
fludarabine phosphate fludarabine phosphate: structure given in first source. fludarabine phosphate : A purine arabinonucleoside monophosphate having 2-fluoroadenine as the nucleobase. A prodrug, it is rapidly dephosphorylated to 2-fluoro-ara-A and then phosphorylated intracellularly by deoxycytidine kinase to the active triphosphate, 2-fluoro-ara-ATP. Once incorporated into DNA, 2-fluoro-ara-ATP functions as a DNA chain terminator. It is used for the treatment of adult patients with B-cell chronic lymphocytic leukemia (CLL) who have not responded to, or whose disease has progressed during, treatment with at least one standard alkylating-agent containing regimenas.	2.08	1	0	nucleoside analogue; organofluorine compound; purine arabinonucleoside monophosphate	antimetabolite; antineoplastic agent; antiviral agent; DNA synthesis inhibitor; immunosuppressive agent; prodrug
bromocriptine Bromocriptine: A semisynthetic ergotamine alkaloid that is a dopamine D2 agonist. It suppresses prolactin secretion.	2.05	1	0	indole alkaloid	antidyskinesia agent; antiparkinson drug; dopamine agonist; hormone antagonist
phenyl acetate phenyl acetate: The ester formed between phenol and acetic acid. Don't confuse with phenylacetic acid derivatives listed under PHENYLACETATES.. phenyl acetate : An acetate ester obtained by the formal condensation of phenol with acetic acid.	2.17	1	0	benzenes; phenyl acetates
triamcinolone Triamcinolone: A glucocorticoid given, as the free alcohol or in esterified form, orally, intramuscularly, by local injection, by inhalation, or applied topically in the management of various disorders in which corticosteroids are indicated. (From Martindale, The Extra Pharmacopoeia, 30th ed, p739). triamcinolone : A C21-steroid hormone that is 1,4-pregnadiene-3,20-dione carrying four hydroxy substituents at positions 11beta, 16alpha, 17alpha and 21 as well as a fluoro substituent at position 9. Used in the form of its 16,17-acetonide to treat various skin infections.	2.05	1	0	11beta-hydroxy steroid; 16alpha-hydroxy steroid; 17alpha-hydroxy steroid; 20-oxo steroid; 21-hydroxy steroid; 3-oxo-Delta(4) steroid; C21-steroid hormone; fluorinated steroid; glucocorticoid; primary alpha-hydroxy ketone; tertiary alpha-hydroxy ketone	anti-allergic agent; anti-inflammatory drug
halazepam halazepam: structure	2.05	1	0	organic molecular entity
dexchlorpheniramine dexchlorpheniramine: RN given refers to parent cpd(S)-isomer	2.05	1	0	chlorphenamine
sodium azide Sodium Azide: A cytochrome oxidase inhibitor which is a nitridizing agent and an inhibitor of terminal oxidation. (From Merck Index, 12th ed). sodium azide : The sodium salt of hydrogen azide (hydrazoic acid).	2.13	1	0	inorganic sodium salt	antibacterial agent; explosive; mitochondrial respiratory-chain inhibitor; mutagen
amoxicillin Amoxicillin: A broad-spectrum semisynthetic antibiotic similar to AMPICILLIN except that its resistance to gastric acid permits higher serum levels with oral administration.. amoxicillin : A penicillin in which the substituent at position 6 of the penam ring is a 2-amino-2-(4-hydroxyphenyl)acetamido group.	2.08	1	0	penicillin allergen; penicillin	antibacterial drug
timolol (S)-timolol (anhydrous) : The (S)-(-) (more active) enantiomer of timolol. A beta-adrenergic antagonist, both the hemihydrate and the maleate salt are used in the mangement of glaucoma, hypertension, angina pectoris and myocardial infarction, and for the prevention of migraine.	2.47	2	0	timolol	anti-arrhythmia drug; antiglaucoma drug; antihypertensive agent; beta-adrenergic antagonist
indoramin Indoramin: An alpha-1 adrenergic antagonist that is commonly used as an antihypertensive agent.	2.08	1	0	tryptamines
oxcarbazepine Oxcarbazepine: A carbamazepine derivative that acts as a voltage-gated sodium channel blocker. It is used for the treatment of PARTIAL SEIZURES with or without secondary generalization. It is also an inducer of CYTOCHROME P-450 CYP3A4.. oxcarbazepine : A dibenzoazepine derivative, having a carbamoyl group at the ring nitrogen, substituted with an oxo group at C-4 of the azepeine ring which is also hydrogenated at C-4 and C-5. It is a anticholinergic anticonvulsant and mood stabilizing drug, used primarily in the treatment of epilepsy.	2.08	1	0	cyclic ketone; dibenzoazepine	anticonvulsant; drug allergen
carbidopa carbidopa (anhydrous) : 3-(3,4-Dihydroxyphenyl)propanoic acid in which the hydrogens alpha- to the carboxyl group are substituted by hydrazinyl and methyl groups (S-configuration). Carbidopa is a dopa decarboxylase inhibitor, so prevents conversion of levodopa to dopamine. It has no antiparkinson activity by itself, but is used (commonly as its hydrate) in the management of Parkinson's disease to reduce peripheral adverse effects of levodopa.	2.08	1	0	catechols; hydrazines; monocarboxylic acid	antiparkinson drug; dopaminergic agent; EC 4.1.1.28 (aromatic-L-amino-acid decarboxylase) inhibitor
amineptin amineptin: used in treatment of neuroses with psychoasthenic, anxio-phobic & depressive manifestations; synonym S 1694 refers to HCl; structure. amineptine : A carbocyclic fatty acid that is 5-aminoheptanoic acid in which one of the hydrogens attached to the nitrogen is replaced by a 10,11-dihydro-5H-dibenzo[a,d][7]annulen-5-yl group. A tricyclic antidepressant, it was never approved in the US and was withdrawn from the French market in 1999 due to concerns over abuse, dependence and severe acne.	2.05	1	0	amino acid; carbocyclic fatty acid; carbotricyclic compound; secondary amino compound	antidepressant; dopamine uptake inhibitor
zidovudine Zidovudine: A dideoxynucleoside compound in which the 3'-hydroxy group on the sugar moiety has been replaced by an azido group. This modification prevents the formation of phosphodiester linkages which are needed for the completion of nucleic acid chains. The compound is a potent inhibitor of HIV replication, acting as a chain-terminator of viral DNA during reverse transcription. It improves immunologic function, partially reverses the HIV-induced neurological dysfunction, and improves certain other clinical abnormalities associated with AIDS. Its principal toxic effect is dose-dependent suppression of bone marrow, resulting in anemia and leukopenia.. zidovudine : A pyrimidine 2',3'-dideoxyribonucleoside compound having a 3'-azido substituent and thymine as the nucleobase.	2.48	2	0	azide; pyrimidine 2',3'-dideoxyribonucleoside	antimetabolite; antiviral drug; HIV-1 reverse transcriptase inhibitor
feprazone Feprazone: A pyrazole that has analgesic, anti-inflammatory, and antipyretic properties. It has been used in mild to moderate pain, fever, and inflammation associated with musculoskeletal and joint disorders. (From Martindale, The Extra Pharmacopoeia, 30th ed, p15)	2.08	1	0	organic molecular entity
flubendazole flubendazole: the p-fluoro analog of mebendazole. flubendazole : A member of the class of mebendazole in which the benzoyl group is replaced by a p-fluorobenzoyl group. A broad-spectrum anthelmintic, it is used, particularly in veterinary medicine, for the treatment of nematodal infections.	2.15	1	0	aromatic ketone; benzimidazoles; carbamate ester; organofluorine compound	antinematodal drug; teratogenic agent
tobramycin Tobramycin: An aminoglycoside, broad-spectrum antibiotic produced by Streptomyces tenebrarius. It is effective against gram-negative bacteria, especially the PSEUDOMONAS species. It is a 10% component of the antibiotic complex, NEBRAMYCIN, produced by the same species.. tobramycin : A amino cyclitol glycoside that is kanamycin B lacking the 3-hydroxy substituent from the 2,6-diaminoglucose ring.	2.08	1	0	amino cyclitol glycoside	antibacterial agent; antimicrobial agent; toxin
paclitaxel Taxus: Genus of coniferous yew trees or shrubs, several species of which have medicinal uses. Notable is the Pacific yew, Taxus brevifolia, which is used to make the anti-neoplastic drug taxol (PACLITAXEL).	2.83	3	0	taxane diterpenoid; tetracyclic diterpenoid	antineoplastic agent; human metabolite; metabolite; microtubule-stabilising agent
etoposide [no description available]	2.47	2	0	beta-D-glucoside; furonaphthodioxole; organic heterotetracyclic compound	antineoplastic agent; DNA synthesis inhibitor
halofantrine halofantrine: used in treatment of mild to moderate acute malaria	2.05	1	0	phenanthrenes
ribavirin Rebetron: Rebetron is tradename	2.08	1	0	1-ribosyltriazole; aromatic amide; monocarboxylic acid amide; primary carboxamide	anticoronaviral agent; antiinfective agent; antimetabolite; antiviral agent; EC 2.7.7.49 (RNA-directed DNA polymerase) inhibitor
amikacin Amikacin: A broad-spectrum antibiotic derived from KANAMYCIN. It is reno- and oto-toxic like the other aminoglycoside antibiotics.. amikacin : An amino cyclitol glycoside that is kanamycin A acylated at the N-1 position by a 4-amino-2-hydroxybutyryl group.	2.08	1	0	alpha-D-glucoside; amino cyclitol glycoside; aminoglycoside; carboxamide	antibacterial drug; antimicrobial agent; nephrotoxin
hydroxymaprotilin hydroxymaprotilin: RN given refers to cpd without isomeric designation	2.05	1	0
methyldopa Methyldopa: An alpha-2 adrenergic agonist that has both central and peripheral nervous system effects. Its primary clinical use is as an antihypertensive agent.. alpha-methyl-L-dopa : A derivative of L-tyrosine having a methyl group at the alpha-position and an additional hydroxy group at the 3-position on the phenyl ring.	2.05	1	0	L-tyrosine derivative; non-proteinogenic L-alpha-amino acid	alpha-adrenergic agonist; antihypertensive agent; hapten; peripheral nervous system drug; sympatholytic agent
tocainide Tocainide: An antiarrhythmic agent which exerts a potential- and frequency-dependent block of SODIUM CHANNELS.. tocainide : A monocarboxylic acid amide in which 2,6-dimethylphenylaniline and isobutyric acid have combined to form the amide bond; used as a local anaesthetic.	2.05	1	0	monocarboxylic acid amide	anti-arrhythmia drug; local anaesthetic; sodium channel blocker
sq-11725 Nadolol: A non-selective beta-adrenergic antagonist with a long half-life, used in cardiovascular disease to treat arrhythmias, angina pectoris, and hypertension. Nadolol is also used for MIGRAINE DISORDERS and for tremor.. nadolol : Nadolol is a diastereoisomeric mixture consisting of equimolar amounts of the four possible 2,3-cis-isomers of 5-[3-(tert-butylamino)-2-hydroxypropoxy]-1,2,3,4-tetrahydronaphthalene-2,3-diol.	2.05	1	0
diltiazem Diltiazem: A benzothiazepine derivative with vasodilating action due to its antagonism of the actions of CALCIUM ion on membrane functions.. diltiazem : A 5-[2-(dimethylamino)ethyl]-2-(4-methoxyphenyl)-4-oxo-2,3,4,5-tetrahydro-1,5-benzothiazepin-3-yl acetate in which both stereocentres have S configuration. A calcium-channel blocker and vasodilator, it is used as the hydrochloride in the management of angina pectoris and hypertension.	2.47	2	0	5-[2-(dimethylamino)ethyl]-2-(4-methoxyphenyl)-4-oxo-2,3,4,5-tetrahydro-1,5-benzothiazepin-3-yl acetate	antihypertensive agent; calcium channel blocker; vasodilator agent
vecuronium bromide Vecuronium Bromide: Monoquaternary homolog of PANCURONIUM. A non-depolarizing neuromuscular blocking agent with shorter duration of action than pancuronium. Its lack of significant cardiovascular effects and lack of dependence on good kidney function for elimination as well as its short duration of action and easy reversibility provide advantages over, or alternatives to, other established neuromuscular blocking agents.. vecuronium bromide : The organic bromide salt of a 5alpha-androstane compound having 3alpha-acetoxy-, 17beta-acetoxy-, 2beta-piperidinino- and 16beta-N-methylpiperidinium substituents.	2.08	1	0	organic bromide salt; quaternary ammonium salt	muscle relaxant; neuromuscular agent; nicotinic antagonist
pinazepam pinazepam: structure	2.05	1	0	benzodiazepine
6-hydroxy-2,5,7,8-tetramethylchroman-2-carboxylic acid [no description available]	2.11	1	0	chromanol; monocarboxylic acid; phenols	antioxidant; ferroptosis inhibitor; neuroprotective agent; radical scavenger; Wnt signalling inhibitor
butibufen butibufen: RN given refers to parent cpd	2.05	1	0	monoterpenoid
nitazoxanide nitazoxanide: a 5-nitrothiazolyl derivative used for a broad range of intestinal parasitic infections including CRYPTOSPORIDIUM and GIARDIA; it is a redox-active nitrothiazolyl-salicylamide prodrug	3.01	4	0	benzamides; carboxylic ester
acarbose [no description available]	2.08	1	0	tetrasaccharide derivative	EC 3.2.1.1 (alpha-amylase) inhibitor; EC 3.2.1.20 (alpha-glucosidase) inhibitor; geroprotector; hypoglycemic agent
lorcainide [no description available]	2.08	1	0	acetamides
fenarimol fenarimol : A racemate comprising equimolar amounts of (R)- and (S)-fenarimol. A sterol demethylation inhibitor, it is used as a fungicide for the treatment of blackspot, mildew and rust in tomatoes, peppers and melons, but is not approved for use within the European Union.. (2-chlorophenyl)(4-chlorophenyl)pyrimidin-5-ylmethanol : A member of the class of pyrimidines that is pyrimidin-5-ylmethanol in which one of the hydrogens attached to the carbon bearing the hydroxy group is replaced by a 2-chlorophenyl group while the other is replaced by a 4-chlorophenyl group.	2.07	1	0	monochlorobenzenes; pyrimidines; tertiary alcohol
paroxetine Paroxetine: A serotonin uptake inhibitor that is effective in the treatment of depression.. paroxetine : A benzodioxole that consists of piperidine bearing 1,3-benzodioxol-5-yloxy)methyl and 4-fluorophenyl substituents at positions 3 and 4 respectively; the (3S,4R)-diastereomer. Highly potent and selective 5-HT uptake inhibitor that binds with high affinity to the serotonin transporter (Ki = 0.05 nM). Ki values are 1.1, 350 and 1100 nM for inhibition of [3H]-5-HT, [3H]-l-NA and [3H]-DA uptake respectively. Displays minimal affinity for alpha1-, alpha2- or beta-adrenoceptors, 5-HT2A, 5-HT1A, D2 or H1 receptors at concentrations below 1000 nM, however displays weak affinity for muscarinic ACh receptors (Ki = 42 nM). Antidepressant and anxiolytic in vivo.	2.05	1	0	aromatic ether; benzodioxoles; organofluorine compound; piperidines	antidepressant; anxiolytic drug; hepatotoxic agent; P450 inhibitor; serotonin uptake inhibitor
captopril Captopril: A potent and specific inhibitor of PEPTIDYL-DIPEPTIDASE A. It blocks the conversion of ANGIOTENSIN I to ANGIOTENSIN II, a vasoconstrictor and important regulator of arterial blood pressure. Captopril acts to suppress the RENIN-ANGIOTENSIN SYSTEM and inhibits pressure responses to exogenous angiotensin.. captopril : A L-proline derivative in which L-proline is substituted on nitrogen with a (2S)-2-methyl-3-sulfanylpropanoyl group. It is used as an anti-hypertensive ACE inhibitor drug.	2.47	2	0	alkanethiol; L-proline derivative; N-acylpyrrolidine; pyrrolidinemonocarboxylic acid	antihypertensive agent; EC 3.4.15.1 (peptidyl-dipeptidase A) inhibitor
staurosporine [no description available]	2.78	3	0	indolocarbazole alkaloid; organic heterooctacyclic compound	apoptosis inducer; bacterial metabolite; EC 2.7.11.13 (protein kinase C) inhibitor; geroprotector
foscarnet sodium trisodium phosphonoformate : The trisodium salt of phosphonoformic acid. It is used as an antiviral agent in the treatment of cytomegalovirus retinitis (CMV retinitis, an inflamation of the retina that can lead to blindness) and as an alternative to ganciclovir for AIDS patients who require concurrent antiretroviral therapy but are unable to tolerate ganciclovir due to haematological toxicity.	2.08	1	0	one-carbon compound; organic sodium salt	antiviral drug
atracurium besylate atracurium besylate : The bisbenzenesulfonate salt of atracurium.	2.08	1	0	organosulfonate salt; quaternary ammonium salt	muscle relaxant; nicotinic antagonist
benzamido-2-nitro-5-thiazole [no description available]	2.1	1	0
nicorandil Nicorandil: A derivative of the NIACINAMIDE that is structurally combined with an organic nitrate. It is a potassium-channel opener that causes vasodilatation of arterioles and large coronary arteries. Its nitrate-like properties produce venous vasodilation through stimulation of guanylate cyclase.. nicorandil : A pyrimidinecarboxamide that is nicotinamide in which one of the hydrogens attached to the carboxamide nitrogen is replaced by a 2-(nitrooxy)ethyl group. It has both nitrate-like and ATP-sensitive potassium channel activator properties, and is used for the prevention and treatment of angina pectoris.	2.08	1	0	nitrate ester; pyridinecarboxamide	potassium channel opener; vasodilator agent
pergolide mesylate pergolide mesylate : A methanesulfonate salt obtained from pergolide by mixing eqimolar amount of pergolide and methanesulfonic acid. A dopamine D2 receptor agonist which also has D1 and D2 agonist properties, it is used in the management of Parkinson's disease, although it was withdrawn from the U.S. and Canadian markets in 2007 due to an increased risk of cardiac valve dysfunction.	2.08	1	0	methanesulfonate salt	antiparkinson drug; dopamine agonist; geroprotector
cefadroxil anhydrous Cefadroxil: Long-acting, broad-spectrum, water-soluble, CEPHALEXIN derivative.. cefadroxil : A cephalosporin bearing methyl and (2R)-2-amino-2-(4-hydroxyphenyl)acetamido groups at positions 3 and 7, respectively, of the cephem skeleton.	2.08	1	0	cephalosporin	antibacterial drug
talniflumate talniflumate: an anti-inflammatory molecule for the treatment of cystic fibrosis, chronic obstructive pulmonary disease and asthma	2.08	1	0	benzofurans
fenoldopam mesylate [no description available]	2.08	1	0	benzazepine
pimonidazole pimonidazole: structure given in first source	4.45	1	1
cefaclor anhydrous Cefaclor: Semisynthetic, broad-spectrum antibiotic derivative of CEPHALEXIN.. cefaclor : A cephalosporin bearing chloro and (R)-2-amino-2-phenylacetamido groups at positions 3 and 7, respectively, of the cephem skeleton.	2.08	1	0	cephalosporin	antibacterial drug; drug allergen
pefloxacin Pefloxacin: A synthetic broad-spectrum fluoroquinolone antibacterial agent active against most gram-negative and gram-positive bacteria.. pefloxacin : A quinolone that is 4-oxo-1,4-dihydroquinoline which is substituted at positions 1, 3, 6 and 7 by ethyl, carboxy, fluorine, and 4-methylpiperazin-1-yl groups, respectively.	2.08	1	0	fluoroquinolone antibiotic; monocarboxylic acid; N-alkylpiperazine; N-arylpiperazine; quinolone antibiotic; quinolone	antibacterial drug; antiinfective agent; DNA synthesis inhibitor
alfentanil Alfentanil: A short-acting opioid anesthetic and analgesic derivative of FENTANYL. It produces an early peak analgesic effect and fast recovery of consciousness. Alfentanil is effective as an anesthetic during surgery, for supplementation of analgesia during surgical procedures, and as an analgesic for critically ill patients.. alfentanil : A member of the class of piperidines that is piperidine having a 2-(4-ethyl-5-oxo-4,5-dihydro-1H-tetrazol-1-yl)ethyl group at the 1-position as well as N-phenylpropanamido- and methoxymethyl groups at the 4-position.	2.05	1	0	monocarboxylic acid amide; piperidines	central nervous system depressant; intravenous anaesthetic; mu-opioid receptor agonist; opioid analgesic; peripheral nervous system drug
cefotetan Cefotetan: A semisynthetic cephamycin antibiotic that is administered intravenously or intramuscularly. The drug is highly resistant to a broad spectrum of beta-lactamases and is active against a wide range of both aerobic and anaerobic gram-positive and gram-negative microorganisms.. cefotetan : A semi-synthetic second-generation cephamycin antibiotic with [(1-methyl-1H-tetrazol-5-yl)sulfanyl]methyl, methoxy and {[4-(2-amino-1-carboxy-2-oxoethylidene)-1,3-dithietan-2-yl]carbonyl}amino groups at the 3, 7alpha, and 7beta positions, respectively, of the cephem skeleton. It is resistant to a wide range of beta-lactamases and is active against a broad spectrum of aerobic and anaerobic Gram-positive and Gram-negative microorganisms.	2.08	1	0
lovastatin Lovastatin: A fungal metabolite isolated from cultures of Aspergillus terreus. The compound is a potent anticholesteremic agent. It inhibits 3-hydroxy-3-methylglutaryl coenzyme A reductase (HYDROXYMETHYLGLUTARYL COA REDUCTASES), which is the rate-limiting enzyme in cholesterol biosynthesis. It also stimulates the production of low-density lipoprotein receptors in the liver.. lovastatin : A fatty acid ester that is mevastatin carrying an additional methyl group on the carbobicyclic skeleton. It is used in as an anticholesteremic drug and has been found in fungal species such as Aspergillus terreus and Pleurotus ostreatus (oyster mushroom).	2.08	1	0	delta-lactone; fatty acid ester; hexahydronaphthalenes; polyketide; statin (naturally occurring)	anticholesteremic drug; antineoplastic agent; Aspergillus metabolite; prodrug
flupirtine flupirtine: RN given refers to parent cpd without isomeric designation	2.08	1	0	aminopyridine
enoximone Enoximone: A selective phosphodiesterase inhibitor with vasodilating and positive inotropic activity that does not cause changes in myocardial oxygen consumption. It is used in patients with CONGESTIVE HEART FAILURE.	2.08	1	0	aromatic ketone
stepronin [no description available]	2.08	1	0	N-acyl-amino acid
piritrexim piritrexim: RN given refers to parent cpd; structure given in first source	2.05	1	0
simvastatin Simvastatin: A derivative of LOVASTATIN and potent competitive inhibitor of 3-hydroxy-3-methylglutaryl coenzyme A reductase (HYDROXYMETHYLGLUTARYL COA REDUCTASES), which is the rate-limiting enzyme in cholesterol biosynthesis. It may also interfere with steroid hormone production. Due to the induction of hepatic LDL RECEPTORS, it increases breakdown of LDL CHOLESTEROL.. simvastatin : A member of the class of hexahydronaphthalenes that is lovastatin in which the 2-methylbutyrate ester moiety has been replaced by a 2,2-dimethylbutyrate ester group. It is used as a cholesterol-lowering and anti-cardiovascular disease drug.	3.05	4	0	delta-lactone; fatty acid ester; hexahydronaphthalenes; statin (semi-synthetic)	EC 1.1.1.34/EC 1.1.1.88 (hydroxymethylglutaryl-CoA reductase) inhibitor; EC 3.4.24.83 (anthrax lethal factor endopeptidase) inhibitor; ferroptosis inducer; geroprotector; prodrug
idazoxan Idazoxan: A benzodioxane-linked imidazole that has alpha-2 adrenoceptor antagonist activity.. idazoxan : A benzodioxine that is 2,3-dihydro-1,4-benzodioxine in which one of the hydrogens at position 2 has been replaced by a 4,5-dihydro-1H-imidazol-2-yl group.	2.08	1	0	benzodioxine; imidazolines	alpha-adrenergic antagonist
remoxipride Remoxipride: An antipsychotic agent that is specific for dopamine D2 receptors. It has been shown to be effective in the treatment of schizophrenia.	2.08	1	0	dimethoxybenzene
cabergoline Cabergoline: An ergoline derivative and dopamine D2-agonist that inhibits PROLACTIN secretion. It is used in the management of HYPERPROLACTINEMIA, and to suppress lactation following childbirth for medical reasons. Cabergoline is also used in the management of PARKINSON DISEASE.. cabergoline : An N-acylurea that is (8R)-ergoline-8-carboxamide in which the hydrogen attached to the piperidine nitrogen (position 6) is substituted by an allyl group and the hydrogens attached to the carboxamide nitrogen are substituted by a 3-(dimethylamino)propyl group and an N-ethylcarbamoyl group. A dopamine D2 receptor agonist, cabergoline is used in the management of Parkinson's disease and of disorders associated with hyperprolactinaemia.	2.08	1	0	N-acylurea	antineoplastic agent; antiparkinson drug; dopamine agonist
bambuterol bambuterol: selective inhibitor of butyrylcholinesterase & acetylcholinesterase. bambuterol : A carbamate ester that is terbutaline in which both of the phenolic hydroxy groups have been protected as the corresponding N,N-dimethylcarbamates. A long acting beta-adrenoceptor agonist used in the treatment of asthma, it is a prodrug for terbutaline.	2.05	1	0	carbamate ester; phenylethanolamines	anti-asthmatic drug; beta-adrenergic agonist; bronchodilator agent; EC 3.1.1.7 (acetylcholinesterase) inhibitor; prodrug; sympathomimetic agent; tocolytic agent
atomoxetine hydrochloride Atomoxetine Hydrochloride: A propylamine derivative and selective ADRENERGIC UPTAKE INHIBITOR that is used in the treatment of ATTENTION DEFICIT HYPERACTIVITY DISORDER.. atomoxetine hydrochloride : The hydrochloride salt of atomoxetine.	2.08	1	0	hydrochloride	adrenergic uptake inhibitor; antidepressant
quinapril Quinapril: A tetrahydroisoquinoline derivative and ANGIOTENSIN CONVERTING ENZYME inhibitor that is used in the treatment of HYPERTENSION and HEART FAILURE.. quinapril : A member of the class of isoquinolines that is (3S)-2-L-alanyl-1,2,3,4-tetrahydroisoquinoline-3-carboxylic acid in which the alpha-amino group of the alanyl residue has been substituted by a 1-ethoxycarbonyl-4-phenylbutan-2-yl group (the all-S isomer). A prodrug for quinaprilat (by hydrolysis of the ethyl ester to the corresponding carboxylic acid), it is used as an angiotensin-converting enzyme inhibitor (ACE inhibitor) used (generally as the hydrochloride salt) for the treatment of hypertension and congestive heart failure.	2.08	1	0	dicarboxylic acid monoester; ethyl ester; isoquinolines; tertiary carboxamide	antihypertensive agent; EC 3.4.15.1 (peptidyl-dipeptidase A) inhibitor; prodrug
mifepristone Mifepristone: A progestational and glucocorticoid hormone antagonist. Its inhibition of progesterone induces bleeding during the luteal phase and in early pregnancy by releasing endogenous prostaglandins from the endometrium or decidua. As a glucocorticoid receptor antagonist, the drug has been used to treat hypercortisolism in patients with nonpituitary CUSHING SYNDROME.	2.08	1	0	3-oxo-Delta(4) steroid; acetylenic compound; tertiary amino compound	abortifacient; contraceptive drug; hormone antagonist; synthetic oral contraceptive
itraconazole Itraconazole: A triazole antifungal agent that inhibits cytochrome P-450-dependent enzymes required for ERGOSTEROL synthesis.. itraconazole : An N-arylpiperazine that is cis-ketoconazole in which the imidazol-1-yl group is replaced by a 1,2,4-triazol-1-yl group and in which the actyl group attached to the piperazine moiety is replaced by a p-[(+-)1-sec-butyl-5-oxo-1,5-dihydro-4H-1,2,4-triazol-4-yl]phenyl group. A potent P-glycoprotein and CYP3A4 inhibitor, it is used as an antifungal drug for the treatment of various fungal infections, including aspergillosis, blastomycosis, candidiasis, chromoblastomycosis, coccidioidomycosis, cryptococcosis, histoplasmosis, and sporotrichosis.	3.56	8	0	aromatic ether; conazole antifungal drug; cyclic ketal; dichlorobenzene; dioxolane; N-arylpiperazine; triazole antifungal drug; triazoles	EC 3.6.3.44 (xenobiotic-transporting ATPase) inhibitor; Hedgehog signaling pathway inhibitor; P450 inhibitor
salmeterol xinafoate Salmeterol Xinafoate: A selective ADRENERGIC BETA-2 RECEPTOR agonist that functions as a BRONCHODILATOR when administered by inhalation. It is used to manage the symptoms of ASTHMA and CHRONIC OBSTRUCTIVE PULMONARY DISEASE.	2.47	2	0	naphthoic acid
finasteride Finasteride: An orally active 3-OXO-5-ALPHA-STEROID 4-DEHYDROGENASE inhibitor. It is used as a surgical alternative for treatment of benign PROSTATIC HYPERPLASIA.. finasteride : An aza-steroid that is a synthetic drug for the treatment of benign prostatic hyperplasia.	2.08	1	0	3-oxo steroid; aza-steroid; delta-lactam	androgen antagonist; antihyperplasia drug; EC 1.3.1.22 [3-oxo-5alpha-steroid 4-dehydrogenase (NADP(+))] inhibitor
imiquimod Imiquimod: A topically-applied aminoquinoline immune modulator that induces interferon production. It is used in the treatment of external genital and perianal warts, superficial CARCINOMA, BASAL CELL; and ACTINIC KERATOSIS.. imiquimod : An imidazoquinoline fused [4,5-c] carrying isobutyl and amino substituents at N-1 and C-4 respectively. A prescription medication, it acts as an immune response modifier and is used to treat genital warts, superficial basal cell carcinoma, and actinic keratosis.	2.08	1	0	imidazoquinoline	antineoplastic agent; interferon inducer
sertindole sertindole : A phenylindole that is 1H-indole which is substituted on the nitrogen by a p-chlorophenyl group, at position 5 by chlorine, and at position 3 by a piperidin-4-yl group, which is itself substituted on the nitrogen by a 2-(2-oxoimidazolidin-1-yl)ethyl group.	2.08	1	0	heteroarylpiperidine; imidazolidinone; organochlorine compound; organofluorine compound; phenylindole	alpha-adrenergic antagonist; H1-receptor antagonist; second generation antipsychotic; serotonergic antagonist
adapalene Adapalene: A naphthalene derivative that has specificity for RETINOIC ACID RECEPTORS. It is used as a DERMATOLOGIC AGENT for the treatment of ACNE.. adapalene : A naphthoic acid that is CD437 in which the phenolic hydroxy group has been converted to its methyl ether.	2.08	1	0	adamantanes; monocarboxylic acid; naphthoic acid	dermatologic drug; EC 2.7.11.22 (cyclin-dependent kinase) inhibitor; non-steroidal anti-inflammatory drug
aromasil [no description available]	2.08	1	0	17-oxo steroid; 3-oxo-Delta(1),Delta(4)-steroid	antineoplastic agent; EC 1.14.14.14 (aromatase) inhibitor; environmental contaminant; xenobiotic
sparfloxacin [no description available]	2.08	1	0	fluoroquinolone antibiotic; N-arylpiperazine; quinolinemonocarboxylic acid; quinolone antibiotic; quinolone
zileuton [no description available]	2.08	1	0	1-benzothiophenes; ureas	anti-asthmatic drug; EC 1.13.11.34 (arachidonate 5-lipoxygenase) inhibitor; ferroptosis inhibitor; leukotriene antagonist; non-steroidal anti-inflammatory drug
cidofovir anhydrous Cidofovir: An acyclic nucleoside phosphonate that acts as a competitive inhibitor of viral DNA polymerases. It is used in the treatment of RETINITIS caused by CYTOMEGALOVIRUS INFECTIONS and may also be useful for treating HERPESVIRUS INFECTIONS.. cidofovir anhydrous : Cytosine substituted at the 1 position by a 3-hydroxy-2-(phosphonomethoxy)propyl group (S configuration). A nucleoside analogue, it is an injectable antiviral used for the treatment of cytomegalovirus (CMV) retinitis in AIDS patients.	2.08	1	0	phosphonic acids; pyrimidone	anti-HIV agent; antineoplastic agent; antiviral drug; photosensitizing agent
bromfenac bromfenac: bromfenac sodium is the active cpd; structure in first source. bromfenac : Amfenac in which the the hydrogen at the 4 position of the benzoyl group is substituted by bromine. It is used for the management of ocular pain and treatment of postoperative inflammation in patients who have undergone cataract extraction. It was withdrawn from the US market in 1998, following concerns over off-label abuse and hepatic failure.	2.08	1	0	aromatic amino acid; benzophenones; organobromine compound; substituted aniline	non-narcotic analgesic; non-steroidal anti-inflammatory drug
gemcitabine hydrochloride [no description available]	2.08	1	0	hydrochloride; organofluorine compound	anticoronaviral agent; antimetabolite; antineoplastic agent; antiviral drug; EC 1.17.4.1 (ribonucleoside-diphosphate reductase) inhibitor; immunosuppressive agent; radiosensitizing agent
aripiprazole Aripiprazole: A piperazine and quinolone derivative that is used primarily as an antipsychotic agent. It is a partial agonist of SEROTONIN RECEPTOR, 5-HT1A and DOPAMINE D2 RECEPTORS, where it also functions as a post-synaptic antagonist, and an antagonist of SEROTONIN RECEPTOR, 5-HT2A. It is used for the treatment of SCHIZOPHRENIA and BIPOLAR DISORDER, and as an adjunct therapy for the treatment of depression.. aripiprazole : An N-arylpiperazine that is piperazine substituted by a 4-[(2-oxo-1,2,3,4-tetrahydroquinolin-7-yl)oxy]butyl group at position 1 and by a 2,3-dichlorophenyl group at position 4. It is an antipsychotic drug used for the treatment of Schizophrenia, and other mood disorders.	2.08	1	0	aromatic ether; delta-lactam; dichlorobenzene; N-alkylpiperazine; N-arylpiperazine; quinolone	drug metabolite; H1-receptor antagonist; second generation antipsychotic; serotonergic agonist
atorvastatin calcium anhydrous [no description available]	2.08	1	0	organic calcium salt
atorvastatin [no description available]	2.17	1	0	aromatic amide; dihydroxy monocarboxylic acid; monofluorobenzenes; pyrroles; statin (synthetic)	environmental contaminant; xenobiotic
lamivudine [no description available]	2.48	2	0	monothioacetal; nucleoside analogue; oxacycle; primary alcohol	allergen; anti-HBV agent; antiviral drug; EC 2.7.7.49 (RNA-directed DNA polymerase) inhibitor; HIV-1 reverse transcriptase inhibitor; prodrug
duloxetine hydrochloride Duloxetine Hydrochloride: A thiophene derivative and selective NEUROTRANSMITTER UPTAKE INHIBITOR for SEROTONIN and NORADRENALINE (SNRI). It is an ANTIDEPRESSIVE AGENT and ANXIOLYTIC, and is also used for the treatment of pain in patients with DIABETES MELLITUS and FIBROMYALGIA.. (S)-duloxetine hydrochloride : A duloxetine hydrochloride in which the duloxetine moiety has S configuration.	2.08	1	0	duloxetine hydrochloride	antidepressant
valsartan Valsartan: A tetrazole derivative and ANGIOTENSIN II TYPE 1 RECEPTOR BLOCKER that is used to treat HYPERTENSION.. valsartan : A monocarboxylic acid amide consisting of L-valine in which the amino hydrogens have been replaced by a pentanoyl and a [2'-(1H-tetrazol-5-yl)biphenyl]-4-yl]methyl group. It exhibits antihypertensive activity.	2.08	1	0	biphenylyltetrazole; monocarboxylic acid amide; monocarboxylic acid	angiotensin receptor antagonist; antihypertensive agent; environmental contaminant; xenobiotic
ibandronic acid Ibandronic Acid: Aminobisphosphonate that is a potent inhibitor of BONE RESORPTION. It is used in the treatment of HYPERCALCEMIA associated with malignancy, for the prevention of fracture and bone complications in patients with breast cancer and bone metastases, and for the treatment and prevention of POSTMENOPAUSAL OSTEOPOROSIS.	2.05	1	0
zolmitriptan zolmitriptan: an antimigraine compound; a serotonin (5HT)-1D receptor agonist. zolmitriptan : A member of the class of tryptamines that is N,N-dimethyltryptamine in which the hydrogen at position 5 of the indole ring has been replaced by a [(4S)-2-oxo-1,3-oxazolidin-4-yl]methyl group. A serotonin 5-HT1 B and D receptor agonist, it is used for the treatment of migraine.	2.08	1	0	oxazolidinone; tryptamines	anti-inflammatory drug; serotonergic agonist; vasoconstrictor agent
adefovir dipivoxil bis(pivaloyloxymethyl)-9-(2-phosphonylmethoxyethyl)adenine: structure given in first source. adefovir pivoxil : An organic phosphonate that is the dipivoxil ester of adefovir. A prodrug for adefovir, an HIV-1 reverse transcriptase inhibitor, adefovir pivoxil is used to treat chronic hepatitis B viral infection.	2.08	1	0	6-aminopurines; carbonate ester; ether; organic phosphonate	antiviral drug; DNA synthesis inhibitor; HIV-1 reverse transcriptase inhibitor; nephrotoxic agent; prodrug
emtricitabine Emtricitabine: A deoxycytidine analog and REVERSE TRANSCRIPTASE INHIBITOR with antiviral activity against HIV-1 and HEPATITIS B viruses. It is used to treat HIV INFECTIONS.. emtricitabine : An organofluorine compound that is 5-fluorocytosine substituted at the 1 position by a 2-(hydroxymethyl)-1,3-oxathiolan-5-yl group (2R,5S configuration). It is used in combination therapy for the treatment of HIV-1 infection.	2.08	1	0	monothioacetal; nucleoside analogue; organofluorine compound; pyrimidone	antiviral drug; HIV-1 reverse transcriptase inhibitor
adenosine quinquefolan B: isolated from roots of Panax quinquefolium L.; RN not in Chemline 10/87; RN from Toxlit	2.21	1	0	adenosines; purines D-ribonucleoside	analgesic; anti-arrhythmia drug; fundamental metabolite; human metabolite; vasodilator agent
dehydroabietylamine dehydroabietylamine: has antimalarial activity; structure in first source	2.13	1	0	diterpenoid
paroxetine hydrochloride paroxetine hydrochloride : The hydrochloride salt of paroxetine. It is an antidepressant drug.	2.08	1	0	hydrochloride	antidepressant; anxiolytic drug; hepatotoxic agent; P450 inhibitor; serotonin uptake inhibitor
bupropion hydrochloride [no description available]	2.08	1	0	aromatic ketone
trazodone hydrochloride Triticum: A plant genus of the family POACEAE that is the source of EDIBLE GRAIN. A hybrid with rye (SECALE CEREALE) is called TRITICALE. The seed is ground into FLOUR and used to make BREAD, and is the source of WHEAT GERM AGGLUTININS.. trazodone hydrochloride : A hydrochloride salt prepared from equimolar amounts of trazodone and hydrogen chloride.	2.08	1	0	hydrochloride	adrenergic antagonist; antidepressant; H1-receptor antagonist; sedative; serotonin uptake inhibitor
trovafloxacin trovafloxacin: a trifluoronaphthyridone derivative of 7-(3-azabicyclo(3.1.0)hexyl)naphthyridone; has antineoplastic activity. trovafloxacin : A 1,8-naphthyridine derivative that is 4-oxo-1,4-dihydro-1,8-naphthyridine-3-carboxylic acid bearing additional 2,4-difluorophenyl, fluoro and 6-amino-3-azabicyclo[3.1.0]hex-3-yl substituents at positions 1, 6 and 7 respectively. A broad-spectrum antibiotic that was withdrawn from the market due to risk of liver failure.	2.05	1	0
doxazosin mesylate Cardura: Trade name in United States.	2.52	2	0	methanesulfonate salt	geroprotector
efavirenz efavirenz: HIV-1 reverse transcriptase inhibitor. efavirenz : 1,4-Dihydro-2H-3,1-benzoxazin-2-one substituted at the 4 position by cyclopropylethynyl and trifluoromethyl groups (S configuration) and at the 6 position by chlorine. A non-nucleoside reverse transcriptase inhibitor with activity against HIV, it is used with other antiretrovirals for combination therapy of HIV infection.	2.49	2	0	acetylenic compound; benzoxazine; cyclopropanes; organochlorine compound; organofluorine compound	antiviral drug; HIV-1 reverse transcriptase inhibitor
nelfinavir Nelfinavir: A potent HIV protease inhibitor. It is used in combination with other antiviral drugs in the treatment of HIV in both adults and children.. nelfinavir : An aryl sulfide that is used (as its mesylate salt) for treatment of HIV and also exhibits some anticancer properties.	2.08	1	0	aryl sulfide; benzamides; organic heterobicyclic compound; phenols; secondary alcohol; tertiary amino compound	antineoplastic agent; HIV protease inhibitor
mevastatin mevastatin: antifungal metabolite from Penicillium brevicopactum; potent inhibitory activity to sterol synthesis; structure. mevastatin : A carboxylic ester that is pravastatin that is lacking the allylic hydroxy group. A hydroxymethylglutaryl-CoA reductase inhibitor (statin) isolated from Penicillium citrinum and from Penicillium brevicompactum, its clinical use as a lipid-regulating drug ceased following reports of toxicity in animals.	2.08	1	0	2-pyranones; carboxylic ester; hexahydronaphthalenes; polyketide; statin (naturally occurring)	antifungal agent; apoptosis inducer; EC 3.4.24.83 (anthrax lethal factor endopeptidase) inhibitor; fungal metabolite; Penicillium metabolite
bupivacaine hydrochloride bupivacaine hydrochloride (anhydrous) : A racemate composed of equimolar amounts of dextrobupivacaine hydrochloride and levobupivacaine hydrochloride. The monohydrate form is commonly used as a local anaesthetic.. 1-butyl-N-(2,6-dimethylphenyl)piperidine-2-carboxamide hydrochloride : A hydrochloride obtained by combining 1-butyl-N-(2,6-dimethylphenyl)piperidine-2-carboxamide with one molar equivalent of hydrochloric acid.	2.08	1	0	hydrochloride; racemate	adrenergic antagonist; amphiphile; EC 3.1.1.8 (cholinesterase) inhibitor; EC 3.6.3.8 (Ca(2+)-transporting ATPase) inhibitor; local anaesthetic
ursolic acid [no description available]	2.05	1	0	hydroxy monocarboxylic acid; pentacyclic triterpenoid	geroprotector; plant metabolite
propamidine propamidine: structure given in first source. propamidine : A polyether that is the bis(4-guanidinophenyl) ether of propane-1,3-diol. Used (as its isethionate salt) for the treatment of minor eye or eyelid infections, such as conjunctivitis and blepharitis.	2.05	1	0	aromatic ether; guanidines; polyether	antimicrobial agent; antiseptic drug
thiazolyl blue thiazolyl blue: RN & II refers to bromide. 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide : The bromide salt of 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium.	2	1	0	organic bromide salt	colorimetric reagent; dye
betulinic acid [no description available]	2.13	1	0	hydroxy monocarboxylic acid; pentacyclic triterpenoid	anti-HIV agent; anti-inflammatory agent; antimalarial; antineoplastic agent; EC 5.99.1.3 [DNA topoisomerase (ATP-hydrolysing)] inhibitor; plant metabolite
arctigenin arctigenin: precursor to catechols; in many plants	2.58	2	0	lignan
plerixafor plerixafor: a bicyclam derivate, highly potent & selective inhibitor of HIV-1 & HIV-2. plerixafor : An azamacrocycle consisting of two cyclam rings connected by a 1,4-phenylenebis(methylene) linker. It is a CXCR4 chemokine receptor antagonist and a hematopoietic stem cell mobilizer. It is used in combination with grulocyte-colony stimulating factor (G-CSF) to mobilize hematopoietic stem cells to the perpheral blood for collection and subsequent autologous transplantation in patients with non-Hodgkin's lymphoma and multiple myeloma.	2.08	1	0	azacycloalkane; azamacrocycle; benzenes; crown amine; secondary amino compound; tertiary amino compound	anti-HIV agent; antineoplastic agent; C-X-C chemokine receptor type 4 antagonist; immunological adjuvant
amprenavir [no description available]	2.08	1	0	carbamate ester; sulfonamide; tetrahydrofuryl ester	antiviral drug; HIV protease inhibitor
diminazene aceturate [no description available]	2.31	1	0
2'-deoxyuridylic acid 2'-deoxyuridylic acid: RN given refers to parent cpd	2.03	1	0	deoxyuridine phosphate; pyrimidine 2'-deoxyribonucleoside 5'-monophosphate	Escherichia coli metabolite; metabolite; mouse metabolite
epigallocatechin gallate epigallocatechin gallate: a steroid 5alpha-reductase inhibitor and antimutagen in green tea (Camellia sinensis). (-)-epigallocatechin 3-gallate : A gallate ester obtained by the formal condensation of gallic acid with the (3R)-hydroxy group of (-)-epigallocatechin.	2.05	1	0	flavans; gallate ester; polyphenol	antineoplastic agent; antioxidant; apoptosis inducer; geroprotector; Hsp90 inhibitor; neuroprotective agent; plant metabolite
ticlopidine hydrochloride [no description available]	2.08	1	0	hydrochloride
epirubicin hydrochloride [no description available]	2.08	1	0
glutathione disulfide Glutathione Disulfide: A GLUTATHIONE dimer formed by a disulfide bond between the cysteine sulfhydryl side chains during the course of being oxidized.	2.45	2	0	glutathione derivative; organic disulfide	Escherichia coli metabolite; mouse metabolite
sinefungin [no description available]	2.05	1	0	adenosines; non-proteinogenic alpha-amino acid	antifungal agent; antimicrobial agent
droxicam droxicam: structure given in first source. droxicam : An organic heterotricyclic compound that is 2H,5H-[1,3]oxazino[5,6-c][1,2]benzothiazine-2,4(3H)-dione 6,6-dioxide substituted at positions 3 and 5 by pyridin-2-yl and methyl groups respectively. A prodrug of piroxicam, it is used for the relief of pain and inflammation in musculoskeletal disorders such as rheumatoid arthritis and osteoarthritis.	2.05	1	0	organic heterotricyclic compound; pyridines	cyclooxygenase 1 inhibitor; hepatotoxic agent; non-narcotic analgesic; non-steroidal anti-inflammatory drug; platelet aggregation inhibitor; prodrug
etofibrate etofibrate: analog of clofibrate with nicotinic acid substituted on the 2-carbon of the ethyl ester group; structure; RN given refers to parent cpd	2.05	1	0	monocarboxylic acid
sertaconazole sertaconazole : A racemate comprising equimolar amounts of (R)- and (S)-sertaconazole. A broad spectrum antifungal with added antipruritic and anti-inflammatory activity used (as its nitrate salt) for treatment of various skin infections.. 1-{2-[(7-chloro-1-benzothiophen-3-yl)methoxy]-2-(2,4-dichlorophenyl)ethyl}imidazole : A member of the class of imidazoles that carries a 2-[(7-chloro-1-benzothiophen-3-yl)methoxy]-2-(2,4-dichlorophenyl)ethyl group at position 1.	2.13	1	0	1-benzothiophenes; dichlorobenzene; ether; imidazoles
lercanidipine [no description available]	2.05	1	0	diarylmethane
azelnidipine azelnidipine: structure given in first source	2.05	1	0	isopropyl ester
pazufloxacin [no description available]	2.08	1	0	quinolines
repaglinide [no description available]	2.08	1	0	piperidines
telmisartan Telmisartan: A biphenyl compound and benzimidazole derivative that acts as an angiotensin II type 1 receptor antagonist. It is used in the management of HYPERTENSION.. telmisartan : A member of the class of benzimidazoles used widely in the treatment of hypertension.	2.08	1	0	benzimidazoles; biphenyls; carboxybiphenyl	angiotensin receptor antagonist; antihypertensive agent; EC 3.4.15.1 (peptidyl-dipeptidase A) inhibitor; environmental contaminant; xenobiotic
dexfenfluramine Dexfenfluramine: The S-isomer of FENFLURAMINE. It is a serotonin agonist and is used as an anorectic. Unlike fenfluramine, it does not possess any catecholamine agonist activity.. (S)-fenfluramine : The S-enantiomer of fenfluramine. It stimulates the release of serotonin and selectively inhibits its reuptake, but unlike fenfluramine it does not possess catecholamine agonist activity. It was formerly given by mouth as the hydrochloride in the treatment of obesity, but, like fenfluramine, was withdrawn wolrdwide following reports of valvular heart defects.	2.05	1	0	fenfluramine	appetite depressant; serotonergic agonist; serotonin uptake inhibitor
synthalin a synthalin A: RN given refers to parent cpd; structure. synthalin : A hydrochloride resulting from the reaction of decamethylenediguanidine with 2 mol eq. of hydrogen chloride.. synthalin A : A member of the class of guanidines that is decane having guanidino groups at the 1- and 10-positions.	2.05	1	0	guanidines	hepatotoxic agent; hypoglycemic agent; nephrotoxin
4-amino-6-chloro-1,3-benzenedisulfonamide 4-amino-6-chloro-1,3-benzenedisulfonamide: metabolite of hydrochlorothiazide	2.08	1	0	sulfonamide
triazoles Triazoles: Heterocyclic compounds containing a five-membered ring with two carbon atoms and three nitrogen atoms with the molecular formula C2H3N3.. triazoles : An azole in which the five-membered heterocyclic aromatic skeleton contains three N atoms and two C atoms.	12.34	41	6	1,2,3-triazole
9-stearolic acid 9-stearolic acid: structure given in first source. stearolic acid : An octadecynoic acid having its triple bond at position 9.	2.21	1	0	octadecynoic acid
disulphane [no description available]	2.08	1	0
miconazole nitrate miconazole nitrate : A racemate composed of equimolar amounts of (R)- and (S)-miconazole nitrate. An antifungal used for the treatment of athlete's foot, jock itch, ringworm and other fungal skin infections. It inhibits the synthesis of ergosterol, a critical component of fungal cell membranes.	2.08	1	0
ibopamine ibopamine: structure given in UD 31;67a & in 2nd source	2.05	1	0	benzoate ester; phenols
zoledronic acid Zoledronic Acid: An imidobisphosphonate inhibitor of BONE RESORPTION that is used for the treatment of malignancy-related HYPERCALCEMIA; OSTEITIS DEFORMANS; and OSTEOPOROSIS.. zoledronic acid : An imidazole compound having a 2,2-bis(phosphono)-2-hydroxyethane-1-yl substituent at the 1-position.	2.47	2	0	1,1-bis(phosphonic acid); imidazoles	bone density conservation agent
talinolol [no description available]	2.52	2	0	ureas
fexinidazole fexinidazole: structure given in first source	5.92	12	0
pirlindole pirlindole: RN given refers to parent cpd; synonym pyrazidol refers to mono-HCl; structure in Negwer, 5th ed, #2812	2.05	1	0	carbazoles
artemisinin (+)-artemisinin : A sesquiterpene lactone obtained from sweet wormwood, Artemisia annua, which is used as an antimalarial for the treatment of multi-drug resistant strains of falciparum malaria.	3.26	5	0	organic peroxide; sesquiterpene lactone	antimalarial; plant metabolite
brinzolamide brinzolamide: an antiglaucoma agent	2.49	2	0	sulfonamide; thienothiazine	antiglaucoma drug; EC 4.2.1.1 (carbonic anhydrase) inhibitor
drospirenone drospirenone: a progestational compound with antimineralocorticoid and antiandrogenic activity; structure given in first source	2.08	1	0	3-oxo-Delta(4) steroid; steroid lactone	aldosterone antagonist; contraceptive drug; progestin
artemether Artemether: An artemisinin derivative that is used in the treatment of MALARIA.. artemether : An artemisinin derivative that is artemisinin in which the lactone has been converted to the corresponding lactol methyl ether. It is used in combination with lumefantrine as an antimalarial for the treatment of multi-drug resistant strains of falciparum malaria.	3.01	4	0	artemisinin derivative; cyclic acetal; organic peroxide; semisynthetic derivative; sesquiterpenoid	antimalarial
1,2,3,4-tetrahydroquinoline 1,2,3,4-tetrahydroquinoline: structure in first source. 1,2,3,4-tetrahydroquinoline : A member of the class of quinolines that is the 1,2,3,4-tetrahydro derivative of quinoline.	2.08	1	0	quinolines
2,4-disulfamyl-5-trifluoromethylaniline 2,4-disulfamyl-5-trifluoromethylaniline: precursor of hydroflumethiazide	2.08	1	0
2,5-diphenylfuran [no description available]	2.15	1	0	diphenylfuran
6-amino-1-hydroxyhexane-1,1-diphosphonate 6-amino-1-hydroxyhexane-1,1-diphosphonate: used for therapy of Paget's disease of bone & malignant hypercalcaemia	2.43	2	0	1,1-bis(phosphonic acid)
uk 68798 [no description available]	2.08	1	0	aromatic ether; sulfonamide; tertiary amino compound	anti-arrhythmia drug; potassium channel blocker
hp 873 iloperidone: an atypical, negative symptom antipsychotic agent. iloperidone : A member of the class of piperidines that is the 4-acetyl-2-methoxyphenyl ether of 3-(piperidin-1-yl)propan-1-ol which is substituted at position 4 of the piperidine ring by a 6-fluoro-1,2-benzoxazol-3-yl group. A member of the group of second generation antipsychotics (also known as an atypical antipsychotics), it is used for the treatment of schizophrenia.	2.08	1	0	1,2-benzoxazoles; aromatic ether; aromatic ketone; methyl ketone; monoamine; organofluorine compound; piperidines; tertiary amino compound	dopaminergic antagonist; second generation antipsychotic; serotonergic antagonist
loxapine succinate [no description available]	2.08	1	0	succinate salt	geroprotector
16-bromoepiandrosterone 16alpha-bromo-3beta-hydroxy-5alpha-androstan-17-one: a synthetic adrenal hormone that reduced the incidence of tuberculosis and other opportunistic infections in AIDS patients	3.82	2	0
voriconazole Voriconazole: A triazole antifungal agent that specifically inhibits STEROL 14-ALPHA-DEMETHYLASE and CYTOCHROME P-450 CYP3A.. voriconazole : A triazole-based antifungal agent used for the treatment of esophageal candidiasis, invasive pulmonary aspergillosis, and serious fungal infections caused by Scedosporium apiospermum and Fusarium spp. It is an inhibitor of cytochrome P450 2C9 (CYP2C9) and CYP3A4.	2.08	1	0	conazole antifungal drug; difluorobenzene; pyrimidines; tertiary alcohol; triazole antifungal drug	P450 inhibitor
betamipron [no description available]	2.08	1	0	organonitrogen compound; organooxygen compound
rexigen clobenzorex: RN given refers to (+)-isomer; structure	2.05	1	0
uroxatral [no description available]	2.08	1	0	hydrochloride
aceclofenac [no description available]	2.47	2	0	amino acid; carboxylic ester; dichlorobenzene; monocarboxylic acid; secondary amino compound	EC 1.14.99.1 (prostaglandin-endoperoxide synthase) inhibitor; non-narcotic analgesic; non-steroidal anti-inflammatory drug
secnidazole [no description available]	3.66	2	0	C-nitro compound; imidazoles; secondary alcohol	epitope
clociguanil clociguanil: RN given refers to parent cpd; structure	2.05	1	0
tebuquine [no description available]	2.05	1	0
thiocolchicoside [no description available]	2.08	1	0	glycoside
lycorine lycorine: from bulbs of LYCORIS & other plants; RN given refers to (1 alpha,2 beta)-isomer; structure in Merck Index, 9th ed, #5444. lycorine : An indolizidine alkaloid that is 3,12-didehydrogalanthan substituted by hydroxy groups at positions and 2 and a methylenedioxy group across positions 9 and 10. Isolated from Crinum asiaticum, it has been shown to exhibit antimalarial activity.	3.31	1	0	indolizidine alkaloid	anticoronaviral agent; antimalarial; plant metabolite; protein synthesis inhibitor
alpha-lapachone alpha-lapachone: structure in first source	2.74	3	0	organic heterotricyclic compound; organooxygen compound
kaurenoic acid [no description available]	2.46	2	0	ent-kaurane diterpenoid	anti-HIV-1 agent; antineoplastic agent; plant metabolite
thiophene-2-carboxylic acid hydrazide thiophene-2-carbohydrazide: structure in first source	2.17	1	0
doripenem Doripenem: A carbapenem derivative antibacterial agent that is more stable to renal dehydropeptidase I than IMIPENEM, but does not need to be given with an enzyme inhibitor such as CILASTATIN. It is used in the treatment of infections such as HOSPITAL-ACQUIRED PNEUMONIA, and complicated intra-abdominal or urinary-tract infections, including PYELONEPHRITIS.	2.08	1	0	carbapenems
pretazettine pretazettine: potent inhibitor of viral reverse transcriptase; narcissus alkaloid; prolongs life of leukemic mice; RN given refers to (6a beta,8 beta)-isomer; structure	3.31	1	0	alkaloid
dehydroleucodine dehydroleucodine: has antimicrobial activity; RN given refers to (3aS-(3aalpha,9aalpha,9bbeta))-isomer	2.46	2	0
new methylene blue [no description available]	2.21	1	0
2-n-propylquinoline 2-propylquinoline: structure in first source	2	1	0
2-bromo-1,4-naphthoquinone 2-bromo-1,4-naphthoquinone: structure in first source	2.51	2	0
atovaquone Atovaquone: A hydroxynaphthoquinone that has antimicrobial activity and is being used in antimalarial protocols.. atovaquone : A naphthoquinone compound having a 4-(4-chlorophenyl)cyclohexyl group at the 2-position and a hydroxy substituent at the 3-position.	3.32	6	0	hydroxy-1,2-naphthoquinone
methyl gentisate methyl gentisate: skin lightening agent; structure in first source	2.11	1	0	benzoate ester; phenols
4-aminopyrazolo(3,4-d)pyrimidine 4-aminopyrazolo(3,4-d)pyrimidine: adenine analog which suppresses growth of E coli & Bacillus cereus; inhibits cell growth & purine biosynthesis in rat hepatoma	2.31	1	0
rosiglitazone [no description available]	2.08	1	0	aminopyridine; thiazolidinediones	EC 6.2.1.3 (long-chain-fatty-acid--CoA ligase) inhibitor; ferroptosis inhibitor; insulin-sensitizing drug
tamiflu [no description available]	2.08	1	0	phosphate salt
cryptolepine cryptolepine: fused indole-quinoline; structure in first source; from CRYPTOLEPIS sanguinolenta. cryptolepine : An organic heterotetracyclic compound that is 5H-indolo[3,2-b]quinoline in which the hydrogen at position N-5 is replaced by a methyl group.	2.46	2	0	indole alkaloid; organic heterotetracyclic compound; organonitrogen heterocyclic compound	anti-inflammatory agent; antimalarial; antineoplastic agent; cysteine protease inhibitor; plant metabolite
bexarotene [no description available]	2.08	1	0	benzoic acids; naphthalenes; retinoid	antineoplastic agent
s20098 [no description available]	2.08	1	0	acetamides
flunisolide flunisolide: flunisolide HFA is a formulation of flunisolide using hydrofluoroalkane (HFA) as propellant in place of chlorofluorocarbon (CFC) ones	2.08	1	0	11beta-hydroxy steroid; 20-oxo steroid; 21-hydroxy steroid; 3-oxo-Delta(1),Delta(4)-steroid; cyclic ketal; fluorinated steroid; primary alpha-hydroxy ketone	anti-asthmatic drug; anti-inflammatory drug; immunosuppressive agent
ketorolac tromethamine Ketorolac Tromethamine: A pyrrolizine carboxylic acid derivative structurally related to INDOMETHACIN. It is a non-steroidal anti-inflammatory agent used for analgesia for postoperative pain and inhibits cyclooxygenase activity.. ketorolac tromethamine : An organoammonium salt resulting from the mixture of equimolar amounts of ketorolac and tromethamine (tris). It has potent non-sedating analgesic and moderate anti-inflammatory effects. It is used in the short-term management of post-operative pain, and in eye drops to relieve the ocular itching associated with seasonal allergic conjunctivitis.	2.08	1	0	organoammonium salt	analgesic; cyclooxygenase 1 inhibitor; cyclooxygenase 2 inhibitor
clarithromycin Clarithromycin: A semisynthetic macrolide antibiotic derived from ERYTHROMYCIN that is active against a variety of microorganisms. It can inhibit PROTEIN SYNTHESIS in BACTERIA by reversibly binding to the 50S ribosomal subunits. This inhibits the translocation of aminoacyl transfer-RNA and prevents peptide chain elongation.. clarithromycin : The 6-O-methyl ether of erythromycin A, clarithromycin is a macrolide antibiotic used in the treatment of respiratory-tract, skin and soft-tissue infections. It is also used to eradicate Helicobacter pylori in the treatment of peptic ulcer disease. It prevents bacteria from growing by interfering with their protein synthesis.	2.08	1	0	macrolide antibiotic	antibacterial drug; environmental contaminant; protein synthesis inhibitor; xenobiotic
5-amino-1,3,4-thiadiazole-2-sulfonamide 5-amino-1,3,4-thiadiazole-2-sulfonamide: structure in first source	2.08	1	0
tretazicar tretazicar: minor descriptor (75-84); on-line & Index Medicus search AZIRIDINES (75-84)	2.4	2	0
nicotine (S)-nicotine : A 3-(1-methylpyrrolidin-2-yl)pyridine in which the chiral centre has S-configuration. The naturally occurring and most active enantiomer of nicotine, isolated from Nicotiana tabacum.	2.08	1	0	3-(1-methylpyrrolidin-2-yl)pyridine	anxiolytic drug; biomarker; immunomodulator; mitogen; neurotoxin; nicotinic acetylcholine receptor agonist; peripheral nervous system drug; phytogenic insecticide; plant metabolite; psychotropic drug; teratogenic agent; xenobiotic
cinchonine [no description available]	2.05	1	0	(8xi)-cinchonan-9-ol; cinchona alkaloid	metabolite
tetrahydroharmane [no description available]	2.05	1	0
gliquidone gliquidone: structure; RN given refers to parent cpd	2.08	1	0	isoquinolines
n-hexadecyl-n,n-dimethyl-3-ammonio-1-propanesulfonate [no description available]	2.05	1	0
sr 2555 [no description available]	1.96	1	0
lopinavir [no description available]	2.08	1	0	amphetamines; dicarboxylic acid diamide	anticoronaviral agent; antiviral drug; HIV protease inhibitor
sugiol sugiol: diterpene with anti-inflammatory activity from Calocedrus formosana bark; structure in first source. sugiol : An abietane diterpenoid that is ferruginol in which the methylene group para to the phenolic hydroxy group has been substituted by an oxo group.	2.11	1	0	abietane diterpenoid; carbotricyclic compound; cyclic terpene ketone; meroterpenoid; phenols	antineoplastic agent; antioxidant; antiviral agent; plant metabolite; radical scavenger
glucuronic acid Glucuronic Acid: A sugar acid formed by the oxidation of the C-6 carbon of GLUCOSE. In addition to being a key intermediate metabolite of the uronic acid pathway, glucuronic acid also plays a role in the detoxification of certain drugs and toxins by conjugating with them to form GLUCURONIDES.. D-glucuronic acid : The D-enantiomer of glucuronic acid.. D-glucopyranuronic acid : A D-glucuronic acid in cyclic pyranose form.	2.17	1	0	D-glucuronic acid	algal metabolite
methyl 5-nitro-2-furoate [no description available]	2.01	1	0	carboxylic ester
desethylchloroquine desethylchloroquine: metabolite of chloroquine	2.05	1	0	aminoquinoline
2-methyl-1,2,3,4-tetrahydroquinoline 2-methyl-1,2,3,4-tetrahydroquinoline: found in brains of Parkinson patients	2.05	1	0
canthin-6-one canthin-6-one: from Zanthoxylum usambarense; structure in first source. canthin-6-one : An indole alkaloid that is 6H-indolo[3,2,1-de][1,5]naphthyridine substituted by an oxo group at position 6.	2.03	1	0	enone; indole alkaloid; organic heterotetracyclic compound	antimycobacterial drug; metabolite
5-iodotubercidin 7-iodotubercidin: inhibits Toxoplasma gondii adenosine kinase	2.21	1	0	organoiodine compound
s-(2,4-dinitrophenyl)glutathione S-(2,4-dinitrophenyl)glutathione : A glutathione conjugate in which the thiol hydrogen of glutathione has been replaced by a 2,4-dinitrophenyl group.	2.15	1	0	glutathione conjugate
1-(2-nitro-1-imidazolyl)-3-aziridino-2-propanol 1-(2-nitro-1-imidazolyl)-3-aziridino-2-propanol: structure given in first source	5.14	3	1
wr 159412 [no description available]	2.05	1	0
hippadine hippadine: isolated from Crinum bulbs	3.31	1	0
moxifloxacin hydrochloride moxifloxacin hydrochloride : A hydrochloride comprising equimolar amounts of moxifloxacin and hydrogen chloride.	2.08	1	0	hydrochloride	antibacterial drug
cinchonidine cinchonidine: has antimalarial activity; diastereoisomer of cinchonine with distinct physiochemical properties; RN given refers to parent cpd(8alpha,9R)-isomer. cinchonidine : 8-epi-Cinchonan in which a hydrogen at position 9 is substituted by hydroxy (R configuration). A diasteroisomer of cinchonine, it occurs in the bark of most varieties of Cinchona shrubs, and is frequently used for directing chirality in asymmetric synthesis.	2.05	1	0	(8xi)-cinchonan-9-ol; cinchona alkaloid	metabolite
benzyloxyamine benzyloxyamine: RN given refers to parent cpd	2.05	1	0
fulvestrant Fulvestrant: An estradiol derivative and estrogen receptor antagonist that is used for the treatment of estrogen receptor-positive, locally advanced or metastatic breast cancer.. fulvestrant : A 3-hydroxy steroid that is 17beta-estradiol in which the 7alpha hydrogen has been replaced by a nonyl group in which one of the hydrogens of the terminal methyl has been replaced by a (4,4,5,5,5-pentafluoropentyl)sulfinyl group. An estrogen receptor antagonist, it is used in the treatment of breast cancer.	2.08	1	0	17beta-hydroxy steroid; 3-hydroxy steroid; organofluorine compound; sulfoxide	antineoplastic agent; estrogen antagonist; estrogen receptor antagonist
mizoribine [no description available]	2.08	1	0	imidazoles	anticoronaviral agent
sr141716 [no description available]	2.08	1	0	amidopiperidine; carbohydrazide; dichlorobenzene; monochlorobenzenes; pyrazoles	anti-obesity agent; appetite depressant; CB1 receptor antagonist
bosentan anhydrous Bosentan: A sulfonamide and pyrimidine derivative that acts as a dual endothelin receptor antagonist used to manage PULMONARY HYPERTENSION and SYSTEMIC SCLEROSIS.	2.08	1	0	primary alcohol; pyrimidines; sulfonamide	antihypertensive agent; endothelin receptor antagonist
artesunic acid [no description available]	2.31	1	0
racecadotril racecadotril: parenterally active enkephalinase inhibitor	2.08	1	0	N-acyl-amino acid
pyronaridine [no description available]	2.05	1	0	aminoquinoline
parthenolide [no description available]	2.05	1	0	germacranolide
tamibarotene tamibarotene: has retinoid-binding activity. tamibarotene : A dicarboxylic acid monoamide resulting from the condensation of one of the carboxy groups of terephthalic acid with the amino group of 5,5,8,8-tetramethyl-5,6,7,8-tetrahydronaphthalen-2-amine.	2.21	1	0	dicarboxylic acid monoamide; retinoid; tetralins	antineoplastic agent; retinoic acid receptor alpha/beta agonist
tadalafil [no description available]	2.08	1	0	benzodioxoles; pyrazinopyridoindole	EC 3.1.4.35 (3',5'-cyclic-GMP phosphodiesterase) inhibitor; vasodilator agent
trypanothione trypanothione disulfide : An organic disulfide resulting from the formal oxidative coupling of the thiol groups of N(1),N(8)-bis(glutathionyl)-spermidine from the insect-parasitic trypanosomatid Crithidia fasciculata.	3.29	6	0	organic disulfide
tafenoquine tafenoquine : A racemate comprising equimolar amounts of (R)- and (S)-tafenoquine.. N(4)-{2,6-dimethoxy-4-methyl-5-[3-(trifluoromethyl)phenoxy]quinolin-8-yl}pentane-1,4-diamine : An aminoquinoline that is 8-aminoquinoline which is substituted by methoxy groups at positions 2 and 6, a methyl group at position 4, and a m-(trifluoromethyl)phenoxy group at position 5, and in which the amino substituent at position 8 is itself substituted by a 5-aminopentan-2-yl group.	2.05	1	0	(trifluoromethyl)benzenes; aminoquinoline; aromatic ether; primary amino compound; secondary amino compound
plavix [no description available]	2.08	1	0	azaheterocycle sulfate salt; organoammonium sulfate salt	anticoagulant; P2Y12 receptor antagonist; platelet aggregation inhibitor
cubebin cubebin: structure in first source. (-)-cubebin : A lignan that consists of tetrahydrofuran-2-ol substituted by two 1,3-benzodioxol-5-ylmethyl groups at positions 3 and 4 respectively (the 2S,3R,4R stereoisomer). It is isolated from the leaves of Piper nigrum and exhibits analgesic, anti-inflammatory, antimicrobial and trypanocidal activities.	2.08	1	0	benzodioxoles; cyclic acetal; lactol; lignan; secondary alcohol	analgesic; anti-inflammatory agent; antimicrobial agent; histamine antagonist; plant metabolite; trypanocidal drug
basic blue 3 Basic Blue 3: structure in first source	2.04	1	0
cynaropicrin cynaropicrin: structure given in first source; RN given for ((3aR-(3aalpha,4alpha,6aalpha,8beta,9aalpha,9bbeta)))-isomer	2.08	1	0	sesquiterpene lactone
clofarabine [no description available]	2.08	1	0	adenosines; organofluorine compound	antimetabolite; antineoplastic agent
mk 436 MK 436: structure	2.9	4	0
pramipexole Pramipexole: A benzothiazole derivative and dopamine agonist with antioxidant properties that is used in the treatment of PARKINSON DISEASE and RESTLESS LEGS SYNDROME.. pramipexole : A member of the class of benzothiazoles that is 4,5,6,7-tetrahydro-1,3-benzothiazole in which the hydrogens at the 2 and 6-pro-S-positions are substituted by amino and propylamino groups, respectively.	2.08	1	0	benzothiazoles; diamine	antidyskinesia agent; antiparkinson drug; dopamine agonist; radical scavenger
valdecoxib [no description available]	2.49	2	0	isoxazoles; sulfonamide	antipyretic; antirheumatic drug; cyclooxygenase 2 inhibitor; non-narcotic analgesic; non-steroidal anti-inflammatory drug
desethylamodiaquine desethylamodiaquine: metabolite of amodiaquine	2.05	1	0
3'-fluoro-3'-deoxyadenosine 3'-fluoro-3'-deoxyadenosine: structure given in first source	2.31	1	0
n,n-dideethylchloroquine [no description available]	2.05	1	0
perchlorate perchlorate: the explosive component of rocket fuel; an environmental contaminant that disrupts THYROID HORMONES. perchlorate : A monovalent inorganic anion obtained by deprotonation of perchloric acid.	2.06	1	0	chlorine oxoanion; monovalent inorganic anion
imatinib mesylate imatinib methanesulfonate : A methanesulfonate (mesylate) salt that is the monomesylate salt of imatinib. Used for treatment of chronic myelogenous leukemia and gastrointestinal stromal tumours.	2.21	1	0	methanesulfonate salt	anticoronaviral agent; antineoplastic agent; apoptosis inducer; tyrosine kinase inhibitor
mk 0663 [no description available]	2.08	1	0	bipyridines; organochlorine compound; sulfone	cyclooxygenase 2 inhibitor; non-steroidal anti-inflammatory drug
gefitinib [no description available]	2.08	1	0	aromatic ether; monochlorobenzenes; monofluorobenzenes; morpholines; quinazolines; secondary amino compound; tertiary amino compound	antineoplastic agent; epidermal growth factor receptor antagonist
n-(n-(3-carboxyoxirane-2-carbonyl)leucyl)isoamylamine N-(N-(3-carboxyoxirane-2-carbonyl)leucyl)isoamylamine: inhibits calcium-activated neutral protease; see also record for E-64; RN given refers to (2-S-(2alpha,3beta)(R*)-isomer)	2.1	1	0	leucine derivative
e 64 E 64: cysteine protease inhibitor of microbial origin, which inhibits cathepsin B (EC 3.4.22.1) and cathepsin L (EC 3.4.22.-)	2.76	3	0	dicarboxylic acid monoamide; epoxy monocarboxylic acid; guanidines; L-leucine derivative; zwitterion	antimalarial; antiparasitic agent; protease inhibitor
desloratadine desloratadine: major metabolite of loratadine. desloratadine : Loratadine in which the ethoxycarbonyl group attached to the piperidine ring is replaced by hydrogen. The major metabolite of loratidine, desloratadine is an antihistamine which is used for the symptomatic relief of allergic conditions including rhinitis and chronic urticaria. It does not readily enter the central nervous system, so does not cause drowsiness.	2.08	1	0	benzocycloheptapyridine	anti-allergic agent; cholinergic antagonist; drug metabolite; H1-receptor antagonist
furamidine furamidine: RN given refers to parent cpd; WR 199385 refers to di-HCl; pafuramidine is a prodrug of this	2.74	3	0
methotrexate [no description available]	2.52	2	0	dicarboxylic acid; monocarboxylic acid amide; pteridines	abortifacient; antimetabolite; antineoplastic agent; antirheumatic drug; dermatologic drug; DNA synthesis inhibitor; EC 1.5.1.3 (dihydrofolate reductase) inhibitor; immunosuppressive agent
3,6-diamino-9-(4-(methylsulfonyl)aminophenyl)aminoacridine [no description available]	2.05	1	0
chlorophenol red galactopyranoside chlorophenol red galactopyranoside: a chromogenic substrate used for detection of beta-galactosidase in transfected mammalian cells	2.02	1	0
ne 58051 NE 58051: inhibits tumor cell adhesion to extracellular matrices; structure in first source	2.43	2	0
1-deazatubercidin 1-deazatubercidin: structure given in first source	2.69	2	0
sulbactam [no description available]	2.08	1	0	penicillanic acids
olmesartan medoxomil Olmesartan Medoxomil: An ANGIOTENSIN II TYPE 1 RECEPTOR BLOCKER that is used to manage HYPERTENSION.	2.08	1	0	biphenyls
4-bromomethyl-3-nitrobenzoic acid 4-bromomethyl-3-nitrobenzoic acid: structure given in first source; a thiol photo-deprotection agent	2.06	1	0
omega-n-methylarginine omega-N-Methylarginine: A competitive inhibitor of nitric oxide synthetase.. N(omega)-methyl-L-arginine : A L-arginine derivative with a N(omega)-methyl substituent.	2.01	1	0	amino acid zwitterion; arginine derivative; guanidines; L-arginine derivative; non-proteinogenic L-alpha-amino acid
abiraterone [no description available]	2.08	1	0	3beta-hydroxy-Delta(5)-steroid; 3beta-sterol; pyridines	antineoplastic agent; EC 1.14.99.9 (steroid 17alpha-monooxygenase) inhibitor
wr 242511 WR 242511: RN given refers to parent cpd	2.05	1	0
febuxostat Febuxostat: A thiazole derivative and inhibitor of XANTHINE OXIDASE that is used for the treatment of HYPERURICEMIA in patients with chronic GOUT.. febuxostat : A 1,3-thiazolemonocarboxylic acid that is 4-methyl-1,3-thiazole-5-carboxylic acid which is substituted by a 3-cyano-4-(2-methylpropoxy)phenyl group at position 2. It is an orally-active, potent, and selective xanthine oxidase inhibitor used for the treatment of chronic hyperuricaemia in patients with gout.	2.08	1	0	1,3-thiazolemonocarboxylic acid; aromatic ether; nitrile	EC 1.17.3.2 (xanthine oxidase) inhibitor
ro 15-0216 [no description available]	1.97	1	0
lexapro Lexapro: Trade name of escitalopram, the active S-enantiomer of the racemic citalopram.	2.08	1	0
docetaxel anhydrous Docetaxel: A semisynthetic analog of PACLITAXEL used in the treatment of locally advanced or metastatic BREAST NEOPLASMS and NON-SMALL CELL LUNG CANCER.. docetaxel anhydrous : A tetracyclic diterpenoid that is paclitaxel with the N-benzyloxycarbonyl group replaced by N-tert-butoxycarbonyl, and the acetoxy group at position 10 replaced by a hydroxy group.	2.08	1	0	secondary alpha-hydroxy ketone; tetracyclic diterpenoid	antimalarial; antineoplastic agent; photosensitizing agent
levofloxacin Levofloxacin: The L-isomer of Ofloxacin.. levofloxacin : An optically active form of ofloxacin having (S)-configuration; an inhibitor of bacterial topoisomerase IV and DNA gyrase.	2.52	2	0	9-fluoro-3-methyl-10-(4-methylpiperazin-1-yl)-7-oxo-2,3-dihydro-7H-[1,4]oxazino[2,3,4-ij]quinoline-6-carboxylic acid; fluoroquinolone antibiotic; quinolone antibiotic	antibacterial drug; DNA synthesis inhibitor; EC 5.99.1.3 [DNA topoisomerase (ATP-hydrolysing)] inhibitor; topoisomerase IV inhibitor
ezetimibe Ezetimibe: An azetidine derivative and ANTICHOLESTEREMIC AGENT that inhibits intestinal STEROL absorption. It is used to reduce total CHOLESTEROL; LDL CHOLESTEROL, and APOLIPOPROTEINS B in the treatment of HYPERLIPIDEMIAS.. ezetimibe : A beta-lactam that is azetidin-2-one which is substituted at 1, 3, and 4 by p-fluorophenyl, 3-(p-fluorophenyl)-3-hydroxypropyl, and 4-hydroxyphenyl groups, respectively (the 3R,3'S,4S enantiomer).	2.08	1	0	azetidines; beta-lactam; organofluorine compound	anticholesteremic drug; antilipemic drug; antimetabolite
cox 189 lumiracoxib: a COX-2 inhibitor. lumiracoxib : An amino acid that is phenylacetic acid which is substituted at position 2 by the nitrogen of 2-chloro-6-fluoroaniline and at position 5 by a methyl group. A highly selective cyclooxygenase 2 inhibitor, it was briefly used for the treatment of osteoarthritis, but was withdrawn due to concersns of hepatotoxicity.	2.08	1	0	amino acid; monocarboxylic acid; organochlorine compound; organofluorine compound; secondary amino compound	cyclooxygenase 2 inhibitor; non-steroidal anti-inflammatory drug
xamoterol Xamoterol: A phenoxypropanolamine derivative that is a selective beta-1-adrenergic agonist.	2.08	1	0	morpholines
cryptolepine monohydrochloride [no description available]	2.44	2	0
naproxen Naproxen: An anti-inflammatory agent with analgesic and antipyretic properties. Both the acid and its sodium salt are used in the treatment of rheumatoid arthritis and other rheumatic or musculoskeletal disorders, dysmenorrhea, and acute gout.. naproxen : A methoxynaphthalene that is 2-methoxynaphthalene substituted by a carboxy ethyl group at position 6. Naproxen is a non-steroidal anti-inflammatory drug commonly used for the reduction of pain, fever, inflammation and stiffness caused by conditions such as osteoarthritis, kidney stones, rheumatoid arthritis, psoriatic arthritis, gout, ankylosing spondylitis, menstrual cramps, tendinitis, bursitis, and for the treatment of primary dysmenorrhea. It works by inhibiting both the COX-1 and COX-2 enzymes.	2.47	2	0	methoxynaphthalene; monocarboxylic acid	antipyretic; cyclooxygenase 1 inhibitor; cyclooxygenase 2 inhibitor; drug allergen; environmental contaminant; gout suppressant; non-narcotic analgesic; non-steroidal anti-inflammatory drug; xenobiotic
atazanavir sulfate Atazanavir Sulfate: An azapeptide and HIV-PROTEASE INHIBITOR that is used in the treatment of HIV INFECTIONS and AIDS in combination with other ANTI-HIV AGENTS.	2.06	1	0	organic sulfate salt
telbivudine [no description available]	2.08	1	0	pyrimidine 2'-deoxyribonucleoside	antiviral drug; EC 2.7.7.49 (RNA-directed DNA polymerase) inhibitor
tipifarnib [no description available]	2.07	1	0	imidazoles; monochlorobenzenes; primary amino compound; quinolone	antineoplastic agent; apoptosis inducer; EC 2.5.1.58 (protein farnesyltransferase) inhibitor
ly 56110 LY 56110: structure given in first source	2.07	1	0
cyc 202 seliciclib : 2,6-Diaminopurine carrying benzylamino, (2R)-1-hydroxybutan-2-yl and isopropyl substituents at C-6, C-2-N and N-9 respectively. It is an experimental drug candidate in the family of pharmacological cyclin-dependent kinase (CDK) inhibitors.	2.05	1	0	2,6-diaminopurines	antiviral drug; EC 2.7.11.22 (cyclin-dependent kinase) inhibitor
7,8-dihydro-5,6-dehydrokawain 7,8-dihydro-5,6-dehydrokawain: from Alpinia speciosa rhizoma; structure given in first source	2.07	1	0	2-pyranones; aromatic ether
4,5-dibromo-2-pyrrolic acid 4,5-dibromo-2-pyrrolic acid: isol from marine sponge Agelas flabelliformis; structure given in first source	2.03	1	0
4-(2-aminoethyl)benzenesulfonamide [no description available]	2.08	1	0
atropine tropan-3alpha-yl 3-hydroxy-2-phenylpropanoate : A tropane alkaloid that is (1R,5)-8-methyl-8-azabicyclo[3.2.1]octane substituted by a (3-hydroxy-2-phenylpropanoyl)oxy group at position 3.	2.47	2	0
lignin Lignin: The most abundant natural aromatic organic polymer found in all vascular plants. Lignin together with cellulose and hemicellulose are the major cell wall components of the fibers of all wood and grass species. Lignin is composed of coniferyl, p-coumaryl, and sinapyl alcohols in varying ratios in different plant species. (From Merck Index, 11th ed). lignin : A polyphenylpropanoid derived from three monolignol monomers: trans-p-coumaryl alcohol, coniferol and trans-sinapyl alcohol. There is extensive cross-linking and no defined primary structure.	2.6	1	0
organophosphonates hydrogenphosphite : A divalent inorganic anion resulting from the removal of a proton from two of the hydroxy groups of phosphorous acid.	2.06	1	0	divalent inorganic anion; phosphite ion
4-methoxy-1-vinylcarboline [no description available]	2.05	1	0
lunularin lunularin: first source misnames compound; structure in first source	2.47	2	0	stilbenoid
deflazacort deflazacort: structure	2.05	1	0	corticosteroid hormone
ancistrocladidine ancistrocladidine: RN given for unspecified stereoisomer; structure in first source	2.02	1	0
etravirine [no description available]	2.1	1	0	aminopyrimidine; aromatic ether; dinitrile; organobromine compound	antiviral agent; HIV-1 reverse transcriptase inhibitor
rhinacanthone rhinacanthone: structure in first source	3.41	1	0
olpadronic acid [no description available]	2.43	2	0
ramelteon ramelteon: melatonin MT1/MT2 receptor agonist	2.08	1	0	indanes
lapatinib [no description available]	2.17	1	0	furans; organochlorine compound; organofluorine compound; quinazolines	antineoplastic agent; tyrosine kinase inhibitor
albaconazole albaconazole: UR-9825 is the (1R,2R)-isomer; structure in first source	2.02	1	0
dapivirine Dapivirine: effectively prevented human immunodeficiency virus (HIV) infection in cocultures of monocyte-derived dendritic cells and T cells, representing primary targets in sexual transmission	2.1	1	0
deferasirox Deferasirox: A triazole and benzoate derivative that acts as a selective iron chelator. It is used in the management of chronic IRON OVERLOAD due to blood transfusion or non-transfusion dependent THALASSEMIA.. deferasirox : A member of the class of triazoles, deferasirox is 1,2,4-triazole substituted by a 4-carboxyphenyl group at position 1 and by 2-hydroxyphenyl groups at positions 3 and 5. An orally active iron chelator, it is used to manage chronic iron overload in patients receiving long-term blood transfusions.	2.08	1	0	benzoic acids; monocarboxylic acid; phenols; triazoles	iron chelator
bms204352 BMS204352: a calcium-sensitive opener of maxi-K potassium channels; structure in first source	2.08	1	0
tbc-11251 sitaxsentan: endothelin A receptor antagonist; structure in first source	2.08	1	0	benzodioxoles
tolvaptan [no description available]	2.08	1	0	benzazepine; benzenedicarboxamide	aquaretic; vasopressin receptor antagonist
lenalidomide [no description available]	2.08	1	0	aromatic amine; dicarboximide; isoindoles; piperidones	angiogenesis inhibitor; antineoplastic agent; immunomodulator
n-(3-chloro-7-indolyl)-1,4-benzenedisulphonamide N-(3-chloro-7-indolyl)-1,4-benzenedisulphonamide: structure in first source. indisulam : A chloroindole that is 3-chloro-1H-indole substituted by a [(4-sulfamoylphenyl)sulfonyl]nitrilo group at position 7. It is a carbonic anhydrase inhibitor and a potential anti-cancer agent currently in clinical development.	2.08	1	0	chloroindole; organochlorine compound; sulfonamide	antineoplastic agent; EC 4.2.1.1 (carbonic anhydrase) inhibitor
lacosamide Lacosamide: An acetamide derivative that acts as a blocker of VOLTAGE-GATED SODIUM CHANNELS. It is used as an anticonvulsant, for adjunctive or monotherapy, in the treatment of PARTIAL SEIZURES.	2.08	1	0	N-acyl-amino acid
deoxycholic acid Deoxycholic Acid: A bile acid formed by bacterial action from cholate. It is usually conjugated with glycine or taurine. Deoxycholic acid acts as a detergent to solubilize fats for intestinal absorption, is reabsorbed itself, and is used as a choleretic and detergent.. deoxycholic acid : A bile acid that is 5beta-cholan-24-oic acid substituted by hydroxy groups at positions 3 and 12 respectively.	2.51	2	0	bile acid; C24-steroid; dihydroxy-5beta-cholanic acid	human blood serum metabolite
2-amino-5-(3,4-dimethoxyphenyl)-1,3,4-thiadiazole 2-amino-5-(3,4-dimethoxyphenyl)-1,3,4-thiadiazole: structure in first source	2.17	1	0
norlapachol norlapachol: structure in first source	2.44	2	0
3-nitrotyrosine 3-nitrotyrosine: RN given refers to parent cpd without isomeric designation. 3-nitrotyrosine : A nitrotyrosine comprising tyrosine having a nitro group at the 3-position on the phenyl ring.	2.1	1	0	2-nitrophenols; C-nitro compound; nitrotyrosine; non-proteinogenic alpha-amino acid
vincaleukoblastine [no description available]	2.54	2	0	acetate ester; indole alkaloid fundamental parent; methyl ester; organic heteropentacyclic compound; organic heterotetracyclic compound; tertiary alcohol; tertiary amino compound; vinca alkaloid	antineoplastic agent; immunosuppressive agent; microtubule-destabilising agent; plant metabolite
vincristine sulfate [no description available]	2.08	1	0	organic sulfate salt	antineoplastic agent; geroprotector
estramustine Estramustine: A nitrogen mustard linked to estradiol, usually as phosphate; used to treat prostatic neoplasms; also has radiation protective properties.. estramustine : A carbamate ester obtained by the formal condensation of the hydroxy group of 17beta-estradiol with the carboxy group of bis(2-chloroethyl)carbamic acid.	2.05	1	0	17beta-hydroxy steroid; carbamate ester; organochlorine compound	alkylating agent; antineoplastic agent; radiation protective agent
lupeol [no description available]	2.05	1	0	pentacyclic triterpenoid; secondary alcohol	anti-inflammatory drug; plant metabolite
wortmannin [no description available]	2.08	1	0	acetate ester; cyclic ketone; delta-lactone; organic heteropentacyclic compound	anticoronaviral agent; antineoplastic agent; autophagy inhibitor; EC 2.7.1.137 (phosphatidylinositol 3-kinase) inhibitor; geroprotector; Penicillium metabolite; radiosensitizing agent
1-(benzenesulfonyl)indole [no description available]	2.15	1	0	sulfonamide
2-guanidine-4-methylquinazoline 2-guanidine-4-methylquinazoline: structure given in first source	2.05	1	0
isocryptolepine isocryptolepine: synthetic antimalarial alkaloid; structure in first source	2.05	1	0
bortezomib [no description available]	2.08	1	0	amino acid amide; L-phenylalanine derivative; pyrazines	antineoplastic agent; antiprotozoal drug; protease inhibitor; proteasome inhibitor
neocryptolepine neocryptolepine: isolated from the roots of the African plant Cryptolepis sanguinolenta; structure in first source	2.75	3	0
korupensamine-b korupensamine A: from Ancistrocladus and triphyophyllum; structure in first source	2.46	2	0	isoquinolines; naphthalenes
ritonavir Ritonavir: An HIV protease inhibitor that works by interfering with the reproductive cycle of HIV. It also inhibits CYTOCHROME P-450 CYP3A.. ritonavir : An L-valine derivative that is L-valinamide in which alpha-amino group has been acylated by a [(2-isopropyl-1,3-thiazol-4-yl)methyl]methylcarbamoyl group and in which a hydrogen of the carboxamide amino group has been replaced by a (2R,4S,5S)-4-hydroxy-1,6-diphenyl-5-{[(1,3-thiazol-5-ylmethoxy)carbonyl]amino}hexan-2-yl group. A CYP3A inhibitor and antiretroviral drug from the protease inhibitor class used to treat HIV infection and AIDS, it is often used as a fixed-dose combination with another protease inhibitor, lopinavir. Also used in combination with dasabuvir sodium hydrate, ombitasvir and paritaprevir (under the trade name Viekira Pak) for treatment of chronic hepatitis C virus genotype 1 infection as well as cirrhosis of the liver.	2.48	2	0	1,3-thiazoles; carbamate ester; carboxamide; L-valine derivative; ureas	antiviral drug; environmental contaminant; HIV protease inhibitor; xenobiotic
tizoxanide tizoxanide: major metabolite of nitazoxanide; structure in first source	2.06	1	0	salicylamides
crinine crinine: structure in first source	3.31	1	0	alkaloid
4-(3-(2-nitro-1-imidazolyl)-propylamino)-7-chloroquinoline hydrochloride 4-(3-(2-nitro-1-imidazolyl)-propylamino)-7-chloroquinoline hydrochloride: structure in first source	2.5	2	0
mequindox Mequindox: a synthetic quinoxaline 1,4-dioxide derivative which can effectively improve growth and feed efficiency in animals; structure in first source	2.06	1	0
1-hydroxypentane-1,1-bisphosphonate [no description available]	2.43	2	0
cimadronate cimadronate: increases serum 1,25-dihydroxyvitamin D in rats via stimulating renal 1-hydroxylase activity; structure given in first source	2.51	2	0
1,1-hydroxyoctanodiphosphonate [no description available]	2.05	1	0
dihydropyridines Dihydropyridines: Pyridine moieties which are partially saturated by the addition of two hydrogen atoms in any position.	2.21	1	0
leupeptins Leupeptins: A group of acylated oligopeptides produced by Actinomycetes that function as protease inhibitors. They have been known to inhibit to varying degrees trypsin, plasmin, KALLIKREINS, papain and the cathepsins.	2.05	1	0
glycogen glycogen : A polydisperse, highly branched glucan composed of chains of D-glucopyranose residues in alpha(1->4) glycosidic linkage, joined together by alpha(1->6) glycosidic linkages. A small number of alpha(1->3) glycosidic linkages and some cumulative alpha(1->6) links also may occur. The branches in glycogen typically contain 8 to 12 glucose residues.	2.25	1	0
n-acetylneuraminic acid N-Acetylneuraminic Acid: An N-acyl derivative of neuraminic acid. N-acetylneuraminic acid occurs in many polysaccharides, glycoproteins, and glycolipids in animals and bacteria. (From Dorland, 28th ed, p1518). N-acetylneuraminic acid : An N-acylneuraminic acid where the N-acyl group is specified as acetyl.	2.21	1	0	N-acetylneuraminic acids	antioxidant; bacterial metabolite; EC 3.2.1.18 (exo-alpha-sialidase) inhibitor; human metabolite; mouse metabolite
oxytocin Oxytocin: A nonapeptide hormone released from the neurohypophysis (PITUITARY GLAND, POSTERIOR). It differs from VASOPRESSIN by two amino acids at residues 3 and 8. Oxytocin acts on SMOOTH MUSCLE CELLS, such as causing UTERINE CONTRACTIONS and MILK EJECTION.. oxytocin : A cyclic nonapeptide hormone with amino acid sequence CYIQNCPLG that also acts as a neurotransmitter in the brain; the principal uterine-contracting and milk-ejecting hormone of the posterior pituitary. Together with the neuropeptide vasopressin, it is believed to influence social cognition and behaviour.	2.05	1	0	heterodetic cyclic peptide; peptide hormone	oxytocic; vasodilator agent
puromycin [no description available]	2.1	1	0	puromycins	antiinfective agent; antimicrobial agent; antineoplastic agent; EC 3.4.11.14 (cytosol alanyl aminopeptidase) inhibitor; EC 3.4.14.2 (dipeptidyl-peptidase II) inhibitor; nucleoside antibiotic; protein synthesis inhibitor
pentostatin Pentostatin: A potent inhibitor of ADENOSINE DEAMINASE. The drug induces APOPTOSIS of LYMPHOCYTES, and is used in the treatment of many lymphoproliferative malignancies, particularly HAIRY CELL LEUKEMIA. It is also synergistic with some other antineoplastic agents and has immunosuppressive activity.. pentostatin : A member of the class of coformycins that is coformycin in which the hydroxy group at position 2' is replaced with a hydrogen. It is a drug used for the treatment of hairy cell leukaemia.	2.08	1	0	coformycins	antimetabolite; antineoplastic agent; Aspergillus metabolite; bacterial metabolite; EC 3.5.4.4 (adenosine deaminase) inhibitor
glutathionylspermidine [no description available]	2.43	2	0	glutathione derivative	Escherichia coli metabolite
quinidine Quinidine: An optical isomer of quinine, extracted from the bark of the CHINCHONA tree and similar plant species. This alkaloid dampens the excitability of cardiac and skeletal muscles by blocking sodium and potassium currents across cellular membranes. It prolongs cellular ACTION POTENTIALS, and decreases automaticity. Quinidine also blocks muscarinic and alpha-adrenergic neurotransmission.. quinidine : A cinchona alkaloid consisting of cinchonine with the hydrogen at the 6-position of the quinoline ring substituted by methoxy.	2.79	3	0	cinchona alkaloid	alpha-adrenergic antagonist; anti-arrhythmia drug; antimalarial; drug allergen; EC 1.14.13.181 (13-deoxydaunorubicin hydroxylase) inhibitor; EC 3.6.3.44 (xenobiotic-transporting ATPase) inhibitor; muscarinic antagonist; P450 inhibitor; potassium channel blocker; sodium channel blocker
meropenem Meropenem: A thienamycin derivative antibacterial agent that is more stable to renal dehydropeptidase I than IMIPENEM, but does not need to be given with an enzyme inhibitor such as CILASTATIN. It is used in the treatment of bacterial infections, including infections in immunocompromised patients.. meropenem : A carbapenemcarboxylic acid in which the azetidine and pyrroline rings carry 1-hydroxymethyl and in which the azetidine and pyrroline rings carry 1-hydroxymethyl and 5-(dimethylcarbamoyl)pyrrolidin-3-ylthio substituents respectively.	2.52	2	0	alpha,beta-unsaturated monocarboxylic acid; carbapenemcarboxylic acid; organic sulfide; pyrrolidinecarboxamide	antibacterial agent; antibacterial drug; drug allergen
digitoxin Digitoxin: A cardiac glycoside sometimes used in place of DIGOXIN. It has a longer half-life than digoxin; toxic effects, which are similar to those of digoxin, are longer lasting. (From Martindale, The Extra Pharmacopoeia, 30th ed, p665). digitoxin : A cardenolide glycoside in which the 3beta-hydroxy group of digitoxigenin carries a 2,6-dideoxy-beta-D-ribo-hexopyranosyl-(1->4)-2,6-dideoxy-beta-D-ribo-hexopyranosyl-(1->4)-2,6-dideoxy-beta-D-ribo-hexopyranosyl trisaccharide chain.	2.47	2	0	cardenolide glycoside	EC 3.6.3.9 (Na(+)/K(+)-transporting ATPase) inhibitor
saquinavir Saquinavir: An HIV protease inhibitor which acts as an analog of an HIV protease cleavage site. It is a highly specific inhibitor of HIV-1 and HIV-2 proteases, and also inhibits CYTOCHROME P-450 CYP3A.. saquinavir : An aspartic acid derivative obtained by formal condensation of the primary amino group of (2S,3R)-4-[(3S,4aS,8aS)-3-(tert-butylcarbamoyl)octahydroisoquinolin-2(1H)-yl]-3-hydroxy-1-phenylbutan-2-ylamine with the carboxy group of N(2)(-quinolin-2-ylcarbonyl)-L-asparagine. An inhibitor of HIV-1 protease.	2.5	2	0	L-asparagine derivative; quinolines	antiviral drug; HIV protease inhibitor
epiandrosterone epiandrosterone : A 3beta-hydroxy steroid that is (5alpha)-androstane substituted by a beta-hydroxy group at position 3 and an oxo group at position 17.	3.82	2	0	17-oxo steroid; 3beta-hydroxy steroid; androstanoid	androgen; human metabolite
perindopril erbumine [no description available]	2.08	1	0	addition compound	antihypertensive agent; EC 3.4.15.1 (peptidyl-dipeptidase A) inhibitor
miglitol [no description available]	2.08	1	0	piperidines
rocuronium bromide rocuronium bromide : The organic bromide salt of a 5alpha androstane compound having 3alpha-hydroxy-, 17beta-acetoxy-, 2beta-morpholino- and 16beta-N-allyllyrrolidinium substituents.	2.08	1	0	organic bromide salt; quaternary ammonium salt	muscle relaxant; neuromuscular agent
linezolid [no description available]	2.08	1	0	acetamides; morpholines; organofluorine compound; oxazolidinone	antibacterial drug; protein synthesis inhibitor
canaline canaline: structure	2.05	1	0	amino acid zwitterion; non-proteinogenic L-alpha-amino acid	antimetabolite; antineoplastic agent; phytogenic insecticide; plant metabolite
hemanthamine [no description available]	3.31	1	0	alkaloid
hippeastrine hippeastrine: isolated from Amaryllidaceae; structure given in first source; RN given refers to (5alpha)-isomer. hippeastrine : An indole alkaloid isolated from the Amaryllidaceae family and has been shown to exhibit cytotoxic activity.	3.31	1	0	delta-lactone; indole alkaloid; organic heteropentacyclic compound; secondary alcohol	antineoplastic agent; metabolite
hinokinin hinokinin: suppresses expression of both HBsAg and HBeAg. hinokinin : A lignan that is dihydrofuran-2(3H)-one (gamma-butyrolactone) substituted by a 3,4-methylenedioxybenzyl group at positions 3 and 4 (the 3R,4R-diastereoisomer).	2.08	1	0	benzodioxoles; gamma-lactone; lignan	trypanocidal drug
lignans Lignans: A class of dibenzylbutane derivatives which occurs in higher plants and in fluids (bile, serum, urine, etc.) in man and other animals. These compounds, which have a potential anti-cancer role, can be synthesized in vitro by human fecal flora. (From Singleton & Sainsbury, Dictionary of Microbiology and Molecular Biology, 2d ed)	2.08	1	0
pancracine pancracine: structure in first source	3.31	1	0	isoquinoline alkaloid fundamental parent; isoquinoline alkaloid
pseudolycorine pseudolycorine: alkaloid isolated from Narcissus tazetta var. chinensis Roem, N. papyraceus or Lycoris radiata Herb; structure in first source	3.31	1	0	phenanthridines
sanguinine sanguinine: from Amaryllidaceae; structure in first source	3.31	1	0	benzazepine
dioncophylline a dioncophylline A: derived from the tropical vine Triphyophyllum peltatum; structure given in first source. dioncophylline A : An isoquinoline alkaloid that is the biaryl resulting from substitution of the hydrogen at the 7-position of (1R,3R)-1,3-dimethyl-1,2,3,4-tetrahydroisoquinolin-8-ol by a 4,5-dimethoxy-2-methylnaphthalen-1-yl group. It is a naphthylisoquinoline alkaloid isolated from the roots and stem barks of Triphyophyllum peltatum and exhibits antifungal, antimalarial, antineoplastic and molluscicidal activites.	2.15	1	0	biaryl; isoquinoline alkaloid; isoquinolines; methoxynaphthalene; methylnaphthalenes; naphthalenes	antifungal agent; antimalarial; metabolite; molluscicide
dioncophylline c dioncophylline C: structure given in first source. dioncophylline C : An isoquinoline alkaloid that is the biaryl resulting from substitution of the hydrogen at the 5-position of (1R,3R)-1,3-dimethyl-1,2,3,4-tetrahydroisoquinolin-8-ol by a 5-hydroxy-4-methoxy-2-methylnaphthalen-1-yl group. It is a naphthylisoquinoline alkaloid isolated from the roots and stem barks of Triphyophyllum peltatum and exhibits antimalarial activity.	2.15	1	0	aromatic ether; biaryl; isoquinoline alkaloid; isoquinolines; methoxynaphthalene; methylnaphthalenes; naphthols	antimalarial; antiplasmodial drug; metabolite
pemirolast potassium salt [no description available]	2.08	1	0
eplerenone Eplerenone: A spironolactone derivative and selective ALDOSTERONE RECEPTOR antagonist that is used in the management of HYPERTENSION and CONGESTIVE HEART FAILURE, post-MYOCARDIAL INFARCTION.	2.08	1	0	3-oxo-Delta(4) steroid; epoxy steroid; gamma-lactone; methyl ester; organic heteropentacyclic compound; oxaspiro compound; steroid acid ester	aldosterone antagonist; antihypertensive agent
ao 128 AO 128: alpha-glucosidase inhibitor; structure given in first source	2.08	1	0	organic molecular entity
loteprednol etabonate Loteprednol Etabonate: An androstadiene derivative corticosteroid that is used as an ANTI-ALLERGIC AGENT for the treatment of inflammatory and allergic eye conditions.	2.08	1	0	11beta-hydroxy steroid; 3-oxo-Delta(1),Delta(4)-steroid; etabonate ester; organochlorine compound; steroid acid ester; steroid ester	anti-inflammatory drug
fluticasone propionate fluticasone propionate : A trifluorinated corticosteroid that consists of 6alpha,9-difluoro-11beta,17alpha-dihydroxy-17beta-{[(fluoromethyl)sulfanyl]carbonyl}-16-methyl-3-oxoandrosta-1,4-diene bearing a propionyl substituent at position 17; has anti-inflammatory, anti-asthmatic and anti-allergic activity.	2.08	1	0	11beta-hydroxy steroid; 3-oxo-Delta(1),Delta(4)-steroid; corticosteroid; fluorinated steroid; propanoate ester; steroid ester; thioester	adrenergic agent; anti-allergic agent; anti-asthmatic drug; anti-inflammatory drug; bronchodilator agent; dermatologic drug
betadex beta-Cyclodextrins: Cyclic GLUCANS consisting of seven (7) glucopyranose units linked by 1,4-glycosidic bonds.	2.77	3	0	cyclodextrin
ergosterol [no description available]	3.53	2	0	3beta-hydroxy-Delta(5)-steroid; 3beta-sterol; ergostanoid; phytosterols	fungal metabolite; Saccharomyces cerevisiae metabolite
tretinoin Tretinoin: An important regulator of GENE EXPRESSION during growth and development, and in NEOPLASMS. Tretinoin, also known as retinoic acid and derived from maternal VITAMIN A, is essential for normal GROWTH; and EMBRYONIC DEVELOPMENT. An excess of tretinoin can be teratogenic. It is used in the treatment of PSORIASIS; ACNE VULGARIS; and several other SKIN DISEASES. It has also been approved for use in promyelocytic leukemia (LEUKEMIA, PROMYELOCYTIC, ACUTE).. retinoic acid : A retinoid consisting of 3,7-dimethylnona-2,4,6,8-tetraenoic acid substituted at position 9 by a 2,6,6-trimethylcyclohex-1-en-1-yl group (geometry of the four exocyclic double bonds is not specified).. all-trans-retinoic acid : A retinoic acid in which all four exocyclic double bonds have E- (trans-) geometry.	2.08	1	0	retinoic acid; vitamin A	anti-inflammatory agent; antineoplastic agent; antioxidant; AP-1 antagonist; human metabolite; keratolytic drug; retinoic acid receptor agonist; retinoid X receptor agonist; signalling molecule
resveratrol trans-resveratrol : A resveratrol in which the double bond has E configuration.	2.51	2	0	resveratrol	antioxidant; phytoalexin; plant metabolite; quorum sensing inhibitor; radical scavenger
tacrolimus Tacrolimus: A macrolide isolated from the culture broth of a strain of Streptomyces tsukubaensis that has strong immunosuppressive activity in vivo and prevents the activation of T-lymphocytes in response to antigenic or mitogenic stimulation in vitro.. tacrolimus (anhydrous) : A macrolide lactam containing a 23-membered lactone ring, originally isolated from the fermentation broth of a Japanese soil sample that contained the bacteria Streptomyces tsukubaensis.	2.08	1	0	macrolide lactam	bacterial metabolite; immunosuppressive agent
mupirocin Mupirocin: A topically used antibiotic from a strain of Pseudomonas fluorescens. It has shown excellent activity against gram-positive staphylococci and streptococci. The antibiotic is used primarily for the treatment of primary and secondary skin disorders, nasal infections, and wound healing.. mupirocin : An alpha,beta-unsaturated ester resulting from the formal condensation of the alcoholic hydroxy group of 9-hydroxynonanoic acid with the carboxy group of (2E)-4-[(2S)-tetrahydro-2H-pyran-2-yl]-3-methylbut-2-enoic acid in which the tetrahydropyranyl ring is substituted at positions 3 and 4 by hydroxy groups and at position 5 by a {(2S,3S)-3-[(2S,3S)-3-hydroxybutan-2-yl]oxiran-2-yl}methyl group. Originally isolated from the Gram-negative bacterium Pseudomonas fluorescens, it is used as a topical antibiotic for the treatment of Gram-positive bacterial infections.	2.08	1	0	alpha,beta-unsaturated carboxylic ester; epoxide; monocarboxylic acid; oxanes; secondary alcohol; triol	antibacterial drug; bacterial metabolite; protein synthesis inhibitor
zithromax Azithromycin: A semi-synthetic macrolide antibiotic structurally related to ERYTHROMYCIN. It has been used in the treatment of Mycobacterium avium intracellulare infections, toxoplasmosis, and cryptosporidiosis.. azithromycin : A macrolide antibiotic useful for the treatment of bacterial infections.	2.08	1	0	macrolide antibiotic	antibacterial drug; environmental contaminant; xenobiotic
cefoxitin Tn antigen: immediate precursor in biosynthesis of Thomsen-Friedenreich (T) antigen; present in about 90% of human carcinoma tissue; proposed as universal carcinoma marker. O-(N-acetyl-alpha-D-galactosaminyl)-L-serine : A non-proteinogenic L-amino acid that is N-acetyl-alpha-D-galactosamine linked via an alpha glycosidic bond to the O at position 3 of L-serine.	2.08	1	0	L-serine derivative; non-proteinogenic L-alpha-amino acid	tumour antigen
decitabine [no description available]	2.08	1	0	2'-deoxyribonucleoside
teniposide [no description available]	2.08	1	0	aromatic ether; beta-D-glucoside; cyclic acetal; furonaphthodioxole; gamma-lactone; monosaccharide derivative; phenols; thiophenes	antineoplastic agent; EC 5.99.1.3 [DNA topoisomerase (ATP-hydrolysing)] inhibitor
valrubicin [no description available]	2.08	1	0	anthracycline; trifluoroacetamide
pa 824 pretomanid: nitroimidazopyran derived from 5-nitroimidazoles; a prodrug that requires activation by a bacterial F420-depedent glucose-6-phosphate dehydrogenase (Fgd) and nitroreductase to activate components that then inhibit bacterial mycolic acid and protein synthesis; structure in first source	2.83	3	0
ketoconazole (2R,4S)-ketoconazole : A cis-1-acetyl-4-(4-{[2-(2,4-dichlorophenyl)-2-(1H-imidazol-1-ylmethyl)-1,3-dioxolan-4-yl]methoxy}phenyl)piperazine which dioxolane moiety has (2R,4S)-configuration.	2.21	1	0	cis-1-acetyl-4-(4-{[2-(2,4-dichlorophenyl)-2-(1H-imidazol-1-ylmethyl)-1,3-dioxolan-4-yl]methoxy}phenyl)piperazine
purvalanol a 6-((3-chloro)anilino)-2-(isopropyl-2-hydroxyethylamino)-9-isopropylpurine: purvalanol A is the (1R)-isomer;	2.05	1	0	purvalanol
melphalan Melphalan: An alkylating nitrogen mustard that is used as an antineoplastic in the form of the levo isomer - MELPHALAN, the racemic mixture - MERPHALAN, and the dextro isomer - MEDPHALAN; toxic to bone marrow, but little vesicant action; potential carcinogen.. melphalan : A phenylalanine derivative comprising L-phenylalanine having [bis(2-chloroethyl)amino group at the 4-position on the phenyl ring.	3.1	5	0	L-phenylalanine derivative; nitrogen mustard; non-proteinogenic L-alpha-amino acid; organochlorine compound	alkylating agent; antineoplastic agent; carcinogenic agent; drug allergen; immunosuppressive agent
benzyloxycarbonylleucyl-leucyl-leucine aldehyde benzyloxycarbonylleucyl-leucyl-leucine aldehyde: proteasome inhibitor. N-benzyloxycarbonyl-L-leucyl-L-leucyl-L-leucinal : A tripeptide that is L-leucyl-L-leucyl-L-leucine in which the C-terminal carboxy group has been reduced to the corresponding aldehyde and the N-terminal amino group is protected as its benzyloxycarbonyl derivative.	2.05	1	0	amino aldehyde; carbamate ester; tripeptide	proteasome inhibitor
tenofovir tenofovir (anhydrous) : A member of the class of phosphonic acids that is methylphosphonic acid in which one of the methyl hydrogens is replaced by a [(2R)-1-(6-amino-9H-purin-9-yl)propan-2-yl]oxy group. An inhibitor of HIV-1 reverse transcriptase, the bis(isopropyloxycarbonyloxymethyl) ester (disoproxil ester) prodrug is used as the fumaric acid salt in combination therapy for the treatment of HIV infection.	2.06	1	0	nucleoside analogue; phosphonic acids	antiviral drug; drug metabolite; HIV-1 reverse transcriptase inhibitor
ravuconazole ER 30346: structure in first source. ravuconazole : A member of the class of triazoles that is 1-butyl-1H-1,2,4-triazole in which the butyl group is substituted at positions 2, 2, and 3 by hydroxy, 2,4-difluorophenyl, and 4-(p-cyanophenyl)-1,3-thiazol-2-yl groups, respectively (the R,R stereoisomer). It exhibits antifungal activity by inhibition of 14alpha demethylase, an enzyme involved in sterol synthesis, resulting in lysis of the fungal cell wall and fungal cell death. (NCIO4)	7.67	8	3	1,3-thiazoles; fluorobenzenes; nitrile; tertiary alcohol; triazoles	antifungal drug; antileishmanial agent; EC 1.14.14.154 (sterol 14alpha-demethylase) inhibitor; ergosterol biosynthesis inhibitor
posaconazole [no description available]	10.1	41	2	aromatic ether; conazole antifungal drug; N-arylpiperazine; organofluorine compound; oxolanes; triazole antifungal drug; triazoles	trypanocidal drug
rubitecan rubitecan: RN refers to (+-)-isomer; anti-HIV agent; DNA Topoisomerases, Type I inhibitor. rubitecan : A pyranoindolizinoquinoline that is camptothecin in which the hydrogen at position 9 has been replaced by a nitro group. It is a prodrug for 9-aminocamptothecin.	2.08	1	0	C-nitro compound; delta-lactone; pyranoindolizinoquinoline; semisynthetic derivative; tertiary alcohol	antineoplastic agent; EC 5.99.1.2 (DNA topoisomerase) inhibitor; prodrug
tak 187 TAK 187: structure in first source; ergosterol biosynthesis inhibitor with possible usage against Trypanosoma	2.02	1	0
6-chloro-1,4-dihydro-4-oxo-1-(beta-d-ribofuranosyl)quinoline-3-carboxylic acid 6-chloro-1,4-dihydro-4-oxo-1-(beta-D-ribofuranosyl)quinoline-3-carboxylic acid: inhibits HSV-1 replication; structure in first source	2.08	1	0
abt 492 WQ 3034: structure in first source	2.17	1	0
5-nitrothiazole 5-nitrothiazole: structure in first source	2.15	1	0
Tetrahydropiperine [no description available]	2.44	2	0	benzodioxoles
carbenoxolone [no description available]	2.05	1	0
komaroviquinone komaroviquinone: trypanocidal agent that fosters generation of reactive oxygen species via semiquinone radical produced by old yellow enzyme; structure in first source. komaroviquinone : A tetracyclic diterpenoid isolated from Dracocephalum komarovii and has been shown to exhibit trypanocidal activity.	2.11	1	0	bridged compound; lactol; p-quinones; tetracyclic diterpenoid	metabolite; trypanocidal drug
chalcone trans-chalcone : The trans-isomer of chalcone.	2.99	4	0	chalcone	EC 3.2.1.1 (alpha-amylase) inhibitor
1,3,5,7-cyclooctatetraene 1,3,5,7-cyclooctatetraene: structure in first source. [8]annulene : An antiaromatic annulene that is cyclooctane having four double bonds at positions 1, 3, 5 and 7.	2.21	1	0
piperine piperine : A N-acylpiperidine that is piperidine substituted by a (1E,3E)-1-(1,3-benzodioxol-5-yl)-5-oxopenta-1,3-dien-5-yl group at the nitrogen atom. It is an alkaloid isolated from the plant Piper nigrum.	2.73	3	0	benzodioxoles; N-acylpiperidine; piperidine alkaloid; tertiary carboxamide	food component; human blood serum metabolite; NF-kappaB inhibitor; plant metabolite
2'-hydroxychalcone 2'-hydroxychalcone : A member of the class of chalcones that is trans-chalcone substituted by a hydroxy group at position 2'.	2.51	2	0	chalcones; phenols	anti-inflammatory agent
phenyl-n-tert-butylnitrone phenyl-N-tert-butylnitrone: a spin-trapping agent	2.47	2	0
ilepcimide ilepcimide: structure given in first source; RN given refers to compound with no isomeric designation	2.44	2	0	benzodioxoles
4'-methoxychalcone 4'-methoxychalcone: RN given refers to compound with no isomeric designation	2.21	1	0	chalcones
benzylidenephthalide [no description available]	2	1	0
flavin-adenine dinucleotide Flavin-Adenine Dinucleotide: A condensation product of riboflavin and adenosine diphosphate. The coenzyme of various aerobic dehydrogenases, e.g., D-amino acid oxidase and L-amino acid oxidase. (Lehninger, Principles of Biochemistry, 1982, p972)	1.96	1	0	flavin adenine dinucleotide; vitamin B2	cofactor; Escherichia coli metabolite; human metabolite; mouse metabolite; prosthetic group
arginine vasopressin Arginine Vasopressin: The predominant form of mammalian antidiuretic hormone. It is a nonapeptide containing an ARGININE at residue 8 and two disulfide-linked cysteines at residues of 1 and 6. Arg-vasopressin is used to treat DIABETES INSIPIDUS or to improve vasomotor tone and BLOOD PRESSURE.. argipressin : The predominant form of mammalian vasopressin (antidiuretic hormone). It is a nonapeptide containing an arginine at residue 8 and two disulfide-linked cysteines at residues of 1 and 6.	2.08	1	0	vasopressin	cardiovascular drug; hematologic agent; mitogen
trilostane trilostane: inhibits conversion of pregnenolone to progesterone; adrenal blocking agent used in treatment of Cushing's syndrome. trilostane : An epoxy steroid that is 3,17beta-dihydroxy-5alpha-androst-2-ene-2-carbonitrile in which the oxygen of the epoxy group is joined to the 4alpha and 5 alpha positions.	2.08	1	0	17beta-hydroxy steroid; 3-hydroxy steroid; androstanoid; epoxy steroid; nitrile	abortifacient; antineoplastic agent; EC 1.1.1.210 [3beta(or 20alpha)-hydroxysteroid dehydrogenase] inhibitor
cefsulodin sodium [no description available]	2.15	1	0	organic molecular entity
benidipine hydrochloride [no description available]	2.21	1	0
benidipine benidipine: RN refers to (R,R)-(+-)-isomer	2.21	1	0
leuprolide acetate leuprolide acetate : An acetate salt obtained by combining the nonapeptide leuprolide with acetic acid. A long lasting GnRH analog, LH-Rh agonist. It is a synthetic nonapeptide analogue of gonadotropin-releasing hormone, and is used as a subcutaneous hydrogel implant for the treatment of prostate cancer and for the suppression of gonadal sex hormone production in children with central precocious puberty.	2.08	1	0	acetate salt	antineoplastic agent; gonadotropin releasing hormone agonist
leuprolide Leuprolide: A potent synthetic long-acting agonist of GONADOTROPIN-RELEASING HORMONE that regulates the synthesis and release of pituitary gonadotropins, LUTEINIZING HORMONE and FOLLICLE STIMULATING HORMONE.. leuprolide : An oligopeptide comprising pyroglutamyl, histidyl, tryptophyl, seryl, tyrosyl, D-leucyl, leucyl, arginyl, and N-ethylprolinamide residues joined in sequence. It is a synthetic nonapeptide analogue of gonadotropin-releasing hormone, and is used as a subcutaneous hydrogel implant (particularly as the acetate salt) for the treatment of prostate cancer and for the suppression of gonadal sex hormone production in children with central precocious puberty.	2.05	1	0	oligopeptide	anti-estrogen; antineoplastic agent; gonadotropin releasing hormone agonist
octotropine methylbromide octotropine methylbromide: minor descriptor (65-86); on line & INDEX MEDICUS search TROPANES (69-86); RN given refers to endo-isomer. anisotropine methylbromide : A quaternary ammonium salt resulting from the reaction of the amino group of anisotropine with methyl bromide.	2.05	1	0
propylthiouracil Propylthiouracil: A thiourea antithyroid agent. Propythiouracil inhibits the synthesis of thyroxine and inhibits the peripheral conversion of throxine to tri-iodothyronine. It is used in the treatment of hyperthyroidism. (From Martindale, The Extra Pharmacopeoia, 30th ed, p534). 6-propyl-2-thiouracil : A pyrimidinethione consisting of uracil in which the 2-oxo group is substituted by a thio group and the hydrogen at position 6 is substituted by a propyl group.	2.08	1	0	pyrimidinethione	antidote to paracetamol poisoning; antimetabolite; antioxidant; antithyroid drug; carcinogenic agent; EC 1.14.13.39 (nitric oxide synthase) inhibitor; hormone antagonist
ipratropium bromide anhydrous [no description available]	2.05	1	0
sesquiterpenes [no description available]	4.98	11	0
mercaptopurine Mercaptopurine: An antimetabolite antineoplastic agent with immunosuppressant properties. It interferes with nucleic acid synthesis by inhibiting purine metabolism and is used, usually in combination with other drugs, in the treatment of or in remission maintenance programs for leukemia.. purine-6-thiol : A thiol that is the tautomer of mercaptopurine.. mercaptopurine : A member of the class of purines that is 6,7-dihydro-1H-purine carrying a thione group at position 6. An adenine analogue, it is used in the treatment of acute lymphocytic leukemia (ALL), chronic myeloid leukemia (CML), Crohn's disease, and ulcerative colitis.	2.08	1	0	aryl thiol; purines; thiocarbonyl compound	anticoronaviral agent; antimetabolite; antineoplastic agent
levosulpiride (S)-(-)-sulpiride : An optically active form of sulpiride having (S)-configuration. The active enantiomer of the racemic drug sulpiride. Selective D2-like dopamine antagonist (Ki values are ~ 0.015. ~ 0.013, 1, ~ 45 and ~ 77 muM at D2, D3, D4, D1 and D5 receptors respectively).	2.08	1	0	sulpiride	antidepressant; antiemetic; antipsychotic agent; dopaminergic antagonist
caffeic acid trans-caffeic acid : The trans-isomer of caffeic acid.	2.15	1	0	caffeic acid	geroprotector; mouse metabolite
flunarizine Flunarizine: Flunarizine is a selective calcium entry blocker with calmodulin binding properties and histamine H1 blocking activity. It is effective in the prophylaxis of migraine, occlusive peripheral vascular disease, vertigo of central and peripheral origin, and as an adjuvant in the therapy of epilepsy.	2.05	1	0	diarylmethane
eszopiclone Eszopiclone: A pyridine, pyrazine, and piperazine derivative that is used as a HYPNOTIC AND SEDATIVE in the treatment of INSOMNIA.. eszopiclone : The (5S)- (active) enantiomer of zopiclone. Unlike almost all other hypnotic sedatives, which are approved only for the relief of short-term (6-8 weeks) insomnia, eszopiclone is approved by the U.S. Food and Drug Administration for long-term use.	2.08	1	0	zopiclone	central nervous system depressant; sedative
curcumin Curcumin: A yellow-orange dye obtained from tumeric, the powdered root of CURCUMA longa. It is used in the preparation of curcuma paper and the detection of boron. Curcumin appears to possess a spectrum of pharmacological properties, due primarily to its inhibitory effects on metabolic enzymes.. curcumin : A beta-diketone that is methane in which two of the hydrogens are substituted by feruloyl groups. A natural dyestuff found in the root of Curcuma longa.	2.88	3	0	aromatic ether; beta-diketone; diarylheptanoid; enone; polyphenol	anti-inflammatory agent; antifungal agent; antineoplastic agent; biological pigment; contraceptive drug; dye; EC 1.1.1.205 (IMP dehydrogenase) inhibitor; EC 1.1.1.21 (aldehyde reductase) inhibitor; EC 1.1.1.25 (shikimate dehydrogenase) inhibitor; EC 1.6.5.2 [NAD(P)H dehydrogenase (quinone)] inhibitor; EC 1.8.1.9 (thioredoxin reductase) inhibitor; EC 2.7.10.2 (non-specific protein-tyrosine kinase) inhibitor; EC 3.5.1.98 (histone deacetylase) inhibitor; flavouring agent; food colouring; geroprotector; hepatoprotective agent; immunomodulator; iron chelator; ligand; lipoxygenase inhibitor; metabolite; neuroprotective agent; nutraceutical; radical scavenger
N-[2-(1H-benzimidazol-2-yl)ethyl]-2-(2-bromophenoxy)acetamide [no description available]	2.1	1	0	benzimidazoles
methimazole Methimazole: A thioureylene antithyroid agent that inhibits the formation of thyroid hormones by interfering with the incorporation of iodine into tyrosyl residues of thyroglobulin. This is done by interfering with the oxidation of iodide ion and iodotyrosyl groups through inhibition of the peroxidase enzyme.. methimazole : A member of the class of imidazoles that it imidazole-2-thione in which a methyl group replaces the hydrogen which is attached to a nitrogen.	2.08	1	0	1,3-dihydroimidazole-2-thiones	antithyroid drug
cinnarizine Cinnarizine: A piperazine derivative having histamine H1-receptor and calcium-channel blocking activity with vasodilating and antiemetic properties but it induces PARKINSONIAN DISORDERS.	2.08	1	0	diarylmethane; N-alkylpiperazine; olefinic compound	anti-allergic agent; antiemetic; calcium channel blocker; geroprotector; H1-receptor antagonist; histamine antagonist; muscarinic antagonist
sulindac Sulindac: A sulfinylindene derivative prodrug whose sulfinyl moiety is converted in vivo to an active NSAID analgesic. Specifically, the prodrug is converted by liver enzymes to a sulfide which is excreted in the bile and then reabsorbed from the intestine. This helps to maintain constant blood levels with reduced gastrointestinal side effects.. sulindac : A monocarboxylic acid that is 1-benzylidene-1H-indene which is substituted at positions 2, 3, and 5 by methyl, carboxymethyl, and fluorine respectively, and in which the phenyl group of the benzylidene moiety is substituted at the para position by a methylsulfinyl group. It is a prodrug for the corresponding sulfide, a non-steroidal anti-inflammatory drug, used particularly in the treatment of acute and chronic inflammatory conditions.	2.47	2	0	monocarboxylic acid; organofluorine compound; sulfoxide	analgesic; antineoplastic agent; antipyretic; apoptosis inducer; EC 1.14.99.1 (prostaglandin-endoperoxide synthase) inhibitor; non-narcotic analgesic; non-steroidal anti-inflammatory drug; prodrug; tocolytic agent
capsaicin ALGRX-4975: an injectable capsaicin (TRPV1 receptor agonist) formulation for longlasting pain relief. capsaicinoid : A family of aromatic fatty amides produced as secondary metabolites by chilli peppers.	2.25	1	0	capsaicinoid	non-narcotic analgesic; TRPV1 agonist; voltage-gated sodium channel blocker
terbinafine [no description available]	2.96	4	0	acetylenic compound; allylamine antifungal drug; enyne; naphthalenes; tertiary amine	EC 1.14.13.132 (squalene monooxygenase) inhibitor; P450 inhibitor; sterol biosynthesis inhibitor
epalrestat epalrestat : A monocarboxylic acid that is 1,3-thiazolidine which is substituted on the nitrogen by a carboxymethyl group, at positions 2 and 4 by thioxo and oxo groups, respectively, and at position 5 by a 2-methyl-3-phenylprop-2-en-1-ylidene group. It is an inhibitor of aldose reductase (which catalyses the conversion of glucose to sorbitol) and is used for the treatment of some diabetic complications, including neuropathy.	2.08	1	0	monocarboxylic acid; thiazolidines	EC 1.1.1.21 (aldehyde reductase) inhibitor
drotaverin drotaverin: Hungarian drug; RN given refers to parent cpd; structure	2.08	1	0	isoquinolines
digoxin Digoxin: A cardiotonic glycoside obtained mainly from Digitalis lanata; it consists of three sugars and the aglycone DIGOXIGENIN. Digoxin has positive inotropic and negative chronotropic activity. It is used to control ventricular rate in ATRIAL FIBRILLATION and in the management of congestive heart failure with atrial fibrillation. Its use in congestive heart failure and sinus rhythm is less certain. The margin between toxic and therapeutic doses is small. (From Martindale, The Extra Pharmacopoeia, 30th ed, p666). digoxin : A cardenolide glycoside that is digitoxin beta-hydroxylated at C-12. A cardiac glycoside extracted from the foxglove plant, Digitalis lanata, it is used to control ventricular rate in atrial fibrillation and in the management of congestive heart failure with atrial fibrillation, but the margin between toxic and therapeutic doses is small.	2.05	1	0	cardenolide glycoside; steroid saponin	anti-arrhythmia drug; cardiotonic drug; EC 3.6.3.9 (Na(+)/K(+)-transporting ATPase) inhibitor; epitope
benzathine dihydrochloride [no description available]	2.1	1	0
tamoxifen [no description available]	2.82	3	0	stilbenoid; tertiary amino compound	angiogenesis inhibitor; antineoplastic agent; bone density conservation agent; EC 1.2.3.1 (aldehyde oxidase) inhibitor; EC 2.7.11.13 (protein kinase C) inhibitor; estrogen antagonist; estrogen receptor antagonist; estrogen receptor modulator
1-octyl-3-methylimidazolium hexafluorophosphate 1-octyl-3-methylimidazolium hexafluorophosphate: is a nonaqueous ionic liquid	2.11	1	0
nadp [no description available]	2.66	3	0
ethionamide Ethionamide: A second-line antitubercular agent that inhibits mycolic acid synthesis.. ethionamide : A thiocarboxamide that is pyridine-4-carbothioamide substituted by an ethyl group at position 2. A prodrug that undergoes metabolic activation by conversion to the corresponding S-oxide.	2.05	1	0	pyridines; thiocarboxamide	antilipemic drug; antitubercular agent; fatty acid synthesis inhibitor; leprostatic drug; prodrug
fusidic acid Fusidic Acid: An antibiotic isolated from the fermentation broth of Fusidium coccineum. (From Merck Index, 11th ed). It acts by inhibiting translocation during protein synthesis.. fusidic acid : A steroid antibiotic that is isolated from the fermentation broth of Fusidium coccineum.	2.08	1	0	11alpha-hydroxy steroid; 3alpha-hydroxy steroid; alpha,beta-unsaturated monocarboxylic acid; steroid acid; steroid antibiotic; sterol ester	EC 2.7.1.33 (pantothenate kinase) inhibitor; Escherichia coli metabolite; protein synthesis inhibitor
artemotil artemotil: structure given in first source; RN given refers to cpd without isomeric designation	2.05	1	0	artemisinin derivative
valinomycin Valinomycin: A cyclododecadepsipeptide ionophore antibiotic produced by Streptomyces fulvissimus and related to the enniatins. It is composed of 3 moles each of L-valine, D-alpha-hydroxyisovaleric acid, D-valine, and L-lactic acid linked alternately to form a 36-membered ring. (From Merck Index, 11th ed) Valinomycin is a potassium selective ionophore and is commonly used as a tool in biochemical studies.. valinomycin : A twelve-membered cyclodepsipeptide composed of three repeating D-alpha-hydroxyisovaleryl-D-valyl-L-lactoyl-L-valyl units joined in sequence. An antibiotic found in several Streptomyces strains.	2.08	1	0	cyclodepsipeptide; macrocycle	antimicrobial agent; antiviral agent; bacterial metabolite; potassium ionophore
uc-781 [no description available]	2.1	1	0
thiocarlide thiocarlide: major descriptor (68-85); on-line search PHENYLTHIOUREA/AA (68-85); Index Medicus search THIOCARLIDE (68-85); Antitubercular Agent	2.05	1	0	thioureas
hmr 3647 [no description available]	2.08	1	0
latoconazole latoconazole: RN refers to cpd without isomeric designation; latoconazole is (E)-isomer; structure given in first source	2.08	1	0	conazole antifungal drug; imidazole antifungal drug
maraviroc [no description available]	2.08	1	0	tropane alkaloid
toremifene citrate [no description available]	2.08	1	0	stilbenoid	anticoronaviral agent
nelarabine nelarabine: prodrug of ara-G. nelarabine : A purine nucleoside in which O-methylguanine is attached to arabinofuranose via a beta-N(9)-glycosidic bond. Inhibits DNA synthesis and causes cell death; a prodrug of 9-beta-D-arabinofuranosylguanine (ara-G).	2.08	1	0	beta-D-arabinoside; monosaccharide derivative; purine nucleoside	antineoplastic agent; DNA synthesis inhibitor; prodrug
gestodene Gestodene: synthetic steroid with progestational activity; RN given refers to (17alpha)-isomer	2.47	2	0	steroid	estrogen
glucametacin glucametacin: indomethacin analog; structure	2.05	1	0
orlistat Orlistat: A lactone derivative of LEUCINE that acts as a pancreatic lipase inhibitor to limit the absorption of dietary fat; it is used in the management of obesity.. orlistat : A carboxylic ester resulting from the formal condensation of the carboxy group of N-formyl-L-leucine with the hydroxy group of (3S,4S)-3-hexyl-4-[(2S)-2-hydroxytridecyl]oxetan-2-one. A pancreatic lipase inhibitor, it is used as an anti-obesity drug.	2.08	1	0	beta-lactone; carboxylic ester; formamides; L-leucine derivative	anti-obesity agent; bacterial metabolite; EC 2.3.1.85 (fatty acid synthase) inhibitor; EC 3.1.1.3 (triacylglycerol lipase) inhibitor
quinine [no description available]	2.74	3	0	cinchona alkaloid	antimalarial; muscle relaxant; non-narcotic analgesic
7-deacetylgedunin 7-deacetylgedunin : A limonoid that is the 7-deacetyl derivative of gedunin. It has been isolated from Azadirachta indica.	2.03	1	0	cyclic terpene ketone; delta-lactone; enone; epoxide; furans; limonoid; pentacyclic triterpenoid	anti-inflammatory agent; antimalarial; metabolite; plant metabolite
azilect [no description available]	2.08	1	0
dasatinib N-(2-chloro-6-methylphenyl)-2-((6-(4-(2-hydroxyethyl)piperazin-1-yl)-2-methylpyrimidin-4-yl)amino)-1,3-thiazole-5-carboxamide: a dasatinib prodrug; structure in first source. dasatinib (anhydrous) : An aminopyrimidine that is 2-methylpyrimidine which is substituted at position 4 by the primary amino group of 2-amino-1,3-thiazole-5-carboxylic acid and at position 6 by a 4-(2-hydroxyethyl)piperazin-1-yl group, and in which the carboxylic acid group has been formally condensed with 2-chloro-6-methylaniline to afford the corresponding amide. A multi-targeted kinase inhibitor, it is used, particularly as the monohydrate, for the treatment of chronic, accelerated, or myeloid or lymphoid blast phase chronic myeloid leukemia. Note that the name 'dasatinib' is used to refer to the monohydrate (USAN) as well as to anhydrous dasatinib (INN).	2.08	1	0	1,3-thiazoles; aminopyrimidine; monocarboxylic acid amide; N-(2-hydroxyethyl)piperazine; N-arylpiperazine; organochlorine compound; secondary amino compound; tertiary amino compound	anticoronaviral agent; antineoplastic agent; tyrosine kinase inhibitor
benzene-1-3-disulfonamide [no description available]	2.08	1	0	sulfonamide
ungeremine [no description available]	3.31	1	0	organic molecular entity	metabolite
naphthoquinones Naphthoquinones: Naphthalene rings which contain two ketone moieties in any position. They can be substituted in any position except at the ketone groups.	2.92	4	0
sitagliptin sitagliptin : A triazolopyrazine that exhibits hypoglycemic activity.	2.08	1	0	triazolopyrazine; trifluorobenzene	EC 3.4.14.5 (dipeptidyl-peptidase IV) inhibitor; environmental contaminant; hypoglycemic agent; serine proteinase inhibitor; xenobiotic
tolcapone Tolcapone: A benzophenone and nitrophenol compound that acts as an inhibitor of CATECHOL O-METHYLTRANSFERASE, an enzyme involved in the metabolism of DOPAMINE and LEVODOPA. It is used in the treatment of PARKINSON DISEASE in patients for whom levodopa is ineffective or contraindicated.. tolcapone : Benzophenone substituted on one of the phenyl rings at C-3 and C-4 by hydroxy groups and at C-5 by a nitro group, and on the other phenyl ring by a methyl group at C-4. It is an inhibitor of catechol O-methyltransferase.	2.08	1	0	2-nitrophenols; benzophenones; catechols	antiparkinson drug; EC 2.1.1.6 (catechol O-methyltransferase) inhibitor
7-chloro-N-(phenylmethyl)-4-quinolinamine [no description available]	2.52	2	0	aminoquinoline
alsterpaullone alsterpaullone: structure in first source. alsterpaullone : An organic heterotetracyclic compound that is 1,3-dihydro-2H-1-benzazepin-2-one which shares its 4-5 bond with the 3-2 bond of 5-nitro-1H-indole.	2.05	1	0	C-nitro compound; caprolactams; organic heterotetracyclic compound	anti-HIV-1 agent; antineoplastic agent; apoptosis inducer; EC 2.7.11.1 (non-specific serine/threonine protein kinase) inhibitor; EC 2.7.11.22 (cyclin-dependent kinase) inhibitor; EC 2.7.11.26 (tau-protein kinase) inhibitor
nor-beta-lapachone nor-beta-lapachone: has antineoplastic activity; structure in first source	3.64	2	0
5,6-dehydrokawain 5,6-dehydrokawain: from Alpinia speciosa rhizoma; RN given for cpd without isomeric designation; structure given in first source	2.07	1	0	2-pyranones; aromatic ether
quercetin [no description available]	2.08	1	0	7-hydroxyflavonol; pentahydroxyflavone	antibacterial agent; antineoplastic agent; antioxidant; Aurora kinase inhibitor; chelator; EC 1.10.99.2 [ribosyldihydronicotinamide dehydrogenase (quinone)] inhibitor; geroprotector; phytoestrogen; plant metabolite; protein kinase inhibitor; radical scavenger
dinoprost Dinoprost: A naturally occurring prostaglandin that has oxytocic, luteolytic, and abortifacient activities. Due to its vasocontractile properties, the compound has a variety of other biological actions.. prostaglandin F2alpha : A prostaglandins Falpha that is prosta-5,13-dien-1-oic acid substituted by hydroxy groups at positions 9, 11 and 15. It is a naturally occurring prostaglandin used to induce labor.	2.41	1	0	monocarboxylic acid; prostaglandins Falpha	human metabolite; mouse metabolite
calcitriol dihydroxy-vitamin D3: as a major in vitro metabolite of 1alpha,25-dihydroxyvitamin D3, produced in primary cultures of neonatal human keratinocytes	2.08	1	0	D3 vitamins; hydroxycalciol; triol	antineoplastic agent; antipsoriatic; bone density conservation agent; calcium channel agonist; calcium channel modulator; hormone; human metabolite; immunomodulator; metabolite; mouse metabolite; nutraceutical
alprostadil [no description available]	2.47	2	0	prostaglandins E	anticoagulant; human metabolite; platelet aggregation inhibitor; vasodilator agent
vitamin d 2 Ergocalciferols: Derivatives of ERGOSTEROL formed by ULTRAVIOLET RAYS breaking of the C9-C10 bond. They differ from CHOLECALCIFEROL in having a double bond between C22 and C23 and a methyl group at C24.. vitamin D2 : A vitamin D supplement and has been isolated from alfalfa.	2.08	1	0	hydroxy seco-steroid; seco-ergostane; vitamin D	bone density conservation agent; nutraceutical; plant metabolite; rodenticide
lipoxin a4 lipoxin A4: an antifibrolytic agent; structure given in first source; a role in ASPIRIN antiinflammatory activity. lipoxin A4 : A C20 hydroxy fatty acid having (5S)-, (6R)- and (15S)-hydroxy groups as well as (7E)- (9E)-, (11Z)- and (13E)-double bonds.	2.53	2	0	hydroxy polyunsaturated fatty acid; lipoxin; long-chain fatty acid	human metabolite; metabolite
amphotericin b Amphotericin B: Macrolide antifungal antibiotic produced by Streptomyces nodosus obtained from soil of the Orinoco river region of Venezuela.. amphotericin B : A macrolide antibiotic used to treat potentially life-threatening fungal infections.	6.39	48	0	antibiotic antifungal drug; macrolide antibiotic; polyene antibiotic	antiamoebic agent; antiprotozoal drug; bacterial metabolite
pulmicort Budesonide: A glucocorticoid used in the management of ASTHMA, the treatment of various skin disorders, and allergic RHINITIS.. budesonide : A glucocorticoid steroid having a highly oxygenated pregna-1,4-diene structure. It is used mainly in the treatment of asthma and non-infectious rhinitis and for treatment and prevention of nasal polyposis.	2.08	1	0	11beta-hydroxy steroid; 20-oxo steroid; 21-hydroxy steroid; 3-oxo-Delta(1),Delta(4)-steroid; cyclic acetal; glucocorticoid; primary alpha-hydroxy ketone	anti-inflammatory drug; bronchodilator agent; drug allergen
oxymetholone Oxymetholone: A synthetic hormone with anabolic and androgenic properties. It is used mainly in the treatment of anemias. According to the Fourth Annual Report on Carcinogens (NTP 85-002), this compound may reasonably be anticipated to be a carcinogen. (From Merck Index, 11th ed). oxymetholone : A 3-oxo-5alpha- steroid that is 4,5alpha-dihydrotestosterone which is substituted by a hydroxymethylidene group at position 2 and by a methyl group at the 17alpha position. A synthetic androgen, it was mainly used for the treatment of anaemias until being replaced by treatments with fewer side effects.	2.08	1	0
eprosartan eprosartan: angiotensin II receptor antagonist. eprosartan : A member of the class of imidazoles and thiophenes that is an angiotensin II receptor antagonist used for the treatment of high blood pressure.	2.08	1	0	dicarboxylic acid; imidazoles; thiophenes	angiotensin receptor antagonist; antihypertensive agent; environmental contaminant; xenobiotic
brompheniramine maleate brompheniramine maleate : The maleic acid salt of brompheniramine. A histamine H1 receptor antagonist, it is used for the symptomatic relief of allergic conditions, including rhinitis and conjunctivitis.	2.08	1	0	maleate salt	anti-allergic agent
dexchlorpheniramine maleate [no description available]	2.08	1	0	organic molecular entity
mycophenolate mofetil mycophenolate mofetil : A carboxylic ester resulting from the formal condensation between the carboxylic acid group of mycophenolic acid and the hydroxy group of 2-(morpholin-4-yl)ethanol. In the liver, it is metabolised to mycophenolic acid, an immunosuppressant for which it is a prodrug. It is widely used to prevent tissue rejection following organ transplants as well as for the treatment of certain autoimmune diseases.	2.08	1	0	carboxylic ester; ether; gamma-lactone; phenols; tertiary amino compound	anticoronaviral agent; EC 1.1.1.205 (IMP dehydrogenase) inhibitor; immunosuppressive agent; prodrug
entacapone entacapone: structure given in first source. entacapone : A monocarboxylic acid amide that is N,N-diethylprop-2-enamide in which the hydrogen at position 2 is substituted by a cyano group and the hydrogen at the 3E position is substituted by a 3,4-dihydroxy-5-nitrophenyl group.	2.08	1	0	2-nitrophenols; catechols; monocarboxylic acid amide; nitrile	antidyskinesia agent; antiparkinson drug; central nervous system drug; EC 2.1.1.6 (catechol O-methyltransferase) inhibitor
isobavachalcone isobavachalcone: RN given for (E)-isomer; structure in first source. isobavachalcone : A member of the class of chalcones that is trans-chalcone substituted by hydroxy groups at positions 4, 2' and 4' and a prenyl group at position 3'.	2.13	1	0	chalcones; polyphenol	antibacterial agent; metabolite; platelet aggregation inhibitor
harman harman: a beta-carboline; RN given refers to parent cpd; structure. harman : An indole alkaloid fundamental parent with a structure of 9H-beta-carboline carrying a methyl substituent at C-1. It has been isolated from the bark of Sickingia rubra, Symplocus racemosa, Passiflora incarnata, Peganum harmala, Banisteriopsis caapi and Tribulus terrestris, as well as from tobacco smoke. It is a specific, reversible inhibitor of monoamine oxidase A.	2.05	1	0	harmala alkaloid; indole alkaloid fundamental parent; indole alkaloid	anti-HIV agent; EC 1.4.3.4 (monoamine oxidase) inhibitor; plant metabolite
usambarensine usambarensine: structure given in first source	2.05	1	0	harmala alkaloid
caryophyllene (-)-beta-caryophyllene : A beta-caryophyllene in which the stereocentre adjacent to the exocyclic double bond has S configuration while the remaining stereocentre has R configuration. It is the most commonly occurring form of beta-caryophyllene, occurring in many essential oils, particularly oil of cloves.. beta-caryophyllene : A sesquiterpene with a [7.2.0]-bicyclic structure comprising fused 9- and 4-membered rings, with a trans-ring junction, a trans-double bond between the 4- and 5-positions of the 9-membered ring, a methylidene group at position 9, and methyl groups at positions 3, 11, and 11. The most commonly occurring form is the (1R,9S)-(-)-enantiomer, which is found in many essential oils, particularly clove oil.. cannabinoid : A diverse group of pharmacologically active secondary metabolite characteristic to Cannabis plant as well as produced naturally in the body by humans and animals. Cannabinoids contain oxygen as a part of the heterocyclic ring or in the form of various functional groups. They are subdivided on the basis of their origin.	2.07	1	0	beta-caryophyllene	fragrance; insect attractant; metabolite; non-steroidal anti-inflammatory drug
myricetin [no description available]	2.07	1	0	7-hydroxyflavonol; hexahydroxyflavone	antineoplastic agent; antioxidant; cyclooxygenase 1 inhibitor; food component; geroprotector; hypoglycemic agent; plant metabolite
cynarine cynarine: active principle of the artichoke; functions primarily as a cholagogue and choleretic and also as antilipemic agent	2.05	1	0	alkyl caffeate ester; quinic acid	plant metabolite
3,4-di-o-caffeoylquinic acid 3,4-di-O-caffeoylquinic acid: isolated from Siphonostegia chinensis	2.15	1	0	quinic acid
l 660,711 [no description available]	2.08	1	0	quinolines
astragalin kaempferol-3-O-glucoside: isolated from the pit of Mahkota dewa; structure in first source. kaempferol 3-O-beta-D-glucoside : A kaempferol O-glucoside in which a glucosyl residue is attached at position 3 of kaempferol via a beta-glycosidic linkage.	2.06	1	0	beta-D-glucoside; kaempferol O-glucoside; monosaccharide derivative; trihydroxyflavone	plant metabolite; trypanocidal drug
cilnidipine [no description available]	2.05	1	0	2-methoxyethyl ester; C-nitro compound; dihydropyridine	antihypertensive agent; calcium channel blocker; cardiovascular drug
travoprost Travoprost: A cloprostenol derivative that is used as an ANTIHYPERTENSIVE AGENT in the treatment of OPEN-ANGLE GLAUCOMA and OCULAR HYPERTENSION.. travoprost : The isopropyl ester of prostaglandin F2alpha in which the pentyl group is replaced by a 3-(trifluoromethyl)phenoxymethyl group. A synthetic analogue of prostaglandin F2alpha, ophthalmic solutions of travoprost are used as a topical medication for controlling the progression of open-angle glaucoma and ocular hypertension, by reducing intraocular pressure. It is a pro-drug; the isopropyl ester group is hydrolysed by esterases in the cornea to the biologically active free acid, fluprostenol.	2.08	1	0	(trifluoromethyl)benzenes; isopropyl ester; prostaglandins Falpha	antiglaucoma drug; antihypertensive agent; ophthalmology drug; prodrug; prostaglandin receptor agonist
tranilast tranilast: antiallergic drug; potent inhibitor of homologous passive cutaneous anaphylaxis. tranilast : An amidobenzoic acid that is anthranilic acid in which one of the anilino hydrogens is replaced by a 3,4-dimethoxycinnamoyl group.	2.08	1	0	amidobenzoic acid; cinnamamides; dimethoxybenzene; secondary carboxamide	anti-allergic agent; anti-asthmatic drug; antineoplastic agent; aryl hydrocarbon receptor agonist; calcium channel blocker; hepatoprotective agent; nephroprotective agent
imipenem [no description available]	2.08	1	0	carbapenems
etretinate retinoid : Oxygenated derivatives of 3,7-dimethyl-1-(2,6,6-trimethylcyclohex-1-enyl)nona-1,3,5,7-tetraene and derivatives thereof.	2.08	1	0	enoate ester; ethyl ester; retinoid	keratolytic drug
isotretinoin Isotretinoin: A topical dermatologic agent that is used in the treatment of ACNE VULGARIS and several other skin diseases. The drug has teratogenic and other adverse effects.. isotretinoin : A retinoic acid that is all-trans-retinoic acid in which the double bond which is alpha,beta- to the carboxy group is isomerised to Z configuration. A synthetic retinoid, it is used for the treatment of severe cases of acne and other skin diseases.	2.08	1	0	retinoic acid	antineoplastic agent; keratolytic drug; teratogenic agent
ketotifen fumarate ketotifen fumarate : An organoammonium salt consisting of equimolar amounts of ketotifen(1+) and fumarate(1-) ions. A blocker of histamine H1 receptors with a stabilising action on mast cells, it is a non-bronchodilator anti-asthmatic drug.	2.08	1	0	organoammonium salt	anti-asthmatic drug; H1-receptor antagonist
dinoprost tromethamine [no description available]	2.08	1	0	organic molecular entity
triprolidine Triprolidine: Histamine H1 antagonist used in allergic rhinitis; ASTHMA; and URTICARIA. It is a component of COUGH and COLD medicines. It may cause drowsiness.. triprolidine : An N-alkylpyrrolidine that is acrivastine in which the pyridine ring is lacking the propenoic acid substituent. It is a sedating antihistamine that is used (generally as the monohydrochloride monohydrate) for the relief of the symptoms of uticaria, rhinitis, and various pruritic skin disorders.	2.05	1	0	N-alkylpyrrolidine; olefinic compound; pyridines	H1-receptor antagonist
rosuvastatin calcium S 4522: structure in first source	2.08	1	0	N-acyl-15-methylhexadecasphinganine-1-phosphoethanolamine; organic calcium salt	anti-inflammatory agent; cardioprotective agent; CETP inhibitor
terbinafine hydrochloride terbinafine hydrochloride : A hydrochloride obtained by reaction of terbinafine with one molar equivalent of hydrogen chloride.	2.08	1	0	allylamine antifungal drug; hydrochloride	EC 1.14.13.132 (squalene monooxygenase) inhibitor; P450 inhibitor
sq-18506 5-Amino-3-((5-nitro-2-furyl)vinyl)-1,2,4-oxadiazole: A nitrovinyl furan used as a schistosomicidal agent and proposed for trypanosomiasis, especially Chagas disease.	1.96	1	0
codeine [no description available]	2.05	1	0	morphinane alkaloid; organic heteropentacyclic compound	antitussive; drug allergen; environmental contaminant; opioid analgesic; opioid receptor agonist; prodrug; xenobiotic
cyclosporine ramihyphin A: one of the metabolites produced by Fusarium sp. S-435; RN given refers to cpd with unknown MF	2.48	2	0	homodetic cyclic peptide	anti-asthmatic drug; anticoronaviral agent; antifungal agent; antirheumatic drug; carcinogenic agent; dermatologic drug; EC 3.1.3.16 (phosphoprotein phosphatase) inhibitor; geroprotector; immunosuppressive agent; metabolite
natamycin [no description available]	2.08	1	0	antibiotic antifungal drug; dicarboxylic acid monoester; epoxide; macrolide antibiotic; monosaccharide derivative; polyene antibiotic	antifungal agrochemical; antimicrobial food preservative; apoptosis inducer; bacterial metabolite; ophthalmology drug
acitretin Acitretin: An oral retinoid effective in the treatment of psoriasis. It is the major metabolite of ETRETINATE with the advantage of a much shorter half-life when compared with etretinate.. acitretin : A retinoid that consists of 3,7-dimethylnona-2,4,6,8-tetraenoic acid having a 4-methoxy-2,3,6-trimethylphenyl group attached at position 9.	2.08	1	0	acitretin; alpha,beta-unsaturated monocarboxylic acid; retinoid	keratolytic drug
dihydrocodeine dihydrocodeine: RN refers to parent cpd(5alpha,6alpha)-isomer	2.05	1	0	morphinane alkaloid
diminazene aceturate diminazene diaceturate : An N-acetylglycinate salt resulting from the reaction of diminazene with 2 mol eq. of N-acetylglycine.	1.98	1	0	N-acetylglycinate salt	antiparasitic agent; trypanocidal drug
dorzolamide dorzolamide: topically effective ocular hypotensive carbonic anhydrase inhibitor; RN refers to mono-HCl (4S-trans)-isomer. dorzolamide : 5,6-Dihydro-4H-thieno[2,3-b]thiopyran-2-sulfonamide 7,7-dioxide in which hydrogens at the 4 and 6 positions are substituted by ethylamino and methyl groups, respectively (4S, trans-configuration). A carbonic anhydrase inhibitor, it is used as the hydrochloride in ophthalmic solutions to lower increased intraocular pressure in the treatment of open-angle glaucoma and ocular hypertension.	2.08	1	0	sulfonamide; thiophenes	antiglaucoma drug; antihypertensive agent; EC 4.2.1.1 (carbonic anhydrase) inhibitor
levetiracetam Levetiracetam: A pyrrolidinone and acetamide derivative that is used primarily for the treatment of SEIZURES and some movement disorders, and as a nootropic agent.. levetiracetam : A pyrrolidinone and carboxamide that is N-methylpyrrolidin-2-one in which one of the methyl hydrogens is replaced by an aminocarbonyl group, while another is replaced by an ethyl group (the S enantiomer). An anticonvulsant, it is used for the treatment of epilepsy in both human and veterinary medicine.	2.08	1	0	pyrrolidin-2-ones	anticonvulsant; environmental contaminant; xenobiotic
ly 163892 loracarbef: 1-carbacephem antibiotic; has a broad spectrum of antimicrobial activity; structure given in first source; carbacephems differ from cephalosporins in the substitution of a sulfur atom in the dihydrothiazine ring with a methylene group to form a tetrahydropyridine ring. loracarbef : A synthetic "carba" analogue of cefaclor, with carbon replacing sulfur at position 1. Used to treat a wide range of infections caused by both gram-positive and gram-negative bacteria.	2.05	1	0	carbacephem; zwitterion	antibacterial drug; antimicrobial agent
nalmefene nalmefene: RN given refers to 5-alpha isomer	2.08	1	0	morphinane alkaloid
naloxone Naloxone: A specific opiate antagonist that has no agonist activity. It is a competitive antagonist at mu, delta, and kappa opioid receptors.. naloxone : A synthetic morphinane alkaloid that is morphinone in which the enone double bond has been reduced to a single bond, the hydrogen at position 14 has been replaced by a hydroxy group, and the methyl group attached to the nitrogen has been replaced by an allyl group. A specific opioid antagonist, it is used (commonly as its hydrochloride salt) to reverse the effects of opioids, both following their use of opioids during surgery and in cases of known or suspected opioid overdose.	2.47	2	0	morphinane alkaloid; organic heteropentacyclic compound; tertiary alcohol	antidote to opioid poisoning; central nervous system depressant; mu-opioid receptor antagonist
topiramate Topiramate: A sulfamate-substituted fructose analog that was originally identified as a hypoglycemic agent. It is used for the treatment of EPILEPSY and MIGRAINE DISORDERS, and may also promote weight loss.. topiramate : A hexose derivative that is 2,3:4,5-di-O-isopropylidene-beta-D-fructopyranose in which the hydroxy group has been converted to the corresponding sulfamate ester. It blocks voltage-dependent sodium channels and is used as an antiepileptic and for the prevention of migraine.	2.49	2	0	cyclic ketal; ketohexose derivative; sulfamate ester	anticonvulsant; sodium channel blocker
morphine Meconium: The thick green-to-black mucilaginous material found in the intestines of a full-term fetus. It consists of secretions of the INTESTINAL GLANDS; BILE PIGMENTS; FATTY ACIDS; AMNIOTIC FLUID; and intrauterine debris. It constitutes the first stools passed by a newborn.	2.05	1	0	morphinane alkaloid; organic heteropentacyclic compound; tertiary amino compound	anaesthetic; drug allergen; environmental contaminant; geroprotector; mu-opioid receptor agonist; opioid analgesic; plant metabolite; vasodilator agent; xenobiotic
demycarosylturimycin h [no description available]	2.08	1	0
ubiquinone 7 ubiquinone 7: RN given refers to (all-E)-isomer. ubiquinone-7 : A compound whose structure comprises a 2,3-dimethoxy-5-methylbenzoquinone nucleus, common to ubiquinones; and a side chain of seven isoprenoid units.	2.31	1	0	ubiquinones
acipimox acipimox: lipolysis inhibitor	2.08	1	0	pyrazinecarboxylic acid
atosiban [no description available]	2.08	1	0	oligopeptide
bimatoprost Bimatoprost: A cloprostenol-derived amide that is used as an ANTIHYPERTENSIVE AGENT in the treatment of OPEN-ANGLE GLAUCOMA and OCULAR HYPERTENSION.	2.08	1	0	monocarboxylic acid amide	antiglaucoma drug; antihypertensive agent
lacidipine [no description available]	2.46	2	0	cinnamate ester; tert-butyl ester
latanoprost Latanoprost: A prostaglandin F analog used to treat OCULAR HYPERTENSION in patients with GLAUCOMA.. latanoprost : A prostaglandin Falpha that is the isopropyl ester prodrug of latanoprost free acid. Used in the treatment of open-angle glaucoma and ocular hypertension.	2.08	1	0	isopropyl ester; prostaglandins Falpha; triol	antiglaucoma drug; antihypertensive agent; EC 4.2.1.1 (carbonic anhydrase) inhibitor; prodrug
nateglinide Nateglinide: A phenylalanine and cyclohexane derivative that acts as a hypoglycemic agent by stimulating the release of insulin from the pancreas. It is used in the treatment of TYPE 2 DIABETES.. nateglinide : An N-acyl-D-phenylalanine resulting from the formal condensation of the amino group of D-phenylalanine with the carboxy group of trans-4-isopropylcyclohexanecarboxylic acid. An orally-administered, rapidly-absorbed, short-acting insulinotropic agent, it is used for the treatment of type 2 diabetes mellitus.	2.08	1	0	phenylalanine derivative
vinorelbine [no description available]	2.05	1	0	acetate ester; methyl ester; organic heteropentacyclic compound; organic heterotetracyclic compound; ring assembly; vinca alkaloid	antineoplastic agent; photosensitizing agent
licochalcone a licochalcone A: has both anti-inflammatory and antineoplastic activities; structure given in first source; isolated from root of Glycyrrhiza inflata; RN given refers to (E)-isomer	2.05	1	0	chalcones
angiotensin amide psilostachyin A: has antineoplastic, anti-inflammatory, leishmanicidal, and molluscicidal activities; isolated from Ambrosia psilostachya; structure in first source	2.08	1	0
tazettine tazettine: from Amaryllidaceae	3.31	1	0	indole alkaloid fundamental parent; indole alkaloid
nifuroxazide nifuroxazide: structure	3.34	6	0	benzoic acids
stilbamidine stilbamidine: RN given refers to parent cpd	2.05	1	0
bay 11-7082 (E)-3-tosylacrylonitrile : A nitrile that is acrylonitrile in which the hydrogen located beta,trans to the cyano group is replaced by a tosyl group. It is an inhibitor of cytokine-induced IkappaB-alpha phosphorylation in cells.	2.05	1	0	nitrile; sulfone	apoptosis inducer; EC 2.7.11.10 (IkappaB kinase) inhibitor; EC 3.1.3.48 (protein-tyrosine-phosphatase) inhibitor; non-steroidal anti-inflammatory drug; platelet aggregation inhibitor
(6E)-7-[3-(4-fluorophenyl)-1-(propan-2-yl)-1H-indol-2-yl]-3,5-dihydroxyhept-6-enoic acid (6E)-7-[3-(4-fluorophenyl)-1-(propan-2-yl)-1H-indol-2-yl]-3,5-dihydroxyhept-6-enoic acid : A dihydroxy monocarboxylic acid that is N-isopropylindole which is substituted at position 3 by a p-fluorophenyl group and at position 2 by a 6-carboxy-3,5-dihydroxyhex-1-en-1-yl group. It has four possible diastereoisomers.	2.08	1	0	dihydroxy monocarboxylic acid; indoles; organofluorine compound
molsidomine [no description available]	2.08	1	0	ethyl ester; morpholines; oxadiazole; zwitterion	antioxidant; apoptosis inhibitor; cardioprotective agent; nitric oxide donor; vasodilator agent
antimony Antimony: A metallic element that has the atomic symbol Sb, atomic number 51, and atomic weight 121.75. It is used as a metal alloy and as medicinal and poisonous salts. It is toxic and an irritant to the skin and the mucous membranes.	2	1	0	metalloid atom; pnictogen
furanoheliangolide furanoheliangolide: structure in first source	2.25	1	0
arsenic Arsenic: A shiny gray element with atomic symbol As, atomic number 33, and atomic weight 75. It occurs throughout the universe, mostly in the form of metallic arsenides. Most forms are toxic. According to the Fourth Annual Report on Carcinogens (NTP 85-002, 1985), arsenic and certain arsenic compounds have been listed as known carcinogens. (From Merck Index, 11th ed)	1.96	1	0	metalloid atom; pnictogen	micronutrient
dextromethorphan Dextromethorphan: Methyl analog of DEXTRORPHAN that shows high affinity binding to several regions of the brain, including the medullary cough center. This compound is an NMDA receptor antagonist (RECEPTORS, N-METHYL-D-ASPARTATE) and acts as a non-competitive channel blocker. It is one of the widely used ANTITUSSIVES, and is also used to study the involvement of glutamate receptors in neurotoxicity.. dextromethorphan : A 6-methoxy-11-methyl-1,3,4,9,10,10a-hexahydro-2H-10,4a-(epiminoethano)phenanthrene in which the sterocenters at positions 4a, 10 and 10a have S-configuration. It is a prodrug of dextrorphan and used as an antitussive drug for suppressing cough.	2.81	3	0	6-methoxy-11-methyl-1,3,4,9,10,10a-hexahydro-2H-10,4a-(epiminoethano)phenanthrene	antitussive; environmental contaminant; neurotoxin; NMDA receptor antagonist; oneirogen; prodrug; xenobiotic
butorphanol Butorphanol: A synthetic morphinan analgesic with narcotic antagonist action. It is used in the management of severe pain.. butorphanol : Levorphanol in which a hydrogen at position 14 of the morphinan skeleton is substituted by hydroxy and one of the hydrogens of the N-methyl group is substituted by cyclopropyl. A semi-synthetic opioid agonist-antagonist analgesic, it is used as its (S,S)-tartaric acid salt for relief or moderate to severe pain.	2.08	1	0	morphinane alkaloid	antitussive; kappa-opioid receptor agonist; mu-opioid receptor agonist; opioid analgesic
cefixime [no description available]	2.08	1	0	cephalosporin	antibacterial drug; drug allergen
lisinopril Lisinopril: One of the ANGIOTENSIN-CONVERTING ENZYME INHIBITORS (ACE inhibitors), orally active, that has been used in the treatment of hypertension and congestive heart failure.	2.08	1	0	dipeptide	EC 3.4.15.1 (peptidyl-dipeptidase A) inhibitor
ramipril Ramipril: A long-acting angiotensin-converting enzyme inhibitor. It is a prodrug that is transformed in the liver to its active metabolite ramiprilat.. ramipril : A dipeptide that is the prodrug for ramiprilat, the active metabolite obtained by hydrolysis of the ethyl ester group. An angiotensin-converting enzyme (ACE) inhibitor, used to treat high blood pressure and congestive heart failure.. quark : Quarks comprise one of two classes of the fundamental particles. Quarks possess fractional electric charges and are not observed in free state. The word "quark" first appears in James Joyce's Finnegans Wake and has been chosen by Murray Gell-Mann as a name for fundamental building blocks of particles.	2.08	1	0	azabicycloalkane; cyclopentapyrrole; dicarboxylic acid monoester; dipeptide; ethyl ester	bradykinin receptor B2 agonist; cardioprotective agent; EC 3.4.15.1 (peptidyl-dipeptidase A) inhibitor; matrix metalloproteinase inhibitor; prodrug
indinavir sulfate Indinavir: A potent and specific HIV protease inhibitor that appears to have good oral bioavailability.	2.08	1	0	dicarboxylic acid diamide; N-(2-hydroxyethyl)piperazine; piperazinecarboxamide	HIV protease inhibitor
piperic acid piperinic acid: from Piper longum; structure in first source. (E,E)-piperic acid : A monocarboxylic acid that is (E)-penta-2,4-dienoic acid substituted by a 1,3-benzodioxol-5-yl group at position 5. It has been isolated from black pepper (Piper nigrum).	2.44	2	0	alpha,beta-unsaturated monocarboxylic acid; benzodioxoles	plant metabolite
dimethylaminochalcone 4-dimethylaminochalcone: a fluorescent probe; structure in first source	2.21	1	0
2-formylpyridine thiosemicarbazone 2-formylpyridine thiosemicarbazone: structure; RN given refers to parent cpd without isomeric designation	2.1	1	0
enalapril maleate enalapril maleate : The maleic acid salt of enalapril. It contains one molecule of maleic acid for each molecule of enalapril. Following oral administration, the ethyl ester group of enalapril is hydrolysed to afford the corresponding carboxylic acid, enalaprilat, an angiotensin-converting enzyme (ACE) inhibitor. Enalapril is thus a prodrug for enalaprilat (which, unlike enalapril, is not absorbed by mouth), and its maleate is used in the treatment of hypertension and heart failure, for reduction of proteinuria and renal disease in patients with nephropathies, and for the prevention of stroke, myocardial infarction, and cardiac death in high-risk patients.	2.08	1	0	maleate salt	antihypertensive agent; EC 3.4.15.1 (peptidyl-dipeptidase A) inhibitor; prodrug
enalapril Enalapril: An angiotensin-converting enzyme inhibitor that is used to treat HYPERTENSION and HEART FAILURE.. enalapril : A dicarboxylic acid monoester that is ethyl 4-phenylbutanoate in which a hydrogen alpha to the carboxy group is substituted by the amino group of L-alanyl-L-proline (S-configuration).	2.53	2	0	dicarboxylic acid monoester; dipeptide	antihypertensive agent; EC 3.4.15.1 (peptidyl-dipeptidase A) inhibitor; geroprotector; prodrug
nitrofurazone Nitrofurazone: A topical anti-infective agent effective against gram-negative and gram-positive bacteria. It is used for superficial WOUNDS AND INJURIES and skin infections. Nitrofurazone has also been administered orally in the treatment of TRYPANOSOMIASIS.. nitrofurazone : A semicarbazone resulting from the formal condensation of semicarbazide with 5-nitrofuraldehyde. A broad spectrum antibacterial drug, although with little activity against Pseudomonas species, it is used as a local application for burns, ulcers, wounds and skin infections.	3.26	6	0
enalaprilat anhydrous Enalaprilat: The active metabolite of ENALAPRIL and one of the potent, intravenously administered, ANGIOTENSIN-CONVERTING ENZYME INHIBITORS. It is an effective agent for the treatment of essential hypertension and has beneficial hemodynamic effects in heart failure. The drug produces renal vasodilation with an increase in sodium excretion.. enalaprilat dihydrate : The dihydrate form of enalaprilat, an angiotensin-converting enzyme (ACE) inhibitor that is used (often in the form of its prodrug, enalapril) in the treatment of hypertension and heart failure, for reduction of proteinuria and renal disease in patients with nephropathies, and for the prevention of stroke, myocardial infarction, and cardiac death in high-risk patients. Unlike enalapril, enalaprilat is not absorbed by mouth but is administered by intravenous injection.. enalaprilat (anhydrous) : Enalapril in which the ethyl ester group has been hydrolysed to the corresponding carboxylic acid. Enalaprilat is an angiotensin-converting enzyme (ACE) inhibitor and is used (often in the form of its prodrug, enalapril) in the treatment of hypertension and heart failure, for reduction of proteinuria and renal disease in patients with nephropathies, and for the prevention of stroke, myocardial infarction, and cardiac death in high-risk patients. Unlike enalapril, enalaprilat is not absorbed by mouth but is given by intravenous injection, usually as the dihydrate.	2.08	1	0	dicarboxylic acid; dipeptide	antihypertensive agent; EC 3.4.15.1 (peptidyl-dipeptidase A) inhibitor
2-acetylpyridine thiosemicarbazone 2-acetylpyridine thiosemicarbazone: RN given refers to parent cpd	2.1	1	0
pafuramidine pafuramidine: a prodrug of furamidine	2.06	1	0
trandolapril trandolapril : A heterobicylic compound that is (2S,3aR,7aS)-1-[(2S)-2-aminopropanoyl]octahydro-1H-indole-2-carboxylic acid in which the hydrogen of the amino group is substituted by a (2R)-1-ethoxy-1-oxo-4-phenylbutan-2-yl group. It is a angiotensin-converting enzyme inhibitor and a prodrug used for the treatment of hypertension.	2.08	1	0	dicarboxylic acid monoester; dipeptide; ethyl ester; organic heterobicyclic compound; secondary amino compound; tertiary carboxamide	antihypertensive agent; EC 3.4.15.1 (peptidyl-dipeptidase A) inhibitor; prodrug
pregabalin Pregabalin: A gamma-aminobutyric acid (GABA) derivative that functions as a CALCIUM CHANNEL BLOCKER and is used as an ANTICONVULSANT as well as an ANTI-ANXIETY AGENT. It is also used as an ANALGESIC in the treatment of NEUROPATHIC PAIN and FIBROMYALGIA.. pregabalin : A gamma-amino acid that is gamma-aminobutyric acid (GABA) carrying an isobutyl substitutent at the beta-position (the S-enantiomer). Binds with high affinity to the alpha2-delta site (an auxiliary subunit of voltage-gated calcium channels) in central nervous system tissues.	2.08	1	0	gamma-amino acid	anticonvulsant; calcium channel blocker
alvimopan anhydrous alvimopan: mu opioid receptor antagonist; intended to treat constipation in patients taking opiates for pain	2.08	1	0	peptide
famotidine [no description available]	2.08	1	0	1,3-thiazoles; guanidines; sulfonamide	anti-ulcer drug; H2-receptor antagonist; P450 inhibitor
4-hydroxylonchocarpin 4-hydroxylonchocarpin: structure in first source	2.13	1	0
2-acetylpyridine-4-methyl-3-thiosemicarbazone [no description available]	2.15	1	0
proguanil Proguanil: A biguanide compound which metabolizes in the body to form cycloguanil, an anti-malaria agent.. proguanil : A biguanide compound which has isopropyl and p-chlorophenyl substituents on the terminal N atoms. A prophylactic antimalarial drug, it works by inhibiting the enzyme dihydrofolate reductase, which is involved in the reproduction of the malaria parasites Plasmodium falciparum and P. vivax within the red blood cells.	2.05	1	0	biguanides; monochlorobenzenes	antimalarial; antiprotozoal drug; EC 1.5.1.3 (dihydrofolate reductase) inhibitor
Lonchocarpin lonchocarpine: has anti-bacterial, anti-inflammatory, antiproliferative, antioxidant, and antiepileptic activities; isolated from Abrus precatorius; structure in first source	2.13	1	0	chalcones
oroidin oroidin: from marine sponges of the genus Agelas; structure in first source	2.03	1	0	pyrroles; secondary carboxamide	metabolite
cci 15641 [no description available]	2.08	1	0	cephalosporin
tenofovir disoproxil fumarate tenofovir disoproxil fumarate : A fumarate salt prepared from equimolar amounts of tenofovir disoproxil and fumaric acid. It is used in combination therapy for the treatment of HIV infection.	2.08	1	0	fumarate salt	antiviral drug; HIV-1 reverse transcriptase inhibitor; prodrug
dexbrompheniramine maleate dexbrompheniramine maleate : The maleic acid salt of the (pharmacologically active) (S)-(+)-enantiomer of brompheniramine. A histamine H1 receptor antagonist, it is used for the symptomatic relief of allergic conditions, including rhinitis and conjunctivitis.	2.08	1	0	brompheniramine maleate	anti-allergic agent; H1-receptor antagonist
rifaximin [no description available]	2.08	1	0	acetate ester; cyclic ketal; lactam; macrocycle; organic heterohexacyclic compound; rifamycins; semisynthetic derivative	antimicrobial agent; gastrointestinal drug; orphan drug
everolimus [no description available]	2.08	1	0	cyclic acetal; cyclic ketone; ether; macrolide lactam; primary alcohol; secondary alcohol	anticoronaviral agent; antineoplastic agent; geroprotector; immunosuppressive agent; mTOR inhibitor
nifuroxime 5-nitro-2-furaldehyde oxime: structure in first source	2.44	2	0
opc-67683 OPC-67683: an antitubercular agent	3.25	1	0	piperidines
cefpodoxime proxetil cefpodoxime proxetil: structure given in first source; prodrug for cefpodoxime. cefpodoxime proxetil : The 1-[(isopropoxycarbonyl)oxy]ethyl (proxetil) ester prodrug of cefpodoxime. After swallowing, hydrolysis of the ester group occurs in the intestinal epithelium, to release active cefpodoxime in the bloodstream. It is used to treat acute otitis media, pharyngitis, and sinusitis.	2.08	1	0	carboxylic acid; carboxylic ester; cephalosporin	antibacterial drug; prodrug
1-methyl-d-lysergic acid butanolamide [no description available]	2.05	1	0	ergot alkaloid; monocarboxylic acid amide	serotonergic antagonist; sympatholytic agent; vasoconstrictor agent
fluphenazine [no description available]	2.08	1	0
nitrofurantoin Nitrofurantoin: A urinary anti-infective agent effective against most gram-positive and gram-negative organisms. Although sulfonamides and antibiotics are usually the agents of choice for urinary tract infections, nitrofurantoin is widely used for prophylaxis and long-term suppression.. nitrofurantoin : An imidazolidine-2,4-dione that is hydantoin substituted at position 1 by a [(5-nitro-2-furyl)methylene]amino group. An antibiotic that damages bacterial DNA.	2.41	2	0	imidazolidine-2,4-dione; nitrofuran antibiotic; organonitrogen heterocyclic antibiotic; organooxygen heterocyclic antibiotic	antibacterial drug; antiinfective agent; hepatotoxic agent
nifurtimox Nifurtimox: A nitrofuran thiazine that has been used against TRYPANOSOMIASIS.	21.44	253	4	nitrofuran antibiotic
butylscopolammonium bromide Butylscopolammonium Bromide: Antimuscarinic quaternary ammonium derivative of scopolamine used to treat cramps in gastrointestinal, urinary, uterine, and biliary tracts, and to facilitate radiologic visualization of the gastrointestinal tract.	2.05	1	0
roxithromycin (E)-roxithromycin : A major geometrical isomer of roxithromycin.	2.47	2	0	roxithromycin	environmental contaminant; xenobiotic
cefdinir [no description available]	2.08	1	0	cephalosporin; ketoxime	antibacterial drug
bisoprolol, fumarate (1:1) salt [no description available]	2.08	1	0
artesunate artesunic acid: RN given for (3R-(3alpha,5abeta,6beta,8abeta,9alpha,10alpha,12beta,(2aR*))-isomer; succinic ester of artemether	2.79	3	0	artemisinin derivative; cyclic acetal; dicarboxylic acid monoester; hemisuccinate; semisynthetic derivative; sesquiterpenoid	antimalarial; antineoplastic agent; ferroptosis inducer
etoposide phosphate [no description available]	2.08	1	0	furonaphthodioxole
ciclesonide ciclesonide: nasal spray approved for seasonal and perennial allergic rhinitis	2.08	1	0	organic molecular entity
temsirolimus [no description available]	2.08	1	0	macrolide lactam
dutasteride Dutasteride: A 5-ALPHA-REDUCTASE INHIBITOR that is reported to inhibit both type-1 and type2 isoforms of the enzyme and is used to treat BENIGN PROSTATIC HYPERPLASIA.. dutasteride : An aza-steroid that is inasteride in which the tert-butyl group is replaced by a 2,5-bis(trifluoromethyl)phenyl group. A synthetic 4-azasteroid, dutasteride is a selective inhibitor of both the type 1 and type 2 isoforms of steroid 5alpha-reductase, an intracellular enzyme that converts testosterone to 5alpha-dihydrotestosterone. Dutasteride is used for the treatment of symptomatic benign prostatic hyperplasia in men with an enlarged prostate gland.	2.08	1	0	(trifluoromethyl)benzenes; aza-steroid; delta-lactam	antihyperplasia drug; EC 1.3.1.22 [3-oxo-5alpha-steroid 4-dehydrogenase (NADP(+))] inhibitor
tekturna [no description available]	2.08	1	0	fumarate salt	antihypertensive agent
vildagliptin [no description available]	2.08	1	0	amino acid amide
cinnamaldehyde thiosemicarbazone cinnamaldehyde thiosemicarbazone: has antimicrobial activity; structure in first source	2.5	2	0
drimane drimane: structure in first source	2.01	1	0	sesquiterpene; terpenoid fundamental parent
sgd 301-76 [no description available]	2.08	1	0	conazole antifungal drug; imidazole antifungal drug; organic nitrate salt	antiinfective agent
fluvoxamine maleate [no description available]	2.08	1	0	(trifluoromethyl)benzenes
nihydrazone nihydrazone: structure	2.54	2	0
mannich bases Mannich Bases: Ketonic amines prepared from the condensation of a ketone with formaldehyde and ammonia or a primary or secondary amine. A Mannich base can act as the equivalent of an alpha,beta unsaturated ketone in synthesis or can be reduced to form physiologically active amino alcohols.	1.97	1	0
thioacetazone Thioacetazone: A thiosemicarbazone that is used in association with other antimycobacterial agents in the initial and continuation phases of antituberculosis regimens. Thiacetazone containing regimens are less effective than the short-course regimen recommended by the International Union Against Tuberculosis and are used in some developing countries to reduce drug costs. (From Martindale, The Extra Pharmacopoeia, 30th ed, p217). thiosemicarbazone : A hydrazone resulting from the formal condensation of an aldehyde or ketone with the non-thioacylated nitrogen of thiosemicarbazide or its substituted derivatives.	2.08	1	0
chlorproguanil chlorproguanil: dichloro-derivative of chloroguanide; RN given refers to parent cpd; structure	2.05	1	0	dichlorobenzene
dexlansoprazole Dexlansoprazole: The R-isomer of lansoprazole that is used to treat severe GASTROESOPHAGEAL REFLUX DISEASE.	2.08	1	0	benzimidazoles; sulfoxide
gemifloxacin mesylate gemifloxacin mesylate : The mesylate salt of gemifloxacin.	2.08	1	0	methanesulfonate salt	antimicrobial agent; topoisomerase IV inhibitor
mocetinostat mocetinostat: undergoing phase II clinical trials for treatment of cancer. mocetinostat : A benzamide obtained by formal condensation of the carboxy group of 4-({[4-(pyridin-3-yl)pyrimidin-2-yl]amino}methyl)benzoic acid with one of the amino groups of benzene-1,2-diamine. It is an orally active and isotype-selective HDAC inhibitor which exhibits antitumour activity (IC50 = 0.15, 0.29, 1.66 and 0.59 muM for HDAC1, HDAC2, HDAC3 and HDAC11).	2.25	1	0	aminopyrimidine; benzamides; pyridines; secondary amino compound; secondary carboxamide; substituted aniline	antineoplastic agent; apoptosis inducer; autophagy inducer; cardioprotective agent; EC 3.5.1.98 (histone deacetylase) inhibitor; hepatotoxic agent
rivaroxaban Rivaroxaban: A morpholine and thiophene derivative that functions as a FACTOR XA INHIBITOR and is used in the treatment and prevention of DEEP-VEIN THROMBOSIS and PULMONARY EMBOLISM. It is also used for the prevention of STROKE and systemic embolization in patients with non-valvular ATRIAL FIBRILLATION, and for the prevention of atherothrombotic events in patients after an ACUTE CORONARY SYNDROME.. rivaroxaban : A monocarboxylic acid amide obtained by formal condensation of the carboxy group of 5-chlorothiophene-2-carboxylic acid with the amino group of 4-{4-[(5S)-5-(aminomethyl)-2-oxo-1,3-oxazolidin-3-yl]phenyl}morpholin-3-one. An anticoagulant used for prophylaxis of venous thromboembolism in patients with knee or hip replacement surgery.	2.08	1	0	aromatic amide; lactam; monocarboxylic acid amide; morpholines; organochlorine compound; oxazolidinone; thiophenes	anticoagulant; EC 3.4.21.6 (coagulation factor Xa) inhibitor
sja 6017 N-(4-fluorophenylsulfonyl)-L-valyl-L-leucinal: structure in first source	2.31	1	0
n1-phenyl-3,5-dinitro-n4,n4-di-n-propylsulfanilamide N1-phenyl-3,5-dinitro-N4,N4-di-n-propylsulfanilamide: a potent, selective antimitotic agent against kinetoplastid parasites; structure in first source	2.05	1	0
hki 272 [no description available]	2.08	1	0	nitrile; quinolines	antineoplastic agent; tyrosine kinase inhibitor
tofacitinib tofacitinib : A pyrrolopyrimidine that is pyrrolo[2,3-d]pyrimidine substituted at position 4 by an N-methyl,N-(1-cyanoacetyl-4-methylpiperidin-3-yl)amino moiety. Used as its citrate salt to treat moderately to severely active rheumatoid arthritis.	2.08	1	0	N-acylpiperidine; nitrile; pyrrolopyrimidine; tertiary amino compound	antirheumatic drug; EC 2.7.10.2 (non-specific protein-tyrosine kinase) inhibitor
zeolites [no description available]	2.69	2	0
ancistroealaine a ancistroealaine A: isolated from Ancistrocladus ealaensis; structure in first source. ancistrotanzanine B : An isoquinoline alkaloid that is (3S)-6,8-dimethoxy-1,3-dimethyl-3,4-dihydroisoquinoline substituted by a 4,5-dimethoxy-7-methylnaphthalen-1-yl group at position 5. It is isolated from the leaves of Ancistrocladus tanzaniensis and exhibits antiplasmodial, antileishmanial and antitrypanocidal activities.	2.7	3	0	aromatic ether; biaryl; isoquinoline alkaloid; isoquinolines; methoxynaphthalene; methylnaphthalenes	antileishmanial agent; antiplasmodial drug; metabolite; trypanocidal drug
gibbilimbol b gibbilimbol B: isolated from Piper gibbilimbum; structure in first source	2.13	1	0
octyl caffeate octyl caffeate: an antioxidant; structure in first source	2.15	1	0
pazopanib pazopanib: a protein kinase inhibitor. pazopanib : A pyrimidine that is 5-(pyrimidin-2-yl}amino-2-methylbenzenesulfonamide substituted at position 4 by a (2,3-dimethylindazol-6-yl)(methyl)amino group. Used as its hydrochloride salt for treatment of kidney cancer.	2.08	1	0	aminopyrimidine; indazoles; sulfonamide	angiogenesis modulating agent; antineoplastic agent; tyrosine kinase inhibitor; vascular endothelial growth factor receptor antagonist
4-ethoxy-3-phenylsulfonylfuroxan [no description available]	2.04	1	0
artenimol artenimol: derivative of antimalarial drug artemisinin (quinghaosu)	2.48	2	0
gibbilimbol a gibbilimbol A: isoalted from Piper gibbilimbum; structure in first source	2.13	1	0
4-phenoxyphenoxyethyl thiocyanate 4-phenoxyphenoxyethyl thiocyanate: has antiparasitic activity; structure in first source	2.78	3	0
arterolane arterolane: a trioxolane with antimalarial activity; structure in first source. arterolane : An oxaspiro compound that is dispiro[cyclohexane-1,3'-[1,2,4]trioxolane-5',2''-tricyclo[3.3.1.1(3,7)]decane] substituted by a 2-[(2-amino-2-methylpropyl)amino]-2-oxoethyl group at position 4s. Its maleic acid salt is used as an antimalarial drug in combination with piperaquine.	2.03	1	0
amg 009 AMG 009: an anti-inflammatory agent; structure in first source	2.08	1	0
oxadiazoles Oxadiazoles: Compounds containing five-membered heteroaromatic rings containing two carbons, two nitrogens, and one oxygen atom which exist in various regioisomeric forms.	2.5	2	0
cefotaxime sodium [no description available]	2.08	1	0	organic sodium salt
levomepromazine maleate 6-hydroxysalvinolone: from Salvia chorassanica; structure in first source	2.13	1	0
montanine montanine: has anxiolytic, antidepressant, and anticonvulsant activities	3.31	1	0
copalic acid copalic acid: a trypanocidal agent isolated from Aristolochia cymbifera; structure in first source	2.07	1	0	diterpenoid
losartan potassium Erythropoietin: Glycoprotein hormone, secreted chiefly by the KIDNEY in the adult and the LIVER in the FETUS, that acts on erythroid stem cells of the BONE MARROW to stimulate proliferation and differentiation.	2.08	1	0
dihydrolycorine [no description available]	3.31	1	0
diflucortolone Diflucortolone: A topical glucocorticoid used in various DERMATOSES. It is absorbed through the skin, bound to plasma albumin, and may cause adrenal suppression. It is also administered as the valerate.	2.05	1	0	21-hydroxy steroid
dextrothyroxine [no description available]	2.15	1	0
sepharose agarose : A linear polysaccharide made up from alternating D-galactose and 3,6-anhydro-alpha-L-galactopyranose residues joined by alpha-(1->3)- and beta-(1->4)-linkages.	2.1	1	0
dactolisib dactolisib: antineoplastic agent that inhibits both phosphatidylinositol 3-kinase and mTOR. dactolisib : An imidazoquinoline that is 3-methyl-2-oxo-2,3-dihydro-1H-imidazo[4,5-c]quinoline substituted at position 1 by a 4-(1-cyanoisopropyl)phenyl group and at position 8 by a quinolin-3-yl group. A dual PI3K/mTOR inhibitor used in cancer treatment.	2.08	1	0	imidazoquinoline; nitrile; quinolines; ring assembly; ureas	antineoplastic agent; EC 2.7.1.137 (phosphatidylinositol 3-kinase) inhibitor; mTOR inhibitor
deoxyartemisinin [no description available]	2.03	1	0
mefloquine Mefloquine: A phospholipid-interacting antimalarial drug (ANTIMALARIALS). It is very effective against PLASMODIUM FALCIPARUM with very few side effects.. mefloquine : A racemate composed of (+)-(11R,2'S)- and (-)-(11S,2'R)-enantiomers of mefloquine. An antimalarial agent which acts as a blood schizonticide; its mechanism of action is unknown.	2.31	1	0
deoxoartemisinin deoxoartemisinin: structure given in first source	2.05	1	0
rabeprazole sodium [no description available]	2.08	1	0	organic sodium salt
nad NAD(1-) : An anionic form of nicotinamide adenine dinucleotide arising from deprotonation of the two OH groups of the diphosphate moiety.	2.74	3	0	organophosphate oxoanion	cofactor; human metabolite; hydrogen acceptor; Saccharomyces cerevisiae metabolite
amodiaquine hydrochloride [no description available]	2.05	1	0
bivalirudin bivalirudin: designed to bind to the alpha-thrombin catalytic site and anion-binding exosite for fibrin(ogen) recognition. bivalirudin : A synthetic peptide of 20 amino acids, comprising D-Phe, Pro, Arg, Pro, Gly, Gly, Gly, Gly, Asn, Gly, Asp, Phe, Glu, Glu, Ile, Pro, Glu, Glu, Tyr, and Leu in sequence. A congener of hirudin (a naturally occurring drug found in the saliva of the medicinal leech), it a specific and reversible inhibitor of thrombin, and is used as an anticoagulant.	2.08	1	0	polypeptide	anticoagulant; EC 3.4.21.5 (thrombin) inhibitor
somatostatin [no description available]	2.08	1	0	heterodetic cyclic peptide; peptide hormone
ly-146032 [no description available]	2.08	1	0	heterodetic cyclic peptide; lipopeptide antibiotic; lipopeptide; macrocycle; macrolide	antibacterial drug; bacterial metabolite; calcium-dependent antibiotics
warfarin sodium warfarin sodium : A racemate comprising equal amounts of (R)- and (S)-warfarin sodium. Extensively used as both an anticoagulant drug and as a pesticide against rats and mice.	2.08	1	0
cellulose DEAE-Cellulose: Cellulose derivative used in chromatography, as ion-exchange material, and for various industrial applications.	2.81	3	0	glycoside
uk 453,061 UK 453,061: a reverse transcriptase inhibitor/anti-HIV agent; structure in first source	2.1	1	0	aromatic ether
pravastatin sodium pravastatin sodium : An organic sodium salt that is the sodium salt of pravastatin. A reversible inhibitor of 3-hydroxy-3-methylglutaryl-coenzyme A (HMG-CoA), it is used for lowering cholesterol and preventing cardiovascular disease. It is one of the lower potency statins, but has the advantage of fewer side effects compared with lovastatin and simvastatin.	2.08	1	0	organic sodium salt; statin (semi-synthetic)	anticholesteremic drug
alendronate sodium [no description available]	2.08	1	0
valproate sodium Epilim: oral sodium valproate used as antidepressive agent. sodium valproate : The sodium salt of valproic acid.. valproate : A branched-chain saturated fatty acid anion that is the conjugate base of valproic acid.	2.05	1	0	organic sodium salt	geroprotector
ubiquinone Ubiquinone: A lipid-soluble benzoquinone which is involved in ELECTRON TRANSPORT in mitochondrial preparations. The compound occurs in the majority of aerobic organisms, from bacteria to higher plants and animals.	2.31	1	0
sl 80.0750 [no description available]	2.08	1	0
chitosan [no description available]	2.81	3	0
mesna Mesna: A sulfhydryl compound used to prevent urothelial toxicity by inactivating metabolites from ANTINEOPLASTIC AGENTS, such as IFOSFAMIDE or CYCLOPHOSPHAMIDE.	2.08	1	0	organosulfonic acid
cefoperazone sodium [no description available]	2.15	1	0	organic molecular entity
clavulanate potassium potassium clavulanate : A potassium salt having clavulanate as the counterion. It acts as a suicide inhibitor of bacterial beta-lactamase enzymes and has only weak anitbiotic activity when administered alone. However it can be used in combination with amoxicillin trihydrate (under the trade name Augmentin) for treatment of a variety of bacterial infections, where it prevents antibiotic inactivation by microbial lactamases.	2.08	1	0	potassium salt	antibacterial drug; antimicrobial agent; EC 3.5.2.6 (beta-lactamase) inhibitor
piperacillin sodium [no description available]	2.08	1	0	organic sodium salt
oxacillin sodium [no description available]	2.08	1	0	organic sodium salt
raltegravir potassium Raltegravir Potassium: A pyrrolidinone derivative and HIV INTEGRASE INHIBITOR that is used in combination with other ANTI-HIV AGENTS for the treatment of HIV INFECTION.	2.06	1	0
cefazolin sodium cefazolin sodium : A cephalosporin organic sodium salt having [(5-methyl-1,3,4-thiadiazol-2-yl)sulfanyl]methyl and (1H-tetrazol-1-ylacetyl)amino side-groups.	2.08	1	0	organic sodium salt
azlocillin sodium [no description available]	2.08	1	0	organic sodium salt
gallinamide a gallinamide A: antimalarial peptide from marine cyanobacteria	2.41	1	0
N-[(2S,3S)-5-[(2R)-1-hydroxypropan-2-yl]-3-methyl-2-[[methyl-[(4-phenoxyphenyl)methyl]amino]methyl]-6-oxo-3,4-dihydro-2H-1,5-benzoxazocin-10-yl]-4-pyridinecarboxamide [no description available]	2.1	1	0	aromatic ether
resolvin d1 resolvin D1: an anti-inflammatory lipid mediator; structure in first source. resolvin D1 : A resolvin that is docosa-4Z,9E,11E,13Z,15E,19Z-hexaenoic acid which is substituted by hydroxy groups at the 7, 8, and 17 positions (the 7S,8R,17S-stereoisomer).	2.31	1	0	hydroxy polyunsaturated fatty acid; resolvin; triol	anti-inflammatory agent
interleukin-8 Interleukin-8: A member of the CXC chemokine family that plays a role in the regulation of the acute inflammatory response. It is secreted by variety of cell types and induces CHEMOTAXIS of NEUTROPHILS and other inflammatory cells.	2.6	1	0
GS-441524 [no description available]	2.31	1	0	aromatic amine; C-nucleoside; nitrile; pyrrolotriazine	anticoronaviral agent; antiviral agent; drug metabolite
letermovir letermovir: has antiviral activity; structure in first source	2.17	1	0
lychnopholide lychnopholide: isolated from Vanillosmopsis erythropappa; structure in first source	3.9	3	0
methylcellulose Methylcellulose: Methylester of cellulose. Methylcellulose is used as an emulsifying and suspending agent in cosmetics, pharmaceutics and the chemical industry. It is used therapeutically as a bulk laxative.	2.06	1	0
butyrolactone i butyrolactone I: selective inhibitor of cdk2 & cdc2 kinase; structure given in first source	2.05	1	0	butenolide
marinoquinoline a marinoquinoline A: pyrroloquinoline from Ohtaekwangia kribbensis (Bacteroidetes); showed weak antibacterial and antifungal activities and moderate cytotoxicity against four growing mammalian cell lines; structure in first source. marinoquinoline A : A pyrroloquinoline that is 3H-pyrrolo[2,3-c]quinoline substituted by a methyl group at position 4. It is a natural product found in Ohtaekwangia kribbensis and Rapidithrix thailandica.	2.06	1	0	pyrroloquinoline	bacterial metabolite
natriuretic peptide, brain Natriuretic Peptide, Brain: A PEPTIDE that is secreted by the BRAIN and the HEART ATRIA, stored mainly in cardiac ventricular MYOCARDIUM. It can cause NATRIURESIS; DIURESIS; VASODILATION; and inhibits secretion of RENIN and ALDOSTERONE. It improves heart function. It contains 32 AMINO ACIDS.	3.04	1	0	polypeptide
ml276 [no description available]	3.51	1	0
ascorbic acid Ascorbic Acid: A six carbon compound related to glucose. It is found naturally in citrus fruits and many vegetables. Ascorbic acid is an essential nutrient in human diets, and necessary to maintain connective tissue and bone. Its biologically active form, vitamin C, functions as a reducing agent and coenzyme in several metabolic pathways. Vitamin C is considered an antioxidant.. L-ascorbic acid : The L-enantiomer of ascorbic acid and conjugate acid of L-ascorbate.. L-ascorbate : The L-enantiomer of ascorbate and conjugate base of L-ascorbic acid, arising from selective deprotonation of the 3-hydroxy group. Required for a range of essential metabolic reactions in all animals and plants.. vitamin C : Any member of a group of vitamers that belong to the chemical structural class called butenolides that exhibit biological activity against vitamin C deficiency in animals. The vitamers include L-ascorbic acid and its salt, ionized and oxidized forms.	3.5	7	0	ascorbic acid; vitamin C	coenzyme; cofactor; flour treatment agent; food antioxidant; food colour retention agent; geroprotector; plant metabolite; skin lightening agent
tetracycline Tetracycline: A naphthacene antibiotic that inhibits AMINO ACYL TRNA binding during protein synthesis.. tetracycline : A broad-spectrum polyketide antibiotic produced by the Streptomyces genus of actinobacteria.	2.47	2	0
oxytetracycline, anhydrous Oxytetracycline: A TETRACYCLINE analog isolated from the actinomycete STREPTOMYCES RIMOSUS and used in a wide variety of clinical conditions.. oxytetracycline : A tetracycline used for treatment of infections caused by a variety of Gram positive and Gram negative microorganisms including Mycoplasma pneumoniae, Pasteurella pestis, Escherichia coli, Haemophilus influenzae (respiratory infections), and Diplococcus pneumoniae.	2.05	1	0
minocycline Minocycline: A TETRACYCLINE analog, having a 7-dimethylamino and lacking the 5 methyl and hydroxyl groups, which is effective against tetracycline-resistant STAPHYLOCOCCUS infections.. minocycline : A tetracycline analogue having a dimethylamino group at position 7 and lacking the methyl and hydroxy groups at position 5.	2.05	1	0
piroxicam [no description available]	2.77	3	0	benzothiazine; monocarboxylic acid amide; pyridines	analgesic; antirheumatic drug; cyclooxygenase 1 inhibitor; EC 1.14.99.1 (prostaglandin-endoperoxide synthase) inhibitor; non-steroidal anti-inflammatory drug
roquinimex roquinimex: structure in first source	2.08	1	0	aromatic amide
mobic Meloxicam: A benzothiazine and thiazole derivative that acts as a NSAID and cyclooxygenase-2 (COX-2) inhibitor. It is used in the treatment of RHEUMATOID ARTHRITIS; OSTEOARTHRITIS; and ANKYLOSING SPONDYLITIS.. meloxicam : A benzothiazine that is piroxicam in which the pyridin-2-yl group is replaced by a 5-methyl-1,3-thiazol-2-yl group. A non-steroidal anti-inflammatory drug and selective inhibitor of COX-2, it is used particularly for the management of rheumatoid arthritis.	2.08	1	0	1,3-thiazoles; benzothiazine; monocarboxylic acid amide	analgesic; antirheumatic drug; cyclooxygenase 2 inhibitor; non-steroidal anti-inflammatory drug
mobiflex tenoxicam : A thienothiazine-derived monocarboxylic acid amide obtained by formal condensation of the carboxy group of 4-hydroxy-2-methylthieno[2,3-e][1,2]thiazine-3-carboxylic acid 1,1-dioxide with the amino group of 2-aminopyridine. Used for the treatment of pain and inflammation in osteoarthritis and rheumatoid arthritis. It is also indicated for short term treatment of acute musculoskeletal disorders including strains, sprains and other soft-tissue injuries.	2.47	2	0	heteroaryl hydroxy compound; monocarboxylic acid amide; pyridines; thienothiazine	antipyretic; EC 1.14.99.1 (prostaglandin-endoperoxide synthase) inhibitor; non-narcotic analgesic; non-steroidal anti-inflammatory drug
isoxicam isoxicam : A monocarboxylic acid amide that is piroxicam in which the pyrid-2-yl group is replaced by a 5-methyl-1,2-oxazol-3-yl group. A non-steroidal anti-inflammatory drug, it was withdrawn from the market in the 1980s following its association with cases of Stevens-Johnson syndrome.	2.08	1	0	benzothiazine; isoxazoles; monocarboxylic acid amide	antirheumatic drug; non-steroidal anti-inflammatory drug
warfarin Warfarin: An anticoagulant that acts by inhibiting the synthesis of vitamin K-dependent coagulation factors. Warfarin is indicated for the prophylaxis and/or treatment of venous thrombosis and its extension, pulmonary embolism, and atrial fibrillation with embolization. It is also used as an adjunct in the prophylaxis of systemic embolism after myocardial infarction. Warfarin is also used as a rodenticide.. warfarin : A racemate comprising equal amounts of (R)- and (S)-warfarin. Extensively used as both an anticoagulant drug and as a pesticide against rats and mice.. 4-hydroxy-3-(3-oxo-1-phenylbutyl)-1-benzopyran-2-one : A member of the class of coumarins that is 4-hydroxycoumarin which is substituted at position 3 by a 1-phenyl-3-oxo-1-butyl group.	2.54	2	0	benzenes; hydroxycoumarin; methyl ketone
rolitetracycline Rolitetracycline: A pyrrolidinylmethyl TETRACYCLINE.. rolitetracycline : A derivative of tetracycline in which the amide function is substituted with a pyrrolidinomethyl group.	2.05	1	0
minocycline hydrochloride [no description available]	2.08	1	0
tigecycline [no description available]	2.08	1	0
lornoxicam lornoxicam : A thienothiazine-derived monocarboxylic acid amide obtained by formal condensation of the carboxy group of 6-chloro-4-hydroxy-2-methylthieno[2,3-e][1,2]thiazine-3-carboxylic acid 1,1-dioxide with the amino group of 2-aminopyridine. Used for the treatment of pain, primarily resulting from inflammatory diseases of the joints, osteoarthritis, surgery, sciatica and other inflammations.	2.08	1	0	heteroaryl hydroxy compound; monocarboxylic acid amide; organochlorine compound; pyridines; thienothiazine	antipyretic; non-narcotic analgesic; non-steroidal anti-inflammatory drug
rpx7009 RPX7009: a beta-lactamase inhibitor; structure in first source	2.17	1	0
hydroxymethylnitrofurazone hydroxymethylnitrofurazone: structure in first source	2.79	3	0
vitamin b 12 Vitamin B 12: A cobalt-containing coordination compound produced by intestinal micro-organisms and found also in soil and water. Higher plants do not concentrate vitamin B 12 from the soil and so are a poor source of the substance as compared with animal tissues. INTRINSIC FACTOR is important for the assimilation of vitamin B 12.	2.07	1	0
cyclosporine Cyclosporine: A cyclic undecapeptide from an extract of soil fungi. It is a powerful immunosupressant with a specific action on T-lymphocytes. It is used for the prophylaxis of graft rejection in organ and tissue transplantation. (From Martindale, The Extra Pharmacopoeia, 30th ed).	2.68	3	0
flavin mononucleotide Flavin Mononucleotide: A coenzyme for a number of oxidative enzymes including NADH DEHYDROGENASE. It is the principal form in which RIBOFLAVIN is found in cells and tissues.	2.08	1	0
silybin Silybin: The major active component of silymarin flavonoids extracted from seeds of the MILK THISTLE, Silybum marianum; it is used in the treatment of HEPATITIS; LIVER CIRRHOSIS; and CHEMICAL AND DRUG INDUCED LIVER INJURY, and has antineoplastic activity; silybins A and B are diastereomers.	2.31	1	0
orabase Orabase: used in therapy of oral mucosal ulcers	2.15	1	0
entecavir entecavir (anhydrous) : Guanine substituted at the 9 position by a 4-hydroxy-3-(hydroxymethyl)-2-methylidenecyclopentyl group. A synthetic analogue of 2'-deoxyguanosine, it is a nucleoside reverse transcriptase inhibitor with selective antiviral activity against hepatitis B virus. Entecavir is phosphorylated intracellularly to the active triphosphate form, which competes with deoxyguanosine triphosphate, the natural substrate of hepatitis B virus reverse transcriptase, inhibiting every stage of the enzyme's activity, although it has no activity against HIV. It is used for the treatment of chronic hepatitis B.	2.08	1	0	2-aminopurines; oxopurine; primary alcohol; secondary alcohol	antiviral drug; EC 2.7.7.49 (RNA-directed DNA polymerase) inhibitor
acyclovir Acyclovir: A GUANOSINE analog that acts as an antimetabolite. Viruses are especially susceptible. Used especially against herpes.. acyclovir : An oxopurine that is guanine substituted by a (2-hydroxyethoxy)methyl substituent at position 9. Used in the treatment of viral infections.	2.52	2	0	2-aminopurines; oxopurine	antimetabolite; antiviral drug
guanine [no description available]	2.1	1	0	2-aminopurines; oxopurine; purine nucleobase	algal metabolite; Escherichia coli metabolite; human metabolite; mouse metabolite; Saccharomyces cerevisiae metabolite
guanosine ribonucleoside : Any nucleoside where the sugar component is D-ribose.	2.07	1	0	guanosines; purines D-ribonucleoside	fundamental metabolite
rifampin Rifampin: A semisynthetic antibiotic produced from Streptomyces mediterranei. It has a broad antibacterial spectrum, including activity against several forms of Mycobacterium. In susceptible organisms it inhibits DNA-dependent RNA polymerase activity by forming a stable complex with the enzyme. It thus suppresses the initiation of RNA synthesis. Rifampin is bactericidal, and acts on both intracellular and extracellular organisms. (From Gilman et al., Goodman and Gilman's The Pharmacological Basis of Therapeutics, 9th ed, p1160)	3.34	6	0	cyclic ketal; hydrazone; N-iminopiperazine; N-methylpiperazine; rifamycins; semisynthetic derivative; zwitterion	angiogenesis inhibitor; antiamoebic agent; antineoplastic agent; antitubercular agent; DNA synthesis inhibitor; EC 2.7.7.6 (RNA polymerase) inhibitor; Escherichia coli metabolite; geroprotector; leprostatic drug; neuroprotective agent; pregnane X receptor agonist; protein synthesis inhibitor
clozapine Clozapine: A tricylic dibenzodiazepine, classified as an atypical antipsychotic agent. It binds several types of central nervous system receptors, and displays a unique pharmacological profile. Clozapine is a serotonin antagonist, with strong binding to 5-HT 2A/2C receptor subtype. It also displays strong affinity to several dopaminergic receptors, but shows only weak antagonism at the dopamine D2 receptor, a receptor commonly thought to modulate neuroleptic activity. Agranulocytosis is a major adverse effect associated with administration of this agent.. clozapine : A benzodiazepine that is 5H-dibenzo[b,e][1,4]diazepine substituted by a chloro group at position 8 and a 4-methylpiperazin-1-yl group at position 11. It is a second generation antipsychotic used in the treatment of psychiatric disorders like schizophrenia.	2.47	2	0	benzodiazepine; N-arylpiperazine; N-methylpiperazine; organochlorine compound	adrenergic antagonist; dopaminergic antagonist; EC 3.4.21.26 (prolyl oligopeptidase) inhibitor; environmental contaminant; GABA antagonist; histamine antagonist; muscarinic antagonist; second generation antipsychotic; serotonergic antagonist; xenobiotic
dacarbazine (E)-dacarbazine : A dacarbazine in which the N=N double bond adopts a trans-configuration.	2.08	1	0	dacarbazine
didanosine Didanosine: A dideoxynucleoside compound in which the 3'-hydroxy group on the sugar moiety has been replaced by a hydrogen. This modification prevents the formation of phosphodiester linkages which are needed for the completion of nucleic acid chains. Didanosine is a potent inhibitor of HIV replication, acting as a chain-terminator of viral DNA by binding to reverse transcriptase; ddI is then metabolized to dideoxyadenosine triphosphate, its putative active metabolite.. didanosine : A purine 2',3'-dideoxyribonucleoside that is inosine in which the hydroxy groups at both the 2' and the 3' positions on the sugar moiety have been replaced by hydrogen. An antiviral drug, it is used as a medication to treat HIV/AIDS.	2.08	1	0	purine 2',3'-dideoxyribonucleoside	antimetabolite; antiviral drug; EC 2.4.2.1 (purine-nucleoside phosphorylase) inhibitor; geroprotector; HIV-1 reverse transcriptase inhibitor
ganciclovir [no description available]	2.08	1	0	2-aminopurines; oxopurine	antiinfective agent; antiviral drug
valtrex [no description available]	2.08	1	0	organic molecular entity
olanzapine Olanzapine: A benzodiazepine derivative that binds SEROTONIN RECEPTORS; MUSCARINIC RECEPTORS; HISTAMINE H1 RECEPTORS; ADRENERGIC ALPHA-1 RECEPTORS; and DOPAMINE RECEPTORS. It is an antipsychotic agent used in the treatment of SCHIZOPHRENIA; BIPOLAR DISORDER; and MAJOR DEPRESSIVE DISORDER; it may also reduce nausea and vomiting in patients undergoing chemotherapy.. olanzapine : A benzodiazepine that is 10H-thieno[2,3-b][1,5]benzodiazepine substituted by a methyl group at position 2 and a 4-methylpiperazin-1-yl group at position 4.	2.08	1	0	benzodiazepine; N-arylpiperazine; N-methylpiperazine	antiemetic; dopaminergic antagonist; histamine antagonist; muscarinic antagonist; second generation antipsychotic; serotonergic antagonist; serotonin uptake inhibitor
raltitrexed [no description available]	2.08	1	0	N-acyl-amino acid
allopurinol Allopurinol: A XANTHINE OXIDASE inhibitor that decreases URIC ACID production. It also acts as an antimetabolite on some simpler organisms.. allopurinol : A bicyclic structure comprising a pyrazole ring fused to a hydroxy-substituted pyrimidine ring.	8.6	19	3	nucleobase analogue; organic heterobicyclic compound	antimetabolite; EC 1.17.3.2 (xanthine oxidase) inhibitor; gout suppressant; radical scavenger
citrovorum factor [no description available]	2.08	1	0	tetrahydrofolic acid
rifapentine rifapentine: cyclopentyl derivative of rifampicin	2.08	1	0	N-alkylpiperazine; N-iminopiperazine; rifamycins	antitubercular agent; leprostatic drug
thiolactomycin thiolactomycin: from actinomycetes; structure given in first source	2.05	1	0
allopurinol riboside allopurinol riboside : A nucleoside analogue that is allopurinol with a beta-D-ribofuranosyl moiety at the 1-position.	2.31	1	0	nucleoside analogue	metabolite
3,4,5-trihydroxybenzamidoxime 3,4,5-trihydroxybenzamidoxime: structure given in first source	2.05	1	0	benzenetriol
phthivazide [no description available]	2.17	1	0
tirapazamine Tirapazamine: A triazine derivative that introduces breaks into DNA strands in hypoxic cells, sensitizing tumor cells to the cytotoxic activity of other drugs and radiation.. tirapazamine : A member of the class of benzotriazines that is 1,2,4-benzotriazine carrying an amino substituent at position 3 and two oxido substituents at positions 1 and 4.	1.97	1	0	aromatic amine; benzotriazines; N-oxide	antibacterial agent; antineoplastic agent; apoptosis inducer
sildenafil citrate Sildenafil Citrate: A PHOSPHODIESTERASE TYPE-5 INHIBITOR; VASODILATOR AGENT and UROLOGICAL AGENT that is used in the treatment of ERECTILE DYSFUNCTION and PRIMARY PULMONARY HYPERTENSION.. sildenafil citrate : The citrate salt of sildenafil.	2.08	1	0	citrate salt	EC 3.1.4.35 (3',5'-cyclic-GMP phosphodiesterase) inhibitor; vasodilator agent
aprepitant Aprepitant: A morpholine neurokinin-1 (NK1) receptor antagonist that is used in the management of nausea and vomiting caused by DRUG THERAPY, and for the prevention of POSTOPERATIVE NAUSEA AND VOMITING.. aprepitant : A morpholine-based antiemetic, which is or the prevention of acute and delayed nausea and vomiting associated with initial and repeat courses of highly emetogenic cancer chemotherapy. Aprepitant is a selective high-affinity antagonist of human substance P/neurokinin 1 (NK1) receptors.	2.08	1	0	(trifluoromethyl)benzenes; cyclic acetal; morpholines; triazoles	antidepressant; antiemetic; neurokinin-1 receptor antagonist; peripheral nervous system drug; substance P receptor antagonist
tegaserod maleate [no description available]	2.08	1	0	maleate salt	serotonergic agonist
rifabutin [no description available]	2.08	1	0
8-hydroxyguanine 7,8-dihydro-8-oxoguanine: was substituted for guanine at G(8), G(9), G(14), or G(15) in the human telomeric oligonucleotide 5'-d[AGGGTTAG(8)G(9)GTT AG(14)G(15)GTTAGGGTGT]-3'. 7,8-dihydro-8-oxoguanine : An oxopurine that is guanine in which the hydrogen at position 8 is replaced by an oxo group and in which the nitrogens at positions 7 and 9 each bear a hydrogen.	2.1	1	0	oxopurine
salicylaldehyde thiosemicarbazone salicylaldehyde thiosemicarbazone: structure given in first source	2.17	1	0
methylnitronitrosoguanidine Methylnitronitrosoguanidine: A nitrosoguanidine derivative with potent mutagenic and carcinogenic properties.. N-methyl-N'-nitro-N-nitrosoguanidine : An N-nitroguanidine compound having nitroso and methyl substituents at the N'-position	2.25	1	0	nitroso compound	alkylating agent
prodigiosin Prodigiosin: 4-Methoxy-5-((5-methyl-4-pentyl-2H-pyrrol-2-ylidene)methyl)- 2,2'-bi-1H-pyrrole. A toxic, bright red tripyrrole pigment from Serratia marcescens and others. It has antibacterial, anticoccidial, antimalarial, and antifungal activities, but is used mainly as a biochemical tool.. prodigiosin : A member of the class of tripyrroles that is a red-coloured pigment with antibiotic properties produced by Serratia marcescens.	2	1	0
db 766 [no description available]	2.48	2	0
abaloparatide abaloparatide: synthetic analog of human PTHrP (Parathyroid Hormone-Related Protein)	2.17	1	0
metallothionein Metallothionein: A low-molecular-weight (approx. 10 kD) protein occurring in the cytoplasm of kidney cortex and liver. It is rich in cysteinyl residues and contains no aromatic amino acids. Metallothionein shows high affinity for bivalent heavy metals.	2.02	1	0
pyrimidinones Pyrimidinones: Heterocyclic compounds known as 2-pyrimidones (or 2-hydroxypyrimidines) and 4-pyrimidones (or 4-hydroxypyrimidines) with the general formula C4H4N2O.	2.06	1	0

benzonidazole

Description

Cross-References

Synonyms (100)

Research Excerpts

Treatment

Toxicity

Pharmacokinetics

Compound-Compound Interactions

Bioavailability

Dosage Studied

Roles (1)

Drug Classes (3)

Protein Targets (16)

Potency Measurements

Inhibition Measurements

Biological Processes (156)

Molecular Functions (79)

Ceullar Components (45)

Bioassays (1875)

Research

Studies (1,220)

Market Indicators

Research Demand Index: 61.47

Study Types

Clinical Trials (20)

Trial Overview

Trial Outcomes

Percentage of Participants With a Successful Response as Measured by Qualitative Polymerase Chain Reaction

benzonidazole

Description

Cross-References

Synonyms (100)

Research Excerpts

Treatment

Toxicity

Pharmacokinetics

Compound-Compound Interactions

Bioavailability

Dosage Studied

Roles (1)

Drug Classes (3)

Protein Targets (16)

Potency Measurements

Inhibition Measurements

Biological Processes (156)

Molecular Functions (79)

Ceullar Components (45)

Bioassays (1875)

Research

Studies (1,220)

Market Indicators

Research Demand Index: 61.47

Study Types

Clinical Trials (20)

Trial Overview

Trial Outcomes

Percentage of Participants With a Successful Response as Measured by Qualitative Polymerase Chain Reaction

Related Drugs (1,187)

Related Conditions (267)